Final Programme

European Congress of Clinical Microbiology and Infectious Diseases

Amsterdam, Netherlands
9 – 12 April 2016
Join us today – our commitment is infectious!

– Become an ESCMID member

– Then sign up for study groups

Good reasons for membership:

• Society’s journals: CMI, NMNI
• Registration discounts for events
• Participation in study groups
• ESCMID newsletter and yearbook
• Discounts to other journals
• Access to the eLibrary and membership directory
• Eligibility for ESCMID awards, research grants, observerships and mentorships
• Right to vote and participate in ESCMID

Apply for membership
Visit our website and join us now!

www.escmid.org/membership
Table of Contents

Introduction
3 Important Addresses
5 Acknowledgements
7 Welcome Address
8 Congress Venue Overview
12 Committees

Awards & Grants 2016
21 ESCMID Award for Excellence
23 ESCMID Young Investigator Awards
25 ESCMID Research Grant 2016

Scientific Programme
24 CME Accreditation
25 Introduction to the Scientific Programme
28 ESCMID Study Group and other Meetings
29 Sessions jointly organized with ESCMID Study Groups and partner
32 Saturday, 9 April 2016
48 Sunday, 10 April 2016
64 Monday, 11 April 2016
82 Tuesday, 12 April 2016

Poster Sessions
98 Saturday, 9 April 2016
120 Sunday, 10 April 2016
146 Monday, 11 April 2016
173 Tuesday, 12 April 2016

ePoster Viewing
194 List of ePoster Viewings

Chairs, Speakers & Authors
245 List of Speakers, Chairs & Authors

Congress Information
xxx Opening Ceremony and Networking Reception
xxx General Information A - Z

Important addresses

Address during the Congress
26th ECCMID
RAI Amsterdam
Europaplein
NL 1078 GZ
Amsterdam, Netherlands
http://www.rai.nl/en/

Administrative Secretariat
Kenes International
Rue François-Versonnex 7
1207 Geneva, Switzerland
Phone: +41 22 908 0488
Fax: +41 22 906 9140
secretariat@eccmid.org

ESCMID President
Prof. Murat Akova
Dept. of Infectious Diseases
Hacettepe University
School of Medicine Sihhiye
Ankara, Turkey

ESCMID Programme Director
Prof. Dr. Winfried V. Kern
Division of Infectious Diseases
Albert-Ludwigs-University
Freiburg, Germany

Scientific Secretariat
26th ECCMID
c/o ESCMID Executive Office
P.O. Box 214
4010 Basel, Switzerland
Phone: +41 61 508 01 72
eccmid@escmid.org
Future Congresses
www.eccmid.org

27th ECCMID
Vienna, Austria
22 – 25 April 2017
Reed Messe Vienna

28th ECCMID
Madrid, Spain
21 – 24 April 2018
IFEMA – Feria de Madrid
Introduction

Acknowledgements

The ECCMID Programme Committee is proud to acknowledge the scientific input from the following organizations in setting up the Scientific Programme and/or organizing joint workshops and symposia:

- American Society for Clinical Microbiology (ASM), Programme Committee of the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)
- Anaerobe Society for Americas (ASA)
- China International Medical Foundation (CIMF), Sino-European Anti-Infection & Clinical Microbiology Scientific Alliance
- European Committee on Antimicrobial Susceptibility Testing (EUCAST)
- European Committee on Infection Control (EUCIC)
- European AIDS Clinical Society (EACS)
- European Centre for Disease Prevention and Control (ECDC)
- European Commission
- French Infectious Diseases Society (SPILF)
- Infectious Diseases Society of America (IDSA)
- International Immunocompromised Host Society (ICHS)
- International Sepsis Forum (ISF)
- International Society for Infectious Diseases and its Program for Monitoring Emerging Diseases (ISID/ProMed)
- Médecins Sans Frontières (MSF)
- Panamerican Association of Infectology (API)
- Paul-Ehrlich Society for Chemotherapy (PEG)
- PREPARE project
- Royal College of Pathologists (UK)

- The European Union of Medical Specialists (UEMS)
- Turkish Clinical Microbiology Society (KLIMUD)
- Turkish Society of Clinical Microbiology and Infectious Diseases (KLIMIK)
- United States National Institute of Allergy and Infectious Diseases (US NIAID)
- World Health Organization, Regional Office for Europe (WHO-Europe)
Don’t miss the TAE Trainees Day with round tables!

For this year’s TAE Trainees Day at ECCMID, the Trainee Association of ESCMID (TAE) will again include the exciting format called “everything you always wanted to discuss directly with an expert”. The participants will apply for the expert(s) of their choice to talk about their dynamic career, highlights of their job, their responsibilities, and possibilities for career building after finishing the training period. Two sessions with 10 round tables each will be hosted in total by 20 renowned experts with different profiles in the fields of clinical microbiology and infectious diseases.

TAE Trainees Day Programme
Saturday, 9 April 2016
Room E106/107, Round tables E104/105

13:00 TAE welcome address and introduction to observerships and mentorships
13:15 TAE Award ceremony
13:30 Round table session I: 10 round tables (E104/105)*
14:30 Break
15:00 3 speeches from Young Investigator Awardees
15:30 Round table session II: 10 round tables (E104/105)*
16:30 Closing ceremony and wrap-up

* Voucher required

Also prepared in collaboration with TAE
Saturday, 9 April 2016, 11:00 – 13:00, Hall F
Undergraduate and postgraduate training and assessments in the infection field – a European discussion

Monday, 11 April 2016, 09:00 – 11:00, Hall K
Affordable healthcare

www.eccmid.org
www.escmid.org/tae
tae@escmid.org
www.facebook.com/ESCMID.TAE

TAE – Trainee Association of ESCMID
Welcome Address

Dear Colleagues and Friends,

It is a great pleasure and privilege to welcome you to the 26th European Congress of Clinical Microbiology and Infectious Diseases in Amsterdam. Originally our idea had been to greet you all in Istanbul, but for the first time in ECCMID’s history, we had to abandon our plans and relocate the congress. Political unrest and unprecedented flows of refugees in Turkey and the region forced us to take this difficult decision. At this time, we sincerely wish to demonstrate that we have managed to take the global spirit of the planned ECCMID at the gateway to Asia all the way to the Venice of the North.

As the leading congress combining clinical microbiology and infectious diseases we see it as our duty to continually increase the scientific excellence of this congress. To achieve this goal the ECCMID Programme Committee has once again prepared a series of symposia, oral sessions, educational workshops and meet-the-expert sessions on parallel tracks, including attractive keynote lectures and the presentations of late-breaking abstracts.

Like every year, ECCMID opens with the educational workshops, which have evolved to become more interactive, allowing participants to become actively involved and get the maximum benefit from the sessions. Organized by ESCMID study groups, its Trainee Association, EUCIC and EUCAST, the 20 workshops explore a wide range of topical subjects and offer superb networking opportunities in addition to their educational value.

This is also true of the meet-the-expert sessions where participants are given the opportunity to more directly interact with experts, to exchange more personal views, ideas and experience. In more than a dozen sessions, experts help finding practical solutions of how to deal with important issues. We will be very happy to receive your suggestions and feedback on how to innovate our sessions and further increase interactivity in the years to come! We want you to be involved as much as possible and rate our congress as convenient, satisfying your professional needs and highly relevant for improved patient care and safety.

ECCMID provides a unique forum for scientific presentations and discussions, while offering ample opportunities for networking and learning about the latest innovations in your fields of expertise. Specialists from all disciplines in the fields of microbiology and infectious diseases have come to take part in our important annual congress. Your attendance has made this 10,000-delegate congress one of the top scientific events of the year.

Amsterdam’s RAI Exhibition and Convention Centre, where the Dutch bicycle industry held its first trade show already at the end of the 19th century, is today a professional host for about 50 international conferences and 70 trade shows. We warmly welcome you to Amsterdam and are excited that you are part of our annual highlight!
Congress Venue Overview
First Level
Congress Venue Overview
Ground Level
**ESCMI presents:**

**EUCAST at ECCMID Amsterdam**

**Saturday, 9 April**

08.45 – 12.45, Hall A

**EUCAST Educational Workshop: Antimicrobial susceptibility testing with EUCAST breakpoints and methods**

Chair: Rafael Cantón (Madrid, ES), Alasdair MacGowan (Bristol, UK)

- Recent developments in EUCAST
  Rafael Cantón (Madrid, ES)
- Revision of breakpoints for major antimicrobial groups
  Christian Giske (Stockholm, SE)
- What does “intermediate” really mean?
  Gunnar Kahlmeter (Växjö, SE)
- VetCAST – antimicrobial breakpoints for veterinary use
  Dik Mevius (Utrecht, NL)
- Moderated panel discussion on questions from the audience. Alasdair P. MacGowan (Bristol, UK)

Coffee break

- Issues and challenges in implementation of EUCAST breakpoints and methods
  Arjana Tambić Andrasevic (Zagreb, HR)
- Revised expert rules for antimicrobial susceptibility testing. Sören G. Gatermann (Bochum, DE)
- Whole genome sequencing and antimicrobial susceptibility testing. Neil Woodford (London, UK)
- Moderated panel discussion on questions from the audience. Alasdair P. MacGowan (Bristol, UK)

EUCAST representatives will be available after the session for at least 30 minutes outside the meeting room.

**18.00 – 19.00, Room G106**

**EUCAST Subcommittee on Antifungal Susceptibility Testing (AFST) General Committee Meeting**

Open meeting

**Sunday, 10 April**

07.45 – 08.45, Hall J

**Meet the Experts: EUCAST frequently asked questions**

Derek F.J. Brown (Peterborough, UK), Erika Matuschek (Växjö, SE)

EUCAST representatives will be available after the session for at least 30 minutes outside the meeting room.

13.30 – 14.30, Poster Area

View EUCAST posters in the following sessions:

- Phenotypic susceptibility testing of Gram-positive organisms
- Antimicrobial susceptibility testing of Gram-negative bacteria

**Monday, 11 April**

13.00 – 14.30, Room G109

**EUCAST General Committee meeting**

Open Meeting

EUCAST representatives will be available after the session for at least 30 minutes outside the meeting room.

17.00 – 18.30, Room G109

**EUCAST Veterinary Subcommittee on Antimicrobial Susceptibility Testing (VetCAST) Stakeholders Meeting**

Open meeting

**Saturday, 9 – Tuesday, 12 April**

**EUCAST posters at ESCMID Network Corner**

European Committee on Antimicrobial Susceptibility Testing 2015/16 ECC 122, EUCAST Development Laboratory (EDL), Clinical Microbiology, Växjö, SE

EUCAST is a standing committee jointly organised by ESCMID, ECDC (European Centre for Disease Prevention and Control) and European national breakpoint committees.

Get more information about EUCAST at the ESCMID World.
Forthcoming Events

Postgraduate Education Courses and Workshops
Receive state-of-the-art knowledge from expert educators.
Gather hands-on experience in your field of interest.
Discuss your work with senior and peer colleagues.

13 – 15 Apr  Population Modelling and Dose Optimization with Pmetrics and BestDose: Antimicrobial Applications
Lyon, France
ESCMID Postgraduate Technical Workshop

29 May – 1 Jun  Infection Prevention and Control: Let’s Get Practical!
Groningen, Netherlands
ESCMID Postgraduate Technical Workshop

2 – 3 Jun  Application of Molecular Diagnostics in Forensic Microbiology
Leuven, Belgium
ESCMID Postgraduate Technical Workshop

3 – 4 Jun  Individualized Medicine in Infectious Diseases: a Practical Approach
Tübingen, Germany
ESCMID Postgraduate Education Course

Lyon, France
ESCMID Postgraduate Education Course

22 – 25 Aug  Medical Biofilm Techniques 2016
Lyngby, Denmark
ESCMID Postgraduate Technical Workshop

4 – 7 Sep  Status Quo of Brain Infections 2016
Izmir, Turkey
ESCMID Postgraduate Education Course

10 – 11 Sep  Antimicrobial Stewardship in Veterinary Medicine
Gothenburg, Sweden
ESCMID Postgraduate Education Course

20 – 23 Sep  Antimicrobial Susceptibility Testing and Surveillance: from Laboratory to Clinic. A EUCAST, ESGARS and EPASG Perspective
Bochum, Germany
ESCMID Postgraduate Technical Workshop

22 – 23 Sep  Management of Infections in Septic Shock Patients
Istanbul, Turkey
ESCMID Postgraduate Education Course

25 – 29 Sep  Infectious Diseases in Pregnant Women, Fetuses and Newborns
Bertinoro, Italy
ESCMID Postgraduate Education Course

26 – 28 Sep  Anaerobic Bacteria: Next Generation Technology Meets Anaerobic Diagnostics
Groningen, Netherlands
ESCMID Postgraduate Technical Workshop

28 – 30 Sep  Difficult-to-Treat Mycobacterial Infections
Brac, Croatia
ESCMID Postgraduate Education Course

14 – 15 Oct  Challenges in the Management of Viral Hepatitis
Cavtat, Croatia
ESCMID Postgraduate Education Course

Seville, Spain
ESCMID Postgraduate Technical Workshop

ESCMID Summer School
An intense one-week course covering diverse topics in the infection field. The high faculty-student ratio and the high level of interactivity make it so popular.

2 – 9 Jul 15th ESCMID Summer School
Seville, Spain

ESCMID Conferences
Get the latest news about your field of work delivered from selected experts. Exchange ideas with your colleagues on hot topics.

21 – 23 Sep  ESCMID Conference on Accelerating Antimicrobial Drug Development
Vienna, Austria

Future ECCMIDs
9 – 12 Apr 26th ECCMID 2016
Amsterdam, Netherlands

22 – 25 Apr 27th ECCMID 2017
Vienna, Austria

More detailed information can be found on the ESCMID website: www.escmid.org
Committees

ESCMID Executive Committee

Murat Akova
Ankara, Turkey
President

Mario Poljak
Ljubljana, Slovenia
President-elect & Secretary General

Gunnar Kahlmeter
Växjö, Sweden
Past President & Communications Officer

Cornelia Lass-Flörl
Innsbruck, Austria
Treasurer

Evelina Taconelli
Tübingen, Germany
Professional Affairs Officer

Jesús Rodríguez-Baño
Seville, Spain
Education Officer

Annelies Zinkernagel
Zurich, Switzerland
Scientific Affairs Officer

ESCMID Ad-hoc Executive Committee Members

Rafael Canton
Madrid, Spain
EUCAST Chairman

Michel Drancourt
Marseille, France
NMNI Editor-in-Chief

William W. Hope
Liverpool, United Kingdom
ESCMID Guidelines Director

Didier Raoult
Marseille, France
CMI Editor-in-Chief

Winfried V. Kern
Freiburg, Germany
ECCMID Programme Director

Giuseppe Cornaglia
Verona, Italy
International Affairs Director

New Executive Committee Members

Alexander W. Friedrich
Groningen, Netherlands

Maurizio Sanguinetti
Rome, Italy
Committees

**ECCMID Programme Committee**

Winfried V. Kern (Freiburg, Germany) – ECCMID Programme Director
Murat Akova (Ankara, Turkey)
Joop E. Arends (Utrecht, Netherlands)
Sevtap Arkan-Akdagl (Ankara, Turkey)
Thierry Calandra (Lausanne, Switzerland)
Francesco Castelli (Brescia, Italy)
Manuel Cuenca-Estrella (Madrid, Spain)
Hakan Erdem (Istanbul, Turkey)
Jon S. Friedland (London, United Kingdom)
Niels Frimodt-Moller (Copenhagen, Denmark)
Hans H. Hirsch (Basel, Switzerland)
Christine Imbert (Poitiers, France)
Gunnar Kahlmeter (Växjö, Sweden)
Jan A.J.W. Kluytmans (Breda, Netherlands)
Cornelia Lass-Flörl (Innsbruck, Austria)
Albert MacGowan (Bristol, United Kingdom)
Surbhi Malhotra-Kumar (Antwerp, Belgium)
Luis Martinez-Martinez (Santander, Spain)
Mihai Gheorghe Netea (Nijmegen, Netherlands)
Mark Patrick Nicol (Cape Town, South Africa)
Hanna Nohynek (Helsinki, Finland)
Dan Otelea (Bucharest, Romania)
Lucia Pastore Celentano (Stockholm, Sweden)
Maria Poljak (Ljubljana, Slovenia)
Jesús Rodríguez-Baño (Seville, Spain)
Mark Everett Shirliff (Baltimore, MD, United States)
Maria Souli (Athens, Greece)
Jean Paul Stahl (Grenoble, France)
Arnfinn Sundsfjord (Trondheim, Norway)
Yupin Suputtamongkol (Bangkok, Thailand)
Evelina Tacconelli (Tübingen, Germany)
Kate Templeton (Edinburgh, United Kingdom)
Ursula Theuretzbacher (Vienna, Austria)
Jean-François Timis (Paris, France)
Linos Vandekerckhove (Ghent, Belgium)
Minggui Wang (Shanghai, China)
Annélies Wilder-Smith (Singapore, Singapore)
Annélies Zinkernagel (Zürich, Switzerland)

**ESCMID Publication Subcommittee (PS)**

Murat Akova, Ankara, Turkey I Chair
Michel Drancourt, Marseille, France
Leonard Eibovici, Petah-Tiqva, Israel
Fiona Macnab, London, United Kingdom I Elsevier Representative

**ESCMID Scientific Affairs Subcommittees (SAS)**

Annelies Zinkernagel, Zurich, Switzerland I Chair
Han Bahnkhy, Riyadh, Saudi Arabia
Rosemary Barnes, Cardiff, United Kingdom
German Bou Arefalo, La Coruña, Spain
Marek Gniadkowski, Cardiff, United Kingdom
Gilbert Greub, Lausanne, Switzerland
Andreas H. Groll, Münster, Germany
Hervé Pelloux, Grenoble, France
Adriana Vince, Zagreb, Croatia

**ESCMID Professional Affairs Subcommittee (PAS)**

Evelina Tacconelli, Tübingen, Germany I Chair
Emmi Anderson, Stockholm, Sweden
Guido Antonelli, Rome, Italy
Patrik Apfel, Linz, Austria
Nur Benzonana, Istanbul, Turkey
Julia Anna Bielenicki, London, United Kingdom
Maria Adriana Cataldo, Rome, Italy
Joana Cortez, Coimbra, Portugal
Achilleas Gikas, Heraklion, Greece
Angela Huttner, Geneva, Switzerland
Ulrik Stenz Justes, Odense, Denmark
Surbi Malhotra-Kumar, Antwerp, Belgium
Dan Otelea, Bucharest, Romania
Leonardo Pagani, Bolzano, Italy
Carlos Palos, Loures, Portugal
Hilipi Raatelin, Uppsala, Sweden I UEMS MM Section representative
Pilar Retamar Gentil, Seville, Spain
Katja Seme, Ljubljana, Slovenia
Chysanthi Skevaki, Athens, Greece
Jean Paul Stahl, Grenoble, France I UEMS ID Section representative
Andrew J. Ullmann, Würzburg, Germany
Joanna Verran, Manchester, United Kingdom
Matthias Willmann, Tübingen, Germany

**Parity Commission (PC)**

Evelina Tacconelli, Tübingen, Germany I Chair
Angela Huttner, Geneva, Switzerland
Dan Otelea, Bucharest, Romania
Chysanthi Skevaki, Athens, Greece
Trainee Association of ESCMID (TAE)
Ceren Atasoy, Istanbul, Turkey
Joana Cortez, Coimbra, Portugal
Alberto Enrico Marafolo, Bologna, Italy
David Ong, Utrecht, Netherlands
Chrysanthi Skevaki, Athens, Greece
Erlangga Yusuf, Brussels, Belgium

ESCMID International Affairs Subcommittee
Adalat Abdullayev, Baku, Azerbaijan
Giuseppe Cornaglia, Verona, Italy
Qiu Haibo, Nanjing, China
Po-Ren Hsueh, Taipei, Taiwan
Roman S. Kozlov, Smolensk, Russian Federation
Marc Mendelson, Cape Town, South Africa
David L. Paterson, Herston, QLD, Australia
Camilla Rodrigues, Mumbai, India
Atef Shibl, Riyadh, Saudi Arabia
Kazuhiro Tateda, Tokyo, Japan
Maria Virginia Villegas, Cali, Colombia

ESCMID Study Groups Chairs
Anaerobic Infections (ESGAI)
www.escmid.org/esgai
Elisabeth Nagy, Szeged, Hungary
nagy.erzsebet@med.u-szeged.hu

Antibiotic Policies (ESGAP)
www.escmid.org/esgap
Bojana Beovic, Ljubljana, Slovenia
bojana.beovic@kclj.si

Biofilms (ESGB)
www.escmid.org/esgb
Thomas Bjarnsholt, Copenhagen, Denmark
tbjarne.sholt@sund.ku.dk

Bloodstream Infections (ESGBIS)
www.escmid.org/esgbis
Winfried V. Kern, Freiburg, Germany
kern@if-freiburg.de

Brain Infections (ESGIB)
www.escmid.org/esgib
Marco Rinaldo Oggioni, Leicester, United Kingdom
mro5@leicester.ac.uk

Clinical Parasitology (ESGCP)
www.escmid.org/esgcp
Titia M. Kortbeek, Bilthoven, Netherlands
titia.kortbeek@rivm.nl

Clostridium difficile (ESGCD)
www.escmid.org/esgcd
Ed J. Kuijper, Leiden, Netherlands
e.j.kuijper@lumc.nl

Critically Ill Patients (ESGCIP)
www.escmid.org/esgcip
Jordi Rello, Barcelona, Spain
jrello@crips.es

Elderly Infections (ESGIE)
www.escmid.org/esgie
Mical Paul, Haifa, Israel
paulm@post.tau.ac.il

Epidemiological Markers (ESGEM)
www.escmid.org/esgem
Hajo Grundmann, Groningen, Netherlands
h.grundmann@umcg.nl

Food/Water Infections (EFWISG)
www.escmid.org/efwisg
Luisa M.V. Peixe, Porto, Portugal
lpeixe@ff.up.pt

Forensic/Postmortem Microbiology (ESGFOR)
www.escmid.org/esgfor
Amparo Fernández-Rodríguez, Madrid, Spain
amparo.fernandezrodriguez@justicia.es

Fungal Infection (EFISG)
www.escmid.org/efisg
Andrew J. Ullmann, Würzburg, Germany
ullmann_a@klinik.uni-wuerzburg.de

Immunocompromised Hosts (ESGICH)
www.escmid.org/esgich
Bernd Salzberger, Regensburg Germany
bernd.salzberger@ukr.de

Implant Infections (ESGIAI)
www.escmid.org/esgiai
Alex Soriano, Barcelona, Spain
asoriano@clinic.ub.es

Legionella Infections (ESGLI)
www.escmid.org/esgli
Valeria Gaia, Bellinzona, Switzerland
valeria.gaia@eoc.ch

Lyme Borreliosis (ESGBOR)
www.escmid.org/esgbor
Gerold Stanek, Vienna, Austria
gerold.stanek@meduniwien.ac.at

Molecular Diagnosis (ESGMD)
www.escmid.org/esgmd
Paul Savelkoul, Maastricht, Netherlands
p.savelkoul@mumc.nl

Mycobacterial Infections (ESGMYC)
www.escmid.org/esgmyc
Emmanuelle Cambau, Paris, France
emmanuelle.cambau@lrb.aphp.fr
Committees

**Mycoplasma Infections [ESGMI]**
www.escmid.org/esgmi
Cecile Bebear, Bordeaux, France
cecilie.bebear@u-bordeaux.fr

**Nosocomial Infections [ESGNI]**
www.escmid.org/esgni
Barry D. Cookson, London, United Kingdom
bsajcookson@btinternet.com

**PK/PD of Anti-Infectives [EPASG]**
www.escmid.org/epasg
William Couet, Poitiers, France
william.couet@univ-poitiers.fr

**Resistance Surveillance [ESGARS]**
www.escmid.org/esgars
Giuseppe Cornaglia, Verona, Italy
giuseppe.cornaglia@univr.it

**Staphylococci [ESGS]**
www.escmid.org/esgs
François Vandenesch, Bron, France
francois.vandenesch@univ-lyon1.fr

**Travel and Migration [ESGITM]**
www.escmid.org/esgitm
Hakan Leblebicioglu, Samsun, Turkey
hakan@omu.edu.tr

**Vaccines [EVASG]**
www.escmid.org/evasg
Susanna Esposito, Milan, Italy
susanna.esposito@unimi.it

**Veterinary Microbiology [ESGVM]**
www.escmid.org/esgvm
Luca Guardabassi, Basseterre, Saint Kitts and Nevis
lguardabassi@rossvet.edu.kn

**Viral Hepatitis [ESGVH]**
www.escmid.org/esgvh
Joop Arends, Utrecht, Netherlands
j.e.arends@umcutrecht.nl
New Microbes and New Infections is a fully open access journal.

Go to www.newmicrobesnewinfections.com to access all issues.

A selection of recently published articles includes:

- Serological and molecular survey for hepatitis E virus in wild boar, in Central Italy
- Fecal Escherichia coli isolates show potential to cause endogenous infection in patients admitted to ICU in a Tertiary Care hospital
- International Mycoplasma pneumoniae typing study: the interpretation of Mycoplasma pneumoniae multilocus variable-number tandem-repeat analysis
- Sphingobacterium multivorum: a case report and literature review

7 REASONS TO PUBLISH IN NMNI

Submit your manuscripts to http://ees.elsevier.com/nmni

1. Rapid publication guarantees fast dissemination of your important work
2. Rigorous and constructive peer-review by experienced editorial team ensures consistently high quality
3. Highly competitive article processing charges give you viable options
4. Open Access articles are licensed under creative commons and in compliance with open access mandates
5. Official publication of ESCMID means that your article will be read by the global community
6. Immediate, free and permanent access to your paper on ScienceDirect and the journal dedicated website
7. Detailed individual feedback on how many times your paper has been read and which countries the readership comes from
Awards & Grants 2016

Annelies Zinkernagel
ESCMID Scientific Affairs Officer
annelies.zinkernagel@escmid.org

We are pleased to announce the recipients of awards and grants for the year 2016. Again, ESCMID increased its support of the award and grant programmes, exemplified by the spending of EUR 330,000 for the 15 newly instituted ESCMID research grants. Together with our generous allocation of funds for ECCMID travel and attendance subsidies for courses, conferences and other scientific events, this year we are investing around EUR 550,000 into scientific advancement and continued learning and exchange.

Robert Bonomo (Cleveland, OH, United States) has been selected to receive the ESCMID Excellence Award for 2016. He has an outstanding record of research productivity and his work has greatly influenced the field of antibiotic resistance. He is a highly collaborative scientist, who has coupled his clinical knowledge in the area of infectious disease with expertise in molecular biology and biochemistry to produce a number of outstanding papers. He has made contributions in a wide range of areas related to antibiotics, including molecular diagnostics, resistance enzyme structure-function, enzyme inhibitor mechanisms of action and drug discovery. His productivity is evidenced by more than 300 publications to date. In addition to his outstanding research, his service to the scientific community includes being an editor for leading publications in his discipline, such as Antimicrobial Agents and Chemotherapy and the Journal of Biological Chemistry as well as being very active in the American Society for Microbiology (ASM). He is also an outstanding teacher, who has trained a long list of scientists and clinicians. The award pays tribute to his more than 30 years of accomplishments in the field.

As was the case last year, the large number of excellent Young Investigator applications led us to choose three recipients for 2016: Sanne Jespersen (Aarhus University Hospital, Denmark), Robert P Ryan (Division of Molecular Microbiology, University of Dundee, United Kingdom) and Timothy M Walker (University of Oxford, United Kingdom). Sanne Jespersen’s work in various countries in the world exemplifies how to apply the latest findings on optimal treatment in extremely resource-poor and politically unstable settings.

Robert Ryan has received several awards and fellowships which have allowed him to gain insights into the complex field of polymicrobial infections. Tim Walker’s work on tuberculosis outbreaks and how genomic mutations can predict phenotypic drug susceptibility contributed to England’s investment in routine whole-genome sequencing for mycobacterial infections.

The winners of this year’s TAE Awards for Training Achievements are Cliodhna Ní Bhuachalla from the Adelaide and Meath Hospital in Dublin, Ireland, as well as Luís Filipe Gomes Malheiro from the Centro Hospitalar de São João in Porto, Portugal.

There were 130 applications for ESCMID Research Grants 2016. Fifteen colleagues with basic or applied research projects were chosen. There were several procedural improvements this year. These are described in the Scientific Affairs article [ESCMID Yearbook 2015/16]. Special thanks to all the experts and reviewers [ESCMID Yearbook 2015/16], who did a tremendous job evaluating all these submissions. As happens every year, one of the Research Grant recipients is also awarded the ESCMID/FEMS Fellowship and this year it goes to Juan Manuel Pericas, Spain.

In addition, ESCMID supports young colleagues with merit-based travel grants and free registration to enable them to attend ECCMID. We are giving 101 young scientists travel grants and free registration for ECCMID Amsterdam 2016, where they will present the results of their work. ESCMID also supports its members early in their careers with attendance grants for other ESCMID conferences, the Summer School, post-graduate educational courses and other educational and/or scientific events.

You can find details of all recipients of awards for 2016 on the following
ESCMID Award for Excellence in Clinical Microbiology and Infectious Diseases 2016

Robert A. Bonomo

Robert A. Bonomo (Cleveland, OH, USA) has been awarded the ESCMID Excellence Award for 2016. This is the latest acknowledgement of his outstanding achievements in medicine and biomedical research, which began with his first award in 1983 for excellence in Cardiovascular Medicine. Having begun his career in internal medicine and infectious diseases, he added geriatrics and within a decade, he was Chairman of the Infection Control Committee for a retirement community in Ohio while an Assistant Professor in Geriatrics at Case Western Reserve University. After this start, he transitioned to study infectious diseases in the elderly and the emergence of antibiotic resistant pathogens in vulnerable populations.

He was awarded tenure at Case Western Reserve University School of Medicine in 2002 and began adding other specialties to his teaching commitments, including Pharmacology, Molecular Biology, Microbiology, Biochemistry, Proteomics and Bioinformatics. For more than 30 years Robert has distinguished himself as a clinician, through his research, teaching, mentoring and well over 340 publications, all of which have contributed greatly to science, particularly in the field of antibiotic resistance. Several of his awards were for excellence in teaching and two were for mentoring, something very dear to his heart. Currently, Robert holds the post of Chief of Medical Service at the Cleveland Veteran Affairs Medical Center, which involves overseeing the activities of 10 major clinical sections delivering care to Veterans in north-eastern Ohio, as well as ensuring there is a robust academic environment for medical students, residents and fellows. In the last eight years he has also been appointed Director of the Geriatric Research Education & Clinical Center of the Veterans Integrated Service Network, co-Chair of the Gram-Negative Committee of the Antibiotic Resistance Leadership Group and Vice Chairman of Veterans Affairs of University Hospitals Case Medical Center.

As well as publishing his own research papers, his service to the scientific community currently includes being on the editorial board of eight journals and a peer reviewer for many more. Between 2002 and 2011 he served on the editorial board of the American Society for Biochemistry and Molecular Biology’s Journal of Biological Chemistry. Since 2002 he has been a member of the Editorial Board for the journal Antimicrobial Agents and Chemotherapy. These are the leading journals of his speciality. Since 2004 he has been on the programme committee of the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). Furthermore, Robert sits on numerous committees and has been responsible for convening many slide sessions and symposia. He is also in demand, both nationally and internationally, as a speaker and gave his first ECCMID keynote speech in 2010. He served the National Institute of Health as a member of different study sections for more than eight years.

Robert’s career path involves administrative responsibilities together with the need to find large sums to fund research. His success can also be measured by the huge financial support he has secured from major pharmaceutical companies. It comes as no surprise that he’s very active in the American Society of Microbiologists and was elected President of Division A (Antimicrobial Chemotherapy) of the ASM, serving a three-year term from 2008 to 2011.

One of the factors which make him such an outstanding scientist is his ability to collaborate at the cutting edge. He has coupled his clinical knowledge in the area of infectious disease with expertise in molecular biology and biochemistry to produce a number of exceptional papers. Following the advice of Karen Bush, Robert began a research programme dedicated to the study of SHV betalactamase.

In a combined effort with James R Knox and Michioshi Nukaga, Robert’s laboratory helped reveal the atomic structure of SHV-1 and the first reported extended spectrum beta-lactamase (ESBL), SHV-2. Together with Focco van den Akker of Case Western Reserve University, the structure of KPC-2 carbapenemase was determined in Cleveland. He also worked with Focco and John Bugnak on characterizing the activity and elucidating the structure of penicillin sulphone BLIs. Moreover, Robert’s lab helped establish that mass spectrometry was an effective way to study the inhibition of beta-lactamases by novel inhibitors. In collaboration with
Krisztina Papp-Wallace of the Cleveland VA and Case Western Reserve University, the mechanistic details of KPC activity were systematically elucidated as this beta-lactamase emerged as a significant threat. With Rachel Powers and Brad Waller the chromosomal beta-lactamase, Acinetobacter derived cephalosporinase (ADC-7), was determined in complex with a novel boronic acid transition state inhibitor designed by Fabio Prati and Emilia Caselli. These studies laid the groundwork for the deeper understanding of new compounds.

Robert and his team have participated in the evaluation of many preclinical and clinical candidates, including the testing of 4 novel antimicrobial agents which progressed to Phase III clinical trials (all now FDA approved) as well as over 100 other investigational beta-lactamase inhibitors. This means his laboratory is at the forefront of studying beta-lactams and beta-lactamase inhibitors against clinically relevant and emerging MDR Gram-negative pathogens.

Of Robert's major contributions to science, important milestones stand out. Robert's primary research efforts focus on structurefunction relationships of clinically important beta-lactamases using microbiological and biochemical testing, medicinal chemistry, structural biology, pharmacological analyses, genetics and molecular epidemiology. His work helped establish the foundation by which novel beta-lactam therapies can be designed. Robert's most recent studies are of metallo-beta-lactamases with Alejandro Vila of Rosario, Argentina and Jim Spencer of Bristol, England. With Graciela Mahler of Uruguay, Alejandro, Jim and Robert have studied novel cross class inhibitors of metallo-beta-lactamases.

Robert has also worked extensively with industry and academia to develop the best ways to determine beta-lactamase resistance and to detect the presence of pathogens when cultures are negative (developing the concept of "salvage microbiology" with John Farrell and Ranga Sampath).

Having studied Acinetobacter baumannii with Mark Adams for more than ten years, Robert helped understand the biology of resistance in MDR A. baumannii and, in collaboration with other researchers, he elucidated its clinical and complex genetic background.

With Brad Spellberg he has also studied the pathobiology and immunology of MDR A. baumannii. Klebsiella pneumoniae has also been studied at his lab since 2007 and it was extremely important to Robert to help form a consortium with David van Duin focusing on the clinical and molecular analysis of KPC-producing K. pneumoniae, first in the Great Lakes region and then throughout the United States. Robert believes the consortium is on the brink of understanding why people with this particular infection have such poor outcomes. Working with Barry Kreiswirth and Liang Chen, Robert has examined the importance of plasmid structure on this epidemic. In Robert's lab, Andrea Endimiani and Federico Perez studied the molecular epidemiology of MDR pathogens and helped map novel genetic constructs.

Finally we come to molecular diagnostics. As a clinician and as a member of the Antibacterial Resistance Leadership Group, Robert feels is it important to appraise the molecular diagnostic platforms currently being developed. As a successful Principal Investigator for almost 20 years, he has guided a concerted research effort that attempts to understand the molecular basis of how Gram-negative bacteria develop the MDR phenotype.

The ESCMID Award pays tribute to his exceptional accomplishments and contributions to his field and to a distinguished career of more than 30 years.

Robert Bonomo will be presented his award at the 26th ECCMID in Amsterdam by Murat Akova, ESCMID President on Sunday, 10 April 2016 from 14:30 – 15:30 in Hall A. During this ceremony he will give his recipient’s lecture: “The renaissance of the beta-lactamase inhibitors".
ESCMID Young Investigator Awards for Research in Clinical Microbiology and Infectious Diseases 2016

Sanne Jespersen
Sanne graduated from Aarhus University where she received her PhD in 2015. Currently she is undertaking her infectious disease training at Aarhus University Hospital and the London School of Hygiene & Tropical Medicine. Motivated by her special interest in HIV, tropical diseases and global health, she has worked in various places, including Lesotho, Ireland, Guinea-Bissau and Greenland. Recently, she has been working with Médecins Sans Frontières, treating Ebola patients in Sierra Leone. During her PhD studies, she investigated HIV treatment in Guinea-Bissau based on data from the Bissau HIV Cohort, which is the largest single centre cohort of HIV-2 infected individuals. Sanne Jespersen has published several articles describing the specific challenges of delivering antiretroviral treatment in sub-Saharan Africa. Her work represents an important contribution to optimal HIV treatment in extremely resource-poor and politically unstable countries and applying the tools of science under difficult circumstances.

Sanne will receive her award during the ESCMID Young Investigator Awards Session at ECCMID on 11 April 2016 from 14.30 – 15.30 in Hall K. During the session, she will give her presentation: ‘The missing link in HIV treatment delivery in Africa illustrated by the Bissau HIV Cohort’ Robert P. Ryan

Robert P. Ryan
Robert is Principal Investigator in the Division of Molecular Microbiology at the University of Dundee. In 2005 he gained a PhD in molecular microbiology and took up a postdoc position at University College Cork. Later, under the auspices of EMBO, HFSP, SFI and Royal Irish Academy fellowships, he worked in laboratories at the Karolinska Institute, Universidade de São Paulo, University of Copenhagen and Dartmouth Medical School. In 2010 he was awarded a Science Foundation Ireland Starting Investigator award to set up his own group at University College Cork and in 2013 he moved to Dundee, having gained a Wellcome Trust Senior Fellowship. In 2015 he was awarded the Lister Institute Research Prize Fellowship award, which seeks to help support and nurture future leaders in biosciences and genetics. His current work centres on understanding the role that interspecies signalling plays in influencing both bacterial virulence and response to therapy in various polymicrobial infections.

Robert will be presented with his award during the ESCMID Young Investigator Awards Session at ECCMID on 11 April 2016 from 14.30 – 15.30 in Hall K. During the session, he will present some of his research under the title: ‘Disrupting the infectious conversation: understanding polybacterial infections as a route towards combating antibiotic resistance’
Timothy M. Walker

Tim first studied politics, philosophy and economics at Oxford before taking the unusual step of retraining in clinical medicine. After qualifying in London he obtained a specialist training position in microbiology and infectious diseases in Oxford where he subsequently took time out to pursue a DPhil within the Modernising Medical Microbiology (MMM) research group as a Medical Research Council training fellow. His current position is NIHR Academic Clinical Lecturer at the University of Oxford where he divides his time between clinical training and further pursuing his research interests within MMM as part of a large multi-disciplinary network of investigators. His research focuses on how whole-genome sequencing of Mycobacterium tuberculosis can better guide public health investigations into tuberculosis outbreaks, and how genomic mutations can predict phenotypic drug susceptibility. This work has influenced the UK government’s decision to invest in routine whole-genome sequencing for mycobacterial infections in England from 2016 onwards.

Tim will receive his award during the ESCMID Young Investigator Awards Session at ECCMID on 11 April 2016 from 14.30 – 15.30 in Hall K. During the session, he will give his presentation: ‘How can whole-genome sequencing help eradicate tuberculosis?’
Travel Grants Awardees

The ECCMID travel grant programme is sponsored by the European Society of Clinical Microbiology and Infectious Diseases (ESCMID). Grants were awarded to those with outstanding abstracts.

Ageevets, Vladimir [St. Petersburg, Russian Federation]
Aguilera Xiol, Elisabet [Barcelona, Spain]
Allemann, Aurélie [Bern, Switzerland]
Alvarez Marin, Rocío [Seville, Spain]
Athavale, Anand [West Orange, United States]
Babenko, Dmitrii [Karaganda, Kazakhstan]
Babitch, Tanya [Petah Tikva, Israel]
Barac, Aleksandra [Belgrade, Serbia]
Bartolini, Andrea [Padova, Italy]
Bordallo Cardona, Mª Angeles [Madrid, Spain]
Brendish, Nathan [Southampton, United Kingdom]
Callarisa Lasa, Anna Elena [Barcelona, Spain]
Caltagirone, Mariasofia [Pavia, Italy]
Carrel, Margaret [Iowa City, IA, United States]
Carvalho Ribeiro Do Valle, Carolina [Santana de Parnaiba, Brazil]
Casella, Tiago [Sao Paulo, Brazil]
Chen, Caroline [North Melbourne, Australia]
Cordioli, Maddalena [Verona, Italy]
Cosgaya Castro, Clara [Barcelona, Spain]
Costerus, Joost Michiel [Amsterdam, Netherlands]
Cremers, Amelieke Johanna Hendrina [Nijmegen, Netherlands]
Dabos, Marie-Laure [Paris, France]
Deg, Asmita [Lucknow, India]
Dias, Sara [Lisbon, Portugal]
Diogo, Mariana [Lisbon, Portugal]
Figueiredo Mello, Claudia [Sao Paulo, Brazil]
Fitzgerald, Felicity [London, United Kingdom]
Floch, Pauline [Bordeaux, France]
Gago, Sara [Manchester, United Kingdom]
García Fernandez, Patricia [La Coruña, Spain]
García-Cobos, Silvia [Groningen, Netherlands]
García-Fernández, Sergio [Madrid, Spain]
Gargis, Amy [Atlanta, United States]
Gelemanovic, Andrea [Samobor, Croatia]
Geraci, Daniela Maria [Palermo, Italy]
Gerver, Sarah [London, United Kingdom]
Heil, Jeanne [Geleen, Netherlands]
Hettiarachchi, Irasha [Cardiff, United Kingdom]
Holten Meier, Camilla [Copenhagen, Denmark]
Jacquet, Caroline [Nancy, France]
Jayaweera, Jinesh [Anuradhapura, Sri Lanka]
Jørgensen, Nis Pedersen [Aarhus, Denmark]
Karageorgos, Spyridon [Keraklion, Greece]
Kloek, Anne [Amsterdam, Netherlands]
Koning, Sonia [Victoria, Australia]
Koopmans, Merel [Amsterdam, Netherlands]
Kramer, Tobias [Neuruppin, Germany]
Kremer, Philip [Amsterdam, Netherlands]
Kumar, Nitin [Cambridge, United Kingdom]
Lacoma, Alicia [Badalona, Spain]
Lau, Katherine [Randwick, Australia]
Liakopoulos, Apostolos [Leilystad, Netherlands]
Liere van, Geneviève [Geleen, Netherlands]
Llorca, Laura [Madrid, Spain]
Ludovisi, Serena [Pavia, Italy]
Machuca, Jesús [Seville, Spain]
Marcos Zambrano, Laura Judith [Madrid, Spain]
Margaruyan, Hasmik [Abovyan, Armenia]
Martins, Williams Brasileiro [Sao Paulo, Brazil]
Mazzaferrì, Fulvia [Verona, Italy]
Meinel, Dominik [Basel, Switzerland]
Minichmayr, Iris K. [Berlin, Germany]
Mizrahi, Assaf [Paris, France]
Mojsoska, Biljana [Roskilde, Denmark]
Montassier, Emmanuel [Nantes, France]
Moore, Luke [London, United Kingdom]
Morales Barroso, Isabel Maria [Seville, Spain]
Morel, Florence [Paris, France]
Moura, Alexandra [Paris, France]
Moyo, Emmanuel [Mersele, United Kingdom]
Muraro Wildner, Letícia [Florianópolis, Brazil]
Nabarro, Laura [London, United Kingdom]
Namdari, Haydeh [Tehran, Iran]
Niculae, Cristian-Mihail [Bucharest, Romania]
Nielsen, Stig Lønberg [Odense, Denmark]
Norris, Rachel [Oxford, United Kingdom]
Orellana-Manzano, Andrea [Santiago, Chile]
Palazzo, Donatella [Rome, Italy]
Pankhurst, Louise [Oxford, United Kingdom]
Parra Millán, Raquel [Seville, Spain]
Pekmezovic, Marina [Pancevo, Serbia]
Peres-da-Silva, Allan [Rio de Janeiro, Brazil]
Perny, Michael [Bern, Switzerland]
Rafael, Agerbe [Seville, Spain]
Salamanca Rivera, Elena [Seville, Spain]
Schneider, Elena [Parkville, Australia]
Schweizer, Marín [Iowa City, IA, United States]
Shankar, Chaitra [Vellore, India]
Sharma, Cheshita [Delhi, India]
Singh, Pradeep Kumar [Delhi, India]
Sips, Meander Esmée [Utrecht, Netherlands]
Spann, András N. [Utrecht, Netherlands]
Šterbenc, Anja [Ljubljana, Slovenia]
Thomson, Calum Bryson [Birmingham, United Kingdom]
Tomusiak, Anna [Krakow, Poland]
Trapani, Filippo [Bologna, Italy]
Trinh, Trang [Detroit, United States]
Vásquez Zorrilla, Victor [Madrid, Spain]
Vazquez-Ucha, Víctor [Madrid, Spain]
Wyllie, Anne Louise [Utrecht, Netherlands]
Zasowski, Evan [Detroit, United States]
CME Accreditation

Educational Objectives
After attending this event, participants should be able to:

• Address individual needs in compliance with their Continuous Professional Development (CPD) plan.
• Exchange ideas and knowledge in the field of microbiology and infectious disease across continents, institutions, and individuals.
• Discuss the latest research outcomes in the field of antimicrobials, molecular biology, virology and infection control.
• Discuss the latest research outcomes in the field of infectious diseases, microbiology and research.
• Discuss outcomes of the latest studies in Europe in the field of public health and vaccines.
• Summarize good and bad immune responses.
• Discuss diagnostics, therapeutics and prevention in the field of infectious diseases.

Target Audience
ECCMID 2016 is the global meeting place for microbiologists, infectious disease specialists and related fields. Because of the diverse, clinically focused educational offering, participants are able to tailor the curriculum to meet the needs of international clinicians of all levels of experience.

Accreditation Statement and Credit Designation
European Accreditation Council for Continuing Medical Education (UEMS/EACCME)

The 26th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) is accredited by the European Accreditation Council for Continuing Medical Education (EACCME) to provide the following CME activity for medical specialists. The EACCME is an institution of the European Union of Medical Specialists (UEMS): www.uems.net

The 26th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) is designated for a maximum of, or up to, XX European external CME credits. Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity.

American Medical Association (AMA)
Through an agreement between the European Union of Medical Specialists and the American Medical Association, physicians may convert EACCME credits to an equivalent number of AMA PRA Category 1 Credits*. Information on the process to convert EACCME credit to AMA credit can be found at www.ama-assn.org/go/internationalcme

Royal College of Physicians and Surgeons of Canada
Live educational activities, occurring outside of Canada, recognized by the UEMS-EACCME for ECMEC credits are deemed to be Accredited Group Learning Activities [Section 1] as defined by the Maintenance of Certification Program of The Royal College of Physicians and Surgeons of Canada. For more information, visit: www.royalcollege.ca

Credit Breakdown
Each participant should claim only those hours of credit that he/she actually spent in the educational activity.

<table>
<thead>
<tr>
<th>Day</th>
<th>Max Credits</th>
</tr>
</thead>
<tbody>
<tr>
<td>Saturday, 9 April 2016</td>
<td>6</td>
</tr>
<tr>
<td>Sunday, 10 April 2016</td>
<td>6</td>
</tr>
<tr>
<td>Monday, 11 April 2016</td>
<td>6</td>
</tr>
<tr>
<td>Tuesday, 12 April 2016</td>
<td>5</td>
</tr>
<tr>
<td>Total</td>
<td>23</td>
</tr>
</tbody>
</table>

To Receive Your CME/CPD Certificate
This year, participants will have the option to receive their CME/CPD Certificate after completing the evaluation of attended sessions and the CME survey.

First step
Evaluation of attended sessions
In order to evaluate the session, participants need to follow these steps:
1. At the end of each session, the participant will click on the ‘Rate this session’ button in the congress app.
2. For those who don’t use the congress app, the evaluation is also available on the ECCMID website or via the onsite CME kiosks.
3. Login with your unique CME ID (printed on your badge).
4. Rate the session*.

Second step – Complete the CME survey
After or during the congress, each participant who completed the evaluation of attended sessions will need to complete the CME survey (11 additional questions).
1. The CME Survey can be completed on any computer through the ECCMID website or via the onsite CME kiosks.
2. Login with your unique CME ID (printed on your badge).
3. Complete the CME survey.
4. Once the participant completes the survey, they will be able to receive the certificate of attendance including the CME points accumulated.

*All evaluations will be saved once you confirm and log out. Please note – the onsite CME kiosks will only be available from Monday, 11 April 2016.

To receive the CME/CPD certificate after the congress:
CME/CPD certificates can be claimed from any computer through the ECCMID website (www.eccmid.org). The certificates will be delivered electronically after completing the evaluation of attended sessions and CME survey.

We thank you for your feedback, as it is an important part of the CME/CPD accreditation process and helps improve future educational offerings.

We thank you for your feedback, as it is an important part of the CME/CPD accreditation process and helps improve future educational offerings.
Disclosure and Resolution of Personal Conflicts of Interest

In accordance with CME/CPD accreditation criteria and standards for commercial support to ensure balance, independence, objectivity, and scientific rigor, those in control of the educational content must disclose potential or actual conflicts of interest. Disclosure information is evaluated and conflicts of interest resolved. Disclosure is made to participants prior to the activity. Participants will be asked on the evaluation to assess the objectivity and independence of the event.

Disclosure information can be viewed on the congress website under the CME information pages.

Introduction to the scientific programme

Educational Workshops

At the beginning of ECCMID, on Saturday morning, 9 April 2016, from 08:45 – 13:00 a series of Educational Workshops will take place. They are organized in cooperation with ESCMID Study Groups, the Trainee Association of ESCMID and partnering organizations. Participation in Educational Workshops is free of charge and corresponding educational material is available online on the congress website. Some of the Educational Workshops decided for an interactive session set-up which includes a Q&A system via mobile devices.

Meet-the-Expert Sessions

Sunday through Tuesday, the day will start at 08:00 with Meet-the-Expert Sessions led by experts in their fields. These sessions depend on active participation of the audience. After a short presentation, the expert will open the session for discussion. Coffee will be offered.

TAE Trainees Day

On Saturday, 9 April 2016, 13.00 – 16.45 the Trainee Association of ESCMID (TAE) organizes the European Trainees Day, a day of dedicated to the unique needs of trainees. For this year’s TAE Trainees Day at ECCMID, the Trainee Association of ESCMID (TAE) will repeat the brand-new and exciting format which is called "everything you always wanted to discuss directly with an expert". Two sessions with 10 round tables each will be hosted in total by 20 renowned experts with different profiles in the fields of clinical microbiology and infectious diseases.

When: Saturday, 9 April 2016, 13:00 – 16:45, E104/105

Keynote and Award Lectures

Sunday through Tuesday at 11:30 and 14:30, lectures of 60 minutes will be given by opinion leaders in their fields as well as by the winner of the ESCMID Excellence Award 2016.

Symposia

On Saturday between 08:45 – 13:00 and from 13:30 – 18:30 and on Sunday and Monday from 09:00 – 12:30 and from 14:30 – 18:00, parallel symposia will convene renowned speakers from Europe and other continents who will cover a wide range of recent developments in their fields. On Tuesday, the last round of symposia takes place from 13:30 – 15:30. A number of symposia are arranged in cooperation with ESCMID Study Groups, while others are jointly organized with partnering societies or organizations.

Symposia arranged by the industry are organized in close cooperation with the ECCMID Programme Committee. For details please see the Integrated Symposia and Exhibition Guide.

Oral Sessions

During the same time slots as the before mentioned symposia, you will also find sessions composed of abstracts selected for oral presentation, which are indicated by the prefix "O" in front of the programme numbers. The presenting author is indicated with an asterisk (*).

ePoster Presentations

Selected ePosters have been scheduled for ePoster presentation from 9 April – 12 April 2016 in parallel to the Poster Sessions. ePoster Presenters must be present at the indicated ePoster Area for presentation and discussion. The presenting author is indicated by an asterisk (*). The ePoster Presentations will be moderated by an expert assigned by the Programme Committee.

Poster Sessions

Most of the accepted abstracts are scheduled for poster presentation from Saturday through Tuesday. The selection is based on a blind review by at least three experts in each field. The posters are displayed in the Poster Area. The poster area is open to all participants on Saturday from 12.00 – 18.30, on Sunday and Monday from 09.00 – 17.30 and on Tuesday from 09:00 – 15:00. Please note that posters are exchanged on a daily basis. Poster authors must be present at their posters for discussion during their poster session (see page 98 for details). The presenting author is indicated by an asterisk (*).

ePoster Viewing

ePosters have been divided in categories, which will be displayed all 4 congress days on 50 ePoster stations within the Bella Center, on the mobile website and application of the congress. The new ePoster format will give participants the possibility to interact with presenters and send the ePoster by email [see page 194]. The presenting author is indicated by an asterisk (*).
## ESCMID Study Group and other Meetings

**Saturday, 9 April 2016**

<table>
<thead>
<tr>
<th>TIME</th>
<th>LOCATION</th>
<th>MEETING NAME</th>
</tr>
</thead>
<tbody>
<tr>
<td>16.00</td>
<td>G101</td>
<td>ESGIE Meeting</td>
</tr>
<tr>
<td>16.45</td>
<td>E101</td>
<td>Young Scientists Reception</td>
</tr>
<tr>
<td>18.00</td>
<td>G106</td>
<td>EUCAST AFST General Committee Meeting</td>
</tr>
</tbody>
</table>

**Sunday, 10 April 2016**

<table>
<thead>
<tr>
<th>TIME</th>
<th>LOCATION</th>
<th>MEETING NAME</th>
</tr>
</thead>
<tbody>
<tr>
<td>11.30</td>
<td>G105</td>
<td>ESGIB Meeting</td>
</tr>
<tr>
<td>12.00</td>
<td>G104</td>
<td>EUCAST AST Subcommittee Meeting</td>
</tr>
<tr>
<td>12.30</td>
<td>E102</td>
<td>ESGIP Meeting</td>
</tr>
<tr>
<td>13.15</td>
<td>G109</td>
<td>EFISG Meeting</td>
</tr>
<tr>
<td>13.15</td>
<td>G107</td>
<td>ESGARS Meeting</td>
</tr>
<tr>
<td>13.15</td>
<td>E104/105</td>
<td>ESGBIS Meeting</td>
</tr>
<tr>
<td>13.15</td>
<td>E106/107</td>
<td>ESGIAI Meeting</td>
</tr>
<tr>
<td>13.15</td>
<td>G111</td>
<td>ESMD Meeting</td>
</tr>
<tr>
<td>13.15</td>
<td>108</td>
<td>ESGNI Meeting</td>
</tr>
<tr>
<td>13.15</td>
<td>G110</td>
<td>ESGVH Meeting</td>
</tr>
<tr>
<td>13.15</td>
<td>G106</td>
<td>ESGVM Meeting</td>
</tr>
<tr>
<td>13.15</td>
<td>Amsterdam Suite</td>
<td>EVASG Meeting</td>
</tr>
<tr>
<td>14.15</td>
<td>E104/105</td>
<td>ESGBIS - ISAC Meeting</td>
</tr>
<tr>
<td>14.45</td>
<td>G104</td>
<td>ESGAI Meeting</td>
</tr>
<tr>
<td>15.45</td>
<td>G104</td>
<td>ESGAI - ENRIA Meeting</td>
</tr>
<tr>
<td>15.45</td>
<td>G111</td>
<td>EUCAST Subcommittee on mycobacterial susceptibility testing</td>
</tr>
<tr>
<td>16.30</td>
<td>E106/107</td>
<td>EUCIC Meeting</td>
</tr>
<tr>
<td>18.15</td>
<td>G111</td>
<td>EFWISG Meeting</td>
</tr>
<tr>
<td>18.15</td>
<td>G104</td>
<td>ESGAP Meeting</td>
</tr>
<tr>
<td>18.15</td>
<td>G106</td>
<td>ESGCD Meeting</td>
</tr>
<tr>
<td>18.15</td>
<td>G109</td>
<td>ESGICH Meeting</td>
</tr>
<tr>
<td>18.15</td>
<td>108</td>
<td>ESGITM Meeting</td>
</tr>
<tr>
<td>18.15</td>
<td>Amsterdam Suite</td>
<td>ESGLI Meeting</td>
</tr>
<tr>
<td>18.15</td>
<td>G101</td>
<td>ESGMI Meeting</td>
</tr>
<tr>
<td>18.15</td>
<td>G105</td>
<td>ESGS Meeting</td>
</tr>
</tbody>
</table>

**Monday, 11 April 2016**

<table>
<thead>
<tr>
<th>TIME</th>
<th>LOCATION</th>
<th>MEETING NAME</th>
</tr>
</thead>
<tbody>
<tr>
<td>8.00</td>
<td>G111</td>
<td>ESGCIP NebAT Guideline Project Meeting</td>
</tr>
<tr>
<td>8.30</td>
<td>G104</td>
<td>CAESAR Meeting</td>
</tr>
<tr>
<td>12.30</td>
<td>G107</td>
<td>ESGAP Student-PREPARE Survey Meeting</td>
</tr>
<tr>
<td>13.00</td>
<td>G109</td>
<td>EUCAST General Committee Meeting</td>
</tr>
<tr>
<td>13.15</td>
<td>E106/107</td>
<td>EPASG Meeting</td>
</tr>
<tr>
<td>13.15</td>
<td>G101</td>
<td>ESGB Meeting</td>
</tr>
<tr>
<td>13.15</td>
<td>G104</td>
<td>ESGBOR Meeting</td>
</tr>
<tr>
<td>13.15</td>
<td>G105</td>
<td>ESGCP Meeting</td>
</tr>
<tr>
<td>13.15</td>
<td>G106</td>
<td>ESGEM Meeting</td>
</tr>
<tr>
<td>13.15</td>
<td>E101</td>
<td>ESGMYC Meeting</td>
</tr>
<tr>
<td>14.15</td>
<td>G105</td>
<td>ESGCP Meeting Leishmania Subgroup</td>
</tr>
<tr>
<td>14.30</td>
<td>G106</td>
<td>ESGFOR Meeting</td>
</tr>
<tr>
<td>16.30</td>
<td>G104</td>
<td>ESCMID Council Meeting</td>
</tr>
<tr>
<td>17.00</td>
<td>G109</td>
<td>VetCAST Meeting [open]</td>
</tr>
<tr>
<td>18.30</td>
<td>G105</td>
<td>ESCMID General Assembly</td>
</tr>
</tbody>
</table>

*If you cannot find the meeting you are looking for, contact our staff at the ESCMID World!*
Sessions jointly organized with ESCMID Study Groups and partnering organizations

American Society for Clinical Microbiology (ASM)
2-hour Symposium
SY146: Genetics of infectious diseases in the era of precision medicine
Hall D, 12 April 2016, 13.30 h - 15.30 h

Anaerobe Society for Americas (ASA)
2-hour Educational Workshop
EW017: Anaerobes and the human microbiome
Hall H, 9 April 2016, 11.00 h - 13.00 h

China International Medical Foundation (CIMF), Sino-European Anti-Infection & Clinical Microbiology Scientific Alliance
2-hour Symposium
SY028: Acinetobacter infections from east to west
E102, 9 April 2016, 13.30 h - 15.30 h
2-hour Educational Workshop
EW021: Challenges in invasive fungal disease
E102, 9 April 2016, 11.00 h - 13.00 h

Meet-the-Expert Session
ME011: Neglected tropical skin and soft tissue fungal infections
E102, 9 April 2016, 9.30 h - 10.30 h

ESCMID Food- and Water-borne Infections Study Group (EFWISG)
2-hour Symposium
SY118: Hidden enemy: hepatitis E
Hall G, 11 April 2016, 16.00 h - 18.00 h

ESCMID Fungal Infection Study Group (EFISG)
2-hour Symposium
SY048: Approaches to individualized management of invasive fungal disease
Hall J, 10 April 2016, 9.00 h - 11.00 h
1-hour Symposium
SY059: Recent top papers in mycology
Hall K, 10 April 2016, 11.30 h - 12.30 h

Keynote Lecture
KL069: The fungal microbiome and human health
Hall J, 10 April 2016, 14.30 h - 15.30 h

Meet-the-Expert Session
ME083: Antifungal stewardship: do we need it in our hospitals?
E104/105, 11 April 2016, 7.45 h - 8.45 h

ESCMID PK/PD of Anti-Infectives Study Group (EPASG)
2-hour Educational Workshop
EW009: Translating PK/PD concepts into the clinics
Hall J, 9 April 2016, 8.45 h - 10.45 h

1-hour Symposium
SY065: CNS distribution of antimicrobial agents revisited
Hall F, 10 April 2016, 14.30 h - 15.30 h

ESCMID Study Group for Anaerobic Infections (ESGAI)
2-hour Educational Workshop
EW017: Anaerobes and the human microbiome
Hall H, 9 April 2016, 11.00 h - 13.00 h

ESCMID Study Group for Antibiotic Policies (ESGAP)
2-hour Educational Workshop
EW019: How to treat patients with Gram-negative infections in high-level resistance settings
Hall J, 9 April 2016, 11.00 h - 13.00 h

2-hour Educational Workshop
EW016: Undergraduate and postgraduate training and assessments in the infection field - a European discussion
Hall F, 9 April 2016, 11.00 h - 13.00 h

1-hour Symposium
SY053: Prevention and management of bloodstream infections: from here to where?
Hall E, 10 April 2016, 11.30 h - 12.30 h

1-hour Symposium
SY091: Affordable healthcare
Hall K, 11 April 2016, 9.00 h - 11.00 h

2-hour Symposium
SY111: Antibiotic de-escalation (Pro-Con debate)
Hall I, 11 April 2016, 14.30 h - 15.30 h

ESCMID Study Group for Antimicrobial Resistance Surveillance (ESGARS)
Meet-the-Expert Session
ME038: Genotypic and phenotypic detection of colistin resistance in Gram-negative bacilli
Hall H, 10 April 2016, 7.45 h - 8.45 h
2-hour Symposium
SY045: Multidrug- and extremely drug-resistant Gram-negative bacilli: the storm is here
Hall G, 10 April 2016, 9.00 h - 11.00 h

ESCMID Study Group for Biofilms (ESGB)
2-hour Symposium
SY130: Combatting biofilm infections: from basic research to clinical practice
Hall E, 12 April 2016, 9.00 h - 11.00 h
ESCMID Study Group for Bloodstream Infections and Sepsis (ESGBIS)
2-hour Educational Workshop
EW015: Contemporary trial methods in clinical effectiveness research
Hall E, 9 April 2016, 11.00 h - 13.00 h

1-hour Symposium
SY053: Prevention and management of bloodstream infections: from here to where?
Hall E, 10 April 2016, 11.30 h - 12.30 h

2-hour Symposium
SY133: Splenic function and infection
Hall K, 12 April 2016, 9.00 h - 11.00 h

2-hour Symposium
SY147: Understanding host-bacterial interactions - getting by with a little help from our friends
Hall E, 12 April 2016, 13.30 h - 15.30 h

ESCMID Study Group for Clinical Parasitology (ESGCP)
2-hour Educational Workshop
EW003: Diagnosis of intestinal protozoan infections: the best way to go
Hall C, 9 April 2016, 8.45 h - 10.45 h

2-hour Symposium
SY131: Tricky points in zoonotic diseases
Hall I, 12 April 2016, 9.00 h - 11.00 h

1-hour Symposium
SY141: Ancient pathogens: paleosciences
Hall I, 12 April 2016, 11.30 h - 12.30 h

2-hour Symposium
SY150: Antiparasitic drugs: good news and bad news
Hall I, 12 April 2016, 13.30 h - 15.30 h

ESCMID Study Group for Clostridium difficile (ESGCD)
2-hour Symposium
SY073: Clostridium difficile infections from East to West
Hall D, 9 April 2016, 16.00 h - 18.00 h

ESCMID Study Group for Critically Ill Patients (ESGCIP)
2-hour Educational Workshop
EW010: Learning from ESCMID clinical practice guidelines: practical aspects of antibiotic nebulization in patients with respiratory infections
nebulization in patients with respiratory infections
Hall K, 9 April 2016, 8.45 h - 10.45 h

ESCMID Study Group for Epidemiological Markers (ESGEM)
2-hour Educational Workshop
EW014: Plasmids without frontiers: mechanisms related to MDR and implications for epidemiology and infection control
Hall D, 9 April 2016, 11.00 h - 13.00 h

2-hour Symposium
SY032: Harnessing whole genome sequence data for public health applications
Hall F, 9 April 2016, 16.30 h - 18.30 h

ESCMID Study Group for Forensic and Postmortem Microbiology (ESGFOR)
1-hour Symposium
SY093: Infectious causes of sudden and unexpected deaths
Hall B, 11 April 2016, 11.30 h - 12.30 h

1-hour Symposium
SY141: Ancient pathogens: paleosciences
Hall I, 12 April 2016, 11.30 h - 12.30 h

ESCMID Study Group for Implant-associated Infections (ESGIAI)
2-hour Symposium
SY152: Update in diagnosis and clinical management of implant-associated infections
Hall K, 12 April 2016, 13.30 h - 15.30 h

ESCMID Study Group for Infections in Compromised Hosts (ESGICH)
2-hour Educational Workshop
EW008: Infection prevention in transplant recipients
Hall I, 9 April 2016, 8.45 h - 10.45 h

ESCMID Study Group for Infections in the Elderly (ESGIE)
2-hour Educational Workshop
EW015: Contemporary trial methods in clinical effectiveness research
Hall E, 9 April 2016, 11.00 h - 13.00 h

2-hour Educational Workshop
EW018: Update on vaccines and vaccination
Hall I, 9 April 2016, 11.00 h - 13.00 h

2-hour Symposium
SY025: Immunity and vaccination in advanced age
Hall I, 9 April 2016, 13.30 h - 15.30 h

ESCMID Study Group for Infections in Travellers and Migrants (ESGITM)
2-hour Educational Workshop
EW013: Skin infections in travellers and migrants
Hall C, 9 April 2016, 11.00 h - 13.00 h

2-hour Symposium
SY023: Mycobacteria in migrants
Hall C, 9 April 2016, 13.30 h - 15.30 h
ESCMID Study Group for Infectious Diseases of the Brain (ESGIB)
2-hour Educational Workshop
EW002: Emerging viral diseases with neurological presentation
Hall B, 9 April 2016, 8.45 h - 10.45 h

2-hour Educational Workshop
EW020: ESCMID guideline for the diagnosis and treatment of community-acquired bacterial meningitis
Hall K, 9 April 2016, 11.00 h - 13.00 h

1-hour Symposium
SY065: CNS distribution of antimicrobial agents revisited
Hall F, 10 April 2016, 14.30 h - 15.30 h

Meet-the-Expert Session
ME082: How to manage brain abscess
E102, 11 April 2016, 7.45 h - 8.45 h

ESCMID Study Group for Molecular Diagnostics (ESGMD)
2-hour Educational Workshop
EW003: Diagnosis of intestinal protozoan infections: the best way to go
Hall C, 9 April 2016, 8.45 h - 10.45 h

2-hour Educational Workshop
EW014: Plasmids without frontiers: mechanisms related to MDR and implications for epidemiology and infection control
Hall D, 9 April 2016, 11.00 h - 13.00 h

Meet-the-Expert Session
ME079: How to diagnose and treat infections due to Mycoplasma genitalium and other emerging sexually transmitted pathogens
Hall D, 11 April 2016, 7.45 h - 8.45 h

ESCMID Study Group for Mycobacterial Infections (ESGMYC)
2-hour Educational Workshop
EW007: Emergent mycobacterial infections
Hall H, 9 April 2016, 8.45 h - 10.45 h

2-hour Symposium
SY023: Mycobacteria in migrants
Hall C, 9 April 2016, 13.30 h - 15.30 h

ESCMID Study Group for Mycoplasma Infections (ESGMI)
Meet-the-Expert Session
ME079: How to diagnose and treat infections due to Mycoplasma genitalium and other emerging sexually transmitted pathogens
Hall D, 11 April 2016, 7.45 h - 8.45 h

ESCMID Study Group for Nosocomial Infections (ESGNI)
4-hour Educational Workshop
EW006: Compendium of strategies to prevent healthcare-associated infections
Hall G, 9 April 2016, 8.45 h - 12.45 h

2-hour Educational Workshop
EW016: Undergraduate and postgraduate training and assessments in the infection field - a European discussion
Hall F, 9 April 2016, 11.00 h - 13.00 h

2-hour Educational Workshop
EW019: How to treat patients with Gram-negative infections in high-level resistance settings
Hall J, 9 April 2016, 11.00 h - 13.00 h

1-hour Symposium
SY053: Prevention and management of bloodstream infections: from here to where?
Hall E, 10 April 2016, 11.30 h - 12.30 h

Meet-the-Expert Session
ME125: Reprocessing endoscopes and DaVinci instruments: new sources for the spread of resistant Gram-negatives
Hall H, 12 April 2016, 7.45 h - 8.45 h

2-hour Symposium
SY143: The hospital in the era of antimicrobial resistance and infection control performance measures
Hall A, 12 April 2016, 13.30 h - 15.30 h

ESCMID Study Group for Staphylococci and Staphylococcal Diseases (ESGS)
2-hour Symposium
SY024: Controversies in interpreting whole genome sequence data
Hall F, 9 April 2016, 13.30 h - 15.30 h

ESCMID Study Group for Veterinary Microbiology (ESGVM)
2-hour Educational Workshop
EW014: Plasmids without frontiers: mechanisms related to MDR and implications for epidemiology and infection control
Hall D, 9 April 2016, 11.00 h - 13.00 h

ESCMID Study Group for Viral Hepatitis (ESGVH)
2-hour Symposium
SY088: What is still hot in hepatitis C?
Hall G, 11 April 2016, 9.00 h - 11.00 h

2-hour Symposium
SY091: Affordable healthcare
Hall K, 11 April 2016, 9.00 h - 11.00 h

1-hour Symposium
SY098: Hot topics in hepatitis B prevention and treatment
Hall G, 11 April 2016, 11.30 h - 12.30 h

ESCMID Vaccine Study Group (EVASG)
2-hour Educational Workshop
EW018: Update on vaccines and vaccination
Hall I, 9 April 2016, 11.00 h - 13.00 h
2-hour Symposium
SY025: Immunity and vaccination in advanced age
Hall I, 9 April 2016, 13.30 h - 15.30 h

2-hour Symposium
SY130: Combating biofilm infections: from basic research to clinical practice
Hall E, 12 April 2016, 9.00 h - 11.00 h

1-hour Symposium
SY142: Recent top papers in paediatric infectious diseases
Hall K, 12 April 2016, 11.30 h - 12.30 h

European AIDS Clinical Society (EACS)
2-hour Symposium
SY044: Evolving practice in HIV care: news that matter the most
Hall F, 10 April 2016, 9.00 h - 11.00 h

European Centre for Disease Prevention and Control (ECDC)
2-hour Symposium
SY032: Harnessing whole genome sequence data for public health applications
Hall F, 9 April 2016, 16.30 h - 18.30 h

2-hour Symposium
SY086: Is pertussis here to stay?
Hall D, 11 April 2016, 9.00 h - 11.00 h

1-hour Symposium
SY105: Redefining HPV vaccination programmes in the EU
Hall C, 11 April 2016, 14.30 h - 15.30 h

2-hour Symposium
SY132: Screening of infectious diseases among migrant populations: challenges and opportunities
Hall J, 12 April 2016, 9.00 h - 11.00 h

European Commission
Meet-the-Expert Session
ME078: Antimicrobial resistance research, supported by funding from the EU and the US NIH/NIAID
Hall C, 11 April 2016, 7.45 h - 8.45 h

European Committee on Infection Control (EUCIC)
4-hour Educational Workshop
EW006: Compendium of strategies to prevent healthcare-associated infections
Hall G, 9 April 2016, 8.45 h - 12.45 h

1-hour Symposium
SY066: Do we have efficient decolonization regimens for MDR Gram-negatives?
Hall G, 10 April 2016, 14.30 h - 15.30 h

Meet-the-Expert Session
ME125: Reprocessing endoscopes and DaVinci instruments: new sources for the spread of resistant Gram-negatives
Hall H, 12 April 2016, 7.45 h - 8.45 h

Meet-the-Expert Session
ME123: Controversies about controlling VRE - possible or impossible?
Hall D, 12 April 2016, 7.45 h - 8.45 h

Meet-the-Expert Session
ME124: Chlorhexidine bathing in critically ill patients
Hall F, 12 April 2016, 7.45 h - 8.45 h

2-hour Symposium
SY143: The hospital in the era of antimicrobial resistance and infection control performance measures
Hall A, 12 April 2016, 13.30 h - 15.30 h

French Infectious Diseases Society (SPILF)
2-hour Symposium
SY033: Challenging complex infections for ID physicians
Hall J, 9 April 2016, 16.30 h - 18.30 h

Infectious Diseases Society of America (IDSA)
2-hour Symposium
SY127: Clinical Grand Rounds
Hall A, 12 April 2016, 9.00 h - 11.00 h

International Immunocompromised Host Society (ICHS)
2-hour Educational Workshop
EW008: Infection prevention in transplant recipients
Hall I, 9 April 2016, 8.45 h - 10.45 h

2-hour Symposium
SY048: Approaches to individualized management of invasive fungal disease
Hall J, 10 April 2016, 9.00 h - 11.00 h

International Sepsis Forum (ISF)
2-hour Symposium
SY022: Sepsis: moving the field forward
Hall A, 9 April 2016, 13.30 h - 15.30 h
International Society for Infectious Diseases and its Program for Monitoring Emerging Diseases (ISID/ProMed)
2-hour Symposium
SY090: Drivers of infectious disease emergence
Hall J, 11 April 2016, 9.00 h - 11.00 h

1-hour Symposium
SY109: MERS update
Hall G, 11 April 2016, 14.30 h - 15.30 h

Médecins Sans Frontières (MSF)
2-hour Symposium
SY114: Challenging AMR in low-resource settings
Hall A, 11 April 2016, 16.00 h - 18.00 h

Panamerican Association of Infectious Diseases (API)
2-hour Symposium
SY131: Tricky points in zoonotic diseases
Hall I, 12 April 2016, 9.00 h - 11.00 h

Paul-Ehrlich Society for Chemotherapy (PEG)
Keynote Lecture
KL138: Microbiota transplantation
Hall E, 12 April 2016, 11.30 h - 12.30 h

PREPARE project
2-hour Educational Workshop
EW005: Preparing interpandemic research trials in Europe
Hall E, 9 April 2016, 8.45 h - 10.45 h

Royal College of Pathologists (UK)
2-hour Symposium
SY152: Update in diagnosis and clinical management of implant-associated infections
Hall K, 12 April 2016, 13.30 h - 15.30 h

The European Union of Medical Specialists (UEMS)
2-hour Educational Workshop
EW016: Undergraduate and postgraduate training and assessments in the infection field - a European discussion
Hall F, 9 April 2016, 11.00 h - 13.00 h

Trainee Association of ESCMID (TAE)
2-hour Educational Workshop
EW016: Undergraduate and postgraduate training and assessments in the infection field - a European discussion
Hall F, 9 April 2016, 11.00 h - 13.00 h

2-hour Symposium
SY091: Affordable healthcare
Hall K, 11 April 2016, 9.00 h - 11.00 h

Turkish Clinical Microbiology Society (KLIIMUD)
2-hour Symposium
SY090: Drivers of infectious disease emergence
Hall J, 11 April 2016, 9.00 h - 11.00 h

Turkish Society of Clinical Microbiology and Infectious Diseases (KLIIMIK)
Meet-the-Expert Session
ME035: Management of diabetic foot infections: what is new in guidelines?
Hall C, 10 April 2016, 7.45 h - 8.45 h

Meet-the-Expert Session
ME037: HIV/AIDS: late presenters in Europe
Hall F, 10 April 2016, 7.45 h - 8.45 h

2-hour Symposium
SY151: Dengue and dengue haemorrhagic fever, 2016
Hall J, 12 April 2016, 13.30 h - 15.30 h

United States National Institute of Allergy and Infectious Diseases (US NIAID)
Meet-the-Expert Session
MED78: Antimicrobial resistance research, supported by funding from the EU and the US NIH/NIAID
Hall C, 11 April 2016, 7.45 h - 8.45 h

World Health Organization, Regional Office for Europe (WHO-Europe)
2-hour Symposium
SY114: Challenging AMR in low-resource settings
Hall A, 11 April 2016, 16.00 h - 18.00 h
## Scientific Programme

### Overview

**Saturday, 9 April 2016**

<table>
<thead>
<tr>
<th>Time</th>
<th>Hall A</th>
<th>Hall B</th>
<th>Hall C</th>
<th>Hall D</th>
<th>Hall E</th>
<th>Hall F</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>08.45 - 12.45</strong></td>
<td>Antimicrobial susceptibility testing with EUCAST breakpoints and methods</td>
<td>Emerging viral diseases with neurological presentation</td>
<td>Diagnosis of intestinal protozoan infections: the best way to go</td>
<td>Bacterial infections in specific patient populations: an update for the infectious diseases consultant</td>
<td>Preparing interpan-demic research trials in Europe</td>
<td></td>
</tr>
<tr>
<td><strong>11.00 - 13.00</strong></td>
<td>Congenital and neonatal infections</td>
<td>Skin infections in travellers and migrants</td>
<td>Plasmids without frontiers: mechanisms related to MDR and implications for epidemiology and infection control</td>
<td>Contemporary trial methods in clinical effectiveness research</td>
<td>Undergraduate and postgraduate training and assessments in the infection field - a European discussion</td>
<td></td>
</tr>
<tr>
<td><strong>13.00 - 13.30</strong></td>
<td>Lunch Break</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>13.30 - 15.30</strong></td>
<td>Sepsis: moving the field forward</td>
<td>Mycobacteria in migrants</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>15.30 - 16.30</strong></td>
<td>State-of-the-art transplantation and clinical virology</td>
<td>Fungal diagnostics</td>
<td></td>
<td>Emerging viruses: what about &quot;Tick&quot;, &quot;Chik&quot; and &quot;Zik&quot;?</td>
<td>Harnessing whole genome sequence data</td>
<td></td>
</tr>
<tr>
<td><strong>19.00</strong></td>
<td>Opening Ceremony followed by Networking Reception</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hall G</td>
<td>Hall H</td>
<td>Hall I</td>
<td>Hall J</td>
<td>Hall K</td>
<td>E 102</td>
<td></td>
</tr>
<tr>
<td>-------</td>
<td>-------</td>
<td>-------</td>
<td>-------</td>
<td>-------</td>
<td>-------</td>
<td></td>
</tr>
<tr>
<td>08.45 – 12.45</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11.00 – 13.00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Anaerobes and the human microbiome</td>
<td>Update on vaccines and vaccination</td>
<td>How to treat patients with Gram-negative infections in high-level resistance settings</td>
<td>ESCMID guideline for the diagnosis and treatment of community-acquired bacterial meningitis</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>13.00 – 13.30 Lunch Break</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>13.30 – 15.30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Late Breaker session: Colistin resistance</td>
<td>Immunity and vaccination in advanced age</td>
<td>MDR Enterobacteriaceae: clinical epidemiology and outcomes</td>
<td>Approaches to individualized therapy in an era of bacterial multidrug resistance</td>
<td>Acinetobacter infections from east to west</td>
<td></td>
<td></td>
</tr>
<tr>
<td>15.30- 16.30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ePoster Sessions, Poster Sessions from Abstracts</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>16.30 – 18.30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Late Breaker session: Refugee and migrant health</td>
<td>Challenging complex infections for ID physicians</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>19.00 Opening Ceremony followed by Networking Reception</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Saturday, 9 April 2016

EW001 08:45-13:00 Hall A
4-hour Educational Workshop

Antimicrobial susceptibility testing with EUCAST breakpoints and methods

Chairs: Rafael Canton Moreno (Madrid, Spain)
       Alasdair P. MacGowan (Bristol, United Kingdom)

08:45 Introduction
Rafael Canton Moreno (Madrid, Spain)

08:55 Recent developments in EUCAST
Rafael Canton Moreno (Madrid, Spain)

09:15 Revision of breakpoints for major antimicrobial groups
Christian G. Giske (Stockholm, Sweden)

09:35 What does "intermediate" really mean?
Gunnar Kahlmeter (Växjö, Sweden)

09:55 VetCAST - antimicrobial breakpoints for veterinary use
Dik Johan Mevius (Lelystad, Netherlands)

10:45 Coffee break

10:15 Moderated panel discussion on questions from the audience
Alasdair P. MacGowan (Bristol, United Kingdom)

11:15 Issues and challenges in implementation of EUCAST breakpoints and methods
Arjana Tambic Andrasevic (Zagreb, Croatia)

11:35 Revised expert rules for antimicrobial susceptibility testing
Sören G. Gatermann (Bochum, Germany)

11:55 Whole genome sequencing and antimicrobial susceptibility testing
Neil Woodford (London, United Kingdom)

12:15 Moderated panel discussion on questions from the audience
Alasdair P. MacGowan (Bristol, United Kingdom)

EW002 08:45-10:45 Hall B
2-hour Educational Workshop

Emerging viral diseases with neurological presentation

Chairs: Alexandra Mailles [Saint-Maurice, France]
        Hakon Erdem [Istanbul, Turkey]

08:45 Borna virus encephalitis: an example of emerging infection revealed by a neurological presentation
Dennis Tappe (Hamburg, Germany)

09:15 Diagnostic challenges and management of herpesvirus encephalitis
Haluk Vahaboglu (Istanbul, Turkey)

EW003 08:45-10:45 Hall C
2-hour Educational Workshop

Diagnosis of intestinal protozoan infections: the best way to go

Chairs: Silvio Vega [Panama City, Panama]
       Titia M. Kortbeek [Bilthoven, Netherlands]

08:45 Classical methods for the detection of protozoal infections in routine clinical practice
Marjan van Esbroeck (Antwerp, Belgium)

09:25 Detection of protozoans using molecular techniques in routine clinical practice
Christen Rune Stensvold [Copenhagen, Denmark]

10:05 Proficiency tests in parasitology: experiences with the Dutch QC scheme on molecular detection of gastro-intestinal parasites
Jaap van Hellemond [Rotterdam, Netherlands]

EW004 08:45-10:45 Hall D
2-hour Educational Workshop

Bacterial infections in specific patient populations: an update for the infectious diseases consultant

Chairs: Elisa Cordero Matias [Seville, Spain]
       Maria Adriana Cataldo [Rome, Italy]

08:45 Haemodialysis
Lul Raka [Prishtina, Kosovo]

09:15 Liver cirrhosis
Pierluigi Viale [Bologna, Italy]

09:45 Severely immunodepressed patients
Elisa Cordero Matias [Seville, Spain]

10:15 Interactive panel discussion with the workshop faculty: answering a selection of questions sent by interested participants before the meeting

EW005 08:45-10:45 Hall E
2-hour Educational Workshop

Antimicrobial susceptibility testing with EUCAST breakpoints and methods

Chairs: Rafael Canton Moreno (Madrid, Spain)
       Alasdair P. MacGowan (Bristol, United Kingdom)

08:45 Introduction
Rafael Canton Moreno (Madrid, Spain)

08:55 Recent developments in EUCAST
Rafael Canton Moreno (Madrid, Spain)

09:15 Revision of breakpoints for major antimicrobial groups
Christian G. Giske (Stockholm, Sweden)

09:35 What does "intermediate" really mean?
Gunnar Kahlmeter (Växjö, Sweden)

09:55 VetCAST - antimicrobial breakpoints for veterinary use
Dik Johan Mevius (Lelystad, Netherlands)

10:45 Coffee break

10:15 Moderated panel discussion on questions from the audience
Alasdair P. MacGowan (Bristol, United Kingdom)

11:15 Issues and challenges in implementation of EUCAST breakpoints and methods
Arjana Tambic Andrasevic (Zagreb, Croatia)

11:35 Revised expert rules for antimicrobial susceptibility testing
Sören G. Gatermann (Bochum, Germany)

11:55 Whole genome sequencing and antimicrobial susceptibility testing
Neil Woodford (London, United Kingdom)

12:15 Moderated panel discussion on questions from the audience
Alasdair P. MacGowan (Bristol, United Kingdom)
EW005 08:45-10:45  Hall E
2-hour Educational Workshop

Preparin inter-pandemic research trials in Europe
Chairs: Julia Bielicki (Basel, Switzerland)
Herman Goossens (Edegem, Belgium)
Line Matthiessen (Brussels, Belgium)

E022  08:45  Arbovirus infections in Europe - burden, outbreak laboratory support and diagnostics
Chantal B.E.M. Reusken (Rotterdam, Netherlands)

E023  09:15  Outbreak research in paediatric settings – undifferentiated fever in children
Julia Bielicki (Basel, Switzerland)

E024  09:45  Establishing the pathogenesis of acute respiratory infections
Jarrit Hofstra (Amsterdam, Netherlands)

E025  10:15  Interactive panel discussion with the workshop faculty: answering a selection of questions sent by interested participants before the meeting

EW006 08:45-13:00  Hall G
4-hour Educational Workshop

Compendium of strategies to prevent healthcare-associated infections
Chairs: Petra Gastmeier (Berlin, Germany)
Eva Melander (Malmö, Sweden)

08:45  Introduction

E026  08:55  Different bundles to prevent infection due to Gram-positive and Gram-negative MDR bacteria?
Evelina Tacconelli (Tübingen, Germany)

E027  09:20  MDR screening for isolation and decolonization
Stephan Harbarth (Geneva, Switzerland)

E028  09:45  Air in the operating room: back to the future?
Jean-Christophe Lucet (Paris, France)

E029  10:10  Ways to improve antibiotic surgical prophylaxis
Nicola Petrosillo (Rome, Italy)

10:35  Coffee break

E030  10:55  Prevention of ventilator-associated pneumonia
Anastasia Antoniadou (Athens, Greece)

E031  11:20  Essentials to reduce cross-border MRSA spreading
Alexander W. Friedrich (Groningen, Netherlands)

E032  11:45  Single rooms and private toilets as a standard of care
Marjolein Kluytmans - van den Bergh (Breda, Netherlands)

E033  12:10  Interactive panel discussion with the workshop faculty: answering a selection of questions sent by interested participants before the meeting

EW007 08:45-10:45  Hall H
2-hour Educational Workshop

Emergent mycobacterial infections
Chairs: Emmanuelle Cambau (Paris, France)
Martina Sester (Homburg, Germany)

E034  08:45  The challenges of MDR and XDR TB diagnosis
Miguel Viveiros (Lisbon, Portugal)

E035  09:15  The enigma of M. abscessus infection
Emmanuelle Cambau (Paris, France)

E036  09:45  M. chimaera: the new epidemic mycobacterial species
Jakko Van Ingen (Nijmegen, Netherlands)

E037  10:15  Interactive panel discussion with the workshop faculty: answering a selection of questions sent by interested participants before the meeting

EW008 08:45-10:45  Hall I
2-hour Educational Workshop

Infection prevention in transplant recipients
Chairs: Dimitrios P. Kontoyiannis (Houston, United States)
Jose Maria Aguado Garcia (Madrid, Spain)

E038  08:45  Prevention of infection in paediatric solid-organ transplant recipients
Maria E. Santolaya (Santiago de Chile, Chile)

E039  09:15  Markers of replication and immunologic responses in the prevention of viral infections in transplant recipients
Hans H. Hirsch (Basel, Switzerland)

E040  09:45  (Re-)Immunization after HSCT and solid organ transplantation
Per Ljungman (Huddinge, Sweden)

E041  10:15  Interactive panel discussion with the workshop faculty: answering a selection of questions sent by interested participants before the meeting
Saturday, 9 April 2016

EW009 08:45-10:45 Hall J
2-hour Educational Workshop
Translating PK/PD concepts into clinics
Chairs: Ursula Theuretzbacher (Vienna, Austria)
Hartmut Derendorf (Gainesville, FL, United States)

<table>
<thead>
<tr>
<th>E042</th>
<th>08:45</th>
<th>Introduction to PK/PD</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Johan Willem Mouton (Rotterdam, Netherlands)</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>E043</th>
<th>09:15</th>
<th>Using PK/PD concepts for treating pneumonia</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Virigina Ramos-Martín (Liverpool, United Kingdom)</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>E044</th>
<th>09:45</th>
<th>Drug-level monitoring and dosing recommendations – facts and myths</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Hartmut Derendorf (Gainesville, FL, United States)</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>E045</th>
<th>10:15</th>
<th>Interactive panel discussion with the workshop faculty: answering a selection of questions sent by interested participants before the meeting</th>
</tr>
</thead>
</table>

EW010 08:45-10:45 Hall K
2-hour Educational Workshop
Learning from ESCMID clinical practice guidelines: practical aspects of antibiotic nebulization in patients with respiratory infections
Chairs: Jordi Rello (Barcelona, Spain)
Garyfallia Poulakou (Athens, Greece)

<table>
<thead>
<tr>
<th>E046</th>
<th>08:45</th>
<th>Formulating recommendations with GRADE: a matter of confidence</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Candela Solé (Barcelona, Spain)</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>E047</th>
<th>09:15</th>
<th>Nebulized antibiotics in patients with COPD or CF: lessons to be learned</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Tobias Welte (Hanover, Germany)</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>E048</th>
<th>09:45</th>
<th>Practical aspects regarding antibiotics to be nebulized</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Garyfallia Poulakou (Athens, Greece)</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>E049</th>
<th>10:15</th>
<th>Interactive panel discussion with the workshop faculty: answering a selection of questions sent by interested participants before the meeting</th>
</tr>
</thead>
</table>

EW012 11:00-13:00 Hall B
2-hour Educational Workshop
Congenital and neonatal infections
Chairs: Susanne Modrow (Regensburg, Germany)
Peter Coyle (Belfast, United Kingdom)

<table>
<thead>
<tr>
<th>E052</th>
<th>11:00</th>
<th>Neonatal herpes simplex virus epidemiology and treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>David Kimberlin (Birmingham, AL, United States)</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>E053</th>
<th>11:30</th>
<th>Cytomegalovirus, are there better treatment options?</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Mike Sharland (London, United Kingdom)</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>E054</th>
<th>12:00</th>
<th>Parvovirus B19: what is the best way to detect and manage cases?</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Susanne Modrow (Regensburg, Germany)</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>E055</th>
<th>12:30</th>
<th>Interactive panel discussion with the workshop faculty: answering a selection of questions sent by interested participants before the meeting</th>
</tr>
</thead>
</table>

EW013 11:00-13:00 Hall C
2-hour Educational Workshop
Skin infections in travellers and migrants
Chairs: Saban Esen (Samsun, Turkey)
TBC

<table>
<thead>
<tr>
<th>E056</th>
<th>11:00</th>
<th>Leprosy</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Diana Lockwood (London, United Kingdom)</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>E057</th>
<th>11:30</th>
<th>Scabies</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Bart Currie (Darwin, Australia)</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>E058</th>
<th>12:00</th>
<th>Leishmaniasis</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Rogelia López-Vélez (Madrid, Spain)</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>E059</th>
<th>12:25</th>
<th>Interactive panel discussion with the workshop faculty: answering a selection of questions sent by interested participants before the meeting</th>
</tr>
</thead>
</table>

EW014 11:00-13:00 Hall D
2-hour Educational Workshop
Plasmids without frontiers: mechanisms related to MDR and implications for epidemiology and infection control
Chairs: Maria Virginia Villegas [Cali, Colombia]
Luca Guardabassi (Basseterre, Saint Kitts and Nevis)

<table>
<thead>
<tr>
<th>E060</th>
<th>11:00</th>
<th>MDR in the food chain - a veterinary, medical and public health issue?</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Alessandra Carattoli (Rome, Italy)</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>E061</th>
<th>11:30</th>
<th>Animal contribution to plasmid-mediated antimicrobial resistance problems in human medicine</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Valeria Bartolai (Copenhagen, Denmark)</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>E062</th>
<th>12:00</th>
<th>Dissemination of resistance genes through specific plasmid lineages - implications for diagnostics, epidemiology and infection control</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Willem van Schaik (Utrecht, Netherlands)</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>E063</th>
<th>12:30</th>
<th>Interactive panel discussion with the workshop faculty: answering a selection of questions sent by interested participants before the meeting</th>
</tr>
</thead>
</table>
EW015 11:00-13:00 Hall E
2-hour Educational Workshop
Contemporary trial methods in clinical effectiveness research

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Title</th>
<th>Chairs</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:00</td>
<td>E064</td>
<td>How biased are observational studies of interventions in infectious diseases?</td>
<td>Jesús Rodríguez-Bañón (Seville, Spain)</td>
</tr>
<tr>
<td>11:30</td>
<td>E065</td>
<td>Regulations, ethics and methods for comparative effectiveness research</td>
<td>Angela Huttner (Geneva, Switzerland)</td>
</tr>
<tr>
<td>12:00</td>
<td>E066</td>
<td>Improving efficiency of randomized controlled trials</td>
<td>Marc J.M. Bonten (Utrecht, Netherlands)</td>
</tr>
<tr>
<td>12:30</td>
<td>E067</td>
<td>An example from the clinics: external validity of trials on sepsis management</td>
<td>Leonard Leibovici (Petah-Tiqva, Israel)</td>
</tr>
</tbody>
</table>

EW016 11:00-13:00 Hall F
2-hour Educational Workshop
Undergraduate and postgraduate training and assessments in the infection field - a European discussion

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Title</th>
<th>Chairs</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:00</td>
<td>E068</td>
<td>Results of the TAE survey of training conditions in Europe</td>
<td>Joana Cortez (Coimbra, Portugal)</td>
</tr>
<tr>
<td>11:20</td>
<td>E069</td>
<td>Final results of the Student-PREPARE survey among European medical students: knowledge and skills for improved antimicrobial prescribing</td>
<td>Oliver James Dyar (Stockholm, Sweden)</td>
</tr>
<tr>
<td>11:40</td>
<td>E070</td>
<td>Update on the European Infectious Diseases curriculum and exam</td>
<td>Nicholas J. Beeching (Liverpool, United Kingdom)</td>
</tr>
<tr>
<td>12:00</td>
<td>E071</td>
<td>Update on the European Medical Microbiology curriculum and exam</td>
<td>Truls Michael Leegaard (Lørenskog, Norway)</td>
</tr>
<tr>
<td>12:20</td>
<td>E072</td>
<td>Infection prevention and control in ID and CM training – how much should there be?</td>
<td>Nico Tom Muters (Heidelberg, Germany)</td>
</tr>
<tr>
<td>12:40</td>
<td>E073</td>
<td>Interactive panel discussion with the workshop faculty: answering a selection of questions sent by interested participants before the meeting</td>
<td></td>
</tr>
</tbody>
</table>

EW017 11:00-13:00 Hall H
2-hour Educational Workshop
Anaerobes and the human microbiome

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Title</th>
<th>Chairs</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:00</td>
<td>E074</td>
<td>An overview of the pathogenesis and resistance of Bacteroides, an invader from the microbiota</td>
<td>Sheila Patrick (Belfast, United Kingdom)</td>
</tr>
</tbody>
</table>

EW018 11:00-13:00 Hall I
2-hour Educational Workshop
Update on vaccines and vaccination

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Title</th>
<th>Chairs</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:00</td>
<td>E075</td>
<td>New concepts in the pathogenesis and treatment of necrotizing clostridial infections</td>
<td>Dennis Stevens (Boise, ID, United States)</td>
</tr>
<tr>
<td>11:30</td>
<td>E076</td>
<td>Leveraging power of whole genome sequence analysis for better understanding the role of anaerobes in the microbiome</td>
<td>Saheer Gharbia (London, United Kingdom)</td>
</tr>
<tr>
<td>11:40</td>
<td>E077</td>
<td>Interactive panel discussion with the workshop faculty: answering a selection of questions sent by interested participants before the meeting</td>
<td></td>
</tr>
</tbody>
</table>

EW019 11:00-13:00 Hall J
2-hour Educational Workshop
How to treat patients with Gram-negative infections in high-level resistance settings

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Title</th>
<th>Chairs</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:00</td>
<td>E078</td>
<td>Vaccines as part of a healthy lifestyle</td>
<td>TBC</td>
</tr>
<tr>
<td>11:30</td>
<td>E079</td>
<td>Immunosenescence: what are the consequences?</td>
<td>Jacques Gaillat (Pringy, France)</td>
</tr>
<tr>
<td>12:00</td>
<td>E080</td>
<td>New vaccines in the immediate pipeline</td>
<td>Susanna Esposito (Milan, Italy)</td>
</tr>
<tr>
<td>12:30</td>
<td>E081</td>
<td>Interactive panel discussion with the workshop faculty: answering a selection of questions sent by interested participants before the meeting</td>
<td></td>
</tr>
</tbody>
</table>

EW020 11:00-13:00 Hall K
2-hour Educational Workshop
How to treat patients with Gram-negative infections in high-level resistance settings

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Title</th>
<th>Chairs</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:00</td>
<td>E082</td>
<td>An outbreak of KPC in an intensive care unit</td>
<td>Diamantis Kafeteridis (Heraklion, Greece)</td>
</tr>
<tr>
<td>11:30</td>
<td>E083</td>
<td>An ESBL-colonized patient with signs of infection in an emergency room</td>
<td>Carolina Navarro-San Francisco (Madrid, Spain)</td>
</tr>
<tr>
<td>12:00</td>
<td>E084</td>
<td>A critically ill patient with VAP caused by carbapenem-resistant Gram-negative bacteria in a resource-limited setting</td>
<td>Heiman Wertheim (Hanoi, Viet Nam)</td>
</tr>
<tr>
<td>12:30</td>
<td>E085</td>
<td>Interactive panel discussion with the workshop faculty: answering a selection of questions sent by interested participants before the meeting</td>
<td></td>
</tr>
</tbody>
</table>

Final Programme 26th ECCMID, Amsterdam, Netherlands, 2016
EW020 11:00-13:00  2-hour Educational Workshop
ESCMID guideline for the diagnosis and treatment of community-acquired bacterial meningitis

Chairs: Matthijs Brouwer (Amsterdam, Netherlands)
       Olga Dzupova (Prague, Czech Republic)

E086 11:00  Clinical diagnosis and complications
      Matthias Klein (Munich, Germany)
E087 11:30  Microbiological diagnosis
           Christian Østergaard (Hvidovre, Denmark)
E088 12:00  Antibiotic and adjunctive treatment
           Diedenk van de Beek (Amsterdam, Netherlands)
E089 12:30  Interactive panel discussion with the workshop faculty: answering a selection of questions sent by interested participants before the meeting

EW021 11:00-13:00  E102
2-hour Educational Workshop
Challenges in invasive fungal disease

Chairs: Sevtap Arikan-Akdaglı (Ankara, Turkey)
       Yunsong Yu (Hangzhou, China)

E090 11:00  Epidemiological evolution of invasive fungal infection in China and elsewhere
           He Wang (Beijing, China)
E091 11:30  Chronic cavitary aspergillosis
           Koichi Izumikawa (Nagasaki, Japan)
E092 12:00  Cryptococcosis
           Nelesh P. Govender (Johannesburg, South Africa)
E093 12:30  Interactive panel discussion with the workshop faculty: answering a selection of questions sent by interested participants before the meeting

SY022 13:30-16:00  2-hour Symposium
Sepsis: moving the field forward

Chairs: Annelies Zinkernagel (Zurich, Switzerland)
       Tom van der Poll (Amsterdam, Netherlands)

S094 13:30  ISF Award for best abstract on sepsis
          TBC
S095 13:40  Sepsis: the year in review
          Thierry Calandra (Lausanne, Switzerland)
S096 14:05  New sepsis definitions: message from the Sepsis Definition Task Force
          Mervyn Singer (London, United Kingdom)
S097 14:35  Will translational science advance the sepsis field?
          Tom van der Poll (Amsterdam, Netherlands)
S098 15:00  Genomic landscape of the individual host response and outcomes in sepsis
          Julian Knight (Oxford, United Kingdom)

SY023 13:30-15:30  2-hour Symposium
Mycobacteria in migrants

Chairs: Jan S. Friedland (London, United Kingdom)
       Delia Goletti (Rome, Italy)
S099 13:30  Periodic migration driving the TB epidemic in Europe
           Christoph Lange (Borstel, Germany)
S100 14:00  Models of screening for migrants with TB
           Sally Hargreaves (London, United Kingdom)
S101 14:30  Testing and treatment of latent tuberculosis infection
           Alberto Matteelli (Brescia, Italy)
S102 15:00  Non-tuberculous mycobacteria in the migrant population
           Christian Wejse (Harlev, Denmark)

SY024 13:30-15:30  2-hour Symposium
Controversies in interpreting whole genome sequence data

Chairs: Surbhi Malhotra-Kumar (Antwerp, Belgium)
        Frédéric Laurent (Lyon, France)
S103 13:30  Can antibacterial resistance phenotypes be predicted from whole genome sequencing data?
           Tim Read (Atlanta, United States)
S104 14:00  How can we design virulome databases?
           Joao Andre Carrico (Lisbon, Portugal)
S105 14:30  Assessing virulence from genomic data - finding the unknown
           Ruth Massey (Bath, United Kingdom)
S106 15:00  Mobile DNA - instability and population variation
           Jodi Lindsay (London, United Kingdom)

SY025 13:30-15:30  2-hour Symposium
Immunity and vaccination in advanced age

Chairs: Marco Tinelli (Lodi, Italy)
        Martina Sester (Homburg, Germany)
S107 13:30  Understanding vaccine responses in the elderly
           Richard Aspinall (Cranfield, United Kingdom)
S108 14:00  Herpes zoster vaccines in the elderly
           Gaetan Savazzi (Grenoble, France)
S109 14:30  Focussing on the implementation of 21th century vaccines for adults
           Pierre Van Damme (Antwerp, Belgium)
S110 15:00  Functional outcomes for the elderly - how to measure them?
           Mical Paul (Haifa, Israel)
OS026 13:30-15:30           Hall J
2-hour Oral Session

**MDR Enterobacteriaceae: clinical epidemiology and outcomes**

**Chairs:** Mario Tumbarello (Rome, Italy)
George L. Daikos (Athens, Greece)

**0111**
Risk factors, duration of carriage and onward transmission of ESBL-producing Enterobacteriaceae acquired during travel: results of a large prospective cohort study of travellers and their households

**0112**
Acquisition of travel-associated antibiotic resistant bacteria occurs within several days
C. von Wintersdorff* (Maastricht, Netherlands), N. Mills, J. Penders, P. Savelkoul, P. Wolffs

**0113**
A longitudinal population-based study of extended-spectrum beta-lactamases in the Netherlands
G. van den Bunt* (Bilthoven, Netherlands), W. van Pelt, L. Mughini-Gras, J. Scharringa, L. Muller, J. Vlaaswijk, M. Bonten, A. Fluit, E. Consortium

**0114**
Colonization rates and risk factors for extended-spectrum beta-lactamase producing coliforms (ESBLPCs) in different sections of the asymptomatic general population in England

**0115**
Comparative study on the impact of quinolone therapy on colonization by ESBL(+) pathogens in non-ICU population

**0118**
Carbapenem-resistant *Klebsiella pneumoniae* bacteraemia: recurrence and impact of antibiotic treatment
M. Giannella* (Bologna, Italy), L. Marconi, E. Graziano, S. Tedeschi, M. Bartoletti, N. Girometti, F. Tumietto, F. Cristini, S. Ambretti, P. Gaibani, R. Lewis, P. Viale

**0119**
Comparing two predictive models for early mortality of patients with bloodstream infection due to carbapenemase-producing Enterobacteriaceae: the INCREMENT project

**0120**
Dynamics of colistin resistance among *Enterobacter cloacae* during prolonged use of selective decontamination of the digestive tract
M. Dautzenberg* (Utrecht, Netherlands), M. de Been, L. Gelincik, C. Jansen, M. Leverstein-van Hall, E. Leyten, A. Muller, T. Ruys, R. van der Starre, A. Fluit, M. Bonten

SY027 13:30-15:30           Hall K
2-hour Symposium

**Approaches to individualized therapy in an era of bacterial multidrug resistance**

**Chairs:** Angela Huttner (Geneva, Switzerland)
Pierluigi Viale (Bologna, Italy)

**0121**
PK/PD measures for guiding individualized antibacterial therapy
William W. Hope (Liverpool, United Kingdom)

**0122**
Individualized mono versus combination therapy to minimize resistance?
Evelina Tacconelli (Tübingen, Germany)

**0123**
Duration of therapy: from arbitrary numbers to biomarkers and algorithm-based guidance
Virginie Vitrat (Metz Tessy, France)

**0124**
Whole genome sequencing for prediction of antimicrobial resistance and optimizing patient care
Sandra Reuter (Cambridge, United Kingdom)

SY028 13:30-15:30           E102
2-hour Symposium

**Acinetobacter infections from east to west**

**Chairs:** Haibo Qiu (Nanjing, China)
Jordi Vila Estape (Barcelona, Spain)

**0125**
Molecular epidemiology worldwide
Harald Seifert (Cologne, Germany)
Saturday, 9 April 2016

**S126 14:00** Intrinsic and acquired antimicrobial resistance in *Acinetobacter*
Germán Bou Arevalo (La Coruña, Spain)

**S127 14:30** Therapy options viewed from the east
Minggui Wang (Shanghai, China)

**S128 15:00** Do we need *Acinetobacter*-specific infection control measures?
Bijie Hu (Shanghai, China)

---

**EP 01 15:30-16:30 ePoster Session**

**EP0009**
Candida krusei: insights about in vitro induction of resistance following exposure to voriconazole

**EP0010**
Efficacy and safety outcomes in patients with probable or proven versus possible invasive mould disease from the phase 3 secure study, evaluating isavuconazole versus voriconazole for the primary treatment of invasive fungal disease caused by *Aspergillus* spp. or other filamentous fungi

---

**EP 02 15:30-16:30 ePoster Session**

**EP0041**
Gram-positive bacterial sepsis induces platelet reactivity and platelet-monocyte aggregation, in contrast to Gram-negative bacterial sepsis
R. Tunjungputri* (Nijmegen, Netherlands), W. van der Heijden, R. Urbanus, P. de Groot, A. van der Ven, O. de Mast

---

**EP0001**
Local inflammatory response associated to *Pneumocystis* colonization in patients with idiopathic pulmonary fibrosis
C. de la Horra* (Seville, Spain), E. Pereira, J. Rodriguez-Portal, V. Friaza, J. Martín-Juan, N. Respolizza, E. Calderon, E. Medrano Ortega

---

**EP0002**
Azole resistant *Aspergillus fumigatus* in Denmark: a laboratory based study on resistance mechanisms and genotypes
R. Jensen, F. Hagen, K. Astvad, A. Tjørn, J. Meis, M. Arendrup* (Copenhagen, Denmark)

---

**EP0003**
Candida endocarditis during candidaemia episodes in children: the Hacettepe experience
A. Kara* (Ankara, Turkey), E. Karadag Oncel, A. Cengiz, M. Ceyhan, T. Karagöz, S. Arikan-Akdagli

---

**EP0004**
Guideline adherence study in invasive candidiasis (GASTON): results from a multicentre clinical trial
A. Tamarkin* (Berlin, Germany), C. Krebes, M. Kaak, A. Hundt, F. Balzer, K. Wernetcke, M. Deja

---

**EP0005**
Nitric oxide: regulator of inflammation in the pathogenesis of allergic bronchopulmonary aspergillosis in Indian children
N. Paul* (Chandigarh, India), M. Singh, J. Kaur, A. Chakrabarti

---

**EP0006**
Pharmacodynamics of isavuconazole in experimental invasive pulmonary aspergillosis: a virtuous cycle between bench and bedside
L. Kovanda* (Northbrook, United States), R. Petraiteiene, V. Petraitis, T. Walsh, A. Desai, P. Bonate, W. Hope

---

**EP0007**
Dose optimization of voriconazole-anidulafungin combination against invasive aspergillosis - preclinical data

---

**EP0008**
Frequency of the paradoxical effect of the 3 echinocandins against *Candida* spp. studied using EUCAST
J. Guzmán-Zambrano* (Madrid, Spain), P. Escribano Martos, C. Sánchez-Carrillo, E. Bouza Santiago, J. Guinea

---

**EP0009**
Candida krusei: insights about in vitro induction of resistance following exposure to voriconazole

---

**EP0010**
Efficacy and safety outcomes in patients with probable or proven versus possible invasive mould disease from the phase 3 secure study, evaluating isavuconazole versus voriconazole for the primary treatment of invasive fungal disease caused by *Aspergillus* spp. or other filamentous fungi
Comparative population genomics and the emergence of opportunistic pathogenicity in the nosocomial bacterial pathogen *Staphylococcus epidermidis*

L. Mageiros* [Swansea, United Kingdom], G. Meric, T. Wilkinson, S. Sheppard

Phenotypic modifications of *Pseudomonas aeruginosa* induced by the low molecular weight alginic OligoG CF-5/20 are associated with alterations in Las and Rhl signalling pathways

A. Jack* [Cardiff, United Kingdom], S. Khan, E. Onseyen, P. Rye, D. Thomas, K. Hill

Role of the *Acinetobacter baumannii* A1S_0114 gene in biofilm formation, attachment, motility and virulence

S. Rumbo-Feal* [La Coruña, Spain], A. Pérez, B. Arivett, T. Ramelot, A. Becerra, J. Vallejo, L. Alvarez-Fraga, M. Merino, E. Ohneck, M. Kennedy, L. Actis, G. Bou Arevalo

Streamlined genomic approaches for studying virulence markers in *Acinetobacter baumannii* (Ab)


Evaluation of the utility of bacterial ribosomal 16S molecular diagnostics to aid management of bone and joint infections presenting to a London teaching hospital

J. Barrett* [London, United Kingdom], P. Grant, S. Kirk, S. Logan, F. Haddad, S. Morris Jones

Rapid detection of methicillin-resistant staphylococci in peri-prosthetic joint infections using the GeneXpert MRSA/SA SSTI assay: a series of 215 consecutive cases

M. Titocat, O. Robineau, S. Nguyen, C. Laize, H. Migaud, E. Senneville* [Tourcoing, France]

Rapid microbiological diagnosis of orthopaedic implant-associated infections by MALDI-TOF of sonication fluid

M. Portillo Bordonabe, C. Martín, D. Sanchez-Guadarmina, A. Áravalo, J. Ruiz, A. Hidalgo, C. Ezpeleta, A. Trampuz* [Berlin, Germany]

Sensitive molecular identification of pathogens causing implant and tissue infections [ITI]

K. Rigler-Hohenwarter, E. Scharfner, W. Pramer, W. Aichinger, S. Eisenberger* [St. Valentin, Austria], B. Ranacher

The timing of pus sampling in relation to antimicrobial chemotherapy in subdural and extradural empyema: results from a twenty-first century cohort from the north of England

J. Melhorn* [Cambridge, United Kingdom], P. Kane

Infectious spondylodiscitis – a challenging problem of differential diagnosis between pyogenic and tuberculous aetiology

A. Orfanu, C. Popescu, A. Leustean, A. Negru, R. Orfanu, R. Catana* [Bucharest, Romania], C. Tiliscan, V. Aroma, S. Arama

Predictive factors of pyogenic vertebral osteomyelitis caused by Gram-negative bacteria

M. Kim* [Seoul, South Korea], W. Jeong, J. Jeong, M. Ahn, Y. Jeon, H. Ann, N. Ku, S. Han, J. Choi, Y. Song, J. Kim

Diagnosing pyogenic spondylodiscitis - a prospective observational study

C. Duncan* [Newcastle upon Tyne, United Kingdom], E. Klejnow, M. Cullinan, A. Watson, I. Emmerson, A. Price, U. Schwab

Is there an association between MRI findings and neurological deficit in vertebral osteomyelitis? A retrospective study of 121 patients.

G. Bart* [Nantes, France], H. Redon, O. Hamel, Y. Maugars, B. Le Golf, D. Boutilier

Diagnostic accuracy of synovial white blood cell count and differential in periprosthetic knee infection

G. Balata* [Naples, Italy], T. Ascione, F. Balboni, P. Pezzati, G. Virgili, A. Baldini

Covert dispersal of *Klebsiella pneumoniae* carbapenemase (KPC) producing Enterobacteriaceae in a successfully controlled outbreak - whole genome sequencing reveals multiple modes of transmission

J. Martin* [Leeds, United Kingdom], H. Phan, N. Orsi, N. Stoesser, D. Eyre, A. Kirby, N. Young, T. Peto, S. Walker, M. Wilcox, D. Crook

Molecular epidemiological analysis of the first outbreaks of OXA-48-producing Enterobacteriaceae in the Czech Republic with an evidence of horizontal gene transfer

A. Skalova* [Plzen, Czech Republic], K. Chudejova, V. Rotava, V. Jakubu, T. Bergerova, H. Zemlickova, C. Papagiannitsis, J. Hrabak
Saturday, 9 April 2016

**EP0182**
Emergence and clonal spread of colistin resistance during an outbreak of CPE in London

**EP0183**
Investigation of NDM-1-producing *Morganella morgani* outbreak using whole-genome sequencing

**EP0184**
Antimicrobial stewardship and universal screening are essential components of a stepwise approach to contain the spread of carbapenemase-producing *Klebsiella pneumoniae* (CPKP)

**EP0185**
*Shewanella* spp. as the origin and reservoir of new variants of the blaOXA-48-like genes
M. Tacão* [Aveiro, Portugal], M. Vendas, S. Araújo, I. Henriques

**EP0186**
Class B1 metallo-beta-lactamase NDM-1: preliminary study of structure-activity relationship
E. Lafeuille, S. Queslati, C. Exilie, M. Herygonin, Y. Boudehen, B. Iorga, T. Naas* [Le Kremlin-Bicêtre, France]

**EP0187**
LMB-1, a novel subclass B3 metallo-beta-lactamase from a carbapenem-resistant *Enterobacter cloacae* isolate
F. Lange* [Bochum, Germany], N. Pfennigwerth, R. Hartl, H. Kerschner, D. Achleitner, S. Gatermann, M. Kaase

**EP0188**
Evolution and dissemination of TMB-type metallo-beta-lactamase
M. Suzuki* [Tokyo, Japan], M. Matsui, R. Hirayama, T. Segawa, S. Suzuki, K. Shibayama

**EP0189**
*In vitro* prediction of OXA-48 evolution toward ceftazidime hydrolysis
L. Poirel* [Fribourg, Switzerland], S. Bontron, P. Nordmann

**EP0211**
*Borrelia* DNA detection in synovial fluid — 10 years of experience
K. Ornstein* [Kristiansand, Sweden], A. Petersson

**EP0212**
The potential utility of QuickFISH™ on positive blood cultures to inform antimicrobial stewardship decisions
T. Bharucha* [London, United Kingdom], R. Garton, M. Hussein, A. Lyons, D. Mack

**EP0213**
New, rapid PCRSERTyping strategy to identify and serotype *S. pneumoniae* from culture and culture-negative serum samples
G. Goig* [Valencia, Spain], A. Gil-Brusola, R. Borras, I. Comas

**EP0214**
Introduction of a molecular method for detection of enteric pathogens in a large community laboratory
A. Upton* [Auckland, New Zealand], L. Bissessor, S. Moore, J. Wilson

**EP0215**
Rapid detection and semi-quantification of lower respiratory tract pathogens in broncho-alveolar lavage specimens using the FilmArray LRTI panel
C. Weber, M. Casse, S. Mogra, O. Barraud, B. François, V. Moucaudel, M. Rogatcheva* [Salt Lake City, UT, United States]

**EP0216**
Missed opportunities for treatment: implementation of molecular diagnostics for paediatric acute gastroenteritis (GE): the FilmArray GI panel IMPACT Study
K. Bourzac* [Salt Lake City, UT, United States], K. Holberg, C. Stockmann, D. Cohen, A. Leber, J. Daly, J. Jackson, R. Selvarangan, J. Bender, J. Dien Bard, A. Festekjian, S. Duffy, A. Pavia, K. Chapin

**EP0217**
Rapid and accurate detection of *Neisseria meningitidis* DNA in clinical specimens using the Hibergene "HG Meningococcus" LAMP assay
D. Fairley* [Belfast, United Kingdom], J. McKenna, J. O. Noland, G. Keating, P. Coyle

**EP0218**
An in-depth analysis of nosocomial bloodstream infections due to Gram-negative bacilli: clinical features, microbiological characteristics and predictors of mortality in a one-year, prospective study in a large tertiary care Italian hospital
D. Delle Rose* [Rome, Italy], P. Pezzotti, C. Fontana, M. Andreoni, L. Sarmati

**EP0219**
Targeted amplification for bacterial identification at the species-level using next-generation sequencing — increased discrimination of closely related species
A. Sabat, E. van Zanten, V. Akkerboom, G. Wisselink, K. van Slochteren, R. de Boer, A. Friedrich, J. Rossen, M. Kooistra-Smid* [Groningen, Netherlands]
<table>
<thead>
<tr>
<th>EP06</th>
<th>15:30-16:30</th>
<th>ePoster Session</th>
<th>Vaccine research news between microbiota, seroprotection and attitudes</th>
<th>Moderator: Hanna M. Nohynek (Helsinki, Finland)</th>
</tr>
</thead>
<tbody>
<tr>
<td>EP0249</td>
<td>Infantis rotavirus vaccine immune response is significantly correlated with intestinal microbiota in rural Ghana V. Harris* (Amsterdam, Netherlands), G. Armah, S. Fuentes, W. Wiersingo, U. Parashar, J. Victor, C. Giaquinto, K. Lewis, W. De Vas</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>EP0250</td>
<td>Treatment of chronic and recurrent vulvovaginitis with autogenous microbial vaccines — a two-year follow-up study M. Czirfuszova* (Komárno, Slovakia), G. Bertaová</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>EP0252</td>
<td>Does influenza vaccination provide year-round seroprotection in the elderly? A systematic review and meta-analysis B. Young* (Singapore, Singapore), C. Parry</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>EP0253</td>
<td>Estimation of the vaccination coverage before and after the warning about a quadrivalent vaccine against mumps, measles, rubella and varicella L. Sanftenberg* (Munich, Germany), H. Schrörs, J. Schelling</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>EP0254</td>
<td>Low rates of severe injection-site and systemic adverse events within 7 days post-vaccination with ZOSTAVAX®; a post hoc analysis of two pivotal phase 3 trials Z. Popmihajlov* (Kenilworth, United States), L. Pang, E. Brawn, S. Su, S. Kaplan, E. Willis</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>EP0255</td>
<td>EDUVAC: a nationwide survey among final-year medical students assessing the undergraduate teaching on vaccination S. Kerneis, C. Jakquet* (Vandoeuvre les Nancy, France), A. Bannay, T. May, P. Verger, O. Launay, C. Pulcini</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>EP0256</td>
<td>Vaccination discrepancies between general practitioners’ attitudes toward their patients and practices for their children: a French nationwide cross-sectional study N. Agrinier, M. Le Marechal, L. Fressard, P. Verger, C. Pulcini* (Vandoeuvre-Lès-Nancy, France)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>EP0257</td>
<td>Knowledge, risk perception and attitude towards vaccination among Austrian healthcare workers N. Harrison* (Vienna, Austria), A. Brand, S. Tobudic, C. Forstner, H. Burgmann</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>EP07</td>
<td>15:30-16:30</td>
<td>ePoster Session</td>
<td>Travel medicine and international health</td>
<td>Moderator: Hakan Erdem (Istanbul, Turkey)</td>
</tr>
<tr>
<td>EP0269</td>
<td>Routine diagnostic methods for sensitive detection of louse-borne relapsing fever due to Borrelia recurrentis based on PCR and fluorescent microscopy used in case cluster in southern Germany 2015 V. Fingerle, T. Löscher, G. Margas, M. Seilmaier, U. van Both, A. Wieser* (Munich, Germany)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>EP0271</td>
<td>MERS corona virus screening in returning Indonesian Umrah pilgrims 2014-2015 M. Pane, F. Kong* (Hong Kong, China), M. Mashud</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>EP0273</td>
<td>Predicting the unpredictable: a kala azar outbreak in South Sudan M. Gonzalez Sanz* (Lankien, South Sudan), S. Poon, N. Sterkenburg, K. Hosmann, A. Wasaj Mullahzada, T. Harrison, A. Abdi Dahir, G. Huismans, K. Ritmeijer</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>EP0274</td>
<td>The prevalence of and risk factors associated with pneumonia in children aged 0-59 months in Mangochi, Malawi M. Cox* (Birmingham, United Kingdom), L. Rose, G. DeWilder, K. Kalua, R. Bailey, J. Hart</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>EP0275</td>
<td>An outbreak of Japanese encephalitis among Lao people from Xaignabouli, Lao PDR at Nan Hospital, Thailand June - July 2014 R. Buathong* (Meuang Nonthaburi, Thailand), L. Voradetwittaya, B. Sangkharak, J. lewongjoaroen</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>EP0277</td>
<td>Sewage treatment plants cause artificial selection of ESBL-producing E. coli threatening public health A. Gundagodu* (Kayseri, Turkey), H. Kiliç, E. Alp</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>EP0278</td>
<td>Testing and repeated testing behaviour of swingers and impact on STI diagnoses at a large Dutch STI clinic, between 2006 and 2013 N. Dukers* (Geleen, Netherlands), G. van Lier, C. Hoebe</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Less people, more machines: better results?

Moderator: François Vandenesch (Lyon, France)

EP0290
Validation of the automated plate assessment system (APAS®) as an effective device for the screening of urine specimens

EP0291
Improving time to result with BD Kiestra laboratory automation solution: finding the optimal reading time of urine culture plates with significant growth
M. Gosnell, M. Brasch, R. Marcelpoin, D. Morel, J. Burton, C. Orny, M. Cisse, T. Wiles, M. Van der Kaap, J. Deutekom, P. Murray* [Sparks, United States]

EP0292
Feasibility of the uf1000i flow cytometer for detecting urinary tract infections: a multicentre study

EP0293
Digital imaging and reading of disk diffusion antimicrobial susceptibility testing results using Kiestra Total Laboratory Automation system compared to conventional disk diffusion reading
J. Germ* [Jubljana, Slovenia], M. Furlan, P. Hrvat, J. Keber, A. Plešec, P. Pretnar, K. Seme

EP0294
Automated, rapid & accurate semi-quantitation of urine cultures in BD Kiestra™ laboratory automation solution: using image analysis with expert systems
M. Gosnell, R. Marcelpoin, D. Morel, J. Burton, C. Orny, M. Cisse, T. Wiles, M. Van der Kaap, P. Murray* [Sparks, United States], M. Brasch, J. Deutekom

EP0295
Copan FecalSwab and WASP automation improved the detection of gastrointestinal bacteria in our microbiology laboratory
V. Cristeо* [Bucharest, Romania], R. Pricop, G. Neacsu, G. Sandu, R. Gilca

EP0296
Use of flow cytometry for screening for the presence of bacteria in biological fluid samples
Y. Zboromyrska* [Barcelona, Spain], E. Rubio, A. Mons, A. Fasanella, I. Alejo-Cancho, J. Bosch, J. Vila
O139  Protein A/G-based immunochromatographic test for serodiagnosis of pythiosis in human and animal subjects from Asia and the Americas

O140  Comparison of a novel semi-quantitative prototype and a commercial lateral flow assay for detection of cryptococcal antigen from thawed whole blood samples
C. Sriruttan* (Johannesburg, South Africa), R. Wake, I. Rukasha, D. Glencross, L. Coetzee, D. Lawrie, N. Govender

O141  Performance of Dynamiker® [1-3]-beta-D glucan assay compared to Fungitell® for the diagnosis of invasive fungal diseases from serum samples
Y. Wang* (Beijing, China), W. Liu, W. Yan, Y. Xu

O142  Comparison of galactomannan and Aspergillus PCR in sputum from patients with ABPA and CPA
S. Fayemiwo* (Ibadan, Nigeria), C. Moore, P. Foden, D. Denning, M. Richardson

OS031  16:30-18:30 Hall E
2-hour Oral Session

Emerging viruses: what about "Tick", "Chik" and "Zik"?

0143  Longitudinal characterization of dysfunctional T cell-activation during human acute Ebola infection

0144  Comparison of children testing positive and negative for Ebola virus disease in Ebola holding units, Sierra Leone

0145  A preliminary report of the ongoing epidemics of Zika in the Department of Risaralda, Colombia

0146  Emerging Zika fever outbreak among healthcare workers in a general hospital in the central region of Thailand, January 2015
R. Buathong* [Meuang Nonthaburi, Thailand], H. Kanjanasombut, O. Suwanchairoib, S. Likansaksul

0147  Dengue and pregnancy in Colombia: 3-year experience in obstetrics intensive care unit

0148  Druya fever, verruga peruana and other forms of bartonelloses: an approach to their epidemiology in Colombia, 2009-2013
A. Rodríguez-Morales, L. Urrutia, F. Arroyave-Velásquez, J. Sabogal* [Pereira, Colombia], A. Patiño-Barbosa, J. Cardona-Ospina

OS032  16:30-18:30 Hall F
2-hour Symposium

Harnessing whole genome sequence data for public health applications

0150  A polyfunctional interferon-gamma dominated CD4+ T cell response is associated with good outcome from Japanese encephalitis

0151  The increased expression of macrophage migration inhibitory factor in tick-borne encephalitis
S. Grygorczuk* [Bialystok, Poland], A. Moniuszko, R. Swierzbinska, P. Czupryna, M. Kondrusik, S. Panczewicz

0152  Resurgence risk for measles, mumps and rubella in France in 2016
B. Guillaume* [Poitiers, France], S. Abrams, D. Levy-Bruhl, D. Antona, P. Beutels, B. Dervaux, N. Hens

SY032  16:30-18:30 Hall F
2-hour Symposium

Next generation sequencing for influenza viruses
Maria Zambon [London, United Kingdom]

Tracking the evolution to antibiotic resistance in Klebsiella pneumoniae genomes
Sylvain Brisse [Paris, France]

Final Programme 26th ECCMID, Amsterdam, Netherlands, 2016 47
17:30 Novel open access tools for WGS-based pathogen surveillance and the identification of high-risk clones
David Aanensen (London, United Kingdom)

18:00 Identifying high-risk clones for public health: typhoid and cholera
Stephen Baker (Ho Chi Minh City, Viet Nam)

16:30 Infection on neurological implanted devices
Anna Conen (Aarau, Switzerland)

17:00 Antibiotic management of mediastinitis
Olivier Epaulard (Grenoble, France)

17:30 Antibiotic management of external necrotizing otitis
Céline Pulcini (Vandoeuvre-Lès-Nancy, France)

18:00 Infections on pacemakers and TAVI
José M. Miro (Barcelona, Spain)

16:30 Intestinal colonization with extended-spectrum cephalosporin-resistant Enterobacteriaceae in healthy Swiss pets: prevalence and risk factors
J. Pires* (Bern, Switzerland), R. Tinguely, S. Kasraian, C. Hauser, M. Hilty, V. Perreten, A. Endimiani

17:00 Similarity and persistence of ESBL-producing Enterobacteriaceae in pig farmers and pigs
W. Dahmen* (Utrecht, Netherlands), A. Liakopoulos, S. van Marm, J. Scharringa, W. van Schaik, M. Bonten, D. Mevius, A. Heederik

18:00 Assessment of indigenous South African herbivores as potential reservoirs for multidrug-resistant Escherichia coli
T. King* (Pietermaritzburg, South Africa), S. Schmidt

16:30 Diversity of extended-spectrum beta-lactamase gene-carrying plasmids harboured by Escherichia coli isolates of diseased food-producing animals
G. Michael* (Neustadt-Marienturm, Germany), A. Siqueira, K. Kadlec, H. Kaspar, S. Schwarz
15th ESCMID Summer School
Seville, Spain
2 – 9 July 2016

Postgraduate and continuing medical education in clinical microbiology and infectious diseases

Including:
- Management of specific infections/situations
- Therapy beyond antibiotics
- Career development and methods
- HIV and HVC
- Other viral infections
- Updating diagnosis
- Present and future in diagnostics and therapy
- International health
- Miscellaneous infections
- Multidrug resistance

Please register at www.escmid.org/summerschool16. Places are limited, apply until 3 June 2016!

Organized by the ESCMID Education Subcommittee
Hosted at the TRH Alcora Hotel **** in San Juan de Aznalfarache, Seville, Spain
Overview  
Sunday, 10 April 2016

- Educational Workshops, Meet the Experts
- Symposia
- Oral Sessions
- Keynote Lectures
- ePoster Presentations

---

<table>
<thead>
<tr>
<th>Time</th>
<th>Hall</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>07.45 – 08.45</td>
<td>Hall C</td>
<td>How to organize antimicrobial stewardship in long-term care facilities</td>
</tr>
<tr>
<td></td>
<td>Hall D</td>
<td>Management of diabetic foot infections: what is new in guidelines?</td>
</tr>
<tr>
<td></td>
<td>E 102</td>
<td>Advances in necrotizing soft tissue infections: from pathophysiology to clinics</td>
</tr>
<tr>
<td></td>
<td>Hall F</td>
<td>Selling your work to colleagues and society: how to get into the leading medical journals and how to use social media</td>
</tr>
</tbody>
</table>

**Hall A**

<table>
<thead>
<tr>
<th>Time</th>
<th>Hall</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>09.00 – 11.00</td>
<td>Hall B</td>
<td>Year in Infection Control</td>
</tr>
<tr>
<td></td>
<td>Hall C</td>
<td>Epidemiology of methicillin- and linezolid-resistant staphylococci from humans and animals</td>
</tr>
<tr>
<td></td>
<td>Hall D</td>
<td>Genotypic and phenotypic detection of colistin resistance in Gram-negative bacteria</td>
</tr>
<tr>
<td></td>
<td>Hall E</td>
<td>EUCAST frequently asked questions</td>
</tr>
<tr>
<td></td>
<td>Hall F</td>
<td>HIV/AIDS: late presenters in Europe</td>
</tr>
</tbody>
</table>

11.00- 11.30 | Coffee Break |
11.30 – 12.30 | Systems vaccinology |

**Hall A**

<table>
<thead>
<tr>
<th>Time</th>
<th>Hall</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>09.00 – 11.00</td>
<td>Hall B</td>
<td>From antifungal susceptibility to resistance</td>
</tr>
<tr>
<td></td>
<td>Hall C</td>
<td>Modelling and metaanalyses of antimicrobial stewardship efficacy</td>
</tr>
<tr>
<td></td>
<td>Hall D</td>
<td>New insights in the epidemiology and treatment of Clostridium difficile</td>
</tr>
<tr>
<td></td>
<td>Hall E</td>
<td>Prevention and management of bloodstream infections: from here to where?</td>
</tr>
<tr>
<td></td>
<td>Hall F</td>
<td>Inflamasomes and infection - translational crosstalks</td>
</tr>
</tbody>
</table>

12.30 – 14.30 | Lunch Break / ePoster Sessions, Poster Sessions from Abstracts |
14.30 – 15.30 | Systems vaccinology |

**Hall A**

<table>
<thead>
<tr>
<th>Time</th>
<th>Hall</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>09.00 – 11.00</td>
<td>Hall B</td>
<td>Tuberculosis: diagnosis &amp; outcomes</td>
</tr>
<tr>
<td></td>
<td>Hall C</td>
<td>Challenges in HIV care in 2016</td>
</tr>
<tr>
<td></td>
<td>Hall D</td>
<td>Severe sepsis and septic shock</td>
</tr>
<tr>
<td></td>
<td>Hall E</td>
<td>Personalized vaccinology – what it could be and what it cannot be (Pro-Con Debate)</td>
</tr>
<tr>
<td></td>
<td>Hall F</td>
<td>CNS distribution of antimicrobial agents revisited</td>
</tr>
</tbody>
</table>

15.30- 16.00 | Coffee Break |
16.00 – 18.00 | Systems vaccinology |

**Hall A**

<table>
<thead>
<tr>
<th>Time</th>
<th>Hall</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>09.00 – 11.00</td>
<td>Hall B</td>
<td>Ageing with HIV</td>
</tr>
<tr>
<td></td>
<td>Hall C</td>
<td>Clostridium difficile infections from East to West</td>
</tr>
<tr>
<td></td>
<td>Hall D</td>
<td>Updates in bloodstream infection epidemiology and management</td>
</tr>
<tr>
<td></td>
<td>Hall E</td>
<td>Still thriving at the host’s expense: parasitic infection</td>
</tr>
<tr>
<td>Hall G</td>
<td>Hall H</td>
<td>Hall I</td>
</tr>
<tr>
<td>-------</td>
<td>-------</td>
<td>-------</td>
</tr>
<tr>
<td><strong>07.45 – 08.45</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Genotypic and phenotypic detection of colistin resistance in Gram-negative bacilli</td>
<td></td>
<td>EUCAST frequently asked questions</td>
</tr>
<tr>
<td>Genotypic and phenotypic detection of colistin resistance in Gram-negative bacilli</td>
<td></td>
<td>EUCAST frequently asked questions</td>
</tr>
<tr>
<td><strong>09.00 – 11.00</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Multidrug- and extremely drug-resistant Gram-negative bacilli: the storm is here</td>
<td>New insights in viral hepatitis</td>
<td>Early antimicrobial drug development news</td>
</tr>
<tr>
<td>Multidrug- and extremely drug-resistant Gram-negative bacilli: the storm is here</td>
<td>New insights in viral hepatitis</td>
<td>Early antimicrobial drug development news</td>
</tr>
<tr>
<td><strong>11.00 – 11.30</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Coffee Break</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Coffee Break</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>11.30 – 12.30</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vancomycin resistance in Staphylococcus aureus: nothing is what it seems to be</td>
<td>Escherichia coli ST131: successful and intriguing</td>
<td>PK/PD-based optimized broad-spectrum beta-lactam therapy</td>
</tr>
<tr>
<td>Vancomycin resistance in Staphylococcus aureus: nothing is what it seems to be</td>
<td>Escherichia coli ST131: successful and intriguing</td>
<td>PK/PD-based optimized broad-spectrum beta-lactam therapy</td>
</tr>
<tr>
<td><strong>12.30 – 14.30</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lunch Break / ePoster Sessions, Poster Sessions from Abstracts</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lunch Break / ePoster Sessions, Poster Sessions from Abstracts</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>14.30 – 15.30</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Do we have efficient decolonization regimens for MDR Gram-negatives?</td>
<td>Animal reservoirs and human infection epidemiology</td>
<td>Comparative clinical trials of infections with resistant Gram-negative bacteria</td>
</tr>
<tr>
<td>Do we have efficient decolonization regimens for MDR Gram-negatives?</td>
<td>Animal reservoirs and human infection epidemiology</td>
<td>Comparative clinical trials of infections with resistant Gram-negative bacteria</td>
</tr>
<tr>
<td><strong>15.30 – 16.00</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Coffee Break</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Coffee Break</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>16.00 – 18.00</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Critical appraisal of new antibiotics</td>
<td>Prevention of surgical site infections: the holy grail of infection control</td>
<td></td>
</tr>
</tbody>
</table>
### Sunday, 10 April 2016

#### Meet-the-Expert Session

**ME035 07:45-08:45**  
**Hall C**  
Management of diabetic foot infections: what is new in guidelines?  

- **M171** Benjamin A. Lipsky (Oxford, United States)  
- **M172** M. Bulent Ertugrul (Aydin, Turkey)

**ME036 07:45-08:45**  
**Hall D**  
Advances in necrotizing soft tissue infections: from pathophysiology to clinics  

- **M173** Anna Norrby-Teglund (Stockholm, Sweden)  
- **M174** Matthew Dryden (Winchester, United Kingdom)

**ME037 07:45-08:45**  
**Hall F**  
HIV/AIDS: late presenters in Europe  

- **M175** Volkan Korten (Istanbul, Turkey)  
- **M176** Nikolaz Chkhartishvili (Tbilisi, Georgia)

**ME038 07:45-08:45**  
**Hall H**  
Genotypic and phenotypic detection of colistin resistance in Gram-negative bacilli  

- **M177**  
- **M178**

**ME039 07:45-08:45**  
**Hall J**  
EUCAST frequently asked questions  

- **M179** Derek F. J. Brown (Peterborough, United Kingdom)  
- **M180** Erika Matuschek (Växjö, Sweden)

**ME040 07:45-08:45**  
**E102**  
Meet-the-Expert Session  
Selling your work to colleagues and society: how to get into the leading-medical journals and how to use social media  

- **M181** Preeti Malani (Ann Arbor, MI, United States)  
- **M182** Jonathan Otter (London, United Kingdom)

#### Meet-the-Expert Session

**ME041 07:45-08:45**  
**E104/105**  
How to organize antimicrobial stewardship in long-term care facilities  

- **M183** Leonardo Paganini (Bolzano, Italy)  
- **M184** Céline Pulcini (Vandoeuvre-Lès-Nancy, France)

#### 2-hour Symposium

**SY042 09:00-11:00**  
**Hall A**  
Year in Infection Control  

- **S185 09:00**  
- **S186 09:30**  
- **S187 10:00**

#### 2-hour Oral Session

**OS043 09:00-11:00**  
**Hall C**  
Epidemiology of methicillin- and linezolid-resistant staphylococci from humans and animals  

- **O188** Is CA-MRSA a threat in the emergency department? A European multicentre study  
  - C. Bouchiat* (Lyon, France), I. Spiliopoulou, C. Prat, B. Schulte, I. Codita, S. Curtis, A. Tristan, M. Bes, A. Kearns, F. Vandenesch

- **O189** Molecular epidemiology and nasal carriage of Staphylococcus aureus and methicillin-resistant S. aureus among healthy adults  
  - V. Gostev* (St. Petersburg, Russian Federation), A. Kruglov, S. Soldatova, I. Popova, S. Zyryanov, S. Sidorenko

- **O190** Characterization of borderline oxacillin-resistant Staphylococcus aureus (BORSA) strains isolated in Belgium  

- **O191** Transmission of Staphylococcus aureus in social networks  
A hospital outbreak of livestock-associated MRSA: characterization of strains by whole-genome sequencing and estimation of costs
M. Skov* (Odense, Denmark), H. Kristiansen, A. Taft, H. Lundgaard, M. Slatt Jensen, A. Holm, H. Kolmos, M. Kemp

Next-generation sequencing (NGS) reveals persistence of livestock-associated methicillin-resistant Staphylococcus aureus (LA-MRSA) in humans
T. Bosch* (Bilthoven, Netherlands), S. Witteveen, M. van Luit, F. Landman, L. Schouls

Recombination drives host adaptation of Staphylococcus aureus following a recent host jump
S. Murray* (Swansea, United Kingdom), G. Meric, K. Yahara, L. Harris, T. Wilkinson, R. Fitzgerald, S. Schwarz, S. Sheppard, B. Pascoe

Circulation of linezolid-dependent ST-2, ST-5, ST-22 and ST-168 linezolid-resistant Staphylococcus epidermidis clinical isolates in German hospitals
F. Layer, V. Karavassilis, B. Stammenger, G. Werner, A. Isokris, S. Pournaras* (Athens, Greece)

Presence of the novel oxazolidinone/phenicol resistance gene optrA in Enterococcus spp. of human and Staphylococcus spp. of animal origin
Y. Wang* (Beijing, China), S. Schwarz, J. Cai, J. Li, A. Feßler, R. Zhang, D. Li, C. Wu, J. Shen

Cfr-mediated multiresistance in staphylococci from veal calves and pigs, from humans at the corresponding farms, and from veterinarians and their family members
C. Cuny, P. Arnold, A. Feßler, Y. Wang, J. Hermes, T. Eckmanns, S. Schwarz, W. Witte* (Wernigerode, Germany)

Is Europe ready for pre-exposure prophylaxis (PreP)?
Jean-Michel Molina (Paris, France)

From HPV to shingles: vaccinations for HIV-positive adults
Anna Maria Geretti (Liverpool, United Kingdom)

Multidrug- and extremely drug-resistant Gram-negative bacilli: the storm is here
Chairs: Po-Ren Hsueh [Taipei, Taiwan]
Camilla Rodrigues [Mumbai, India]

Carbapenemases 2016, a worldwide overview
Giuseppe Cornaglia [Verona, Italy]

Antimicrobial resistance at European borders: the CAESAR project results
Nienke van de Sande-Bruinsma [Copenhagen, Denmark]

Epidemiology of multi/extreme drug resistance in Enterobacteriaceae
Patrice Nordmann [Fribourg, Switzerland]

Resistance in Acinetobacter baumannii to non-beta-lactam agents
Luis Martinez-Martinez [Santander, Spain]

Trace and treat hidden hepatitis C cases using a birth cohort approach via general practitioners in higher prevalence areas: the hotspot study
J. Heil* [Geleen, Netherlands], C. HoeBeek, H. ter Waarbeek, P. Jacobs, G. Koek, A. Bos, G. Kok, K. Massar, S. Gruijters, J. Cals, I. van Loo, N. Dukers

Hepatitis C virus (HCV) infects gastrointestinal cells that can represent an extrahepatic virus reservoir and may play a role in HCV persistence and post-transplantation recurrence
G. Russelli* [Palermo, Italy], P. Pizzillo, F. Barbera, G. Iannato, E. Badami, F. Tuzzolino, R. Liotta, M. Traina, G. Vizzini, B. Gridelli, P. Conaldi
Sunday, 10 April 2016

0208 09:24 The added role of pharmaceutical intervention on hepatitis C virus (HCV) treatment in the DAA ERA: a single center observational prospective cohort analysis

0209 09:36 Glomerular and tubular kidney involvement in HCV cirrhosis

0211 09:48 Characteristics of patients failing new direct active drug (DAA) combinations in HIV/HVC coinfection

0212 10:00 Hepatitis B in pregnant migrants and their household contacts: an epidemiological study in Rome setting
S. Giachè, L. Foroghi* (Rome, Italy), G. Taliani

0213 10:12 Clearance of HBV DNA in immunized children born to HBsAg positive mothers, years after being diagnosed with occult HBV infection
S. Jazayeri* (Tehran, Iran), A. Sadeghi, Y. Yahyapoor, V. Poortahmasebi, M. Roggendorf, H. Karimzadeh, S. Alavian

0214 10:24 Hepatitis E virus genotype 3 - a health concern in the Netherlands

0215 10:36 Hepatitis E virus genotype 3 in sewage and genotype 1 in sporadic acute hepatitis cases in Israel

SY048 09:00-11:00 Hall I 2-hour Symposium
Early antimicrobial drug development news
Chairs: Roman S. Kozlov (Smolensk, Russian Federation) Alasdair P. MacGowan (Bristol, United Kingdom)

S216 09:00 Identifying effective dosing regimens in the early drug development process – new EMA guidelines
Lena Friberg (Uppsala, Sweden)

S217 09:30 Preclinical studies – predicting emergence of resistance
Dan I. Andersson (Uppsala, Sweden)

S218 10:00 Phase 1 studies in the Gram-negative field – pitfalls and opportunities
Markus Zeitlinger (Vienna, Austria)

SY049 09:00-11:00 Hall J 2-hour Symposium
Approaches to individualized management of invasive fungal disease
Chairs: Thomas Patterson (San Antonio, TX, United States) Andrew J. Ullmann (Würzburg, Germany)

S220 09:00 Assessing the individual risk of fungal infection
Dimitrios P. Kontoyiannis (Houston, United States)

S221 09:30 Approaches to patient-specific antifungal drug monitoring
William W. Hope (Liverpool, United Kingdom)

S222 10:00 Applying individualized integrated care paths for invasive fungal disease
Monica Slavin (East Melbourne, Australia)

S223 10:30 Individualized management of breakthrough infection
Georg Maschmeyer (Potsdam, Germany)

KL049 11:30-12:30 Hall A Keynote Lecture
Systems vaccinology
Chair: Donata Medaglini (Siena, Italy)

K224 11:30 Bali Pulendran (Atlanta, GA, United States)

OS050 11:30-12:30 Hall B 1-hour Oral Session
From antifungal susceptibility to resistance
Chairs: Emmanuel Raulides (Thessaloniki, Greece) Ana Alastruey-Izquierdo (Madrid, Spain)

C. Sharma* (Delhi, India), R. Kumar, S. Kathuria, P. Kumar Singh, D. Gupta, A. Chowdhary

0226 11:42 Predicting azole treatment failure with PCR-based detection of A. fumigatus cyp51A mutations on bronchoalveolar lavage. A multicentre validation study in 201 haematology patients with suspected invasive aspergillosis
0227 11:54  *In vitro* activity of isavuconazole against *Candida* and *Aspergillus*
M. Arendrup, R. Jensen, K. Astvad* (Copenhagen, Denmark)

0228 12:06  Identification and antifungal susceptibility of *Penicillium* isolates from clinical samples
M. Guevara* (Reus, Spain), J. Cano-Lira, D. Sutton, D. Garcia, A. Martin, J. Gené, J. Guarro

0229 12:18  Molecular identification and antifungal susceptibility of cryptic *Aspergillus* section *Fumigati* isolated in a multicenter study in Spain (Madrid Aspergillus Resistance Study)

0230 11:30-12:30  1-hour Oral Session
**Modelling and metaanalyses of antimicrobial stewardship efficacy**
Chairs: Katja De With (Dresden, Germany) José Ramón Pano-Pardo (Zaragoza, Spain)

0231 11:30-12:30  1-hour Oral Session
**Clinical effectiveness of antimicrobial stewardship in reducing antibiotic resistance rate: a meta-analysis**
P. Beryl, D. Bau, F. Foschi, E. Tacconelli* (Tübingen, Germany)

0232 11:30-12:30  1-hour Oral Session
**A quantitative analysis of the implementation of antimicrobial stewardship to prevent *C. difficile* infection**
E. Van Kleeft* (London, United Kingdom), S. Deeny, B. Cookson, S. Deeny, M. Bonten, J. Robotham

0233 11:30-12:30  1-hour Oral Session
**Quantifying where selection occurs: a mathematical modelling approach to better inform antimicrobial resistance control**
G. Knight* (London, United Kingdom), C. Costella, L. Moore, J. Robotham, A. Holmes

0234 11:30-12:30  1-hour Oral Session
**A systematic review and meta-analysis of current evidence on hospital antimicrobial stewardship objectives**

0235 11:30-12:30  1-hour Oral Session
**Prevalence of community-associated *Clostridium difficile* infection in England**
S. Gerver* (London, United Kingdom), J. Davies, N. Hinton, A. Johnson, M. Wilcox, R. Hope

0236 11:30-12:30  1-hour Oral Session
**Global spread of multiple-antibiotic resistant *Clostridium difficile* between animals and humans**
C. Knetusch* (Leiden, Netherlands), N. Kumar, T. Connor, J. Cover, E. Kuiper, J. Lawley

0237 11:30-12:30  1-hour Oral Session
**Complications and long term-follow-up of faecal microbiota transplantation for treatment of recurrent *Clostridium difficile* infection**
Y. van Beurden* (Amsterdam, Netherlands), P. De Groot, E. van Nood, M. Nieuwdorp, A. Goorhuis

0238 11:30-12:30  1-hour Oral Session
**Use of intravenous tigecycline in patients with severe *Clostridium difficile* infection: a retrospective case-control study**
B. Szabo* (Budapest, Hungary), B. Kádár, K. Lénárt, B. Dezsényi, K. Fried, K. Kamatsay, N. Radko, G. Prinz

0239 11:30-12:30  1-hour Oral Session
**Clostridium difficile** infection (CDI) attributable 1-year mortality and nursing home admission in the US Medicare population
E. Dubberke* (St. Louis, MO, United States), D. Stwalley, C. Demont, M. Olsen

0240 11:30-12:30  1-hour Oral Session
**Quality management of bloodstream infections today - setting standards**
Luis Eduardo Lopez-Cortes (Seville, Spain)

0241 11:30-12:30  1-hour Oral Session
**Achievements in preventing central line-associated bloodstream infection**
Issam Raad (Houston, TX, United States)

0242 11:30-12:30  1-hour Oral Session
**Inflammasomes and infection - translational crosstalks**
Chairs: Thierry Calandra (Lausanne, Switzerland) Jon S. Friedland (London, United Kingdom)

0243 11:30-12:30  1-hour Oral Session
**Inflammasome signalling and activation of innate immunity**
TBC
Sunday, 10 April 2016

**S243** 12:00 Inflammasome inhibition and infection
Mihai Gheorghe Netea (Nijmegen, Netherlands)

**KL055** 11:30-12:30 Hall G

**Keynote Lecture**

Vancomycin resistance in *Staphylococcus aureus*: nothing is what it seems to be

*Chairs: François Vandenesch (Lyon, France)*

**K244** 11:30 Benjamin Peter Howden (Parkville, Australia)

**OS056** 11:30-12:30 Hall H

**1-hour Oral Session**

*Escherichia coli* ST131: successful and intriguing

*Chairs: Youri Guipczynski (Yvoir, Belgium) Christa Ewers (Giessen, Germany)*

**0245** Significant differences in ST131 prevalence across Europe: results of an active ESBL-*E. coli* surveillance screening programme

**0246** The emergence of *Escherichia coli* ST131 H30 that produce CTX-M-27 in Japan

**0247** Genome-based comparison of *Escherichia coli* ST131 associated bloodstream infection and carriage by long-term care facility residents in the United Kingdom
H. Bradrick* [Cambridge, United Kingdom], K. Raven, T. Kallonen, B. Blane, M. Török, J. Parkhill, S. Peacock

**0248** Multidrug-resistant extra-intestinal pathogenic *Escherichia coli* sequence type 131 subclones H30-R and H30-Rx in retail chicken meat, Italy
A. Ghodousi* [Palermo, Italy], C. Bonura, C. Mammina

**0249** Emergence of KPC-type producing *Escherichia coli* ST131 from three acute care hospitals and two long term and rehabilitation facilities in northern Italy

**SY058** 11:30-12:30 Hall J

**1-hour Symposium**

Food-producing animals as source of antibiotic resistance in humans

*Chairs: Christina Greka [Uppsala, Sweden] Robert Leo Skov [Copenhagen, Denmark]*

**0250** 11:30 Achieving pharmacokinetic/pharmacodynamic (PK/PD) targets of beta-lactams in critically ill patients at first dose: can we do it with standard dosing?
I. Dealttre* [Brussels, Belgium], F. Taccone, F. Jacobs, T. Dugernier, H. Spapen, P. Laterre, P. Wallerma, V. Tam, F. Van Bambeke

**0251** 11:42 Piperacillin-tazobactam pharmacokinetics-pharmacodynamics in critically ill children: an urgent plea for revising dosing recommendations
P. De Cock* [Ghent, Belgium], S. van Dijkman, A. de Jaeger, J. Dejonckere, J. Delanghe, H. Robays, J. Vande Walle, O. Della Pasqua

**0252** 11:54 Standard drug regimens of piperacillin-tazobactam are insufficient to treat difficult-to-treat pathogens in obese, non-critically ill patients
M. Hites* [Brussels, Belgium], F. Wolff, P. Jessica, F. Cotton, F. Jacobs

**0253** 12:06 Optimizing meropenem dosing in severely septic Australian indigenous patients
D. Tsar* [Brisbane, Australia], P. Stewart, R. Goud, S. Gourley, S. Hewagama, S. Krishnaswamy, J. Lipman, J. Roberts

**0254** 12:18 Risk factors for not reaching 100 % time over actual or estimated minimal inhibitory concentrations in intensive care unit patients on broad spectrum beta-lactam antibiotics

**S255** 11:30 New insights on animal to human transmission of MRSA
Lance B. Price [Washington, DC, United States]

**S256** 12:00 New insights on animal to human transmission of cephalosporin-resistant Enterobacteriaceae
Dik Johan Mevius [Lelystad, Netherlands]
SY059 11:30-12:30  Hall K
1-hour Symposium
Recent top papers in mycology

|---------|---------------------------------------------------|---------------------------------|

S257 11:30  Top papers in diagnostic mycology
Maiken Cavling Arendrup [Copenhagen, Denmark]

S258 12:00  Top papers in clinical mycology
Andrew J. Ullmann [Würzburg, Germany]

EP09 13:00-14:00  ePoster Area 1
ePoster Session
Interesting stories about virulence and pathogenesis

<table>
<thead>
<tr>
<th>EP0031</th>
<th>Staphylococcus aureus targets the Duffy antigen receptor for chemokines (DARC) to lyse erythrocytes</th>
</tr>
</thead>
<tbody>
<tr>
<td>A. Spaan* [Utrecht, Netherlands], T. Reyes-Robles, K. Van Kessel, F. Vandenesch, M. Jennings, C. Le Van Kim, Y. Colin, J. Van Strijp, T. Henry, V. Torres</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>EP0032</th>
<th>A mechanism for variation in type I interferon induction by diverse Mycobacterium tuberculosis strains</th>
</tr>
</thead>
<tbody>
<tr>
<td>K. Viennas* [New York, United States], J. Ernst</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>EP0033</th>
<th>An intracellular phase at the initiation of sepsis for an extracellular pathogen - the pneumococcus</th>
</tr>
</thead>
<tbody>
<tr>
<td>G. Ercoli, M. Oggiioni* [Leicester, United Kingdom]</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>EP0034</th>
<th>Diagnosis and challenges in the treatment of disseminated non-tuberculous mycobacterial infection due to autoantibodies against interferon-gamma</th>
</tr>
</thead>
<tbody>
<tr>
<td>N. Janssen* [Nijmegen, Netherlands], M. Berrevoets, J. van Ingen, O. de Mast, M. van Deuren, M. Neete, R. van Crevel, F. van de Veerendonk</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>EP0036</th>
<th>Human natural killer cells and Aspergillus fumigatus differentially influence their gene expression profile</th>
</tr>
</thead>
<tbody>
<tr>
<td>A. Schneider, M. Blatzer, S. Schmidt, W. Posch, C. Lass-Flörli, T. Lehrnbecher* [Frankfurt, Germany]</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>EP0037</th>
<th>Crimea-Congo haemorrhagic fever virus interferes with autophagy in infected hepatocytes</th>
</tr>
</thead>
<tbody>
<tr>
<td>M. Moroso* [Lyon, France], P. Verlhac, O. Ferraris, C. Peyrefitte, H. Endtz, M. Faure, G. Paranhas-Bacallà</td>
<td></td>
</tr>
</tbody>
</table>

EP010 13:00-14:00  ePoster Area 2
ePoster Session
News on the diverse mycobacterial infections

<table>
<thead>
<tr>
<th>EP0039</th>
<th>Deregulation of microRNAs in a mouse model of Helicobacter pylori-associated gastric lymphomagenesis</th>
</tr>
</thead>
<tbody>
<tr>
<td>P. Flach* [Bordeaux, France], C. Capdevielle, C. Staedel, F. Megraud, P. Lehours</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>EP0040</th>
<th>Longitudinal analysis of the nasal microbiota of inpatients with MRSA incident colonization and non-colonized controls</th>
</tr>
</thead>
<tbody>
<tr>
<td>M. Bessesen* [Denver, United States], J. Benoit, B. Wagner, D. Frank</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>EP0050</th>
<th>Associated genetic mutations in XDR &amp; non-XDR tuberculosis with HIV co-infection in north India</th>
</tr>
</thead>
<tbody>
<tr>
<td>S. Verma* [Lucknow, India], M. Kumar, S. Kashyap, T. Dhole</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>EP0051</th>
<th>Evaluation of MALDI-TOF MS as an alternative method for epidemiological cluster analysis of Mycobacterium tuberculosis isolates</th>
</tr>
</thead>
<tbody>
<tr>
<td>E. Andre* [Brussels, Belgium], M. Delmée, J. De Beer, F. Bressant, A. Simon, D. van Saalingen, A. Verroken</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>EP0052</th>
<th>Emerging trends in non-tuberculous Mycobacterium - an epidemiological analysis over five years at a large teaching hospital in London</th>
</tr>
</thead>
<tbody>
<tr>
<td>T. Bharucha* [London, United Kingdom], N. Shah, M. Murphy, I. Copley, M. Lipman, S. Hopkins</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>EP0053</th>
<th>Status of drug-resistant tuberculosis in China: a systematic review and meta-analysis</th>
</tr>
</thead>
<tbody>
<tr>
<td>X. Hu* [Chengdu, China], J. Zhang, B. Ying</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>EP0054</th>
<th>Predictors of adherence to isoniazid preventive therapy in HIV patients in Ethiopia: a prospective cohort study</th>
</tr>
</thead>
<tbody>
<tr>
<td>H. Ayele* [Utrecht, Netherlands], M. van Mourik, M. Bonten</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>EP0055</th>
<th>Molecular typing of Mycobacterium tuberculosis complex species isolated from tuberculosis lymphadenitis cases in Addis Ababa, Ethiopia</th>
</tr>
</thead>
<tbody>
<tr>
<td>A. Worku* [Addis Ababa, Ethiopia], O. Zewdie, G. Ameni</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>EP0056</th>
<th>Rapid mycobacterial culture in resource-limited settings by Decomics and TK SLC medium</th>
</tr>
</thead>
<tbody>
<tr>
<td>S. Thakur* [Jalandhar, India], T. Kocagoz, V. Singh, D. Sharma, K. Sharma, B. Sharma, P. Dutta, D. Mahajan</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>EP0057</th>
<th>Improved culture sensitivity and growth rate of mycobacteria from clinical specimens</th>
</tr>
</thead>
<tbody>
<tr>
<td>I. Szpinda, T. Tonjum* [Oslo, Norway]</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>EP0058</th>
<th>Acquisition of Mycobacterium abscessus among ventilator-dependent patients in Taiwan chronic respiratory care facilities</th>
</tr>
</thead>
<tbody>
<tr>
<td>P. Hsueh* [Taipei, Taiwan], M. Lee, C. Yu</td>
<td></td>
</tr>
<tr>
<td>EP0059</td>
<td>Mycobacterium tilburgii: the first sequenced genome</td>
</tr>
<tr>
<td>J. Zoll* (Nijmegen, Netherlands), J. Van Ingen, S. Kuipers, W. Melchers</td>
<td></td>
</tr>
</tbody>
</table>

| EP0060 | VideoScan: a novel method for investigating biofilms |
| J. Schiebel* (Senftenberg, Germany), A. Böhm, J. Nitschke, J. Weinreich, K. Rapsch, S. Rädiger, P. Schierack |

| EP0061 | Streptokinase treatment reverses biofilm-associated antibiotic resistance in Staphylococcus aureus in vitro |
| N. Jørgensen* (Aarhus, Denmark), N. Zobek, J. Haaber, H. Ingmer, O. Larsen, R. Meyer |

| EP0062 | Liposomal amphotericin B shows poor antifungal activity against Candida tropicalis biofilms |
| L. Marcos-Zambrano* (Madrid, Spain), P. Escribano Martos, C. Sánchez-Carrillo, E. Bouza Santiago, J. Guinea |

| EP0063 | Prevention of biomaterial-associated infection using preoperative incubation with human cells |
| R. Perez Tanoira* (Helsinki, Finland), A. Aarnisalo, X. Han, A. Soininen, V. Tiainen, K. K. Eklund, T. J. Kinnari |

| EP0064 | Subacute toxicity and pharmacokinetics of colistin in rats following two intravenous doses of colistin sulfate and dextrin-colistin conjugates |
| E. Ferguson* (Cardiff, United Kingdom), D. Thomas, P. Chan, C. Singley |

| EP0065 | The low molecular weight alginate OligoCF 5/20 modifies the formation of Pseudomonas aeruginosa mucoid biofilms in vitro |
| L. Powell* (Cardiff, United Kingdom), M. Pritchard, E. Ferguson, K. Powell, A. Jack, E. Onseyen, P. Rye, K. Hill, D. Thomas |

| EP0066 | Retrieval of microorganisms from explanted device biofilm: efficacy of three elution methods |
| F. Tessarolo* (Trento, Italy), F. Piccoli, E. Bonomi, M. Rigoni, G. Nollo, P. Caciagli, I. Caola |

| EP0067 | Does biomass production correlate with metabolic activity in Staphylococcus aureus? |
| M. Guembe* (Madrid, Spain), M. Pérez-Granda, C. Sánchez-Carrillo, R. Cruces, E. Bouza Santiago |

| EP0130 | Variability of colistin plasma protein binding during intravenous treatment |
| E. van Kan* (Apeldoorn, Netherlands), A. Otten, E. Olyslager, B. Koch, A. van Zanten, M. van Westreenen, L. van Gendt-de Jong |

| EP0131 | In vitro activity of nicosamide in combination with colistin against colistin-susceptible and colistin-resistant Gram-negative bacilli |
| V. Sánchez Encinales, R. Ayerbe* (Seville, Spain), P. Raquel, M. Pachon-Ibáñez, J. Sánchez Cespedes, J. Pachon-Díaz, Y. Smani |

| EP0132 | In vitro synergistic activity of colistin and daptomycin combination against carbapenem-resistant Acinetobacter baumannii |
| E. Berk* (Kayseri, Turkey), H. Demiraslan, B. Erçol, E. Kaya, E. Alp, H. Kılıç |

| EP0133 | Subacute toxicity and pharmacokinetics of colistin in rats following two intravenous doses of colistin sulfate and dextrin-colistin conjugates |
| E. Ferguson* (Cardiff, United Kingdom), D. Thomas, P. Chan, C. Singley |

| EP0134 | Molecular epidemiology and antimicrobial susceptibilities of Clostridium difficile isolated from a university teaching hospital in Beijing, China |
| J. Cheng* (Beijing, China), X. Meng, Y. Xu |
EP0137  Early identification of colistin-induced renal dysfunction  
M. Veve, S. Davis, M. Ghazi* [Detroit, United States], R. Kenney, J. Wagner

EP0138  Predicting the risk of nephrotoxicity in patients receiving colistimethate sodium  
K. Phe, R. Shields, F. Tverdek, S. Aitken, D. Guervil, W. Lam, R. Musgrove, A. Luce, V. Tam* [Houston, United States]

EP0139  Impact of colistin therapeutic drug monitoring in a clinical setting  

EP0160  Distribution of commensal Streptococcus pneumoniae capsular types in nine European countries  
R. Yahiaoui* [The Hague, Netherlands], C. Den Heijer, H. Bootsma, G. Pluister, J. Paget, E. Stobberingh

EP0161  Streptococcus pneumoniae serotypes nasopharyngeal carriage in healthy children in the Republic of Kazakhstan  
B. Ramazanova, L. Yeraliyeva* [Almaty, Kazakhstan], K. Mustafina, E. Koloskova, A. Kuatbayeva

EP0162  Important gender differences in invasive pneumococcal disease and the impact of pneumococcal conjugate vaccination, the Netherlands  
G. Wagenvoort* [Nieuwegein, Netherlands], M. Knol, B. Wainiinckx, K. Elberse, H. de Melker, A. van der Ende, E. Sanders

EP0163  Field effectiveness of elderly immunization with pneumococcal conjugate vaccine in Northern Italy  
F. Ansoldi, A. Orsi* [Genoa, Italy], P. Durando, C. Alcino, C. Trucchi, C. Paganino, J. Barberis, D. De Florentiis, M. Zaccconi, E. Albanese, V. Turello, S. Schiaffino, G. Icardi

EP0164  Summarized data of carried pneumococcus before and after PCV vaccinations between 2009-2013 in Hungary  
A. Tothpal* [Budapest, Hungary], E. Kavács, K. Laub, S. Kardos, T. Tirczka, M. van der Linden, O. Dobay

EP0165  Serotype distribution and antibiotic sensitivity of invasive pneumococcal disease-causing Streptococcus pneumoniae in adults in 13-valent pneumococcal conjugate vaccine  

EP0220  Time to positivity in blood cultures as a diagnostic tool – can it be used for preliminary discrimination between Staphylococcus aureus and coagulase-negative staphylococci?  
M. Larsson* [Karlskrona, Sweden], O. Ekelund

EP0221  Blood cultures performed on infectious patients are an essential part of a diagnostic bundle and reduce length of stay  
J. Dik* [Groningen, Netherlands], R. Hendrix, J. Lo-Ten-Foe, A. Friedrich, B. Sinha

EP0222  Borrelia miyamotoi in Finland  
E. Sajanti* [Turku, Finland], R. Penttinen, J. Hytönen, S. Moreno Guillén

EP0223  Acinetobacter dijkshoornii sp. nov., a new member of the Acinetobacter calcoaceticus-Acinetobacter baumannii complex recovered from clinical samples in different countries  
EP0224 Genotypic relatedness between clinical and environmental isolates of *Staphylococcus pettenkoferi*
E. Månsson* (Västerås, Sweden), B. Hellmark, M. Sundqvist, B. Söderquist

EP0225 The effect of culture-enrichment on pneumococcal detection in a longitudinal study of infants with and without symptoms of respiratory tract infection
A. Wyllie* (Utrecht, Netherlands), D. Bogaert, J. van Engelsdorp Gastelaars, E. van der Ent, E. Sanders, K. Trzci ski

EP0226 NGS in sepsis for microbiome and resistome detection: is it too early or not?
C. Ravry, B. François, M. Ploy, P. Vignon, O. Barraud* (Limoges, France)

EP0227 *Clostridium difficile* infection point-prevalence study (Basel, Switzerland): a two-step protocol with GDH/PCR is equally sensitive as PCR alone for detection of toxigenic *C. difficile*
S. Tschudin-Sutter* (Basel, Switzerland), A. Egli, R. Schindler, V. Spaniol, D. Goldenberger, R. Frei, A. Widmer

EP0228 *Clostridium difficile* infections in general practice: results of a laboratory-based cohort study

EP0229 Sulfadiazine resistance in *Toxoplasma gondii*: transcriptomic approach
A. Mzabi* (Reims, France), S. Escotte-Binet, D. Aubert, I. Villena

EP0230 Production of nanovaccine, dendrimer nanoparticle containing TSA recombinant plasmid of *Leishmania major* and evaluation of its immunogenicity in balb/c mice
F. Tabatabaei* (Tehran, Iran), S. Zarrati, N. Mohdavi, M. Karamian* (Birjand, Iran), F. Haghighi, M. Hemmati, A. Saleh Abadi

EP0231 Scabies control in high prevalence settings: could mass drug administration be the way forward?

EP0232 Treatment of *Dientamoeba fragilis* and *Enterobius vermicularis* coinfected patients

EP0233 Phylogenetic analysis of *Echinococcus canadensis* genotype 6; the main causative agent of cystic echinococcosis in Birjand, Eastern Iran
M. Karamian* (Birjand, Iran), F. Haghighi, M. Hemmati, A. Saleh Abadi

EP0234 Superinfection with an endosymbiotic bacterium *Parvibaculum lavamentivorans* leads to manifest *Leishmania donovani* as post-kalaazar dermal leishmaniasis
S. Singh* (New Delhi, India), A. Gupta, S. Srivastava, A. Singh

EP0235 Detection and genetic characterization of *Cryptosporidium* spp. among patients infected with HIV and renal transplant recipients, by conventional and molecular techniques
A. Dey* (Lucknow, India), U. Ghoshal, V. Agarwal, U. Ghoshal

EP0236 Severe imported vivax malaria: a case series from the United Kingdom
N. Venkatraman* (Oxford, United Kingdom), T. Morris, A. Rosser, N. Jesudason, M. Wiselka

EP0237 Changing causes of eosinophilia in London
L. Macpherson, J. Barrett, C. Warrell* (London, United Kingdom)

EP0238 Clinical follow-up and tolerance of Chagas infected patients treated with benznidazole

EP15 13:00-14:00 ePoster Session
Clinical parasitology news
Moderator: Rogelio López-Vélez (Madrid, Spain)

EP0279 Sulfadiazine resistance in *Toxoplasma gondii*: transcriptomic approach
A. Mzabi* (Reims, France), S. Escotte-Binet, D. Aubert, I. Villena

EP0280 Production of nanovaccine, dendrimer nanoparticle containing TSA recombinant plasmid of *Leishmania major* and evaluation of its immunogenicity in balb/c mice
F. Tabatabaei* (Tehran, Iran), S. Zarrati, N. Khabaz Zadeh Tehrani, A. Imani Fooladi, M. Mohdavi, M. Roudbar

EP0281 Scabies control in high prevalence settings: could mass drug administration be the way forward?

EP0282 Treatment of *Dientamoeba fragilis* and *Enterobius vermicularis* coinfect ed patients

K060 14:30-15:30 Hall A
Keynote Lecture
Excellence Award Lecture
Chairs: Murat Akova (Ankara, Turkey) Gunnar Kahlmeter (Växjö, Sweden)

K259 14:30 Robert A. Bonomo [Cleveland, OH, United States]

OS061 14:30-15:30 Hall B
1-hour Oral Session
Tuberculosis: diagnosis & outcomes
Chairs: Mark Patrick Nicol (Cape Town, South Africa) Miguel Viveiros (Lisbon, Portugal)

OS260 Comparison of a tuberculin skin testing-based and a QuantiFERON®-TB Gold in-tube-based strategy for tuberculosis contact tracing: the OPTIMIST study
First independent evaluation of QuantiFERON-TB Gold Plus performance

Diagnosis and resistotyping of Mycobacterium tuberculosis by whole genome sequencing: prospective comparison with routine practice
G. Smith* (Birmingham, United Kingdom), Z. Bawa, P. Rathod, J. Mowbray, T. Quan, P. Welch, L. Pankhurst, T. Walker, S. Gharbia, S. Walker, T. Petro, D. Crook, D. Wyllie

Diagnostic accuracy of the novel C-Tb skin test for LTBI, results from two phase III trials
M. Ruhwald* (Copenhagen, Denmark), J. Cayla, H. Aggerbaek, K. Dheda, P. Andersen

Mortality and co-morbidities among Danish tuberculosis patients 1998-2010
A. Fleé* (Aarhus, Denmark), A. Lekke, R. Ibsen, O. Hilberg

The improving trend in the HIV continuum of care in Croatia in the period 2010-2014

Minimum adherence threshold needed for maintenance of virologic suppression
J. Yager, T. Lodise, N. Patel* (Albany, United States)

Alexithymia predicts increased IMT and vascular events in a multicentre HIV cohort

Dynamics of HIV epidemic and transmission networks within new diagnoses, France 2012-2014

Greater HIV proviral decline in acute compared to recent cART-treated infections
I. Abbate, C. Pinnetti, G. Rozera, N. Orchi, R. Libertone, V. Bordoni, A. Amendola, A. Antinori, A. Ammassari, M. Capobianchi* (Rome, Italy)

S063 14:30-15:30 Hall D
1-hour Oral Session
Severe sepsis and septic shock
Chairs: Evangelos Giamarellos-Bourboulis (Athens, Greece) Willem Joost Wiersinga (Amsterdam, Netherlands)

The dearth of funding for sepsis research: a systematic analysis of UK and USA NIH infectious disease research investments
R. Brown* (Southampton, United Kingdom), M. Head, S. Clarke

Infectious diseases team for the early management of severe sepsis and septic shock in the emergency department
S. Tedeschi* (Bologna, Italy), F. Tumietto, F. Cristini, M. Bartoletti, M. Giannella, L. Raumer, G. Virgili, A. Berlingeri, M. Brizi, M. Cavazza, P. Viale

Efficacy of a sepsis dedicated training programme in a non-tertiary care hospital. A before-and-after study
S. Torri* (Milan, Italy), B. Antonini, P. Pedroni, L. Signorini, R. Stellini, L. Suardi, P. Colombini, F. Castelli, A. Indelicato

S070 14:30-15:30 Hall E
1-hour Oral Session
Challenges in HIV care in 2016
Chairs: Dan Otelea (Bucharest, Romania) Anna Maria Geretti (Liverpool, United Kingdom)

The improving trend in the HIV continuum of care in Croatia in the period 2010-2014

Minimum adherence threshold needed for maintenance of virologic suppression
J. Yager, T. Lodise, N. Patel* (Albany, United States)

Alexithymia predicts increased IMT and vascular events in a multicentre HIV cohort

Dynamics of HIV epidemic and transmission networks within new diagnoses, France 2012-2014

Greater HIV proviral decline in acute compared to recent cART-treated infections
I. Abbate, C. Pinnetti, G. Rozera, N. Orchi, R. Libertone, V. Bordoni, A. Amendola, A. Antinori, A. Ammassari, M. Capobianchi* (Rome, Italy)

S064 14:30-15:30 Hall E
1-hour Symposium
Personalized vaccinology – what it could be and what it cannot be [Pro-Con Debate]
Chairs: Susanna Esposito (Milan, Italy) Pierre Van Damme (Antwerp, Belgium)

Personalized vaccinology - we are almost there
Gregory A. Poland (Rochester, MN, United States)

Personalized vaccinology - still very far away I am afraid!
Outi Vaarala (Helsinki, Finland)

S277 14:30 Hall F
1-hour Symposium
CNS distribution of antimicrobial agents revisited
Chairs: Markus Zeitlinger (Vienna, Austria) Elisabet Nielsen (Uppsala, Sweden)

What can we learn about antibiotic CNS distribution using microdialysis?
Claire Dahyot-Fizelier (Poitiers, France)
Sunday, 10 April 2016

S278 15:00 Distribution of antivirals in brain: what do we know?  
   Marie Studahl [Gothenburg, Sweden]

SY066 14:30-15:30 Hall G  
1-hour Symposium  
Do we have efficient decolonization regimens for MDR Gram-negatives?  
Chairs:  
   Achilleas Gikas [Heraklion, Greece]  
   Maria Virginia Villegas [Cali, Colombia]

S279 14:30 Decolonization strategies for ESBL: who, how and when?  
   Loreen Herwaldt [Iowa City, IA, United States]

S280 15:00 Decolonization strategies for CRE: future perspectives  
   Andreas F. Widmer [Basel, Switzerland]

OS067 14:30-15:30 Hall H  
1-hour Oral Session  
Animal reservoirs and human infection epidemiology  
Chairs:  
   Antonio Battisti [Rome, Italy]  
   Hakan Leblebicioglu [Samsun, Turkey]

0281 Sheep are reservoir of pathogenic Yersinia enterocolitica of bioserotypes 2:09 and 5:03  
   K. Eklund, S. Joutsen, M. Fredriksson-Ahomaa* [Helsinki, Finland]

0282 Molecular epidemiology of Campylobacter jejuni and Campylobacter coli circulating in a model ecosystem with intense agricultural activity and high rates of campylobacteriosis  
   E. Taboada, S. Mutschall* [Lethbridge, Canada], B. Hetman, V. Boras, P. Hodgkinson, V. Suttrop, D. Inglis

0283 Do raccoons play a significant role in the transmission dynamics of Campylobacter jejuni at the interface of wild animal populations and livestock?  
   S. Mutschall* [Lethbridge, Canada], C. Jardine, E. Taboada

0284 Wild birds (kelp gulls) as a reservoir of extended-spectrum cephalosporin-resistant Salmonella spp and E. coli in Ushuaia, Argentina  
   A. Liakopoulos* [Lelystad, Netherlands], Y. Geurts, K. Artursson, C. Berg, J. Bonnedahl, B. Olsen, D. Mevius

0285 Cost-effectiveness of shorter versus longer antibiotic therapy in patients with borreliosis-attribute persistent symptoms  
   A. Berende* [Nijmegen, Netherlands], B. Kullberg, L. Nieuwenhuis, H. ter Hofstede, F. Vos, A. Evers, A. Adang

OS068 14:30-15:30 Hall I  
1-hour Oral Session  
Comparative clinical trials of infections with resistant Gram-negative bacteria  
Chairs:  
   Maria Souli [Athens, Greece]  
   Pilar Retamar Gentil [Seville, Spain]

0286 Colistin versus ceftazidime/avibactam in the treatment of carbapenem-resistant Klebsiella pneumoniae infections  
   D. van Duin* [Chapel Hill, United States], E. Cober, S. Richter, F. Perez, R. Salata, R. Kalayjian, R. Watkins, N. Scalera, Y. Dori, K. Kaye, S. Evans, V. Fowler, R. Banamo

0287 Efficacy of ceftazidime-avibactam against ceftazidime-resistant Gram-negative pathogens: a pooled analysis from the ceftazidime-avibactam clinical trial programme  
   L. Gasink, G. Stone, J. Armstrong, H. Broadhurst, P. Newell, A. Wardman* [Alderley Park, United Kingdom]

0288 Interim analysis of the efficacy of POL7080 co-administered with standard-of-care (SoC) in a phase II study in patients with ventilator-associated pneumonia (VAP) due to suspected or documented Pseudomonas aeruginosa infection  

K291 14:30 Mahmoud A. Ghannoum [Cleveland, OH, United States]
OS070 14:30-15:30 Hall K
1-hour Oral Session
Crash course in pneumovaccinology

Chairs: Nicola Principi [Milan, Italy]
Amelieke Cremers [Nijmegen, Netherlands]

OS072 16:00-18:00 Hall C
2-hour Symposium
Ageing with HIV

Chairs: Annemarie Wensing [Utrecht, Netherlands]
Barbara Hasse [Zurich, Switzerland]

S029 16:00 Metabolic dysfunctions in people living with HIV: an update
Philip E. Tan [Basel, Switzerland]

S030 16:30 Long-term HIV infections in young people
Adrian Streinu-Cercel [Bucharest, Romania]

S031 17:00 HIV infection management: alternatives to minimize the cardiovascular risk
Esteban Martinez [Barcelona, Spain]

S032 17:30 Protecting renal function in people living with HIV
Lene Ryom [Copenhagen, Denmark]

SY071 16:00-18:00 Hall A
2-hour Symposium
Year in Infectious Diseases

Chairs: Maria Souli [Athens, Greece]
Aukse Mickiene [Kaunas, Lithuania]

S297 16:00 Part 1
Karin Thursky [Melbourne, Australia]

S298 16:30 Part 2
Jordi Carratala [Barcelona, Spain]

S299 17:00 Part 3
Souha S. Kanj [Beirut, Lebanon]

S300 17:30 Panel Discussion

SY073 16:00-18:00 Hall D
2-hour Symposium
Clostridium difficile infections from East to West

Chairs: Sarah Tschudin-Sutter [Basel, Switzerland]
Ed J. Kuijper [Leiden, Netherlands]

S305 16:00 CDI in Eastern Europe: challenges and opportunities for surveillance
Agnes Hajdu [Budapest, Hungary]

S306 16:30 News from CDI surveillance across Europe
Carl Suetens [Stockholm, Sweden]

S307 17:00 National burden of CDI in USA
Alice Ghu [Atlanta, GA, United States]

S308 17:30 The Canadian success of CDI outbreak control
Vivian Loo [Montreal, Canada]

SY074 16:00-18:00 Hall E
2-hour Oral Session
Updates in bloodstream infection epidemiology and management

Chairs: Anastasia Antoniadou [Athens, Greece]
Issam Raad [Houston, TX, United States]

S309 16:00 Trends in nosocomial and community-acquired bacteraemia in the Netherlands, 2008-2013 – contribution of highly resistant microorganisms
S. Woudt* [Bilthoven, Netherlands], T. Leenstra, A. Vlek

S310 16:30 Clinical and microbiological characteristics of enteric fever in Phnom Penh, Cambodia, 2008-2015
L. Kuipers* [Antwerp, Belgium], T. Phe, C. Veng, D. Sar, P. Chung, I. Sovann, C. Kham, E. Vlieghe, K. Lim, J. Jacobs, W. Peetermans
Sunday, 10 April 2016

0311 Microbiology of early-onset and late-onset bloodstream infection in neutropenic patients after high-dose chemotherapy: a prospective multicentre cohort study of 3029 bloodstream infections
C. Theilacker* [Basel, Switzerland], S. Tschudin-Sutter, H. Bertz, M. Dettenkofer, W. Kern, A. Widmer

0312 Bloodstream infection in cirrhotic patients: a prospective multicentre study [bichrome]

0313 Analysis of 3029 bloodstream infections in neutropenic patients after high-dose chemotherapy: A prospective multicentre cohort study
C. Theilacker* [Basel, Switzerland], M. Weisser, W. Kern, H. Bertz, R. Babikir, M. Dettenkofer, A. Widmer

0314 Genomic tracks behind spread of bacteraemic group A Streptococcus type emm89 in Finland, 2004-2014

0315 Phenotypic and genotypic risk factors of infectious mortality in Staphylococcus aureus infective endocarditis – preliminary results
N. Fernandez-Hidalgo* [Barcelona, Spain], N. Larrosa, D. Pérez, E. Viedma, C. Sáez, M. García López, M. Góbbi, A. Bacigalupo, M. Mikulská, C. Viscoli

0316 Extremely high mortality rates in patients with carbapenem-resistant, string test-positive Klebsiella pneumoniae infections
C. Shankar* [Veilore, India], L. Nabano, S. Anandan, E. Munusamy, P. Babu, R. Ravi, V. Jegaseelan, G. Mathew, V. Balaji

0317 Previous scores for extended-spectrum beta-lactamase-producing Enterobacteriaceae in community-onset bloodstream infections show low predictive ability

0318 A pooled analysis of clinical cure and mortality with cefotibipro medocaril versus comparators in staphylococcal bacteraemia in complicated skin infections, and community- and hospital-acquired pneumonia
J. Rello* [Barcelona, Spain], G. Rahav, T. Scheeren, M. Soulay, M. Engelhardt, T. Welte

0319 Standardization of diagnostic assays for parasitic diseases
D. Padley* [Potters Bar, United Kingdom]

0320 Community deworming alleviates geoheirmith-induced immune hyposresponsiveness: a household-clustered randomized controlled trial

0321 Is there an easier way to differentiate phases of Toxoplasma gondii infection in pregnant women?
A. Pietrzyk, P. Kochan* [Kraków, Poland], B. Papir, M. Bulanda

0322 Leishmaniasis in a low-endemicity area of northern Italy: a 10-years retrospective study
P. Tatarelli* [Genoa, Italy], G. Fornara, V. Del Bono, G. Mazzarella, F. Guola, L. Giannoni, A. Raiola, M. Gobbi, A. Bacigalupo, M. Mikulská, C. Viscoli

0323 A new emerging tick-borne infection in Scandinavia? Prevalence and diversity of Babesia spp in Ixodes ricinus ticks that have bitten humans and the clinical outcome
M. Lövmar, P. Wilhelmsson, H. Nielsen, K. Krogfelt, P. Forsberg, P. Lindgren* [Linköping, Sweden]

0324 Osseous cystic echinococcosis: a European multicentre study
L. Cattaneo* [Pavia, Italy], C. Cretu, M. Giordani, A. Angheben, A. Bartoloni, L. Zammarchi, J. Richter, P. Chiodini, G. Godbole, T. Junghanss, M. Stojkovic, F. Benazzo, F. Cuzzocrea, F. Tamarozzi, E. Brunetti

0325 CellsCheck® automated malaria diagnosis: a new tool in the fight against malaria
S. Houze* [Paris, France], V. Hubert, C. Marechal, N. Argy, T. Lamy, S. Salpeter

0326 Diagnosis of active Schistosoma infection in travellers and migrants using the ultra sensitive in-house lateral flow test for detection of schistosomal circulating anodic antigen (CAA) in serum
R. van Grootveld* [Leiden, Netherlands], G. van Dam, C. de Dood, J. van Vries, P. Corstjens, L. van Lieshout

0327 A real-time PCR to detect Leishmania infantum DNA in immunocompetent patients with chronic inflammatory rheumatism living in rural Northern Italy and treated with biologic drugs
M. Maritati* [Ferrara, Italy], P. Marty, S. Hanau, G. Michel, F. Dallocchio, T. Bellini, G. Rugna, S. Bonazza, M. Govoni, S. Almoghadam, C. Contini

0328 Chairs: Peter Chiodini (London, United Kingdom)
Miriam José Alvarez Martinez (Barcelona, Spain)
2-hour Symposium

**Critical appraisal of new antibiotics**

**Chairs:**
- Inge C. Gyssens (Nijmegen, Netherlands)
- Arnfinn Sundsfjord (Tromsø, Norway)

**S329 16:00**
First experiences with new beta-lactam/beta-lactamase inhibitor combinations

David L. Paterson (Herston, Australia)

**S330 16:30**
The new and coming oxazolidinones and glycopeptides: best for whom?

Angela Huttner (Geneva, Switzerland)

**S331 17:00**
Modern tetracyclines and fluoroquinolones

Winfried V. Kern (Freiburg, Germany)

**S332 17:30**
What other new antibiotics will soon come to market?

Ursula Theuretzbacher (Vienna, Austria)

2-hour Oral Session

**Prevention of surgical site infections: the holy grail of infection control**

**Chairs:**
- Eli Perencevich (Iowa City, IA, United States)
- Maaike S.M. van Mourik (Utrecht, Netherlands)

**O333**
Does opening doors affect the air contamination in clean surgery? A prospective, cross-sectional study (the ARIBO project)


**O334**
Duration of antibiotic therapy in post-operative peritonitis: the Durapop study


**O335**
Development of a prediction model to estimate the risk of *S. aureus* surgical site infection or bacteraemia after cardiothoracic surgery


**O336**
Mupirocin ointment for preventing *Staphylococcus aureus* infections in nasal carriers undergoing surgery: a systematic review

M. van Rijen* (Breda, Netherlands), B. Allegranzi, J. Salomkin, J. Kluymans

**O337**
Targeting lower perioperative glucose levels to reduce surgical site infections without an increased risk of mortality or stroke - a systematic review and meta-analysis

F. de Vries* (Amsterdam, Netherlands), S. Gans, J. Salomkin, B. Allegranzi, M. Egger, P. Dellinger, M. Boermeester

**Antimicrobial-coated sutures to decrease surgical site infections: a systematic review**

X. Wu* (Nanjing, China), Z. Kubilay, J. Ren, B. Allegranzi, B. Zayed, D. Pittet, J. Li

**Optimal duration for antibiotic prophylaxis - a systematic review and meta-analysis**

S. de Jonge* (Amsterdam, Netherlands), B. Zayed, J. Solomkin, P. Dellinger, B. Allegranzi, M. Boermeester

**It is all about the tube: a systematic review [SR] of hyperoxygenation in the prevention of surgical site infection**

J. Solomkin* (Cincinnati, United States), S. de Jonge, B. Zayed, M. Egger

**Epidemiology and outcome differences in surgical site infections associated elective colon and rectal surgery. Are we talking about the same surgical procedure?**

A. Gomila* (Barcelona, Spain), J. Badia, V. Diaz-Brito, A. Cruz, D. Camprubi, R. Escofet, D. Fracaccavieri, E. Shaw, M. Piriz, E. Limón, F. Gudiel, M. Pujol Roja, D. VINCat Program

**Semi-automated surveillance of deep surgical site infections after primary total hip and knee arthroplasty**

M. Sips* (Utrecht, Netherlands), M. Bonten, M. van Mourik
Overview
Monday, 11 April 2016

<table>
<thead>
<tr>
<th>Time</th>
<th>Hall A</th>
<th>Halle B</th>
<th>Halle C</th>
<th>Halle D</th>
<th>Halle E</th>
<th>Halle F</th>
</tr>
</thead>
<tbody>
<tr>
<td>07.45-08.45</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Antifungal stewardship: do we need it in our hospitals?</td>
<td>Quiz busters: you think you know mycology?</td>
<td>Antimicrobial resistance research, supported by funding from the EU and the US NIH/NIAID</td>
<td>How to diagnose and treat infections due to Mycoplasma genitalium and other emerging sexually transmitted pathogens</td>
<td>How to manage brain abscess</td>
<td>Hepatitis C - search and destroy? Screening and eradication strategies</td>
</tr>
<tr>
<td>09.00 – 11.00</td>
<td>Year in Clinical Microbiology</td>
<td>Is pertussis here to stay?</td>
<td>Zoonotic diseases</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11.00-11.30</td>
<td>Coffee Break</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11.30 – 12.30</td>
<td>Antimicrobial resistance: an economics perspective</td>
<td>Infectious causes of sudden and unexpected deaths</td>
<td>Emerging infections in the returning traveller</td>
<td>Clinical trials in community-acquired pneumonia</td>
<td>Phages and antibiotic resistance</td>
<td>Vaccines in the pipeline: far and close</td>
</tr>
<tr>
<td>13.00 – 14.00</td>
<td>Lunch Break / ePoster Sessions, Poster Sessions from Abstracts</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>14.30 – 15.30</td>
<td>How antibiotics for non-human use affect public health</td>
<td>Rising the challenge: novel techniques in microbiology</td>
<td>Redefining HPV vaccination programmes in the EU</td>
<td>Endocarditis</td>
<td>Do we always need antibiotics to treat infections?</td>
<td>Latest news on the clinical front of immunocompromised patients</td>
</tr>
<tr>
<td>15.30-16.00</td>
<td>Coffee Break</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>16.00 – 18.00</td>
<td>Challenging AMR in low-resource settings</td>
<td>Microbiome in disease and treatment</td>
<td>Recent advances of viral immune evasion strategies</td>
<td>Fresh views on research and development beyond classical antibiotics</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Time</td>
<td>Hall G</td>
<td>Hall H</td>
<td>Hall I</td>
<td>Hall J</td>
<td>Hall K</td>
<td></td>
</tr>
<tr>
<td>------------------</td>
<td>-------------------------------</td>
<td>------------------------------------------------------------------------</td>
<td>------------------------------------------------------------------------</td>
<td>------------------------------------------------------------------------</td>
<td>------------------------------------------------------------------------</td>
<td></td>
</tr>
<tr>
<td>07.45-08.45</td>
<td>Computational resources in infectious disease</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>09.00-11.00</td>
<td>What is still hot in hepatitis C?</td>
<td>New insights in the control of multi-resistant Gram-negatives</td>
<td>Drivers of infectious disease emergence</td>
<td>Affordable healthcare</td>
<td></td>
<td></td>
</tr>
<tr>
<td>11.00-11.30</td>
<td>Coffee Break</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11.30-12.30</td>
<td>Hot topics in hepatitis B prevention and treatment</td>
<td>MRSA transmission: good theory, bad practice</td>
<td>Tuberculosis in the 21st century</td>
<td>Neglected parasitic diseases: overview and update</td>
<td>Challenges in antifungal treatment</td>
<td></td>
</tr>
<tr>
<td>13.00-14.00</td>
<td>Lunch Break / ePoster Sessions, Poster Sessions from Abstracts</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>14.30-15.30</td>
<td>MERS update</td>
<td>New insights into host-pathogen interactions</td>
<td>Antibiotic de-escalation (Pro-Con debate)</td>
<td>New drugs for tuberculosis: from genome to patient</td>
<td>Young Investigator Award Lectures</td>
<td></td>
</tr>
<tr>
<td>15.30-16.00</td>
<td>Coffee Break</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>16.00-18.00</td>
<td>Hidden enemy: hepatitis E</td>
<td>Treatment of bone infections</td>
<td>DMICS for infectious diseases</td>
<td>Frontiers in tuberculosis</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Monday, 11 April 2016

**ME078 07:45-08:45**  
Hall C  
Meet-the-Expert Session  
Antimicrobial resistance research, supported by funding from the EU and the US NIH/NIAID  

- Arjen Van Hengel (Brussels, Belgium)  
- Dennis M. Dixon (Bethesda, MD, United States)

**ME079 07:45-08:45**  
Hall D  
Meet-the-Expert Session  
How to diagnose and treat infections due to *Mycoplasma genitalium* and other emerging sexually transmitted pathogens  

- Lisa Manhart (Seattle, WA, United States)  
- Jørgen Skov Jensen (Copenhagen, Denmark)

**ME080 07:45-08:45**  
Hall F  
Meet-the-Expert Session  
Hepatitis C - search and destroy? Screening and eradication strategies  

- Sharon Hutchinson (Glasgow, United Kingdom)  
- Angelos Hatzakis (Athens, Greece)

**ME081 07:45-08:45**  
Hall H  
Meet-the-Expert Session  
Computational resources in infectious disease  

- TBC  
- Frank M. Aarestrup (Copenhagen, Denmark)

**ME082 07:45-08:45**  
E102  
Meet-the-Expert Session  
How to manage brain abscess  

- Nur Benzonana (Istanbul, Turkey)  
- Pierre Tattevin (Rennes, France)

**ME083 07:45-08:45**  
E104/105  
Meet-the-Expert Session  
Antifungal stewardship: do we need it in our hospitals?  

- Karin Thursky (Melbourne, Australia)  
- Patricia Munoz (Madrid, Spain)

**ME084 07:45-08:45**  
E106/107  
Meet-the-Expert Session  
Quiz busters: you think you know mycology?  

- Arunaloke Chakrabarti (Chandigarh, India)  
- Rosa Bellmann-Weiler (Innsbruck, Austria)

**SY085 09:00-11:00**  
Hall A  
2-hour Symposium  
Year in Clinical Microbiology  
Chairs: Niels Frimodt-Moller (Copenhagen, Denmark)  
Emilia Cercenado (Madrid, Spain)

S357 09:00 Part 1  
Luisa Maria Vieira Peixe (Porto, Portugal)

S358 09:30 Part 2  
Herman Goossens (Edegem, Belgium)

S359 10:00 Part 3  
Gilbert Greub (Lausanne, Switzerland)

S360 10:30 Panel Discussion

**SY086 09:00-11:00**  
Hall D  
2-hour Symposium  
Is pertussis here to stay?  
Chairs: Lucia Pastore Celentano (Stockholm, Sweden)  
Hanna M. Nohynek (Helsinki, Finland)

S361 09:00 The truth and the myths on pertussis resurgence  
Alberto Eugenio Tazzi (Rome, Italy)

S362 09:30 Why we still have to improve our diagnostic approach to pertussis  
Qiushui He (Turku, Finland)

S363 10:00 Bridging the immunity gap - current status of prevention of severe pertussis in early life  
Peter McIntyre (Sydney, Australia)

S364 10:30 Will we have new pertussis vaccines?  
Camille Locht (Lille, France)
IC Infection Control Practitioners  
ID Infectious Diseases Fellows  
CM Clinical Microbiologists

OS087 09:00-11:00 Hall F  
2-hour Oral Session  
**Zoonotic**

**Chairs:** Javier Garau (Sant Joan, Spain)  
Amel Letaief (Sousse, Tunisia)

0365 TFN-238 single nucleotide polymorphism is associated with susceptibility for brucellosis and brucellar spondylitis  
E. Giannitsioti, A. Stefos, G. Damarakis, S. Georgiadou, M. Pavlaki, E. Giamarellos-Bourboulis* (Athens, Greece), G. Dalekos

0366 Whole genome phylogeny of Swiss *Francisella tularensis* holarctica isolates  
M. Wittwer* (Spiez, Switzerland), C. Beuret, P. Pilo, N. Schuerch

0367 Early diagnosis of tularemia using flow cytometry - a proof of concept study  
A. Chrdle* (Ceske Budejovice, Czech Republic), P. Tinavskia, P. Filipova, K. Batistava, V. Hnetilova, V. Chmelik, P. Zampach, A. Semper, N. Beeching

0368 Human leptospirosis in French Guiana: first multicentric transversal study (2007-2014)  
P. Le Turnier* (Cayenne, French Guiana), L. Epelboin, E. Mosnier, R. Schaub, A. Jolivet, A. Berliz-Arthaud, P. Baurhy, M. Picardeau, M. Demar, F. Djossou

0369 The value of FDG-PET/CT in diagnosis and during follow-up of 271 patients suspected of chronic Q fever  
I. Kouijzer* (Nijmegen, Netherlands), L. Kamperschreur, P. Wever, C. Hoekstra, M. van Kasteren, M. Leclercq, M. Nabuurs-Franssen, M. van Kasteren, M. Leclercq, M. van Kasteren, M. Leclercq, M. van Kasteren, M. Leclercq

0370 Pneumonic tularemia: experience of 60 cases from 2000-2012  
H. Kauma, E. Saarela* (Oulu, Finland), T. Harju, J. Henry

0371 Mediterranean spotted fever: a cross-sectional retrospective study from a Portuguese Infectious Diseases Service  
A. Silva-Pinto, F. Ceia, L. Santos* (Porto, Portugal), A. Sarmento

0372 Brucellosis in a third-level Mediterranean hospital. A retrospective study  
A. Hernandez Torres, D. Loaiza Ortiz, S. Otálora Valdarrama, B. Robles Rabasco, M. Cotugno, L. Guirado Torrecillas, P. Fernández-Montesinos Aniorte, E. Garcia Vázquez* (Murcia, Spain)

SY088 09:00-11:00 Hall G  
2-hour Symposium  
**What is still hot in hepatitis C?**

**Chairs:** Dominique Salmon-Ceron (Paris, France)  
Joop E. Arends (Utrecht, Netherlands)

S374 09:00  
HCV therapy in 2016: current status  
Jürgen Rockstroh* (Bonn, Germany)

S375 09:30  
Hepatitis C can be cured globally, but at what cost?  
Andrew Hill (London, United Kingdom)

S376 10:00  
Virological tests for monitoring hepatitis C treatment and resistance: any future?  
Heiner Wedemeyer (Hanover, Germany)

S377 10:30  
Barriers to diagnosing and treating hepatitis C in intravenous drug users and how to overcome them  
Adriana Vince (Zagreb, Croatia)

OS089 09:00-11:00 Hall I  
2-hour Oral Session  
**New insights in the control of multi-resistant Gram-negatives**

**Chairs:** Gian Maria Rossolini* (Siena, Italy)  
Lance B. Price (Washington, DC, United States)

0378 Screening for CPE: sensitivity of serial admission screens  
S. Mookerjee, E. Dyakova, F. Davies, K. Bamford, E. Brannigan, A. Holmes, J. Otter* (London, United Kingdom)

0379 The prevention paradox of extended-spectrum beta-lactamase-producing Enterobacteriaceae (ESBL-E): species-specific risk and burden of transmission  
M. Kluytmans - van den Bergh* (Breda, Netherlands), J. Rassen, A. Friedrich, C. Vandenbroucke-Grauls, M. Bonten, J. Kluytmans

0380 Quantifying hospital-acquired carriage of extended-spectrum beta-lactamase-producing Enterobacteriaceae in Dutch hospitals  
M. Kluytmans - van den Bergh, S. van Mens* (Utrecht, Netherlands), M. Haverkate, M. Bootsma, J. Kluytmans, M. Bonten
**Monday, 11 April 2016**

**0381** Impact of combination and sequential antibiotic therapies in selecting resistance  
A. Gorska, G. Marasca, P. Beryl, G. De Angelis, B. Carević, L. Preotescu, Y. Carmeli, S. Malhotra-Kumar, E. Tacconelli* (Tübingen, Germany)

**0382** Source tracking *Pseudomonas aeruginosa* infections in augmented care units using whole-genome sequencing  
F. Halsted, M. Niebel, J. Quick, M. Garvey, R. Smith, T. Neal, K. Hardly, F. Hawkey, N. Loman, J. Walker, B. Oppenheim* (Birmingham, United Kingdom)

**0383** Modelling costs and benefits of strategies to control the spread of extended-spectrum beta-lactamase-producing Enterobacteriaceae (ESBL-PE) in an intensive care unit  
L. Kardas-Sloma* (Paris, France), J. Lucet, C. Pelat, A. Perozzelli, G. Birgand, C. Dupuis, P. Boëlle, A. Andremont, Y. Yazdanpanah

**0384** ERCP duodenoscopes in Dutch ERCP centres: high prevalence of bacterial contamination despite reprocessing  
A. Rauwers* (Rotterdam, Netherlands), A. Voor In’t Holt, R. De Groot, J. Buijs, M. Bruno, M. Vos

**0385** Multicentre point-prevalence survey of multidrug-resistant organisms among nursing home residents in Belgium  
T. Huang* (Yvoir, Belgium), B. Jans, D. Schoevaerdts, P. Bogaerts, K. Latour, B. Catry, D. Denis, M. leven, Y. Glupczynski

**0386** Epidemiological differences in controlling the spread of carbapenem-resistant bacterial strains in hospitalized patients  
P. Beryl, T. Vilken, A. Bernhard, E. Tacconelli* (Tübingen, Germany)

**0387** The effects of selective decontamination on mortality in surgical and medical ICU patients: an individual patient data network meta-analysis  
N. Plantinga* (Utrecht, Netherlands), E. de Jonge, D. Bergmans, W. Krueger, A. de Smet, M. Bonten

**SY090** 09:00-11:00  
Hall J  
2-hour Symposium  
**Drivers of infectious disease emergence**  
Chairs: Koray Ergunay (Ankara, Turkey)  
Jonathan Cohen (Brighton, United Kingdom)

**S388** 09:00 Climate change and infectious disease dynamics  
David Fisman (Toronto, Canada)

**S389** 09:30 Displaced populations, political instability and emerging diseases  
Osman Dar (London, United Kingdom)

**S390** 10:00 Emerging and re-emerging vector-borne diseases  
Rémi Charrel (Marseille, France)

**S391** 10:30 Innovations in emerging disease detection  
Sumiko Mekaru (Boston, MA, United States)

**SY091** 09:00-11:00  
Hall K  
2-hour Symposium  
**Affordable healthcare**  
Chairs: Chrysanthi Skevaki (Athens, Greece)  
Marc Mendelson (Cape Town, South Africa)

**S392** 09:00 Affordability and availability of the new anti-HCV regimens - chances to overcome health systems' defaults?  
Graham Cooke (London, United Kingdom)

**S393** 09:30 Cost-efficacy of simplified regimens against HIV - paradigm shift?  
Karine Lacombe (Paris, France)

**S394** 10:00 Multifaceted infection control programmes - better patient safety for free?  
Jan A.J.W. Kuijtmans (Breda, Netherlands)

**S395** 10:30 Panel discussion - economic constraints for evidence-based drug prescribing and patient safety infrastructure

**KL092** 11:30-12:30  
Hall A  
**Keynote Lecture**  
**Antimicrobial resistance: an economics perspective**  
Chair: Murat Akova (Ankara, Turkey)

**K396** 11:30 Hala Audi (London, United Kingdom)

**SY093** 11:30-12:30  
Hall B  
1-hour Symposium  
**Infectious causes of sudden and unexpected deaths**  
Chairs: Gülhan Yagmur (Istanbul, Turkey)  
Katja Seme (Ljubljana, Slovenia)

**S397** 11:30 Identifying the cause of death in developing countries: microbiology results from the CaDMIA study  
Miguel J. Martinez (Barcelona, Spain)

**S398** 12:00 Identifying the cause of death in developed countries: microbiology results from a prospective Belgian study  
Veroniek Saegeman (Leuven, Belgium)

**SY094** 11:30-12:30  
Hall C  
1-hour Symposium  
**Emerging infections in the returning traveller**  
Chairs: Yupin Suputtamongkol (Bangkok, Thailand)  
Francesco Castelli (Brescia, Italy)

**S399** 11:30 Zika virus infection  
Jonas Schmidt-Chanasit (Hamburg, Germany)

**S400** 12:00 Plasmodium knowlesi malaria  
Babir Singh (Sarawak, Malaysia)
**Clinical trials in community-acquired pneumonia**

**Chairs:** Carolina Garcia Vidal (Barcelona, Spain) 
Marc Falcone (Rome, Italy)

**0401** Empirical treatment and adjustment in hospitalized patients with community-acquired pneumonia in the Netherlands: a prospective observational study

I. van Heijl* (Hilversum, Netherlands), V. Schweitzer, C. Van Werkhoven, P Van Der Linden, S. Huijs, J. Dorigo-Zetsma, M. Bonten

**0402** Severe community-acquired pneumonia (sCAP) in the elderly: impact of empirical antibiotic therapy without respiratory fluoroquinolones (RF) nor third generation cephalosporins (Ceph-3)

C. Aillet* (Nice, France), J. Courjon, E. Demonchy, K. Risso, E. Cua, P. Roger

**0403** Pathogen- and antibiotic therapy-specific effects of adjunct prednisone in community-acquired pneumonia: subanalysis of a double-blind, randomized, placebo-controlled trial

S. Wirz, C. Blum, P. Schuetz, W. Albrich, C. Müller, M. Christ, P. Tarr* (Basel, Switzerland)

**0404** Macrolide addition to beta-lactam treatment for community-acquired pneumonia in hospitalized people living with HIV: preliminary findings from randomized clinical trial

C. Figueiredo Mello* (Sao Paulo, Brazil), P. Naucler, M. Negra, A. Sara Levin

**0405** Practical application of response adjusted for days of antibiotic risk (RADAR) in the empirical antibiotic treatment of community-acquired pneumonia

V. Schweitzer* (Utrecht, Netherlands), C. Van Werkhoven, D. Postma, J. Oosterheert, M. Bonten

**Vaccines in the pipeline: far and close**

**Chairs:** Hanna M. Nohynek (Helsinki, Finland) 
Gregory A. Poland (Rochester, MN, United States)

**0408** Safety and immunogenicity of the heterologous prime-boost Ebola virus vaccine regimen - CHAD3-EBO Z followed by MVA-EBO Z in healthy UK adults


**0409** A phase Ia clinical trial of the blood-stage Plasmodium falciparum vaccine ChAd63-MVA RH5


**Phages and antibiotic resistance**

**Chairs:** Tamás Maria (La Coruña, Spain) 
Ville-Petri Friman (York, United Kingdom)

**0413** Prevention of mother-to-child transmission of hepatitis B: challenges and solutions

Monday, 11 April 2016

**OS099  11:30-12:30**  
*1-hour Oral Session*

**MRSa transmission: good theory, bad practice**

*Chairs:* Barry Cookson (London, United Kingdom)  
Waleria Hryniewicz (Warsaw, Poland)

**0415**  
Genetic adaptations in hospital-acquired MRSA upon switch from a colonizing to infecting lifestyle in patients developing pneumonia  

**0416**  
Genomic context of a colonization and pathogenicity determinant, SasX, in methicillin-resistant *Staphylococcus aureus*  

**0417**  
Investigating an outbreak of methicillin-resistant *Staphylococcus aureus* surgical site infection following elective breast surgery: drilling down the genome  
J. Orendi* (Stoke-on-Trent, United Kingdom), N. Gordon, I. Stanton, A. Normington, B. Pichon, A. Kearns

**0418**  
Patient-related gowns and gloves in the care of very low birth weight infants (VLBWI, <1500g), colonized with methicillin-sensitive *Staphylococcus aureus* (MSSA) may reduce the incidence of MSSA-sepsis  
W. Lindner* (Ulm, Germany), E. Essig, H. Hummler, H. von Baum

**0419**  
Association between universal glove use, MDRO acquisition and healthcare-associated infections: a meta-analysis  

**SY100  11:30-12:30**  
*1-hour Symposium*

**Tuberculosis in the 21st century**

*Chairs:* Christoph Lange (Borstel, Germany)  
Miguel Viveiros (Lisbon, Portugal)

**0420**  
Personalized medicine in tuberculosis  
Sebastien Gagneux (Basel, Switzerland)

**0421**  
Host-directed therapies in tuberculosis  
Markus Maeurer (Stockholm, Sweden)

**KL101  11:30-12:30**  
*Keynote Lecture*

**Neglected parasitic diseases: overview and update**

*Chair:* Eduardo Gotuzzo (Lima, Peru)

**K422  11:30**  
David Molyneux (Liverpool, United Kingdom)

**OS102  11:30-12:30**  
*1-hour Oral Session*

**Challenges in antifungal treatment**

*Chairs:* Andreas H. Groll (Münster, Germany)  
Katrien Lagrou (Leuven, Belgium)

**0423**  
Isavuconazole versus caspofungin in the treatment of candidemia and other invasive *Candida* infections: the ACTIVE trial  

**0424**  
Intra-subject variability and exposure-response relationship of isavuconazole in the phase 3 SECURE study in patients with invasive mould disease caused by *Aspergillus* spp. and other filamentous fungi  
T. Kaindl* (Basel, Switzerland), M. Engelhardt, R. Townsend, L. Kovanda, M. Saulay, A. Schmitt-Hoffmann

**0425**  
The safety and single-dose pharmacokinetics of CD101IV: results from a phase 1, dose-escalation study  
S. Helou, D. Armas, J. Lee, V. Ong, D. Thyge* (San Diego, United States)

**0426**  
Retrospective analysis of 1mg/kg/day dose of liposomal amphotericin for empirical treatment of potential invasive mould disease in at-risk adult haematology patients whilst awaiting further results  
T. Collyns* (Leeds, United Kingdom), H. Wilson, G. Cook, M. Gilleece, Q. Hill, R. Johnson

**0427**  
The impact of guidelines-concordant management on the outcomes of candidemia  
**Escherichia coli: diverse, complex, evolving**

*Moderator: Ana Budimir (Zagreb, Croatia)*

**EP0070**

Faecal carriage of antibiotic-resistant *Escherichia coli* in asymptomatic children and associations with primary care antibiotic prescribing: a systematic review and meta-analysis

A. Bryce* (Bristol, United Kingdom), C. Costelloe, C. Hawcroft, M. Wootton, A. Hay

**EP0071**

Global antibiotic resistance prevalence in paediatric *Escherichia coli* urinary tract infections and associations with routine use of primary care antibiotics: a systematic review and meta-analysis

C. Costelloe* (London, United Kingdom), A. Bryce, A. Hay

**EP0072**

Effect of trimethoprim/nitrofurantoin prescribing on the incidence and antibiotic susceptibility patterns of *Escherichia coli* bacteraemia nationally at the GP practice level (2012-2014)


**EP0073**

Susceptibility of *Escherichia coli* to fluoroquinolones and 3rd-generation cephalosporins by age group and gender – results from the German antimicrobial resistance surveillance system 2014

I. Noll* (Berlin, Germany), B. Schweickert, M. Feig, M. Abu Sin, T. Eckmanns

**EP0074**

Age and sex mainly predict antimicrobial resistance in *E. coli* from urinary tract specimens: analysis of 7361 urine samples

S. Erb, R. Frei, S. Tschudin-Sutter, A. Egli, M. Dangel, G. Bonkat, A. Widmer* (Basel, Switzerland)

**EP0075**

Background: bacteraemia due to non-ESBL-producing *Escherichia coli* ST131: risk factors and outcome


**EP0076**

Faecal carriage of multidrug-resistant Gram-negative bacteria by patients on admission to two Ulaanbaatar Hospitals in Mongolia


**EP0077**

Multidrug resistance to oral antibiotics in *Escherichia coli* urine isolates from outpatients in Germany and in vitro activity of nitroxoline: results of the PEG 2013 study

M. Kresken* (Rheinbach, Germany), B. Köber-Irrgang, D. Hafner, W. of the Paul-Ehrlich-Society for Chemotherapy

**EP0078**

Phenotypic and genotypic characterization of the ancestral *Escherichia coli* strains: the good old time when *Escherichia coli* was hypersusceptible to antibiotics

J. Decousser* (CRETEIL, France), M. Desroches, M. Darty, C. Rodriguez, O. Clermont, E. Denamur

**EP0079**

Whole genome sequence comparison of endemic multi-resistant *Escherichia coli* clones

T. Havnhøj Frandsen* (Copenhagen, Denmark), R. Marvig, L. Percival Andersen

**EP0100**

WGS analysis of horizontally transferred DNA gyrase genes between *Campylobacter species* M. Gunell* (Turku, Finland), J. Iirona, S. Pietilä, J. Jalava, P. Huovinen, J. Vuopio, A. Hakkarén

**EP0101**

Comparison of *Streptococcus pyogenes* isolates from invasive and skin and soft tissue infections reveal differences in the capacity to interact with host proteins

C. Pato* (Lisbon, Portugal), A. Frías, M. Ramírez, J. Mello-Cristino

**EP0102**

Molecular characterization and diversity of shiga toxin-producing *E. coli* (STEC) isolates obtained in the Netherlands

M. Ferdeaux* (Groningen, Netherlands), A. Friedrich, H. Grundmann, R. de Boer, P. Croughs, M. Islam, M. Kluytmans - van den Bergh, A. Koostra-Smidt, J. Rossen

**EP0103**

First European external quality assessment (EQA) for *Staphylococcus aureus* by a network of 11 European referring laboratories

A. Deplano, F. Laurent, A. Tristan, F. Vandenesch, D. Olivier* (Brussels, Belgium)

**EP0104**

Genome-based epidemiological surveillance of *Listeria monocytogenes* on a global scale


**EP0105**

Molecular characterization of the first outbreak of *C. difficile* 027 detected in Spain

M. Marín* (Madrid, Spain), A. Martin, L. Alcala, M. González Del Vecchio, E. Reigados Ramírez, R. Onori, E. Bouza
Monday, 11 April 2016

EP0106  Genomic subtyping advances our understanding of the epidemiology of campylobacteriosis: a study from Nova Scotia, Canada
E. Schleihauf, E. Taboada, B. Billard, S. Mutschall, D. Haldane* (Halifax, Canada)

EP0107  Group B streptococcal (GBS) colonization among non-pregnant adults in Portugal: prevalence, serotypes, genetic lineages and resistance
E. Ferreira Martins* (Lisbon, Portugal), J. Melo-Cristino, M. Ramirez

EP0108  Molecular characterization and antimicrobial resistance of scarlet fever and invasive Streptococcus pyogenes in England and Wales, 2014
J. Coelho* (London, United Kingdom), M. Doumith, R. Pike, R. Daniel, C. Dhami, M. Prest, T. Chambers, R. Hill, N. Woodford, V. Chalker

EP0109  Characterization and genetic relatedness of methicillin-susceptible Staphylococcus aureus strains circulating in the Pretoria region, South Africa: a cross-sectional study
M. Potgieter, M. Kock, F. Ismail, M. Ehlers* (Pretoria, South Africa)

EP0110  Validation of a rapid analysis tool for next-generation sequencing-based pathogen detection for routine diagnostic application

EP0111  Economic impact of a new rapid PCR assay for detecting influenza virus in an emergency department and hospitalized patients
M. Soto* (Barcelona, Spain), L. Sampetro-Colom, A. Villega, E. Pantoja, M. Asenjo, R. Arjona, J. Hurtado, A. Trilla, M. Alvarez Martinez, J. Vila, M. Marcos

EP0112  Prevalence and clinical outcomes of viral respiratory tract infections in critically ill patients requiring invasive ventilation — the COURSE study

EP0113  Point-of-impact testing in the emergency department: rapid diagnostics for respiratory viral infections
R. Poelman* (Groningen, Netherlands), J. van der Meer, C. van Leer-Bouter, A. Riezebos-Brilman, H. Nieters

EP0114  On the role of weather conditions on social interactions relevant to the spread of infectious diseases
B. Guillaume* (Poitiers, France), L. Willem, P. Beutels, N. Hens, B. Dervaux

EP0115  Winter adult hospitalizations for acute respiratory conditions: prevalence of bacterial and viral infections in a population with high level of comorbidities
M. Bourgeois* (Yvoir, Belgium), N. Ausselet, V. Gérard, L. De Canniere, I. Michaux, Y. Glupczynski, T. Huang, P. Bogaerts, B. Debeer

EP0116  How punctual are RSV and hMPV? A 10-year follow-up
L. Cattoir* (Aalst, Belgium), A. Vankeerberghen, K. Van Vaerenberghen, A. Boel, H. De Beenhouwer

EP0117  Clinical features of human metapneumovirus infection in adults
U. Karlsson* (Lund, Sweden), B. Böttiger, E. Melander

EP0118  High morbidity in adults presenting to hospital with human metapneumovirus
K. Kong* (Melbourne, Australia), T. Korman, D. Kotsanaas, M. Graham, R. Junckerstorff, R. Bhamjee, H. Haran

EP0119  Pattern of transmission of Middle East Respiratory Syndrome (MERS) infection in a large hospital outbreak — Riyadh, Saudi Arabia, 2015
T. Enazi* (Riyadh, Saudi Arabia), M. Shomrani, A. El-Saed, H. Boffae-Bonnie, Y. Arabi, H. Balkhy

EP0120  Prevalence and clinical outcomes of viral respiratory tract infections in critically ill patients requiring invasive ventilation — the COURSE study

EP0150  Long-term impact of late-onset cytomegalovirus replication on chronic lung allograft dysfunction and mortality in lung transplant recipients receiving antiviral prophylaxis
N. Jaamei* (Lausanne, Switzerland), A. Koutsokera, J. Pasquier, P. Meylan, M. Pascual, J. Aubert, D. Manuel

EP0151  A randomized controlled trial comparing voriconazole and placebo for antifungal prophylaxis in patients with acute myeloid leukaemia receiving chemotherapy
D. Dhissayakamol* (Bangkok, Thailand), C. Suankratay
Impact of infections on waiting list survival in patients with end-stage liver disease
L. Alferink* (Rotterdam, Netherlands), C. Schurink, B. Hansen, H. Metselaar

Infections in patients with Berlin Heart as bridge to transplantation therapy

Variants in non-coding RNAs are involved in genetic susceptibility to aspergillosis
S. Gago* [Manchester, United Kingdom], D. Denning, P. Bowyer

Genetic variants influencing susceptibility to pneumococcal meningitis identified by an exome array analysis
A. Kloek* [Amsterdam, Netherlands], B. Ferwerda, J. Van Setten, A. van der Ende, M. Valls Seran, M. Brouwer, D. van de Beek

Risk factors and outcomes related to bloodstream infections caused by extended spectrum beta-lactamase producing Enterobacteriaceae in cancer patients
S. Ceken* [Ankara, Turkey], G. Iskender, H. Gedik, F. Dugcu, D. Mert, A. Kaya, F. Altuntas, M. Ertek

Epidemiology, clinical characteristics and outcome of early bacterial and fungal infections in liver transplantation: a single-centre, nine-year experience
R. Montalti, P. Castelli, D. Nicolini, S. Staffolani, F. Macchegiani, E. Manso, A. Fiorentini, M. Vivarelli, F. Barchiesi* [Ancona, Italy]

Epstein-Barr virus re-activation in the post-kidney transplant period: risk factors and post transplant lymphoproliferative disorders
E. Franceschini* [Modena, Italy], J. Plessi, S. Zona, A. Santoro, M. DiGaetano, A. Bedini, M. Cadeluppi, L. Potenza, P. Comoli, W. Gennari, D. Zona, E. Bouza Santiago

Molecular and epidemiological study of Clostridium difficile reveals unusual heterogeneity in strains circulating in different regions from Portugal

The risk for Clostridium difficile colitis during hospitalization in asymptomatic carriers
Y. Vienneau-Well* [Jerusalem, Israel], S. Carmel-Kagan, L. Kashat, E. Ben-Chetrit, A. M. Yinnon, M. Assous

Clostridium difficile infection (CDI) mortality in Scotland 2010 to 2014
A. Banks, J. Bishop, O. Mesalles-Naranja, D. Brown, H. Mather, J. Coia* [Glasgow, United Kingdom], C. Wiuff

Distinguishing C. difficile recurrence from reinfection – poor performance of current recommendations
A. Durovic, A. Widmer, R. Frei, S. Tschudin-Sutter* [Basel, Switzerland]

Adverse outcomes for missed cases of CDI; results from retrospective data collection on patients with samples received during the European, multi-centre, prospective bi-annual point prevalence study of Clostridium difficile infection in hospitalized patients with diarrhea [EUCLID2]

SYN-004, a clinical-stage, orally delivered beta-lactamase therapy that protects the gut microbiome from IV antibiotics is also efficacious with oral antibiotics in a pig model
S. Connelly* [Rockville, United States], A. Bristol, S. Hubert, N. Hasan, P. Subramanian, C. Furlan Freguia, J. Sliman, M. Kaleko

Efficacy of bezlotoxumab, the monoclonal antibody targeting C. difficile toxin B, for prevention of C. difficile infection (CDI) recurrence in patients at high risk of recurrence or CDI-related adverse outcomes

Ridinilazole for Clostridium difficile infections: safety and efficacy compared with vancomycin from the CoDIFy phase 2 clinical trial

Disease progression and resolution in rodent models of Clostridium difficile infection: impact of antitoxin antibodies and vancomycin
P. Warn, P. Thommes, A. Sattar, A. Flattery, Z. Zhang, L. Hernandez, A. Therien* [Kenilworth, United States]
**Monday, 11 April 2016**

| EP0179 | Comparisons of microbiomes from US and European populations suggest that SER-109 may have clinical utility in broad geographic locations for the treatment of patients with recurrent *Clostridium difficile* infection. E. O’Brien* [Cambridge, United States], M. Henn |
| EP0198 | Plasmids or no plasmids? A comparison between the Agilent TapeStation and whole-genome sequencing data in a large-scale bacterial sequencing project. S. Alexander* [London, United Kingdom], M. Fazal, E. Burnett, N. Halroyd, K. Oliver, A. Deheer-Graham, J. Parkhill, J. Russell |
| EP0199 | Micelle PCR reduces artifact formation during 16S rRNA microbiota profiling. R. Jansen, S. Boers* [Rotterdam, Netherlands], J. Hays |

### Microbiome Research

| Moderator | Hilpi Rautelin [Uppsala, Sweden] |
| EP0190 | Increased microbial diversity in paediatric patients with *Dientamoeba fragilis* infection. E. de Groot* [Amsterdam, Netherlands], T. de Meij, I. van Maldeghem, F. Plötz, A. Budding |
| EP0191 | Dysbiosis around the time of conception in African women; a DNA-triple-PCR tool applied to V. Jespers* [Antwerp, Belgium], L. Hardy, J. van de Wijgert |
| EP0193 | The cervico-vaginal microbiome in *Chlamydia trachomatis* exposed women: a case-control study at the sexually transmitted infection outpatient clinic in Amsterdam. C. van der Veer* [Amsterdam, Netherlands], S. Bruisten, J. van der Helm, H. de Vries, R. van Houdt |
| EP0194 | Antibiotic therapy alters lung microbiome in paediatric cystic fibrosis patients. L. Kramna* [Prague, Czech Republic], K. Kalá ová, K. Vilimovská D de ková, P. Drevinek, O. Cinek |
| EP0195 | Relationship between histological findings and body mass index (BMI) with gastric microbiome, including *Helicobacter pylori*, in a paediatric population. L. Llorca* [Madrid, Spain], G. Pérez, P. Urruzuno, M. Martínez, T. Alarcon Cavero |
| EP0196 | Reduced intestinal bacteria diversity in CD, pouch and active UC patients in comparison to healthy controls. H. Mirsepasi-Lauridsen* [Copenhagen, Denmark], J. Engberg, A. Fries-Møller, I. Nordgaard-Lassen, S. Wildt, K. Krogfelt, A. Petersen |
| EP0197 | The NCTC 3000 project: development and optimization of DNA extraction methods for 3000 different bacterial strains suitable for long-read PacBio SMRT sequencing. M. Fazal* [London, United Kingdom], S. Alexander, E. Burnett, K. Oliver, J. Parkhill, J. Russell |

### Getting better and faster: resistance detection

| Moderator | Marek Gniadkowski [Warsaw, Poland] |
| EP0229 | Automatic digital analysis of chromogenic media for vancomycin-resistant enterococci screens using the WASPLab interpretation software. M. Faron* [Milwaukee, United States], B. Buchan, T. Liebregts, A. van Bree, A. Jansz, G. Soucy, J. Krover, N. Ledeboer |
| EP0232 | Development and application of real-time PCR assay for detection of mutations associated with macrolide resistance in *Mycoplasma genitalium* directly in clinical specimens. I. Edelstein* [Smolensk, Russian Federation], A. Kilic, E. Dogan, S. Kaya, S. Oren, N. Ardic* [Istanbul, Turkey], M. Baysallar |
### EP0264
Development of a new isothermal amplification method combining recombinase polymerase amplification method with rolling circle amplification for detection of leishmaniasis
M. Kuskucu* [Istanbul, Turkey], E. Dogan, A. Abdelkareem, M. Hakelek, K. Midilli

### EP0265
Serological responses against species-specific recombinant MSP-10 antigens as markers of malaria exposure in the Peruvian Amazon

### EP0266
Leishmaniasis in Turkey: first demonstration of the proteins identified only in hybrid Leishmania isolates in autochthonous cases of cutaneous leishmaniasis
A. Özbilgin, G. Culha, F. Yıldız Zeyrek, I. Akyar, I. Östan, Ü. Kurt* [Istanbul, Turkey], T. Kocagoz, C. Gündüz, S. Tüz, I. Cavus, Y. Özbel

### EP0267
New prototype VIDAS Toxo IgM assay: comparison with Toxo Isaga, Vidas Toxo IgM and Architect Toxo IgM on different populations (pregnant woman, children, immunosuppressed and healthy people)
A. Foussadier* [Marcy l’Etoile, France], J. David, N. Ripoll

### EP0268
Development of Nanosphere’s Verigene EP Flex Test (IUO) for rapid detection of a broad range of gastrointestinal parasites directly from Cary-Blair and non-formalin-based fixatives
S. Marla, F. Sun, D. Morrow, S. Powell* [Northbrook, United States], J. Hully

---

**Diagnostic parasitology**

**Moderator:** Martin P. Grubusch [Amsterdam, Netherlands]

### EP0259
Molecular diagnosis of toxoplasmosis by the Q-Lamp method
F. Genco* [Pavia, Italy], M. Prestia, S. Pasinetti, A. Corcione, V. Meroni

### EP0260
A newly developed membrane-based assay for the simultaneous serologic screening and differentiation of echinococcosis
L. Schönfeld* [Lübeck, Germany], T. Scheper, J. Warnecke, B. Gottstein

### EP0261
Evaluation of a newly developed anti-Trypanosoma cruzi ELISA (IgG) as a screening assay for Chagas disease
N. Beier, A. Eichelmann, J. Warnecke, K. Steinhagen* [Lübeck, Germany]

### EP0262
Comparison of nested PCR and microscopy for the detection of Plasmodium and subspecies of Plasmodium in malaria endemic province, Sanliurfa, Turkey
N. Yentur Doni* [Sanliurfa, Turkey], F. Yıldız Zeyrek, A. Seyrek

### EP0263
Relationship between Dientamoeba fragilis, Blastocystis and Enterobius vermicularis in gastroenteritis cases and controls
M. de Boer* [Hengelo, Netherlands], M. Vermeer, T. Schuurs, J. Weel, L. Brujinesteijn van Coppenraet, G. Ruijs, W. Van der Reijden, C. Stensvold, J. Verweij, A. van der Zanden, B. Mulder

---

**Rapid susceptibility testing: reliable, fast, ultrafast**

**Moderator:** Holger Rohde [Hamburg, Germany]

### EP0314
Rapid high throughput binary typing paired with whole genome sequencing for prospective nosocomial surveillance of MRSA transmission
M. O’Sullivan* [Westmead, Australia], M. Ramsperger, N. Holmes, F. Zhou, R. Sadsad, V. Sintchenko, L. Gilbert

### EP0315
Addressing limitations in detecting antibiotic resistance: evaluation of a microfluidic qPCR device in a hospital setting

### EP0316
Improved detection algorithms for label-free time-lapse cytometry of bacterial microcolonies for rapid antibiotic susceptibility testing
P. Yuen* [Uppsala, Sweden], C. Malmberg, P. Lagerbäck, D. Cars, T. Tängdén
Monday, 11 April 2016

EP0317 Rapid point-of-care genome assembly in-your-pocket resolves multidrug-resistant Gram-negative bacterial genomes
R. Norris* (Oxford, United Kingdom), A. Sheppard, N. Stoesser, A. Votintseva, D. Crook, Z. Iqbal

EP0318 The evaluation of UroHBB&L™ for rapid susceptibility testing of Gram-negative bacteria isolated in a blood culture
Y. Zbaramyrska* [Barcelona, Spain], J. Bosch, L. Alejo-Cacho, A. Fasanella, F. Morales, M. Almela, F. Marco Reverte, J. Vila

EP0319 Can a flow cytometric method be used to test antibiotic susceptibility in Bacteroides fragilis? A pilot study
N. Ardic* [Ankara, Turkey], S. Kaya, E. Dogan, S. Oren, A. Kilic, M. Baysallar

EP0320 Rapid disk diffusion of Enterobacteriaceae: inhibition zones for extended-spectrum cephalosporins can be reliably read after only six hours of incubation.
I. Fröding* [Stockholm, Sweden], M. Vandraecze, C. Giske

EP0321 Rapid reading of ESBL combination disk-diffusion tests
W. van den Bijlhaardt* [Tilburg, Netherlands], M. Janssens, A. Buiting, J. Mouton, A. Muller

EP0322 Rapid detection of polymyxin resistance in Enterobacteriaceae
P. Nordmann* [Fribourg, Switzerland], A. Jayol, L. Poirel

EP0323 Rapid identification and susceptibility results from positive blood cultures with the Maldi Sepsityper™ kit
K. Maelegheer* [Brugge, Belgium], T. Lowyck, P. Notteboom, E. Nulens

KL103 14:30-15:30 Hall A
Keynote Lecture
How antibiotics for non-human use affect public health
Chair: Luca Guadabassi [Basseterre, Saint Kitts and Nevis]

K428 14:30 Lance B. Price [Washington, DC, United States]

OS104 14:30-15:30 Hall B
1-hour Oral Session
Rising to the challenge: novel techniques in microbiology
Chairs: Christina Vandenbroucke-Grauls [Amsterdam, Netherlands]
Michel Drancourt [Marseille, France]

0429 Optical elastic scattering for the early label-free detection of Staphylococcus aureus on chromogenic biplate medium ChromID MRSA/ChromID S. aureus
P. Marcoux* [Grenoble, France], V. Genuer, J. Méteau, D. Decq, D. Gol, E. Schultz, M. Mourin

0430 A novel gene expression diagnostic can robustly distinguish viral from bacterial infections
T. Sweeney* [Stanford, United States], H. Wang, J. Andrews, D. Spain, P. Khatri

0431 Whole-genome sequencing directly from blood culture to diagnose and predict antibiotic susceptibility for Escherichia coli and Klebsiella spp. bacteraemia
L. Pankhurst* [Oxford, United Kingdom], H. Phan, N. Stoesser, L. Anson, S. Walker, T. Peto, D. Crook

0432 A three-way comparative proteomic analysis of Clostridium difficile of different PCR-ribotypes using TMT quantitative proteomics
M. Fang* [London, United Kingdom]

0433 Evaluation of three MALDI-TOF based techniques for the detection of carbapenemase-producing Enterobacteriaceae
L. Dortet* [Le Kremlin-Bicêtre, France], D. Tandé, D. De Briel, S. Bernabeu, C. Lasserre, G. Gregorowicz, T. Naas

SY105 14:30-15:30 Hall C
1-hour Symposium
Redefining HPV vaccination programmes in the EU
Chairs: Mario Poljak [Ljubljana, Slovenia]
Hanna M. Nohynek [Helsinki, Finland]

S434 14:30 Gender-neutral HPV vaccination
Margaret Anne Stanley [Cambridge, United Kingdom]

S435 15:00 When to start giving HPV vaccine and how many doses are needed?
Joakim Dillner [Stockholm, Sweden]

OS106 14:30-15:30 Hall D
1-hour Oral Session
Endocarditis
Chairs: Willy Peetermans [Leuven, Belgium]
José M. Miro [Barcelona, Spain]

0437 Effectiveness and safety of daptomycin in patients with endocarditis undergoing heart valve replacement: a subgroup analysis from a real-world study
A. Guleri* [Blackpool, United Kingdom], R. Utili, P. Dohmen, R. Pathan, K. Hamed

0438 Daptomycin (DAP) + fosfomycin (FOM) or cloxacillin (CLO) has better activity than CLO + gentamicin (GEN) against meticillin-susceptible Staphylococcus aureus (MSSA) in experimental endocarditis (EE)
Mitral valve repair in patients with infective endocarditis - results of a national prospective registry
G. Cuerpo* (Madrid, Spain), H. Rodríguez, A. Pinto, F. Gutierrez, A. Sarraíde, C. Mestres, E. Quintana, K. Reviejo, A. Gonzalez-Calle, R. Rodríguez, J. Regueira Iglesias, I. Antorrena, P. Munáez, E. Bouza Santiago, G. Study Group

Propionibacterium acnes: an elusive cause of prosthetic valve endocarditis
J. Banzon* (Cleveland, United States), S. Rehm, S. Gordon, S. Hussain, G. Pettersson, N. Shrestha

0439

Evaluation of long-term immunity to varicella, measles, mumps and rubella in haematopoietic stem cell transplant survivors
E. Ariza-Heredia* (Houston, United States), G. Viola, K. Blue Schanneville, A. Gulbis, D. Chemaly, K. Rolston, K. Stolar

0446

Baseline serum hepcidin-25 levels predict the occurrence of surgical-site infection after kidney transplantation: role of iron overload in the pathogenesis of post-transplant infection

0447

Do we always need antibiotics to treat infections?
Chairs: Waleria Hryniewicz (Warsaw, Poland) Agnes Wechsler-Fördös (Vienna, Austria)

SY107 14:30-15:30 Hall E
1-hour Symposium

S414 14:30 Treating urinary tract infections without antibiotics
Eva Hummers-Pradier (Göttingen, Germany)

S422 15:00 Treating community-acquired pneumonia without extended coverage
Cornelis H. Van Werkhoven (Utrecht, Netherlands)

SY109 14:30-15:30 Hall G
1-hour Symposium

MERS update
Chairs: Ziad A. Memish (Riyadh, Saudi Arabia) Marjorie Polack (New York, United States)

S448 14:30 MERS: a zoonotic disease disguised as a pandemic threat
Christian Drosten (Bonn, Germany)

S449 15:00 Risk factors for nosocomial outbreaks of MERS-CoV infection - some comparisons with SARS-CoV infection
David Shu Cheong Hui (Hong Kong, China)

OS108 14:30-15:30 Hall F
1-hour Oral Session

Latest news on the clinical front of immunocompromised patients
Chairs: Claudio Viscoli (Genoa, Italy) Lubos Drgona (Bratislava, Slovakia)

OS110 14:30-15:30 Hall H
1-hour Oral Session

New insights into host-pathogen interactions
Chairs: Dorothea Orth-Hoeller (Innsbruck, Austria) Willem Joost Wiersinga (Amsterdam, Netherlands)

OS410 14:30-15:30 Hall I
1-hour Oral Session

Role of within-host evolution in Staphylococcus aureus infection

OS451 14:30 Phage-derived gene is involved in platelet activation and associated with increased mortality in patients with invasive pneumococcal disease
R. Tunjungputri* (Nijmegen, Netherlands), F. Mabegi, A. Cremers, C. van der Gaast, G. Ferwerda, S. van Hijum, A. van der Ven, Q. de Mast, A. Zomer, M. de Jonge

OS452 14:30 Bacterial lysis through interference of peptidoglycan synthesis increases biofilm formation by non-typeable Haemophilus influenzae
Monday, 11 April 2016

0453  Nasopharyngeal microbiota, host transcriptome and disease severity in children with respiratory syncytial virus infection  
W. de Steenhuijsen Piters, S. Heinonen, R. Hasrat, B. Smith, E. Bunsow, M. Suárez-Arrabal, E. Sanders, O. Ramilo, D. Bogaert* (Utrecht, Netherlands), A. Mejias

0454  Caveolin-1-mediated Japanese encephalitis virus entry into human neuronal cells requires a two-step regulation of actin reorganization initiated by EGFR signalling  
O. Xu, M. Cao, Y. Zhu, P. Zhao, Z. Qi* (Shanghai, China)

SY111  14:30-15:30  Hall I  
1-hour Symposium
Antibiotic de-escalation [Pro-Con debate]  
Chairs: Benedikt Huttner [Geneva, Switzerland]  
Catherine Dumartin [Bordeaux, France]

S455  14:30  A key pillar of antibiotic stewardship  
Jean-François Timsit [Paris, France]

S456  15:00  Much ado about nothing  
Jeroen Schouten [Nijmegen, Netherlands]

KL112  14:30-15:30  Hall J  
Keynote Lecture  
New drugs for tuberculosis: from genome to patient  
Chair: Jan S. Friedland [London, United Kingdom]

K457  14:30  Stewart T. Cole [Lausanne, Switzerland]

SY113  14:30-15:30  Hall K  
1-hour Symposium
Young Investigator Award Lectures  
Chairs: Annelies Zinkernagel [Zurich, Switzerland]

S458  14:30  The missing link in HIV treatment delivery in Africa illustrated by the Bissau HIV Cohort  
Sanne Jespersen [Aarhus, Denmark]

S459  14:50  Disrupting the infectious conversation: understanding polybacterial infections as a route towards combating antibiotic resistance  
Robert P. Ryan [Dundee, Ireland]

S460  15:10  How can whole-genome sequencing help eradicate tuberculosis?  
Timothy Walker [Oxford, United Kingdom]

SY114  16:00-18:00  Hall A  
2-hour Symposium
Challenging AMR in low-resource settings  
Chairs: Danilo Lo Fo Wong [Copenhagen, Denmark]  
Antoine Andremont [Paris, France]

S461  16:00  Building laboratory capacity to identify patterns and emergence of resistance  
Önur Karatuna [İstanbul, Turkey]

S462  16:30  Clinical bacteriology in low-resource settings – not tomorrow’s but today’s solutions  
Jean-Baptiste Ronat [Paris, France]

S463  17:00  Do we have cost-effective infection control and antibiotic stewardship programmes for low-resource settings?  
Nandini Shetty [London, United Kingdom]

S464  17:30  Improving the assessment and treatment of children with fever at OPD level: MSFeCARE field experience  
Clotilde Rambaud-Althaus [Geneva, Switzerland]

OS115  16:00-18:00  Hall C  
2-hour Oral Session  
Microbiome in disease and treatment  
Chairs: Susana Delgado [Villaviciosa, Spain]  
Pieter Vos [Wageningen, Netherlands]

S465  Development of upper respiratory tract microbiota in infancy is affected by mode of delivery  
A. Bosch, E. Levin, M. van Houten, R. Hasrat, G. Kalkman, G. Biesbroek, W. de Steenhuijsen Piters, B. Keijser, E. Sanders, D. Bogaert* (Utrecht, Netherlands)

S466  The upper respiratory tract microbiota of children suffering from otitis media in relation to gastro-oesophageal reflux disease (GERD)  
S. Boers, M. de Zeeuw, R. Jansen, M. van der Schraeff, A. van Rossum, J. Hays, S. Verhaegh* (Rotterdam, Netherlands)

S467  Discrepancy between upper and lower respiratory tract microbiota in infants with cystic fibrosis  

S468  Comparison of culture with T-RFLP, 16S rDNA sequencing and metagenomics for routine diagnostics of respiratory microbiota in patients with cystic fibrosis  
P. Moran Losada, J. Yang, P. Chouvarine, S. Woltemate, L. Wiehlmann, S. Suerbaum, M. Herrmann, B. Tümmler, C. Jost, R. Bals, L. van Müller* (Coesfeld, Germany)
0469 Oral microflora and selection of resistance after a single dose of amoxicillin
D. Khalil* [Stockholm, Sweden], M. Hultin, M. Rashid, B. Lund

0470 The effect of selective digestive tract decontamination on the intestinal microbiota
M. van Doorn-Schepens* [Amsterdam, Netherlands], E. Abis, S. Oosterling, M. van Egmund, J. Banier, H. Stockmann, P. Savelkoul, A. Budding

0471 Infusion of faecal microbiota combined with antibiotic treatment to prevent recurrent infections by multidrug-resistant Pseudomonas aeruginosa
J. Stalenhoef* [Leiden, Netherlands], L. Terveer, I. Vlasveld, A. Gaasbeek, J. Keller, L. Visser, E. Kuijper

0472 Early detection of necrotizing enterocolitis by intestinal microbiota composition
E. de Groot* [Amsterdam, Netherlands], T. de Meij, D. Berkhour, P. Savelkoul, M. van Weissenbruch, A. Budding

0473 Analyses of the cervicovaginal Lactobacillus iners and L. crispatus proteome and the cervicovaginal microbiome identify proteins associated with maintaining a Lactobacillus-dominated microbiome.
H. Borgdorff* [Amsterdam, Netherlands], S. Armstrong, H. Tjtgdt, D. Xia, G. Ndayisaba, J. Wastling, J. van de Wijgert

0474 Women of Dutch ethnic origin have lower prevalence of vaginal microbiota dysbiosis than women of other ethnic origin residing in Amsterdam - the HELIUS study
H. Borgdorff* [Amsterdam, Netherlands], C. van der Veer, R. van Houdt, C. Alberts, H. de Vries, S. Bruisten, M. Snijder, M. Prins, S. Geerlings, M. Schim van der Loeff, J. van de Wijgert

SY116 16:00-18:00 Hall D
2-hour Symposium
Recent advances of viral immune evasion strategies
Chairs: Kate Templeton [Edinburgh, United Kingdom] Anne-Mieke Vandamme [Leuven, Belgium]

S475 16:00 Innate defences against Ebola and viral countermeasures
Stefan Pöhlmann [Göttingen, Germany]

S476 16:30 How does HIV evade the innate immune system?
Greg Towers [London, United Kingdom]

S477 17:00 Sensing and resisting the alien: the APOBEC family
Nevan Krogan [San Francisco, CA, United States]

S478 17:30 Overcoming viral evasion: possible strategies
Akihide Ryo [Yokohama, Japan]
Monday, 11 April 2016

0499 16:30 Infectious disease diagnostics using metabolomics for rapid identification of causative bacteria and antibiotic resistance traits
Anders Johansson [Umea, Sweden]

S499 17:00 Role of pathogen genomics in assessing disease transmission - Salmonella
Vitali Sintchenko [Sydney, Australia]

S500 17:30 Proteome composition and dynamics in Mycobacterium tuberculosis
Ben Collins [Zurich, Switzerland]

0512 16:00-18:00 Hall J
2-hour Oral Session
Frontiers in tuberculosis

Chairs:  Joyoti Basu [Kolkata, India]
Christoph Lange [Borstel, Germany]

0501 Challenges and limitations of genomic epidemiology of Mycobacterium tuberculosis an on-going population-based study
I. Comas* [Valencia, Spain], I. Cancino, V. Group

0502 Model-based translational prediction of early bactericidal activity of rifampicin against M. tuberculosis
S. Wicha* [Uppsala, Sweden], R. Svensson, O. Clewe, U. Simonsson

0503 Cerebrospinal fluid metabolomics in tuberculosis meningitis shows that increased tryptophan metabolism is linked to patient survival
A. van Laarhoven* [Nijmegen, Netherlands], C. Clish, S. Dian, R. Notebaart, C. Ruesen, J. Annisa, L. Chaidir, M. Netea, B. Alisjahbana, V. Kumar, A. Ganiem, R. van Crevel

0504 Intensified antibiotic treatment for tuberculous meningitis; two phase 2 clinical trials conducted in Indonesia

0505 Latency associated antigens Rv2032 and Rv2626c emerge as good vaccine candidates against Mycobacterium tuberculosis
S. Singh* [Delhi, India], K. Pandey, I. Saraav, M. Sharma, S. Sharma

S507 16:00-18:00 Hall I
2-hour Symposium
OMICS for infectious diseases

Chairs:  Sebastien Gagneux [Basel, Switzerland]
Anders Johansson [Umea, Sweden]

0507 16:00 A genome-wide Salomonella typhimurium infection screen using high-throughput microscopy
Bachir El Debs [Heidelberg, Germany]

0508 16:30 Infectious disease diagnostics using metabolomics for rapid identification of causative bacteria and antibiotic resistance traits
Anders Johansson [Umea, Sweden]

0509 17:00 Role of pathogen genomics in assessing disease transmission - Salmonella
Vitali Sintchenko [Sydney, Australia]

0510 17:30 Proteome composition and dynamics in Mycobacterium tuberculosis
Ben Collins [Zurich, Switzerland]

0512 16:00-18:00 Hall J
2-hour Oral Session
Frontiers in tuberculosis

Chairs:  Joyoti Basu [Kolkata, India]
Christoph Lange [Borstel, Germany]

0501 Challenges and limitations of genomic epidemiology of Mycobacterium tuberculosis an on-going population-based study
I. Comas* [Valencia, Spain], I. Cancino, V. Group

0502 Model-based translational prediction of early bactericidal activity of rifampicin against M. tuberculosis
S. Wicha* [Uppsala, Sweden], R. Svensson, O. Clewe, U. Simonsson

0503 Cerebrospinal fluid metabolomics in tuberculosis meningitis shows that increased tryptophan metabolism is linked to patient survival
A. van Laarhoven* [Nijmegen, Netherlands], C. Clish, S. Dian, R. Notebaart, C. Ruesen, J. Annisa, L. Chaidir, M. Netea, B. Alisjahbana, V. Kumar, A. Ganiem, R. van Crevel

0504 Intensified antibiotic treatment for tuberculous meningitis; two phase 2 clinical trials conducted in Indonesia

0505 Latency associated antigens Rv2032 and Rv2626c emerge as good vaccine candidates against Mycobacterium tuberculosis
S. Singh* [Delhi, India], K. Pandey, I. Saraav, M. Sharma, S. Sharma

0507 16:00 A genome-wide Salomonella typhimurium infection screen using high-throughput microscopy
Bachir El Debs [Heidelberg, Germany]

0508 16:30 Infectious disease diagnostics using metabolomics for rapid identification of causative bacteria and antibiotic resistance traits
Anders Johansson [Umea, Sweden]

0509 17:00 Role of pathogen genomics in assessing disease transmission - Salmonella
Vitali Sintchenko [Sydney, Australia]

0510 17:30 Proteome composition and dynamics in Mycobacterium tuberculosis
Ben Collins [Zurich, Switzerland]
ESCMID / ASM Conference on
Drug Development to Meet the Challenge of Antimicrobial Resistance

Vienna, Austria
21 – 23 September 2016

**Organizing Committee**
- David Hooper, Boston, USA
- William Hope, Liverpool, UK
- Gunnar Kahlmeter, Växjö, SE
- Ursula Theuretzbacher, Vienna, AT

**Programme Committee**
- David Andes, Madison, USA
- Marco Cavaleri, London, UK
- Ed Cox, Silver Spring, USA
- George Drusano, Lake Nona, USA
- William Hope, Liverpool, UK
- Gunnar Kahlmeter, Växjö, SE
- Jason Roberts, Brisbane, AU
- Keith Rodvold, Chicago, USA
- Ursula Theuretzbacher, Vienna, AT

Contact: vienna2016@escmid.org

Find more information and registration information on our website
www.escmid.org/Vienna2016

• Discovery efforts in the face of AMR
• Pharmacokinetics and Pharmacodynamics
• Update on Regulatory Processes by EMA and FDA
• Breakpoints for new agents
• Clinical trial design for AMR
• Development of new drugs for special populations
• Getting AMR research funded
• Interactive sessions: bring your drug development problem and ask!
<table>
<thead>
<tr>
<th>Hall A</th>
<th>Hall B</th>
<th>Hall C</th>
<th>Hall D</th>
<th>Hall E</th>
<th>Hall F</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>07.45-08.45</strong></td>
<td></td>
<td>Challenges in ventilator-associated pneumonia</td>
<td>Controversies about controlling VRE - possible or impossible?</td>
<td></td>
<td>Chlorhexidine bathing in critically ill patients</td>
</tr>
<tr>
<td><strong>09.00 –11.00</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Clinical Grand Rounds</td>
<td></td>
<td>Discovery and novel developments in antibacterial drugs and drug potentializers</td>
<td>New and rapid detection of antimicrobial resistance</td>
<td>Combating biofilm infections: from basic research to clinical practice</td>
<td></td>
</tr>
<tr>
<td><strong>11.00-11.30 Coffee Break</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>11.30 –12.30</strong></td>
<td></td>
<td>Translating evolutionary biology findings into antibiotic stewardship strategies</td>
<td>Harnessing whole-genome sequencing for diagnostics and typing</td>
<td>Tackling MDR &amp; XDR tuberculosis</td>
<td>The evolution of antibacterial resistance - new insights</td>
</tr>
<tr>
<td><strong>13.00 –14.00 Lunch Break / ePoster and Poster Viewing</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>14.30 –15.30</strong></td>
<td></td>
<td>The hospital in the era of antimicrobial resistance and infection control performance measures</td>
<td>Resistance mechanisms in Gram-negatives</td>
<td>Tools and interventions to improve hospital antimicrobial prescription quality</td>
<td>Genetics of infectious diseases in the era of precision medicine</td>
</tr>
<tr>
<td>Hall G</td>
<td>Hall H</td>
<td>Hall I</td>
<td>Hall J</td>
<td>Hall K</td>
<td></td>
</tr>
<tr>
<td>--------</td>
<td>--------</td>
<td>--------</td>
<td>--------</td>
<td>--------</td>
<td></td>
</tr>
<tr>
<td>08.45 – 09.00</td>
<td>Reprocessing endoscopes and DaVinci® instruments: new sources for the spread of resistant Gram-negatives</td>
<td>How to manage patients with suspected dengue or chikungunya fever</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>09.00 – 11.00</td>
<td>Fungal disease and epidemiology</td>
<td>Tricky points in zoonotic diseases</td>
<td>Screening of infectious diseases among migrant populations: challenges and opportunities</td>
<td>Splenic function and infection</td>
<td></td>
</tr>
<tr>
<td>11.00 – 11.30</td>
<td>Coffee Break</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11.30 – 12.30</td>
<td>What do we know about polyfungal infections? Challenges in laboratory interpretation and treatment</td>
<td>Challenges with papilloma and polyoma viruses</td>
<td>Ancient pathogens: paleosciences</td>
<td>Migrants, infections and public health</td>
<td>Recent top papers in paediatric infectious diseases</td>
</tr>
<tr>
<td>13.00 – 14.00</td>
<td>Lunch Break / ePoster and Poster Viewing</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>14.30 – 15.30</td>
<td>How to diagnose more fungal disease and less colonization</td>
<td>Infections of the brain and meningitis</td>
<td>Antiparasitic drugs: good news and bad news</td>
<td>Dengue and dengue haemorrhagic fever, 2016</td>
<td>Update in diagnosis and clinical management of implant-associated infections</td>
</tr>
</tbody>
</table>
Tuesday, 12 April 2016

**ME122 07:45-08:45**
**Hall C**
Meet-the-Expert Session

**Challenges in ventilator-associated pneumonia**

M510 Asuman Sengöz Inan (Istanbul, Turkey)
M511 Candela Solé (Barcelona, Spain)

**ME123 07:45-08:45**
**Hall D**
Meet-the-Expert Session

**Controversies about controlling VRE - possible or impossible?**

M512 Yves Longtin (Montreal, Canada)
M513 Andreas Voss (Nijmegen, Netherlands)

**ME124 07:45-08:45**
**Hall F**
Meet-the-Expert Session

**Chlorhexidine bathing in critically ill patients**

M514 Didier Pittet (Geneva, Switzerland)
M515 Susan S. Huang (Irvine, CA, United States)

**ME125 07:45-08:45**
**Hall H**
Meet-the-Expert Session

**Reprocessing endoscopes and daVinci® instruments: new sources for the spread of resistant Gram-negatives**

M516 Margreet C. Vas (Rotterdam, Netherlands)
M517 Petra Gastmeier (Berlin, Germany)

**ME126 07:45-08:45**
**Hall J**
Meet-the-Expert Session

**How to manage patients with suspected dengue or chikungunya fever**

M518 Annelies Wilder-Smith (Singapore, Singapore)
M519 Fabrice Simon (Marseille, France)

**SY127 09:00-11:00**
**Hall A**
2-hour Symposium

**Clinical Grand Rounds**

Moderator: Robert C. Read (Bath, United Kingdom)
Experts: Souha S. Kanj (Beirut, Lebanon)
Dennis Stevens (Boise, ID, United States)
David L. Paterson (Herston, Australia)
Vukan Kerton [Istanbul, Turkey]
Manica Slavin (East Melbourne, Australia)
Nicholas J. Beeching (Liverpool, United Kingdom)

S520 09:00 Case 1
Tomas-Paul Cusack (Portsmouth, United Kingdom)

S521 09:20 Case 2
Federico Foschi (Tübingen, Germany)

S522 09:40 Case 3
Inmaculada López Montesinos (Seville, Spain)

S523 10:00 Case 4
Güzin Surat (Würzburg, Germany)

S524 10:20 Case 5
Serhat Vahip Okar (Ankara, Turkey)

S525 10:40 Case 6
Evelyn Van Hauwermeiren (Brescia, Italy)

**OS128 09:00-11:00**
**Hall C**
2-hour Oral Session

**Discovery and novel developments in antibacterial drugs and drug potentiators**

Chairs: Alasdair P. MacGowan (Bristol, United Kingdom)
Françoise Van Bambeke (Brussels, Belgium)

O526 Identification of VαnR inhibitors re-sensitising vancomycin-resistant enterococci (VRE) towards glycopeptide antibiotics
B. Schellhorn, C. Kemmer, V. Lucchini, S. Gartenmann, V. Turock, F. Deroose, P. Sennhenn, S. Locciro, M. Tigges, M. Gitzinger, M. Pieren* [Basel, Switzerland]

O527 Inhibition of LpxC increases susceptibility to rifampicin, azithromycin and vancomycin in Acinetobacter baumannii
M. García Quintanilla* [Seville, Spain], J. Caro-Vega, M. Pulido, P. Moreno-Martínez, J. Pachon-Díaz, M. McConnell
### O528
**Assessing target engagement in vitro and in vivo of MvfR inhibitors in Pseudomonas aeruginosa**

### O529
**Novel broad-spectrum inhibitors of serine and metallo carbapenemases**

### O530
**Antimycobacterial and efflux inhibitory activity of 2-aminothiazole lead compound against Mycobacterium tuberculosis**
D. Machado* (Lisbon, Portugal), E. Azzali, S. Santos Costa, G. Costantine, I. Couto, M. Pieroni, M. Viveiros

### O531
**Structure-activity relationships of a novel lipid II inhibitor**
J. Chauhan, T. Opperman, A. MacKerell, S. Fletcher, E. De Leeuw* (Baltimore, United States)

### O532
**Investigating the mechanism of action of the novel antimicrobial BDM-I**
M. Rodzieta* (Liverpool, Australia), B. Espedido, C. Malladi, J. Coorssen, J. Phillips, S. Jensen

### O533
**Apidaecin Api137 is highly efficient against susceptible and resistant Escherichia coli and Klebsiella pneumoniae in murine intramuscular thigh and ascending urinary tract infections**
D. Knappe* (Leipzig, Germany), R. Schmidt, R. Hoffmann, K. Adermann

### O534
**Novel synthetic antimicrobial peptides against Streptococcus pneumoniae**
H. Jinđal* (Kuala Lumpur, Malaysia), R. Velayuthan, S. Sekaran

### O535
**Gram-negative bactericidal activity of novel antimicrobial peptide M33: insight into the mode of action**
H. van der Weide* (Rotterdam, Netherlands), J. Brunetti, D. Vermeulen - de Jongh, C. Ambrosini, I. Bakker-Woudenberg, W. Goessens, C. Falciani, A. Pini, J. Hays

### SY129 09:00-11:00 Hall D
2-hour Symposium
**New and rapid detection of antimicrobial resistance**

**Chairs:**
- Mark Patrick Nicol (Cape Town, South Africa)
- Margareta leven (Edegem, Belgium)

### S536 09:00
**Rapid phenotypic susceptibility testing**
Gunnar Kahlmeter (Växjö, Sweden)

### S537 09:30
**MALDI-TOF and resistance detection: beyond beta-lactamases**
Jaroslav Hrabak (Plzen, Czech Republic)

### S538 10:00
**Whole genome sequencing for antimicrobial susceptibility testing**
Neil Woodford (London, United Kingdom)

### S539 10:30
**Clinical implications of rapid results of antimicrobial susceptibility testing**
Esther Calbo (Barcelona, Spain)

### SY130 09:00-11:00 Hall E
2-hour Symposium
**Combatting biofilm infections: from basic research to clinical practice**

**Chairs:**
- Mark E. Shirtliff (Baltimore, MD, United States)
- Gianfranco Donelli (Rome, Italy)

### S540 09:00
**Fungal biofilms: future strategies against Candida**
Christine Imbert (Poitiers, France)

### S541 09:30
**Polymicrobial biofilms: systemic staphylococcal disease caused by Candida albicans infection**
Mark Everett Shirtliff (Baltimore, MD, United States)

### S542 10:00
**Multispecies biofilms in chronic infections: clinical impact and treatment considerations**
Thomas Bjarnsholt (Copenhagen, Denmark)

### S543 10:30
**Novel therapeutic regimens for chronic biofilm disease**
Claus Moser (Copenhagen, Denmark)

### SY131 09:00-11:00 Hall I
2-hour Symposium
**Tricky points in zoonotic diseases**

**Chairs:**
- Hakan Erdem (Istanbul, Turkey)
- Sergio Cimerman (Sao Paulo, Brazil)

### S544 09:00
**Pulmonary brucellosis**
Asuman Sengöz Iinan (Istanbul, Turkey)

### S545 09:30
**Globalization of Chagas disease: an update**
Alfonso J. Rodriguez-Morales (Pereira, Colombia)
Tuesday, 12 April 2016

**546** 10:00 Injectional anthrax - a new clinical entity
Roland Grunow [Berlin, Germany]

**547** 10:30 Minimally invasive techniques for cystic echinococcosis
Okan Akan [Ankara, Turkey]

**SY132 09:00-11:30 Hall J**

**2-hour Symposium**

**Screening of infectious diseases among migrant populations: challenges and opportunities**

*Chairs:* Manuel Carballo [Geneva, Switzerland]
Piotr Kramarz [Stockholm, Sweden]

**548** 09:00 What are the public health benefits of screening migrants for infectious diseases?
Hilary Kirkbride [London, United Kingdom]

**549** 09:30 The US approach to screening of infectious diseases among migrants: cost-effectiveness
Marty Cetron [Atlanta, GA, United States]

**550** 10:00 Screening of hepatitis B and C among migrants
Irene Veldhuijzen [Bilthoven, Netherlands]

**551** 10:30 Developing EU guidance on screening for infectious diseases among migrants
Teymur Noori [Stockholm, Sweden]

**SY133 09:00-11:00 Hall K**

**2-hour Symposium**

**Splenic function and infection**

*Chairs:* Frank Martin Brunkhorst [Jena, Germany]
Jolanda Lammers [Amsterdam, Netherlands]

**552** 09:00 OPSI today
Christian Theilacker [Basel, Switzerland]

**553** 09:30 Splenic function and B cells - consequences for clinical management
Maria Manuela Rosado [Rome, Italy]

**554** 10:00 Learning from splenectomy registries
Denis Spelman [Melbourne, Australia]

**555** 10:30 Infection and other outcomes of splenectomy in adults and children
Hélène Coignard-Biehler [Paris, France]

**05135 11:30-12:30 Hall B**

**1-hour Oral Session**

**Harnessing whole-genome sequencing for diagnostics and typing**

*Chairs:* Paul Savelkoul [Maastricht, Netherlands]
Holger Rohde [Hamburg, Germany]

**0557**

*C. difficile (CD)* ribotypes exhibit variable patient-to-patient transmission rates, as determined by whole-genome sequencing (WGS), suggesting differing reservoirs and modes of acquisition

J. Martin* [Leeds, United Kingdom], D. Eyre, W. Fawley, S. Walker, D. Crook, M. Wilcox

**0558**

Whole-genome multicloud sequence typing of ESBL-producing *Escherichia coli*: discriminatory power and optimal cut-off

M. Klytmans - van den Bergh* [Breda, Netherlands], J. Rossen, R. Willems, A. Friedrich, C. Vandenbroucke-Grauls, M. Bonten, J. Klytmans, O.,

**0559**

Comparison of PFGE and NGS based typing of *Listeria monocytogenes* isolates
A. Pietzka* [Graz, Austria], P. Hyden, A. Murer, A. Lennkh, F. Allenberger, B. Springer, C. Sensen, W. Ruppitsch

**0560**

Whole genome sequencing (WGS) to investigate a series of *Corynebacterium diphtheriae* wound infections in East African refugees, May to August 2015 in Switzerland and Southern Germany


**0561**

Practical use of genomic *Streptococcus pyogenes* data in reference microbiology

V. Chalker* [London, United Kingdom], J. Coelho, R. Tewolde, S. Platt, A. Jironkin, A. Underwood, G. Kapatai

**05136 11:30-12:30 Hall C**

**1-hour Oral Session**

**Tackling MDR & XDR tuberculosis**

*Chairs:* David Moore [London, United Kingdom]
Piret Viiklepp [Tallinn, Estonia]

**0562**

Central Asian origin and dissemination history of the multidrug-resistant *Mycobacterium tuberculosis* BO/W148 Russian clone

M. Barbier* [Paris, France], J. Rasigade, M. Merker, S. Niemann, P. Supply, T. Wirth
Multi- and extensively drug-resistant tuberculosis in Eastern Europe today: risk factors and survival

Y. Balabanova (Lenz)* (London, United Kingdom), O. Ignatyeva, L. Pieb, V. Riekstina, M. Danilovits, K. Joana, E. Davidaviciene, B. Radiulite, C. Papa, E. Koszarava, V. Nikolayevsky, F. Dabrowski

A retrospective review of the tolerability and utility of linezolid in a large North West London cohort of multi and extensively drug resistant tuberculosis

A. Abbara (London, United Kingdom), A. Lievesley, J. Biswas, S. Collin, T. Corrah, A. McGregor, L. John, R. Davidson

Antitubercular profile of GSK070 a Mycobacterium tuberculosis leucyl-tRNA synthetase inhibitor

A. Mendoza (Madrid, Spain), E. Perez-Herran, A. Palencia, S. Cusack, X. Li, Y. Zhou, M. Alley, D. Barros

1-hydroxy-2-thiopyridines kill both replicating and dormant Mycobacterium tuberculosis

E. Salina (Moscow, Russian Federation), O. Ryabova, A. Vocat, S. Cole, V. Makarav

The evolution of antibiotic resistance - new insights

Chairs: Teresa Coque (Madrid, Spain), Arnfinn Sundsfjord (Tromsø, Norway)

Collateral sensitivity and resistance networks - potential clinical implications

Viktória Lázár (Szeged, Hungary)

Selection pressure and antimicrobial resistance evolution

Erda Toprak (Dallas, TX, United States)

Microbiota transplantation

Chairs: Werner Soibach (Lübeck, Germany)

Vincent B. Young (Ann Arbor, MI, United States)

What do we know about polyfungal infections? Challenges in laboratory interpretation and treatment

Chairs: Hamdi Akan (Ankara, Turkey), Maiken Cavling Arendrup (Copenhagen, Denmark)

Multiple species candidaemia

Cornelia Lass-Flörl (Innsbruck, Austria)

Mixed Aspergillus and Mucorales infections

Andrew J. Ullmann (Würzburg, Germany)

Challenges with papilloma and polyoma viruses

Chairs: Katja Seme (Ljubljana, Slovenia), Christine Hanssen Rinaldo (Tromsø, Norway)

Risk factors in the progression of low grade intraepithelial neoplasia [LSIL] to high grade intraepithelial neoplasia [HSIL] in a cohort of HIV-positive MSM

C. Hidalgo Tenorio (Granada, Spain), C. Gil-Anguita, J. Ramirez Taboada, M. Lopez Ruiz, M. Omar Mohamed Balghahta, M. Gutierrez, J. Esquivias, R. Javier, J. Pasquau

Prevalence and distribution of high-risk human papillomavirus (HPV) types in Slovenian women screened for cervical cancer

A. Ostrbenk (Ljubljana, Slovenia), T. Triglav, K. Seme, M. Poljak

Increased p16/Ki-67 expression is associated with high risk human papillomavirus persistence and cervical histology: a 3-year cohort study in China

L. Yu (Beijing, China), W. Chen, H. Guo, Y. Qiao

Renal transplant recipients treated with tacrolimus versus cyclosporine A: a delicate balance between BK virus infection and rejection

L. Gard (Groningen, Netherlands), W. van Doesum, H. Niesters, W. van Son, A. Diepstra, C. Stegeman, A. Riezebos-Brilman, J. Sanders

BK-polyomavirus seroreactivity in kidney donors predicts viraemia and nephropathy in recipients: a retrospective cohort study

H. Wunderink (Leiden, Netherlands), E. van der Meijsden, C. van der Blij-de Brouwer, M. Mallot, G. Haasnoot, E. van Zwer, E. Claas, J. de Fijter, A. Kroes, F. Arnold, A. Touze, F. Claas, J. Rotmans, M. Feltkamp

Ancient pathogens: paleosciences

Chairs: Giuseppe Carnaglia (Verona, Italy), Amparo Fernández-Rodríguez (Madrid, Spain)

Ancient pathogen genomics: what we learn from historic pandemics

Johannes Krause (Jena, Germany)

Paleoparasitology, from ancient to future

Miriam José Alvarez Martinez (Barcelona, Spain)
Tuesday, 12 April 2016

**Recent top papers in paediatric infectious diseases**

**Chairs:**
- Jesus Feris Iglesias [Santo Domingo, Dominican Republic]
- Julia Bielicki [Basel, Switzerland]

**11:30 - 12:30 ePoster Session**

**Respiratory tract infection - diagnostic studies**

**Moderator:** Ron Dagan [Beer Sheva, Israel]

**EP0011**

A model to identify patients from the community with infection by pathogens not covered by the guidelines


**EP0012**

Undiagnosed Bordetella pertussis among Chlamydia pneumoniae and Mycoplasma pneumoniae patient samples – a pilot study

K. Gullsby* [Gävle, Sweden], H. Al-Ansari, B. Olsen, K. Bondeson

**EP0013**

Nasopharyngeal carriage of Streptococcus pneumoniae in older adults with community-acquired pneumonia in Italy, 2013 - 2015

D. Martinelli, F. Fortunato, M. Cappelli, P. Ciavarella, A. De Robertis, M. Chironna, R. Prato* [Foggia, Italy]

**EP0014**

Viral and bacterial co-infection triggers innate immune responses and enhances IP-10, a potential biomarker of severe pneumonia: a translational study


**EP0015**

Clinical reassessment versus prophylactic use to reduce antibiotic use in community-acquired pneumonia - the CLINPCT randomized controlled trial


**EP0016**

Monocyte HLA-DR expression in community-acquired pneumonia hospitalized patients

A. Simonetti* [Barcelona, Spain], D. Vivas Perez, C. Garcia Vidal, E. De la Bonda, J. Niübb, J. Dorca, J. Carratala

**EP0017**

Low positivity rate of pneumococcal urinary antigen in a prospective population-based surveillance of community-acquired pneumonia in adults in three cities in Latin-America


**EP0018**

A novel host-protein signature outperforms standard laboratory parameters in differential diagnosis of lower respiratory tract infections


**EP0020**

Utility of different serum biomarkers in patients with community-acquired pneumonia and chronic heart failure

A. Babylev, S. Rychina, S. Avdeev, R. Kazlov* [Smolensk, Russian Federation], V. Mladov

**EP0021**

Revisiting the WHO "How to handrub" standard technique

F. Bellissimo-Rodrigues* [Ribeirão Preto, Brazil], H. Soule, D. Pires, A. Gayet-Ageron, D. Pittet

**EP0022**

Survival of extended-spectrum beta-lactamase (ESBL)-producing Escherichia coli on inanimate surface, in four different suspension fluids: an in vitro experiment

V. Weterings* [Nijmegen, Netherlands], A. Kleefman, C. Verhulst, I. Willemsen, J. Veenemans, M. Kluftman - van den Bergh, J. Kluftmans

**EP0024**

Evaluation of bactericidal activity of chlorhexidine against methicillin-resistant Staphylococcus aureus clinical isolates; in vitro time kill assay

S. Lee, J. Kim* [Seoul, South Korea], J. Lee

**EP0025**

Increasing rates of reduced susceptibility to chlorhexidine and octenidine dihydrochloride in S. aureus are associated with increasing usage

K. Hardy* [Birmingham, United Kingdom], S. Shabir, K. Sunnuck, H. Gil, P. Hawkey, M. Webber
Outbreak of *Serratia marcescens* associated with contaminated chlorhexidine
F. Arribas, R. Fernández, A. Méndez, S. Vázquez, J. Valverde, A. Delgado-Iribarren* [Alcorcón, Spain]

Prolonged survival of *Serratia marcescens* in chlorhexidine
R. Fernández, F. Arribas, A. Méndez, S. Vázquez, J. Valverde, A. Delgado-Iribarren* [Alcorcón, Spain]

Efficacy of octenidine against antibiotic resistant *S. aureus* epidemic clones
T. Conceição, H. De Lencastre, M. Aires de Sousa* [Lisbon, Portugal]

Effect of storage conditions on chemical properties and subsequent biocidal efficacy of two hypochlorous acid-based disinfectants
S. Ali, P. Wilson, S. Ali* [London, United Kingdom]

Silver phosphate polymer-coated screen to prevent multidrug-resistant bacteria colonization in an intensive care unit
J. Ruiz, E. Villarreal, M. Gordon, J. Frasquet, P. Ramirez Galleymore* [Valencia, Spain], A. Castellanos

Clinical outcomes and predictors of mortality following bacteraemia with KPC-producing Enterobacteriacea in a large teaching hospital in the UK: a retrospective case review
L. Sweeney* [Manchester, United Kingdom], R. Wilson, P. Cleary, A. Dodgson, W. Welfare

Daptomycin versus vancomycin in the treatment of proven or suspected infections with methicillin-resistant staphylococci or beta-lactam-resistant enterococci in neutropenic cancer patients: a pilot study
F. Tissot* [Lausanne, Switzerland], N. Perrottet, L. Decosterd, T. Buclin, G. Prod’hom, C. Orasch, D. Marchetti, T. Calandra, V. Erard

Ceftaroline fosamil for the treatment of patients with CSSTI or CAP and concurrent bacteraemia: analysis of six phase III trials
D. Melnick* [Jersey City, United States], D. Wilson, J. Iaconis, H. Friedland, I. Critchley, S. Das

Changing serotypes of *Streptococcus agalactiae* causing invasive infections in adults in Portugal [2009-2014]
E. Ferreira Martins* [Lisbon, Portugal], T. Fernandes, E. Lopes, J. Melo-Cristino, M. Ramirez

An analysis of 7 years of blood cultures: epidemiology, resistance patterns and mortality
N. Friedman* [Geelong, Australia], T. Braun, N. Fallach, V. Carmeli

Thirty-day all-cause mortality among bloodstream infections caused by Gram-negative bacteria in England
S. Gerver* [London, United Kingdom], J. Abernethy, A. Johnson, R. Hope

*Escherichia* cryptic clades identified from a collection of *Escherichia coli* blood isolates using next-generation sequencing
T. Kalonen* [Helsinki, United Kingdom], N. Brown, V. Martin, S. Peacock, J. Parkhill

Scoring systems for identifying patients at risk of resistant Enterobacteriacea bacteraemia at sepsis onset: results from a Dutch multicentre nested case-control study
W. Rottier* [Utrecht, Netherlands], Y. Bamberg, C. Van Werkhoven, H. Ammerlaan, M. Bonten, O. the ESBL Prediction Researchers

A comparison of piperacillin/tazobactam and ceftazidime for the treatment of AmpC-inducible Enterobacteriacea infections
M. Barron, M. Jeffres* [Aurora, United States], C. Foster, M. Bessesen, R. Fugit, B. McCollister

Peripheraly inserted central catheters (PICCs) versus central venous catheters (CVCs) in critically ill patients: is there a different risk for central line-associated bloodstream infections?
V. Pitrigo* [Athens, Greece], P. Mariatos, C. Karamanou, P. Kanellopoulos, K. Sagris, G. Georgiadis, J. Dendrinos, A. Tsakris, G. Saroglou

Hospital-wide central line bundle implementation and impact on bloodstream infections
V. Pitrigo* [Athens, Greece], P. Mariatos, C. Karamanou, P. Kanellopoulos, K. Sagris, G. Georgiadis, J. Dendrinos, A. Tsakris, G. Saroglou

Clinical outcomes following Gram-negative catheter-related bloodstream infection (CRBSI) and catheter-colonization (CC) in adults with tunneled intra vascular access devices
B. Sethi* [Birmingham, United Kingdom], J. Martin, C. Berry, A. Kirby, J. Sandoe

Catheter-associated ventriculitis: clinical characteristics, microbiology and outcomes in a university tertiary care hospital
S. Karageorgos* [Crete, Greece], C. Tsioptis, S. Stratakou, D. Karabetsos, G. Koyuentakis, A. Gikas

Simplifying the WHO protocol: three steps versus six steps for performance of hand hygiene - a cluster randomized trial
Tuesday, 12 April 2016

EP0095
S. Tschudin-Sutter* [Basel, Switzerland], D. Sepulcri, H. Gebreselassie, R. Frei, A. Widmer
An infection control intervention for the healthcare workers of Bangladesh on standard hand hygiene practices for preventing healthcare-associated infections.
L. Ara* [Dhaka, Bangladesh], S. Vashkar, S. Mowla, M. Hossain, U. Mandal

EP0096
Bacterial contamination of the hands of intensive care unit staff during respiratory tract care: should a specific sequence of care be recommended?

EP0097
Assessing first-line treatments and associated clinical outcomes among hospitalized patients with nosocomial pneumonia (NP) based on interim analysis in Europe and Russia of the RECOMMEND study
S. Karve* [Gaithersburg, United States], K. Ryan, P. Peeters, E. Baelen, D. Potter, S. Rojas Farreras, Y. Tazir, E. Pascaud, J. Rodriguez-Baro

EP0098
Trends of ventilator-associated pneumonia incidence in the elderly patients admitted to French intensive care units between 2007 and 2014
C. Dananché* [Lyon, France], A. Machut, A. Savey, P. Vanhems, T. Bénét

EP0099
Intervention to reduce the incidence of hospital-acquired pneumonia outside the intensive care unit: preliminary results of the pre-intervention phase study
V. Isernia* [Badalona, Spain], N. Sopena, Y. Lopez-Loureiro, L. Pedro-Botet, A. Smithson, R. Benitez, C. Cilloniz, I. Casas, I. Guasch, M. Sabrià

EP0101
The PIRASOA® programme: implementation and first outcomes of an antimicrobial stewardship programme based on educational interviews in primary care of the public health system of Andalusia, Spain

EP0102
Systematic infectious disease consultation in rehabilitation facilities: the most effective model for antimicrobial stewardship
F. Trapani* [Bologna, Italy], S. Tedeschi, M. Giannella, F. Cristini, F. Turmietta, A. Liverani, S. Pignanelli, R. Pederzini, A. Cavina, P. Viale

EP0103
Antimicrobial prescribing in Australian residential aged care facilities: results and evaluation of the pilot aged care national antimicrobial prescribing survey
C. Chen* [Melbourne, Australia], N. Bennett, S. Koning, R. James, K. Buisin, K. Thursky

EP0104
A modified McNulty-Zelen design randomized controlled trial to evaluate the TARGET antibiotics toolkit (Treat Antibiotics Responsibly, Guidance, Education, Tools) and its implementation
C. McNulty* [Gloucester, United Kingdom], M. Hawking, L. Jones, R. Owens, N. Francis, C. Butler, P. Moore, T. Nichols, A. Charlett, D. Lecky

EP0105
Complications following upper respiratory tract infections: a population based cohort study in Stockholm County, Sweden
J. Hellman* [Solna, Sweden], T. Cars, I. Eriksson, A. Granath, C. Norman, A. Tenhag

EP0106
Quantity metrics assessing antibiotic use in the outpatient setting: a global consensus procedure

EP0107
Comparison of ideal to actual antibiotic prescribing in primary care in England
T. Smieszek* [London, United Kingdom], J. Rabotham

EP0108
Antibiotic prescribing trends and patterns among out-of-hours providers, England, 2010-2014
M. Edelstein, A. Agbeiyi* [London, United Kingdom], T. Raj, S. Hopkins

EP0109
“Just in case”: antibiotic prescribing behaviour among out-of-hours practitioners in England
M. Edelstein, T. Raj, A. Agbeiyi* [London, United Kingdom], A. Schreijer, D. Lo Fo Wong
<table>
<thead>
<tr>
<th>Session</th>
<th>Time</th>
<th>Type</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>EP30</td>
<td>12:30-13:30</td>
<td>ePoster Area 6</td>
<td>A potpourri of microbes</td>
<td>Moderator: Denis Pierard (Brussels, Belgium)</td>
</tr>
<tr>
<td>EP0200</td>
<td></td>
<td></td>
<td>Population genomics reveals evidence of speciation in Clostridium difficile</td>
<td>N. Kumar* (Hinxton, United Kingdom), H. Browne, M. Stares, T. Connor, T. Lawley</td>
</tr>
<tr>
<td>EP0201</td>
<td></td>
<td></td>
<td>Modulation of Staphylococcus aureus spreading by water</td>
<td>W. Ke, C. Liu, M. Lin* (Taoyuan, Taiwan)</td>
</tr>
<tr>
<td>EP0203</td>
<td></td>
<td></td>
<td>In vitro co-evolution of Pseudomonas aeruginosa with Staphylococcus aureus selects lipopolysaccharide modifications conferring competitive advantage and increased antibiotic resistance</td>
<td>M. Tognon* (Geneva, Switzerland), T. Köhler, M. Beaume, C. van Delden</td>
</tr>
<tr>
<td>EP0208</td>
<td></td>
<td></td>
<td>Prototeteca wickerhamii genome sequencing project – a preliminary report</td>
<td>Z. Bakula* (Warsaw, Poland), P. Siedlecki, J. Gawor, R. Gromadka, T. Jagielski</td>
</tr>
<tr>
<td>EP0209</td>
<td></td>
<td></td>
<td>Prototheca wickerhamii genome sequencing project</td>
<td>Z. Bakula* (Warsaw, Poland), P. Siedlecki, J. Gawor, R. Gromadka, T. Jagielski</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Session</th>
<th>Time</th>
<th>Type</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>EP31</td>
<td>12:30-13:30</td>
<td>ePoster Area 7</td>
<td>Vaccines in the forefront</td>
<td>Moderator: Roman Prymula (Hradec Karlove, Czech Republic)</td>
</tr>
<tr>
<td>EP0239</td>
<td></td>
<td></td>
<td>Reverse vaccinology: developing vaccines against MDR pathogens in the post-antibiotic era</td>
<td>P. Sharma* (Chandigarh, India)</td>
</tr>
<tr>
<td>EP0241</td>
<td></td>
<td></td>
<td>Naked DNA vaccination with full-length attachment gene of Saudi strain human respiratory syncytial virus induces protective immune response with no enhancement of pulmonary inflammation</td>
<td>F. Almajhdi* (Riyadh, Saudi Arabia), M. Hamad, M. Farrag, H. Amer</td>
</tr>
<tr>
<td>EP0243</td>
<td></td>
<td></td>
<td>Significant protection against Staphylococcus aureus targeting novel surface associated proteins by vaccination with humanized antibodies or their corresponding epitope-peptides</td>
<td>A. Nicolai* (Cologne, Germany), S. Mertins, F. Becker, D. Krut, M. Kränke, A. Klímka</td>
</tr>
<tr>
<td>EP0245</td>
<td></td>
<td></td>
<td>Protective efficacy of a D-glutamate auxotrophic live vaccine against Acinetobacter baumannii acute lethal infection</td>
<td>M. Cabral* (La Coruña, Spain), P. García, A. Beceiro, C. Rumba, A. Pérez, M. Moscoso, G. Bou Arevalo</td>
</tr>
<tr>
<td>EP0246</td>
<td></td>
<td></td>
<td>Protective efficacy of a D-glutamate auxotrophic live vaccine against Staphylococcus aureus acute lethal infection</td>
<td>P. Garcia* (La Coruña, Spain), M. Cabral, A. Beceiro, C. Rumba, A. Pérez, M. Moscoso, G. Bou Arevalo</td>
</tr>
<tr>
<td>EP0247</td>
<td></td>
<td></td>
<td>Development of pneumococcal surface protein antigen (PsPA)-based pneumococcal vaccine showing enhanced protective immunity when conjugated to Vi capsular polysaccharide from Salmonella typhi</td>
<td>N. Kothari* (Seoul, South Korea)</td>
</tr>
</tbody>
</table>
EP0248  Immunogenic and protective properties of the preparation consisting of *Escherichia coli* O157:H7, O104:H4 lipopolysaccharids with low endotoxicity and conjugated protein (intimin + Stx2B)

EP0297  Comparison of PCR/16S rRNA gene sequencing with PCR/ESI-MS for the detection of bacteria in excised heart valves
B. Peeters* (Leuven, Belgium), P. Herijgers, K. Beuselinck, W. Peetermans, M. Herregods, S. Desmet, K. Lagrou

EP0298  The optimization of the MALDI-TOF MS database for the identification of anaerobic bacteria
A. Veloo* (Groningen, Netherlands), A. van Winkelhoff

EP0299  Direct MALDI-TOF from blood culture bottles: evaluation of two methods and impact on patient management
K. Varettas* (Sydney, Australia), D. Siebert, A. Kizny Gordon

EP0300  MALDI-TOF mass spectrometry for the detection of carbapenemase production in Gram-negative bacteria
A. Calderaro* (Parma, Italy), M. Buttrini, M. Piergiani, S. Montecchini, M. Martinelli, G. Piccolo, M. Medici, M. Arconeletti, C. Chezzi, F. De Conta

EP0301  Direct diagnosis of urinary tract infections by combining MALDI-TOF (Matrix-assisted laser desorption ionization-time of flight) Coral UTI Screen TM system and Gram stain
J. Guzmán-Puche, I. Gracia-Ahufinger* (Cádiz, Spain), M. Causse, R. Tejero-García, F. Rodríguez-López, M. Casai-Roman

EP0302  MALDI-TOF MS identification of non-tuberculous mycobacteria directly from solid-medium colonies using a simplified method
B. Rodríguez-Sánchez* (Madrid, Spain), M. Ruiz-Serrano, A. Ruiz, M. Simon, E. Bouza

EP0303  Development of MALDI-TOF MS-based method for serotyping of *Listeria monocytogenes*

EP0304  Evaluation of MALDI-TOF-MS hydrolysis assay for the detection of ESBL-producing Gram-negative bacilli
Y. Zboromyrska* (Barcelona, Spain), M. Ferrer-Navarra, A. Vergara Gómez, C. Pitart, I. Campo, J. Bosch, M. Almela, E. Marco Reverte, J. Vila

EP0305  Bruker matrix-assisted laser desorption/ionization time-of-flight mass spectrometry identification of *Neisseria gonorrhoeae* is improved by a database extension
V. Schweitzer* (Utrecht, Netherlands), A. van Dam, I. Hananto, R. Schuurman, H. Kusters, R. Rentenaar
Core genome MLST of successful clones of extremely drug-resistant (XDR) carbapenemase-producing K. pneumoniae
M. Kabir* (Stockholm, Sweden), A. Ormala, P. Gyarmati, S. Brisse, C. Giske

Development of an online database and web application for analysis of SNP typing data of Acinetobacter baumannii
A. Fedintsev, E. Sheck, M. Edelstein* (Smolensk, Russian Federation)

The hospital in the era of antimicrobial resistance and infection control performance measures
Chairs: Alison H. Holmes (London, United Kingdom), Sebastian W. Lemmen (Aachen, Germany)

Metagenomics approaches for analysis of hospital environment contamination
John Rossen (Groningen, Netherlands)

Automated monitoring of nosocomial infections
Maaiko S.M. van Mourik (Utrecht, Netherlands)

Monitoring of care processes: do we need a big brother?
Eli Perencevich (Iowa City, IA, United States)

Smart design enhances compliance
Walter Zingg (Geneva, Switzerland)

The TRIC target evaluation platform revealed an AdeR unrelated tigecycline resistance mechanism in XDR Acinetobacter baumannii clinical isolates
V. Trebosc, S. Gartenmann, B. Schellhorn, K. Royet, P. Manfredi, M. Tигges, M. Pieren* (Basel, Switzerland), S. Laciuro, M. Gitzinger, C. Kemmer

Detection of a lipid A variant from two Escherichia coli mutants exhibiting partial resistance to the efflux pump inhibitor PAbetaN
S. Schuster* (Freiburg, Germany), J. Bohnert, M. Vavra, K. Zhou, J. Rossen, W. Kern

Multi-hospital spread of a pan-resistant Klebsiella pneumoniae clone with an IS256-directed blaOXA-181 insertion into the mgrB gene in the United Arab Emirates

Effective use of antibiotic resistance gene databases for whole genome and metagenomic sequencing data
A. Das* (Wilrijk, Belgium), X. Basil Britto, G. Cochrane, S. Kumar-Singh, F. Aarestrup, H. Goossens, S. Malhotra-Kumar

Amino acid substitutions of CrrB responsible for resistance to colistin in Klebsiella pneumoniae
Y. Cheng* (Taipei, Taiwan), T. Lin, Y. Lin, J. Wang

Identification of the intrinsic resistance to colistin in Proteus vulgaris by a genomic comparative approach and in vitro tests
S. Baron, J. Rolain* (Marseille, France)

Functional characterization of the new metallo-beta-lactamase (aMBL-2) presented in Gram-negative pathogens
T. Maria* (La Coruña, Spain), L. Blasco, F. Rodriguez-Calviño, F. Ruiz, E. Santillana, A. Romero

The genome and colistin-resistance mechanisms of an IMI-1 carbapenemase-producing Enterobacter cloacae
Z. Zong* (Chengdu, China), L. Huang

Colistin-resistant Klebsiella pneumoniae in patients with major burn trauma

Novel mgrB variants identified in colistin-resistant Klebsiella pneumoniae
X. Basil Britto* (Wilrijk, Belgium), N. Plantinga, C. Lammens, L. Poirel, P. Nordmann, M. Bonten, H. Goossens, S. Malhotra-Kumar

Human resources needed to perform antimicrobial stewardship teams’ activities in French hospitals: a cross-sectional nationwide survey
P. Le Coz, J. Carlet, F. Coazenave-Roblot, C. Pulcini* [Vandoeuvre-Lés-Nancy, France]

Modifiable factors related to antimicrobial treatment inadequacy in an emergency department observation unit
F. Ólafsson, M. Nunez, M. Portilla, C. Navarro, J. Rodríguez-Baño* (Seville, Spain), P. Retamar Gentil
Tuesday, 12 April 2016

0597 Development of quality indicators to monitor appropriate antibiotic use at intensive care units
M. Kallen* [Amsterdam, Netherlands], M. Blom, N. de Keizer, J. Prins, D. Dongelmans

0598 The PIRASOA® programme: implementation and first outcomes of an antimicrobial stewardship programme based on educational interviews in all hospitals of the public health system of Andalusia, Spain.
J. Rodríguez-Baño* [Seville, Spain], C. Pinto, M. Rojo Martin, A. Estella, J. Bautista, M. Perez-Moreno, O. Neth, A. Irastorza, J. Cisneros Herreros

0599 Quality indicators of antibiotic use in the inpatient setting: a global consensus procedure

0600 Antibiotic rotation strategies to reduce Gram-negative antimicrobial resistance in intensive care units: a cluster-randomized cross-over trial
P. van Duijn* [Groningen, Netherlands], D. Annane, M. Deja, F. Esteves, M. Jereb, P. Jorens, B. Misset, F. Sapoph, V. Tomic, M. Bonten

0601 MACC score (antibiotic prescribing score)
R. Rajendran* [Macclesfield, United Kingdom], M. Stevens, S. Stubington

0602 Postprescription antimicrobial review by a multidisciplinary team using computerized tools in shared access
F. Bouchand* [Garches, France], A. Roux, B. Davido, L. Margaux, M. Hugues, F. El Sayed, C. Lawrence, V. Maryvonne, A. Crémioux, A. Dinh

0603 The global point prevalence survey of antimicrobial consumption and resistance (Global-PPS) in 335 hospitals worldwide
A. Versporten* [Antwerp, Belgium], N. Drapier, P. Zarb, I. Ciancua, M. Gros, M. Miller, V. Jarlier, D. Nathwani, H. Goossens

0604 Code name ICATB2: first results of the national structure and process indicators on antibiotic stewardship activities in France, 2013
C. Dumartin* [Bordeaux, France], J. Dillivier, M. Péfau, C. Bervas, P. Parneix, A. Ragues

S607 13:30 Human genetic variation in HIV disease
Jacques Fellay [Lausanne, Switzerland]

S608 13:30 Human genetic and metabolite variation reveal a prognostic biomarker for death in sepsis
Dennis Ko [Durham, NC, United States]

SY147 13:30-15:30 Hall E 2-hour Symposium
Understanding host-bacterial interactions - getting by with a little help from our friends

S609 13:30 The host defence against pathogens: an overview anno 2016
Tom van der Poll [Amsterdam, Netherlands]

S610 14:00 Treating biofilm infections by killing the messenger - quorum sensing
Thomas Bjarnsholt [Copenhagen, Denmark]

S611 14:30 Immune evasion and adhesion mechanisms in Staphylococcus aureus as targets for therapeutic interventions
Mona Johannessen [Trondheim, Norway]

S612 15:00 Disarming the pathogen to treat bacterial infections - know your enemy
Annelies Zinkernagel [Zurich, Switzerland]

SY148 13:30-15:30 Hall G 2-hour Symposium
How to diagnose more fungal disease and less colonization
Chairs: Cornelia Lass-Flörl [Innsbruck, Austria] Manuel Cuenca-Estrella [Madrid, Spain]

S613 13:30 What to order when - which specimen for which fungal test?
Manuel Cuenca-Estrella [Madrid, Spain]

S614 14:00 Seeking solutions: molecular mycology?
Michaela Lackner [Innsbruck, Austria]

S615 14:30 Antigen tests: a critical dispute
Maurizio Sanguinetti [Rome, Italy]

S616 15:00 Practical guidance how to use antifungal susceptibility data
Ana Alastrauey-Izquierdo [Madrid, Spain]

SY146 13:30-15:30 Hall D 2-hour Symposium
Genetics of infectious diseases in the era of precision medicine
Chairs: Dennis Ko [Durham, NC, United States] BJ Kullberg [Nijmegen, Netherlands]

S605 13:30 Genetic deficiencies in the IL-17 pathway in infectious diseases
Anne Puel [Paris, France]

S606 13:30 Host-pathogen relationships in tuberculosis
Erwin Schurr [Montreal, Canada]
OS149 13:30-15:30           Hall H
2-hour Oral Session
Infections of the brain and meningitis
Chairs: Marco Rinaldo Oggioni [Leicester, United Kingdom]
Alexandra Mailles [Saint-Maurice, France]

0617  O617 In experimental pneumococcal meningitis, the small molecule brain-derived neurotrophic factor mimetic LM22A-4 attenuates cerebrospinal fluid inflammation but not brain injury
D. Grandgirard* [Bern, Switzerland], L. Marti, S. Leib

0618  O618 Cerebrospinal fluid inflammatory mediators associated with outcome in patients with pneumococcal meningitis
M. Geldhoff* [Amsterdam, Netherlands], M. Brouwer, M. Valls Seron, A. Zwinderman, A. van der Ende, D. van de Beek

0619  O619 V-akt murine thymoma viral oncogene homolog 3 [AKT3] influences outcome of pneumococcal meningitis
M. Valls Seron* [Amsterdam, Netherlands], B. Ferwerda, V. Jaspers, A. van der Ende, M. Brouwer, D. van de Beek

0620  O620 Time to antibiotic therapy and outcome in bacterial meningitis
J. Bodilsen* [Aalborg, Denmark], M. Dalager-Pedersen, H. Schonheyder, H. Nielsen

0621  O621 CSF lactate level and bacterial encephalitis
M. Maillet* [Grenoble, France], A. Mailles, J. Stahl

0622  O622 N-methyl-D-aspartate receptor autoimmunity affects cognitive performance in herpes simplex encephalitis
G. Westman* [Uppsala, Sweden], M. Studahl, C. Ahlm, B. Eriksson, B. Persson, J. Rönnelid, S. Schliamser, E. Aurelius

0623  O623 Genome-wide analysis identifies benzalkonium resistance genes to be associated with outcome in Listeria monocytogenes meningitis
P. Kremer* [Amsterdam, Netherlands], J. Lees, B. Ferwerda, A. van der Ende, M. Brouwer, S. Bentley, D. van de Beek

0624  O624 Setup of a Listeria monocytogenes meningitis mouse model with and without antibiotic treatment
M. Koopmans* [Amsterdam, Netherlands], M. Valls Seron, V. Jaspers, M. Brouwer, D. van de Beek

0625  O625 Epidemiology of Listeria monocytogenes meningitis in the Netherlands, 1985-2014
M. Koopmans* [Amsterdam, Netherlands], M. Bijlsma, M. Brouwer, A. van der Ende, D. van de Beek

0626  SY150 13:30-15:30           Hall I
2-hour Symposium
Impact of national guidelines implementation on diagnostic and therapeutic interventions in community-acquired bacterial meningitis
J. Costerus* [Amsterdam, Netherlands], M. Brouwer, M. Bijlsma, A. van der Ende, D. van de Beek

SY150 13:30-15:30           Hall I
2-hour Symposium
Antiparasitic drugs: good news and bad news
Chairs: Yupin Suputtamongkol [Bangkok, Thailand]
Zeno Bisoffi [Verona, Italy]

S627  S627 13:30 Twice-yearly ivermectin for onchocerciasis: the time is now
Moses Katabarwa [Atlanta, GA, United States]

S628  S628 14:00 Ivermectin as a complementary strategy to kill mosquitoes and stop malaria transmission?
Guida Bastiaens [Nijmegen, Netherlands]

S629  S629 14:30 Fasciola: resistant in livestock and now in humans
Peter Chiodini [London, United Kingdom]

S630  S630 15:00 Giardia: confirming resistance and alternatives to the nitroimidazoles
Kristine March [Bergen, Norway]

SY151 13:30-15:30           Hall J
2-hour Symposium
Dengue and dengue haemorrhagic fever, 2016
Chairs: Onder Ergonul [Ankara, Turkey]
Annelies Wilder-Smith [Singapore, Singapore]

S631  S631 13:30 Epidemics and severe dengue disease
Maria G. Guzman [Havana, Cuba]

S632  S632 14:00 Predicting outcome from dengue
Sophie Yacoub [Ho Chi Minh City, Viet Nam]

S633  S633 14:30 Immunopathogenesis and vaccine development: current status
Juthathip Mongkolsapaya [London, United Kingdom]

S634  S634 15:00 Ivermectin: a promising anti-dengue replication treatment
Panisadee Avirutnan [Bangkok, Thailand]
Tuesday, 12 April 2016

SY152  13:30-15:30           Hall K
2-hour Symposium

Update in diagnosis and clinical management of implant-associated infections

Chairs:  Prema Seetulsingh [Watford, United Kingdom]
         Stefania Stefani [Catania, Italy]

S635  13:30  Microbiological diagnosis of implant infections
       Yvonne Achermann [Zurich, Switzerland]
S636  14:00  Management of prosthetic joint infections
       Alex Soriano [Barcelona, Spain]
S637  14:30  Management of breast-implant infections
       Joe M. O’Donoghue [Newcastle, United Kingdom]
S638  15:00  Management of endovascular graft infections
       Barbara Hasse [Zurich, Switzerland]
 editor: Leonard Leibovici

Clinical Microbiology and Infection (CMI) is a monthly publication of the European Society of Clinical Microbiology and Infectious Diseases and publishes peer-reviewed papers that present basic and applied research relevant to therapy and diagnostics in the fields of microbiology, infectious diseases, virology, parasitology, immunology and epidemiology.

• Supports Open Access
• Mobile app now available for iOS and Android

READ FREE ONLINE COLLECTION
Infection Hot Topics – 2015

• The ignored pandemic of typhoid
• Is it the end of the nervous breakdown on avian influenza?
• What is hot in infectious diseases?
• Chimeric antigen receptor (CAR)-redirected T cells: is there a place for them in infectious diseases?
• The compliance of clinicians and patients cannot be globalized
• Worldwide decrease in methicillin-resistant Staphylococcus aureus: do we understand something?
• From one Nobel Prize (P. Ehrlich) to another (Tu Youyou): 100 years of chemotherapy of infectious diseases
• Refugee crisis and re-emergence of forgotten infections in Europe

PUBLISH YOUR RESEARCH
Submit your manuscripts to http://mc.manuscriptcentral.com/cmi

Benefits to Authors

Share Link—A personal, customized short link that you will receive after final publication of your article, providing 90 days free access to your newly-published article on ScienceDirect to anyone clicking on the link.

My Research Dashboard—Personalized dashboard for immediate feedback about the impact of your research, offering efficient tracking metrics about your paper including citations, usage, views, scholarly mentions, sharing and more.

Virtual Microscope—Complement conventional (low-res) slide images in your paper with high res whole slide scan equivalents viewable using a standard browser with features such as zoom, pan and rotate.

www.clinicalmicrobiologyandinfection.com
Poster Sessions

Saturday, 9 April 2016

100

Final Programme 26th ECCMID, Amsterdam, Netherlands, 2016
P0016 Maintenance of non-HIV cardiometabolic comorbidity control among HIV-infected veterans’ affairs patients: a comparison between single tablet and multiple tablet antiretroviral regimens
N. Patel* (Albany, United States), Z. Hecox, C. Morse, S. Sullivan, A. Hoye-Simek, J. Yager, T. Lodise

P0017 Prevalence and factors associated with discordant intima-media thickness and arterial stiffness combined measurements in people living with HIV
M. Jean* (Perpignan, France), M. Saada, C. Fideline, F. Roustant, H. Aumaître

P0018 Temporal trends in demographic and clinical characteristics of HIV-infected patients in an intensive care unit
J. Alves, R. Duro* (Porto, Portugal), A. Santos, P. Figueiredo, A. Sarmento, L. Santos

P0019 Risk factors for loss to follow-up after a positive HIV test at the emergency department: a case-control study, 2010-2014
A. Almeida* (Lisbon, Portugal), M. Boattini, P. Guedes, S. Gouveira, J. Carvalho, A. Simas, P. Fortuna, T. Fevereiro, H. Brazao

P0021 Spacial dynamics and social risk factors for AIDS in isolated area in French Guiana
E. Mosnier* (Cayenne, French Guiana), L. Epelbion, F. Huber, P. Brusseau, N. Guiraud, F. Djassou, B. Guarmit, M. Ville, M. Nacher

P0022 Geomapping HIV outcomes
A. O’Rourke, C. Saraghan, D. Robinson, G. Boyle, C. Bergin, C. Ni Cheallaigh* (Dublin, Ireland)

15:30-16:30
HIV biomarkers, resistance and diagnostics

P0023 Transmitted drug resistance (TDR) in newly diagnosed HIV-1-infected subjects in Estonia in 2013

P0024 Development of HIV-1 integrase cross resistance against dolutegravir and elvitegravir in raltegravir-experienced patients in western Germany from 2009-2015
F. Wiesmann, P. Braun* (Aachen, Germany), T. Goodarzi, H. Knecht

P0026 Single-centre study of trends in HIV drug resistance mutations
G. Perren-Llerena* (Lucerne, Switzerland), M. Garcia-Deltoro, M. Rosas, C. Rubia-Córdova, P. López-Lam, E. Ortega G.

P0028 Performance evaluation of BIO-FLASH HIV 1+2 Ag/Ab on Biokit’s BIO-FLASH® analyser
M. Costa* (Barcelona, Spain), L. Heredia, D. Casagolda, S. León, S. Hernanz, C. Hervás, C. Rodríguez, S. Foraudo, J. Relave, H. Scheiblauer, L. Taberner

P0029 Predictive signal to cut-off value and clinical risk factors of false positives for HIV screening test in a low-prevalence area
H. Jang, J. Kim, S. Kang, S. Jung* (Gwangju, South Korea), K. Park, J. Shin

P0030 Evaluation of DxN VERIS system for HIV-1 viral load quantification in clinical practice
A. Lombardi* (Milan, Italy), N. Zanchetta, D. Mileto, A. Mancon, V. Micheli, P. Meraviglia, S. Rusconi, G. Rizzardini, M. Galli, M. Gismondo

P0031 sCD40L levels in HIV-infected patients
B. Díaz-Pollán* (Madrid, Spain), V. Estrada, D. Gómez-Garré, M. Fuentes-Ferrer, J. San Román

P0032 Inosine triphosphate pyrophosphohydrolase (ITPase) expression is decreased in leucocytes of HIV-seropositive patients using combination antiretroviral therapy
C. Peltenburg* (Rotterdam, Netherlands), M. Leers, J. Bakker, S. Lowe, W. Vroemen, A. Paulussen, B. van den Bosch, J. Bierau, A. Verbon

P0033 A new biomarker in combination with anti-retroviral treatment for human immunodeficiency virus infection: association of adverse events with inosine triphosphate pyrophosphohydrolase activity
C. Peltenburg* (Rotterdam, Netherlands), J. Bierau, J. Bakker, J. Schippers, S. Lowe, A. Paulussen, B. van den Bosch, M. Leers, B. Hansen, A. Verbon

P0034 High pro-inflammatory gene expression in BAL associated with mycobacterial lung infections among individuals infected with HIV
Y. Keynan* (Winnipeg, Canada), A. Trajtman, P. McLaren, L. Velez, Z. Rueda

P0035 Analysis of the mRNA expression of DNA damage response genes in HIV-1 infected patients
F. Falasca, D. Di Carlo, G. Tranquilli, G. D’Ettorre, A. Fantauzzi, G. Antonelli, O. Turriziani* (Rome, Italy)

15:30-16:30
Novel diagnostics for viral hepatitis

P0036 A European multicentric study on the analytical performance of DxN Veris System HCV assay
P0037 Use of an automated HCV core-antigen test to follow HCV-infected patients treated with new direct-acting antivirals
R. Alonso* (Madrid, Spain), E. Reigadas, D. Ampuero, F. Pérez-García, E. Bouza

P0038 VERIS HBV assay accurately quantifies different HBV genotypes (genotypes A to G) in plasma
S. Fournat* (Creteil, France), D. Challine, J. Poveda, S. Laperche, B. Magali, A. Soulier, L. Poiteau, J. Pawlatsky, S. Chevaliez

P0039 Evaluation of Architect HCV core antigen assay to monitor viral load in patients on antiviral therapy

P0040 Development of synthetic molecular standards for hepatitis B and hepatitis C virus
S. Ashraf, D. Mittar, L. Kerrigan* (Manassas, VA, United States)

P0041 Preliminary data for the identification of a threshold value predicting positivity with immunoblot for a commercial anti-HCV screening assay
M. De Paschale* (Milan, Italy), M. Manco, L. Belvisi, V. Ricucci, D. Cagnin, T. Cerulli, A. Paganini, C. Agrappi, P. Mirri, P. Clerici

P0042 Validation of a new highly sensitive real-time RT-PCR for detection of hepatitis E virus in human plasma
M. Sander, T. Vollmer, J. Dreier, O. Matusik, B. Kraemer, C. Reichhuber* (Neuried, Germany), F. Schwarzmann, E. Soutschek, V. Eremine

P0043 Dried blood spots specimens for serological diagnosis of hepatitis B and C: two systematic reviews and meta-analyses of diagnostic accuracy studies

P0044 HCV NAT assays and the challenge of genetic variants in drug therapy
C. Morris* (Hertfordshire, United Kingdom), R. Anderson, J. Fryer, G. Prescott, P. Minor, N. Almond

P0045 Comparative evaluations of the access HCV Ab V3 assay
D. Nogues, C. Mazure, A. David, L. Marchylije, J. Leroy, R. Falcou-Briatte* (Marnes-la-coquette, France)

P0046 Comparison of the recently launched Hologic Aptima HCV Quant Dx assay with the established Abbott RealTime HCV assay in viral load measurement
R. Ehret* (Berlin, Germany), M. Andrew, M. Schuetze, M. Obermeier

P0047 Clinical evaluation of the Veris HCV assay for hepatitis C virus RNA quantification
S. Haim-Boukobza, L. Izquierdo, C. Prêgermain, A. Roque-Afonso* (Villejuif, France)

P0048 Xpert® HCV viral load RT-PCR assay (Cepheid) for urgent sample hepatitis C virus quantification
A. Maleska* (Montpellier, France), A. Mondain, L. Ottomani, J. Ducos

P0049 Semi-quantitative real-time PCR for hepatitis B diagnosis: a simple and cost-effective approach to identify and monitor low replicative chronic hepatitis B-infected patients in resource-limited countries

P0050 Prolonged fever in adults: clinical and biological study
K. Ikbel, B. Hajer, M. Wafa, A. Aouam, A. Loussieuf* (Monastir, Tunisia), A. Toumi, C. Mohamed

P0051 The molecular genetic variety of the hepatitis C virus in Belarus
E. Gasich* (Minsk, Belarus), V. Eremine

P0052 Cytokine pattern involved in the inflammatory response in acute viral hepatitis type A and B in adults
M. Horvat* (Cluj Napoca, Romania), C. Cismaru, M. Muntean, M. Valeanu, M. Lupse, A. Slavcovici, I. Daniela

15:30-16:30
What is hot in diagnosis of viral infections?

P0053 Development and evaluation of an automated BKV quantitative assay using the Abbott m2000 system
F. Wu* (New York, United States), R. Wywadi, J. Shi, S. Whittier

P0054 Ensuring the quality of polyomavirus diagnosis in immunocompromised patients
S. Govind* (Hertfordshire, United Kingdom), K. Doris, R. Anderson, N. Almond, C. Morris

P0055 Preliminary performance evaluation of BIO-FLASH anti-HTLV I/II on Biokit’s BIO-FLASH® analyser
A. Lermo* (Barcelona, Spain), G. Colom, M. Montilla, D. Casagolda, M. Garcia, C. Cebrúan, M. Cabello, L. Taberner

P0056 Clinical diagnostics of HTLV-1 and HTLV-2 using droplet digital PCR for absolute quantification and determination of proviral load
P0057 Establishment and evaluation of Torque Teno virus (TTV)-analysis in the course of allogeneic haematopoetic stem cell transplantation (allo-HSCT)
R. Gilles* (Cologne, Germany), M. Herling, C. Scheidt, H. Pfister, R. Kaiser, V. di Cristanziano

P0058 Prevalence and epidemiology of the human astrovirus species HAstV, VA/HMO and MLB in Leiden, the Netherlands
R. Nijhuis* (Leiden, Netherlands), E. Wessels, I. Sidorov, A. Gulyaeva, A. Garboleny, E. Claas

P0059 Entero- and poliovirus stool surveillance in Switzerland by quantitative nucleic acid testing
R. Gosert* (Basel, Switzerland), H. Hirsch

P0060 The potential of high throughput sequencing as a diagnostic tool for norovirus infections
F. Thorburn* (Glasgow, United Kingdom), P. Murcia, R. Gunson

P0061 Detection of the emerging rotavirus g12p[8] genotype at high frequency in Brazil in 2014: successive replacement of predominant strains
A. Luchs* (Sao Paulo, Brazil), A. Cilli, S. Morillo, D. Gregorio, K. Souza, H. Vieira, A. Fernandes, R. Carmona, M. Timenetsky

P0062 Assessment of nasopharyngeal swab sample stability for use with the Luminex NxTAG® respiratory pathogen panel
V. Brown-Ritchie, P. Cheung, H. Zhang* (Toronto, Ontario, Canada)

P0063 Evaluation of the analytical performance of the multiplex R-DiaFlu® kit (Diagenode) for the detection of influenza A and B viruses in nasopharyngeal specimens
B. Vanmassenhove* (Oostende, Belgium), L. Persijn, L. Vynckier, G. Alliet

P0064 Evaluation of Alere i influenza A & B isothermal nucleic acid assay: importance to analyze fresh samples for rapid diagnosis of influenza

P0065 Molecular point-of-care diagnostics of influenza A and by lab-in-a-tube testing; the cobas LIAT system
W. Melchers* (Nijmegen, Netherlands), J. Kuijpers, J. Rahamat-Langendoen


P0067 Prevalence of immunoglobulin G (IgG) antibodies to mumps virus in the Czech population
N. Sojkova* (Prague, Czech Republic), D. Franova, M. Kocmanova, P. Horyna

P0068 Performance of BIO-FLASH® Measles IgG on Biokit’s BIOFLASH® Analyser
S. Li, M. Hartmann, T. Herzog, M. Alba* (Llúcia d’Amunt, Spain), T. Bari, M. Wendling, T. Schumacher, J. Serra

P0069 Evaluation of the FilmArray® BioThreat panel with various potential biothreat agents in comparison to validated realtime PCR assays
C. Beuret* (Spiez, Switzerland), D. Siegrist

P0070 Google Trends as surveillance tool for seasonal rotavirus in the Netherlands and Belgium
M. Nipshagen* (Utrecht, Netherlands), R. Van Gaalen, M. Sabbe, P. Buijning-Verhagen

15:30-16:30
Emerging and pre-emerging viruses

P0071 Epidemiology of microcephaly in Colombia, 2009-2013: implications for surveillance of Zika

P0072 Possible aetiology of Guillain-Barré syndrome following a Zika epidemic in French Polynesia: analysis of 42 cases

P0073 Recent increase in Shigella gastroenteritis in a region in the north of Spain
M. Alkorta* (Donostia-San Sebastian, Spain), J. Marimon, M. Gomariz, M. Alonso, E. Perez-Trallero

P0074 Ten treatment cases of severe fever and thrombocytopenia syndrome in a single hospital
H. Kim* (Daegu, South Korea), K. Kwon

P0075 Knowledge, attitudes and practice among healthcare workers at risk of acquiring Crimean-Congo haemorrhagic fever

P0076 Congenital dengue and chikungunya virus infection in Tolima, Colombia: a case series in 2015
A. Sarmiento-Ospina, H. Vásquez-Serna, C. Jimenez-Canizales* (Ibagué, Colombia), A. Rodriguez-Morales
P0077  Characteristics of dengue outbreak in Dar es Salaam - Tanzania, 2014

P0078  Emergence of dengue fever in Hong Kong: assessment in a non-endemic city
K. Kam* (Hong Kong, China), D. Chan, M. Cheung, D. Kwan, S. Lee

P0079  Four-year surveillance of imported dengue virus infection in North-Western Italy
E. Burdino, T. Allice, M. Milia, G. Gregori, T. Ruggiero, A. Proietti, M. Malta, I. Torta, G. Calleri, P. Caramello, V. Ghisetti* (Torino, Italy)

P0080  Detection and differentiation of dengue virus serotypes with a DNA microarray chip
M. Khan* (Ribeirao Preto, Brazil), V. Hugo

P0081  Dengue score, a simple and highly specific test for diagnosis of dengue infection
S. Nimitvilai* (Nakhonpathom, Thailand), S. Jarupongprapa, K. Jintanapramote

P0082  Early clinical characteristics and risk factors of dengue patients with severe organ involvement
V. Pang* (Singapore, Singapore), Y. Leo, D. Lye

P0083  Overcoming challenges to develop effective assistance in an epidemic area of dengue fever
I. Boszczowski* (Sao Paulo, Brazil), A. Luiz Pires Maciel, M. Maria Baraldi, A. Gonzaga Juca, T. Pereira da Silva, I. Lima, L. Felipe Gastaldo Poletti, C. Cristina Pires do Nascimento, I. Machado Ribeiro, C. Schmitt

P0084  Dengue fever in oncology patients: a single centre experience in an endemic area in Brazil
D. Peixoto* (Sao Paulo, Brazil), M. Freire, R. Itto, V. Menegatti, E. Lopes, L. Pierotti, E. Abdala

P0085  Ebola preparedness in Australia: a rapid approach for proficiency testing
K. Lau* (St Leonards, Australia), T. Theis, J. Gray, R. William D.

P0086  Reference materials for Ebola virus diagnosis and the analysis of serological immunity
M. Page, D. Wilkinson, G. Mattiuzzo, M. Hassall, J. Ashall, S. Myhill, R. Harvey, N. Almond* (Hertfordshire, United Kingdom), P. Minor

P0087  Persistence of virus replication markers in respiratory samples from human Ebola virus infection

P0088  Does suspicion of Ebola virus disease have consequences on the diagnosis delay for other infectious diseases?

P0089  Ebola virus disease in healthcare settings; implications for infection control — Nigeria 2015

P0090  Cross-sectional study of Ebola virus disease preparedness among designated hospitals in Japan
T. Toyokawa* (Boston, United States), N. Hori, Y. Kata, N. Toyama, R. Cash

P0091  Surveillance of suspected Ebola cases in patients returning from Africa in France: ensuring healthcare workers' safety and optimal medical management
A. Maillès* (Saint-Maurice, France), H. Noel, S. Vandentorren, C. Rapp, K. Wyndels, Y. Yazdanpanah, C. Chidiac, H. Coignard-Biehler, D. Panettier, S. Baize

P0092  Bottlenecks in health systems functioning for control of Ebola virus disease in Connaught Hospital, Freetown, Sierra Leone
C. Brown* (Freetown, Sierra Leone), Q. Kessete, P. Baker, D. Youkee, N. Walker, T. Kamara, O. Johnson, M. Lado

P0093  Ebola virus disease in children in Sierra Leone: a retrospective cohort study

P0094  Several cases of EVD survivors with unusual presentation of post-EVD syndrome
M. Lado* (Freetown, Sierra Leone), P. Howlett

P0095  Hospital outbreak of Middle East respiratory syndrome (MERS) in a large tertiary care hospital — Riyadh, Saudi Arabia, 2015
P0096 Maintained screening & surveillance for MERS-CoV in returning travellers from the Middle East over Ramadan and Hajj seasons 2013-2015
S. Atabani* [Birmingham, United Kingdom], S. Wilson, C. Overton-Lewis, J. Workman, E. Smit, H. Osman

P0097 Clinical characteristics of Middle East respiratory syndrome coronavirus infected patients
M. Garbati, S. Fogba, L. Skakni, T. Wani, M. Joseph, M. Peiris, A. Hakawi* [Riyadh, Saudi Arabia]

P0098 Duration of isolation precautions for Middle East respiratory syndrome coronavirus infection
Y. Seo* [Seoul, South Korea], J. Heo, H. Jeong, J. Lee, Y. Choi, J. Lee

P0099 Lack of transmission among healthcare workers in contact with a MERS patient in Thailand
S. Wiboonchutikul* [Nonthaburi, Thailand], W. Manosuthi, S. Likansakul, C. Sangsoja, P. Kongsanan, R. Nitiyanantakij, V. Thientong, H. Lerdseramnan, P. Puthavathana

P0100 Clinical evaluation of commercial Middle East respiratory syndrome corona virus real-time RT-PCR assays
A. Samity* [Riyadh, Saudi Arabia], D. Mohamed

P0101 Close ancestor of Civet SARS-CoV from SARS-related coronavirus from greater horseshoe bats in Yunnan, China

P0103 Measles epidemic in the Netherlands: changing epidemiology?
T. Woudenberg* [Bilthoven, Netherlands], R. van Binnendijk, E. Sanders, J. Wallinga, H. de Melker, H. Ruijs, S. Hahné

P0104 Management of hospitalized patients in the season 2015 with high influenza activity
J. Becker* [Frankfurt, Germany], A. Ambrosch, F. Rockmann

15:30-16:30 Recent advances in diagnosis of herpes viruses

P0105 Evaluation of BIO-FLASH HSV IgM
F. de Grin Manchón* [Madrid, Spain], P. Bolfagan, T. Minguito, J. De la Fuente

P0106 Performance of BIO-FLASH HSV IgM on Biokit’s BIO-FLASH® analyser
L. Taberner* [Barcelona, Spain], B. Bosch, M. Montilla, C. Tavira, M. Cedó, J. Serra

P0107 Availability of 24/7 rapid HSV PCR test directly impacts acyclovir exposure in paediatric patients
T. Van, M. Lustestica, B. Bowland, J. Dien Bard* [Los Angeles, United States]

P0108 CE-IVD validation of CMV ELITe MGB® assay in combination with ELITe InGenius®, an innovative sample-to-result solution for quantitative transplant pathogen monitoring
C. Bitto, S. Costa, M. Enrietto, S. Patanè, C. Olivo, G. Stefanuto, F. Garreta, W. Mahoney, A. Estampes* [Puteaux, France]

P0109 Quantification of cytomegalovirus DNA in whole blood samples using two molecular methods: pHe® CMV DNA assay vs O-CMV real-time complete kit
R. Santangelo* [Rome, Italy], V. Prete, S. Soldini, L. Romeno, G. Delogu, M. Sanguinetti

P0110 Comparison of CMV patient quantitation using the Abbott RealTime CMV (ART) and cobas Amplicrep cobas TaqMan CMV assay (CAP/CTM)
G. Moussa, C. Herman, D. Lucic* [Des Plaines, United States], T. Mazzulli

P0111 An evaluation of the fully automated DxN VERIS system for the detection of CMV DNA in multiple specimen types
A. Yates* [Sheffield, United Kingdom], D. Whittaker, M. Raza

P0112 Role of the IL28B rs12979860 C/T single nucleotide polymorphism on the incidence of active cytomegalovirus infection in autologous stem cell transplant recipients

P0114 Are Epstein-Barr virus viral load results comparable between laboratories: evidence from UK NEQAS EQA panels
B. Kele* [London, United Kingdom], E. Elenoglou, H. Seyedzadeh, P. Jovanovic, B. Senechal, C. Walton

P0115 Evaluation of the diagenode H-DiaEBV quantitative kit

P0116 Evidence of human herpesvirus-6 and -7 reactivation in miscarrying women with pityriasis rosea
F. Drago* [Genoa, Italy], G. Ciccarese, A. Parodi

P0118 A novel scoring system for assessing neurological damage in acute encephalitis on magnetic resonance images
S. Defres* [Liverpool, United Kingdom], H. Juul, S. Keller, K. Das, T. Solomon, E. Study Group
15:30-16:30
Respiratory virus diagnostics

P0119 Copan eNAT medium stabilizes nucleic acids for the detection of viruses with the xTAG respiratory viruses panel
A. Squassina, S. Castriciano* (Brescia, Italy)

P0120 Evaluation of the Alere TM Influenza A&B test compared to CLART TM PneumoVir
M. Sauca, C. Segura* (Barcelona, Spain), V. Plasencia, D. Saenz, G. Soria, T. Torrella

P0121 Point-of-care testing for respiratory viruses in hospitalized adults improves the detection rate of influenza, the use of neuraminidase inhibitors and may reduce unnecessary antibiotic use and duration of hospitalization
N. Brendish* (Southampton, United Kingdom), A. Malachira, T. Clark

P0122 The impact of viral respiratory infections in the first year post-transplant period of paediatric haematopoietic stem cell transplant (HSCT) recipients
A. Piralla* (Pavia, Italy), A. Girelli, G. Campanini, M. Premoli, N. Descembrino, L. Rubert, P. Comoli, M. Zecca, F. Baldanti

P0123 A rapid antigentest for diagnosing influenza can be performant in children but not in adults
Y. Overmeire* (Ghent, Belgium), I. Cox, E. Vanlaere, H. De Beenhouwer, C. Verfaillie, A. Van den Abeele, J. Van Acker

P0124 Comparison of Copan MSwab™ rapid direct nucleic acid extraction to traditional nucleic acid extractions for the detection of enteric pathogens in stool samples with the R-Biopharm RIDA®GENE real-time PCR
S. Castriciano* (Brescia, Italy), R. Botrugno, A. Giambra, A. Squassina

P0125 Clinical evaluation of Seegene allplex respiratory panel 1 assay for the detection of seasonal influenza and human respiratory syncytial viruses
L. Gimferrer* (Barcelona, Spain), C. André, M. Codina, J. Esperalbo, M. Martin, F. Fuentes, T. Pumarola Sole, A. Anton

P0126 Idylla respiratory (IFV-RSV) panel (CE) demonstrates rapid results and the potential of differentiation of influenza A, influenza B and respiratory syncytial viruses
J. Baden, J. Painter, J. Jones, P. Shah, T. Astacio, R. Isla, A. Capt* (Beerse, Belgium)

P0127 Performance improvement of influenza A/H1N1pdm09 complete genome massive sequencing by setting a cycle threshold cut-off in monoplex PCR

P0128 Trajectories of cD8+ T-Cells and CD4/CD8 ratio in a cohort of HIV-1 infected individuals
J. Alves* (Lisbon, Portugal), S. Peres, K. Mansinho

P0129 Imbalance of NK cells at the time of HIV primary infection suggests that NKG2C+ cells help to control HIV viraemia level at the time of primary infection

P0130 Viral tropism and naïve CD4+ cells predict immune recovery in very advanced patients
C. Manzardo* (Barcelona, Spain), A. Guarda, M. Casadella, E. Ferrer, P. Domingo, E. De Lazzari, M. Plana, A. Cruceta, J. Gatell, J. Miró

P0131 Identification of a host factor that restores the antiviral activity of APOBEC3G by disrupting HIV-1 Vif-mediated counteraction
K. Miyakawa* (Yokohama, Japan), S. Matsunaga, A. Kudoh, A. Ryo

P0132 A mature NK profile is associated with virologic control in primary HIV infection

P0133 Can we space CD4+ T lymphocytes count monitoring for patients with a suppressed viral load and CD4+ lymphocytes < 500/mm3?
E. Denes* (Limoges, France), J. Pascual, C. Genet, S. Ducaix-Roubertau, P. Pinet, H. Duray, P. Weinbreck

P0134 Is there a gender effect in the CD4/CD8 ratio, immunomeactivations and immunosenescence in HIV-infected subjects with long-term viral suppression?
M. Cordioli* (Verona, Italy), F. Mazzaferrari, P. Del Bravo, M. Lanzafame, E. Concia

P0135 Long-term immune recovery and viral reservoir dynamics in advanced HIV infected patients
C. Manzardo* (Barcelona, Spain), A. Guarda, S. Sanchez-Palomin, A. Zarama, M. Linsà, D. Nicolás, J. Ambrosioni, M. Plana, J. Gatell, J. Miró

P0136 Decidual T-cell subpopulations in viraemic pregnant women with chronic HBV infection with or without HBV-DNA presence in cord blood
I. Elefsiniotis* (Athens, Greece), G. Barla, M. Aspioti, E. Vezali, I. Nikolou
Comparative characteristics of plasmacytoid dendritic cells of patients with HIV monoinfection and in combination with HBV

Evaluation of immune system role in the pathogenesis of chronic hepatitis C viral infection
D. Rios, P. Caciato, E. De Matteo, M. Caldriola, M. Gaillard, L. Bezrodnik, E. Mullen, B. Ameigeiras, C. Brodersen, P. Valva* [Buenos Aires, Argentina], M. Preciado

107

15:30-16:30
New treatment options for mycobacterial infections
P0139 In vivo antitubercular activity of GSK070, a Mycobacterium tuberculosis leucyl-tRNA synthetase inhibitor
L. Guijarro López* [Madrid, Spain], J. Rullas, D. Barros Aguirre, M. Alley, X. Li

P0140 Discovery of potent and specific M. tuberculosis leucyl-tRNA synthetase inhibitors [GSK070]

P0141 Time-kill kinetics analysis of new anti-tuberculosis agents MXF, LZD, VP, CST and SQ109
G. de Knegt* [Rotterdam, Netherlands], A. van der Meijden, C. de Vogel, L. Bakker-Woudenberg, R. Aarnoutse, J. de Steenwinkel

P0142 Early safety of GSK070 - a new antitubercular agent
E. Jimenez* [Madrid, Spain], S. Gresham, S. Robinson, R. Lincoln, S. Turner, P. Bushdid, X. Li, M. Alley, D. Barros

P0143 Predicting the human dose for a novel LeuRS inhibitor, GSK070, for the treatment of tuberculosis
S. Crouch* [Madrid, Spain], F. Ortega, R. Gomez, L. Alameda, S. Ferrer, D. Barros, M. Alley, X. Li

P0144 Antibodies targeting PE_PGRS33 neutralize the ability of Mycobacterium tuberculosis to enter macrophages
M. Minerva* [Rome, Italy], F. De Maio, S. Carnassa, I. Palucci, M. Sanguinetti, M. Sali, G. Delogu

P0145 Antimycobacterial activity of sesquiterpene lactones isolated from Brazilian plants
L. Murana Wildner* [Florianópolis, Brazil], T. Cardoso Lima, M. Weber Biavatti, S. Waddell, M. Bazzo

P0146 A pharmacokinetic evaluation of sulfamethoxazole 800 mg once daily in the treatment of tuberculosis
N. Alsaad* [Groningen, Netherlands]

P0147 Activity of anti-tuberculosis drugs against latent nutrient-deprived Mycobacterium tuberculosis
E. Portell* [Barcelona, Spain], G. Tudd, A. López, J. Gonzalez-Martin

P0148 Outcome of treatment of Mycobacterium bovis versus Mycobacterium tuberculosis: a retrospective study in northern Italy and a systematic review of the literature
G. Sulis* [Brescia, Italy], G. Pinsì, I. El Hamad, P. Giorgetti, P. Rodari, F. Castelli, A. Matteelli

P0149 Immunotherapy improves WHO-recommended treatment in mouse pulmonary tuberculosis
B. Maurik* [Rotterdam, Netherlands], P. Leenen, G. de Knecht, R. Huizenga, I. Bakker-Woudenberg, B. van der Eerden, J. Wang, C. Krois, J. Napoli, J. de Steenwinkel

15:30-16:30
Pathology, diversity and clinical outcome in TB
P0151 Understanding establishment of Mycobacterium tuberculosis infection
M. Ryndak, S. Laal* [New York, United States]

P0152 Genetic diversity of Mycobacterium tuberculosis isolates in southwestern Greece by 24 MIRU-VNTR loci genotyping in association with clinical characteristics and susceptibility testing

P0153 Low frequency of mixed Mycobacterium tuberculosis infection in a large prospective UK series, as assessed using whole genome sequencing
K. Hong* [Seoul, South Korea], S. Shin

P0154 Spoligotypes of Mycobacterium tuberculosis isolated from tuberculosis patients in Odessa, Ukraine
E. Nikolaevskaya, O. Pavlovska, B. Molina, P. Brannberg, I. Marynova, K. Krylova, T. Ivanitsa, V. Filuk, A. Lacoma, J. Dominguez* [Badalona, Spain], O. Rzhepishevska, C. Prat
Changes in VNTR profiles are associated with bacteriological reversions and poorer outcomes in tuberculosis patients
I. Kontsevaya, V. Nikolayevskyy, A. Kovalyov, O. Ignatyeva, E. Vasilievska, G. Skenders, Y. Balabanova, F. Drobniewski* [London, United Kingdom]

Selective identification of latent- and active-TB biomarkers using Mycobacterium tuberculosis secretome phage library and immunoscreening
T. Chiliza* [Durban, South Africa], M. Pillay, K. Naidoo, B. Pillay

Case findings for tuberculosis injection drug use
S. Nandaula* [Kampala, Uganda]

Tuberculosis in a Portuguese cohort
A. Maio* [Aveiro, Portugal], O. Silva Coutinho, S. Nunes, J. Velez, F. Freitas, C. Oliveira

Tuberculosis and nontuberculous mycobacteria among HIV-infected individuals in Ghana

Response scores for the evaluation of patients with tuberculosis from a multi-centric cohort study in Germany
J. Heyckendorf* [Borstel, Germany], I. Olaru, C. Ehlers, J. Hofmeister, L. Busenbender, P. Sanchez-Carballo, E. Terhalle, K. Kalsdorf, N. Wassilew, C. Lange

Extra-pulmonary tuberculosis: a retrospective study of ?? cases at a tertiary care hospital in Dubai, UAE
E. Rehman* [Dubai, United Arab Emirates], L. Al Dabal, A. Shadan

Estimation of tuberculosis incidence at prisons from Colombia, 2007-2013
D. Castañeda-Hernández* [Pereira, Colombia], A. Rodriguez-Morales

Risk factors for incident latent tuberculosis in health care workers after exposure to tuberculosis patients: a prospective follow-up study
S. Pan* [Taipei, Taiwan], H. Lin, J. Wang, F. Chi-Tai, S. Chang

Changing profile and uptake of chemoprophylaxis for latent tuberculosis: UK experience
A. Ravindran, M. Roza* [Milton Keynes, United Kingdom]

Postsurgical meningitis by Pseudomonas aeruginosa: prognostic factors and evolution

Pseudomonas aeruginosa meningitis in neurosurgical patients in a tertiary referee hospital

Tigecycline in the treatment of multidrug-resistant (MDR) Acinetobacter baumannii meningitis: a review of 21 cases

Performance characteristics of MeningoFinder®, 2SMART, a novel 22-plex molecular diagnostic assay for meningitis or encephalitis
J. Ossel* [Maastricht, Netherlands], A. Brink, J. van Wegberg, K. Siemieniewicz, G. Simons

Comparison of FilmArray® Meningitis/Encephalitis Panel assay and conventional techniques on the turnaround time of cerebrospinal fluid microbiological testing

Evaluation of the FilmArray™ ME-panel for the diagnostics of pathogens causing meningitis and encephalitis

Utility of the commercial multiplex PCR test FilmArray for the aetiological diagnosis of acute meningitis
J. Marimon, G. Cilla, M. Alkorta* [Donostia-San Sebastián, Spain], M. Lopez Olazola, E. Pérez-Trallero

Rapid multiplex molecular CSF testing for early diagnosis of meningitis or encephalitis

Intrathecal daptomycin (itDAP) and intravenous linezolid (ivLIN) as therapy of external ventricular drain-associated ventriculitis (EVDV)
A. Arnaiz-Garcia* [Santander, Spain], I. Valduvieco-Juaristis, J. Pinto-Rafael, D. Matañás, J. Martino-González, J. De la Fuente Jiménez
Four cases of cerebral nocardiosis
M. Annovazzi Lodi* (Pavia, Italy), M. Leoni, M. Mussa, A. Di Matteo, L. Minoli

First description of a rifampicin-resistant Neisseria meningitidis Y serogroup strain causing recurrent invasive meningococcal disease in Hungary
Á. Tóth* [Stockholm, Sweden], B. Berta, T. Tirczka, C. Jekkel, A. Abrahám, Z. Prohaszka, Z. Bognár, T. Erdi

May Vii nerve palsy in the course of neuroborreliosis be caused by HSV reactivation? A preliminary study
J. Zajkowska* [Białystok, Poland], A. Moniuszko, K. Guziejko, J. Dunaj, P. Czupryna, M. Kondrusik, S. Grygorczuk, S. Pancewicz

Cure of Acanthamoeba encephalitis in a renal transplant recipient with a drug regimen that included an investigational drug - miltefosine
A. Athavale* [Livingston, United States], B. Saha, P. Weiner

Macrophage/microglia biomarkers in central nervous system infection following neurosurgery
L. Scorzolini* [Rome, Italy], C. Mascia, M. Lichtner, M. Storto, V. Esposito, S. Vita, A. Oliva, P. Zuccala, C. Mastroianni, V. Vullo

Transient encephalitis associated with acute Coxiella burnetii infection
D. Florea, C. Niculae* [Bucharest, Romania], R. Hrisca, A. Hristea, R. Moroti

Paediatric causes of encephalitis and meningitis, the first PACEM study results
A. Bruning* [Amsterdam, Netherlands], J. Wildenbeest, K. Wolthers, D. Pajkrt, P. study group

15:30-16:30

Resistance mechanisms in staphylococci

Detection of agr system and antimicrobial resistance in S. epidermidis producer biofilm isolated at a university hospital over 20 years
M. Ribeiro de Souza da Cunha* [Botucatu, Brazil], V. Cataneli Pereira, L. Pinheiro, A. Oliveira, D. Moraes Riboli

An investigation of the clonality and mechanisms of linezolid resistance among Staphylococcus aureus and coagulase-negative staphylococci from humans in Ireland
A. Lazaris* [Dublin, Ireland], A. Shore, P. Kinneye, D. Coleman, B. Pichon, A. Kearns, G. Brennan, B. O’Connell, A. Feßler, S. Schwarz, O. Brennan

Comparative in vitro activity of tedizolid and linezolid against methicillin-resistant staphylococci, emergence and mechanisms of oxazolidinone resistance in Russia
V. Gostev* [St. Petersburg, Russian Federation], D. Kalinogorskaya, A. Kruglov, V. Ageevets, I. Lazareva, S. Sidorenko

Assessment of linezolid resistance mechanisms among clinical isolates of Staphylococcus epidermidis in a tertiary teaching hospital in Spain
C. Pitart, L. Morata* [Barcelona, Spain], A. Soriano, J. Vila Estape, F. Marco Reverte

Activity of tedizolid against methicillin-resistant Staphylococcus aureus strains with different resistance mechanisms to linezolid isolated from patients with cystic fibrosis
J. Caballero Pérez* [Madrid, Spain], M. Pastor, A. Vindel, L. Máz, G. Yagüe, C. Salvador García, M. Cobo, M. Marosi Reilly, R. del Campo, R. Canton Moreno, G. Grupo Español de Investigación en Fibrosis Quística

A biophysical study of the influence of mild acidity on the role of lysyl-phosphatidylglycerol in defensive peptide resistance
H. Marbach* [London, United Kingdom], R. Rehal, A. Sacranie, J. Edgeworth, R. Harvey

Molecular characterization of an outbreak of linezolid-resistant coagulase-negative staphylococci in a tertiary hospital
M. Aranzamendi Zaldumbide* [Barakaldo, Spain], F. Román Alonso, C. Marcos Moreno, J. Hernández Almaraz, M. Sota Busselo

Correlation of cyclic-di-AMP levels with vancomycin-resistant phenotypes of methicillin-resistant Staphylococcus aureus
L. Lin, J. Lu* [Taoyuan, Taiwan], H. Yeh

Mass spectra based systematic analysis of antibiotic resistant environmental staphylococci
Z. Xu* [London, United Kingdom], K. Vranckx, H. Shah, H. Mkrtchyan, R. Cutler, B. Pot

Characterization of methicillin-sensitive, glycopeptide-intermediate Staphylococcus aureus [MSSA, GISA] isolated from a patient with endocarditis
D. Zabicka* [Warsaw, Poland], M. Brzozowska, M. Tomczak, T. Blauciak, L. Grydz, W. Hryniewicz, J. Empel

Antimicrobial activity of ceftaroline against a collection of methicillin-resistant Staphylococcus aureus [MRSA] isolates collected in 2013-2014 at the Geneva University Hospitals [HUG]
P0193 Adaptation to vancomycin pressure of heterogeneously vancomycin-resistant Staphylococcus aureus
C. Dupieux* (Lyon, France), M. Butin, O. Dumitrescu, O. Nacour, A. Martra, C. Bouveyron, M. Bes, A. Tristan, G. Lina, F. Vandenesch, F. Laurent, J. Rasigade

P0194 Very limited development of mutational resistance by Staphylococcus aureus towards the novel Gram-positive antibiotic [ATx201]
T. Pires dos Santos* (Frederiksberg, Denmark), B. Jana, M. Sommer, L. Guardabassi

15:30-16:30 MRSA - one health worldwide

P0195 The temporal evolution of a successful MRSA lineage in its city of origin
C. Thomson* (Birmingham, United Kingdom), K. Hardy, M. Holden, P. Hawkey

P0196 Emergence and dissemination of ST772-V methicillin-resistant Staphylococcus aureus (MRSA) in Kuwait hospitals
S. Boswahi* (Kuwait, Kuwait), E. Udo, N. Al-Sweih

P0197 Identification of a dominant CC5 PVL-positive methicillin-resistant Staphylococcus aureus clone in Sri Lanka

P0198 Methicillin-resistant Staphylococcus aureus bloodstream infections: clinical and microbiological characteristics and attributable mortality in a cohort of 252 hospitalized patients at the Nantes University Hospital France, 2005-2014
L. Cazet, C. Bourigault, M. Juvin, G. Aubin, S. Corvec, P. Bemer, J. Caillon, D. Lepelletier* (Nantes, France)

P0199 Prevalence of MRSA and ESBL-producing Escherichia coli and Klebsiella pneumoniae in a tertiary care hospital in a five-year period
N. Fajfar* (Golnik, Slovenia), D. Luznik, V. Tomic

P0200 The changing epidemiology of the methicillin-resistant Staphylococcus aureus (MRSA): community-associated MRSA as key actor of paediatric infections in a third-level hospital
D. Dolce* (Florence, Italy), N. Ravenni, S. Campana, E. Camera, C. Braggion, C. Montagnani, L. Galli, F. Armanini, N. Segata, M. de Martino, G. Taccetti

P0201 Emerging multi-resistant Bengal Bay clone ST772-MRSA-V in Norway – cross contamination or parallel import? A cross sectional study
A. Blomfeldt* (Lorenskog, Norway), A. Moghen, H. Aamot, K. Haugum, S. Jørgensen

P0202 First report on MRSA in the community in Luanda, Angola: worrying prevalence among children
T. Conceição, C. Coelho, I. Santos Silva, H. De Lencastre, M. Aires de Sousa* (Lisbon, Portugal)

P0203 Community-associated Staphylococcus aureus (CA-MRSA) is associated with low-level resistance against oxacillin, cefoxitin, and vancomycin
W. Wang* (Taichung, Taiwan), S. Tsao

P0204 Prevalence and molecular characterization of methicillin-resistant Staphylococcus aureus (MRSA) in long-term care facilities in Italy

P0205 Caught in transition? Methicillin-resistant S. aureus and vancomycin-resistant enterococci co-colonization among newly admitted long-term and post-acute care residents
K. Heinze, E. Martin, M. Kabela, L. Mody* (Ann Arbor, United States)

P0206 Results of a Staphylococcus aureus surveillance scheme in the Yorkshire and Humber region of the UK provide reassurance at a time when antibiotic resistance is a threat to the treatment of infectious disease
C. Horner* (Leeds, United Kingdom), L. Utsi, L. Coole, M. Denton

P0207 Molecular epidemiology of Staphylococcus aureus respiratory carriage in Belgian cystic fibrosis patients: results from a national multicentre study
M. Dodemont* (Brussels, Belgium), M. Argudín, E. Vanderhelst, J. Willekens, C. Nonhoff, A. Deplano, A. Malfroot, O. Denis

P0208 Molecular typing and virulence profiling of Staphylococcus aureus isolates from a non-tertiary hospital in South Korea
G. Lim* (Cheonju, South Korea), G. Kang, J. Kim, J. Cha, H. Kim, K. Lee, C. Park, I. Kim

P0209 Genomic diversity of clinical MRSA isolates – insights from the Indian subcontinent
N. Nagasundaram* (Puducherry, India), S. Sistla

P0210 Molecular epidemiology of methicillin-resistant Staphylococcus aureus bloodstream isolates in Changhua, Taiwan, 2007-2013
C. Lee* (Lukang Township, Taiwan), Y. Fang, Y. Chang, T. Wu

P0211 Major clones of Staphylococcus aureus circulating in Ecuador
P. Barba, D. Ortega-Paredes, S. Rivadeneira, J. Zurita* (Quito, Ecuador)
P0212 Methicillin-resistant *Staphylococcus aureus* from infections in horses in Germany frequently colonize veterinarians but are rare among MRSA from infections in humans

P0213 Lysogenic conversion of meticillin-resistant *Staphylococcus aureus* CC398 by virulence gene containing phages
B. Kraushaar* (Berlin, Germany), M. Kienoel, M. Heinig, N. Sperling, J. Hammerl, A. Fetsch, S. Hertwig

P0214 Characterization of community-acquired CC398 methicillin-resistant *Staphylococcus aureus* cases without pig contact in Denmark, 2014
C. Holten Møller* (Copenhagen, Denmark), S. Gillesberg Lassen, A. Koch

P0215 Sp-type t2741 predominates in Finnish pigs carrying livestock-associated meticillin-resistant *Staphylococcus aureus* clonal complex 398 (MRSA CC398)
A. Heikinheimo* (Helsinki, Finland), L. Karvonen, M. Fredriksson-Ahomaa

P0216 Diffusion of clindamycin- and erythromycin-resistant meticillin-susceptible *Staphylococcus aureus* (MSSA) bacteraemia in United States Veterans Administration Hospitals, 2003-2014: the spread of potential ST398 M. Carrel* (Iowa City, United States), M. Goto, M. Schweizer, E. Perencevich

P0217 Genetic characterization and profiling of *Staphylococcus aureus* strains isolated from bovine intramammary infections and close human contacts
T. Schmidt, M. Kock, M. Ehlers* (Pretoria, South Africa)

P0218 Carriage of coagulase-positive staphylococci among healthy owners and their dogs
E. Kovacs* (Budapest, Hungary), K. Laub, S. Kardos, K. Kristof, D. Dobay, A. Tothpal

P0219 High frequency of *Staphylococcus aureus* detection in game animals with identification of meC gene in MRSA isolates of wild rabbits

P0220 Prevalence of multi-resistant *Staphylococcus aureus* spp. in faeces of urban birds
M. Virgailis, J. Armalyte, R. Siugzdiniene, J. Skerniskyyte, I. Klimiene, R. Krasauskas, E. Szuiedeliene, M. Ruzauskas, L. Vaskeviciute* (Kaunas, Lithuania)

P0221 Temporal profile of antimicrobial resistance exhibited by strains of *Staphylococcus* spp. isolated from cases of bovine mastitis over 20 years (1992-2011)
A. Kowalski, G. Maboni, C. Bolzan* (Santa Maria, Brazil), J. Pires Espindola, A. Foletto, S. de Avila Boton, L. Pötter, A. Vargas

P0222 Genotypic and phenotypic characterization of *Staphylococcus aureus* isolates from human and animal origin in Portugal
V. Salgueira, V. Manageiro* (Lisbon, Portugal), L. Clemente, E. Ferreira, M. Caniça

P0223 Methicillin-resistant *Staphylococcus aureus* (MRSA) and extended-spectrum and AmpC beta-lactamase-producing Enterobacteriaceae (ESBL-E) in people living near livestock farms
E. van Duijkeren* (Bilthoven, Netherlands), A. van Hoek, P. Hengeveld, C. Veenman, T. Zomer, L. Smit, C. Maassen

P0224 Methicillin-resistant *Staphylococcus aureus* carriage among retail pork and personnel selling pork in Taiwan
H. Wei* (Taoyuan, Taiwan), Y. Chen

P0225 Detection of meticillin-resistant *Staphylococcus aureus* in Danish retail meat
Y. Tang* (Frederiksborg, Denmark), J. Kjeldgaard, H. Ingmer, P. Andersen, R. Skov, J. Larsen

P0226 The epidemiology and genotypic characteristics of *Staphylococcus aureus* isolates causing bacteraemia in a tertiary hospital in South Africa
K. Karayem, H. Orth, E. Wasserman, A. Whitelaw* (Cape Town, South Africa), K. Hoek

P0227 Evaluation of sampling locations in pregnant women and newborns for the detection of colonization with antibiotic-resistant bacteria

P0228 Survey of resistance of *S. aureus* strains isolated in urinary infections from 2008 to 2014, in the French community
S. Thibaut* (Nantes, France), A. Marquet, G. Guy, D. Boutaille, J. Caillon, M. MedQual-Network

P0229 *Staphylococcus aureus* a leading aetiological agent of healthcare- and community-acquired bloodstream infections
H. Marchel, G. Dulny, A. Kra nicka, M. Wroblewska* (Warsaw, Poland)
| P0230 | Molecular epidemiology of *Staphylococcus aureus* strains isolated from blood cultures in six tertiary care hospitals, Italy, 2012  
E. Carretto* (Reggio Emilia, Italy), S. Andreoni, D. Barbarini, F. Bravaron, E. Manso, P. Morone, C. Scarparo, E. Scotti, C. Farina |
| P0231 | Comparative genomics of an environmental multiple antibiotic-resistant *Staphylococcus epidermidis*  
Z. Xu, R. Misra, H. Mkrtchyan* (London, United Kingdom), G. Paterson, S. Gharbia, R. Cutler |
| P0232 | Common SCCmec genes among *S. aureus* and coagulase-negative staphylococci from the nares of healthy individuals with limited healthcare contact  
P. Budri* (Dublin, Ireland), A. Shore, D. Coleman, H. Humphreys, D. Fitzgerald-Hughes |
| P0233 | Characterization of methicillin-resistant *Staphylococcus aureus* carrying Florfenicol exporter (*fexA*)-mediated chloramphenicol resistance  
E. Udo* (Kuwait City, Kuwait), S. Boswih, T. Verghese, B. Noranha, B. Mathew |
| P0234 | Trends in methicillin-resistant *Staphylococcus aureus* control in Italy 2009-2014: the ProSA1 and ProSA2 surveys  
P. Budri* (Dublin, Ireland), A. Shore, D. Coleman, H. Humphreys |

15:30-16:30

**Focus Acinetobacter**

| P0235 | Incidence and risk factors for multi-resistant *Acinetobacter baumannii* carriage in a burn intensive care unit - a prospective study  
| P0236 | Detection of acquired OXA-23 oxacillinases in clinical isolates of carbapenem-resistant Acinetobacter baumannii in Vojvodina Province, Serbia  
D. Medic* (Novi Sad, Serbia), V. Gusan, M. Mihajlovic-Ukropina, A. Trudic, B. Zivlak, M. Djilas, Z. Jeliesic |
| P0237 | Ten-year resistance patterns of nosocomial Acinetobacter baumannii strains in an Ankara training and research hospital  
F. Erdinç, C. Bulut, C. Ataman Hatipoglu* (Ankara, Turkey), G. Tuncer, A. Demiröz, N. Tulek, S. Kinkli |
| P0238 | The LH92 11085 gene plays a role in the virulence of the Acinetobacter baumannii MAR002 strain  
L. Alvarez-Fraga* (La Coruña, Spain), A. Pérez, S. Rumbo-Feal, M. Merino, J. Vallejo, E. Ohneck, R. Edelmann, A. Beceira, J. Vazque-Ucha, L. Actis, G. Bou Arevalo, M. Poza |

| P0239 | *Acinetobacter baumannii*: factors associated with infection rather than colonization  
A. Martin-Aspas, D. Gutierrez-Saborido* (Cadiz, Spain), F. Guerrero-Sanchez, F. Garcia-Colchero, J. Girón-González |
| P0240 | Differences in *Acinetobacter baumannii* infection according to admission place: intensive care unit or medical/surgical ward  
A. Martin-Aspas, F. Garcia-Colchero, D. Gutierrez-Saborido* (Cadiz, Spain), F. Guerrero-Sanchez, J. Girón-González |
| P0241 | Antimicrobial susceptibility profiles for *Acinetobacter baumannii* from Europe: TEST 2014-2015  
M. Hackel* (Schaumburg, IL, United States), D. Sahm, H. Leister-Tebbe |
| P0242 | Genetic diversity of carbapenem-resistant *Acinetobacter baumannii* (CRAB) isolated in Hue Central Hospital, Vietnam  
S. Aberkane* (Montpellier, France), M. Kempf, M. Hypolite, T. Mai Van, C. Laurens, F. Compain, B. Bourinbi, A. Ouedraogo, L. Thi Nam, A. Banuls, H. Jean-Pierre, S. Godreuil |
| P0243 | Detection of multidrug resistant (MDR) *Acinetobacter baumannii* clonal complex 92 in Iran  
S. Rematzadeh, C. Giske* (Stockholm, Sweden), F. Shahcheraghi |
| P0244 | Molecular epidemiological investigation of clinical *A. baumannii* isolates from two health care settings in Tshwane, South Africa  
M. Lowings* (Pretoria, South Africa), M. Ehlers, F. Ismail, M. Kock |
| P0245 | Molecular epidemiology of carbapenem-resistant *Acinetobacter baumannii* isolated in intensive care units in Moscow, Russia  
D. Kryzhanovskaya* (Moscow, Russian Federation), N. Alyabieva, A. Lazareva, Y. Bocharov, I. Chebotar, N. Mayanskij |
| P0246 | Faecal carriage of carbapenem-resistant *Acinetobacter baumannii* in an intensive care unit in Tunisia  
E. Maamar, S. Hammami, L. Madiouni, Z. Hamzaoui, S. Ghdira, I. Boutiba-Ben Boubaker* (Tunis, Tunisia), M. Houissa, A. Slim |
| P0247 | Prevalence of carbapenem resistance among *Acinetobacter baumannii* clinical isolates from two Mediterranean countries  
E. Dahdouh, M. Hajjar, M. Gomez-Gilmira, J. Mingorance, S. Pacho, M. Suarez* (Madrid, Spain), Z. Daoud |
P0248 Molecular epidemiology of carbapenem-resistant Acinetobacter baumannii in Istria county, Croatia
M. Vranic-Ladavac* [Pula, Croatia], N. Barisic, R. Ladavac, N. Kar, A. Stojanovic, A. Ferencic, J. Vranes, M. Krilanic, S. Francula-Zaninovic, B. Bedenic
P0249 Emergence of PER-7-producing Acinetobacter baumannii in France, 2012-2015
A. Patron* [Besançon, France], A. Mille, D. Fournier, K. Jeannot, P. Plésiat
P0250 Phenotypic and genotypic detection of beta-lactamases in Acinetobacter spp. isolated from Lebanese patients over a period of one year
M. Hajjar* [Beirut, Lebanon], Z. Daoud, D. Karam Sarkis
P0251 Rapid increase of extensively drug-resistant (XDR) blaOXA-23-producing Acinetobacter baumannii in a Greek hospital
A. Mavroidi* [Athens, Greece], E. Pollo, M. Katsiari, S. Likousi, O. Kordanouli, Z. Roussou, E. Platsouka
P0252 Acinetobacter baumannii isolated from rectal screening samples as part of the MagicBullet clinical trial: molecular epidemiology and susceptibility to carbapenems, tigecycline and colistin
E. Zander* [Cologne, Germany], J. Nowak, P. Higgins, I. Roca Subira, J. Vila Estape, H. Seifert
P0253 Co-occurrence of carbapenemase genes in Acinetobacter baumannii - a myth or a reality?
L. Hadjadj, J. Rolain* [Marseille, France]
P0254 Transition of blaOXA-58-like to blaOXA-23-like in IC2 Acinetobacter baumannii clinical isolates in Greece, 2015: a nationwide study
S. Pournaras, K. Dagpoupolou* [Larissa, Greece], G. Vrioni, O. Zarkotou, L. Skoura, A. Poulou, E. Perivolioti, V. Gogou, A. Gikas, M. Panopoulou, S. Levidiotou, A. Tsakris
P0255 Early detection of metallo-beta-lactamase NDM-1 and OXA-23 carbapenemase-producing Acinetobacter baumannii in Libyan hospitals
N. Mathlouthi, A. Ali El Salabi, S. Bakour, C. Elbagssari, A. Zorgani, A. Kraiem, D. Elahmer, J. Rolain, Chouchani* [Hammam-Lif, Tunisia]
P0256 Molecular epidemiology and carbapenem-resistance mechanisms of Acinetobacter pittii isolated from Germany
E. Zander, M. Kaase, H. Wisplinghoff, H. Seifert, P. Higgins* [Cologne, Germany]
P0257 Occurrence of Acinetobacter calcoaceticus-baumannii complex in municipal wastewater
D. Skoric* [Zagreb, Croatia], J. Hrenovic, M. Seruga Music, S. Kazazic, M. Ganja, I. Goic-Barisic
P0258 Evaluation of carriage and environmental spread of carbapenem-resistant Acinetobacter baumannii
A. Nutman* [Tel-Aviv, Israel], A. Lerner, D. Schwartz, Y. Carmeli
P0259 Acinetobacter baumannii bacteraemia during intensive care unit stay: risk factors and predictors of mortality
M. Papadimitriou-Olivgeris* [Patras, Greece], A. Spiliopoulou, F. Fligou, A. Zatou, A. Spyropoulooul, V. Dadou, M. Marangos, E. Anastassiou, I. Spiliopoulou, M. Christofidou
P0260 Inhaled colistin therapy with combined reduced intravenous dose for pneumonia caused by multidrug-resistant Acinetobacter baumannii
B. Bozca* [Afyonkarahisar, Turkey], T. Kacan
P0261 OXA-23 carbapenemase-producing A. baumannii isolates detected in hospitals from Cochabamba [Bolivia]
P0262 Daptomycin as adjunctive treatment to colistin for the management of experimental infection by Acinetobacter baumannii with intermediate susceptibility to colistin
G. Poulakou, D. Draggiti, M. Georgiati, E. Sabracos, G. Giamarellos-Bourboulis* [Athens, Greece]
P0263 Impact of colistin therapy on multidrug-resistant and colistin-sensitive Acinetobacter baumannii bacteraemia mortality in critically ill patients
T. Amat, A. Gutiérrez, J. Garnacho-Montero, I. Machuca, I. Gracia, E. Pérez-Nadales, Á. Torre-Giménez, J. Cisneros Herreros, J. Torre Cisneros* [Cordoba, Spain]
P0264 Effectiveness of carbapenems in combination therapy with fosfomycin on multidrug-resistant Acinetobacter baumannii
M. Chomnawang* [Bangkok, Thailand], A. Poungplub, P. Khuntayaporn, K. Thirapanmethee
P0265 In vitro activity of eravacycline and comparators against Acinetobacter baumannii, including carbapenem-resistant strains, and Stenotrophomonas maltophilia isolated from patients in Europe
M. Bassetti, I. Morrissey, T. Grossman, K. Luepke, P. Scoble* [Watertown, MA, United States], J. Sutcliffe
P0266 Polymyxin B associated with meropenem is able to eradicate persisters from Acinetobacter calcoaceticus - Acinetobacter baumannii
S. Gallo* [Porto Alegre, Brazil], C. Ferreira, S. Oliveira
15:30-16:30

Non-culture techniques for challenging situations in diagnostics

P0267 Periodontal disease: detection and quantification of periodontopathogens by two different kits
S. Trombert Paolantoni* [Saint Ouen l’Aumone, France], E. Hedbaut, C. Vincent

P0268 Increase of clinical isolation of Actinomyces using MALDI-TOF MS at a university hospital in Korea: is actinomycosis emerging?
J. Rim* [Seoul, South Korea], H. Kim, M. Kim, D. Yang, K. Lee

P0269 Diagnostic performance of a multiplex PCR assay for the detection of pathogens in respiratory specimens from patients with severe pneumonia
S. Sabine, P. Rath, J. Steinmann* [Essen, Germany]

P0270 Effective diagnosis of lower respiratory tract infections using a combination of 16S rDNA based next-generation sequencing and species specific real-time qPCRs
E. van den Munckhof* [Rijswijk, Netherlands], M. Leverstein-van Hall, M. de Koning, W. Quint, L. van Doorn

P0271 The FilmArray® system for lower respiratory tract infections: performance comparison in BAL and sputum
B. Graham* [Salt Lake City, UT, United States], U. Spaulding, M. Jones, K. Bourzac, J. Green, B. Buchan, M. Faron, R. Crisp, M. Rogatcheva

P0272 Comparison of MALDI-TOF MS and automated biochemical-based phenotypic identification systems for rapid identification of bacteria and yeast in routine clinical microbiology
C. Hahm* [Incheon, South Korea]

P0273 Use of MALDI-TOF MS to probe the diversity of Propionibacterium acnes and search for their distribution in clinical samples
I. Dekio* [Tokyo, Japan], H. Klenk, K. Aplin, C. McDonald, T. Suzuki, S. Kinoshita, M. Tanaka, S. Gharbia, H. Shah

P0274 Rapid identification of microorganisms by the use of Vitek®MS bioMérieux (MALDI-TOF) from positive BacT-Alert® bioMérieux culture bottles: comparison of five methods.
M. Ruas* [Pamplona, Spain], A. Pérez-García, C. Losa, L. Armendariz, A. Ramos, S. Castejon, L. González-Aguado, M. Fernández-Alonso, J. Leiva

P0275 Implementation of selection criteria to identify samples for which 16S RNA gene amplicon sequencing is clinically relevant
B. Depreter, L. Coorevits, P. Coels, E. Padalka, I. Leraux-Roels, J. Boelens, G. Cloeys, B. Verhasselt* [Ghent, Belgium]

P0276 A streamlined library protocol for multiplexed analysis of full-length 16S rDNA by single molecule real time sequencing

P0277 Increased detection of bacterial and fungal pathogens in culture negative specimens using Universal Microbe Detection assay compared to routine 16S and 28S analyses in a diagnostic laboratory
C. Stavnsbjerg* [Copenhagen, Denmark], C. Moser, N. Frimodt-Moller, T. Bjarnsholt

P0278 Application of next generation sequencing in the qualitative assessment of the bacterial flora of duodenal biopsy specimens of patients with obesity and type 2 diabetes
A. Sroka* [Krakow, Poland], T. Gosiewski, D. Salamon, A. Ludwig-Galezowska, P. Radkowski, P. Major, M. Stanek, M. Matłok, P. Wolkow, M. Malecki, M. Bulanda

P0279 Development and application of next-generation sequencing (NGS) technology for the direct detection and analysis of bacterial species from complex bacterial samples
D. Rajendram* [London, United Kingdom]

P0281 Strainseeker – fast identification of bacterial strains from unassembled sequencing reads using user-provided guide trees
M. Roosaare* [Tartu, Estonia], M. Vaheer, L. Kaplinski, M. Möls, R. Andreson, M. Lepamets, T. Kõressaar, P. Naaber, S. Kõljalg, M. Remm

P0282 Direct identification of microorganisms from blood culture bottles with polymicrobial growth
M. Almuhayawi* [Stockholm, Sweden], M. Kynning, P. Lüthje, G. Sandstrom, M. Ullberg, V. Özenç

P0283 Development of two new diagnostic tests on the TRAPiST V6 instrument, based on multiplex microfluidic PCR and oligochromatography detection, for identification of the major bacterial species involved in sepsis and their antibiotic resistance markers
I. Ote, F. Nazé, L. Auvrain* [Gembloux, Belgium], M. Massart, P. Baggaerts, R. De Mendonca, O. Denis, Y. Glupczynski, P. Mertens
P0284  Detection of bacterial DNA in the blood of patients with sepsis and healthy volunteers using the next-generation sequencing method – the phenomenon of DNAemia  
A. Sroka* (Krakow, Poland), K. Ufir, D. Salamon, M. Bulanda, T. Gosiewski

P0285  Rapid detection of resistance traits in blood cultures of patients with bloodstream infections: systematic review and meta-analysis of diagnostic test accuracy  

P0286  Evaluation of the HemoFISH assay for the presumptive identification of bacteria from positive blood culture bottles  
V. LaBombardi* (Flushing, United States), N. Ledeboer, M. Guralnik, M. Faron

P0287  "FISHing" in endocarditis: fluorescence in situ hybridization for the detection of microorganisms  

P0288  Rapid differentiation of Staphylococcus aureus from coagulase-negative staphylococci directly from positive blood cultures: prospective comparison of four rapid methods  
G. Satta, R. Garton* (London, United Kingdom), M. Hussein, A. Williams, N. Alston, D. Mack

P0289  Identification of clinical isolates of nontuberculous mycobacteria in flagged mycobacteria growth indicator tubes by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry  
P. Hsueh* (Taipei, Taiwan), J. Chien, C. Yu

P0290  Rapid identification and antimicrobial susceptibility profiles of Enterobacteriella lenta blood culture isolates in a Swedish tertiary hospital  
K. Liderot, P. Ratcliffe, P. Lüthje, E. Tidholm, V. Özenci* (Stockholm, Sweden)

P0291  Accurate identification of common pathogenic Nocardia species: evaluation of a multilocus sequence analysis platform and matrix-assisted laser desorption ionization-time of flight mass spectrometry  
X. Meng* (Beijing, China), L. Pang, S. Chen, X. Fan, F. Kong, Y. Xu

15:30-16:30  Bacterial strain typing

P0292  Typing of multidrug resistant Pseudomonas aeruginosa strains using high resolution MALDI-FTICR MS  
F. Fleurbaaij* (Leiden, Netherlands), S. Nicolardi, M. Kraakman, E. Claas, K. Veldkamp, M. Yos, H. van Leeuwen, P. Hensbergen, E. Kuijper

P0293  Molecular epidemiology of Providencia spp. harbouring NDM carbapenemase in Argentina  
D. Faccone, F. Pasteran* (Buenos Aires, Argentina), E. Albomaz, P. Ceriana, S. Gomez, C. Lucero, M. Rapoport, N. Argentina Group, A. Corso

P0294  Population structure of Enterobacter cloacae complex collected from outpatients of county hospitals in China  
K. Zhou* (Hangzhou, China), W. Yu, J. Rossen, H. Grundmann, L. Li, Y. Xiao

P0295  Capsular genotyping of bovine mastitis Streptococcus agalactiae [Group B Streptococcus, GBS] based on sequences of the capsular polysaccharide synthesis (cps) gene cluster  
C. Alves Barroca* (Cafarica, Portugal), M. Severo Ramundo, R. Mato, R. Bexiga, B. Ferreira-Carvalho, A. Figueiredo, I. Santos Sanches

P0296  Antimicrobial resistance and molecular characterization of capsular types and CRISPR1 loci of group B streptococci recovered from a colonized female adult  

P0297  In vitro activity of ceftazidime-avibactam and comparators against Pseudomonas aeruginosa from Europe 2012–2014  
M. Hackel* (Schaumburg, IL, United States), G. Stone, B. DeJonge, D. Sahm

P0298  Integrated analysis pipelines for whole-genome MLST and whole-genome SNP in BioNumerics® 7.6 applied to publicly available Listeria monocytogenes isolates  
K. Vranckx* (Sint-Martens-Latem, Belgium), K. De Bruyne, B. Pot, H. Pouseele

P0299  Genomic determination of minimum multi-locus sequence typing schemas for Mycoplasma hominis to represent genomic phylogeny  
A. Jironkin* (London, United Kingdom), R. Brown, A. Underwood, V. Chalker

P0300  Detection of the lag-1 gene and MAB3/1 in Legionella pneumophila serogroup 1 strains  
L. Franzin* (Torino, Italy), V. Demarie, C. Avanzini
P0301  High genetic diversity among *Stenotrophomonas maltophilia* isolates from single hospitals; multiclonal outbreaks or genotypic profile changes during subcultures
M. Güvenir* [Icosia, Cyprus], B. Otu, E. Tunç, N. Cakir, K. Suer

P0302  New ST profile identified in *Stenotrophomonas maltophilia* resistant to sulfamethoxazole/trimethoprim: ST 144
C. Rizek, R. Stabler, J. Isaac Garcia Paez, J. Ferraz Rosa, F. Rossi, A. Sara Levin, S. Figueiredo Costa* [Sao Paulo, Brazil]

P0303  Increased prevalence of *Streptococcus pneumoniae* serotype 15A isolated from sputum with reduced antimicrobial susceptibility in Scotland, UK: a comparison of isolates associated with invasive disease
K. Khalsa* [Glasgow, United Kingdom], A. Marek, A. Smith, B. Denham, D. Lindsay, A. Smith-Palmer, K. Scott, R. Ure, A. Brown, B. Jones, C. Cameron, E. Mcdonald

P0304  Introduction of virulent African clon ST3081 *Streptococcus pneumoniae* serotype 1 in Catalonia

P0305  Phenotypic diversity and molecular characterization of *Cronobacter sakazakii* isolates from environmental and food sources
K. Ibrahim* [Nottingham, United Kingdom], S. Forsythe

P0306  Band pattern analysis of mutations observed in rifampicin resistance strain of *M. tuberculosis* complex by line probe assay
H. Vashistha* [New Delhi, India], S. Saini, K. Chopra, D. Shrivastava, M. Honif

P0307  Virulence potential of *Staphylococcus aureus* isolates in Buruli ulcer patients

P0308  Is it time to re-assess the utility of thermonuclease for the identification of *S. aureus*?
S. McTavish* [London, United Kingdom], B. Pinchon, M. Ganner, A. Kearns

P0309  Clone-specific epidemiology of *Staphylococcus aureus* in sub-Saharan Africa and Germany

P0310  *In silico* determination of spa type using the blastn tool implemented in MIST
D. Babenko* [Karaganda, Kazakhstan], M. Toleman

P0311  Comparison of the rep-PCR, MLST, MALDI-TOF and whole genome sequencing for the typing of *Staphylococcus epidermidis* isolates responsible for an outbreak
D. Girlich* [Le Kremlin-Bicêtre, France], P. Glaser, R. Bonnin, D. Imanci, T. Naas, L. Dortet

P0312  Identifying genetic determinants of persistent *Staphylococcus aureus* during bacteraemia and lower respiratory tract infections
A. Lacoma* [Badalona, Spain], C. Wu, S. Monecke, S. Molinos, M. Gomes-Fernandes, R. Ehrich, D. Wilson, C. Prat

P0313  Differences in virulence gene profiles in strains of MRSA CC22, t032 from an outbreak in a neonatal department compared to non-outbreak strains of the same type
M. Slott Jensen* [Odense, Denmark], M. Skov, M. Detlefsen, A. Holm, H. Kolmos, M. Kemp

P0314  Genomic molecular epidemiology and evolution of *Staphylococcus aureus* colonization and infection in a burn unit of a tertiary care hospital, Ghana

P0315  Practical experiences with capillary electrophoresis ribotyping applied to Czech *Clostridium difficile* isolates collected over 3 years (2013-2015)
M. Krutova* [Prague, Czech Republic], O. Nyc, F. Allerberger, M. Wilcox, E. Kuijper

P0316  Diagnosis and epidemiology of toxigenic *Clostridium difficile* in a tertiary care university hospital in Rome, Italy
V. Visconti* [Rome, Italy], A. Giordano, M. Ghezzi, G. Brunetti, M. Falcone, M. Venditti, G. Raponi

P0317  Sentinel hospital surveillance of *Clostridium difficile* infections in the Netherlands during 2009-2015; ribotype 078/126 in relation to pig density
S. van Dorp* [Leiden, Netherlands], C. Harmanus, I. Sanders, D. Dekkers, C. Ketels, D. Notermans, S. de Greeff, E. Kuijper

P0318  Investigating the population structure of clinical and environmental Austrian *Vibrio cholerae* non-O1/ non-O139 2000-2015 by NGS
S. Hirk* [Vienna, Austria], S. Huhulescu, F. Allerberger, M. Bloschitz, D. Harmsen, P. Hufnagl, S. Lepuschitz, F. Netroufal, S. Rehak, W. Ruppitsch, S. Weil, A. Indra
Susceptibility trends for old and new antibiotics

P0319  Resistance to rifaximin among third-generation cephalosporin-resistant Enterobacteriaceae isolates obtained during a German multicentre hospital admission screening project - a DZIF-ATHOS cooperative study
P. Baumert, A. Mischink* [Freiburg, Germany], S. Schuster, M. Vavra, A. Hamprecht, H. Seifert, P. Gastmeier, W. Kern

P0320  Pivmecillinam; an antibiotic from the past, for the future: a retrospective multicentre observational study of comparative urine susceptibilities in a healthcare network in the United Kingdom
H. Farah* [London, United Kingdom], L. Moore, M. Gilchrist, J. Hatcher

P0321  Antimicrobial activity of tigecycline and piperacillin-tazobactam against Enterobacteriaceae from the Asia-Pacific region
D. Biedenbach, D. Sahm, M. Hackel* [Schaumburg, IL, United States], H. Leister-Tebbe

P0322  In vitro activity of tigecycline and comparator agents against Enterobacteriaceae from intra-abdominal infection [IAI] isolates collected in Italy
M. Renteria, D. Biedenbach, D. Sahm* [Schaumburg, IL, United States], H. Leister-Tebbe

P0323  In vitro activity of tigecycline against beta-lactam-resistant Enterobacteriaceae isolates collected in European countries as part of the Tigecycline European Surveillance Trial (TEST) in 2014
K. Kazmierczak* [Schaumburg, IL, United States], M. Hackel, H. Leister-Tebbe, D. Sahm

P0324  In vitro activity of tigecycline and comparators against extended spectrum beta-lactamase (ESBL) positive isolates of Escherichia coli and Klebsiella pneumoniae from Germany
D. Biedenbach, D. Sahm* [Schaumburg, IL, United States], M. Hackel, H. Leister-Tebbe

P0325  In vitro activity of tigecycline and comparators against Gram-negative pathogens in France with complicated intra-abdominal [IAI] and skin and soft tissue infections [SSTI]
D. Biedenbach, D. Sahm, M. Hackel* [Schaumburg, IL, United States], H. Leister-Tebbe

P0326  Prevalence of multidrug resistance among bacterial pathogens obtained from patients in hospitals and the role of tigecycline: results of the PEG 2013 study
M. Kresken* [Rheinbach, Germany], B. Körber-Irrgang, D. Hofner, M. Kaase, F. Loyer, I. Klare, G. Werner, H. Seifert, W. of the Paul-Ehrlich-Society for Chemotherapy

P0327  Antimicrobial susceptibility profiles of bacterial isolates from intra-abdominal and skin and skin structure infections in eastern and western Europe
D. Biedenbach, D. Sahm* [Schaumburg, IL, United States], M. Hackel, H. Leister-Tebbe

P0328  Antimicrobial activity of tigecycline and ceftoperazone/subactam tested against 14,950 Gram-negative organisms from Europe and the Asia-Pacific region [2013-2014]
H. Sader* [North Liberty, United States], R. Flamm, R. Mendes, D. Farrell, R. Jones

P0329  In vitro activity of piperacillin-tazobactam and comparators against Enterobacteriaceae and Pseudomonas aeruginosa from multiple infection sources encountered in selected European countries:
TEST data 2012-2015
D. Hoban, M. Hackel, D. Biedenbach, D. Sahm* [Schaumburg, IL, United States], H. Leister-Tebbe

P0330  Global activity of meropenem against Gram-negative isolates collected in 2012-2014
M. Hackel* [Schaumburg, IL, United States], K. Kazmierczak, B. DeJonge, D. Sahm

P0331  In vitro activity of aztreonam-avibactam [ATM-AVI] against Gram-negative pathogens from Europe collected in 2014
K. Kazmierczak* [Schaumburg, IL, United States], M. Hackel, B. DeJonge, D. Sahm, P. Bradford

P0332  Activity of ceftazidime-avibactam against carbapenem-non-susceptible Enterobacteriaceae isolated from patients in Europe 2012–2014
M. Hackel* [Schaumburg, IL, United States], G. Stone, B. DeJonge, D. Sahm

P0333  Beta-lactamase characterization of baseline Enterobacteriaceae from phase 3 trials of ceftazidime-avibactam [CAZ-AVI] for the treatment of complicated urinary tract infections (cUTIs)
R. Mendes* [North Liberty, United States], M. Castanheira, L. Woosley, G. Stone, P. Bradford, R. Flamm, R. Jones

P0334  Activity of ceftazidime-avibactam against carbapenem-non-susceptible Enterobacteriaceae with and without additional ESBL and/or class C beta-lactamases isolated from a global surveillance programme, 2012–2014
K. Kazmierczak* [Schaumburg, IL, United States], M. Hackel, B. DeJonge, G. Stone, D. Sahm
P0335 Activity of ceftazidime-avibactam against clinical and isogenic laboratory Pseudomonas aeruginosa isolates expressing combinations of most relevant beta-lactam resistance mechanisms

P0336 Activity of ceftazidime/avibactam and ceftolozane/tazobactam against multidrug-resistant Gram-negative isolates
E. Hirsch* (Boston, United States), T. Arriola, P. Zucchi, A. Chen, T. Lasco, J. Kirby, S. Leonard, K. Krevalin, C. Emery, T. Bias

P0337 Activity of ceftolozane/tazobactam tested against organisms from urinary tract pathogens collected from 41 medical centres in Europe and Israel (2014)
D. Farrell* (North Liberty, United States), H. Sader, R. Mendes, R. Jones

P0338 Ceftolozane/tazobactam activity against intra-abdominal pathogens collected from 41 medical centres in Europe and Israel (2014)
D. Farrell* (North Liberty, United States), H. Sader, R. Mendes, R. Jones

P0339 Antimicrobial activity of ceftolozane/tazobactam from the PACTS programme tested against Enterobacteriaceae isolated from patients hospitalized in intensive care units from 20 European countries and Israel (2013-2014)
D. Farrell* (North Liberty, United States), R. Flamm, M. Castanheira, R. Jones

P0340 Antimicrobial activity of ceftolozane/tazobactam from the PACTS programme tested against Pseudomonas aeruginosa isolated from patients hospitalized in intensive care units from 20 European countries and Israel (2013-2014)
D. Farrell* (North Liberty, United States), R. Flamm, M. Castanheira, R. Jones

P0341 In vitro activity of plazomicin tested against contemporary clinical isolates collected in Asia-Pacific, Europe and Latin America
M. Castanheira* (North Liberty, United States), T. Doyle, D. Farrell, R. Jones

P0342 Eravacycline in vitro activity against clinical isolates obtained from urinary and gastro-intestinal sources, including drug-resistant pathogens, from patients in Europe
M. Bassetti, I. Morrissey, T. Grossman, M. Olesky, H. Patel* (Watertown, United States), J. Sutcliffe

P0343 In vitro activity of eravacycline and comparators in Gram-negative organisms, including drug-resistant phenotypes, isolated from respiratory sources in Europe
M. Bassetti, I. Morrissey, T. Grossman, M. Olesky, H. Patel* (Watertown, United States), J. Sutcliffe

P0344 In vitro activity of eravacycline and comparators against Enterobacteriaceae, including subgroups of strains with resistance to carbapenems or 3rd/4th-generation cephalosporins, isolated from patients in Europe
M. Bassetti, I. Morrissey, T. Grossman, K. Luepke, P. Scoble* (Watertown, MA, United States), J. Sutcliffe

P0345 Activity of novel antibiotic POL7080 against clinical isolates from a surveillance programme in China (2012 and 2013)
G. Dale* (Allschwil, Switzerland), P. Rhomberg, I. Nojera, C. Zampolani, R. Flamm

P0346 Activity of aminoglycosides in Pseudomonas and Enterobacteriaceae in the UK and Ireland
V. Martin* (Bristol, United Kingdom), S. Mushtaq, D. Livermore, B.

15:30-16:30
Fungal infection epidemiology

P0347 Incidence, outcome and risk factors for invasive aspergillosis - a case control study in 663 allogeneic stem cell transplantation patients
C. Visser* (Rotterdam, Netherlands), G. Chong, J. Versluis, J. Cornelissen, A. Broers, B. Rijnders

P0348 Aspergillus ustus and Scopulariopsis spp.: two emerging causes of breakthrough invasive mould infections in patients receiving triazoles
F. Lamoth* (Lausanne, Switzerland), L. Damonti, B. Alexander

P0349 Emerging azole-resistant Aspergillus fumigatus in haematological patients in the Netherlands
D. Scoop* (Leeuwarden, Netherlands), P. van dem Borne, E. Kuiper, M. van der Beek

P0350 Candida guilliermondii complex is characterized by high antifungal resistance but low attributable mortality: a report of 20 cases of candidaemia

P0351 Invasive mycoses (IM) caused by non-Aspergillus moulds in patients (pts) with haematological malignancies (HM)
V. Okhmat* (Moscow, Russian Federation), A. Bogdanova, E. Parovichnikova, E. Gribanova, S. Kravchenko, G. Galstyan, G. Klyasova
P0352 Estimation of incidence rates of a tropical endemic mycosis in Colombia, 2009-2013: coccidioidomycosis

P0353 Should we perform the serum cryptococcal antigen test in HIV-infected patients hospitalized due to a community-acquired pneumonia episode?
A. Paulino da Silva, C. Toniolo, C. Figueiredo Mello* (Sao Paulo, Brazil), M. Negra, A. Sara Levin, J. Vidal Bermúdez

P0354 The trichosporonosis collaboration project

P0355 Clinical Scedosporium/Pseudallescheria isolates from a Spanish teaching hospital: incidence, molecular identification and antifungal susceptibility

P0356 Epidemiology of invasive pulmonary mycosis in children after alloigenic haematopoietic stem cells transplantation
M. Popova, L. Zubarovskaya, B. Afanasyev, T. Bogomolova, S. Ignatyeva, N. Klimko* [St. Petersburg, Russian Federation], B. Smirnov

P0357 Candida contamination of liver, kidney and heart preservation fluids: a ten-year monocentric retrospective study

P0358 Potential in-fa-family transmission of microorganisms that colonize cystic fibrosis patients
R. Morilla, E. Quintana, A. Caizada, V. Friaza, E. Campano, J. Varela, E. Calderon, F. Medrano Ortega, C. de la Horra* [Seville, Spain]

P0359 Aetiology of recurrent vulvovaginal candidiasis in St. Petersburg, Russia
Y. Dolgo-Saburova, T. Bogomolova* [St. Petersburg, Russian Federation], D. Zharzh, I. Vybornova, A. Mirzabalaeva, D. Shurpitskaya, N. Klimko

P0360 Invasive mycoses (IM) in patients (pts) with haematopoietic stem cell transplant (HSCT): RIFI study
G. Klyosova* [Moscow, Russian Federation], V. Okhmat, M. Popova, A. Volkova, N. Gorburnova, J. Kruchkova, T. Zagorskina, D. Motorin, T. Bogdan, E. Skorobogatova, U. Sveshnikova, V. Rossiev, E. Parovychnikova, V. Savchenko

P0361 Prevalence of Aspergillus species in clinical sample isolates in the Reference Hospital Virgen del Rocio [Andalusia, Spain]
M. Vidal-Acuña* [Seville, Spain], M. Torres-Sánchez, M. Ruiz-Pérez de Pipaón, J. Aznar

P0362 Malignant otitis externa caused by Candida
M. Gargouri, M. Koubba, T. Ben Jemaa, H. Marsit, F. Smaoui, C. Marrantchi, M. Ben Jemaa* [Sfax, Tunisia]

P0363 Fungal infections in patients with extracorporeal membrane oxygenation (ECMO)
M. Rubio López* [Santander, Spain], M. López Sánchez

P0364 Mucosal immunity in haematological patients with oropharyngeal candidiasis

P0365 Occupational hazard of marijuana hunters - an outbreak of presumed acute pulmonary histoplasmosis
J. Dixon* [Newcastle, United Kingdom], F. Charlton, J. Majo, S. Worth, M. Richardson, D. Denning, U. Schwab

P0366 A national retrospective study of Candida infections of the central nervous system

P0367 European study on Pneumocystis jirovecii short tandem repeats genotyping reveals wide population diversity with geographic specificities

P0368 Impact of fungal presence in the air on development of fungal rhinosinusitis
A. Barac* [Belgrade, Serbia], M. Pekmezovic, V. Tomic Spicir, Z. Rakacevic, A. Chakrabarti

P0369 Molecular epidemiology and in vitro antifungal susceptibility testing of 108 clinical Cryptococcus isolates from Denmark
R. Jensen, J. Meis, M. Arendrup, F. Hagen* [Nijmegen, Netherlands]

P0370 Temporal trends in adult and paediatric patients with fungal infection in peritoneal fluids: single centre 24-year experience
P0371 Epidemiology of mucormycosis in Greece; results from a 10-year multicentre nationwide survey
M. Drogari-Apiranthitou* (Athens, Greece), A. Skiada, G. Petrikkos

P0372 Concomitant respiratory tract infection with influenza virus and Aspergillus fumigatus: a 4-winter retrospective study
C. Bannal, N. De Prost, C. Rodriguez, F. Foulet, N. Ait-Ammar, C. Brun-Buisson, F. Botterel Chartier* (Crétel, France)

P0373 Allergic bronchopulmonary aspergillosis in cystic fibrosis patients in St. Petersburg, Russia
Y. Kozlova* [St. Petersburg, Russian Federation], Y. Borzova, O. Aak, T. Bogomolova, S. Ignatieva, E. Burginya, N. Klimko

P0374 Estimating serious fungal infections in the Peruvian population
B. Bustamante, P. Campos, D. Denning* [Manchester, United Kingdom]

P0375 Mucormycosis in immunocompromised and immunocompetent patients in St. Petersburg, Russia
N. Klimko* [St. Petersburg, Russian Federation], S. Khostelidi, T. Bogomolova, O. Shadrivova, A. Volkova, E. Shaguleeva, Y. Borzova, A. Kolbin, M. Popova

P0376 Dynamics of Candida spp. isolates in patients hospitalized in the Department for Haematology in University Clinical Centre Ljubljana from 2006 to 2015
A. Krasevac Glaser* [Maribor, Slovenia], T. Matos, S. Zver

P0377 A single-centre survey of invasive mould disease due to azole-resistant Aspergillus fumigatus in patients with haematological malignancies
P. Lestrange* [Nijmegen, Netherlands], W. van der Velde, F. Bouwman, A. Marouane, F. Stoop, P. Verweij, J. Donnelly

P0378 Microsatellite genotyping and antifungal susceptibility profile of clinical and environmental Aspergillus flavus strains from Iran
M. Taghizadeh* [Sari, Iran], M. Hedayati, W. Melchers, J. Zoli, H. Rafati, S. Ansari, H. van der Lee, P. Verweij, S. Seyedmousavi

P0379 Apophysomyces elegans, a cause of malignant otitis externa complicated by skull-base osteomyelitis in an otherwise healthy non-diabetic individual: an uncommon form of mucormycosis from northern India
D. Shah* [Lucknow, India], R. Marak, S. Bhadania, T. Dhole, L. Pal

Vascular and vascular access infections

P0380 The Tego™ needleless connector for haemodialysis catheters may protect against catheter colonization
M. Guembe* [Madrid, Spain], M. Pérez-Granda, R. Cruces, L. Alcalá, E. Bouza Santiago

P0381 Improvement of the incidence of short-term peripheral catheter blood stream infection through intervention to modify skin preparation using 0.2% chlorhexidine in a Japanese tertiary hospital
M. Mawatari* [Tokyo, Japan], K. Hayakawa, Y. Katanami, K. Yamamoto, Y. Fujiiya, S. Kutsuna, N. Takeshita, Y. Sugiki, N. Ohmagari

P0382 Outcomes of primary and central-line associated Acinetobacter baumannii bacteremia
C. Moon* [Busan, South Korea], Y. Lee, H. Kim, J. Shin

P0383 Tauridine-citrate lock solution for the prevention of central line-associated bloodstream infection
I. Gross* [Jerusalem, Israel], M. Dranitzki Elhalal, C. Schwartz, M. Razon, L. Lipkin, A. Moses, S. Benenson

P0384 Femoral, jugular or subclavian site placement of central venous catheters: is there an impact on the risk of CLABSI?
V. Pitiriga* [Athens, Greece], P. Mariatos, C. Karamanou, P. Kanellopoulos, E. Campos, J. Dendrinos, A. Tsakiris, G. Saroglou

P0385 Reducing access-related bloodstream infections (AR-BSI) in the haemodialysis unit by monitoring and intervention
J. Gross* [Jerusalem, Israel], M. Dranitzki Elhalal, C. Schwartz, M. Razon, L. Lipkin, A. Moses, S. Benenson

P0386 Current epidemiology of catheter-related bloodstream infection (CRBSI) in a tertiary care centre: do not forget the peripheral catheter!

P0387 The NeutraClear® needleless connector protects from catheter colonization
M. Guembe* [Madrid, Spain], M. Pérez-Granda, R. Cruces, L. Alcalá, E. Bouza Santiago

P0388 The relation between the compliance with an intervention bundle and the risk of central line associated bloodstream infections
E. Smid* [Bilthoven, Netherlands], S. de Greeff, S. Geerlings, M. Vos, M. Koek
P0389 A prospective randomized controlled trial of 2% chlorhexidine in 70% ethanol, compared with 5% povidone-iodine in 70% ethanol as cutaneous antiseptics for prevention of central venous catheter colonization
S. Saëlaö* (Bangkok, Thailand), C. Suankratay

P0390 Evaluating the need to replace peripheral intravenous lines every 3 - 4 days in order to prevent infectious complications
L. Nesher* (Beer Sheva, Israel), K. Rolston, R. Nativ, I. Livshiz-Riven, R. Smolyakov, L. Saidel-Odes, A. Borer

P0391 In vitro efficacy of ethanol 40% as non-antibiotic antimicrobial agent for central venous catheter “lock therapy”
E. De Canale, C. Bergo, W. Akkouche, G. Forner, E. Solimbergo, C. Mengoli, M. Basso, S. Parisi* (Padova, Italy), G. Palu

P0392 External ventricular drain infection: a quality improvement intervention can make a difference
R. Connolly* (Limerick, Ireland), H. Humphreys, K. Burns, D. O’Brien, M. Skally, E. Smyth

P0393 A distinct post-LVAD implantation syndrome?
Y. Chan* (Singapore, Singapore), Y. Teh, T. Tan, B. Tan, C. Lim, D. Sim

P0394 Microbiology of prosthesis vascular graft infections (PVGI). Causative organisms at different surgical sites and microbiological pattern by time from graft implantation to onset of infection
D. Sousa Regueiro, L. Castelo Corral, A. Naveiras Calvo, S. Fuente Cosío, A. Porto Pérez, P. Piñeiro Parga, G. Barbeito, M. Rodríguez Mayo, M. Gude Gonzalez, G. Bou Arevalo* (La Coruña, Spain), P. Llinares

P0395 Characteristics and prognosis of patients with prosthetic vascular graft infection (PVGI) followed by positron emission tomography (PET) scan: a prospective cohort of 67 patients
A. Pasquet* (Tourcoing, France), D. Robineau, P. D’Elia, M. Valette, S. Vondamme, P. Patoz, O. Leroy, J. Voitot, E. Senneville

P0396 Nosocomial bloodstream infections in a paediatric intensive care unit in Albania
G. Kasmi* (Tirana, Albania), I. Kasmi

P0397 Pre-emptive replacement of peripherally inserted central catheters (PICCs) to prevent a ‘possible’ central line-associated bloodstream infection (CLABSI) in patients with haematological malignancies
N. de Jonge* (Amsterdam, Netherlands), M. Caris, J. Janssen, M. van Agtmael
Sunday, 10 April 2016

12:30-13:30

Viral pathogenesis and treatment targets

P0398 Human cytomegalovirus-encoded receptor US28 is expressed in renal allografts and facilitates cell-to-cell infection in vascular smooth muscle cells in vitro


P0399 Characterization of HBoV infection induced morphological changes of airway epithelia

S. Khalfaoui, M. Pieper, W. Arnold, O. Schildgen, V. Schildgen* (Cologne, Germany)

P0400 Genetic variability of UL5 helicase gene in clinical herpes simplex virus type 1

E. Frobert, M. Linas, B. Lina, F. Morfin* (Lyon, France)

P0401 Role of de-ubiquitylating enzymes in influenza A infection

S. Akhee* (Hong Kong, China), M. Lestra, S. Sanyal

P0402 Post-mortem detection of Herpesviridae DNA (HHV-1, HHV-2 and VZV) in trigeminal and facial ganglia of human brain

J. Dunaj* (Bialystok, Poland), I. Ptaszynska-Sarasiek, J. Zajkowska, S. Panczewicz

12:30-16:30

Cytomegalovirus infection in at-risk populations

P0403 Adequate immune response following influenza vaccination in children with malignancies

A. Kafasi* (Athens, Greece), D. Dagonis, N. Spanakis, M. Tsolia, A. Tsakris

P0405 Pneumovirus-induced lung disease in mice is independent of neutrophil driven inflammation

B. Cortjens* (Amsterdam, Netherlands), L. Boon, R. Bem, J. van Woensel

P0406 Usefulness of differential cell count and CRP level in blood as predictors for Middle East respiratory syndrome coronavirus infection in acute febrile patients during nosocomial outbreak

G. Park* (Seoul, South Korea), C. Kang, H. Seok, J. Ko, J. Lee, J. Lee, S. Cho, Y. Ha, K. Peck, J. Song, D. Chung

12:30-13:30

Diagnosis of emerging viral infections

P0407 Effect on hearing of antiviral treatment for symptomatic congenital cytomegalovirus infection

F. Mazzaferrri* (Verona, Italy), M. Cordioli, C. Richelli, M. Conti, E. Cancio, M. Merighi

P0408 Prevalence and genotypic distribution of cytomegalovirus in Taiwanese childbearing mother and newborn

C. Lee* (Lukang Township, Taiwan), Y. Fang, Y. Chang, Y. Chan

P0409 Foetal magnetic resonance imaging in congenital cytomegalovirus infection

M. Diago* (Lisbon, Portugal), S. Dias, C. Conceição, E. Calado

P0410 Severe human cytomegalovirus infection early post-transplantation results in interstitial fibrosis and tubular atrophy and irreversible loss of renal function


P0411 Tumoural existence of human cytomegalovirus and the outcome of non-elderly patients with colorectal cancer: clinical and in vitro findings of favourable oncomodulatory effects

H. Chen* (Taipei, Taiwan), J. Jiang, C. Yang, Y. Chan

P0412 Rapid detection of cDNA from Ebola virus isolate by laser PCR


P0413 Differences between test agreements for the detection of dengue IgG/IgM antibodies and NS1 antigen

P. Bittel* (Bern, Switzerland), D. Mayor, J. Kalimashi, C. Saegesser, F. Suter-Riniker

P0414 Evaluation of the modified serotyping-NS1-ELISA to detect dengue NS1 and identify dengue serotypes in patient specimens

C. Puttikhunt* (Bangkok, Thailand), T. Prommaol, P. Sethanan, N. Phaenthaisong, N. Thangthawarnchaikul, P. Avirutnan, P. Malasit

P0415 The clinical utility of BIOTEK-M in the diagnosis of dengue virus infections in the Philippines

R. Berba* (Manila, Philippines), C. Aguirre, J. Petronio, L. Gonzalez, J. Lecciones, R. Destura, C. Padilla

P0416 Comparison of the viral yield between nasopharyngeal swabs and lower respiratory tract samples in MERS-CoV infected patients

N. Alzahrani* (Riyadh, Saudi Arabia), S. Al Johani, T. Enazi, Y. Arabi
P0417 Rare group C enterovirus genotypes detected in the Netherlands
C. van Leer-Buter* [Groningen, Netherlands], R. Poelman, R. Borger, H. Niesters

12:30-13:30
STI due to Chlamydia trachomatis and Neisseria gonorrhoeae

P0419 Determination of [extra]genital Chlamydia trachomatis bacterial loads and comparison between women, heterosexual men and men who have sex with men
L. Eppings, N. Dukers, P. Wolfis, G. van Liere, J. Dirks, C. Hoebe* [Geleen, Netherlands]

P0420 Anti-bacterial activity of 17 strains of lactobacilli against elementary bodies of Chlamydia trachomatis
A. Marangoni* [Bologna, Italy], P. Nardini, C. Parolin, R. Nahui Palomino, B. Vitali, L. Laghi, C. Foschi, R. Cevenini

P0421 Chlamydia trachomatis serovar distribution in the age of molecular testing
C. Foschi* [Bologna, Italy], A. Marangoni, P. Nardini, N. Banzola, A. D’Antuono, R. Cevenini

P0422 An outbreak of lymphogranuloma venereum in Detroit, MI, USA
D. Richmond, L. Crane, H. Salimnia* [Detroit, United States], M. Fairfax, P. Lephart, Z. Mahdi, J. Cohn

P0423 Ano-rectal Chlamydia trachomatis and Neisseria gonorrhoeae: clinical diagnostic and therapeutic aspects of 221 consecutive patients in France
M. Dahaun* [Paris, France], J. Lourtet, M. Cohen, J. Nguyen Van, M. Aubert, E. Pommaret, A. Mizrahi, N. Lemarchand, V. De Paradis, A. Le Mannier

P0424 Chlamydia trachomatis and Neisseria gonorrhoeae prevalence in asymptomatic women and association between human papillomavirus coinfection
N. Yilmaz* [Izmir, Turkey], A. Bayram, Y. Karaca Derici, M. Sanci, N. Agus, M. Gokcu, M. Sinir, S. Yilmaz Hanci, P. Samioglu, A. Diniz Unlu

P0425 Leucocyte esterase urine tests in men who have sex with men with urethritis symptoms; the answer towards more efficient gonorrhoea antibiotic use?
G. van Liere* [Geleen, Netherlands], A. Verhaegh-Haasnoot, N. Dukers, C. Hoebe, P. Wolfis, M. Werner

P0426 Optimal pre-analytical and analytical conditions for culture of Neisseria gonorrhoeae
C. Foley* [Dublin, Ireland], S. Knowles, A. Curry

P0427 Resistance trends and sequence type distribution of Neisseria gonorrhoeae from 1989 to 2015 in Switzerland
V. Dona* [Bern, Switzerland], S. Kosraian, R. Zbinden, B. Savic, F. Imeri, H. Furrer, N. Low, E. Endimiani

P0428 Molecular typing and antimicrobial resistance amongst different Neisseria gonorrhoeae infections
C. Foley* [Dublin, Ireland], L. Morley, S. Knowles, C. De Gascun

P0429 A comprehensive overview of Neisseria gonorrhoeae test practices in a Dutch region among different STI care providers for urogenital, anorectal and oropharyngeal sites: a cross-sectional study to identify missed opportunities in NG control
C. den Heijer, C. Hoebe* [Geleen, Netherlands], G. van Liere, J. van Bergen, J. Cals, F. Stals, N. Dukers

P0430 Does social deprivation influence the risk of antimicrobial resistance in Neisseria gonorrhoeae in different ethnicities?
H. Bolt* [London, United Kingdom], M. Furegato, K. Town, A. Kundu, G. Hughes

P0431 Decreased azithromycin susceptibility of Neisseria gonorrhoeae isolates in patients recently treated with azithromycin
C. Wind* [Amsterdam, Netherlands], E. de Vries, M. Schim van der Loeff, M. van Rooin, A. van Dam, H. de Vries

P0432 Antimicrobial resistance of Neisseria gonorrhoeae towards ceftriaxone and cefixime remains low in Germany
S. Dudareva-Vizule* [Berlin, Germany], S. Buder, K. Jansen, A. Loenenbach, S. Nikisins, A. Sailer, E. Guhl, P. Kohl, V. Bremer

P0433 Gonorrhoea treatment failures: reports from specialist clinics in England and Wales 2013-2015
H. Fifer* [London, United Kingdom], K. Town, H. Bolt, G. Hughes

12:30-13:30
Tuberculosis - diagnosis and drug resistance

P0434 Evaluation of a time-and-motion methodology for assessment of the working time required to perform TB laboratory diagnostic assays: a multicentre study
V. Mathys, V. Nikolayevskyy* [London, United Kingdom], P. Raftery, R. Groenheit, D. Folkvardsen, D. Homorodean, F. Drobniewski

P0435 Diagnosis of pulmonary tuberculosis and detection of resistance to rifampin and isoniazid through direct molecular methods in stool samples
K. Abdellrahim* [Riyadh, Saudi Arabia], A. Asmoa, M. Ahmed, M. Sherief
P0436  Performance of the Xpert MTB/RIF assay for TB and rifampicin resistance detection in routine settings in Lithuania: a nationwide study  
E. Pimkina* (Vilnius, Lithuania), R. Zablockis, V. Nikolayevskyy, E. Danila, E. Davidaviciene

P0437  Diagnostic role of real-time PCR in clinically suspected cases of tubercular meningitis  
S. Kashyap* (Lucknow, India), S. Verma, M. Kumar, T. Dhole

P0438  Comparison of three automated auramine staining methods with manual auramine stain  
N. Falah Makki* (Leuven, Belgium), M. De Leye, J. Verhaegen, V. Saegeman

P0439  Comparison between PCR and culture as a diagnostic tool for tubercular meningitis: nine years’ experience of a Portuguese infectious disease centre  
T. Vieira Azevedo* (Lisbon, Portugal), F. Filipe, R. Santos, S. Peres, F. Borges, K. Mansinho

P0440  Detection of multidrug-resistant Mycobacterium tuberculosis strains in a health department - potential application of phenotypic and genotypic methods  

P0441  Performance of GenoType MTBDRplus and MTBDRsl in identification of resistance among Mycobacterium tuberculosis isolates, as compared to MGIT  
L. Gkaravela, M. Papadimitriou-Olivgeris* (Patras, Greece), A. Foka, M. Athanassiou, N. Lazarou, F. Kolonitsiou, A. Spiliopoulou, M. Marangos, E. Anastassiou, I. Spiliopoulou

P0442  A novel rapid automated assay for the detection of tuberculosis, multi and extensive drug resistance - a proof of principle study  
F. Drabniewski* (London, United Kingdom), N. Casali, A. Brada, V. Nikolayevskyy, T. Bagdanova, Y. Balabanova, G. Blackwell, R. Bowker, H. Khan, W. Hussain

P0443  Early diagnosis of tuberculous mediastinal lymphadenopathy using Xpert MTB/RIF on endobronchial ultrasound aspirates  
L. Maynard Smith* (London, United Kingdom), S. Morris-Jones

P0444  Evaluation of the performance of nitrate reductase assay for rapid drug susceptibility testing of Mycobacterium tuberculosis in a rural medical college of northern India  
R. Farooq* (Srinagar, India), D. Singh, S. Mehta, S. Pottathil

P0445  The role of Quantiferon-TB Gold In-Tube in the diagnosis and treatment monitoring of active tuberculosis  
F. Bartolesi* (Florence, Italy), M. Spinicci, J. Mencarini, S. Veloci, E. Nencetti, A. Bartolani

P0446  Evaluation of a new reagent for preservation of sputum samples for diagnosis of Mycobacterium tuberculosis  

P0447  Compensatory mutations of rifampicin resistance facilitate transmission of multidrug-resistant Mycobacterium tuberculosis in China  
W. Jiao* (Beijing, China), Q. Li, I. Mokrousov, H. Huang, A. Shen

P0448  Mutations in gyrA and gyrB among fluoroquinolone- and multidrug-resistant Mycobacterium tuberculosis isolates  
P. Hsueh* (Taipei, Taiwan), J. Chien, C. Yu

P0449  First insights into the drug resistance and genetic diversity of Mycobacterium tuberculosis in Luanda, Angola  

P0450  Descriptive patterns of drug-resistant tuberculosis in HIV patients in St. Peter’s general hospital in Ethiopia  
H. Ayele* (Utrecht, Netherlands), M. van Mourik, M. Bonten

P0451  Multidrug resistant (MDR) tuberculosis amongst adolescents in the Free State Province, South Africa  
A. Van der Spooel van Dijk, A. Hoosen* (Bloemfontein, South Africa)

P0452  Magnitude of gene mutations conferring drug resistance in Mycobacterium tuberculosis strains among presumptive multidrug-resistant tuberculosis cases in south-west Ethiopia  
M. Tadesse* (Jimma, Ethiopia), D. Aragaw

P0453  Treatment response under optimal circumstances in patients with M/XDR-TB at a referral centre in Germany  
J. Olaru* (Borstel, Germany), J. Heyckendorf, E. Terhalle, N. Smitsman, S. Grossmann, C. Lange

P0454  Multidrug-resistant tuberculosis in a referral center for 10 years  
P. Baghaei Shiva, P. Tabarsi* (Tehran, Iran), A. Moniri, M. Marjani, P. Farnia, D. Mansouri, A. Velayati

P0455  Extensively drug resistant tuberculosis plus linezolid resistance: the first report of linezolid resistance development in Lisbon, Portugal  
POSTER SESSIONS

Final Programme 26th ECCMID, Amsterdam, Netherlands, 2016

12:30-13:30

Severe sepsis and septic shock

P0467 CD8 T-cell percentages may help predict severe sepsis and septic shock among ICU patients colonized with MDROs
A. Frattari* [Pescara, Italy], T. Ursini, E. Polilli, M. Tontodonati, R. Zocara, V. Cortesi, G. Parruti, T. Spina

P0468 Assessment of interleukin-17A, C5a and RANTES for early diagnosis of neonatal sepsis – a preliminary study
B. Kasztelewicz* [Warsaw, Poland], E. Piotrowska, J. Tółłoczka, M. Karnacka, K. Dzierzanowska-Fangrat

12:30-13:30

Bloodstream infection risk factors and pathogenesis

P0473 Aspirin and statin use and mortality in patients with community-acquired bacteraemia: population-based propensity score matched cohort studies
M. Dalager-Pedersen* [Aalborg, Denmark], R. Thomsen, H. Schonheyder, H. Nielsen

P0474 Oxidative burst of human phagocytes induced by different microbial cultures as a prospective indicator for septic complications
I. Obraztsov* [Moscow, Russian Federation], K. Shirokikh, M. Sukhina

P0475 Inflammasome activation in Staphylococcus aureus sepsis
G. Rasmussen* [Örebro, Sweden], B. Asfaw, S. Monecke, K. Strålin, E. Särndahl, B. Söderquist
P0476  Biofilm production: assessment of the clinical impact in 104 Staphylococcus aureus bacteraemia cases  
M. Guembe* [Madrid, Spain], M. Pérez-Granda, C. Sánchez-Carrillo, R. Cruces, E. Bouza Santiago

P0477  Impact of vancomycin population analysis profile (PAP) minimum inhibitory concentration (MIC) in high-inoculum methicillin-resistant Staphylococcus aureus (MRSA) bloodstream infections (BSI)  
T. Trinh* [Detroit, United States], E. Zasowski, K. Claey, A. Casapao, M. Rybak

P0478  A new immunoscore based on immunoglobulin levels influencing mortality risk in sepsis  
A. Rodríguez Fernandez, J. Bermejo-Martin, R. Herran-Mange, A. Muriel-Bombin, P. Merino, R. Ortiz de Lejarazu* [Valladolid, Spain], J. Blanco

12:30-13:30  Gram-positive and Gram-negative bacteraemia

P0479  Epidemiology of Streptococcus pyogenes bacteraemia  
A. Jorge, G. Aran, R. Martínez-Ruíz, J. Saez-Nieta, P. Villalon, B. Orden* [Madrid, Spain]

P0480  Clinical manifestations and outcomes of invasive group B streptococcal infection in nonpregnant adults  
T. Sripongboonsi* [Chonburi, Thailand]

P0481  Clinical and microbiological characteristics of cases of atypical invasive pneumococcal disease  
A. Sousa* [Vigo, Spain], M. Pérez-Rodríguez, L. Martinez-Lamas, F. Vasallo, R. Lorenzo Castro, N. Val-Domínguez, A. Baraja, A. Nodar, M. Álvarez-Fernández

P0482  Clinical characteristics and mortality of mucoid and non-mucoid Streptococcus pneumoniae bacteraemia: a retrospective cohort study  
A. Takamatsu* [Sapporo Hokkaido, Japan], S. Matsuzaka, F. Kodama, S. Constantine, T. Hashi, Y. Serizawa

P0483  Relationship between duration of methicillin-resistant Staphylococcus aureus bloodstream infection and mortality  
E. Zasowski* [Detroit, United States], T. Trinh, K. Claey, A. Casapao, N. Sabagha, J. Hallesy, M. Rybak

P0484  Increased mortality, dissemination and polyarticular infections with Staphylococcus aureus in patients with rheumatoid arthritis are independent of immunoospressive therapy  

P0485  Development of complications during Staphylococcus aureus bacteraemia: clinical and microbiological aspects  
S. Molinas* [Badalona, Spain], M. Giménez, I. Casas, A. Lacoma, N. Sopena, R. Benitez, C. Prat

P0486  Impact of a bacteraemia programme on Staphylococcus aureus bacteraemia mortality  
M. Pérez-Rodríguez* [Vigo, Spain], A. Nodar, L. Martinez-Lamas, I. Villaverde, A. Martínez-Vidal, N. Val-Domínguez, A. Sousa-Dominguez, R. Lorenzo Castro, A. Baraja Basanta, F. Vasallo Vidal, M. Álvarez Fernández

P0487  Antibiotic stewardship-guided management of Staphylococcus aureus bacteraemia at a university hospital: epidemiology and outcome  
S. Öztürk Mert, A. Dudakova, U. Graf* [Göttingen, Germany], M. Schulze

P0488  Evaluation of empirical antibiotic therapy for suspected Staphylococcus aureus bacteraemia in the era of increasing prevalence of methicillin resistance  
P. Park* [Seoul, South Korea], J. Ko, K. Pleck, H. Seok, S. Cho, Y. Ha, J. Song, C. Kang, D. Chung

P0489  Anti-infective therapy in bloodstream infection – current data of the Thuringian registry on blood culture diagnostics AlertsNet  
R. Schmitz* [Jena, Germany], A. Karch, F. Rißner, M. Jakob, R. Mikolajczyk, F. Brunkhorst

P0490  Bloodstream infections in England caused by Gram-negative bacteria  
S. Gerver, J. Abernethy, A. Johnson, R. Hope* [London, United Kingdom]

P0491  Predictive model of 30-day mortality in a cohort of patients with bacteraemia due to extended spectrum beta-lactamases producing Enterobacteriaceae (ESBL-E): the INCREMENT project  

P0492  Characterization of Escherichia coli phylogenetic groups associated with bloodstream infections in the “Hospital Clínico Universitario Virgen de la Arrixaca”  
J. Segura, C. Salvador, M. Simon Poez, C. Vázquez García, M. Roig Cardells, M. Martínez Toldos, A. Blazquez Abellán, G. Yagüe* [Murcia, Spain], M. Segovia Hérandez
P0494 Malaria and invasive non-typhoid *Salmonella* disease – estimating the strength of association  
R. Krumkamp* (Hamburg, Germany), B. Kreuels, N. Sarpong, H. Zeeb, Y. Adu-Sarkodie, J. May

P0495 Seasonal peaks in community-acquired Gram-negative rod bloodstream infection: a nationwide cohort study of US veterans  
M. Goto* (Iowa City, United States), J. McDanel, D. Livorsi, M. Schweizer, E. Perencevich

P0496 Gut colonization with Gram-negative bacteria and ICU-acquired bacteremia  
B. Wittekamp* (Utrecht, Netherlands), N. Plantinga, M. Bonten

P0497 Characterization and clinical impact of bacteremia caused by ESBL-producing *E. coli* in a third level hospital in Ecuador  

P0498 Clinical and bacterial predictors of mortality in children with carbapenem-resistant Enterobacteriaceae bloodstream infection  

P0499 Infection by carbapenem resistant Gram-negative bacteria: the impact on febrile neutropenia outcome  

P0500 Community-onset bloodstream infections caused by carbapenemase-producing Enterobacteriaceae in a healthcare district in northern Madrid  
L. Maria Beleln, B. Díaz-Pollán* (Madrid, Spain), M. Romera, M. Gomez-Gilmira, A. Rivera, J. Garcia Rodriguez, J. Pano-Pardo

P0501 A life-saving approach for managing CPE sepsis: individualized antibiotic regimen  
Z. Fang, H. Panigrahi, E. Hughes, E. Trautt, I. Cartmill, Z. Fang* (Oldham, United Kingdom)

P0502 Risk factors for extended-spectrum beta-lactamase-producing *Escherichia coli* bloodstream infection among rectal carriers in the intensive care unit  
L. Min-Xue, X. Yi* (ChengDu, China), Y. Xiao, M. Ying, M. Kang, L. Wu

P0503 Good tolerability of high-dose colistin-based therapy in patients with haematologic malignancies  
S. Grignola* (Genoa, Italy), P. Tattarelli, V. Del Bona, F. Guola, G. Rivoli, A. Ghiso, A. Riala, A. Bacigalupu, M. Gobbi, C. Viscoli, M. Mikulska

P0504 Colistin monotherapy or in combination against multidrug-resistant bacteria: systematic review and meta-analysis  
O. Zusman* (Petah-Tiqva, Israel), S. Altunin, F. Koppel, L. Leibovici, M. Paul

P0505 Carbapenem-resistant Gram-negative bacteremia - risk factors and mortality from an emergency room  
W. Kwang-Sook* (Busan, South Korea), H. Lim, B. Kim, J. Han, J. Kim, K. Kim

P0506 Gram-negative bacteremia - service evaluation of clinical liaison service in three teaching hospitals in London  

12:30-13:30  
Bone and prosthetic joint infection

P0507 Microbial aetiology of hip hemiarthroplasty (HHA) infections versus those associated with total hip arthroplasty (THA): impact of antimicrobial resistance  

P0508 Aetiology of prosthetic joint infections during 2014 in Madrid, Spain  

P0509 Pyogenic spinal infections in adults: a 5-year experience from a tertiary care centre  
O. Dzupova* (Prague, Czech Republic), R. Cihlarova, J. Benes

P0510 Clinical features and prognosis of prosthetic joint infection caused by *Staphylococcus lugdunensis* - a multi-centre retrospective study  

P0511 Vertebral osteomyelitis: long-term functional outcome and prognostic factors  
J. Ruiz-Mesoa* (Málaga, Spain), B. Sabrina, M. Jiménez-Majas, L. Vallenete de Santis, A. Plata Ciézar, J. Palomo, J. Colmenero Castillo
**P0512** S. caprae, S. capitís and S. lugdunensis: a pathogenic role in bone and joint infection?
L. Bergon, C. Roques-Ceshin, A. Debard, P. Delabel, E. Oswald, J. Laffosse, M. Grare* (Toulouse, France)

**P0513** Staphylococcus non-aureus and pathophysiological mechanisms of bone and joint infections: interspecies heterogeneity and specific behaviour of the species S. pseudintermedius

**P0514** Bacterial adherence to different components of total hip prosthesis in patients with prosthetic joint infection
R. Lass* (Vienna, Austria), A. Giurea, B. Kubista, A. Hirschl, W. Graninger, E. Presterl, R. Windhager, J. Holinka

**P0515** Variability and clinical impact of biofilm production in Staphylococcus spp. causing prosthetic joint infections
M. del Toro* (Seville, Spain), C. Velasco, I. García, A. Suárez, C. Peñas, J. Rodríguez-Baño, A. Pascual Hernandez

**P0516** Increasing incidence of Streptococcus dysgalactiae subspecies equisimilis osteoarticular infections
O. Oppegaard* (Bergen, Norway), B. Kittang, S. Skrede, H. Mylvaganam

**P0517** Bone and joint infections (BJI) since certification of complex BJI reference centres in France: before/after study
E. Laurent* (Tours, France), G. Gras, J. Druon, P. Rosset, A. Le Louarn, E. Rusch, L. Bernard, L. Grammatico-Guillon

**P0518** Native vertebral osteomyelitis in a Greek tertiary general hospital
D. Chalkiadaki, M. Bompoli* (Athens, Greece), A. Argyris, C. Fotinou, A. Lioni, M. Lazanas

**P0519** Trends in total hip and knee arthroplasty infection adjusted for comorbidities in a nationwide hospital cohort

**P0520** Diagnosis of bone and joint infections by electrospray ionization mass spectrometry (IRIDICA)

**P0521** Molecular analysis of pooled bead-milled intraoperative samples from periprosthetic joint infections using Curetis’ Unyvero i60 ITI
Y. Grenier, N. Mézi, J. Herrmann, J. Gaillard, A. Roux, M. Rottman* (Garches, France)

**P0522** Comparison of commercially available molecular test systems for the diagnosis of prosthetic joint infections
A. Boesl* (Feldkirch, Austria), K. Baruschke, H. Dirschmid, F. Offerer

**P0523** Evaluation of BJI Inoplex test for diagnosis of prosthetic joint infection in one French reference centre
A. Roux, F. El Sayed, B. Heym, T. Bauer, J. Gaillard, M. Rottman* (Garches, France)

**P0524** Performances of prove-it bone and joint assay in the microbial diagnosis of osteoarticular infections

**P0525** Interest of systematic collection of specimens for microbiological diagnosis in total hip arthroplasty revisions
A. Quercy, P. Delabel, J. Toulemonde, P. Bonneville, J. Laffosse, M. Grare* (Toulouse, France)

**P0526** Propionibacterium acnes: agent of bone infection or colonization? A retrospective study of 69 cases including 33 persons with definite infection
H. Dutranc* (Bordeaux, France), D. Gilles, F. Dauchy, C. Cazanove, G. Wirth, B. De Barbeyrac, M. Dupon

**P0527** Clonal relationship of Propionibacterium acnes isolates recovered from bone and joint infections: multi-locus sequence typing of multiple intraoperative isolates
F. El Sayed, A. Roux, J. Robes, P. De Mazancourt, J. Herrmann, J. Gaillard, T. Bauer, M. Rottman* (Garches, France)

**P0528** Characteristics of prosthetic joint infections (PJI) due to Enterobacter cloacae

**P0529** Management of bone and joint infections

**P0529** Suppressive antibiotic therapy: about 73 cases of prosthetic joint infections
V. Meyssonnier* (Paris, France), V. Zeller, F. Ducroquet, Y. Keraoumi, S. Marmor, J. Ziza

**P0530** Antibiotic impregnated cement in the treatment of prosthetic joint and bone infections
R. Ghani* (London, United Kingdom), A. Vris, K. Hossenbaccus, P. Achau, N. Heidari, J. Dave, M. Millar

**P0531** Activity of clindamycin and vancomycin-containing bone cements on Staphylococcus aureus and Staphylococcus epidermidis
W. Pfister* (Jena, Germany), F. Waeldrich
P0532 Retrospective evaluation of silver coated tumour prosthesis in complex joint infection with major bone destruction: about 10 cases with 40 months follow up
F. Fiorenza, E. Denes* [Limoges, France], A. Izzaoui, Y. Asloum, T. Roger, C. Martin, J. Charissoux, C. Mabit

P0533 Osteomyelitis caused by Klebsiella pneumoniae producing carbapenemase: a new challenge for treatment
E. Goerger, E. Honnorat, H. Savini, P. Pinelli, E. Bergmann, M. Coulange, F. Simon, P. Seng* [Marseille, France], A. Stein

P0534 The role of daptomycin (DAP) based combination therapy in prosthetic bone-joint infection caused by vancomycin resistant enterococci (VRE)
J. Vasant* [Bristol, United Kingdom], M. Albur, G. Beckley, A. Noel, K. Bowker

P0535 Cotrimoxazole in antibiotic combination to treat device-related bone infections is as efficacious and safe as other combinations: a retrospective cohort study in a French reference centre
A. Le Bourgeois* [Nantes, France], G. Bart, O. Boutouille, S. Touchais, S. Corvec, P. Bemer, L. Hippi, F. Raffi, S. Nusinovici, N. Asseray

P0536 Non-contact electromagnetic induction heating for treating infections of orthopaedic implants: in vitro findings
B. Pijls* [Leiden, Netherlands], I. Sanders, E. Kuijper, R. Nelissen

P0537 Titanium alloy surfaces with antibacterial and bioactive properties to counteract prosthetic bacterial infections
V. Allizond* [Turin, Italy], A. Cuffini, E. Marra, G. Piersigilli, S. Spriano, S. Ferraris, M. Miola, E. Bertane, G. Banche

P0538 Resistance profile study of Gram-negative bacteria originated from biofilm of sonicated orthopaedic implants
A. Stylianakis* [Athens, Greece], V. Papaioannou, A. Adamopoulos, S. Kamaritis, P. Lepetsos, P. Mantzanas, S. Katara, M. Lelekis

P0544 Incidence of haematological malignancies in Dutch patients with chronic Q fever
S. van Roeden* [Utrecht, Netherlands], W. van der Hoek, P. Wever, L. Kampshoor, C. Bleeker-Rovers, J. Oosterheert, A. Hoepeelman

P0545 Failure of interferon-gamma treatment in a patient with chronic Q fever
A. Jansen* [Nijmegen, Netherlands], T. Schoffelen, M. van Deuren, C. Bleeker-Rovers

P0546 Matrix metalloproteinase expression, production and polymorphisms in Q fever
A. Jansen* [Nijmegen, Netherlands], T. Schoffelen, J. Textoris, J. Mege, C. Bleeker-Rovers, E. van de Vosse, H. Roest, M. van Deuren

P0548 The pathogenic microorganisms in ticks, collected in Belarus in the year 2015
V. Kniazeva* [Minsk, Belarus], K. Timofeenko, Y. Pahotskaya, A. Krasko

P0549 Serum lipopolysaccharide binding protein, neopterin and interferon-gamma levels in patients with acute brucellosis
I. Sannikova* [Stavropol, Russian Federation], O. Makhinya, N. Kovalevich, V. Pasechnikov, D. Deineka

P0550 Infections due to the Brucella melitensis REV-1 vaccine strain in Greece, 2001-2015
J. Papaparaskevas* [Athens, Greece], A. Kandili, A. Pantazatou, C. Gartzonika, N. Charalampakis, A. Statthi, K. Tarpatzi, E. Refene, A. Mageropoulou, A. Tsakris

P0551 Clinical and laboratory features, and therapeutic outcome of brucellosis in 70 patients
J. Erdem* [Tekirdag, Turkey], R. Kara Ali, S. Elbasan, M. Dogan, T. Koc, H. Gunes, A. Eren Topkaya

P0552 Study of the analytical changes caused by tick-borne relapsing fever
M. Domínguez Jiménez* [Seville, Spain], M. Gómez Sanchez, M. Florida Novarro, A. Roldán Garrido, E. Torres Martas, M. Roldán Fontana
P0554 **The trends of rickettsiosis in Denmark from 2008-2015**
S. Schjørring* (Stockholm, Sweden), P. Valentiner-Branth, B. Kantsø, K. Krogfelt

P0555 **Epidemiology of *Pasteurella* spp. in a local university hospital between 2002 and 2015, in Hungary**
K. Sándor, G. Terhes, A. Lázár, M. Poppné Abrók, É. Urbán* (Szeged, Hungary)

12:30-13:30

**Diagnostic parasitology**

P0556 **Potential usefulness of highly sensitive real-time polymerase chain reaction for pre-emptive diagnosis of visceral leishmaniasis in solid organ transplant recipients**
O. Opota* (Lausanne, Switzerland), Z. Balmpouzis, C. Berutto, J. Kaiser, G. Greub, J. Aubert, G. Prod’hom, O. Manuel, K. Jaton

P0557 **Comparative evaluation of different serological tests in the diagnosis of Mediterranean visceral leishmaniasis**
M. Ortalli* (Bologna, Italy), D. Lorrai, P. Gaibani, G. Rossini, C. Vocale, M. Landini, S. Varani

P0558 **Use of a Chagas urine nanoparticle test (Chunap) to correlate with parasitaemia levels in T. cruzi/HIV co-infected patients**
Y. Castro* (Baltimore, United States), R. Gilman, L. Liotta, C. Bern, A. Luchini

P0559 **Malaria parasite detection in matched peripheral and placental blood samples from delivering women in Blue Nile State, Sudan**
S. Omer* (Khartoum, Sudan), M. Abdrahim, M. Elhassan

P0560 **Evaluation of the VIKIA Malaria Ag Pf/Pan malaria rapid diagnostic test in a non-endemic setting**
V. Hubert, C. Marechal, N. Aryg, F. Gay Andrieu, A. Bertrand-Pinault, S. Houze* (Paris, France)

P0561 **Development and performance evaluation of enzyme linked immunosorbent assay and linebiot for serological diagnosis of *Trichinella* in humans and animals**
A. Lutz, C. Flechsig, H. Duchmann* (Dietzenbach, Germany)

P0562 **Simultaneous screening of serum anti-*Echinococcus granulosus* and *E. multilocularis* antibodies by ELISA**
B. Oesterreich, K. Steinhagen* (Lübeck, Germany), J. Warnecke, B. Gottstein

P0563 **A multicentre performance evaluation of an ELISA for the detection of *Cryptosporidium* spp. antigen in clinical human stool samples**

P0564 **Comparative evaluation of Bailenger stool concentration assays for the detection of helminth and protozoa parasites**
D. Leméteil, G. Gargala, L. Favennec* (Rouen, France)

P0565 **Comparison of two commercial real-time PCR assays for detection of parasitic infections**
E. Machetti-Mareca, R. Escosa-Vela, M. Gil-Rodriguez* (Zaragoza, Spain)

P0566 **A new flow cytometry-based modified antibody-dependent cellular inhibition (ADCI) assay for malaria vaccine evaluation**
C. Pakjamsai* (Bangkok, Thailand), D. Dhiraachaikulpanich, K. Saraprajum, P. Sratongno, C. Roussilhon, P. Yenchitsomanus, S. Khusmith, P. Chimma

P0567 **A quick and reliable antigen test to detect *Giardia* and *Cryptosporidium* in stool samples**
S. Jonckheere* (Ieper, Belgium), A. Vankeerberghen, K. Van Vaerenbergh, A. Boel, H. De Beenhouwer

P0568 **Purification and characterization of *Echinococcus granulosus* cathepsin B**
I. Aly, R. Zalat* (Cairo, Egypt)

P0569 **Next generation sequencing of nuclear ribosomal genes of intestinal parasites in human faecal samples with a view to developing a diagnostic tool for comprehensive detection and identification of intestinal parasites in stool**
L. Andersen* (Copenhagen, Denmark), J. Beg, C. Stensvold, N. Larsen, H. Nielsen

P0570 **First report on genetic diversity of *Enterocytozoon bieneusi* among renal transplant recipients**
U. Ghoshal* (Lucknow, India), S. Khanduja, R. Sharma, U. Ghoshal

P0571 **Protein losing enteropathy secondary to intestinal capillariasis – a case report from Singapore**
J. Sim* (Singapore, Singapore), J. Sim, J. Chien

12:30-13:30

**Travel medicine and international health**

P0572 **Disseminated skin nodules in a Pakistani patient**
G. Sulis* (Brescia, Italy), M. Gulletta, P. Rodari, A. Apostoli, S. Caligaris, A. Matteelli, F. Castelli

P0573 **Louse-borne relapsing fever (LBRF) in Europe - description of four individual cases in Switzerland, June – October 2015**
D. Goldenberger* (Basel, Switzerland), A. Schibli, D. Fadini, P. Lardelli, M. Osthoff
<table>
<thead>
<tr>
<th>Poster Number</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>P0575</td>
<td>Congenital Plasmodium vivax malaria in a non-endemic country, an unique case-report in the Netherlands</td>
<td>S. Clemens, R. Tijs, M. Jager, T. Mank* (Haarlem, Netherlands), P. Winter, S. Sloat</td>
</tr>
<tr>
<td>P0576</td>
<td>Ricketsial infections: not as benign as we thought!</td>
<td>M. Gargouri, Y. Mejdoub, M. Koubao, A. Znaeni, A. Tlijani, T. Ben Jemaa, I. Chaabene, A. Hammami, C. Marrakchi, M. Ben Jemaa* (Sfax, Tunisia)</td>
</tr>
<tr>
<td>P0577</td>
<td>Admissions of patients with imported malaria in Vicenza, Italy - a 15-year study</td>
<td>M. Giordani* (Vicenza, Italy), M. Conforto, V. Manfrin, F. Tamarozzi, E. Brunetti, A. Neumayr</td>
</tr>
<tr>
<td>P0578</td>
<td>Acquisition of carbapenemase-producing Acinetobacter baumannii and Escherichia coli during Hajj</td>
<td>T. Leangapichart* (Marseille, France), P. Gautret, P. Brouqui, D. Raoult, J. Rolain</td>
</tr>
<tr>
<td>P0579</td>
<td>A 6 year retrospective case review of acute dengue infection in north east London</td>
<td>A. Riddell* (London, United Kingdom), Z. Babiker, J. Osborne</td>
</tr>
<tr>
<td>P0581</td>
<td>Evaluation of a novel multiplex real-time PCR assay for the diagnosis of traveller's diarrhoea</td>
<td>Y. Zboromyrska* (Barcelona, Spain), J. Hurtado, I. Alejo-Conche, M. Alvarez Martinez, M. Valls, J. Vila</td>
</tr>
<tr>
<td>P0582</td>
<td>Evaluation of Toxoplasma gondii, rubella, cytomegalovirus seroprevalences in female Syrian refugees of reproductive age, in Sanliurfa, Turkey</td>
<td>N. Yentur Doni* (Sanliurfa, Turkey), Z. Simsek, N. Hilali, M. Aksoy, B. Ozek</td>
</tr>
<tr>
<td>P0583</td>
<td>Management of dengue fever in travellers (MODFIT) study: does the WHO 2009 classification apply to travellers, and what are the best management strategies in caring for this population?</td>
<td>A. Tai, R. Rabosa, S. Mcguinness, K. Huang, K. Leder, A. Padigiane, I. Ratnam, T. Korman, D. Turner, D. Johnson* (Melbourne, Australia)</td>
</tr>
<tr>
<td>P0584</td>
<td>Cutaneous leishmaniasis cases in Syrians; an experience of a centre from Central Anatolia</td>
<td>N. Tulek* (Ankara, Turkey), M. Oszoy, F. Erdinç, C. Moroglu Demircan, M. Sonmez, C. Bulut, C. Ataman Hatipoglu, G. Ertem</td>
</tr>
<tr>
<td>P0585</td>
<td>The ongoing challenge when dealing with tuberculosis and brucellosis spondylodiscitis</td>
<td>M. Gargouri, M. Koubao, I. Chaabene, A. Bahloul, T. Ben Jemaa, H. Marsit, C. Marrakchi, M. Ben Jemaa* (Sfax, Tunisia)</td>
</tr>
<tr>
<td>P0586</td>
<td>Microbiological aspects of 139 French soldiers repatriated from overseas for an open traumatic injury</td>
<td>S. Clemens, R. Tijs, M. Jager, T. Mank* (Haarlem, Netherlands), P. Winter, S. Sloat</td>
</tr>
<tr>
<td>P0587</td>
<td>The capacities of peripheral health units [PHUs] to manage Ebola and other infectious diseases in the district of Kambia, Sierra Leone , March to April 2015</td>
<td>M. Pane* (Jakarta, Indonesia), Y. Kang, G. Samaan</td>
</tr>
<tr>
<td>P0588</td>
<td>Economic cost of combination therapy to treat XDR Gram-negatives: a knockout blow to the developing world!</td>
<td>A. Ghafur* (Chennai, India), V. Devarajan, E. Jose</td>
</tr>
<tr>
<td>P0589</td>
<td>Dermatoses in returning travellers: the London experience</td>
<td>D. Collier* (London, United Kingdom), L. Buss, C. Webster, R. Bailey</td>
</tr>
<tr>
<td>P0591</td>
<td>Engaging healthcare professionals and members of the public in tackling antibiotic resistance during World Antibiotic Awareness Week (16-22 November 2015)</td>
<td>A. Bhattacharya* (London, United Kingdom), D. Ashiru-Oredope</td>
</tr>
</tbody>
</table>
P0595 Survey on the activities of the World Health Organization (WHO) against antimicrobial resistance (AMR)
I. Vikan* [Tromsø, Norway], D. Wernli, S. Harbarth, J. Röttingen, G. Simonsen

P0596 Addressing the final hurdle towards the elimination of Hansen’s disease; a critical review of stigma in leprosy
T. Rawson* [London, United Kingdom], L. Moore, P. Rao, P. Rao

P0597 Rubella immunity in the antenatal population: trends and risk factors for non-immunity
L. Snell* [London, United Kingdom], C. Smith, S. Chaytor, K. Mcrae, M. Patel, P. Griffiths

P0598 Antibiotics usage in infants during the first 18 months of life in Benin: a population-based study
A. Brembilla, F. Mauny, A. Garcia, K. Koura, P. Deloron, J. Faucher* [Besançon, France]

P0599 Disease severity associated genomic variation among Campylobacter jejuni isolates from asymptomatic and acute infection in children of the Peruvian Amazon
B. Pascoe* [Swansea, United Kingdom], S. Murray, G. Meric, M. Hitchings, Y. Friedmann, T. Wilkinson, M. Kosek, S. Sheppard

P0600 Healthcare providers’ perspective on the HIV care for migrants in the Netherlands
S. Been* [Rotterdam, Netherlands], A. Verbon

12:30-13:30

Clostridium difficile: drug susceptibility, treatments, outcomes

P0601 Emergence of Clostridium difficile infection caused by multi-resistant and highly virulent strains: the Italian experience in the last decade
P. Spigaglia* [Rome, Italy], F. Barbanti

P0602 ClosER: results from a 3-year pan-European surveillance study of antimicrobial resistance in Clostridium difficile pre-and post-fidaxomicin introduction [2011-2014]
J. Freeman* [Leeds, United Kingdom], J. Vernon, S. Pilling, K. Morris, C. Longshaw, M. Wilcox

P0603 Antimicrobial susceptibility of Clostridium difficile 027-related ribotypes 176, 198 and 244 recovered during MODIFY I and MODIFY II clinical trials conducted between 2012 and 2014
D. Citron* [Culver City, CA, United States], S. Sambol, S. Johnson, E. Best, M. Wilcox, M. Darr, E. Goldstein

P0604 Molecular epidemiology and antimicrobial susceptibility of Clostridium difficile isolated from a university teaching hospital in Greece
C. Chatedaki* [Larissa, Greece], I. Voulgaridi, S. Sarrou, Z. Flarou, E. Petinaki

P0605 Molecular typing and antibiotic susceptibility of Clostridium difficile strains isolated from hospitalized patients

P0606 Poor outcome of Clostridium difficile infection in patients with cancer: a hospital-based study in a tertiary care hospital in Barcelona
T. Larrainzar-Coghen, D. Rodríguez-Pardo* [Barcelona, Spain], I. Ruiz, P. Barba, A. Garrido-Castro, M. Puig-Asensio, V. Rodríguez, B. Almirante

P0607 Are we overtreating patients with diarrhoea on the sole basis of a positive polymerase chain reaction [PCR] assay for Clostridium difficile?

P0608 Toxin identification and clinical outcomes among patients with Clostridium difficile infection: a systematic review and meta-analysis
K. Bunnell* [Chicago, IL, United States], L. Danziger, W. Trick, S. Johnson

P0609 Is ATLAS score for Clostridium difficile infection useful in predicting response to therapy?
M. Lupse* [Cluj-Napoca, Romania], M. Rus, M. Flanta, C. Cancel, V. Siladi, A. Asiminoaei, A. Lupu, M. Tuns, N. Todor

P0610 Clinical prediction tool for recurrent Clostridium difficile infection

P0611 Impact of surotomycin and vancomycin exposure on gut microbiota and correlation with clinical outcomes from a phase 3 trial of patients with Clostridium difficile-associated diarrhoea
L. Chesnel, D. Devorris, J. Nary, S. Dale* [Rochester, NY, United States]

P0612 Primary clinical outcomes from a phase 3, randomized, double-blind, active-controlled study of surotomycin in patients with Clostridium difficile-associated diarrhoea
V. Boix* [Alicante, Spain], Y. Pesant, R. Fedorak, K. Mullen, U. Stoutenburgh, M. Jin, D. Guris, L. Chesnel, Y. Murata
Susceptibility and molecular epidemiology of *Clostridium difficile* isolated in Europe from a phase 3 trial of surotomycin compared with vancomycin in patients with *C. difficile*-associated diarrhoea

Different treatment strategies evaluated during the first outbreak of *Clostridium difficile* infection due to ribotype 027 B1/NAP1 in Spain
E. Bouza, V. de Egea* (Madrid, Spain), M. González Del Vecchio, M. Valeria Minero, P. Munoz, M. Marin, E. Reigadas Ramirez, L. Alcala

Comparative susceptibilities of *Clostridium difficile* isolates to fidaxomicin obtained from community and hospitalized patients: results of the PEG 2013 study
B. Körber-Irrgang* (Rheinbach, Germany), L. von Müller, J. Westenberger, D. Hafner, M. Kresken, W. of the Paul-Ehrlich-Society for Chemotherapy

A cost comparison of treating *Clostridium difficile* with fidaxomicin or vancomycin from the German third-party payer perspective
M. Watt* (Chertsey, United Kingdom), S. Heimann, C. Longshaw

Factors associated with the use of tigecycline in treating *C. difficile* infection
E. Manea* (Bucharest, Romania), R. Jipa, S. Benea, I. Lapadat, L. Aleksandru, A. Hristea

Significant reduction of case fatality rate of *Clostridium difficile* infection in Copenhagen
B. Olesen* (Herlev, Denmark), M. Chaine, S. Gubbels, J. Nielsen, C. Østergaard, N. Frimodt-Moller, J. Jarløv, K. Mølbak

Non-compliance to transmission-based precautions in 13% of isolated patients, an observational study
S. van Groenendael, M. Bos, M. Wieland, G. Terlaak-Harbers, A. Voss, A. Tostmann, J. Hopman* (Nijmegen, Netherlands)

The role of private rehabilitation centres in intra-hospital multi- and pandrug-resistance transmission to the community; experience of 8-month monitoring in Central Greece
A. Ikonomidis* (Alexandroupolis, Greece), A. Demiri, A. Grapsa, A. Syros, D. Bitos, S. Anagnostolopoulos, M. Panopoulou

Product and process innovations to manage diarrhoeic episodes among patients from rehabilitation and long-term cares facilities
M. Salmona, S. Jollivet, M. Duprilot, A. Clément, S. Fourati, J. Decousser* (Creteil, France)

Low compliance rate with contact precautions in patients with a recently documented MDR bacteria infection or colonization admitted to the emergency department

Strengthening infection prevention and control in acute care hospitals with the help of infection control link nurses (ICLN) – which strategies are successful? – a systematic literature review
D. Peter* (Cologne, Germany), C. Kugler, M. Meng, F. Mattner

Is the cell phone a potential source for bacteria transfer in the operating room?
O. Schwartz Harari* (Haifa, Israel), A. Fridman, M. Boaz, I. Laniado

Mobile phones: friends or fomites?
M. Haider* (New Delhi, India), A. Hasan, R. Tewari, M. Duda, A. Das, S. Nandy, S. Alam

Are knowledge and practices of health-care workers (HCWs) related to excreta [urine and faeces] management associated with extended-spectrum beta-lactamase producing Enterobacteriaceae [ESBL-PE] incidence rate? A quantitative evaluation of 700 HCWs and linear regression analysis in a French university hospital
H. Nguyen, C. Bourigault, A. Guille des Buttes, V. Guillet, M. Juvin, J. Caillon, G. Birgand, E. Batard, D. Lepelletier* (Nantes, France)

International survey on the current practice of endoscope-reprocessing

Delayed isolation precautions for varicella-zoster virus have minimal impact on health care workers: management and outcomes in a high-prevalence area
F. Kessler* (Bern, Switzerland), B. Lämmli Millauer, P. Iseli, J. Marschall, R. Sommerstein

Risk factors for contact patients to become a carrier of multidrug-resistant organisms
F. Maechler* (Bern, Switzerland), F. Schwab, G. Piarski, A. Kola, P. Gastmeier
P0630  Risk factors for cross-transmission of carbapenem-resistant Enterobacteriaceae (CRE): variables related to exposed patients, CRE-carriers and wards
P. Ciobotaro* (Rehovot, Israel), N. Flaks-Manov, M. Oved, M. Hoshen, A. Akriv, O. Zimhony

P0631  Efficacy of routine use of hyperdrymist® micro-nebulized hydrogen peroxide in reducing Clostridium difficile infections in a tertiary hospital
C. Garzoni* (Lugano, Switzerland), M. Ferrari, A. Anesi, A. Bocconi

P0632  Quantifying patient-to-patient transmission of norovirus in a tertiary care centre
S. Korte* (Muenster, Germany), A. Kossow, A. Pettke, S. Willems, A. Mellmann

12:30-13:30  Update on hand hygiene
P0633  Automation versus human auditing of hand hygiene
M. McLaws* (Sydney, Australia), S. Azim, A. Kwok

P0634  Monitoring hand hygiene compliance upon entry and exit of a patient’s room overestimates compliance with all five hand hygiene indications
S. Ischudin-Sutter* (Basel, Switzerland), F. Rudolf, M. Dangel, H. Schuhmacher, A. Widmer

P0635  A successful multimodal intervention to increase hand hygiene compliance at a university hospital (WP5 PaSO project)
C. Fariñas-Alvarez* (Santander, Spain), T. Portal, V. Flor, A. Aja, M. Faba, S. Lanza, R. Lobeira, R. Morena, N. Polo, M. Sixto, M. Ballesteros, L. Yañez, M. Bartolomé, C. Armiñanzas

P0636  Impact of a multimodal strategy of hand hygiene in a tertiary health care centre in Colombia
S. Valderrama* (Bogotá, Colombia), A. Gonzalez, C. Linares, C. Alvarez

P0638  Epidemiology of multidrug resistant bacteria carriers and impact of hand-hygiene programme implementation in long-term care facilities
V. Diaz-Brito* (Barcelona, Spain), A. Rodenas, A. Gonzalez, A. Capella, E. Sanchez, L. Castro, Y. Delgado, R. Romero, D. Cuadras

P0639  Effect of a multifaceted intervention on hand hygiene compliance at the internal medicine wards and ICU of a tertiary teaching hospital
R. King* (Manila, Philippines), R. Berba, A. Rabe

P0640  Improving hand hygiene adherence through an intervention bundle that includes an electronic monitoring system that provides real-time personal feedback to staff
N. Kenters* (Dordrecht, Netherlands), B. den Broed, E. Huijskens

P0641  Hand hygiene challenge: when team work really matters
D. Wiltgen* (Porto Alegre, Brazil), R. Marco, A. Boff

13:30-14:30  MDR Gram-negatives in food and the environment
P0642  Molecular characterization of CTX-M-15 producing isolates from food in Germany
A. Irrgang* (Berlin, Germany), J. Fischer, S. Schmoger, B. Guerra, A. Kaebohrer

P0643  Selective enrichment of ESBL, AmpC and carbapenemase producing E. coli in meat and cecal samples - additional validation for poultry samples
L. Cavaco* (Lyngby, Denmark), R. Hendriksen, Y. Agerø, C. Aaby Svendsen, H. Nielsen, B. Guerra, R. Peran, H. Hasman

P0644  Decreasing presence of extended-spectrum beta-lactamase producing E. coli and Klebsiella spp. (ESBL-EK) in retail chicken meat; a comparison of repeated cross-sectional measurements
P. Huizinga* (Breda, Netherlands), M. Kluytmans - van den Bergh, I. Willemsen, C. Verhulst, A. Friedrich, M. Bonten, J. Kluytmans

P0645  Extended-spectrum cephalosporin resistance and plasmid-mediated quinolone resistance in emerging Salmonella serotypes from traded food products in Portugal

P0646  Similar extended spectrum beta-lactamase encoding genes in uncooked retail meat and human population
D. Morris, B. Mahon, R. Madden, C. Kelly, L. Moran, S. Kavanagh, K. Staunton, A. English, C. Carroll, M. Cormican* (Galway, Ireland)

P0647  Occurrence of ESBL-, AmpC- and carbapenemase encoding genes in E. coli isolates from animal-derived food products in Germany
J. Fischer* (Berlin, Germany), A. Irrgang, S. Schmoger, B. Guerra, A. Kaebohrer

P0648  Contamination of bean sprouts with extended-spectrum beta-lactamase-producing Klebsiella spp. (ESBL-K)
P. Huizinga* (Breda, Netherlands), M. Kluytmans - van den Bergh, I. Willemsen, C. Verhulst, A. Friedrich, K. van der Zwaluw, J. Kluytmans
**P0649**  Wastewater effluents as potential source of multidrug resistant *Escherichia coli* for wildlife
M. Masarikova* (Brno, Czech Republic), M. Dolejska, A. Cizek, I. Literak

**P0650**  Biofilms in hospital effluent: a carbapenemase hotspot between hospital and environment?
G. Bricheux* (Aubiere, France), J. Gry, O. Traore, C. Forestier

**P0651**  Antibiotic susceptibility of *Escherichia coli*, isolated from the whole course of the river Danube
C. Kittinger* (Graz, Austria), M. Lipp, B. Folli, R. Baumert, A. Grisold, H. Galler, A. Kirschner, G. Zorfel

**P0652**  16S methyltransferases in the environment and waste water treatment plants

**P0653**  Antibiotic resistance among bacteria in the Enterobacteriaceae family isolated from Norwegian bivalves
D. Grevskott* (Bergen, Norway), C. Svanevik, B. Lunestad

**P0654**  Extended-spectrum beta-lactamase *Klebsiella pneumoniae* and carbapenemase-producing *Enterobacter* spp. in algae products marketed as health supplements
L. Ryan* (Waterford, Ireland), M. Molloy, E. McGrath, L. Evans, A. Quinn, E. Burke, M. Cormican

**P0655**  The susceptibility of antibiotic resistant bacteria to heavy metals among strains isolated from the wastewater treatment plant
M. Piotrowska* (Warsaw, Poland), M. Popowska

**P0656**  Genetic and species diversity of environmental GIM-1-producing bacteria down the drain
A. Wendel* (Duesseldorf, Germany), S. Ressina, S. Kolbe-Busch, C. MacKenzie

**P0657**  Comparative genomics of the pandemic *Enterococcus faecium* ST117 lineage
A. Pedrosa Tedim* (Madrid, Spain), V. Fernandez Lanza, C. Rodríguez, P. Ruiz-Garbajosa, R. Canton Moreno, F. Baquero, T. Coque

**P0658**  MLST typing of bloodstream isolates of VRE/ *Enterococcus faecium* isolates from German hospital patients reveals prevalence of prominent strain types and a distinct level of strain dynamics over time
G. Werner* (Wernigerode, Germany), C. Fleige, U. Geringer, J. Bender, I. Klare

**P0659**  Population structure of *Enterococcus* spp. from bacteriaemia isolated in a Spanish tertiary hospital (1996-2015)
A. Pedrosa Tedim* (Madrid, Spain), M. López, M. Rodríguez-Baños, C. Rodríguez, E. Loza, R. Canton Moreno, C. Torres, F. Baquero, T. Coque

**P0660**  Termination of an outbreak of vancomycin-resistant (vanB) *E. faecium* (VRE) at a neuro-intensive unit
S. Skov* (Copenhagen, Denmark), D. Strange, L. Bergen, L. Percival Andersen, N. Frimodt-Moller

**P0661**  Virulence characterization of international *Enterococcus faecium* from diverse sources (1986-2014): unveiling specific markers of hospital isolates

**P0662**  Unexpected vancomycin-resistant *Enterococcus faecium* outbreak in a tertiary hospital in Madrid during a carbapenemase-producing Enterobacteriaceae active surveillance programme
A. Sanchez Diaz* (Madrid, Spain), A. Pedrosa Tedim, L. Martínez García, C. Torres, R. Canton Moreno

**P0663**  Antimicrobial resistance and molecular epidemiology of *Enterococcus faecium* isolated from blood in 25 university hospitals in Korea
H. Lee* (Seoul, South Korea), K. Jung Ok, J. Hong, S. Park, D. Yong, S. Jeong, K. Lee

**P0664**  Vancomycin-resistant enterococci in different human specimens
G. Jankoska* (Skopje, Macedonia), E. Trajkovska-Dokic, N. Panovski, Z. Cekavska, A. Kaftandzieva, L. Labacevska, M. Petrovska

**P0665**  Fitness cost of Tn1546-vanA carrying plasmids in different enterococcal clonal backgrounds
A. Pedrosa Tedim* (Madrid, Spain), V. Fernandez Lanza, C. Rodríguez, F. Baquero, T. Coque

**P0666**  Diversity of vanA-plasmids among *Enterococcus faecium* from wild birds: a comparison with hospitalized humans and environmental strains
V. Dravcova* (Brno, Czech Republic), A. Freitas, T. Coque, M. Francia, L. Peixe, I. Literak
P0667  Prevalence of extended spectrum beta-lactamase-producing Enterobacteriaceae and vancomycin-resistant enterococci in hospitals and the community in the northern Netherlands

P0668  Vancomycin-resistant enterococci (VRE) in a renal population - does it really matter?

P0669  Resistant CC17 E. faecium causing urinary tract infections in companion animals
C. Marques* [Lisbon, Portugal], C. Aboim, A. Belas, C. Pomba

P0670  The complexities of screening for vancomycin-resistant Enterococcus faecium – experience over 2 years in a UK hospital
N. Wickramasinghe* [Birmingham, United Kingdom], N. Ratnaraaj, T. Saliuja

P0671  Clonal spread of vanA-positive E. raffinosus in a Belgian nursing home
K. Loens* [Edegem, Belgium], B. Jans, S. Verkroost, P. Cox, M. leeven, H. Goossens

P0672  Emergence of linezolid-resistant Enterococcus faecium in Portugal: a patient co-infected with three ST117 isolates with variable antibiotic resistance profiles
A. Freitas* [Porto, Portugal], C. Novais, A. Read, V. Alves, L. Peixe

P0673  Unexpected antibacterial activity of caspofungin against Enterococcus faecium
C. Isnard* [Caen, France], F. Joalland, S. Hernandez, D. Goux, F. Cava, V. Cattoir

P0674  Dissecting the components required for the transfer of the conjugative transposon Tn1549 that spreads vancomycin resistance
L. Lambertsen* [Heidelberg, Germany], O. Barabas

P0675  First 2 cases of vancomycin variable Enterococcus faecium in Belgium
K. Loens* [Edegem, Belgium], S. Verkroost, M. leeven, H. Goossens

P0676  Multilevel antimicrobial resistance [antibiotic, biocide and heavy metal] and plasmid diversity in Enterococcus faecalis from wild and migratory birds
R. León-Sampredo* [Madrid, Spain], E. Martins, R. del Campo, M. Rodríguez-Bañós, A. Pedrosa Tedim, M. Francia, M. Pazuelo, L. Peixe, A. Freitas, C. Novais, F. Baquero, T. Coque

P0677  Carriage dynamics of beta-lactam-resistant Escherichia coli and enterococci through treatment with amoxicillin and amoxicillin/clavulanic acid in dogs
C. Espinosa-Gongora* [Frederiksborg, Denmark], I. Kieler, D. Gudeta, N. Saint Lu, J. de Gunzburg, C. Bjørnvad, L. Jessen, L. Guardabassi

13:30-14:30  Antimicrobial resistance in anaerobes

P0678  Epidemiology and antimicrobial susceptibility profile of anaerobic actinomycetes: a monocentric retrospective study in Paris, France, with a special focus on hidradenitis suppurativa

P0679  Antibiotic susceptibility profiles of recent European Gram-negative anaerobes
M. Hackel* [Schaumburg, IL, United States], M. Bailey-Person, D. Sahm, H. Leister-Tebbe

S. Schwensen* [Odense, Denmark], K. Hansen, S. Hoegh, T. Sydenham, U. Justesen

P0681  Noticeable levels of reduced antimicrobial susceptibility in Bacteroides fragilis group bacteria isolated from faecal samples from healthy children in Denmark
T. Vognbjerg Sydenham* [Odense, Denmark], B. Jensen, A. Petersen, K. Krogefelt, U. Justesen

P0682  Prevalence of division II [cfiA-positive] isolates among Bacteroides fragilis in Slovenia as determined by MALDI-TOF and its influence on phenotypic resistance to imipenem
S. Jeverica* [Ljubljana, Slovenia], J. Soki, M. Kostrzewa, L. Papst, B. Beovic, M. Mueller-Premru, E. Nagy

P0683  Antibiotic resistance status of the anaerobes in the Middle East and Europe
W. Jamal* [Jabriya, Kuwait], V. Rotimi

P0684  Prevalence of resistance in gut bacteria from patients receiving broad-spectrum antibiotics
K. Hansen* [Odense, Denmark], S. Schwensen, D. Henriksen, U. Justesen, T. Sydenham
P0685  First description of a conjugative transposon harbouring resistance genes for clindamycin and tetracycline in *Prevotella bivia*  
A. Velo* (Groningen, Netherlands), A. van Winkelhoff

P0686  An analysis of the antibiotic resistance gene content of intestinal *Bacteroides* isolated using a novel chromogenic agar  

P0687  Evaluation of *cfIA* gene positive and negative *Bacteroides* species with Carba NP test  
I. Akyar* (Istanbul, Turkey), M. Kaya, O. Karatuna

13:30-14:30
Emergence and worldwide outbreaks of carbapenemase-producing bacteria

P0688  Correlating *K. pneumoniae* genomics with metadata - what makes an outbreak?  
D. Sassera, F. Comandatore, S. Gaiarsa, M. Corbella* (Pavia, Italy), A. Flariano, C. Bandi, P. Marone

P0689  The first outbreak of a New Delhi-metallo-beta-lactamase (NDM)-producing organism in a New Zealand healthcare facility  
J. Howard* (Christchurch, New Zealand), J. Creighton, H. Heffernan, D. Williamson, M. Schousboe, S. Metcalfe, J. Green, R. Barratt, D. Murdoch, A. Werno

P0690  First autochthonous cluster of New Delhi metallo-beta-lactamase (NDM)-producing *Klebsiella pneumoniae* associated infections in Austria 2015  
M. Hell* (Salzburg, Austria), R. Prof. Pointner, R. Wenzel, P. Prim. Dr. Eberl, H. Hettegger, A. Brunauer, M. Priv Doz Dr Dünser, A. Lechner, D. Achleitner, L. Baskova, M. Bender, M. Blaschitz, A. Indra, F. Allerberger

P0691  Emergence and nosocomial spread of carbapenem-resistant *Klebsiella pneumoniae* in Brunei Darussalam  
L. Phee, D. Wareham, H. Fikry* (London, United Kingdom)

P0692  Ongoing outbreak due to *Klebsiella pneumoniae* OXA-48 in an Italian referral hospital  
A. Knezevich* (Trieste, Italy), F. Arena, M. Mascarello, M. Di Santalo, C. Fabris, V. Conte, M. Busetti, R. Luzzati, G. Rossalini

P0693  Carbapenemase-producing Enterobacteriaceae and their clinical impact in an outbreak context in the university hospital of Angers  
H. Pailhoriès* (Angers, France), C. Lemarié, M. Kempf, C. Mahaza, M. Joly-Guillou, M. Eveillard

P0694  Multiclonal outbreaks with colistin-resistant carbapenemase-producing *K. pneumoniae* isolates responsible for bloodstream infections in Turkey  
A. Jayol, P. Nordmann, Z. Gülçay, M. Bicmen, S. Alpcavus, L. Poirel* (Fribourg, Switzerland)

P0695  Retrospective study on prevalence of *Klebsiella pneumoniae* carbapenemase–producing (Kcp) bacteria at the S. Giovanni Addolorata Hospital in Rome  
P. Placanica* (Rome, Italy), R. La Mancusa, M. Gaudia

P0696  Emergence of *Citrobacter farmeri* harbouring KPC in Australia: identification of an environmental reservoir  
K. Cronin* (Melbourne, Australia), J. Cocks, J. Greenough, M. Waters

P0697  Five parallel regional outbreaks of KPC-producing *Klebsiella pneumoniae* in Poland, 2010-2012  
A. Baraniak* (Warsaw, Poland), R. Izdebski, J. Fiett, S. Suszynska, K. Bojarska, M. Herda, D. Zabicka, W. Hryniewicz, M. Gniadkowski

P0699  Clonal outbreak of an ST147 *Klebsiella pneumoniae* strain co-producing KPC-2 and VIM-1 carbapenemases in a Greek tertiary care hospital  

P0700  GES-5 carbapenemase-producing *Klebsiella oxytoca* causing clinical infection in a UK haematopoietic stem cell transplantation unit  

P0701  Surveillance of GES-5 carbapenemase producing organisms in northern Osaka, Japan  
A. Ukimura* (Takatsuki, Japan), Y. Shibata, T. Yamada, F. Goto, T. Nakanishi, Y. Ooi, T. Nakano

P0702  Emergence and characterization of hospital-acquired *Klebsiella pneumoniae* carbapenem-(KPC) and colistin-resistant isolates in paediatric intensive care units (PICU) in Vietnam  
H. Hanberger* (Linköping, Sweden)
P0703 First description of the carbapenemase OXA-58 in *Proteus mirabilis*
F. Lange* (Bochum, Germany), N. Pfennigwerth, S. Gerigk, F. Gohlke, O. Klaus, I. Pur, N. Wohanka, S. Gatermann, M. Kaase

P0704 Dissemination of blaOXA-181 on IncX3 plasmids in the United Arab Emirates
A. Sonnevend* (Al Ain, United Arab Emirates), D. Darwish, A. Ghazawi, R. Hashmey, Z. AlDeesi, T. Pal

P0705 Carbapenem-resistant *Klebsiella pneumoniae* carriage, colonization and infection in intensive care units in Catania, Italy
A. Agodi* (Catania, Italy), M. Barchitta, A. Quattrocchi, A. Maugeri, M. La Rosa, C. Bonura, A. Aleo, C. Mammina

P0706 Molecular epidemiology of carbapenemase-producing Gram-negatives in a paediatric hospital in Angola
L. Poirel* (Fribourg, Switzerland), N. Kieffer, M. Aires de Sousa, P. Nordmann

P0707 Molecular epidemiology of carbapenem-, colistin- and tigecycline-resistant Enterobacteriaceae from the private sector in Durban, South Africa
J. Sekyere, S. Govinen Usha* (Durban, South Africa), A. Peer, O. Samuelsen, B. Aasnaes, A. Sundsfjord, S. Issack

P0708 Simultaneous circulation of five different *Klebsiella pneumoniae* strains producing combinations of KPC-2, KPC-3, OXA-48, VIM-1 and VIM-19 carbapenemases in a single ICU

P0709 Emergence of pan-resistant Gram-negative superbugs: is humanity at the edge of impending doom?
I. Khan* (Kolkata, India)

P0710 Dissemination of NDM producers in Argentina [2013-2015]: escalation of Enterobacteriaceae belonging to the Proteaeae tribe
F. Pasteran* (Buenos Aires, Argentina), M. Rapoport, E. Albornoz, C. Lucero, P. Ceriana, D. Faccone, S. Gomez, N. Argentina Group, A. Carso

P0711 First occurrence of VIM-1 producing *Escherichia coli* clinical isolates in a Greek tertiary hospital: inter-species or clonal spread?
E. Kranotiaki* (Athens, Greece), E. Perivalioti, M. Mpourinia, M. Nepka, V. Papastamopoulos, A. Skoutelis, K. Fountoulis

P0712 Emergence of OXA-48 in carbapenem-resistant Enterobacteriaceae among cancer patients in Egypt
D. Kayed* (Cairo, Egypt), H. El-Mahallawy, A. Atta, A. Hashem, T. Mansour

P0713 Emergence of metallo-beta-lactamase-producing *Escherichia coli* among hospitalized patients with urinary tract infections in tertiary care centres of Nepal
B. Shrestha* (Kathmandu, Nepal), B. Rijal, J. Sherchand, B. Pahrel

P0714 Prevalence of *Klebsiella pneumoniae* strains producing carbapenemases and increase of resistance to colistin in an Italian teaching hospital from January 2012 to November 2015
S. Parisi* (Padova, Italy), A. Bartolini, E. Santacatterina, A. Berto, E. Franchin, N. Menegotto, E. De Canale, I. Tommasini, M. Bassa, S. Stefani, G. Palu

P0715 A ten-year epidemiological study of carbapenemase-producing *Klebsiella pneumoniae* in a tertiary Greek university hospital: predominance of KPC over MBL-producing isolates
A. Spyrouloupoulou, M. Papadimitriou-Olivgeris* (Patras, Greece), C. Bartzavali, S. Varvakapolou, M. Marangos, I. Spiliopoulou, E. Anastassiou, M. Christofidou

P0716 Prevalence of carbapenemase genes among 16S rRNA methyltransferase-producing Enterobacteriaceae isolated from cancer patients
S. Sabtcheva* (Sofia, Bulgaria), I. Ivanov, B. Todorova, K. Ivanova, E. Dobreva, T. Kantardjieva

P0717 Characterization of Enterobacteriaceae resistant to carbapenem in a university hospital in Portugal
A. Santos-Silva* (Porto, Portugal), A. Silva, E. Costa, I. Faria-Ramos, E. Ricardo, R. Teixeira-Santos, S. Costa-de-Oliveira, A. Rodrigues, C. Pina-Vaz

P0718 Diversity of carbapenemase-producing Enterobacteriaceae colonizing hospitalized patients in a teaching hospital from Barcelona, Spain
J. Cámara, F. Tubau, M. Cubero, E. Shaw, P. Ciercoles, M. Pujol Raja, C. Ardanuy Tisair, M. Domínguez Luzan* (Barcelona, Spain)

P0719 Clonal relatedness between non-sequence type 258 carbapenemase-producing *Klebsiella pneumoniae* causing bloodstream infections: results from a microbiological and epidemiological survey in a large teaching hospital in northern Italy
E. Coppo, D. Giacobbe* (Genoa, Italy), V. Del Bono, C. Viscoli, A. Marchese

P0720 Prevalence of acquired Carbapenemases among Gram-negative bacteria causing neonatal sepsis - a study from Pakistan
R. Zahra* (Islamabad, Pakistan), F. Farrukh, T. Walsh, R. Kamran
P0721 Emerging extensively drug-resistant bacteria (EXDR) in an Algerian emergency hospital: characterization and recommendations  
M. Hamidi* [Algiers, Algeria], N. Aggounne Khinaache, H. Tali Maamar, N. Benamrouche, A. Nafissa, S. Bouharaoua, F. Assaous, B. Guettou, K. Rahal

P0722 Epidemiology of carbapenemase-producing Enterobacteriaceae in a tertiary hospital in Spain: trends and impact of infection control measures  
N. López-Fresnería, C. Díaz-Agero, A. Rincón Carvallia, M. Hernández Garcia* [Madrid, Spain], P. Ruiz-Garbajosa, A. Sanchez Diaz, J. Aranaz Andrés, R. Canton Moreno

P0723 Carbenem-resistant Enterobacter cloacae clinical isolates in a hospital setting  
E. Kraniotaki* [Athens, Greece], E. Perivaliati, M. Mpournia, M. Nepka, V. Papastamopoulos, A. Skoutelis, K. Fountoulis

P0724 Surveillance of carbapenemase-producing Enterobacteriaceae: colonization and infection data collected in Sant’Anna Hospital, Como, Italy, 2013-2015  
A. Genasetti, M. Valli, S. Armitana, E. Martella, L. Villa, G. Tagliabue, S. Cimetti, M. Busnelli, L. Bonvini, R. Mauri, D. Santoro, F. Pigioni, E. Sala, R. Mauri* [Como, Italy]

P0725 Hospital-acquired carbapenem-resistant Enterobacteriaceae (CRE) in a tertiary care health centre, India  
B. Mohan* [Chandigarh, India], A. Prasad, H. Kaur, V. Hallur, N. Gautam, N. Taneja

P0726 Prediction of antibiotic resistance phenotypes using the genomes of carbapenem-resistant pathogens of five different species isolated at a Swedish hospital  
A. Johnning* [Gothenburg, Sweden], N. Karami, E. Tång Hallbäck, I. Adlerberth, E. Kristiansson

P0727 Emergence and diffusion of NDM-1-producing Klebsiella pneumoniae at Charles Nicolle Hospital of Tunis, Tunisia  

13:30-14:30  
News on ESBL and AmpC

P0728 ESBL-plasmids do not reduce fitness but influence chromosomally encoded genes important for biofilm formation and motility in E. coli  
K. Schaufler, T. Semmler, D. Pickard, M. de Toro, F. de la Cruz, L. Wieler, C. Ewers, S. Guenther* [Berlin, Germany]

P0729 A study indicating the possibility of horizontal transfer of blaCTX-M gene between uropathogenic and gut Escherichia coli in the human intestine  
P. Sekar* [Chennai, India], J. Malaiyan, S. Nasimuddin, S. Gnanadesikan, P. Krishnan

P0730 Characterization of beta-lactam resistance mechanisms among UTI isolates collected from women attending primary care across Europe – R-GNOSIS  
J. Tyrrell, A. Aboklaish, J. Richards, C. Butler, M. Wootton, T. Walsh, M. Carvalho* [Cardiff, United Kingdom]

P0731 Detection of plasmid-mediated AmpC in Proteus mirabilis: a challenging phenotypic diagnosis  
A. López-Collejo, M. Gómez, V. Vela, F. Pilar, M. Vicente, M. Capapé, A. Marcen, I. Ferrer, A. Rezusta* [Zaragoza, Spain], M. Revillo

P0732 Resistance phenotype prediction from whole genome sequencing data in ESBL or plasmid-AmpC-producing E. coli or K. pneumoniae: results from bloodstream isolates collected during an international multicentre randomized trial  
P. Harris* [Herston, Australia], H. Zowawi, A. Wailan, N. Ben Zakour, D. Paterson

P0733 Extended-spectrum-beta-lactamase (ESBL) producing Enterobacteriaceae in maternal urine cultures and related neonates’ cultures  
A. Guri, N. Flaks-Manov, A. Gilai, M. Hoshen, A. Benis, D. Fidel, P. Ciobotaru* [Rehovot, Israel], O. Zimhony

P0734 Molecular characterization of third-generation cephalosporin-resistant Enterobacteriaceae – results from a large multicentre study  

P0735 Serogentotyping and identification of extended-spectrum beta-lactamase genes in non-typhoidal Salmonella: first report from Saudi Arabia  
G. Garaweens, A. Samiul, A. Raji* [Riyadh, Saudi Arabia], S. Braun, R. Ehricht, W. Al-Kattan, A. Shibil, A. Senak

P0736 Emergence of extended spectrum beta-lactamase producing Enterobacteriaceae causing bloodstream infections in rural Ghana, 2007-2012  
D. Eibach* [Hamburg, Germany], C. Belmar Campos, R. Krumkamp, H. Al-Emran, D. Dekker, Y. Adu-Sarkodie, M. Aepfelbacher, F. Marks, J. May

P0737 Implementing the ESBL-E toolkit in Italy: organization and results of a European project  
V. Mondain* [Nice, France], G. Secondo, R. Guttmann, G. Ferrea, A. Dusi, M. Giacomin, C. Pradier

13:30-14:30  
Surveillance of carbapenemases: they will not stop!

P0738 WGS reveals the diversity that dominated CPE in the United Kingdom during 2014 and 2015  
M. Ellington* [London, United Kingdom], K. Hopkins, M. Doumith, D. Meunier, J. Turtan, N. Woodford

P0740 Establishment of a rapid screening network for carbapenemase-producing Enterobacteriaceae (CPE)
A. Alvarez-Buylla* (Birmingham, United Kingdom), L. Xu, McCrae, A. Raza, M. Ellington, D. Ironmonger, B. Hilton, J. Workman, T. Barnett, F. Jones, K. Hopkins, N. Woodford, P. Hawkey

P0741 Unstopable carbapenemase-producing Enterobacteriaceae in the mid-west of Ireland? A retrospective epidemiological and microbiological review of 134 isolates from 2009-2015

P0742 Four years of surveillance reveals low prevalence of carbapenemase-producing Enterobacteriaceae in the Netherlands
K. van der Zwaluw* (Bilthoven, Netherlands), T. Bosch, J. van Beelen, F. Landman, M. van Santen, M. Timmer, L. Schouls, H. Bootsma

P0743 Carbapenemase-producing Enterobacteriaceae in Belgian hospitals: surveillance data 2012-2014
B. Jans* (Brussels, Belgium), T. Huang, P. Bogaerts, B. Catry, O. Denis, Y. Glupczynski

P0744 Spread of KPC-producing ST11, ST101, ST5712 high risk Klebsiella pneumoniae clones in Spain

P0745 The role of cross-border transmission in the emergence of NDM-producing Enterobacteriaceae in Hungary

P0746 Report of the national reference laboratory for multidrug-resistant Gram-negative bacteria on carbapenemases in Germany in 2015
M. Kaase* (Bochum, Germany), N. Pfennigwerth, F. Lange, N. Ester, A. Anders, S. Gatermann

P0747 Carbapenemase-producing Enterobacteriaceae isolates in Portuguese hospitals: results of the European survey on carbapenemase-producing Enterobacteriaceae (EuSCAPE)
V. Managería* (Lisbon, Portugal), E. Ferreira, I. Moura, R. Graça, M. Caniça

P0748 Characterization of carbapenemase-producing Escherichia coli isolates from France between 2012-2013
L. Gautier, G. Cuzon, L. Dorret, N. Fortaineu, T. Naas* (Le Kremlin-Bicêtre, France)

P0749 Emergence of OXA-48 beta-lactamase in Enterobacteriaceae in Croatia

P0750 Clonal relationship between NDM-1-positive Klebsiella pneumoniae isolates collected from 14 Turkish hospitals
O. Karatuna* (Istanbul, Turkey), D. Kaya, S. Kocagoz, M. Kaya, I. Akyar, T. Kocagoz

P0751 Low frequency of BKC-1-producing Klebsiella spp. isolates in Brazil
W. Martins* (Sao Paulo, Brazil), A. Nicoletti, S. Santos, L. Fehlberg, J. Sampaio, A. Gales

P0752 Refining national surveillance algorithms to facilitate local outbreak detection of carbapenem resistant organisms
L. Moore* (London, United Kingdom), R. Freeman, A. Charlett, J. Otter, H. Donaldson, A. Holmes

13:30-14:30

Pseudomonas aeruginosa: an evergreen pathogen

P0753 Pseudomonas aeruginosa’s profile of resistance to quinolones and carbapenems parallel to usage of quinolones and carbapenems
J. Choucair* (Beirut, Lebanon), K. Nadim

P0754 Nosocomial spread of class 1 integron-carrying extensively drug-resistant Pseudomonas aeruginosa isolates in an Istanbul hospital centre
C. Rasoandrainy* (Istanbul, Turkey)

P0755 Network analysis of relationships between patients identified with VIM-positive Pseudomonas aeruginosa isolates from lower tract respiratory samples
A. Bellés Bellés* (Zaragoza, Spain), S. Algarate, C. Seral, J. Bueno, F. Peiró, B. Roja-Bezares, F. Castillo, Y. Saenz

P0756 Class 1 integrons from Pseudomonas aeruginosa isolated from an ICU in Bucharest
I. Gheorghe, I. Czobor* (Bucharest, Romania), D. Banu, M. Papa, I. Porumbita, V. Lazar, M. Chifiriuc
POSTER SESSIONS
Final Programme 26th ECCMID, Amsterdam, Netherlands, 2016

13:30-13:30
The complexity of antibacterial resistance mechanisms

P0761
Emergence of plasmid-mediated MCR-1 protein leading to colistin resistance in South Africa
L. Pairet* [Fribourg, Switzerland], A. Brink, P. Nordmann

P0762
Cooperation between active efflux and porin alteration is sufficient to confer high-level resistance to meropenem (MEM) in Pseudomonas aeruginosa [Pa] clinical isolates
H. Chalhoub, Y. Saenz, H. Rodriguez-Villalobos, D. Denis, B. Kahl, F. Van Bambeke* [Brussels, Belgium]

P0763
Contribution of the AcrAB-ToIC efflux pump to the resistance profile of a multidrug-resistant clinical Escherichia coli isolate
S. Schuster* [Freiburg, Germany], T. Schwegger, L. Greim-Kuczewski, M. Vavra, Y. Matsumura, W. Kern

P0764
Association of the 16S rRNA methylase rmtB gene to a novel insertion sequence from ISL3 family
F. Morel* [Paris, France], J. Decousser, S. Kumsank, E. Cambau, B. Bercot

P0765
Transposition during natural transformation facilitates spread of antibiotic resistance determinants
J. Kloos* [Tromsø, Norway], S. Abel, K. Nielsen, P. Johnsen, K. Harms

P0766
Single amino acid substitution G186V in AdeS restores TGC susceptibility of Acinetobacter baumannii
T. Chiueh* [Taipei, Taiwan]

P0767
Insertion sequences ISaBα1 and ISaBα125 are associated with tigecycline resistance in Acinetobacter baumannii
S. Gerson* [Cologne, Germany], J. Nowak, E. Zander, O. Krut, H. Seifert, P. Higgins

P0768
Whole-genome sequence to decipher the resistome of Chryseobacterium indolgenes, a multidrug-resistant bacterium isolated from a cystic fibrosis patient in Marseille, France
T. Cimmino* [Marseille, France], J. Rolain

P0769
Collateral sensitivity networks in clinical Escherichia coli isolates
N. Poddnecky* [Tromsø, Norway], E. Fredheim, J. Kloos, A. Utne, R. Primicerio, D. Samuelsen, P. Johnsen

P0770
Quantitative proteome analysis of Escherichia coli exposed to tetracycline reveals multiple affected cytoplasmic metabolic processes
D. Jones-Dias* [Lisbon, Portugal], A. Carvalho, I. Moura, B. Dill, H. Molina, M. Caniça, R. Matthiesen

P0771
Significant increases of carbapenem MICs in the presence of N-acetylcysteine in clinical Klebsiella pneumoniae and Acinetobacter baumannii isolates
H. Dogan* [Istanbul, Turkey], B. Aksu, M. Hasdemir

P0772
Identification and characterization of methyltransferases in aminoglycoside resistant human and animal clinical isolates from Serbia

P0773
In vitro activity of tigecycline and resistance mechanisms due to efflux pump production in Gram-negative isolates in Portugal
V. Manageiro, J. Almeida, S. Pires, D. Jones-Dias, E. Ferreira, M. Caniça* [Lisbon, Portugal]

P0774
Genomic sequencing of two Streptococcus agalactiae with high level gentamicin resistance, collected in the BSAC bacteraemia surveillance
M. Doumith, S. Mushtaq, V. Martin, J. Coelho, V. Chalker, N. Woodford, A. MacGowan, D. Livermore* [Norwich, United Kingdom], B. Surveillance Standing Committee

P0775
Is whole-genome sequencing a reliable tool for predicting penicillin resistance in Bacillus anthracis?
A. Gargas* [Atlanta, United States], D. Sue, C. Lascols, J. Gee, C. Marston, D. Livermore* [Norwich, United Kingdom], B. Surveillance Standing Committee

P0776
Identical novel multidrug-resistant integrative conjugative island found in Haemophilus influenzae strains of different sequence types from the same geographical region of Norway
K. Hegstad* [Tromsø, Norway], D. Skaare, A. Sivertsen, T. Pedersen, H. Mylvaganam
P0777 | Fluoroquinolone, macrolide and ketolide resistance in H. parainfluenzae from the private sector in Durban, South Africa  
R. Abotsi, S. Govinen Usha, K. Moodley, S. Essack*  
[Durban, South Africa]  

P0778 | Antimicrobial susceptibility and molecular mechanisms of acquired resistance in Actinotignum (Actinobaculum) schoalii isolated in patients with hirudinoidis suppurativa  

P0779 | Macrolide resistance detection in M. pneumoniae strains following a respiratory infection treatment  
B. Rivaya Sanchez, G. Fernández Rivas, E. Bascuñana, E. Jordana Lluch, S. Molinos, N. Lópeez González, M. Méndez, L. Matas Andreu* [Badalona, Spain]  

P0780 | Study of novel mechanisms of Moraxella catarrhalis resistan to macrolide based on comparative genomics  
Y. Liu, X. Meng, Y. Xu, Y. Zhao* [Beijing, China]  

P0781 | Synergistic effect of metallic nanoparticles; copper, cobalt, zinc and silver against Staphylococcus aureus and Escherichia coli  
F. Raja* [Birmingham, United Kingdom], T. Warthington, R. Martin  

P0782 | Transcriptional response of Clostridium difficile to sub-minimum inhibitory concentrations of antimicrobial compounds  
E. van Eijk* [Leiden, Netherlands], I. Sanders, G. Wright, E. Kuijper, W. Smits  

13:30-14:30 Colonization with MDR Enterobacteriaceae  

P0783 | Faecal carriage of resistant Enterobacteriaceae in children with cystic fibrosis  
P. Knudsen* [Oslo, Norway], K. Gammelsrud, M. Steinbakk, T. Abrahamsen, F. Müller  

P0784 | Timing for colonization of four multidrug-resistant microorganisms in a public hospital of Rio de Janeiro  
S. Castra, E. Castra* [Rio de Janeiro, Brazil], V. Berqua, B. Mello, J. Delgado Correal  

P0785 | Genotyping of Enterobacteriaceae producing extended-spectrum beta-lactamases isolated from blood and gut in haematological patients  
A. Korobova, S. Khrulnova* [Moscow, Russian Federation], V. Okhmat, I. Frolova, G. Klyasova  

P0786 | Risk factors for colonization with multidrug-resistant organisms after health care abroad  
E. Melander* [Malmö, Sweden], U. Karlsson, E. Gustafsson  

P0787 | Faecal carriage of Enterobacteriaceae producing extended spectrum beta-lactamases in neonatology  
D. Chaima, S. Hoornmari, Z. Hamzoua, E. Maoamar, S. Ferjani, R. Amel, M. Saidani, E. Ben Hamida, Z. Marrakchi, I. Boutiba-Ben Boubaker* [Tunis, Tunisia], A. Slim  

P0788 | Are active surveillance cultures useful to predict Klebsiella pneumoniae extended-spectrum beta-lactamase infections in the neonatal intensive care unit?  

P0789 | Significant decrease of admission prevalence of 3rd generation cephalosporin-resistant Enterobacteriaceae colonization in one university hospital  

P0790 | In vitro susceptibility of Enterobacteriaceae resistant to third generation cephalosporins on hospital admission – results of a German nationwide prevalence study (ATHOS study)  
A. Mischnik* [Freiburg, Germany], P. Baumert, V. Ihle, A. Hamprecht, A. Rohde, S. Feihl, B. Obermann, S. Peter, A. Serr, P. Gastmeier, H. Seifert, W. Kern  

P0791 | Co-expression of extended-spectrum beta-lactamase and plasmid-encoded AmpC beta-lactamase genes in Enterobacteriaceae: a multi-centre study on rectal carriage in Dutch hospitalized patients  
E. den Drijver* [Breda, Netherlands], T. Warthington, R. Martin  

P0792 | Colonization with extended-spectrum beta-lactamase-producing Enterobacteriaceae and the incidence of subsequent bacteremia  
K. Nadrah, M. Pirs, S. Terzi, M. Mueller-Premru, B. Beovic* [Ljubljana, Slovenia]  

P0793 | Positive faecal screening is of low predictive value for subsequent clinical infection with ESBL-producing Escherichia coli and Klebsiella pneumoniae  
A. Lindblom* [Gothenburg, Sweden], N. Karami, T. Magnusson, C. Åhrén  

P0794 | Antimicrobial resistance carriage in Dutch long term care facilities  
L. Verhoef* [Bilthoven, Netherlands], M. Roukens, S. de Greeff, M. Meessen, S. Natsch, E. Stobberingh  

P0795 | Long-term carriage of KPC-producing Klebsiella pneumoniae ST258 over five years  
A. Jouset* [Le Kremlin-Bicêtre, France], R. Bonnin, D. Girlich, G. Cuzon, L. Doret, P. Glaser, T. Naas
**POSTER SESSIONS**

**Final Programme 26th ECCMID, Amsterdam, Netherlands, 2016**

**P0796** Faecal carriage of carbapenem-resistant Enterobacteriaceae in food handlers in Kuwait
O. Moghnia* (Kuwait City, Kuwait), N. Al-Sweih, V. Rotimi

**P0797** Faecal carriage rates of carbapenemase-producing Enterobacteriaceae in community setting in Tunisia
B. Mnif* (Sfax, Tunisia), N. Sallem, E. Chiboub, A. Hammami

**P0798** Colonization by multidrug-resistant Gram-negative bacteria in residents of long-term care facilities in Graz, Austria
E. Leitner, R. Krause, C. Pux, G. Pichler, W. Schippinger, I. Zollner-Schwetz* [Graz, Austria]

13:30-14:30

**Antimicrobial susceptibility testing of Gram-negative bacteria**

**P0799** Evaluation of ceftazidime-avibactam gradient strip MIC, broth microdilution MIC and 10-4 disk methods for Enterobacteriaceae and Pseudomonas aeruginosa
L. Koeth* [Westlake, United States], J. DiFranco-Fisher, G. Stone

**P0800** Phenotypic detection of ciprofloxacin susceptible non-wild type Enterobacteriaceae by disk diffusion
O. Ekelund* [Växjö, Sweden], S. Al-Bayati, E. Matuschek

**P0801** Comparison of Vitek2 and broth microdilution for susceptibility testing to sulbactam of clinical isolates of Acinetobacter baumannii: proposal of a new breakpoints
R. Cristina Ruedas Martins* [Sao Paulo, Brazil], D. Barbosa dos Santos Mongelos, L. Perdigão Neto, F. Rossi, R. Stabler, A. Sara Levin, S. Figueiredo Costa

**P0802** Multicentric evaluation of the reliability and the reproducibility of synergy testing using the MIC test strip – synergy application system (MTS-SAS”)
E. Carretto* [Reggio Emilia, Italy], F. Bravarane, P Gaibani, G. Russello, C. Farina

**P0803** Evaluation of the Scan® 1200, a rapid tool for reading antibiotic susceptibility testing by the disk diffusion technique
S. Le Page* [Marseille, France], G. Dubourg, J. Rolain

**P0804** Kingella kingae - antimicrobial susceptibility testing with disk diffusion and broth microdilution using EUCAST media
J. Åhman* [Växjö, Sweden], E. Matuschek, P Yagupsky, G. Kahlmeter

**P0805** Evaluation of Etest, M.I.C.E. and MIC Test Strip beta-lactam gradient tests for beta-lactamase negative Haemophilus influenzae with beta-lactam resistance due to PBP mutations
C. Karlsson* [Växjö, Sweden], A. Varga, E. Matuschek, D. Skaare, G. Kahlmeter

**P0806** WCK 4282 (cefepime-tazobactam) MIC quality control ranges using a multi-laboratory study design
J. Ross, R. Flamm, R. Jones, H. Sader* [North Liberty, United States]

**P0807** Amoxicillin-clavulanic acid susceptibility testing: fixed ratio versus fixed concentration of clavulanic acid and clinical outcome implications in bacteraemia caused by Enterobacteriaceae

13:30-14:30

**Mycobacterium tuberculosis - susceptibility testing methods**

**P0810** Discordance across phenotypic and molecular methods for drug susceptibility testing of drug-resistant Mycobacterium tuberculosis isolates in a low TB incidence country
M. Mokaddas* [Kuwait City, Kuwait], S. Ahmad, H. Saad Aldeen, N. Al Mutairi, S. Mohamaddi

**P0811** Comparative study of quinolone-based combinations against susceptible and resistant M. tuberculosis using in vitro and ex vivo models
A. López* [Barcelona, Spain], E. Portell, G. Tuddó, J. Gonzalez-Martín

**P0812** Pyrazinamide is active against Mycobacterium tuberculosis at neutral pH at the clinical breakpoint concentration under specific conditions
A. den Hertog* [Amsterdam, Netherlands], S. Menting, M. Warns, S. Siddiqi, R. Pfeltz, R. Anthony

**P0813** MALDI-TOF for drug resistance testing in Mycobacterium tuberculosis

**P0814** Thionamide testing: issues regarding quality of results and its implications for the diagnostic laboratory
X. Gonzalo* [London, United Kingdom], F. Drobniewski
Comparison of line probe assay with conventional culture for detection of drug resistance in *Mycobacterium tuberculosis*  
*P. Suttha* (Nonthaburi, Thailand), N. Panitantum, U. Thawornwan, P. Chathaisong

13:30-14:30

Phenotypic susceptibility testing of Gram-positive organisms

Comparison of solithromycin MICs generated by BSAC and CLSI methods  
*H. Dwight* (Rochester, United States), D. Vicino, J. Li, P. Fernandez, K. Keedy

Evaluation of tedizolid Liofilchem MIC test strips: a comparison broth microdilution MIC results for *Staphylococcus* spp.  
*L. Koeth, J. DiFranco-Fisher, R. Skov, A. Petersen, M. Bensaci, C. Tan* (Kenilworth, United States)

Antimicrobial susceptibility profile of *Staphylococcus saprophyticus* using EUCAST clinical breakpoints  
*J. Sampaio* (Sao Paulo, Brazil), S. Sampaio, J. Camargo, M. Rehem, A. Yassui, V. Oliveira, J. Scotti, J. Pereira, C. Lázari

Are both oxacillin and cefoxitin testing necessary for the detection of methicillin resistance in coagulase-positive staphylococci?  
*E. Cercenado* (Madrid, Spain), C. Oscar, F. Román Alonso, A. Vindel, M. Marin, E. Bouza Santiago, S. Study Group

Evaluation of susceptibility testing for fastidious microorganisms on MHF by disk diffusion and Etest methods with EUCAST recommendations  
*N. Bereksi* (Lyon, France), C. Tamiotti, D. Giraud, F. Joyeux, F. Villeval, G. Zambardi

Performance of antibiotic disks for detecting *Staphylococcus aureus* resistance to macrolides and related antibiotics  
*E. Hodille* (Lyon, France), M. Canizares, C. Bouveyron, M. Bes, C. Dupieux, A. Tristan, F. Vandenesch, G. Lina, F. Laurent, O. Dumitrescu

Evaluation of EUCAST zone diameter screening breakpoint for high-level streptomycin resistance in enterococci  
*J. Åhman* (Växjö, Sweden), C. Alexandersson, E. Matuschek, D. Brawn, G. Kahlmeter

Antimicrobial disks for susceptibility testing from nine manufacturers – a follow-up study  
*J. Åhman* (Växjö, Sweden), E. Matuschek, G. Kahlmeter

EUCAST zone diameter breakpoints and quality control criteria for cefotibiprole 5 μg  
*E. Matuschek* (Växjö, Sweden), J. Åhman, A. Santerre Henriksen, G. Kahlmeter

EUCAST MIC broth microdilution of Streptococcus spp. and *Haemophilus influenzae* - evaluation of broth with and without beta-NAD and with different concentrations of lysed horse blood  
*E. Matuschek* (Växjö, Sweden), J. Åhman, C. Alexandersson, G. Kahlmeter

Evaluation of vancomycin susceptibility among isolates of *Staphylococcus aureus* infections by broth microdilution and Vitek2, during 4 years in Aveiro, Portugal  
*R. Diaz* (Aveiro, Portugal), B. Gago, V. Afreixo, E. Ramalheira

Multi-site evaluation of Sensititre™ susceptibility MIC standard panel using EUCAST breakpoints for *Staphylococcus* species  
*M. Wang* (Skejby, Denmark), E. Scopes, C. Giske, D. Paulmann, S. Petersson, J. Lundmark, J. Screen

Multi-site evaluation of Sensititre™ susceptibility MIC panel using EUCAST breakpoints for enterococci  
*M. Wang* (Skejby, Denmark), E. Scopes, C. Giske, D. Paulmann, S. Petersson, J. Lundmark, J. Screen

Multicentre evaluation of vancomycin MIC results at 18 hours for staphylococci and enterococci using MicroScan dried overnight performance evaluation device panel  
*M. Weinstein, P. Schreckenberger, J. Tjio, C. Polage, R. Humphries, J. Hindler, M. Evans, G. Brookman* (West Sacramento, CA, United States), J. Chau, D. Carpenter

Multicentre evaluation of clindamycin MIC results for staphylococci using MicroScan dried Gram-positive MIC panels  
*P. Schreckenberger, J. Tjio, R. Humphries, J. Hindler, C. Polage, M. Weinstein, M. Evans, G. Brookman, A. Chipman, J. Chau, D. Carpenter* (West Sacramento, CA, United States)

Problems in antimicrobial susceptibility testing

Confirmation of colistin resistance in *Klebsiella pneumoniae* as detected by VITEK 2 with gradient strip tests and broth microdilution method  
*D. Karatuna* (İstanbul, Turkey), M. Kaya, D. Kaya, I. Akyar

Evaluation of the Phoenix automated microbiology system to detect polymyxin-resistant strains of enterobacteria: failure to detect heteroresistant *Enterobacter cloacae* isolates  
*A. Jayot* (Fribourg, Switzerland), L. Poiré, V. Dubois, P. Nordmann
Colistin stability and MIC testing in agar dilution in comparison to E-test, micro- and macrobroth
A. Turlej-Rogacka* [Wilrijk, Belgium], X. Basil Britto, L. Janssens, C. Lammens, O. Zarkotou, Y. Glupczynski, H. Goossens, S. Malhotra-Kumar

Assessing the reliability of gradient diffusion assays to determine meropenem MIC value in oxa-48 producing Klebsiella pneumoniae
P. Pescador-Martín, M. Gámez-Gil, G. Ruiz-Carrascosa, M. Romero-Gómez, J. Garcia Rodriguez, J. Pano-Pardo* [Zaragoza, Spain]

Role of mutant frequency on fosfomycin MIC discrepancies by agar dilution and microdilution method
M. Ballestero Téllez* [Seville, Spain], F. Docobo Perez, J. Rodriguez Martinez, M. Conejo, M. Ramos-Gueifa, J. Blazquez, J. Rodríguez-Bañó, A. Pascual Hernandez

Detection of carbapenem-resistant Enterobacteriaceae [CRE] by automated real-time PCR versus carbaNP test
S. Boonsong* [Bangkok, Thailand], W. Laolerd, P. Santanirand

Molecular detection of antimicrobial susceptibility: changing paradigm of laboratory testing for multidrug-resistant organisms
L. Malone, M. Stonebraker, P. Dawson, D. Stalons, E. Grigorenko* [Huntsville, United States]

Evaluation of molecular and biochemical methods to detect carbapenemase-producing Acinetobacter baumannii
C. Thoma, M. Bacchi, B. Bedenic, G. Cornaglia, A. Mazzariol* [Verona, Italy]

Evaluation of a rapid diagnostic test for the detection of OXA-48 carbapenemase
E. Rubio* [Barcelona, Spain], Y. Zboromyrska, C. Pitart, I. Alejo-Cancho, I. Campo, A. Fasanella, F. Marco Reverte, J. Vila

Extended-spectrum beta-lactamase (ESBL) detection directly from urine samples with the rapid isothermal amplification-based easyplex® SuperBug CRE assay: proof of concept study
V. Hinic, J. Ziegler, C. Straub, D. Goldenberger* [Basel, Switzerland], R. Frei

Rapid meropenem susceptibility testing using MALDI biotyper antibiotic susceptibility test rapid assay (MBT-ASTRA)
R. Sussie* [Slagelse, Denmark], N. Mikkel B., R. Dargis, B. Reder, J. Christensen

Evaluation of loop-mediated isothermal amplification (LAMP) assay for detection of carbapenem-resistant Enterobacteriaceae in cultures
P. Rydström* [Växjö, Sweden], H. Janson

Molecular screening for ESBL and carbapenemase during a prevalence study in two Dutch hospitals
I. Op Den Buijs* [Veldhoven, Netherlands], R. Roymans, M. Nijs, L. van Dommelen, I. Overdevest, J. van de Bovenkamp

Rapid susceptibility testing and resistance detection

Reliability of the Xpert MRSA NxG assay and the BD MAX MRSA XT assay to detect genetically diverse mecA/mecC MRSA and mecA drop-out MSSA isolates from Europe

Clinical and economical impact of a rapid susceptibility testing regarding blood cultures with Gram negative bacilli

Rapid detection of vancomycin-resistant enterococci by laser monitoring of microbial growth
E. Idelevich* [Münster, Germany], M. Hoy, M. Barowski, D. Görlich, D. Knaack, B. Grünstel, G. Peters, K. Becker

Evaluation of BD MAX®StaphSR assay for rapid identification of Staphylococcus aureus and methicillin-resistance among S. aureus and coagulase-negative staphylococci in positive blood culture broth
J. Lee, H. Lee, Y. Park* [Seoul, South Korea]

Rapid detection of vancomycin-resistant enterococci (VRE) carriers in a tertiary Greek hospital
S. Sarrou* [Larissa, Greece], Z. Florou, E. Mili, E. Petinaki

Tentative breakpoints for early reading of disk diffusion tests for Escherichia coli, Klebsiella pneumoniae, Staphylococcus aureus and Streptococcus pneumoniae
E. Jonasson* [Växjö, Sweden], E. Matuschek, M. Sundqvist, G. Kahlmeter

Shortening of the incubation time for AST by disk diffusion for Enterobacteriaceae: how short can it be and are results accurate?
W. van den Bijlkoort* [Tilburg, Netherlands], A. Buiting, J. Mouton, A. Muller
P0852 Rapid antibiotic susceptibility testing of clinical *Escherichia coli* isolates directly in suspension by the means of Raman spectroscopy combined with dielectrophoresis

P0853 Accuracy of *H. pylori* resistance to clarithromycin based on melt-curve and amplification signal difference analysis of 23S rRNA gene
E. Beckman* (Cincinnati, United States), G. Fiorini, I. Saracino, C. Clark, V. Slepnev, D. Patel, C. Gomez, R. Panoka, S. Elagin, B. Vaira

P0854 Clinical antimicrobial susceptibility testing as a routine experience
C. Fontana* (Rome, Italy), M. Favaro, S. Manelli, A. Altieri, M. Bossa, C. Favalli

P0855 Simultaneously rapid detection of mutations in the quinolone resistance determining regions of *gyrA* and *parC* in *Escherichia coli* by multiplex allele specific-polymerase chain reaction
P. Ratthawongjirakul* (Bangkok, Thailand), S. On-Sidang

P0856 Rapid automated antimicrobial susceptibility testing of *Bacillus anthracis* and *Burkholderia pseudomallei* by optical screening
H. McLaughlin* (Atlanta, United States), A. Gargis, P. Michel, D. Sue, L. Weigel

P0857 Rapid and reagent-free identification of antibiotic-resistant nosocomial bacteria by attenuated total reflectance Fourier transform infrared spectroscopy
H. Kim, P. Lebel* (Montreal, Canada), T. Lam, A. Choudhuri, J. Sedman, S. Levesque, C. Gaudreau, A. Ismail

13:30-14:30

Vaccines in public health

P0858 Identifying obstacles to vaccination - a central step towards higher immunization rates?
L. Englert, L. Sanftenberg* (Munich, Germany), H. Schrärs, J. Schelling

P0859 Overcoming barriers in adult vaccination
M. Obed* (La Plata, Argentina), A. Myktiuk, M. Alzagaray, G. Chaparro, M. Garcia, M. Alcorta, A. Palaoro, M. Avila

P0856 Perceptions of HBV infection and hepatitis B vaccine in a French urban free testing centre for sexually transmitted infections
L. Moyroud, S. Hustache, L. Goinard, M. Hauzanneau, O. Epaulard* (Grenoble, France)

P0860 Annual influenza vaccination rates in children with renal disease and the causes for non-vaccination
D. Schueerman* (Petah Tiqva, Israel), I. Levy, M. Davidovits, E. Zilber, G. Chodik

P0861 The effectiveness of influenza vaccination of early age children in orphanage
M. Garas* (Chernivtsi, Ukraine)

P0862 Factors associated with influenza and pneumococcal vaccine uptake among Danish rheumatoid arthritis patients invited to participate in a pneumococcal vaccine trial (Immunovax RA)
M. Nguyen* (Odense, Denmark), H. Lindegaard, O. Hendricks, N. Friis-Møller

P0863 The global status of recommendations, reimbursement policies and impact on the uptake of herpes zoster vaccine
E. Bresnitz* (West Point, PA, United States)

P0864 Rubella susceptibility in pregnant women and focus on postpartum vaccination in the Lodi province, Italy
L. Panceri, A. Belloni, G. Marazza, E. Rossetti, E. Pintaudi, D. Baroni, S. Asticcia, A. Anesi* (Lodi, Italy)

P0865 Assessment of effects on impact and costs of varicella hospitalizations under different regional vaccination policies, in Italy, for the period 2006-2011
A. Di Pietro* (L'Aquila, Italy), M. Sbarbati, A. Mattei

P0866 Health economic evaluation of pneumococcal conjugate vaccines in the kingdom of Saudi Arabia: what does cost effectiveness and budget impact analysis show in light of recent evidence?
K. Meszaros* (Wavre, Belgium), O. Leeuwenkamp, S. Noibi, A. Jalil

P0867 Molecular epidemiology, antigenic profile and macrolide resistance of *Bordetella pertussis* clinical isolates circulating in Barcelona from 2007 to 2014
A. Mir-Cros, M. Martin, M. Codina, T. Pumarola Sole, J. González-López* (Barcelona, Spain)

P0868 Pertussis surveillance and control in the Netherlands: exploring variations and delays in GPs’ diagnoses, laboratories’ testing and public health services notifications
J. Heil* (Geleen, Netherlands), H. ter Waarbeek, C. Hoebe, P. Jacobs, D. van Dam, T. Trienekens, J. Cals, I. van Loo, N. Dukers

13:30-14:30

News in vaccine research

P0869 Immunization with recombinant hepatitis B vaccine in Japanese recipients
A. Ukimura* (Tokatsuki, Japan), Y. Shibata, T. Yamada, F. Goto, Y. Doi, T. Nakano
P0872 Local skin reactions as potential indicators of vaccine-specific memory CD8+ T-cell immune responses to influenza vaccination

P0873 Differential analysis of the administration of Pandemrix monovalent vaccine against A/H1N1pdm09 flu virus in patients with autoimmune diseases against healthy controls
I. Sanz* (Valladolid, Spain), S. Roja, S. Tamames, R. Mónica, R. Ortíz de Lejarazu

P0874 A preliminary study of T cell responses to infectious attenuated Japanese encephalitis vaccine SA14-14-2 in adults

P0875 Plaque formation by Newcastle virus strain V4 on cell culture and characterization with RT-PCR
J. Mehrabanpour* (Shiraz, Iran), S. Sabhani, D. Mehrabanpour

P0876 Seroprotection against influenza A/09/H1N1 in allogeneic stem cell recipients after two doses of inactivated non-adjuvanted trivalent vaccine over a follow-up of 180 days

P0877 Randomized, double-blind, multi-centre, phase III clinical trial to evaluate the immunogenicity and safety of MG1109 (egg-based pre-pandemic influenza A/H5N1 vaccine) in healthy adults

P0878 Pulmonary CD103+ and CD11b-high dendritic cells prime T helper-1 (Th1) and T helper-2 (Th2) responses to influenza virus-like particles (VLP)
H. Namdari* (Shiraz, Iran), F. Rezaei

P0879 Genotyping of G/P no typable group A rotavirus strains revealed G2 and G9 genotype circulations in Moroccan children fully vaccinated with Rotarix®
H. Boulahyaoui, S. Alouai Amine, C. Loutfi, E. El Mostapha, N. Touli* (Rabat, Morocco), M. Saad

P0883 Evaluation of the protective potential of immunodominant B-cell epitopes within virulent surface proteins of S. pneumoniae in an experimental model of invasive pneumococcal disease
T. Papastamatiou* (Athens, Greece), J. Routsi, M. Movrouli, O. Koutsoni, E. Dotsika, V. Spoulou, A. Tsakris

P0884 Molecular characteristics of Streptococcus agalactiae deficient in alpha-like protein encoding genes
J. Afset* (Trondheim, Norway), R. Lyng, C. Gabrielsen, A. Radtke, J. Meland

P0885 Protective efficacy of a D-glutamate auxotrophic live vaccine against Pseudomonas aeruginosa acute lethal infection
M. Cabral* (La Coruña, Spain), P. García, A. Beceiro, C. Rumbo, A. Pérez, M. Moscoso, G. Bou Arevalo

P0886 The use of antipseudomonal vaccine in the prevention of nosocomial infection in burn patients and its impact on antibiotic consumption
V. Bagin* (Yekaterinburg, Russian Federation), V. Rudnov, A. Savitskiy, M. Astafyeva, I. Korobko, V. Vein

P0887 In silico studies, construction and expression of novel fusion protein MrpH.FimH.FliC against urinary tract infections

P0888 Bioinformatics analysis of the structure and epitopes of Echinococcus spp. antigens for identification of vaccine candidates
A. Caner* (Izmir, Turkey), Y. Guruz
Monday, 11 April 2016

12:30-13:30

**Pneumococcus and pneumococcal diseases in the conjugate vaccine era**

**P0889** Invasive pneumococcal disease (IPD) in splenectomized patients shortly after introduction of conjugated pneumococcal vaccines (PCVs) - a nation-wide study


**P0890** Safety and immunogenicity of 13-valent pneumococcal conjugate vaccine in adults 50 to 65 years of age in India: an open-label trial


**P0891** Pneumococcal carriage and serotype distribution in patients with acute otitis media in Switzerland, 2004-2014

A. Allemann* (Bern, Switzerland), M. Hilty, M. Küffer

**P0892** Change in aetiology of acute otitis media - impact of universal pneumococcal vaccination

G. Rodríguez Seville, M. García Coca, J. Esteban* (Madrid, Spain), I. Gadea Gironés

**P0893** Impact of pneumococcal conjugate vaccines on paediatric invasive pneumococcal disease in Cantabria, Spain (2001-2015)

I. Angulo López* (Santander, Spain), E. González Escartín, M. Fernández Torres, C. Fernández Mazzarra, J. Calvo Montes, L. Martinez-Martinez, M. Cabero Pérez

**P0894** Estimation of serotype distribution of *Streptococcus pneumoniae* causing meningitis in infants in selected countries of the European and Asian regions (2009-2014)

E. Voropaeva, Y. Yegorova, Y. Urban, A. Voropaev* (Moscow, Russian Federation), A. Wasley, D. Videbaek, V. Alyoshkin, A. Oganesian

**P0895** Antibiotic resistance of invasive *Streptococcus pneumoniae* isolates in the vaccine era in Italy

M. Del Grasso* (Rome, Italy), R. Camilli, F. D’Ambrosio, G. Errico, G. Gherardi, P. D’Ancora, A. Pantosti

**P0896** Serotypes and antimicrobial resistance of invasive *Streptococcus pneumoniae* isolates from eastern Algeria (2006-2014)

A. Hannachi-Hecini* (Constantine, Algeria), C. Bentchaala, A. Lezzar, K. Benlabed, S. Farida

**P0897** Invasive pneumococcal disease (IPD) in adults after introduction of pneumococcal conjugate vaccine (PCV13) in children in Spain (2010-2015). The ODIN study

A. Fenoll, E. Cercenado, F. Marco Reverte, A. Fleites, M. Rodríguez Mayo, J. López-Hontangas, B. Palop, A. Aller, B. Buendia, I. Cifuentes, J. Linares* (Barcelona, Spain)

**P0898** Impact of pneumococcal vaccination in children on serotype distribution in adult community-acquired pneumonia

M. Pietz, S. Ewig, G. Rohde, H. Schütte, J. Rupp, T. Welte, N. Suttrop, C. Förstner* (Vienna, Austria)

**P0899** Epidemiology of invasive pneumococcal disease in the Netherlands four years after implementation of 10-valent pneumococcal conjugate vaccination

A. van der Ende* (Amsterdam, Netherlands), A. Arends, I. Schuurman, M. Feller, W. Keijzers, H. de Melker, E. Sanders, M. Knol

12:30-13:30

**New treatments for skin infection**

**P0900** Real-world use of daptomycin across a wide range of geographical regions: a pooled analysis from the CORE and EU-CORE registries

A. Seaton* (Glasgow, United Kingdom), A. Gonzalez-Ruiz, K. Cleveland, K. Couch, R. Pathan, K. Hamed

**P0901** Treatment of acute bacterial skin and skin structure infection (ABSSSI) with single-dose dalbavancin in an outpatient setting

S. Puttagunta, K. Guptha, M. Dunne, U. Rappo* (Jersey City, United States)

**P0902** Ozenoxacin antibacterial activity against worldwide Gram-positive bacteria causing skin and soft tissue infections

M. García-Castillo* (Madrid, Spain), M. Tato, F. García-Alonso, D. Gargallo-Viola, R. Canton Moreno

**P0903** Bactericidal effect of photoresponsive carbon monoxide releasing non-wovens against MRSA biofilms

M. Klinger-Strobel* (Jena, Germany), S. Glaeser, D. Makarewicz, R. Wyrwa, J. Weiss, M. Pietz, A. Schiller

**P0904** Antimicrobial coatings based on copper and zinc alginate nanofilms for bioactive wound dressings

A. Grumezescu* (Bucharest, Romania), E. Andronescu, A. Ficai, V. Grumezescu, F. Iordache, A. Holban, M. Chifiriuc, A. Bolocan
P0905 Novel psychoactive substances (NPS): changing injecting practices and skin infection catastrophes
N. Lane* [Edinburgh, United Kingdom], N. Henderson, S. Joshi, K. Morrison, D. Inverarity

P0906 In vitro release pharmacokinetics of amikacin and teicoplanin compared to polyhexanid and macrogol in a platelet rich fibrin – layer [PRF]
D. Knafl* [Vienna, Austria], M. Vossen, F. Thalhammer

P0907 Pseudomonas aeruginosa in vitro response to novel antibacterial and biological burn wound bandage formulations

12:30-13:30 Microbial colonization and infection of the skin

P0908 Whole-genome sequencing of a Staphylococcus condimenti isolate from a patient with a severe soft tissue infection
C. Gabrielsen* [Trondheim, Norway], N. Kols, J. Afset, K. Bergh

P0909 Impact of oral and nasal colonization on infected eczema in children: results from the CREAM [ChildRen with Eczema, Antibiotic Management] study
M. Wootton* [Cardiff, United Kingdom], J. Richards, L. Davies, C. Butler, K. Hood, R. Howe

P0910 The impact of genotypes and virulence factors on the course of Staphylococcus aureus infections: a cohort study from the Democratic Republic of Congo, 2013-2015

P0911 The impact of antibiotic therapy towards resistant community-acquired microorganisms identified in lower extremities open fractures-associated infections in a middle-income country
I. de Paula, G. Klaoutau, J. Gomes, P. Tonio, J. Melardi, M. Mercadante, R. Christian, I. Chakhour, M. Salles* [Sao Paulo, Brazil]

12:30-13:30 Focus Helicobacter pylori

P0914 Surveillance of Helicobacter pylori resistance to antibiotics in France in 2014
F. Megraud, A. Ducournau* [Bordeaux, France], L. Benejat, E. Sifré, E. Bessede, P. Lehours

P0915 Helicobacter pylori rifamycin resistance in France: should we change the cut-off?
C. Hays, A. Leleu, T. Cong Tri, T. Delerue, P. Lehours, H. De Reuse, C. Peyrat, C. Burucoa* [Poitiers, France], J. Raymond

P0917 The dupA genes in Helicobacter pylori strains and their relationship with gastroduodenal diseases in north-west Croatia
D. Varda-Brikic* [Zagreb, Croatia], A. Presecki-Stanko, L. Zele-Starcevic, V. Tripkovic, I. Marekovic, S. Franculova-Zanovnic, B. Bedenic

P0918 Where to perform biopsy to detect Helicobacter pylori and how many biopsies to detect antibiotic resistance in a human stomach? Gastric mapping of Helicobacter pylori infection

P0919 In vitro gastrointestinal model to study the effect of encapsulated Lactobacillus sp., Bifidobacterium sp. strains against Helicobacter pylori
S. Agudo Pena* [Poznan, Poland], K. Goderska, J. Nowak, T. Alarcon Cavero

P0920 Incidence of infection of gastric mucosa with different strains of Helicobacter pylori in children and adolescents - preliminary study
G. Go ciniak, M. Biernat* [Wroclaw, Poland], A. Bi kowska, B. Iwo czak

P0921 Growth of Helicobacter pylori in an in vitro gastrointestinal model
S. Agudo Pena* [Poznan, Poland], K. Goderska, J. Nowak, T. Alarcon Cavero

P0922 The significance of Helicobacter pylori genotype profiles in the development of pre-neoplastic gastric lesions in children
A. Šterbenc* [Ljubljana, Slovenia], M. Homan, B. Kocjan, N. Zidar, M. Poljak
12:30-13:30 Use of non-culture diagnostics for genital and urinary infection

**P0923** Prevalence of pharyngeal *Neisseria gonorrhoeae* and *Chlamydia trachomatis* infection among men who have sex with men (MSM) in Slovenia as determined with NAAT and culture-based methods

**P0924** Cross reactivity – a serious challenge in sero diagnosis of chlamydial infection
M. Baier* [Jena, Germany], B. Löffler, J. Roedel, E. Straube

**P0925** Study of diagnostic accuracy and practicability of Illumigene® *Chlamydia* and gonorrhoea DNA amplification assays
N. Istaces* [Charleroi, Belgium], B. Marchetti, M. Marechal, D. Govaerts, S. Lali

**P0926** Multiplex real-time PCR assay targeting macrolide resistance mutations in *Mycoplasma genitalium*
O. Thellin* [Liege, Belgium], B. El Moualij, W. Zorzi, P. Quatresooz, J. Jensen, R. Close, M. Le Guern Fellous

**P0927** Development of a women’s health panel on the Luminex® NxTAG® platform
D. Irwin* [Toronto, Canada], S. Gonsalves, L. Mazur, D. Mihalov, B. Baitadjeva, H. Zhang

**P0928** An evaluation study using the AnyplexTM STI-7 assay for the simultaneous detection of sexually transmitted pathogens
M. Karrasch* [Jena, Germany], B. Haschke, B. Löffler, M. Baier

**P0929** Evaluation of a new microspot array for detection of IgG and IgM antibodies to *Treponema pallidum* in human serum samples
K. Kropf, K. Drescher, E. Hoechel, D. Loester, S. Porstmann, P. Porstmann, I. Stier* [Darmstadt, Germany]

**P0930** Multiplex assay for simultaneous detection of *Mycoplasma genitalium* and macrolide resistance using PlexPCR
S. Tabrizi* [Parkville, Australia], L. Tan, S. Walker, M. Poljak, J. Twin, C. Bradshaw, C. Fairley, E. Makany, S. Garland

**P0931** Identification of bacterial species directly from positive urine samples using single-cell MALDI-TOF
H. Dekter* [Leiden, Netherlands], R. Parchen, F. Kayuncu, A. van der Zee, W. Leeuwen

**P0932** Vitek MS® [bioMérieux] multiple IVD database reliability and strain discrimination potential for *Aerococcus urinae*
S. Grandjean Lapierre* [Montréal, Canada], J. Leduc, S. Dufresne, M. Domingo

12:30-13:30 Diagnosing gastrointestinal tract infection

**P0933** What are we missing? Should the UK stop focusing on the detection of four key gastrointestinal pathogens?
S. Gale* [Birmingham, United Kingdom], D. Hutley, S. Ming, M. Cummins, M. Wilks, D. Ready, R. Manuel

**P0934** Evaluation of a real-time PCR assay for the detection of enteraggregative E. coli directly in stool specimens
U. Eigner* [Heidelberg, Germany], A. Veldenzer, R. Schwarz, M. Hoffelder

**P0935** Prevalence of cagA- and babA2-positive *Helicobacter pylori* strains in patients with chronic gastritis and gastric adenocarcinoma
A. Bahadori* [Adana, Turkey], M. Esmaeillu, T. Guven, M. Agin, M. Marzi, F. Köksal

**P0936** Molecular tools for early detection and control of spread of multidrug resistant organisms in the healthcare setting
I. Bosczkowski* [Sao Paulo, Brazil], M. Freire, T. Guimaraes, P. Dantas da Silva Rebelo, L. Maria Brasileira Gomes, I. Crsitina Vilela Soares Oshiro, A. Natile da Silva Barros, D. Rodrigues Boberg, M. Oliveira de Carvalho, L. Felipe Valter de Oliveira, A. Sara Levin

**P0937** Toxigenicity of *Clostridium difficile* strains isolated from GDH-positive faecal samples and epidemiological relevance for the management of CDI patients
P. Roberts, C. Nakamura, T. Neal, M. Beadsworth, M. Pirmohamed, F. Miyajima* [Liverpool, United Kingdom]

**P0938** Rapid detection of colonization of multiple nosocomial infections utilizing the NATEXpert®, a novel molecular microarray system
Z. Greenberg* [Ashdod, Israel], V. Hurgin, J. Leitman, D. Hodko

**P0939** Prospective, multicentre study comparing loop-mediated isothermal amplification [LAMP] of *tcdB* with standard diagnostic assays for *Clostridium difficile* infection
O. Benedek, E. Klupp, T. Kramer, A. Podbielski, H. Rohde, M. Herrmann, L. von Müller* [Coesfeld, Germany]

**P0940** Comparison of the CERTEST *Clostridium difficile* GDH+Toxin A+B test with the C. DIFF QUIK CHEK COMPLETE® assay
J. Boone, J. Boone* [Blacksburg, United States], J. Stevens, M. Goodykoontz

**P0941** Evaluation of a multiplex PCR assay for simultaneous detection of bacterial enteropathogens in stool samples of paediatric patients
C. Laurent* [Toulouse, France], E. Gouteau, D. Dubois, E. Oswald, M. Prere
P0942 Clostridium difficile diagnostics in asymptomatic carriers admitted to hospital
L. Terveer* (Leiden, Netherlands), I. Sanders, M. Crobach, M. Vas, K. Verduin, E. Kuipper

P0943 Development of an immuno real-time PCR assay for the quantitative determination of Clostridium botulinum toxin by using poultry immunoglobulins (IgY)
A. Abdelkareem, M. Kuskucu, K. Midilli* [Istanbul, Turkey]

12:30-13:30
Recent studies of non-culture techniques for detection of resistance
P0944 Evaluation of the novel Xpert® Carba-R v2 assay for the detection of carbapenemase-producing Enterobacteriaceae
L. Dortet, M. Fusaro, N. Fortineau, T. Naas* [Le Kremlin-Bicêtre, France]

P0945 Development of an immunochromatographic test for identification of OXA-48-like and OXA-163 subfamily of carbapenemase in Enterobacteriaceae
L. Denorme, I. Ote, P. Bogaerts, S. Evrard, Y. Glupczynski, T. Leclipteux, P. Mertens* [Gembloux, Belgium]

P0946 The Coris BioConcept OXA48 K-SeT lateral-flow line assay detects OXA48-type carbapenemases with high sensitivity and specificity

P0947 Carbatem-resistant in B. fragilis: a MALDI affair
M. Cordovana* [Bologna, Italy], M. Kostrzewa, G. Roncarati, S. Ambretti, M. Landini

P0948 Evaluation of GeneXpert® CARBA-R system on pooled surveillance rectal swabs
A. Bielli* [Milan, Italy], M. Oggioni, C. Lacchini, G. Lombardi, C. Vismara, G. Gesu

P0949 Use of the Rapidec Carba NP® test [BioMérieux] for the detection of carbapenemase-producing Gram-negatives directly from positive blood cultures
S. Vourli* [Athens, Greece], E. Kalogeropoulou, A. Spiliopoulou, L. Zerva

P0950 Rapid carbapenemase- and ESBL-producing strain detection from positive blood culture by using CarbaNP and ESBL-NDP tests
E. Pilotta, L. Maccaroni, M. Pegoraro, G. Cornaglia, A. Mazzariol* [Verona, Italy]

P0951 Rapid protocol for routine detection of KPC-producing strains by using the Maldi-TOF Vitek-MS system
E. Pilotta, A. Centonze, M. Bragantini, G. Cornaglia, A. Mazzariol* [Verona, Italy]

P0952 Evaluation of OXA-48 K-SeT immunochromatographic assay for the detection of OXA-48-like carbapenemases in suspected Enterobacteriaceae
L. Dortet, A. Jousset, V. Sainte-Rose, G. Cuzon, T. Naas* [Le Kremlin-Bicêtre, France]

P0953 Evaluation of check-direct ESBL real-time PCR kit for the detection of ESBL-producing Enterobacteriaceae from faecal sample
M. Kabir* [Stockholm, Sweden], A. Karczmarek, C. Giske

P0954 MALDI-TOF-based imipenem hydrolysis assay applied to Acinetobacter baumannii derived from positive blood cultures
M. Oviña García* [La Coruña, Spain], K. Sparbier, M. Barba Miramontes, M. Kostrzewa, G. Bou Aarevalo

P0955 Evaluating the Sepsis Flow Chip kit for detecting multidrug-resistant bacteria
A. Galiana, J. Carrero, A. Olmo* [Granada, Spain], S. Azrak, J. Rodríguez

12:30-13:30
Lab automation
P0956 WASPTM and WASPLabTM fully automated disk diffusion antimicrobial susceptibility testing [AST]: from streaking to interpretation
L. Navaria* [Brescia, Italy], A. Giamba, S. Diani, R. Botrugno, S. Castriciano

P0957 Accelerated time to diagnosis by automated processing of positive blood cultures on COPAN WASPLab
M. Jetter, M. Marchesi, P. Keller, M. Hombach* [Zurich, Switzerland]

P0958 Laboratory evaluation of the BacT/ALERT® VIRTUO® automated blood culture system
F. Liatti, G. Menchinelli, G. De Angelis* [Rome, Italy], B. Fiori, T. D’Inzea, F. De Maio, M. Ventriglia, M. Sanguinetti, T. Spanu

P0959 Walk away automated disk diffusion susceptibility testing by Copan WASPLAB
J. van der Linden, A. Jansz, T. Liebregts, J. Stalpers, N. Arents, L. van der Velden* [Veldhoven, Netherlands]

P0960 Evaluation of the BacT/ALERT® Virtuo and the BacT/ALERT® 3D automated microbial detection systems
Y. Cheong, K. Chew* [Singapore, Singapore], R. Jureen

P0961 Automatic digital analysis of chromogenic media for MRSA using the WASPLab chromogenic detection module
A. Bielli* [Milan, Italy], C. Lacchini, M. Oggioni, C. Vismara, G. Gesu
P0962 Integration of the WASP automated inoculation instrument in the era of ISO 15189 accreditation in clinical bacteriology
V. Fihman* [Créteil, France], M. Desraches, S. Bleunven, B. Nebbad-Lechani, J. Le Glaunec, F. Maillebuau, I. De Rochebouet, J. Decousser

P0963 Evaluation of the Plus Finder++ Analyzer for the rapid detection of bacteria in human sterile fluid samples
A. Cellini, M. Meloni, M. Pedna, V. Sambri* [Pievevesina di Cesena, Italy]

P0964 Automated digital quantitation of urine cultures using the WASPLab
M. Faron, B. Buchan, N. Ledeboer* [Vienna, Austria]

P0965 Staining of acid-fast bacteria using the new RAL-stainer automate
S. Nys* [Hasselt, Belgium], K. Magerman, L. Waumans, R. Cartuyvels

P0967 Bacterial colonization of the lungs of cystic fibrosis patients: early culture-based detection of small colony variants, morphotype recognition by digital imaging and direct bacterial identification by hyperspectral imaging
G. Durand, C. Fulchiron* [La Baume les Grottes, France], D. Archeny, J. Gorse, D. Leroux, A. van Belkum

12:30-13:30
Non-culture diagnostics for Gram-positives

P0968 Mass spectrometry proteotyping of Streptococcus pneumoniae and commensal Streptococcus: identification of biomarkers for infectious strain characterization

P0969 Detection of group B streptococci (GBS) directly and after LIM broth enrichment from E-Swab specimens by loop-mediated isothermal amplification (LAMP) as compared to culture
P. Jayaratne* [Hamilton, Canada], Y. Emond, K. Gregory-Miller, D. Harris

P0970 Development of PCRSqTyping – a novel molecular assay for concurrent detection and typing of S. pneumoniae
S. Geetha* [Bangalore, India], R. Kadahalli Linge Gowda, F. Ganaie, V. Govindan

P0971 Evaluation of different MALDI-TOF mass spectrometry platforms for differentiation within the Streptococcus mitis group
J. van Prehn* [Amsterdam, Netherlands], S. van Veen, J. Schelfaut, E. Wessels

P0972 Usefulness of MALDI-Biotyper® to identify Streptococcus bovis/equinus complex isolates causing bacteraemia
D. Berbel, D. Rodriguez, A. Carrera, J. Câmara, F. Tubau, M. Dominguez Luzon, C. Ardanuy Tisoire* [Barcelona, Spain]

P0973 Simplified detection of vancomycin-resistant enterococci (VRE) with the fully automated BD MAX system
A. Dalpe, M. Hofko, S. Zimmermann* [Heidelberg, Germany]

P0974 Impact of the Cepheid Xpert® vanA/vanB on the management of patients at risk of carrying glycopeptide-resistant enterococci
F. Jaureguy* [Bobigny, France], T. Billard-Pomares, D. Seytre, V. Walewski, A. Cainte, A. Jacolot, B. Picard, E. Carbonnelle

P0975 Impact of swab model on Xpert® vanA/vanB PCR assay performances
S. Rasoanandrasana, L. Raskine, J. Decousser, C. Domrane, V. Fihman, H. Jacquier* [Paris, France], E. Cambau

P0976 Accuracy of multiplex PCR for MRSA and MSSA depends on selected gold standard tests
M. Malecki* [Cologne, Germany], S. Messler, E. Stoelben, F. Mattner

P0977 Comparison of nasal versus combined nasal/throat sampling sites applying the Cepheid Xpert® MRSA Gen 3 system
D. Knaack* [Münster, Germany], J. Lemke, G. Peters, E. Idelevich, K. Becker

P0978 Evaluation of three different detection strategies for methicillin resistant Staphylococcus aureus (MRSA) in clinical samples
P. Målling* [Örebro, Sweden], M. Neander, B. Söderquist, M. Sundqvist

P0979 Examination of the analytical sensitivity of a novel rapid, point-of-care (POC) urinary antigen diagnostic test for Streptococcus pneumoniae utilizing a fluorescence detection methodology
C. Kerber, R. Coulin, J. Langit, D. Kroll, J. Tamerius* [San Diego, United States]

P0980 The role of a rapid diagnostic test to diagnose group A streptococcal pharyngitis in a paediatric emergency department: a diagnostic accuracy study
C. Bird, G. Winzer* [Birmingham, United Kingdom], K. Lemon, J. Gray, T. Newton
12:30-13:30

More microbiology and infectious diseases

E. Björnsdóttir* (Reykjavík, Iceland), E. Martins, H. Erlendsdóttir, M. Ramirez, G. Haraldsson, J. Mello-Cristino, K. Kristinsson

P0982 Epidemiology of prepubertal vulvovaginitis in young Greek girls over the last 8 years
G. Kavarnou, G. Chronopoulou* (Athens, Greece), E. Katzilierakis, H. Chatzoudi, K. Arafioti

P0983 Worldwide distribution of Nocardia rhamnosiphila: human cases reported in North America and northern Spain
D. Marimón Ortiz de Zárate, M. Ercibengoa Arana* (Donostia, Spain), M. Bell, P. Pérez Trallero

P0984 Infections caused by Sphingomonas paucimobilis: Clinical features and microbiological characteristics
S. Malik* (Abha, Saudi Arabia), M. Mahfouz

P0985 Turicella otitidis: colonizer or pathogenic agent?
F. Reibel, C. Emeraud, M. Deray, D. Sterkers, V. Jarlier, F. Brossier* (Paris, France)

P0986 Eikenella corrodens causing deep-seated infections - six-year experience in a Spanish university hospital
L. Rodriguez Rojas*, M. Bell, P. Pérez Trallero

P0987 Outbreak of scarlet fever-like disease due to Arcanobacterium haemolyticum in a rural elementary school: the importance of awareness of the bacteria in throat cultures
Y. Keness* (Afula, Israel), O. Admoni, L. Valinsky, J. Jaffe, D. Miron, O. Vinitsky

P0988 Susceptibility of ESBL-producing Escherichia coli to commercial bacteriophage cocktails originating in Georgia
A. Gundaoglu* (Kayseri, Turkey), H. Kiliç, D. Balıkvadze

P0989 Avian pathogenic Escherichia coli (APEC) vaccine strain inhibition by phase
I. Mutuku, A. Moodley, P. Butaye* [Basseterre, Saint Kitts and Nevis]

P0990 Growth-kill dynamics between newly isolated phages and carbapenemase-producing Pseudomonas aeruginosa strains
S. Latz* (Aachen, Germany), K. Ritter, H. Horz

P0991 Antimicrobial activity of essential oils harvested from Bogota, Colombia, against six pathogenic multiresistant bacterial strains
F. Arroyave* (Chía-Cundinamarca, Colombia), R. Prieto Correa

P0992 In vitro activity of penicillin, ceftriaxone, gentamicin and dapomycin alone and in combination against Aerococcus urinae
C. Hirzel* [Bern, Switzerland], L. Hirzberger, J. Marschall, H. Furrer, E. Endimiani

P0994 E-competency in the clinical microbiology laboratory
M. Ling, F. Tahar* [Singapore, Singapore], S. Goh, P. Tan, L. Ong, L. Tan, A. Tan

P0995 Immunomodulatory effects of probiotics, especially Bifidobacterium and Lactobacillus strains, in a rat model
M. Karamese* [Kars, Turkey], H. Aydin, E. Sengul, V. Gelen, C. Sevim, D. Ustek, E. Karakus

P0996 Comparative sequence analysis of avian pathogenic Escherichia coli phages
I. Mutuku, A. Moodley, P. Butaye* [Basseterre, Saint Kitts and Nevis]

P0997 Modulation of ompW gene expression by the OmpR regulator protein of Yersinia enterocolitica 0:9
M. Nieckarz* [Warsaw, Poland], A. Raczkowska, J. Frindt, K. Wieliczko, K. Brzostek

P0998 Multilocus sequence typing of two strains of Burkholderia pseudomallei from melioidosis patients in the Philippines
A. Masbang* [Quezon City, Philippines], C. Tayco, M. Norris, A. Tuanyok, C. Yu

12:30-13:30

Microbiota

P1000 The rise and fall of resistance determinants in the gut microbiome during antibiotic treatment as detected by shotgun metagenomics
B. Young* [Singapore, Singapore], K. Chng, A. Ng, T. Barkham, C. Lui, K. Yang, N. Nagarajan

P1001 Intestinal microbiota composition in patients with multiple sclerosis
E. Tarasova* [St. Petersburg, Russian Federation], I. Abdurasulova, A. Matsulevich, D. Skulgabin, G. Bisaga, E. Ermolenko, A. Suvarov, V. Kilmenko

P1002 Sputum microbiome of legionellosis-associated patients vs. other pneumonia patients
A. Peretz* [Teberias, Israel], H. Mizrahi, Y. Aizenberg-Gershtein, S. Martinez, Y. Sharaby, R. Lesnik, N. Pastukh, I. Brettor, M. Höfle, M. Kolpern
P1004 The contribution of bronchoalveolar lavage (BAL) in the differential diagnosis of pulmonary infections
D. Esendagli* [Ankara, Turkey], E. Karkmaz, F. Ibrahimov, A. Sandal, E. Yazici, O. Karcigli, D. Koksal, S. Emri

P1005 Comparative distribution of the rectal microbiome in a paediatric population colonized or not with Helicobacter pylori
L. Llorca, G. Pérez, A. Blanca Suárez* [Madrid, Spain], T. Alarcon Cavero

P1006 Effect of antibiotic therapy on Lactobacillus composition of vaginal microbiota
A. Melkumyan* [Moscow, Russian Federation], T. Priputnevich, L. Lyubasovskaya, V. Muravieva, A. Ankirskaya, G. Sukhikh

P1007 Neonatal microbiota can be classified into two distinct settler types with different development over time
A. Budding* [Amsterdam, Netherlands], N. Rutten, A. Eck, G. Rijkers, P. Savelkoul, A. Vlieger

P1008 Faecal microbiota transfer: a novel approach to treat a dysbiotic microbiome in functional gastrointestinal disorders
C. Thoeringer, N. Wantia* [Munich, Germany], R. Cruz Aguilar, D. Busch, T. Buch, M. Gerhard

P1009 The quantitative analysis of intestinal microbiota by fluorescent real-time PCR as an alternative to bacteriological assays
V. Lioudyno* [St. Petersburg, Russian Federation], D. Stepanova, M. Suvorova

P1010 Faecal microbiota transplant using a pool of frozen stool from non-related donors vs. vancomycin for first-line treatment of hospitalized patients with Clostridium difficile infection

P1011 Development of a national donor faeces bank for faecal microbiota transplantation in the Netherlands

12:30-13:30
Culture-based diagnostic bacteriology

P1012 A 5-year evaluation of compliance with NHSGGC Primary Care Guidelines for the investigation of vaginal discharge in women of reproductive age
L. Cottom* [Glasgow, United Kingdom], P. Wright

P1013 Solid phase microbead array for the multiplex 0 serotyping of E. coli

P1015 Multicentre evaluation supports accuracy of the Beckman Coulter Gram-negative identification panel with improved database for clinically significant bacteria
J. Hindler, P. Schreckenberger, C. Beck, D. Nothaf, J. Babolish, D. Carpenter* [West Sacramento, CA, United States], L. Mann, O. Madriaga, T. Wong, L. Smoot

P1016 Flow cytometry technique for rapid identification of negative urine cultures in microbiology laboratory
S. Satilmis* [Istanbul, Turkey], S. Özsoy, Z. İli, E. Eren, G. Soyletir

P1017 A universal screening culture medium for polymyxin-resistant Gram-negative bacteria
P. Nordmann, A. Jayol, L. Poirel* [Fribourg, Switzerland]

P1018 Evaluation of different media for introduction of a CPE-screening programme at a UK hospital
F. Davies, H. Donaldson, P. Shibuya* [London, United Kingdom], J. Dronovalli, N. Bartholomew, M. Rebec, S. Goonsekkera, S. Mookerjee, J. Otter

P1019 Performance of the carbapenemase inhibition method [CIM] to accurately identify carbapenemase-producing organisms [CPO] and the impact of decreasing carbapenem inactivation times [CIT]
B. Willey* [Toronto, Canada], S. Rajadurai, D. Grohn, R. Laboni, X. Trimi, G. Ricci, P. La, T. Mazzulli, S. Poutanen

P1020 Comparison of original SLSolution [SLS1] to the new SLSolution [SLS2] to pre-treat mucus specimens for WASP automation processing for the detection of bacteria
L. Canter* [Brescia, Italy], B. Massetti, R. Paroni, S. Castriciano

P1021 Evaluation of a novel and rapid diagnostic test for the detection and differentiation of ESBL- and carbapenemase-producing Enterobacteriaceae
J. Tyrell* [Cardiff, United Kingdom]

P1022 Impact of the isolation medium for the detection of OXA-48 and KPC-producing Gram-negative bacteria by immunochromatographic assays
P. Bogaerts* [Yvoir, Belgium], S. Evrard, Y. Glupczynski

P1023 Direct entry of blood culture vials at the emergency department leads to earlier results
M. Bruins* [Zwolle, Netherlands], M. Wolfhagen
<table>
<thead>
<tr>
<th>ID No.</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>P1024</td>
<td>Comparison of the novel blood culture system DL-Bt112TM with BacT/Alert 3DTM</td>
<td>M. Altindis* (Sakarya, Turkey), T. Demiray, M. Koroglu, U. Kilic, A. Ogutlu, N. Aybala Alagöz, O. Karabay</td>
</tr>
<tr>
<td>P1025</td>
<td>Identification and antibiotic susceptibility of positive blood cultures after a 3-hour subculture</td>
<td>J. Fernandez-Suarez* (Oviedo, Spain), A. Perez-Garcia, J. Fernández, R. Fernandez-Santiago, F. Vazquez, S. Roja</td>
</tr>
<tr>
<td>P1026</td>
<td>Evaluation of Versatrek single aerobic blood culture supplemented with antioxidants for aerobic and anaerobic bacteria</td>
<td>G. Dubourg* (Marseille, France), E. Tomei, E. Guilhot, J. Casalta, P. Lévy, K. Saber, D. Raoult</td>
</tr>
<tr>
<td>P1027</td>
<td>Clinical relevance of the study of time to positivity of blood cultures</td>
<td>J. Fernandez-Suarez, A. Perez-Garcia, C. Rodríguez Lucas* (Oviedo, Spain), C. Sabater, R. Fernandez-Santiago, A. Rodríguez-Guardado</td>
</tr>
<tr>
<td>P1028</td>
<td>Coagulase-negative staphylococci in blood culture bottles: contaminant or the real pathogen: hard to decide</td>
<td>Y. Gulseren, G. Turkoğlu, A. Karakoç* (Ankara, Turkey), C. Bulut</td>
</tr>
</tbody>
</table>

**Surveillance and control of nosocomial pathogens and infection**

<table>
<thead>
<tr>
<th>ID No.</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>P1029</td>
<td>Assessing the impact of infection prevention - an incremental cost-benefit analysis</td>
<td>J. Dik* (Groningen, Netherlands), M. Lokate, A. Dinkelacker, R. Hendrix, J. Lo-Ten-Foe, M. Postma, B. Sinha, A. Friedrich</td>
</tr>
<tr>
<td>P1031</td>
<td>Significant steps towards a national healthcare associated infection surveillance in Australia</td>
<td>P. Russo* (Brisbane, Australia), L. Hall</td>
</tr>
<tr>
<td>P1032</td>
<td>Factors associated with transmission of carbapenemase producing Enterobacteriaceae around a known carrier</td>
<td>C. Legeay* (Angers, France), V. Thépat Seegers, D. Hilliquin, Z. Zahar</td>
</tr>
<tr>
<td>P1033</td>
<td>Scope and magnitude of nosocomial Intensive Care Unit infections - a risk analysis</td>
<td>G. Kasmi* (Tirana, Albania), I. Kasmi</td>
</tr>
<tr>
<td>P1034</td>
<td>Dutch-German cross-border epidemiology of multi drug resistance: major differences for MRSA and carbapenem-resistant Gram-negative bacteria</td>
<td>A. Jurke* (Münster, Germany), I. Daniels-Haardt, R. Hendrix, N. al Naiemi, I. Lede, J. Hermann, R. Köck, A. Friedrich</td>
</tr>
<tr>
<td>P1036</td>
<td>Infection incidence after colonization with multidrug resistant Gram-negative organisms</td>
<td>R. Leistner* (Berlin, Germany), P. Gastmeier, L. Denkel</td>
</tr>
<tr>
<td>P1039</td>
<td>Dynamics of lower airways colonization in mechanically ventilated patients during a lengthy Acinetobacter baumannii outbreak</td>
<td>R. Alvarez-Marín* (Seville, Spain), R. Lopez-Rojas, A. Gutiérrez, J. Domínguez-Herrera, F. Concepción-Cuenca, M. Gómez-Gómez, J. Garrocho, J. Pachón-Diaz</td>
</tr>
<tr>
<td>P1041</td>
<td>Epidemiology of methicillin-resistant and sensitive Staphylococcus aureus strains isolated in the cardiosurgical area of a university hospital in Milan, Italy</td>
<td>A. Di Gregorio* (Milan, Italy), B. Gentile, S. Rinaldi, C. Pagani, G. Cagnoni, C. Savi, F. Lista, P. Olivieri, P. Vaneli, C. Anton, M. Gismondo</td>
</tr>
<tr>
<td>P1042</td>
<td>Methicillin-resistant Staphylococcus aureus (MRSA) isolates with reduced sensitivity to chlorhexidine in Kuwaiti hospitals</td>
<td>M. Al-Shemmarri, A. Dashti* (Kuwait City, Kuwait), L. Vali</td>
</tr>
</tbody>
</table>
Both nare and throat samples are necessary when screening for *Staphylococcus aureus* — a cross-sectional study
H. Aamot* (Lorenskog, Norway), S. Jørgensen, P. Eskansipo, A. Blomfeldt

Characterization of *Staphylococcus aureus* isolated from a renal haemodialysis (HD) patient
M. Almogbel* (Ha’il, Saudi Arabia), Ashankyty, F. AlRashid, A. Ali Katpar, A. Hassain, A. Gowhar, G. Menezes, M. Khan

**Outbreaks**

Outbreak of *Mycobacterium abscessus* infection after laparoscopic surgery and control with rapid interventions
R. Ghosh* (Kolkata, India), S. Das, H. Kela

Molecular epidemiology of *Staphylococcus aureus* strains isolated from newborns and healthcare workers during an outbreak in a neonatal intensive care unit: effectiveness of control measures
J. Gagnaire* (Saint-Etienne, France), F. Grattard, C. Haddar, R. Stéphanie, M. Sophie, F. Jaziri, C. Fichtner, I. Rayet, B. Pozzetto, E. Botelho-Nevers, H. Patural, P. Berthelot, P. Verhoeven

An outbreak of skin infections caused by *Staphylococcus aureus* carrying exfoliative toxin “A” in newborns
F. Pimentel De Araujo, M. Tinelli* (Lodi, Italy), M. Monaco, A. Ercoli, A. Anesi, A. Pantosti

Successful control of an outbreak of staphylococcal scalded skin syndrome involving two hospitals and the community

Next-generation sequence (NGS) analysis reveals methicillin-resistance transfer to a methicillin-susceptible *Staphylococcus aureus* (MSSA) strain that subsequently caused a methicillin-resistant *S. aureus* (MRSA) outbreak
V. Weterings* (Nijmegen, Netherlands), T. Bosch, S. Witteveen, F. Landman, L. Schouls, J. Kluytmans

Feeling thirsty? A pseudo-outbreak with fungal contamination of soft drinks in a haematological isolation unit
B. Wiggli, S. Erb, J. Passweg, R. Frei, M. Battegay, A. Widmer* (Basel, Switzerland)
P1060 An outbreak of *Burkholderia cepacia* pseudobacteraemia caused by intrinsically contaminated commercial 0.5% chlorhexidine solution in a neonatal intensive care unit (NICU)
Y. Kwak* (Goyang, South Korea), T. Um, C. Cha, J. Hwang, K. Oh

P1061 Detection of carbapenemase-producing Enterobacteriaceae in the healthcare setting: an environmental insight into the possible CPE reservoirs in an outbreak scenario
E. Ochoa Toasa* (Manchester, United Kingdom), S. Thomas, C. Yates

P1062 Clinical and molecular characteristics of hypervirulent (hypermucoviscous) *Klebsiella pneumoniae* (HvKp) strains in a teaching hospital in Shanghai, China
L. Tian* (Shanghai, China), J. Liu, H. Qu

P1063 Nosocomial transmission of *Listeria monocytogenes*

P1064 Long term nosocomial outbreak of *Pseudomonas fluorescens* bloodstream infection in a coronary care unit
Y. Oka* (Osaka, Japan), T. Nakajima, S. Ogura, Y. Miyazato

P1065 Acquisition of epidemic *Pseudomonas aeruginosa* strains in bronchiectasis patients
C. Keil, S. Manzoor, S. Gossain, K. Hardy* (Birmingham, United Kingdom), J. Whitehouse

P1066 The rise and fall of an epidemic clone of *Pseudomonas aeruginosa* ST395: 17 years of evolution during its spread in a hospital
M. Petitjean* (Besancon, France), B. Valot, X. Bertrand, D. Hocquet

P1067 Investigation of an uncommon *Ralstonia pickettii* bacteraemia outbreak and confirmation of the source of saline contamination
Y. Chan* (Taipei, Taiwan), F. Kuo, Y. Chen, S. Lee, Y. Chen, F. Wang

P1068 Outbreak of *Prototheca wickerhamii* aalgemia and sepsis in a tertiary care chemotherapy oncology unit
I. Khan* (Kolkata, India)

P1069 Outbreak of *Pneumocystis jirovecii* pneumonia among heart transplant recipients: role of prophylaxis?

P1070 Effect of adjunctive of hydrogen peroxide vapour decontamination on MRO detection in a hospital burns unit
T. Gottlieb* [Sydney, Australia], G. McKew, T. Phan, S. Taggart, C. Parker, T. Cai, P. Hoersch, P. Maitz, D. Goltsman, E. Cheong

P1071 Metallic copper and other alloys with different copper content as an antimicrobial surface - pilot study
A. Chmielarczyk* (Krakow, Poland), A. Róa a ska, D. Romaniszyn, M. Bulanda

P1072 Efficacy of disinfectants against polymicrobial biofilms: development of a dental unit laboratory model
D. Costa, M. Girardot, J. Bertaux, J. Verdon, C. Imbert* [Poitiers, France]

P1074 Efficiency of disinfection wipes and sprays against outbreak strains
N. Kenter* (Dordrecht, Netherlands), E. Huijskens, S. de Wit, A. Voss

P1075 Impact on workflow of ATP testing to monitor manual cleaning of gastroscopes

P1076 Evaluation of environmental cleaning in a community hospital
K. Couch* (Maryland, United States)

P1077 Pulsed xenon ultraviolet disinfection efficacy against Ebola virus and anthrax spores in the laboratory setting
M. Stibich* [San Antonio, United States], S. Simmons, C. Dale, J. Holt, J. Stachowiak

P1078 Antimicrobial efficacy of disinfectants in dental unit waterlines – a case study
D. Costa, A. Mercier, K. Gravouil, J. Lesobre, J. Verdon, C. Imbert* [Poitiers, France]

P1079 Development and evaluation process of an enzymatic cleaner for biofilm removal from endoscopes
S. Mauerhofer, U. Rosenberg, K. Maniura, P. Stiefel, Q. Ren* [St. Gallen, Switzerland]

P1080 Impact of exposition of methicillin-resistant *Staphylococcus aureus* (MRSA) to polyhexanide and chlorhexidine in vitro
P1081 General use of octenidine to decrease nosocomial bloodstream infections and multiresistant organisms: a time series analysis of data from 17 intensive care units
P. Gastmeier* (Berlin, Germany), K. Kaempf, M. Behnke, C. Geffers, F. Schwab

P1082 Universal decontamination with chlorhexidine gluconate 4% in intensive care settings: the DUCLIOREXINT study, ad interim analysis
C. Pallotto* (Perugia, Italy), M. Fiorio, V. De Angelis, E. Franciosini, L. Quondam Girolamo, F. Volpi, P. Iorio, F. Baldelli

P1083 Evaluation of a new process for thermolabile gastrointestinal endoscope storage: results of the first hundred microbiological samples
C. Minebois* (Grenoble, France), P. Saviuc, J. Shum, P. Tuvignon, I. Pelloux, M. Brenier-Pinchart, C. Landelle, M. Mallaret

12:30-13:30 Clostridium difficile: epidemiology and risk factors

P1084 Physician knowledge of Clostridium difficile: a Latin American survey
A. Cane, D. Curcio* (Buenos Aires, Argentina), A. Quintana

P1085 Recovery of C. difficile from the hospital environment – results depend on the media
S. Tschudin-Sutter* (Basel, Switzerland), V. Spaniol, H. Gebreselassie, R. Frei, A. Widmer

P1086 Epidemiology of Clostridium difficile infection in Ireland 2014 & 2015
K. Stein* (Dublin, Ireland), C. Harmanus, S. Fitzgerald, F. Roche, S. Hennessy, D. Drudy, L. Kyne, S. McDermott, K. Burns, F. Fitzpatrick, E. Kuiper, L. Fenelon

P1087 Genetic relatedness among clinical Clostridium difficile strains within a specific region in Scotland
N. De Souza* (Dundee, United Kingdom), G. Douce, C. Goswami, U. Ijaz, D. Brown, J. Coia, P. Donnan, C. Wiuff, P. Davey, M. Bennie, J. Lindstrom, C. Marwick

P1088 Update on the molecular epidemiology of Clostridium difficile infections in the Czech Republic, 2015

P1089 Different distribution of Clostridium difficile PCR-ribotypes in acute care and long-term care wards of Czech hospitals
M. Krutova* (Prague, Czech Republic), O. Nyc, J. Matejkova, K. Laskafeldova, D. Vesela, D. Zamazalova, N. Bartonikova, E. Kuiper

P1090 Clostridium difficile epidemiology in a tertiary care hospital
H. Bilgin* (Istanbul, Turkey), E. Sayin, H. Perk Gurun, E. Tukanmez-Tigan, N. Ulger Toprak, V. Karten

P1091 Clinical and microbiological characteristics of Clostridium difficile infection among hospitalized children in the Netherlands: a six-year surveillance S. van Dorp* (Leiden, Netherlands), E. Smajlovi, D. Netermans, S. de Greeff, E. Kuiper

P1092 The epidemiology and risk factors for hospital-acquired Clostridium difficile infection and colonization in a university hospital in Shanghai
B. Zhao, M. Yu, Z. Yang, E. Chen, E. Mao, Y. Chen* (Shanghai, China)

P1093 Evolution of Clostridium difficile infection incidence in a tertiary Spanish hospital

P1095 Different geographic distribution of Clostridium difficile ribotype 027 in Hesse, Germany
M. Arvand* (Berlin, Germany), G. Bettge-Weller, V. Martin, B. Scholl, S. Winter

P1096 Clostridium difficile infection in hepato-cellular carcinoma patients increased risk of inpatient mortality
A. Kurniawan* (Tangerang, Indonesia), N. Lugito

P1097 Clostridium difficile infection (CDI) in solid organ transplantation (SOT)
R. Rodriguez* (Barakaldo, Spain), A. Voldivieso Lopez, O. Carmona Larusso, J. Goikoetxea Agirre, M. Gastaca Mateo, J. Perales Palacios, E. Bereciartua Bastarrica, M. Montejo Baranda

P1099 IBD and CDI: the contrasting views of different clinical professionals across Europe

P1100 Low frequency of asymptomatic carriage of toxicogenic Clostridium difficile in an acute care geriatric hospital: prospective cohort study in Switzerland
M. Costa Pires* (Geneva, Switzerland), V. Prendki, G. Renzi, C. Fankhauser, V. Savouan, B. Huttner, J. Schrenzel, S. Harbarth
P1101 Phenotypic characterization of toxin A negative, *Clostridium difficile* PCR ribotype 017 strains in London, England
M. Cairns* [London, United Kingdom], E. Valiente, B. Wren

P1102 *In vitro* assessment of *Clostridium difficile* PCR ribotype 002: the most prevalent *C. difficile* ribotype in the United Kingdom
S. Baines* [Hatfield, United Kingdom], I. Ameh, J. Freeman, W. Fawley, M. Wilcox

P1103 Nosocomial *Clostridium difficile* infection among patients over 90 years old – for the coming unprecedented ageing society
M. Miyamae* [Tokyo, Japan], S. Tase, T. Yamada, S. Takahashi, S. Asahata-Tago, Y. Hirai

P1104 Point prevalence survey of *Clostridium difficile* and multidrug-resistant bacteria in a Dutch elderly care facility
M. Wong* [Leiden, Netherlands], I. van Aangenendt, M. Coljouw, E. Kuipper

P1105 Prevalence of intestinal colonization by *Clostridium difficile* and ESBL-producing Enterobacteriaceae in rehabilitation clinics in Germany
C. Ruscher* [Berlin, Germany], M. Arvand

P1106 Burden of *Clostridium difficile*-associated disease among residents of long-term care facilities: a US population-based cohort study
H. Yu* [Collegeville, United States], O. Baser, L. Wang

P1107 Epidemiology and outcomes of hospitalization with *Clostridium difficile* infection among Medicare patients discharged to a nursing home: a population-based cohort study
M. Zilberberg* [Goshen, United States], J. Tjia, K. Lapane, W. Jesdale, A. Shorr

P1108 No diarrhoea but positive for toxigenic *Clostridium difficile? Prevalence and risk factors for toxigenic* *Clostridium difficile* carriage in geriatrics
K. Nissle, D. Kapf, J. Becker* [Frankfurt, Germany], A. Rösler

P1109 *Clostridium difficile* infections following systemic antibiotic administration in randomized controlled trials
K. Vardakas, K. Trigkidis, E. Boukouvala, M. Falagas* [Athens, Greece]

P1110 Antibiotic exposure and the risk of hospital-acquired diarrhoea and *Clostridium difficile* infection: a cohort study
V. Schechner* [Tel Aviv, Israel], N. Fallach, T. Braun, Y. Carmeli

P1111 Variable sporulation response of *Clostridium difficile* strains after *in vitro* exposure to antibiotics
S. Garcia-Fernández* [Madrid, Spain], M. Morasini Reilly, M. Cobo, C. Robledo, J. Romero, R. Canton Moreno, R. del Campo

P1112 Resource use associated with hospitalizations for recurrent *Clostridium difficile* infection

P1113 Albumin prevents *Clostridium difficile*-related cytotoxicity through toxin B binding
A. di Masi, S. Turla, S. Di Bella, L. Leboffe, A. Arcovito, G. Nocco, P. Stano, P. Ascenzi, N. Petrosillo* [Rome, Italy]

P1114 Antibodies against *Clostridium difficile* - differences between antibodies against recombinant antigens and neutralizing antibodies against conditioned media from ribotype 014 and 027
S. Roth, M. Jäger, M. Herrmann, J. Boone, L. von Müller* [Coesfeld, Germany]

P1115 Functional heterogeneity of human memory CD4+ T cells specific for *C. difficile* toxins in patients with active disease
L. Cook, M. Wong, M. Levings, T. Steiner* [Vancouver, Canada]

12:30-13:30 Prevention of hospital and healthcare-associated infection

P1116 Contextual factors affecting adoption and implementation of infection prevention practices in European hospitals – a qualitative study of the PROHIBIT experience

P1117 Current status of facilities and personnel for infection prevention and control programmes among the hospitals in the Republic of Korea: Multicentre cross-sectional analysis
Y. Yoon* [Seoul, South Korea], J. Kim, S. Lee, B. Seo, H. Kim, K. Yang, M. Kim, J. Sohn

P1118 The PIRASOA® programme: implementation and first outcomes of an infection control programme based on educational intervention bundle in all hospitals of the public health system of Andalusia, Spain

P1119 Seasonal changes in *Legionella* spp. concentrations in hospital in-building water systems
E. Kruse* [Cologne, Germany], A. Wehner, H. Wisplinghoff
**P1120**  
*Staphylococcus aureus* carriage at admission predicts early-onset pneumonia after burn trauma  
A. Fournier* [Lausanne, Switzerland], P. Voiron, M. Krähenbühl, C. Bonnemain, C. Fournier, E. Dupuis-Lozeron, D. Pantet, J. Pagani, J. Revelly, F. Sadeghipour, P. Eggimann, Y. Oue

**P1121**  
Universal bathing with chlorhexidine has no impact on MRSA in a rehabilitation facility  
B. Ang* [Singapore, Singapore], Z. Wei, A. Chow

**P1122**  
Eradication of carriage of MRSA in the throat — a randomized trial comparing mupirocin nasal ointment and chlorhexidine soap alone or in combination with two oral antibiotics  
A. Lindgren* [Helsingborg, Sweden], A. Nilsson, P. Åkesson, E. Melander

**P1123**  
To screen or not to screen?  
S. Smith* [London, United Kingdom], R. Manuel, M. Cummins

**P1124**  
Improving the quality of oral hygiene care in intensive care unit  
J. Dry* [Clermont-Ferrand, France], E. Rayboud, C. Russell, B. Cosserant, J. Faure, R. Guérin, L. Calvet, D. Guelon, O. Traore

**P1125**  
Multidrug-resistant *Klebsiella pneumoniae* bacteraemia: a threat in patients with neoplasia  
D. Kofteridis* [Heraklion, Greece], A. Andrianaki, M. Plataki, S. Maraki, A. Christidou, A. Valachis, I. Papadakis, M. Zacharioudaki, G. Samonis

**P1126**  
Oral gentamicin for KPC-*Klebsiella pneumoniae* for gut colonization in patients with haematologic malignancies  
S. Fortunato* [Pisa, Italy], C. Tascini, C. Fravre, F. Simonetti, G. Casazza, M. Menconi, A. Stefanelli, D. Taccola, A. Leonildi, P. Lambelet, F. Menichetti

**P1127**  
Screening neonates for *Pseudomonas aeruginosa*; does it help prevent infection in babies at risk?  
E. Darley* [Bristol, United Kingdom], F. Hammond, R. Wach, J. Turton

**P1128**  
Aetiology and frequency of risk factor for late onset neonatal sepsis in a IIIb level NICU  
A. Marín-Lozano, A. Alonso-Ójambarrera, F. Galán-Sánchez, M. Rodríguez-Iglesias* [Cadiz, Spain], S. Lubián-López

**P1129**  
Bactericidal effect of fluoride-TiO2 nanotubular anodic layers on Ti6Al4V loaded with gentamicin and vancomycin  

**P1130**  
Cefazolin dosage recommendations in morbidly obese patients undergoing sleeve gastrectomy based on population pharmacokinetic modelling and simulations  
M. Grégoire* [Lille, France], R. Dumont, L. Ranci, V. Atthar, E. Letessier, R. Cinotti, A. Raquilly, G. Deslandes, P. Jolliet, K. Asehounoue, E. Dailly

**P1131**  
What is the most effective surgical hand antisepsis technique for preventing surgical site infections? A systematic review  
Z. Kubilay* [Geneva, Switzerland], B. Zayed, D. Pittet, J. Salomkin, B. Allegranzi

**P1132**  
Antibiotic surgical prophylaxis impacts the nasal staphylococcal microbiome  
C. McMurray* [Birmingham, United Kingdom], K. Hardy, S. Calus, N. Loman, P. Hawkey

**P1133**  
The role of the operating room’s ventilation system in the prevention of surgical site infections: a systematic review  
P. Bischoff* [Berlin, Germany], Z. Kubilay, B. Allegranzi, P. Gastmeier

**P1134**  
Optimal timing for preoperative antibiotic prophylaxis. A systematic review and meta-analysis  
S. de Jonge* [Amsterdam, Netherlands], S. Gans, A. Jasper, Z. Kubilay, J. Solomkin, P. Dellinger, B. Allegranzi, M. Boermeester

**P1135**  
Does maintenance of normovolaemia influence the incidence of surgical site infections? A systematic review  
S. Gans* [Amsterdam, Netherlands], J. Solomkin, P. Dellinger, B. Allegranzi, M. Boermeester

**P1136**  
TAPIR preliminary results: is 6-week antimicrobial therapy effective for early-onset spinal implant infections?  
M. Fernandez-Gerlinger* [Paris, France], R. Arvieu, J. Mainardi, P. Guigui, B. Bouyer

**P1137**  
Infectious complications after oesophagectomy: treatment, outcome and costs  
M. Bruins* [Zwolle, Netherlands], L. Smit, G. Patijn, G. Ruijs

**P1138**  
*Staphylococcus aureus* pre- and post-operative rapid screening and decolonization strategy (RSDS): a 5-year audit  
G. Richealet* [Caen, France]

**P1139**  
Mediastinitis after cardiac surgery: role of skin disinfection and implantation of antibiotic-releasing sponge  
T. Madej* [Dresden, Germany], T. Wallo, K. Ploe etze, K. Matschke
Gentamicin-collagen sponges for the prevention of surgical-site infections: a meta-analysis of randomized controlled trials
A. Konstantelias, K. Polyzos, M. Falagas* [Athens, Greece]

Nosocomial meningitis in a neurosurgery department during a-13 year period
Z. Özkurt* [Erzurum, Turkey], H. Kadioglu

Epidemiology of surgical site infection following breast reconstructive surgery
I. Wiser, A. Rosental, E. Ziv, T. Friedman, N. Friedman, D. Marchaim* [Beer Yaacov, Israel], L. Heller

To swab or not to swab – obtaining samples during appendectomy for bacteriological testing
A. Jarchow-MacDonald* [Dundee, United Kingdom], J. Mcilhenny, W. Wong, E. MacDonald

Contribution of prior, multiple- and re-operational procedures to the risk of surgical site infections in the Netherlands
J. Verberk* [Bilthoven, Netherlands], A. Meijs, M. Vos, S. Geerlings, S. de Greeff, M. Koek

Infection risk related to leech therapy: practices and knowledge gap of French infectious diseases specialists and plastic surgeons
R. Masson* [Montpellier, France], D. Grau, M. Villiet, F. Bekara, J. Reynes, V. Le Moing, B. Lamy

Development of an automated support system for the detection of surgical site infections at the regional university hospital of Nancy: pilot study
D. Pivot* [Dijon, France], A. Florentin, L. Bresler, C. Rabaud, S. Aho, N. Jay

Is infectious endocarditis different in oncological patients?

A nationwide population-based survey of HACEK bacteraemia in Denmark
L. Lützen* [Herlev, Denmark], T. Danish HACEK Study Group

Characteristics of 132 healthcare-associated infective endocarditis patients
F. Camou, M. Dijos, C. Greib, G. Wirth, P. Poustis, O. Peuchant, L. Barandon, N. Issa, F. Camou* [Bordeaux, France]

Pooled analysis of 1270 published infective endocarditis cases in Turkey
O. Sipahi* [Izmir, Turkey], S. Garakhanova, F. Gul, A. Vahabi

Microbiological, epidemiological and clinical characteristics of 60 cases of infective endocarditis in the last 6 years in a teaching hospital, Rio de Janeiro, Brazil
J. Silva* [Rio de Janeiro, Brazil], J. Delgado Correal, B. da Silva Dias, J. Jazbik, M. Bueno Castiê, A. Assim Cabral, A. Tapia Barbosa, A. Paula Rasa Ignácio, R. Souza Leão, P. Damasco

Characteristics and outcome of patients with S. aureus endocarditis - a retrospective single centre study 2005–2015
P. Starzengruber, E. Presterl, L. Segagni-Lusignani, T. Wrba, M. Diáb-Elschahawi, W. Graninger, E. Presterl* [Vienna, Austria]

Infective endocarditis affecting cardiac implantable electronic devices (IE-CIED) - multicentric prospective cohort study - preliminary results

Ceftaroline fosamil for the treatment of methicillin-resistant Staphylococcus aureus infective endocarditis
E. Zasowski* [Detroit, United States], T. Trinh, K. Claeyes, A. Casapao, N. Sabagha, M. Rybak

Infectious endocarditis in a community hospital: impact of a set rating system with a reference hospital
D. Nunes Lopes* [Barcelona, Spain]

Length of bacteraemia and mortality in S. aureus infective endocarditis
K. Claeyes, D. Levine* [Detroit, United States]

Erysipelothrix rhusiopathiae: an uncommon zoonotic case of bacteraemia with mitral valve endocarditis following confirmed occupational exposure to poultry
P. Nel* [Parow, South Africa], H. Piek
P1159 Diagnostic value of imaging in infective endocarditis: a systematic literature review and a proposal of an updated diagnostic work-up
A. Gomes* [Groningen, Netherlands], A. Glaudemans, D. Taw, J. van Melle, T. Willems, A. Maass, E. Notaur, N. Prakken, R. Borra, P. van Geel, R. Slart, S. van Assen, B. Sinha

P1160 Predictive factors for surgical treatment in infective endocarditis: a multivariate analysis
A. Topan* [Cluj Napoca, Romania], A. Slavcovich, D. Carstina, N. Todor, M. Lupse

13:30-14:30 Epidemiology of brain infections

P1161 Decrease in incidence of bacterial meningitis in Finland 1995-2014
A. Polkowska* [Tampere, Finland], M. Toropainen, J. Ollgren, L. Lytikainen, P. Nuorti

P1162 The PACEM study: causes of paediatric and adult encephalitis and meningitis
U. Khatib* [Amsterdam, Netherlands], D. van de Beek, M. Brouwer

P1163 Hearing loss in experimental pneumococcal meningitis: dose-effect of bacteria on inflammation, inner ear damage and hearing function
M. Perny* [Bern, Switzerland], D. Grandgirard, M. Roccio, P. Senn, S. Leib

P1164 Sex-based differences in patients with community-acquired bacterial meningitis: a prospective nationwide cohort study
S. Dias* [Lisbon, Portugal], M. Brouwer, M. Bijlsma, A. van der Ende, D. van de Beek

P1165 The seroprevalence of Mycoplasma pneumoniae IgG and IgM antibodies in patients with ischaemic stroke
M. Raham* [Tehran, Iran]

P1166 Audit of the management of community acquired Streptococcus pneumoniae meningitis and HIV testing in invasive pneumococcal disease [2014-2015]
I. Hettiarachchi* [Cardiff, United Kingdom]

P1167 Spontaneous bacterial meningitis in cancer patients: characteristics and outcome
V. Pamar* [Barcelona, Spain], M. Benito Hernandez, J. Lopez-Contreras, P. Coll, M. Gurgui, P. Domingo

P1168 Acute meningitis aetiology and clinical manifestations for adults
J. Kucina* [Riga, Latvia], J. Kucina, A. Krumina, B. Rozental

13:30-14:30 Deciphering carbapenem resistance

P1170 Perinatal listeriosis: a prospective series from 82 neonates
C. Charlier* [Paris, France], A. Leclercq, E. Perrodeau, P. Ravaud, M. Lecuit

P1171 Whole-genome sequence of a Sphingobacterium spiritivorum isolated from bacteraemia, a potential progenitor of carbapenemases
R. Bonnin* [Le Kremlin-Bicêtre, France], L. Dartet, D. Girlich, T. Naas

P1172 Characterization of BRPMBL, the bleomycin-resistance protein associated with NDM carbapenemases
L. Dartet* [Le Kremlin-Bicêtre, France], D. Girlich, A. Virlouvet, B. Iorga, T. Naas

P1173 Biochemical characterization of KHM-2, a novel subclass B1 metallo-beta-lactamase
N. Pfennigwerth* [Bochum, Germany], S. Gatermann, M. Koase

P1174 Characterization of class 1 integrons carrying blaVIM-2 and blaVIM-4 gene cassette in Pseudomonas aeruginosa isolated in the University Clinical Hospital of Białystok [northeastern Poland]
P. Sacha* [Białystok, Poland], H. Grze, T. Hauschild, D. Ojdana, P. Wieczorek, E. Tryniszewska

P1175 Transformation of XDR Citrobacter species into a pandrug-resistant strain under antibiotic treatment: a genomic time series investigation
S. Peter* [Tübingen, Germany], D. Bezdan, P. Oberhettinger, W. Vogel, D. Dörfel, M. Marschal, J. Liese, C. Weidenmaier, S. Ossowski, I. Autenrieth, M. Willmann

P1176 Complete nucleotide sequences of three IncA/C2-type plasmids carrying blaVIM-like integrons with blaVIM genes from Enterobacteriaceae isolates of Greek origin
K. Papagiannitsis* [Plzen, Czech Republic], M. Dolejska, R. Izdebski, P. Giakkoupi, A. Skalova, K. Chud javá, H. Dobiasova, V. Vatopoulos, L. Derde, M. Bonten, M. Gniadkowski, J. Hrabak

P1177 Description of a carbapenem-resistant Pseudomonas aeruginosa co-harbouring VIM-36 and IMP-1 by whole-genome sequencing
P. Neves, J. Ramos, R. Stabler, F. Rossi, A. Sara Levin, S. Figueiredo Costa* [Sao Paulo, Brazil]
P1178 Characterization of E. coli isolates carrying blaNDM from the normal flora of patients admitted to a South Asian hospital
M. Carvalho* [Cardiff, United Kingdom], B. McCarthy, A. Mushtaq, T. Walsh

P1179 Biochemical and structural characterization of OXA-405, an OXA-48 variant with extended-spectrum beta-lactamase activity
S. Oueslati* [Le Kremlin-Bicêtre, France], P. Retailleau, L. Dortet, B. Iorga, T. Naas

P1180 Loop swap between OXA-48 and OXA-18: impact in substrate specificity
L. Dabos* [Le Kremlin-Bicètre, France], R. Bonnin, L. Dortet, B. Iorga, T. Naas

P1181 Biochemical and structural investigation of the role of beta5-beta6 loop in substrate specificity of OXA-48–like enzymes
L. Dabos* [Le Kremlin-Bicètre, France], R. Bonnin, L. Dortet, B. Iorga, T. Naas

P1182 The molecular epidemiology of OXA-48 carbapenemase during a hospital outbreak
L. Hidalgo* [Utrecht, Netherlands], M. de Been, M. Rogers, A. Schurch, J. A. van der Zee, M. Bonten, A. Fluit

P1183 Whole-genome sequence of a clinical Enterobacter aerogenes resistant to carbapenem: first description of transposon Tn1331 harbouring blaOXA-09 in Brazil
C. Rizek, R. Stabler, J. Ferraz Rosa, F. Rossi, A. Sara Levin, S. Figueiredo Costa* [Sao Paulo, Brazil]

P1184 Persistence of blaOXA-48-bearing plasmids in different clonal populations within members of the Enterobacteriaceae family
N. Piedra-Carrasco, T. Cornejo-Sánchez, M. Viñado, M. Larrosa, J. González-López* [Barcelona, Spain]

P1185 P174E replacement in GES-5 class A carbapenemase reduces activity towards penicillins
A. Piccinilli, F. Marcoccia, M. Colapietro, B. Segatore, G. Amicosante, M. Perilli* [L’Aquila, Italy]

P1186 Characterization of a novel variant of KPC with decreased susceptibility to phenylboronic acid
L. Lopez Cerezo* [Seville, Spain], F. Fernández-Cuenca, J. Rodríguez Martínez, J. Machuca, L. Serrano-Rocha, A. Pascual Hernandez

P1187 The biological costs and plasmid sequence of two Klebsiella pneumoniae blaKPC-2- and blaVIM-1-carrying plasmids in different Escherichia coli clinical isolates
M. Di Luca* [Trondheim, Norway], V. Sørum, J. Kloos, P. Johnsen, O. Samuelsen

P1188 Complete sequences of two IncF/M plasmids carrying blaOXA-48 genes from first isolates detected in Russia
V. Ageevets* [St. Petersburg, Russian Federation], J. Sapova, I. Lazareva, M. Malakhova, D. Popov, V. Babenko, E. Ilina, E. Kastruykava, S. Sidorenko

P1189 Characterization of plasmids harbouring blaKPC-3, blaCTX-M-15, aac(6’)-Ib-cr and qnrB genes in new emerging clones of Klebsiella pneumoniae
D. Fortini* [Rome, Italy], C. Feudi, L. Villa, C. Mammina, A. Carattoli, C. Banura

P1190 Genetic context of blaNDM-1 isolated from Acinetobacter baumannii and Klebsiella pneumoniae from India, Belgium and Iraq

13:30-14:30

PK/PD of agents against Gram-positives

P1191 Standard vs. alternative dosing regimens for linezolid against S. aureus: potential value of front-loaded regimens
S. Wicha* [Berlin, Germany], C. Kloft

P1192 AUC/MIC versus T>MIC: which PK/PD index is more indicative of linezolid efficacy in plasma and interstitial tissue space of septic patients with different weight?
I. Minichmayr* [Berlin, Germany], S. Wicha, C. Kloft

P1193 Therapeutic drug monitoring of linezolid in liver failure. Quantification of liver function with maximal liver function capacity test (LiMAx test)
M. Kaffarnik* [Berlin, Germany], S. Wicha, O. Frey, J. Pratschke, M. Stockmann

P1194 Population pharmacokinetics of linezolid as it applies to therapeutic drug monitoring: a comparison of ten approaches
A. Farkas, S. Luque, A. Roehr* [Heidenheim, Germany], O. Frey, S. Grau, J. Roberts

P1195 Testing the mutant selection window hypothesis in Staphylococcus aureus resistance studies with linezolid using a mixture of antibiotic-susceptible cells and resistant mutants in an in vitro dynamic model
K. Alieva* [Moscow, Russian Federation], E. Strukova, Y. Portnoy, M. Golikova, S. Zinner, A. Firsov

P1196 Comparative pharmacodynamics of ceftaroline and linezolid against Staphylococcus aureus in an in vitro dynamic model
M. Golikova* [Moscow, Russian Federation], S. Dovzhenko, M. Kobrin, Y. Portnoy, S. Zinner, A. Firsov
<table>
<thead>
<tr>
<th>Paper Number</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>P1198</td>
<td>Intrapulmonary and plasma concentrations of dalbavancin in healthy adults after a single 1500 mg infusion</td>
<td>M. Dunne* (Old Saybrook, CT, United States), U. Rappa, S. Puttagunta, J. Baldassarre, S. Su, D. Desai-Krieger, M. Inoue</td>
</tr>
<tr>
<td>P1200</td>
<td>Vancomycin prescription changes in real time based on drug plasma monitoring against <em>Staphylococcus</em> spp. MIC 2mg/l in critically ill paediatric burn patients</td>
<td>C. Sanches-Giraud* (Divinopolis, Brazil), V. Aparecida Bueno Da Silva, A. Nascimento Coelho, C. Vieira Silva Jr, S. Santos, B. Souza Gomez</td>
</tr>
<tr>
<td>P1201</td>
<td>Vancomycin continuous infusion dose optimization for the treatment of &quot;MIC Creep&quot; methicillin-resistant <em>Staphylococcus aureus</em> infections in critically ill Thai patients</td>
<td>E. Setiawan* (Surabaya, Indonesia), P. Montakantikul, B. Chindavijak</td>
</tr>
<tr>
<td>P1202</td>
<td>Urine vancomycin concentration as an alternative for serum drug monitoring</td>
<td>S. Shokouhi, I. Alavi Darazam* (Tehran, Iran), M. Zamanian</td>
</tr>
<tr>
<td>P1203</td>
<td>The impact of vancomycin protein binding on target attainment in critically ill children</td>
<td>S. Desmet* (Ghent, Belgium), P. De Cock, A. de Jaegher, E. Dhont, V. Stave, P. De Poepe, D. Biarent, D. Vens</td>
</tr>
<tr>
<td>P1204</td>
<td>Serum and cerebrospinal fluid concentrations of vancomycin in neurosurgical critically ill patients with central nervous system infections</td>
<td>U. Blassmann* (Munich, Germany), A. Roehr, O. Frey, C. Vetter-Kerkhoff, N. Thon, J. Briegel, V. Hildebrandt</td>
</tr>
<tr>
<td>P1205</td>
<td>Effects of targeting higher versus lower vancomycin trough levels on clinical outcomes of methicillin-resistant <em>Staphylococcus aureus</em> bacteraemia: prospective multicentre randomised study</td>
<td>S. Kang* (Gwangju, South Korea), G. Kang, U. Kim, J. An, K. Park, S. Jung, J. Kim, H. Jang</td>
</tr>
<tr>
<td>P1206</td>
<td>The importance of therapeutic drug monitoring of vancomycin in cases of empirical treatment and staphylococcal infections</td>
<td>J. Meo Rauber, B. Baggio, R. Soares, M. Basso Zanotta, M. Carneiro, A. Moura Valim, P. Alves d'Azevedo* (Porto Alegre, Brazil)</td>
</tr>
<tr>
<td>P1209</td>
<td>Antibiotic stewardship interventions on patient level during weekly proactive audits in four intensive care units: impact on antimicrobial prescribing</td>
<td>K. Wike* (Dresden, Germany), S. Helbig, A. Christoph, K. De With</td>
</tr>
<tr>
<td>P1210</td>
<td>Antimicrobial stewardship: interventions in a Dutch general hospital</td>
<td>C. van der Hoeven* (Dirksland, Netherlands), S. Lugtenbrug, C. Roggeveen, G. van Asselt</td>
</tr>
<tr>
<td>P1211</td>
<td>Impact of an antibiotic checklist on broad-spectrum Gram-positive antibiotic use in leukaemia patients</td>
<td>S. Aitken, K. Marx, F. Tverdek, M. Taremi, A. Jones, D. Chemaly, V. Mulanovich, S. Shelburne, K. Rolston* (Houston, United States)</td>
</tr>
<tr>
<td>P1212</td>
<td>Antibiotic de-escalation is safe and feasible in pre-engraftment phase of allogeneic haematopoietic stem cell transplantation</td>
<td>M. Mikulska, G. Gustinetti* (Genoa, Italy), E. Balletto, A. Raiola, F. Galaverna, R. Varaldo, F. Gualandi, A. Ghiso, A. Bacigalupo, C. Viscoli</td>
</tr>
<tr>
<td>P1213</td>
<td>A survey to identify barriers of implementing an antibiotic checklist</td>
<td>F. van Daalen* (Amsterdam, Netherlands), S. Geerlings, J. Prins, M. Hulscher</td>
</tr>
<tr>
<td>P1214</td>
<td>Electronic recording of infection clinical consultations: impact on hospital acquired infections and antimicrobial stewardship</td>
<td>A. Hussain* (Birmingham, United Kingdom), R. Bhogal, D. Pillay</td>
</tr>
</tbody>
</table>
13:30-14:30

Uses of prescription point prevalence surveys

P1222 The global point-prevalence survey of antimicrobial consumption and resistance (Global-PPS): worldwide variation of prophylactic prescribing
A. Versporten* [Antwerp, Belgium], N. Drapier, P. Zarb, I. Caniaux, M. Gros, M. Miller, V. Jarlier, D. Nathwani, H. Goossens

P1223 The global point prevalence survey of antimicrobial consumption and resistance (Global-PPS) in 335 hospitals worldwide: management of adult patients with pneumonia
V. Nussenblatt* [Antwerp, Belgium], A. Versporten, N. Drapier, P. Zarb, I. Caniaux, M. Gros, M. Miller, V. Jarlier, D. Nathwani, H. Goossens

P1224 Risk adjustment using simple inpatient antibiotic prescribing point prevalence survey data can enable benchmarking of carbapenem use
J. Bielicki* [London, United Kingdom], D. Cromwell, A. Versporten, H. Goossens, M. Sharland

13:30-14:30

Colistin and polymyxin B pharmacokinetics

P1228 Efficacy of different clinical dosing regimens of colistin against carbapenemase-producing Klebsiella pneumoniae isolates in an in vitro PK-PD model

P1229 Population pharmacokinetics of colistin: implications for clinical use for Gram-negative pathogens
M. Pachon-Ibáñez* [Seville, Spain], F. Dacobo Perez, R. Blanquero-Bravo, J. Garnacho-Montero, S. Benitez Peña, G. Dimopoulos, C. Rosso, A. Gutiérrez-Valencia, L. López-Cortés, J. Lisneros Herreros

P1230 Comparison of continuous versus intermittent intravenous infusion of colistimethate sodium [colistin] for treatment of carbapenem-resistant Gram-negative bacterial infections
J. Curello* [Los Angeles, United States], Z. Kassamali, A. Gregson
P1231 Arterial blood levels of colistin after application of aerosolized CMS — a way to monitor dosing and toxicity?
L. Wagner* (Berlin, Germany), S. Tafelski, S. Angermair, U. Tröger, M. Deja

P1232 Efficacy and safety of polymyxin B for infections caused by extensively drug-resistant (XDR) Gram-negative bacteria in Thailand
T. Ngamprasertchai* (Bangkok, Thailand), A. Boonyasiri, L. Charoenpong, S. Nimitvilai, N. Lorchirachoonkul, L. Wattanamongkonsil, V. Thamilikitkul

P1233 Synergy of imipenem-colistin combination against imipenem-resistant multidrug-resistant Enterobacter cloacae in a Galleria mellonella model
H. Yang* (Hefei, China), J. Li

P1234 Clinical evolution of patients with Acinetobacter baumannii infection when low dose of colistin was used
A. Martin-Aspas, F. Garcia-Colchero, F. Guerrero-Sanchez, D. Gutierrez-Saborido* (Cadiz, Spain), J. Girón-González

P1235 Revival of old antibiotics: pharmacokinetic study of multiple-dose intravenous polymyxin B in patients with severe burn injury undergoing continuous renal replacement therapy
L. Hu* (Nanjing, China), H. Shao, Y. Huang, R. Xu, J. He, Y. Yang, H. Du

P1236 Pharmacokinetics of intravenous colistin dosed as in normal renal function in critically ill patients undergoing continuous renal replacement
N. Corti* (Zurich, Switzerland), A. Taegtmeyer, I. Marti, S. Weiler, L. Decosterd, T. Buclin

P1237 Population analysis of colistin resistance in carbapenemase producing Klebsiella pneumoniae (CP-Kp) isolates

P1238 Accurin nanoparticles improve the therapeutic index of colistin in preclinical models of infection
D. Zaytseva-Zotova* (Moscow, Russian Federation), A. Ziphenko, T. Levada, D. Andreev, Y. Shilov, E. Safarova, A. Horha, G. Traiano, S. Zale

13:30-14:30

PK/PD of agents against Gram-negatives

PK/PD of agents against Gram-negatives

P1239 Pharmacokinetic/pharmacodynamic analysis of meropenem in critically ill patients
L. Ehmann* (Berlin, Germany), M. Zoller, C. Scharf, I. Minichmayr, M. Vogeser, L. Frey, J. Zander, C. Kloft

P1240 High concentration of meropenem in endotracheal aspirate does not eradicate susceptible Pseudomonas aeruginosa in mechanically ventilated pigs with pneumonia
L. Fernandez-Barat, A. Matos, L. Guerrero, D. Soy, G. Li Bassi, E. Aguileria Kiol* (Barcelona, Spain), M. Rigal, R. Amaro, A. Torres

P1241 Imipenem serum measurements in real time for target attainment against more aggressive strains MIC>2mg/l in septic burns
C. Sanches-Giraud* (Divinopolis, Brazil), C. Vieira Silva Jr, J. de Toledo Bagatin, S. Santos, D. Souza Gomez

P1242 Proficiency testing for meropenem and piperacillin therapeutic drug monitoring: preliminary results from the SBIMC/BVIKM PK-PD working group
M. Carlier* (Ghent, Belgium), A. Athanasopoulos, D. Borrey, P. Colin, F. Cotton, R. Denooz, H. Neels, I. Spriet, V. Stove

P1243 Development of a pharmacokinetic model for piperacillin-tazobactam in non-critically ill patients with bloodstream infection due to Enterobacteriaceae
A. Valiente Mendez* (Seville, Spain), V. Merino Bohórquez, M. Cameán, M. Delgado, A. Pascual Hernandez, W. Hope, J. Rodríguez-Báñez

P1244 Emergence of ceftazidime-resistant Pseudomonas aeruginosa during exposure to high concentrations of ceftazidime in vitro and in vivo
C. Hodiamont* (Amsterdam, Netherlands), Y. Feng, M. Schokkin, B. ter Kuile, N. Jufermans, C. Schultz, R. Mathôt, R. van Hest

P1245 Pharmacodynamics of cefepime and tazobactam against carbapenemase positive strains in a neutropenic mouse model
J. Mouton* (Rotterdam, Netherlands), D. Donnelly, S. Bhagwat, M. Patel

P1246 Which renal marker best predicts cefepime clearance in critically ill patients?
S. Jonckheere* (Ieper, Belgium), N. De Neve, H. De Beenhouwer, M. Berth, A. Vermeulen, J. Van Bocxlaer, P. Colin

P1247 The ANTIBIOPERF study: a nationwide cross-sectional survey on beta-lactams administration and therapeutic drug monitoring practices in critically ill patients in France
P1248 Clinical validation of a simple method which could be performed in any microbiological laboratory in order to facilitate therapeutic drug monitoring for broad spectrum beta-lactam antibiotics in intensive care unit patients
J. Fridlund, H. Woksepp, T. Schön* (Kalmar, Sweden)

P1249 Population pharmacokinetics of ceftaroline in healthy volunteers – comparison of target attainment achieved by standard versus intensified dosing
I. Minichmayr* [Berlin, Germany], M. Zeitlinger, P. Matzneller, C. Kloft

P1250 Pharmacokinetics and pharmacodynamics of cefotiboprole in adults who are severely obese
A. Schmitt Hoffmann* [Basel, Switzerland], M. Engelhardt, J. Spickermann, M. Jones, A. Kaufhold

P1251 Bone penetration of the new-generation cephalosporin cefotiboprole in patients following hip replacement surgery
A. Schmitt Hoffmann* [Basel, Switzerland], M. Engelhardt, J. Spickermann, M. Jones, A. Kaufhold

P1252 Pharmacokinetics of cefotiboprole in paediatric patients
J. Blumer* [Toledo, United States], A. Schmitt Hoffmann, M. Engelhardt, J. Spickermann, M. Jones, A. Kaufhold

P1253 Administration of aminoglycosides in the ICU: how can we do better?
C. Bretonnière* [Nantes, France], G. Deslandes, J. Laurence, E. Dailly, G. Potel, J. Caillon, D. Boutouille, C. Guitton

P1254 Insufficient gentamicin peak concentrations in patients with sepsis at the emergency department
M. Hoesecker* [Maastricht, Netherlands], R. van den Biggelaar, P. Stassen, D. Pothouwer, T. Havenith, F. van Tiel

P1255 Amikacin: a landscape survey of prescribing, toxicity and therapeutic drug monitoring in locally approved guidelines
A. Jenkins* [Birmingham, United Kingdom], A. Thomson, N. Brown, Y. Semple, C. Sluman, A. MacGowan, A. Lovering, P. Wiffen

P1256 Antibacterial activity of human simulated epithelial lining fluid concentrations of amikacin inhaled alone and in combination with meropenem against Acinetobacter baumannii
I. Ghazi* [Hartford, United States], M. Grupper, D. Nicolau

P1257 Pharmacodynamics of inhaled amikacin studied in an in vitro pharmacokinetic model of infection
K. Bowker* [Bristol, United Kingdom], A. Noel, S. Tomaselli, M. Attwood, A. MacGowan

P1258 Comparative effect of equal dose of continuous veno-venous haemofiltration and continuous veno-venous haemodiafiltration on ciprofloxacin population pharmacokinetics in septic patients
C. Roger, S. Wallis, J. Lipman, J. Lefrant, J. Roberts* [Brisbane, Australia]

13:30-14:30

Cefepime-tazobactam

P1259 WCK 4282 [high-dose cefepime-tazobactam] – assessment of synergy through time-kill curve and MIC determination against Pseudomonas aeruginosa producing OXA and VEB beta-lactamases
J. Prashant, H. Khande, S. Bhagwat, M. Patel* [Aurangabad, India]

P1260 Safety, tolerability and pharmacokinetics of WCK 4282 [fep-taz] in healthy adult subjects
A. Bhatia* [Delhi, India], R. Chugh, M. Gupta, P. Iwanowski

P1261 In vitro activity of WCK 4282 [high-dose cefepime-tazobactam] against resistant subsets of Enterobacteriaceae collected worldwide (2014)
H. Sader* [North Liberty, United States], P. Rhomberg, M. Castanheira, R. Jones

P1262 Antimicrobial activity of WCK 4282 [high-dose cefepime-tazobactam] tested against Gram-negative organisms from medical centres located in Europe and the Asia-Pacific region
H. Sader* [North Liberty, United States], D. Farrell, R. Flamm, M. Castanheira, R. Jones

P1263 WCK4282 [high-dose cefepime-tazobactam] antimicrobial activity against Gram-negative organisms from United States [USA] and Latin American medical centres [2014]
H. Sader* [North Liberty, United States], M. Castanheira, R. Flamm, D. Farrell, R. Jones

P1264 WCK 4282 [high-dose cefepime-tazobactam]: Complimentary features drive efficacy against KPC-producing pathogens
H. Khande, J. Prashant, S. Palwe, K. Umakar, S. Takalkar, S. Bhagwat* [Aurangabad, India], M. Patel

P1265 WCK 4282 [high-dose cefepime-tazobactam] against multi-resistant Gram-negative bacteria
D. Livermore* [Norwich, United Kingdom], S. Mushtaq, M. Warner, N. Woodford

P1266 WCK 4282 [high-dose cefepime-tazobactam] – time-kill studies correlate with in vivo efficacy studies against AmpC-producing Pseudomonas aeruginosa
K. Umakar, J. Satav, A. Uday, A. Kulkarni, H. Khande, S. Palwe, S. Takalkar, S. Bhagwat, M. Patel* [Aurangabad, India]
13:30-14:30

Levonadifloxacin

P1267 Plasma and intrapulmonary pharmacokinetics of levonadifloxacin in healthy adult subjects
R. Chugh* [Mumbai, India], A. Bhatia, M. Gupta, N. Sharma, M. Gotfried, K. Rodvold

P1268 Safety and pharmacokinetics of multiple ascending doses of WCK 771 and WCK 2349
R. Chugh* [Mumbai, India], F. Lackdavala, A. Bhatia

P1269 Electrocardiographic effects of WCK 2349
J. Mason* [Salt Lake City, United States], R. Chugh, F. Lackdavala, A. Bhatia

P1270 Single-centre, phase-1, open label, single dose study to evaluate the pharmacokinetics and safety of wck 2349 in patients with hepatic impairment
R. Preston* [Miami, United States], R. Chugh, A. Bhatia

13:30-14:30

Discovery of new antibacterial drugs

P1271 Mapping of polymyxin lipopeptide antibody binding epitopes: A chemical biology approach

P1272 The in vitro activity of CAP-18(31), a derivative of CAP-18, against colistin-resistant Acinetobacter baumannii
A. Callarisa* [Barcelona, Spain], X. Vila-Farrés, D. Lo Re, I. Roca, E. Gilart, J. Vila Estepe

P1273 A novel class of antimicrobial compounds active against multidrug-resistant Gram-negative bacteria
C. Hind* [Salisbury, United Kingdom], P. Piccioni, R. Islam, M. Wand, M. Rahman, M. Sutton

P1274 Bacteriophage treatment for the treatment of P. aeruginosa infections in cystic fibrosis patients
S. Morales* [Sydney, Australia]

P1275 Peptide nucleic acid anti-mazE antitoxin as a novel strategy for eradication of antibiotic-resistant Staphylococcus aureus
S. Ghaforian* [Tehran, Iran], N. Sadeghi, R. Mohamad, B. Badakhsh

P1276 ATx201: a novel antibiotic for treatment of skin infections caused by multidrug-resistant bacteria
P. Li, J. Hansen, T. Pires dos Santos, E. Delavenne, P. Priemel, B. Jana, H. Moerk Nielsen, L. Guardabassi, C. Vingsbo Lundberg, M. Sommer* [Hørsholm, Denmark]

P1277 Mode of antimicrobial and anti-biofilm activity of peptide mimetics
B. Mojskova* [Roskilde, Denmark], P. Saparito, R. Mateiu, H. Jenssen

P1278 Novel class of dual topoisomerase II inhibitors: study on mode of action
C. Bartella* [Rome, Italy], N. D’Antonasio, C. Apicella, F. Mancini, M. Vitelli, R. Ombrato, A. Capezzone de Joannon, G. Mangano, F. Garofalo, S. Tangiani

P1279 Biological profiling of novel bacterial topoisomerase inhibitors with broad-spectrum antibacterial activity

P1280 Antimicrobial and anti-biofilm activities of biologically synthesized selenium nanoparticles
E. Cremonini* [Verona, Italy], E. Zanaro, S. Lampis, M. Donini, S. Dusi, M. Boaretti, M. Lleó Fernandez, G. Vallini

P1281 Advanced use of high-throughput screening tools for the identification of novel OXA-48 beta-lactamase inhibitors for infection treatment

P1282 Development of an integrated NMR/MS metabolomics approach for the determination of the novelty of new antimicrobials mechanisms of action based on their metabolic signature
F. Bequet* [Lyon, France], A. Bunescu, X. Meniche, D. Ouattara, E. Bilout, C. Boisse, J. Tambasco, A. Troesch

P1283 Assessment of a penicillin sulphone (LN-1-255) as inhibitor for Acinetobacter baumannii class D carbapenemases
J. Vazque-Ucha* [La Coruña, Spain], M. Martinez-Guitian, M. Pozo, G. Bau Arvelo, C. Gonzalez-Bello, A. Beceiro

P1284 Identification of novel IMP-1, VIM-1 and NDM-1 metallo-beta-lactamase inhibitors
N. D’Antonasio* [Rome, Italy], G. Mangano, G. Corso, A. Capezzone de Joannon, R. Ombrato, C. Milanese, F. Garofalo, S. Tangiani

P1285 Antimicrobial activity of OP0595 in combinations with cefepime against ESBL-producing K. pneumoniae in a pneumonia mouse model
N. Kaku* [Nagasaki, Japan], K. Kosai, K. Takeda, Y. Marinaga, T. Miyazaki, K. Izumikawa, H. Mukae, K. Yanagihara

P1286 In vitro activity of cefepime-AA101 vs. drug-resistant Klebsiella pneumoniae clinical isolates
Y. Carmeli* [Tel Aviv, Israel], A. Adler, L. Rashi, R. Pypstra, S. Shapiro
P1297 Magnetite nanoparticles functionalized with plant derived compounds reduce the resistance and persistence of opportunistic pathogens
A. Holban* (Bucharest, Romania), E. Andronescu, A. Grumezescu, L. Ditu, C. Iordache, V. Lazar, V. Grumezescu, M. Chifiriuc

P1298 LN-1-255, a penicillin sulphone able to inhibit the class D carbapenemase OXA-48
J. Vazquez-Ucha* (La Coruña, Spain), J. Vallejo, M. Martinez-Guitian, C. Gonzalez-Bello, M. Poza, J. Buynak, C. Bethel, R. Bonomo, G. Bou Arevalo, A. Beceiro

P1299 Vaborbactam (RPX7009) plus meropenem is active against the newly discovered BKC-1 and FR-1 carbapenemases
O. Lamovskaya* (San Diego, United States), R. Tsivkovski

13:30-14:30 Antimicrobial consumption in the hospital
P1290 Antimicrobial resistance rates do not drive antibiotic consumption in Europe
P. Beryl, T. Vilken, P. Shamsrizi, W. Kern, E. Tacconelli*
(Tübingen, Germany)

P1291 Metrics for quantifying antimicrobial use in the inpatient setting: results from a systematic review

P1292 Patterns of recent antibiotic use in German acute care hospitals - an analysis focussed on 128 non-university hospitals
W. Kern* (Freiburg, Germany), G. Först, M. Steib-Bauert, M. Fellhauer, K. De With

P1293 Evaluation of paediatric beta-lactam prescribing in hospitals
R. Bruyndonckx* (Antwerp, Belgium), N. Hens, M. Aerts, A. Versporten, H. Goossens, J. Bielicki, C. Barker, M. Sharland

P1294 Variation in indicators of antibiotic use among and within different settings: a systematic review

P1295 Possible variance in assessment of antimicrobial consumption in multi-field hospitals with paediatric inpatients: conventional vs. novel paediatric-adjusted methodology
Y. Belkova, S. Rochina, R. Kozlov* (Smolensk, Russian Federation), V. Mischenko, A. Andreeva, S. Paliutin, U. Portnyagina

P1296 Prescribing of last resort antibiotics in the hospital sector continues to increase in England
B. Muller-Pebody* (London, United Kingdom), A. Johnson, G. Rooney, D. Ladenheim, D. Ashiru-Oredope, S. Hopkins

P1297 Four-year experience of monitoring meropenem consumption in a UK hospital
N. Wickramasinghe* (Birmingham, United Kingdom), C. Jamieson

P1298 Appropriate use of carbapenems: a regional audit in seven hospitals

P1299 Broad-spectrum antibiotic consumption in French hospitals: longitudinal trends over five years (2010-2014)
A. Marquet, S. Thibaut, J. Caillon, J. Maupetit, D. Boutaille*
(Nantes, France), E. Batard

13:30-14:30 Education and competence in antimicrobial stewardship
P1300 Assessment of cross-specialty engagement in antimicrobial stewardship; a cross-sectional, observational analysis of UK medical specialty curricula
T. Butters* (London, United Kingdom), T. Rawson, L. Moore, A. Holmes

P1301 Knowledge, attitude and behaviour towards antibiotic use among medical students and residents in Tawam Hospital, UAE
Y. Salam* (Al Ain, United Arab Emirates), O. Hakmi, A. Saleem, A. Khan, H. Ibrahim, K. Rafeea, N. Nuaimi, R. Hashmey

P1302 Young doctors' perspectives on antibiotic use and resistance in Europe in 2015 (YPAR): preliminary results

P1303 Assessing the implementation of national antimicrobial prescribing and stewardship competences into undergraduate curricula

P1304 How prepared do Swedish medical students feel in relation to prudent antibiotic use?
### New antibiotics against Gram-negative bacteria

<table>
<thead>
<tr>
<th>Presentation Number</th>
<th>Title</th>
<th>Authors</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>P1305</td>
<td>Do medical students in France feel prepared to prescribe antibiotics responsibly?</td>
<td>O. Dyar* [Stockholm, Sweden], D. Nathwani, I. Gyssens, C. Strålsby Lundborg, C. Pulcini, ESCMID Study Group for Antibiotic Policies</td>
<td>Amsterdam, Netherlands</td>
</tr>
<tr>
<td>P1307</td>
<td>Metabolism and excretion of the novel macrocycle antibiotic POL7080</td>
<td>O. Kuhlmann, C. Brealey, S. Simon, M. Ullah, M. Pantze, A. Wach, G. Dale* [Allschwil, Switzerland]</td>
<td>Amsterdam, Netherlands</td>
</tr>
<tr>
<td>P1308</td>
<td>Pharmacokinetics and safety of POL7080 in subjects with impaired renal function</td>
<td>A. Halabi, M. Peterson-Sylla, K. Sommerville, A. Wach, K. Dembowsky, M. Rangaraju, G. Dale* [Allschwil, Switzerland]</td>
<td>Amsterdam, Netherlands</td>
</tr>
<tr>
<td>P1309</td>
<td>Pharmacokinetics of POL7080 co-administered with standard of care (SoC) in patients with ventilator-associated pneumonia (VAP) due to suspected or documented Pseudomonas aeruginosa infection</td>
<td>A. Armaganidis, F. Frantzeskaki, C. Diakaki, S. Zakynthinos, E. Ischaki, K. Mandragos, C. Katsenos, M. Paraschos, M. Potrani, E. Giamarellos-Bourboulis, N. Antonakos, G. Damoraki, M. de la Torre-Prados, K. Sommerville, M. Rangaraju, K. Dembowsky, L. Haofrtn, A. Wach, G. Dale* [Allschwil, Switzerland], A. Torres</td>
<td>Amsterdam, Netherlands</td>
</tr>
<tr>
<td>P1310</td>
<td>TP-6076 is efficacious in a mouse pneumonia model with carbapenem-resistant Acinetobacter baumannii (CRAB) and retains potency against common tetracycline-resistance mechanisms.</td>
<td>T. Grossman* [Watertown, MA, United States], C. Fyfe, K. Kerstein, X. Xiao, C. Sun, J. Newman, P. Nguyen, M. Pulse, W. Weiss, J. Dumas, J. Sutcliffe</td>
<td>Amsterdam, Netherlands</td>
</tr>
<tr>
<td>P1311</td>
<td>Dose adjustment of S-649266, a siderophore cephalosporin, for patients requiring haemodialysis</td>
<td>T. Katsume* [Osaka, Japan], T. Wajima, T. Ishibashi, J. Arjona Ferreira, R. Echols</td>
<td>Amsterdam, Netherlands</td>
</tr>
<tr>
<td>P1313</td>
<td>Analysis of ceftolozane pharmacokinetics in a porcine model of mechanical ventilation and severe pneumonia</td>
<td>E. Aguilera Xio* [Barcelona, Spain], G. Li Bassi, D. Nicolau, C. Sutherland, C. Tavri, A. Chiaruzzi, L. Fernandez-Boat, A. Motos, R. Amara, L. Guerrera, D. Say, M. Rigo, A. Torres</td>
<td>Amsterdam, Netherlands</td>
</tr>
<tr>
<td>P1314</td>
<td>In vitro activity of ceftolozane-tazobactam against Pseudomonas aeruginosa and Enterobacteriaceae isolates recovered from hospitalized patients in Germany</td>
<td>M. Kresken* [Rheinbach, Germany], B. Körber-Irrgang, H. Seifert, G. Study Group</td>
<td>Amsterdam, Netherlands</td>
</tr>
<tr>
<td>P1315</td>
<td>Activity of ceftazidime/avibactam against Enterobacteriaceae producing extended-spectrum beta-lactamases and acquired AmpC beta-lactamases, including those lacking porin expression</td>
<td>M. Conejo* [Seville, Spain], N. Alonso, M. Fernández-Martínez, L. Zamarro, B. Mirelis, A. Oliver, L. Martinez-Martínez, F. Navarro, A. Pascual Hernandez</td>
<td>Amsterdam, Netherlands</td>
</tr>
<tr>
<td>P1316</td>
<td>Synergistic activity of aztreonam and ceftazidime-avibactam against metallo-beta-lactamase producing Gram-negative pathogens</td>
<td>E. Wenzler* [Chicago, United States], M. Deraedt, A. Harrington, L. Danziger</td>
<td>Amsterdam, Netherlands</td>
</tr>
<tr>
<td>P1317</td>
<td>Omadacycline in vitro and in vivo</td>
<td>R. Flamm* [North Liberty, United States], D. Farrell, H. Soder, R. Mendes, R. Jones</td>
<td>Amsterdam, Netherlands</td>
</tr>
<tr>
<td>P1318</td>
<td>Effect of age and gender on the pharmacokinetics of oral and IV omadacycline, a new class of aminomethylcyclines</td>
<td>K. Tanaka, E. Tzanis, S. Villano* [Boston, United States]</td>
<td>Amsterdam, Netherlands</td>
</tr>
<tr>
<td>P1319</td>
<td>Single and multiple-dose pharmacokinetics and tolerability of intravenous omadacycline in healthy volunteers</td>
<td>K. Tanaka, S. Villano, E. Tzanis* [Boston, United States]</td>
<td>Amsterdam, Netherlands</td>
</tr>
<tr>
<td>P1320</td>
<td>Population pharmacokinetics (PPK) of omadacycline following intravenous (IV) or oral administration to phase 1 subjects</td>
<td>S. VanWart* [Latham, United States], A. Manley, S. Bhavnani, K. Tanaka, E. Loh, C. Rubino, E. Tzanis, P. Ambrose</td>
<td>Amsterdam, Netherlands</td>
</tr>
<tr>
<td>P1321</td>
<td>Omadacycline, an aminomethylcycline antibiotic, has no effect on QT/QTc intervals in healthy subjects</td>
<td>S. Villano* [Boston, United States], K. Tanaka</td>
<td>Amsterdam, Netherlands</td>
</tr>
</tbody>
</table>
POSTER SESSIONS

Final Programme 26th ECCMID, Amsterdam, Netherlands, 2016

171
P1 322 Bactericidal activity of omadacycline, a novel aminomethylcycline
S. Hawser* [Epalinges, Switzerland], C. Siegmund, P. Jeandey, E. Genet, S. Magnet, I. Morrissey, K. Tanaka

P1 323 In vitro bacterial and intracellular activity of omadacycline against Legionella pneumophila
J. Dubois* [Sherbrooke, Canada], M. Dubois, J. Martel, K. Tanaka

P1 324 Effects of omadacycline on gut microbiota populations and Clostridium difficile germination, proliferation and toxin production in an in vitro model of the human gut
C. Chilton* [Leeds, United Kingdom], S. Todhunter, D. Ewin, J. Vernon, M. Wilcox

P1 325 Activity and efficacy of omadacycline against Clostridium difficile
O. Kim* [Boston, United States], R. Leahy, M. Traczewski, A. Macone, J. Steenbergen, K. Tanaka

P1 326 A pooled analysis of two randomized multicentre, evaluator-blind studies comparing the safety and efficacy of omadacycline and linezolid for the treatment of complicated skin and skin structure infections
K. Tanaka, S. Chitra, L. Garrity-Ryan, E. Tzanis* [Boston, United States], E. Loh

13:30-14:30

News on outpatient antibiotic prescribing quality

P1 327 Acceptance of C-reactive protein (CRP) point of care (POC) testing for non-severe acute respiratory infections (ARIs) among patients and healthcare workers in the primary healthcare setting of Vietnam – a qualitative study
N. Do* [Hanoi, Viet Nam], H. Nguyen, H. Vu, L. Hoang, B. Nadjm, H. van Doorn, K. Nguyen, A. Audier, H. Wertheim

P1 328 Quality indicators assessing antibiotic use in the outpatient setting: a systematic literature review followed by a consensus procedure

P1 329 Misuse of antibiotics reserved for the hospital settings in outpatients: a single-centre prospective study
M. Roche, C. Bornet, P. Monges, A. Stein, S. Gensollen, P. Seng* [Marseille, France]

P1 330 Is self-medication the only problem regarding antibiotic use among Vilnius residents?
A. Barkus* [Vilnius, Lithuania], I. Lisauskien

P1 331 National study of antimicrobial prescribing for urinary tract infection in the community: its effect on bacterial resistance
A. Leanord, S. Barry, N. Ramporsad, C. Wuiff, W. Malcolm, C. McCowan, A. Leanord* [Glasgow, United Kingdom]

P1 332 Availability of guidance, decision support tools and education to enable appropriate antimicrobial prescribing in English primary care settings
E. Budd* [London, United Kingdom], C. McNulty, E. Beech, A. Bhattacharya, M. McLeod, D. Ashiru-Dedope

13:30-14:30

New agents in clinical development against Gram-positive bacteria

P1 333 Activity of Debio 1452 against Staphylococcus spp. in 2013/2014
S. Hawser, M. Gueny, C. Le Bras, I. Morrissey, T. Valmont, S. Magnet, F. Wittke, G. Dieppois* [Lausanne, Switzerland]

P1 334 Activity of the novel FabI inhibitor Debio 1452 against intracellular forms of susceptible and resistant S. aureus: comparison with linezolid, vancomycin and daptomycin
F. Peyrusson, F. Van Bambeke, P. Tulkens* [Brussels, Belgium]

P1 335 In vitro activity of solithromycin against anaerobic bacteria in the normal intestinal microbiota
A. Weintraub* [Stockholm, Sweden], M. Rashid, C. Nord

P1 336 Ecological effect of solithromycin on the normal human intestinal microbiota
M. Rashid, S. Rosenborg, G. Panagiotidis, K. Söderberg Lüfdal, A. Weintraub* [Stockholm, Sweden], C. Nord

P1 337 Microbial characterization using multiple diagnostic methods in the first oral phase 3 community-acquired bacterial pneumonia (CAPB) trial with solithromycin
K. Keedy* [Chapel Hill, United States], B. Jamieson, A. Sheets, K. Clark, H. Dwight, P. Fernandes, D. Oldach

P1 338 SOLITAIRE-IV: a phase 3 IV to oral trial evaluating solithromycin in adults with community-acquired bacterial pneumonia
B. Jamieson* [Chapel Hill, United States], B. Sokowlowska, C. Tanaseanu, V. Vucinic-Mihailovic, D. Taylor, A. Sheets, K. Keedy, D. Oldach, P. Fernandes

P1 339 Delafoxacin activity tested against bacterial pathogens from 44 medical centres in Europe and Israel [2014]
R. Flamm* [North Liberty, United States], D. Farrell, H. Sader, R. Jones

P1 340 Bezlotoxumab decreases CDI recurrence and is associated with a reduction in 30-day readmissions: European analysis
V. Prabhu, S. Marcella, M. Hanson, J. Liao, A. Pedley, M. Darr, E. Bouza, O. Cornelij* [Cologne, Germany]
<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>P1342</td>
<td>Understanding the mechanism of action for SMT19969, a novel treatment for Clostridium difficile</td>
<td>E. Basseres* (Houston, TX, United States), B. Endres, K. Mohammed, F. Miraftabi, M. Alam, R. Vickers, K. Garey</td>
</tr>
<tr>
<td></td>
<td>13:30-14:30 New and old antibiotics against Gram-positive cocci in vitro</td>
<td></td>
</tr>
<tr>
<td>P1343</td>
<td>Cefotibiprole resistance in Danish MRSA</td>
<td>A. Larsen* (Copenhagen, Denmark), A. Petersen, F. Hansen, A. Santerre Henriksen, R. Skov</td>
</tr>
<tr>
<td>P1344</td>
<td>New drugs active against both rifampin- and methicillin-resistant Staphylococcus aureus (MRSA) isolates from an Italian surveillance study</td>
<td>F. Campanile* (Catania, Italy), D. Bongiorno, S. Benvenuta, V. Cafiso, M. Santagati, S. Stefani</td>
</tr>
<tr>
<td>P1345</td>
<td>Comparison of MRSA susceptibility to cefotibiprole as determined by either Etest or microdilution methods</td>
<td>L. Galia, G. Cornaglia, A. Mazzariol* (Verona, Italy)</td>
</tr>
<tr>
<td>P1346</td>
<td>In vitro activity of vancomycin and ceftaroline against various clones of methicillin-resistant Staphylococcus aureus (MRSA) isolates from a tertiary hospital in Australia</td>
<td>S. Subedi* (Sydney, Australia), C. Finemore, M. O’Sullivan, F. Zhou, R. Balgham, J. Branley M</td>
</tr>
<tr>
<td>P1347</td>
<td>Comparative activities of ceftaroline and ceftriaxone against bacterial pathogens associated with community-associated respiratory infections</td>
<td></td>
</tr>
<tr>
<td>P1348</td>
<td>Activity of ceftaroline tested against Staphylococcus collected from a nationwide study in Spain in 2014</td>
<td>E. Cercenado* (Madrid, Spain), C. Oscar, A. Vindel, F. Román Alonso, M. Marin, E. Bouza Santiago, S. Study Group</td>
</tr>
<tr>
<td>P1349</td>
<td>Characterization of MRSA-resistance to ceftaroline, responsible for skin and soft tissue infections in Poland 2010-2013</td>
<td>K. Bójarska, D. Zabicka* (Warsaw, Poland), M. Herda, W. Hryniewicz</td>
</tr>
<tr>
<td>P1350</td>
<td>In vitro antimicrobial activity of ceftaroline against coagulase-negative staphylococci: global report from the assessing worldwide antimicrobial resistance evaluation (Aware) 2012-2014 programme</td>
<td>D. Biedenbach, J. Iaconis, D. Sahm* (Schaumburg, IL, United States)</td>
</tr>
<tr>
<td>P1341</td>
<td>New and old antibiotics against Gram-positive cocci in vitro</td>
<td></td>
</tr>
<tr>
<td>P1342</td>
<td>Understanding the mechanism of action for SMT19969, a novel treatment for Clostridium difficile</td>
<td></td>
</tr>
<tr>
<td>P1343</td>
<td>Cefotibiprole resistance in Danish MRSA</td>
<td></td>
</tr>
<tr>
<td>P1344</td>
<td>New drugs active against both rifampin- and methicillin-resistant Staphylococcus aureus (MRSA) isolates from an Italian surveillance study</td>
<td></td>
</tr>
<tr>
<td>P1345</td>
<td>Comparison of MRSA susceptibility to cefotibiprole as determined by either Etest or microdilution methods</td>
<td></td>
</tr>
<tr>
<td>P1346</td>
<td>In vitro activity of vancomycin and ceftaroline against various clones of methicillin-resistant Staphylococcus aureus (MRSA) isolates from a tertiary hospital in Australia</td>
<td></td>
</tr>
<tr>
<td>P1347</td>
<td>Comparative activities of ceftaroline and ceftriaxone against bacterial pathogens associated with community-associated respiratory infections</td>
<td></td>
</tr>
<tr>
<td>P1348</td>
<td>Activity of ceftaroline tested against Staphylococcus collected from a nationwide study in Spain in 2014</td>
<td></td>
</tr>
<tr>
<td>P1349</td>
<td>Characterization of MRSA-resistance to ceftaroline, responsible for skin and soft tissue infections in Poland 2010-2013</td>
<td></td>
</tr>
<tr>
<td>P1350</td>
<td>In vitro antimicrobial activity of ceftaroline against coagulase-negative staphylococci: global report from the assessing worldwide antimicrobial resistance evaluation (Aware) 2012-2014 programme</td>
<td></td>
</tr>
</tbody>
</table>
In vitro activity of tigecycline against commonly isolated pathogens of skin and skin structure infections (SSI) in Spain
B. Johnson* (Schaumburg, IL, United States), D. Biedenbach, D. Sohn, M. Hackel, H. Leister-Tebbe

Antimicrobial susceptibility of Enterococcus spp. isolated from blood in haematological patients: results of a multicentre study in Russia

IL-33 contributes to the parasite persistence in the spleen during visceral leishmaniasis
A. Lamberet, S. Belaiz, O. Rostan, C. Manuel, A. Jan, J. Gangneux, F. Robert-Gangneux* [Rennes, France]

Influence of Candida species on the granuloma reaction through a new in vitro human model
B. Misne Aucouturier, M. Albassier, N. Alvarez Rueda, P. Le Pape* [Nantes, France]

Reversal of mitochondrial DNA depletion-induced immune suppression by interferon-gamma
J. Widdrington* [Newcastle-upon-Tyne, United Kingdom], A. Gomez-Duran, A. Pyle, M. Ruchaud-Sparagano, J. Simpson, P. Chinnery

Effect of extracellular polysaccharide substances on Staphylococcus epidermidis biofilm infections in the invertebrate host model Caenorhabditis elegans
B. Kjellerup* [College Park, United States], C. Adams, S. Edwards, A. Houston

Implementation of a murine model of Acinetobacter baumannii digestive-tract colonization and preliminary information for future applications
C. Noémie, S. Pavlickova, A. Godefroy, H. Pailhoriès* [Angers, France], M. Kempf, M. Joly-Guillou, M. Eveillard

Genetic variations in cytokine genes (IL10 and IL6) and Toll-like receptors (TLRs 3, 4, 7 and 8) in patients with DF and DHF
S. Khaliq* [Lahore, Pakistan]

Surfactant protein A recognizes outer membrane protein OprH on Pseudomonas aeruginosa cystic fibrosis isolates
M. Oadi* [Palma de Mallorca, Spain], M. Mateu, S. Izquierdo, C. Lopez Causape, J. Goldberg, A. Oliver, S. Alberti

Electrical impedance and cytokine profiling of dengue virus-infected endothelial cells
H. Soe* [Kuala Lumpur, Malaysia], S. Talebi, C. Samudi Raju, S. Sekaran

The frequency of herpes simplex virus reactivation is associated with HSV-specific CD8+ T cell exhaustion in the trigeminal ganglia of latently infected animals
A. Alami Chentoufi* [Riyadh, Saudi Arabia], S. Wechsler, L. Benmohamed

A comparison of the ATP-generating pathways used by S. typhimurium to fuel replication within human and murine macrophage and epithelial cell lines
A. Chidlaw, E. Garcia, G. Le Gall, S. Bowden, D. Kelly, J. M. Thompson* [Norwich, United Kingdom]

Variable susceptibility of Enterococcus faecium against the antimicrobial polypeptide RegIII gamma
I. Gawryszewska* [Warsaw, Poland], E. Sadowy, R. Willems, A. Hendrickx

Role of transcriptional factor EB (TFEB) in the pathogenesis of Acinetobacter baumannii
P. Raquel* [Seville, Spain], R. Agerer, M. Pachon-Ibáñez, J. Pachon-Diaz, Y. Smani

Toll-like receptor-4 is essential for Arcobacter butzleri induced colonic and systemic immune responses in gnotobiological IL-10−/− mice
M. Heimesaat* [Berlin, Germany], G. Karadas, A. Fischer, U. Göbel, T. Alter, S. Bereswill, G. Götz

Androgen receptors and microbial-induced experimental bone loss
L. Spolidorio* [Araraquara, Brazil], A. Kantarci, C. Rossa Junior, T. Van Dyke, D. Palomari Spolidorio, J. Steffens

Differential adhesion, aggregation and host attachment in a two-species biofilm
P. Alves, P. Jones, E. Uturutia, K. Purdy, S. Maddocks* [Cardiff, United Kingdom]
P1380  
*Arcobacter butzleri* induce colonic, extra-intestinal and systemic inflammatory responses in gnotobiotic IL-10 deficient mice in a strain-dependent manner


P1381  
Identification of C3 as a critical factor of innate and adaptive responses to poxvirus

J. Delaloye* (Lausanne, Switzerland), D. Le Roy, G. Pantaleo, C. Gomez, B. Perdiguero, M. Esteban, T. Roger, T. Calandra

P1382  
Effect of mycophenolate mofetil on cellular and inflammatory responses in a model of *Staphylococcus aureus* sepsis


P1383  
Analysis of proinflammatory and anti-inflammatory cytokine release in a *Candida albicans*-infected mouse model

B. Erdal Yildirim* (Tekirdag, Turkey), T. Imir

P1384  
Subinhibitory concentrations of micafungin exert species-dependent differential effects on *Candida* and modulate the antifungal activity of human neutrophils against mature biofilms

M. Simitsopoulou* (Thessaloniki, Greece), T. Karampatakis, D. Kyritzi, A. Geladari, P. Kadiatzoglou, C. Antachopoulos, T. Walsh, E. Roilides

P1384A  
*Mycobacterium marinum* can cross the blood-brain barrier via different migration routes

L. van Leeuwen* (Amsterdam, Netherlands), M. van Furth, W. Bitter, M. van der Kuip, A. van der Sar
Tuesday, 12 April 2016

12:30-13:30

**Influenza - clinical epidemiology**

**P1385** Tracing of influenza A H3N2 outbreaks in two nursing homes and a hospital in Bavaria by whole genome sequencing within the Bavarian Influenza Sentinel dataset
D. Meinel* (Basel, Switzerland), S. Heinzinger, U. Eberle, N. Ackermann, K. Schönberger, H. Blum, A. Sing

**P1386** Factors associated with severity in adults hospitalized for influenza infection in France: a three-year multicentric prospective study

**P1387** Severity of influenza in northern Greece, 2014-2015
M. Exindari, G. Gioula* (Thessaloniki, Greece), A. Melidou, N. Malisiovas

**P1388** Emergence of the novel ON1 genotype of respiratory syncytial virus A in France in between 2010 and 2014: relations with clinical features
M. Bouscambert-Duchamp, C. Jean-Sebastien, A. Gaymard, E. Frobert, J. Vallee, B. Lina, F. Morfin* (Lyon, France)

**P1389** A novel diagnostic approach to detection of respiratory tract infections in immunocompromised patients based on the NanoCHIP® microarray system

**P1390** Computational modelling of influenza outbreaks as a tool to predict the impact of epidemics
T. Stadler, D. Vogt, Y. Hollenstein, A. Egli* (Basel, Switzerland)

**P1391** Occurrence and diversity of viruses in acute respiratory tract infections in hospitalized children in wet and dry zones of Sri Lanka

**P1392** Comparison of procalcitonin and C-reactive protein to predict intensive care unit admission with hospital-admitted influenza patients

**P1393** Clinical significance of Streptococcus pneumoniae co-infection during respiratory syncytial virus infections in young children
J. Brealey* (Brisbane, Australia), P. Sly, P. Young, K. Chappell

**P1394** Evaluation of the clinical, operational and infection control effects after implementing the Cepheid Xpert Flu Assay in-house at a district general hospital
S. Reeves* (Liverpool, United Kingdom), I. Kustos, J. Gardiner

**P1395** Reassortment events and pandemic risk assessment of avian influenza viruses in Central Asia
K. Sharshov* (Novosibirsk, Russian Federation), D. Kurskaya, I. Sobolev, M. Gulyaeva, A. Alekseev, A. Shestopolov

**P1396** Influenza virus shedding in the upper and lower respiratory tract of invasively ventilated critically ill patients

**P1397** Predictors of mortality from infection by influenza virus in geriatric population

**P1398** Epidemiological analysis of virulent mutations of A/H1N1pdm09 in hospitalized and out-patients during 2013-14 and 2014-15 epidemic seasons in Spain

**P1399** The prevalence, virological studies and clinical outcome of patients with dual-positive rapid influenza diagnostic test in a tertiary care hospital
J. Lin* (Changhua, Taiwan), F. Kung, C. Lin, C. Hsu, Y. Yeh

**P1400** Influence of viral load in the mortality of infection by influenza A in elderly patients
C. Menendez, M. Alvarez, D. Caravia, A. García, M. de Oña, S. Melan, J. Alonso, A. Rodriguez-Guardado* (Oviedo, Spain)

**P1401** Detection of mutations in haemagglutinin and neuraminidase genes coding for oseltamivir resistance and enhanced virulence/transmissibility among Indian strains of swine influenza A(H1N1)pdm09 viruses
N. Palani* (Puducherry, India), S. Sistla

**P1402** Cellular microRNAs profiling in response to influenza A viral infection based on high-throughput sequencing
J. Makkoch* (Bangkok, Thailand), W. Poamipak, S. Saengchoowong, K. Khongnamnan, K. Praianantathavorn, Y. Poovorawan, S. Payungporn
Clinical profile of patients hospitalized with complicated influenza in 2014-2015 season – a single-centre experience
M. Rus* (Cluj-Napoca, Romania), A. Asiminoaei, C. Cancel, V. Sikadi, M. Flonta, M. Lupse

Hepatitis B vaccination and transmission

Seroprevalence of HBV infection and vaccine escape mutants: 22 years after infant HBV vaccination in Iran
M. Aghasadeghi, A. Aghakhani, S. Mamishi, M. Nabavi, S. Saleymani, M. Haghi Ashtiani, M. Banjazi, R. Vahabpour, F. Matevalli, A. Ramezani* (Tehran, Iran)

HBsAg seroprevalence in Turkish and immigrant pregnant women in Istanbul
R. Bakar, A. Mammadzada, S. Gürsoy* (Istanbul, Turkey), K. Kart Ya ar, B. Done

T. Yang* (Cheongju-si, South Korea), D. Kim, C. Jung, J. Hong

Evaluation of the assay for hepatitis B virus (HBV) surface antigen quantification in the laboratory diagnosis of HBV infection
F. De Conto, A. Fazzi, M. Medici, M. Arcangeletti, F. Pinardi, F. Ferraglia, C. Chezzi, A. Calderaro* (Parma, Italy)

Missed treatment in an Italian HBV infected patients cohort: HBV RER
G. Cuomo* (Modena, Italy), V. Borghi, P. Andreone, M. Massari, E. Villa, A. Pietrangelo, G. Verucchi, P. Ferrari

Hepatitis B in HIV patients in Chile – a cross-sectional multicentre study

Hepatitis C virus (HCV) genotype 1b as a risk factor for hepatocellular carcinoma development in chronic HCV positive patients in southern Italy
A. Petruzzelli* (Naples, Italy), S. Mariglione, G. Loquercio, R. Guarino, F. Izza, C. Cacciapuoti

Understanding the lack of simeprevir drug-resistance Q80K detection in hepatitis C virus subtype 1a clade 2 sequences
A. Peres-da-Silva* (Rio de Janeiro, Brazil), D. Antunes, A. Torres, E. Caffarena, E. Lampe

Detection of Q80K polymorphism using real-time PCR and next-generation sequencing prior to simeprevir therapy in HCV
S. Galli* (Bologna, Italy), D. Dal Monte, A. Barbieri, M. Tamburini, M. Compri, A. Denicolò, M. Meliconi, G. Furlini

Safety and efficacy of DAA therapy in non-genotype 1 HIV/HCV patients in clinical practice

HCV treatment with new direct-acting antivirals (DAAs): are elderly a special population? Real-life experience in a tertiary Italian hospital
S. Ludovisi* (Pavia, Italy), G. Chieffo, S. Novati, R. Gulminetti, R. Maserati, M. Mondelli, L. Minoli

Plasma ribavirin concentration in HCV cirrhotic patients treated with direct acting antivirals (DAAs)

Isolation and characterization of hepatitis C virus resistant to a novel phenanthridinone derivative
M. Baba* (Kagoshima, Japan), W. Ito, M. Okamoto, Y. Hashimoto

How to diagnose and transmit hepatitis E

Multiplex serology for hepatitis A and hepatitis E virus infections – differentiation between natural infection and vaccination
K. Bohm* (Braunschweig, Germany), A. Filomena, N. Schneiderhan-Marra, G. Krause, C. Sievers

Anti-hepatitis E antibody in haemodialysis patients in Isfahan, Iran: prevalence and risk factors
B. Atrae* (Isfahan, Iran), M. Alavian, D. Pirhaji

The epidemiological features of hepatitis E virus infection in Romania
V. Gheorghita* (Bucharest, Romania), A. Streinu-Cercel, O. Sandulescu, A. Barbu, C. Caruntu, A. Streinu-Cercel
P1424  Autochthonous HEV infection in Vicenza, Italy
M. Giordani* [Vicenza, Italy], P. Fabris, L. Romenò, M. Tosti, C. Salata, E. Franchin, L. Bradanini, E. Brunetti, S. Pischke, H. Dalton

P1425  Seroprevalence of hepatitis E virus in humans working with animals in non-porcine consumption areas of Turkey
H. Aydin* [Erzurum, Turkey], M. Uyanik, M. Karamese, M. Timurkan

P1426  Different seroprevalence of hepatitis E virus among Dutch and first-generation migrant populations in Amsterdam, the Netherlands
S. Sadik, M. van Rooijen, G. Sonder, G. van Rijckevorsel, S. Bruisten* [Amsterdam, Netherlands]

P1427  Serum levels of soluble CD26, a novel prognostic marker for hepatitis E infection
A. Rafiei* [Sari, Iran], A. Mirabi, M. Safaar

12:30-13:30  Non-tuberculous mycobacteria

P1428  Identification of non-tuberculous mycobacteria by using commercial DNA probes and gene sequencing: nine-year experience of a single centre in Italy
F. Frascaro* [Modena, Italy], G. Fregni Serpini, A. Grottola, A. Fabio, W. Gennari, S. Tagliazucchi, N. Nanni, G. Farbicini, R. Magnani, F. Rumpianesi, M. Pecorari

P1429  Evaluation of the GenoType Mycobacterium 2.0 PCR-assay for the direct detection of Mycobacterium species in patient specimens
U. Eigner* [Heidelberg, Germany], E. Richter, C. Tauber, R. Schwarz, M. Hofelder

P1430  Nontuberculous mycobacteria: epidemiological pattern in a reference laboratory and risk factors associated with pulmonary disease

P1431  Nontuberculous mycobacteria in an adult cystic fibrosis unit in Madrid
A. Miqueliz Zapatero* [Madrid, Spain], A. Martín, M. Guerrero, R. Girón, D. Domingo

P1432  The rpoB gene as first identification tool of non-tuberculous mycobacteria in developing countries
A. Fateh, P. Afrough* [Tehran, Iran]

P1433  An evaluation of the TB/NTM multiplex real-time PCR assay for detection of nontuberculous mycobacteria
N. Yang, H. Chung, J. Lee, Y. Ryu, J. Chang, S. Lee, M. Lee* [Seoul, South Korea]

P1434  Evaluation of a novel 16S-23S internal transcribed spacer region PCR and capillary gel electrophoresis method for identification of slowly growing non-tuberculous mycobacteria
S. Subedi* [Sydney, Australia], F. Kang, V. Sintchenko, P. Jeifs, S. Chen

P1435  The prevalence of neuropathic pain and its impact on the functional capacity and wellbeing of leprosy patients in Indonesia
N. Abdul Rahman* [London, United Kingdom], Y. Listiawan, D. Lockwood

P1436  Clinical validation of a ND-O–LID ELISA test to detect multibacillary and paucibacillary leprosy
M. Muñoz, J. Beltrán Alzate, M. Duthie, N. Cordona-Castro* [Sabaneta, Colombia]

P1437  Mycobacterium marinum mmar 2318 and mmar 2319 are responsible for lipo-oligosaccharide biosynthesis and virulence towards Dictyostelium
Y. Chen* [Taipei, Taiwan], F. Yang, S. Wu, T. Lin, J. Wang

P1439  Pharmacokinetics of extended-release clarithromycin in patients with Mycobacterium ulcerans infection
S. Kiis* [Groningen, Netherlands], Y. Stienstra, K. Abass, J. Abotts, S. Mireku, J. Alffenaar, T. van der Werf

P1440  Identification of Mycobacterium chelonae as cause of culture-negative prosthetic valve endocarditis
J. Kikhney* [Berlin, Germany], A. Wießner, L. Kursawe, C. Bauhuis, H. Grubitzsch, A. Hiergeist, U. Reischl, A. Moter

P1441  Whole-genome sequencing of Mycobacterium abscessus infected patients in the Oxfordshire area
K. Turner* [Derby, United Kingdom], J. Wrightson, T. Walker, D. Crook, L. Pankhurst

P1442  Mycobacterium abscessus infection in adult patients with cystic fibrosis: clinical and microbiological outcomes
B. Er, N. Emiralioglu, Ç. Inkaya, E. Karkmaz, M. Akova* [Ankara, Turkey], U. Özçelik, N. Kiper, E. Gunes Yalçın, D. Dogru Ersöz, S. Emri

P1443  Inhibition of Mycobacterium abscessus biofilms by Methylobacterium sp.
M. Muñoz-Egea, M. Esteban, J. Esteban* [Madrid, Spain]

P1444  Imperfect correlation between phenotypic and genotypic susceptibility testing of Mycobacterium avium complex and M. abscessus
J. Schildkraut* [Nijmegen, Netherlands], C. Congiu, S. Kuipers, M. Wattenberg, A. De Jong, J. Van Ingen
Phosphate starvation as a signalling factor for PE_PGRS3, but not PE_PGRS4, expression in M. smegmatis
F. De Maio* (Rome, Italy), B. Battah, M. Minerva, S. Camassa, I. Palucci, M. Sanguinetti, M. Sali, G. Delogu

The Mycobacterium smegmatis MSMEG3765 (TetR-like) protein is involved in stress response
F. Perrone* (Caserta, Italy), G. Merola, V. Vastano, R. Marasco, S. Kendall, L. Muscariello, M. Sacco

Disseminated Mycobacterium chimaera infection involving the aortic vascular graft due to a healthcare-associated source presenting early after index surgery with haemophisis
S. Helbig* (Dresden, Germany), K. Wilke, K. De With

Lyme disease

Borrelia burgdorferi seropositivity in various cutaneous disorders
A. Kaya* (Istanbul, Turkey), A. Parlak, A. Aydinli

Application of immunoblot to detect intrathecal response to antigens of B. burgdorferi among patients with early Lyme neuroborreliosis
J. Zajkowska* (Bialystok, Poland), P. Czupryna, J. Dunaj, R. Swierzbinska, A. Moniuszko, S. Pancewicz

Neuroborreliosis mimicking acute encephalopathy: the use of CXCL13 as biomarker in CNS manifestations of borreliosis
M. Karrasch* (Jena, Germany), V. Fingerle, K. Boden, A. Darr, M. Baier, E. Straube, I. Nenadic

Comparison of two CXCL13 assays for diagnosis of neuroborreliosis
S. Desmet* (Leuven, Belgium), K. Lagrou, V. Saegeman

Comparison of symptoms and basic laboratory parameters in patients with B. burgdorferi sensu lato infection to those also co-infected with others tick-borne pathogens
J. Dunaj* (Bialystok, Poland), J. Zajkowska, A. Moniuszko, M. Kondrusik, S. Grygorczuk, P. Czupryna, R. Swierzbinska, S. Pancewicz

A case of neuroborreliosis in Portugal: the importance of laboratory tests in the diagnosis
M. Manaças* (Lisbon, Portugal), S. Llobet, D. Carvalho, J. Cristino, L. Lito

Effectiveness of short-course treatment with ceftriaxone for curing Borrelia burgdorferi infection and preventing urinary tract abnormalities in a mouse model of early Lyme disease
C. Pavia* (Old Westbury, United States), M. Plummer, A. O’Connor

12:30-13:30

Urinary tract infections

The pre-analytical phase, an important step for potential error: a study of 300 requisition and report cards of samples received for urine culture from general practice in Hedmark and Oppland fylker, Norway
S. Hartsen* [Lillehammer, Norway], C. Bahlseide, A. Hartsen

Length of stay and mortality associated with healthcare-associated urinary tract infections: a multistate model
B. Mitchell* (Sydney, Australia), J. Ferguson, M. Anderson, J. Sear, A. Barnett

An economic evaluation of the targeted infection prevention (TIP) programme to reduce multi-drug-resistant organisms (MDROs) and infections in high risk nursing Home Residents
D. Hutton, A. Kolli, R. Lynem, S. Saint, S. Krein, L. Mody* (Ann Arbor, United States)

Bacteriuria due to carbapenem-resistant Enterobacteriaceae in critically ill patients: what comes next?
L. Perez* (Porto Alegre, Brazil), D. Rodrigues, F. Ramos, C. Dias

Healthcare associated urinary tract infections: how different are they when compared to community acquired infections?
H. Ben Ayed, M. Koubaa, T. Ben Jemaa, B. Mnif, M. Gargouri, A. Hammami, C. Marrakchi, M. Ben Jemaa* (Sfax, Tunisia)

Catheter-associated urinary tract infection rates: impact the check-list

Study of paraoxonase-1 in patients with asymptomatic catheter-associated bacteriuria and relation with recent surgical procedure
S. Ifitimie Ifitimie* (Reus, Spain), A. Garcia-Heredia, L. Ana Felisa, A. Cordoba, I. Pujoj, F. Ballester, J. Joven, A. Castro, J. Camps

Long-term care facilities are an important reservoir of urinary tract bacteria resistant to antibiotics
A. Rosello* (London, United Kingdom), A. Hayward, S. Hopkins, C. Horner, D. Ironmonger, P. Hawkey, S. Deeny

Evolution of uropathogens and antimicrobial susceptibility of the putative E. coli isolates in uncomplicated cystitis in Belgium: a 20 year surveillance
S. Heytens, A. De Sutter, T. Christiaens, J. Boelens, G. Claeyss* (Ghent, Belgium)
P1465  Epidemiology of Gram-positive cocci urinary tract infections: about 801 cases in a French hospital
F. Camelena, B. Pilmis, J. Nguyen Van, A. Mizrahi* [Paris, France], A. Le Mannier, J. Lauret

P1466  Acute pyelonephritis in adults: clinical, microbiological and imaging features of 198 patients at a single centre
J. Testa* [Varese, Italy], D. Radrizzani, D. Lombardi, A. Petrola, A. Romenin, D. Dalla Gasperina, P. Grossi

P1467  Acute lower urinary tract infections: aetiology, antimicrobial resistance patterns and treatment results
I. Erdem* [Tekirdag, Turkey], S. Elbasan, R. Kara Ali, M. Dogan, H. Gunes, R. Mutlu, A. Eren Topkaya

P1468  Characterization of pathogens and their antibiotic susceptibility patterns among neonates and infants, with or without jaundice, suffering from urinary tract infection
M. Pooya* [Tehran, Iran], F. Mir-Marashi, S. Bouzari, M. Mardani

P1469  ESBL-producing E. coli of O25b-ST131 clone as a cause of recurrent urinary tract infections in comparison to other ESBL-producing E. coli
V. Linden, E. Moore, C. Ahrén, N. Karami* [Gothenburg, Sweden]

P1470  The occurrence of virulence factors in relation to resistance to quinolones and chloramphenicol among uropathogenic Escherichia coli strains isolated from community-acquired patients
S. Chmielewska* [Białystok, Poland], K. Fiedoruk, K. Leszczyńska

P1471  Investigating the presence of Mycoplasma hominis - Ureaplasma urealyticum and in vitro antimicrobial susceptibilities in patients with sterile pyuria
M. Seleń* [Istanbul, Turkey], B. Bektöre, T. Kula Atik, B. Yalçın, O. Baylan, M. Özçayır

P1472  Susceptibilities of E. coli recovered from urine considered urinary tract infection [UTI] positive and contaminated
M. Wootton* [Cardiff, United Kingdom], J. Richards, A. Bryce, A. Hay, R. Howe

P1473  Relationship between conventional cultures and flow cytometry for the diagnosis of urinary tract infection
M. García Coca, G. Rodríguez Seville, I. González Pallarés, I. Gadea Gironés, J. Esteban* [Madrid, Spain]

P1474  Should we perform voiding cystography in all the children after urinary tract infection?
N. Wasilewska, A. Dzik, K. Szwarc, A. Czyż, A. Wasilewska* [Białystok, Poland]

P1475  Replacement of urinary catheter does not reduce clinical failure or fatality rates among inpatients with catheter-associated urinary tract infections - a prospective observational study
T. Babich* [Petah Tikva, Israel], O. Zusman, M. Elbaz, M. Paul, L. Leibovici, T. Avni

P1476  Long-term survival among patients with catheter associated urinary tract infection - a prospective observational study
T. Babich* [Petah Tikva, Israel], O. Zusman, M. Elbaz, M. Paul, L. Leibovici, T. Avni

P1477  Evaluating treatment patterns and clinical outcomes among hospitalized patients with complicated urinary tract infection [cUTI] based on an interim analysis in Europe and Russia of the RECOMMEND Study
K. Ryan* [Gaithersburg, United States], S. Karve, P. Peeters, E. Baalen, Y. Tazir, S. Rojas Farreras, D. Patte, J. Rodríguez-Baño

P1478  Effect of a probiotic preparation (VSL#3) and rifaximin to prevent recurrent lower UTI in diabetic patients
A. Perrella* [Naples, Italy], C. Sbreglia, P. Bellopede, D. Perrella

P1479  Revival of an old antibiotic, efficacy of cefoxitin versus carbapenem in male urinary tract infections caused by extended-spectrum-beta-lactamase producing Escherichia coli: a retrospective cohort study
O. Senard* [Créteil, France], V. Fihman, N. Oubaya, F. Canoui-Poitrine, M. Perraoudin, P. Lesprit, R. Lepeule

P1480  Cefoxitin-based antibiotic therapy for ESBL-producing Enterobacteriaceae prostatitis: a prospective pilot-study
E. Demonchy* [Nice, France], J. Courjon, V. Mondain, C. Touati, R. Garraffo, P. Roger

P1481  Treatment of ESBL-producing E. coli prostatitis by ertapenem: is it as good as other carbapenems?
J. Chaucair* [Beirut, Lebanon], A. Mroué

P1482  Reporting patterns and cost of care associated with empirical antibiotic therapy for inpatients with community-acquired urinary tract infections [ca-UTIs]: experience from a Greek tertiary hospital medical care unit
K. Akinosoglou* [Patras, Greece], C. Koutsouri, V. Niarou, M. Kolosaka, C. Gogos

P1483  Potentially inappropriate treatment of catheter-associated urinary tract infections in hospitalized patients
M. Molina* [Barcelona, Spain], E. Acosta, À. Jaen, M. Xercavins, Q. Jordano
Investigating the healthcare resource utilization associated with complicated urinary tract infections in three phase 3 trials for ceftazidime-avibactam
R. Lawson, K. Ryan* (Gaithersburg, United States)

The role of piperacillin-tazobactam as carbapenem-sparing antibiotic therapy for treating acute pyelonephritis due to extended-spectrum beta-lactamase-producing Escherichia coli
Y. Yoon* (Seoul, South Korea), J. Kim, J. Sohn, K. Yang, M. Kim

Successful treatment of recurrent and complicated urinary tract infection in an immunocompromised patient caused by carbapenem- and colistin-resistant Klebsiella pneumoniae with the association of chloramphenicol and ertapenem
L. Perdigão Neto, A. Matos Porto, T. Di Gioia, R. Garcia da Silva, R. Barbosa Cunha de Souza, S. Mayer Coutinho, F. Camello, S. Bezerra Cappi, S. Figueiredo Costa* (Sao Paulo, Brazil), M. Salaroli de Oliveira

Diabetic foot infection

Epidemiology of diabetic foot infections and predictive factors for amputation
N. Saltoglu* (Istanbul, Turkey), M. Yemisen, S. Surme, M. Ozyazar, H. Tuzun, Y. Aydin, M. Diabetic Foot Study Group

Blood cultures after bone debridement in patients with diabetic foot osteomyelitis
P. Letertre-Gibert* (Clermont-Ferrand, France), M. Garonnaire, F. Desbiez, M. Vidal, N. Mrozek, B. Pereira, I. TAUVERON, O. LESENS

Infection and gut colonization by KPC-producing Klebsiella pneumoniae as risk factors for mortality in patients with diabetic foot infections: a multicentre case-control study

Acinetobacter infections in diabetic foot patients
S. Taori* (London, United Kingdom), P. Vas, N. Desai

Deep foot infection caused by Fusobacterium russii
E. Ullrich* (Graz, Austria), A. Grisold, G. Feierl, D. Lumenta, E. Leitner

Local use of antibiotic beads for the treatment of foot osteomyelitis in patients with type 2 diabetes
A. Xanthopoulos* (Alexandroupolis, Greece), P. Panagopoulos, G. Drosos, N. Papanas, E. Maltezos

Quinolone resistance

Compared transcriptomic profile of isogenic Escherichia coli strains harbouring quinolone resistance mechanisms in the presence of ciprofloxacin
J. Rodriguez Martinez* (Seville, Spain), A. Briales, J. Machuca, P. Diaz de Alba, E. Recacha, A. Pascual Hernandez

Prevalence of qnr in extended spectrum -beta-lactamase -producing Klebsiella pneumoniae from the university hospital establishment of Oran, Algeria
A. Zemmour* (Oran, Algeria), R. Abi Ayad, N. Saidi-Duahmani, R. Bouabdellah, C. Giske

Bias in the mutational spectrum of efflux mutations in ciprofloxacin-resistant Escherichia coli: is there a selective advantage?
L. Praski Alzrigat* (Uppsala, Sweden), D. Huseby, D. Hughes

Effect of Aac(6’)-Ib-cr combined with chromosomal mediated fluoroquinolone resistance mechanisms on quinolone susceptibility and bacterial fitness in Escherichia coli
M. Ortiz Padilla, J. Machuca* (Seville, Spain), P. Diaz de Alba, E. Recacha, A. Pascual Hernandez, J. Rodriguez Martinez

Overexpression of efflux pump genes in quinolone resistant ST131 Escherichia coli
N. Atac* (Istanbul, Turkey), F. Can, O. Azap, O. Ergonul

Antimicrobial activity of silver nitrate and its combinations with quinolones against quinolone resistant Escherichia coli

Genotypes behind nalidixic acid-resistant, ciprofloxacin-susceptible phenotype in E. coli
L. Víñuela Sandoval, A. García Señán, J. Munoz-Bellido* (Salamanca, Spain)

Investigation of qnrD-harbouring plasmid in Morganella morgani

Induction of PMQR gene expression by fluoroquinolones among clinical isolates of Enterobacteriaceae with identical QRDR mutation profile: a first report
Y. Thiyagarajan* (Puducherry, India), B. Harish
Antibacterial resistance: the animal and food production part of one health

P1502

Monophasic Salmonella typhimurium and the pig’s life cycle – a longitudinal study
L. Fernandes* (Lisbon, Portugal), M. Centeno, T. Nunes, V. Almeida, L. Alban, C. Pomba

P1503

Comparison of Escherichia coli ESBL from human and fattening pig faeces in Styria, Austria
G. Zarfel, H. Galler, J. Luxner, J. Habib, D. Haas, C. Petternel, P. Piess, F. Reinthaler* (Graz, Austria), G. Feierl

P1504

Quantification of fluoroquinolone-resistant zoonotic bacteria in pigs during one year following enrofloxacin treatment
P. Damborg* (Frederiksberg, Denmark), E. Okholm Nielsen, M. Nielsen, B. Lorenzen, P. Bækbo, J. Olsen

P1505

Good news from German stables: no carbapenemases found in the national monitoring of resistances of commensal and ESBL/AmpC-producing E. coli

P1506

Antibiotic resistance of Escherichia coli isolated from poultry farms in Greece: preliminary results
A. Xexaki* (Thessaloniki, Greece), G. Filiousis, T. Papadopoulos, E. Sassidou, E. Petridou

P1507

Transfer potential of a commonly occurring conjugative IncK plasmid with blacMY-2 in Escherichia coli from poultry into different bacterial hosts under variable conditions
S. Mo* (Oslo, Norway), M. Sunde, H. Ilag, S. Langsrud, E. Heir

P1508

Identification of third-generation cephalosporin-resistant Escherichia coli from chicken and chicken meat in Brazil
T. Casella* (São José do Rio Preto, Brazil), M. Haenni, T. Salvetti Eugenia, M. Nogueira, J. Madec

P1509

Characterization of IncX3 plasmids harbouring blacSHV-12 in Escherichia coli from human and animal origin
A. Liakopoulos* (Lelystad, Netherlands), F. Haders, A. Kant, M. Brauwer, D. Ceccarelli, H. Smith, D. Mevius

P1510

Prevalence of extended-spectrum beta-lactamase and carbapenemases in feces of poultry from Algeria
S. Chabou* (Marseille, France), H. Leulmi, B. Davoust, A. Aouadi, B. Raoult, J. Rolain

P1511

Multidrug-resistant (MDR) extended-spectrum beta-lactamase (ESBL) producing Enterobacteriaceae in intestinal colonization of Portuguese sheep
H. Ferreira, J. Palmeira* (Porto, Portugal)

P1512

Quinolone-resistant Escherichia coli from poultry in Norway - characterization, comparison to human isolates and molecular risk assessment
J. Slettemeås* (Oslo, Norway), C. Sekse, M. Sunde, M. Norström, A. Wester, K. Lagesen, G. Simonsen, C. Ulstad, A. Urdaahl

P1513

‘One Health’ laboratory surveillance and characterization of multidrug-resistant Escherichia coli in the upper USA
Midwest: preliminary report
T. Fritsche* (Marshfield, United States), B. Olson, M. Hall, S. Shukla, T. Novicki, F. Moore, D. Ortiz

P1514

Analysis of blacSHV-12-carrying plasmids in Escherichia coli from human, animal and food sources
C. Alonso* (Logroño, Spain), G. Michael, J. Li, S. Somalo, C. Simón, Y. Wang, C. Torres, S. Schwarz

P1515

Intestinal colonization of Brazilian cattle with multidrug-resistant (MDR) non-fermenting Gram-negative bacilli (NFGNB)
J. Palmeira* (Porto, Portugal), H. Ferreira

P1516

Spread of major human ESBL and AmpC-producing Escherichia coli lineages in companion animals with UTI over 17 years in Portugal
A. Belas, C. Marques, A. Franco, C. Pomba* (Lisbon, Portugal)

P1517

Dynamics of faecal carriage of ESBL-producing Escherichia coli in dairy cattle

P1518

Gulls’ microbiota: a study on multiresistant bacteria

P1519

Prevalence of ESBL and/or carbapenemase-producing Escherichia coli isolated from yellow–legged gulls from Barcelona, Spain
A. Vergara Gómez* (Barcelona, Spain), C. Pitart, T. Montalvo, J. Hurtado, S. Sabate, R. Planell, F. Marco Reverte, B. Ramirez, V. Peracho, M. de Simón, J. Vila

P1520

Expansion of ESBL-producing high-risk virulent ST15 Klebsiella pneumoniae lineage causing urinary tract infection in companion animals
C. Marques* (Lisbon, Portugal), J. Menezes, G. Trigueiro, A. Duedraogo, L. Jean-Pierre, S. Godreuil

P1521

Characterization of antimicrobial resistance in Pseudomonas spp. isolates from healthy animals and children
L. Ruiz-Roldán, B. Rojo-Bezares, C. Casado, J. Azcona, C. Torres, Y. Saenz* (Logroño, Spain)
P1522 High prevalence of beta-lactamase-producing Enterobacteriaceae: also in captivity animals from zoological gardens in Belgium
L. Bauwens, P. Bogaerts* (Yvoir, Belgium), Y. Glupczynski, F. Vercammen

12:30-13:30
Lessons from surveillance of resistance in Gram-negatives

P1523 From surveillance cultures to clinical practice, should they guide antibiotic therapy?

P1524 Laboratory network collaboration is necessary to generate comparable local resistance data

P1525 Age related antimicrobial resistance
M. Heginbothom* (Cardiff, United Kingdom), R. Howe

P1526 High frequency of Gram-negative drug-resistant bacteria both in community- and hospital-acquired bloodstream infections (BSI) in a hospital setting from northern Italy

P1527 Trend of antibiotic resistance compared to antibiotic consumption at a referral university hospital during a 7-year period (2008-2014)
J. Monticelli* (Trieste, Italy), M. Simonetti, M. Mascarello, M. Busetti, A. Knezevic, L. Torelli, P. Schincariol, R. Luzzati

S. Newitt* (Nottingham, United Kingdom), D. Ironmonger, A. Bains, R. Puleston, A. Johnson, D. Edeghere

P1529 Antimicrobial resistance trends in Escherichia coli and Klebsiella pneumoniae urinary isolates from Switzerland over a 5-year period (2009-2014)
V. Zanichelli* (Geneva, Switzerland), B. Huttner, M. De Kraker, S. Harbarth, A. Chronopoulou

P1530 A 3-year retrospective study of bacterial spectrum and antimicrobial resistance in patients with bacteraemia
C. Vossou* (Athens, Greece), A. Kouki, M. Katsani, N. Chiotinis, G. Chronopoulou

S. Lob, K. Kazmierczak, R. Badal* (Schaumburg, IL, United States), A. Johnson, D. Sahm

P1532 Antimicrobial susceptibility of Gram-negative pathogens causing intra-abdominal infections in paediatric and adult patients in France, Germany, Italy and Spain
D. Biedenbach, D. Sahm, M. Hackel* (Schaumburg, IL, United States), H. Leister-Tebbe

P1533 Trends and molecular characterization on beta-lactamase ESBL in Enterobacteriaceae in intraabdominal and urinary tract infections in Central America and Dominican Republic - the SMART study 2009-2013
S. Vega Degracias* (Panamá City, Panama), C. Rodriguez-Taveras, C. Mejía Villatoro, L. González Patzán, Y. Gil

P1534 Continuous increase of antimicrobial resistance in urinary tract microorganisms over 20 years: analysis of 422’000 urinary specimens
S. Erb, S. Tschudin-Sutter, R. Frei, A. Egli, M. Dangel, G. Bonkat, A. Widmer* (Basel, Switzerland)

P1535 Molecular characterization of beta-lactam resistant pathogens isolated from urinary infections in Lebanon and Jordan: an evaluation of SMART data 2010-2014
A. Hajj* (Beirut, Lebanon), W. Hayajneh, T. Itani, A. Adame, R. Alsamarneh, R. Badal, D. Karam Sarkis

P1536 Distribution of beta-lactamases in Gram-negative pathogens from urinary tract infections in Europe – SMART 2010-2014
K. Kazmierczak, S. Lob, R. Badal* (Schaumburg, IL, United States), S. Bouchillou, D. Sahm

P1537 Trends and molecular characterization of beta-lactamases ESBL in Enterobacteriaceae in intraabdominal and urinary tract infections in the Dominican Republic: the SMART study 2002-2013
C. Rodriguez Taveras* (Santo Domingo, Dominican Republic), Y. Gil

P1538 Increasing impact of multiresistant Gram-negative bacilli in a neonatal intensive care unit (NICU): a 5-year surveillance prospective cohort study
D. Geraci* (Palermo, Italy), G. Graziano, L. Saporito, D. Vecchio, V. Insigni, M. Giuffe, C. Mammina

P1539 In vitro susceptibility of multidrug-resistant (MDR) Escherichia coli (EC) and Klebsiella pneumoniae (KPN) from eastern and western Europe during 2012-2015 surveillance years (TEST Program)
D. Biedenbach, D. Sahm* (Schaumburg, IL, United States), D. Biedenbach, M. Hackel, H. Leister-Tebbe

P1540 Resistance patterns among Escherichia coli and Klebsiella pneumoniae isolates from four European regions: SMART 2012-2014
S. Lob, K. Kazmierczak, D. Hoban, R. Badal* (Schaumburg, IL, United States), D. Sahm
<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>P1541</td>
<td>Antimicrobial susceptibility and multi-drug resistance in the Middle East: SMART 2012-2014</td>
<td>S. Lob, R. Badal* (Schaumburg, IL, United States), D. Hoban, A. Johnson, D. Sahm</td>
</tr>
<tr>
<td>P1542</td>
<td>The emergence of multidrug resistant Gram-negative pathogens in blood cultures of inpatients at “Venizeleio” General Hospital of Crete: review of the first semester 2015</td>
<td>M. Rigkas* (Heraklion, Greece), X. Papachatzaki</td>
</tr>
<tr>
<td>P1544</td>
<td>Elizabethkingia species: organisms difficult to identify and with frequent resistance to multiple antimicrobial agents</td>
<td>H. Kim* (Seoul, South Korea), M. Han, Y. Lee, M. Kim, D. Yang, S. Jeong, K. Lee, Y. Chang</td>
</tr>
<tr>
<td>P1545</td>
<td>Stenotrophomonas maltophilia infection in patients after haematopoietic stem cell transplantation (HSCT) at HC-FMUSP from 2001 to 2014</td>
<td>L. Mau* (Sao Paulo, Brazil), M. Batista, G. Villas Boas do Prado, F. Rossi, T. Guimaraes, M. Martins de Almeida Macedo, F. Spadao, J. Isaac Garcia Paez, S. Figueiredo Costa</td>
</tr>
<tr>
<td>P1547</td>
<td>Emergence of uncommon non-fermenting Gram-negative bacilli in a tertiary care hospital in Karachi</td>
<td>S. Anwar* (Karachi, Pakistan)</td>
</tr>
<tr>
<td>P1548</td>
<td>Emerging of tetracycline resistance among V. cholerae isolates during the last decade in Iran</td>
<td>M. Rahbar* (Tehran, Iran), R. Sabourian, M. Hajia</td>
</tr>
<tr>
<td>P1550</td>
<td>Emergence of extensive fluoroquinolone resistance in Campylobacter gastroenteritis in Liverpool, United Kingdom</td>
<td>A. Stockdale* (Liverpool, United Kingdom), N. Beeching, J. Anson, M. Beadsworth</td>
</tr>
<tr>
<td>P1551</td>
<td>Molecular analysis of antibiotic resistance gene clusters in Plesiomonas sp. clinical isolates</td>
<td>S. Selim* (Sakaka, Saudi Arabia)</td>
</tr>
<tr>
<td>P1552</td>
<td>Candidaemia due to fluconazole non-sensitive strains</td>
<td>E. Cantero* (Madrid, Spain), M. Soriano Segura, A. Lerma Verdejo, A. Ramos Martinez, B. Orden</td>
</tr>
<tr>
<td>P1553</td>
<td>Epidemiology of bloodstream infection due to Candida species in a tertiary care hospital in Japan over 12 years: importance of peripheral-line associated candidaemia</td>
<td>M. Ishikane* (Tokyo, Japan), K. Hayakawa, S. Kutsuna, N. Takeshita, N. Ohmagari</td>
</tr>
<tr>
<td>P1554</td>
<td>Genotyping demonstrated a reduction in the nosocomial transmission of Candida albicans and Candida parapsilosis after a campaign to control catheter-related infection</td>
<td>P. Escriva Martos, L. Marcos-Zambrana, P. Munoz, C. Sánchez-Carrillo, E. Bouza Santiago, J. Guinea* (Madrid, Spain)</td>
</tr>
<tr>
<td>P1555</td>
<td>Association between fungaemia and colonization of gastrointestinal tract of the infants</td>
<td>L. Lyubasovskaya* (Moscow, Russian Federation), T. Priputnevich, A. Gardeev, A. Melkumyan, V. Muravieva, J. Rodchenko, D. Dubodelov, V. Zubkov, G. Sukhikh</td>
</tr>
<tr>
<td>P1557</td>
<td>Analysis of bloodstream infections by Saprochaete clavata and Saprochaete capitata, two emerging pathogens in immuno-compromised patients</td>
<td>A. Hamprecht* (Cologne, Germany), M. Desnos-Ollivier, S. Göttig, O. Bader, A. Pranada, A. Haas, M. Aigner, A. Saleh, F. Dromer, M. Koeppe</td>
</tr>
<tr>
<td>P1558</td>
<td>Meta-analysis of incidence and mortality from candidaemia in Europe</td>
<td>P. Köhler* (Cologne, Germany), O. Cornel, D. Tacke, M. Vehreschild, H. Wisklinghoff, J. Vehreschild</td>
</tr>
</tbody>
</table>
P1560 Epidemiology, species distribution and antifungal susceptibility activity of Candida bloodstream infections in a university hospital

P1561 Epidemiology of fungaemia in haematological malignancies: preliminary report of SEIFEM-2015 survey

P1562 Risk factors for nosocomial candidaemia in medicine wards compared to surgery and intensive care units: a multicentre study in elderly patients
R. Luzzati* (Trieste, Italy), C. Rosin, M. Merelli, F. Ansaldi, A. Azzini, S. Cavinato, P. Brugnaro, C. Vedovelli, A. Cattelan, S. Grandesso, M. Busetti, E. Concia, M. Bassetti

P1563 Clinical features and risk factors for candidaemia in cirrhotic patients
C. Campoli, M. Bartoletti, L. Raumer, S. Tedeschi, F. Cristini, S. Ambretti, P. Caraceni, M. Bernardi, M. Giannella, P. Viale, M. Bartoletti* (Bologna, Italy)

P1564 Risk factors for nosocomial candidaemia in non-neutropenic patients admitted to internal medicine wards: results from a multicentre case-control study

P1565 Characteristics of candidaemia in oncology differ from those in haematology: a prospective study over a decade

P1566 Changing trends of candidaemia in Colombian tertiary care hospitals from 2008 to 2014
P. Pinzon* (Bogota, Colombia), A. Leal Castro, J. Cortes, C. Alvarez, C. Zapata, M. Ovalle

P1567 Use of transthoracic echocardiography in Candida bloodstream infection
M. Sredkova* (Pleven, Bulgaria), H. Hitkova, A. Bachvarova-Nedelcheva, R. Iordanova

P1568 Population pharmacokinetics of isavuconazole in patients with invasive Candida infections (IC) and combined analysis of patients with IC or invasive aspergillosis
A. Desai* (Northbrook, United States), L. Kovanda, C. Lademacher, R. Townsend, S. Mujais, P. Bonate

P1569 Determination of a EUCAST PK/PD breakpoint for voriconazole and Candida glabrata
P. Georgiou* (Athens, Greece), M. Siopi, L. Kanioura, M. Arendrup, J. Mouton, J. Meletiadis

P1570 Pharmacokinetics of anidulafungin in critically ill patients in the intensive care unit with suspected or proven invasive fungal infections
R. Brüggemann* (Nijmegen, Netherlands), V. Middel-Baars, D. de Lange, A. Colbers, A. Girbes, P. Pickkers, N. Swart

P1571 Pharmacokinetics and absolute bioavailability of voriconazole administered through a nasogastric tube with continuous enteral feeding to critically ill ventilated patients
C. Padoin* (Bobigny, France), P. Koroubi, A. Rabbat, C. Huang, J. Oziel, G. Van Der Meersch, Y. Tandjaoui-Lombiotte, F. Gonzalez, C. Clech, Y. Cohen

P1572 Activity against fungi of nonhydrolytic synthesized TiO2
M. Svedkova* (Pleven, Bulgaria), H. Hitkova, A. Stoyanova, A. Bachvarova-Nedelcheva, R. Iordanova

P1573 Invasive mycoses (IM) and prescribing of antifungal drugs (AFD) in adult patients (pts) with newly diagnosed acute lymphoblastic leukaemia (ALL): RIFI study
G. Klyasova* (Moscow, Russian Federation), V. Okhmat, V. Vasilieva, I. Toropova, K. Kaplanov, T. Zagoskina, O. Karobicina, E. Parovichnikova, V. Savchenko

P1574 The novel orotomide F901318 demonstrates potent in vitro antifungal activity against Lomentospora and Scedosporium species
A. Marangoni* (Bologna, Italy), C. Foschi, M. Micucci, R. Nahui Palomino, B. Vitali, P. Nardini, R. Cevenini, R. Budriesi

P1575 In vitro anti-Candida activity of a Spirulina platensis extract: a new approach for the treatment of fungal infections?
A. Marangoni* (Bologna, Italy), C. Foschi, M. Micucci, R. Nahui Palomino, B. Vitali, P. Nardini, R. Cevenini, R. Budriesi

P1576 A randomized clinical trial of the efficacy and safety of clotrimazole vaginal tablet versus oral fluconazole in treating severe vulvovaginal candidiasis
X. Liu* (Shenzhen, China), S. Fan
P1578 Allometric scaling and the chimpanzee as a surrogate for human pharmacokinetics of CD101, a novel echinocandin
V. Ong* [San Diego, United States], K. Bartizal

P1579 Cost-effectiveness analysis of combination antifungal therapy with voriconazole and anidulafungin versus voriconazole monotherapy for primary treatment of invasive aspergillosis

P1580 Proven invasive candidiasis in intensive care units: do echinocandins improve the prognosis compared to azoles?

P1581 Micafungin serum levels in critically ill patients on continuous venovenous haemodialysis using high cut-off membranes [CVVHD-HCM]

P1582 The impact of colistin upon the fungicidal effect of liposomal amphotericin B

P1583 Pharmacokinetic-pharmacodynamic analysis of micafungin in critically ill ICU patients

P1584 In vitro activity of isavuconazole against azole-resistant environmental Aspergillus fumigatus isolates, cryptic Candida strains and emerging yeasts
P. Le Pape* [Nantes, France], B. Aniza, C. Lage, R. Lavergne, F. Maria, C. Picot, S. Valderrama, C. Alvarez

P1585 Activity of rifampin on planktonic and biofilm Candida spp. (alone and in combination with amphotericin B) determined by microcalorimetry
M. Czuban* [Berlin, Germany], E. Maiolo, A. Trampuz

P1586 Differences in cytokine levels in diabetic versus non-diabetic mice challenged with Candida albicans and treated with liposomal amphotericin B
J. Olson* [Pomona, United States], A. Varela, J. Adler-Moore

P1587 Pharmacokinetics of micafungin in patients receiving extracorporeal membrane oxygenation
M. López Sánchez* [Santander, Spain], S. Grau, I. Moreno Puigdollers, M. Rubio López, S. Luque, J. Roberts

P1588 Diagnosis and management of invasive fungal diseases at an English district general hospital; antifungal stewardship – a much needed intervention
H. Habayeb* [London, United Kingdom], C. Grundy, J. Rangaiah, M. Barker

P1589 A point-prevalence study of antifungal therapy in Greek hospitals
D. Kofiteridis* [Heraklion, Greece], A. Andrianaki, M. Marangos, M. Papadimitriou-Olivergeris, N. Sipsas, E. Apostolidi, E. Maltezos, P. Panagopoulos, D. Karapiperis, I. Papadakis, C. Bikis, G. Samonis

P1590 Approaches for using of antifungal drugs [AFD] in adult patients [pts] with newly diagnosed acute myeloid leukaemia (AML) in real clinical practice in Russia: RIFI study
G. Klyasova* [Moscow, Russian Federation], V. Okhmat, T. Kaporskaya, I. Sveshnikova, K. Kaplanov, I. Taropava, T. Zagoskina, O. Korkicina, T. Bogdan, V. Lariunova, A. Pritysta, E. Blakhina, E. Parovichnikova, V. Savchenko

P1591 Utility of the IA diagnosis biomarker bis(methylthio) gliotoxin to monitor voriconazole treatment
M. Vidal-García* [Zaragoza, Spain], S. Redrado, M. Domingo, B. de Rueda, L. Costilla, M. Sanz, L. Rcu, M. Delgado, M. Revilla, J. Pardo Jimeno, E. Galvez, A. Rezusta

P1592 Treatment of recurrent oesophageal candidiasis (REC) in HIV-negative patients in St. Petersburg, Russia
N. Klímková* [St. Petersburg, Russian Federation], J. Melekhina, V. Shevyakov, J. Avedenso, E. Frolova, T. Bogomolova, I. Vybornova, N. Vasilyeva

P1593 Cost-effectiveness analysis of prophylaxis therapies for invasive fungal infections following allogeneic haematopoietic stem cell transplantation in Mexico

P1594 Cost-effectiveness of posaconazole tablets compared to oral fluconazole or itraconazole in the prevention of invasive fungal diseases among high-risk neutropenic patients with either acute myelogenous leukaemia or myelodysplastic syndrome in Spain
R. Cámara, S. Grau, M. Jurado, J. Sanz, S. Poz, B. Aragón, R. Cavanillas* [Madrid, Spain]
P1595 Therapeutic drug monitoring of antifungal drugs: another tool to improve patient outcome?
A. Vena* [Madrid, Spain], P. Muñoz, M. Mateos, F. Cajuste, J. Guinea, P. Escribano Martos, M. Valerio Minera, E. Bouza Santiago

P1596 Is fluconazole resistance (FLU-R) in Cryptococcus neoformans predictive of clinical outcome?
A. Vena* [Madrid, Spain], P. Muñoz, T. Peleaz Garcia, J. Guinea, F. Braojos Sanchez, C. Martos Diaz, M. Valerio Minera, E. Bouza Santiago

P1597 Factors correlated to the length of antifungal therapy in a cohort of patients with candidaemia
M. Fantoni, G. Scoppettuolo, G. Ventura, F. Giovannenze, F. Taccari, I. Mastrorosa, B. Posteraro, M. Sanguinetti, R. Cauda, R. Murri* [Rome, Italy]

P1598 Anti-biofilm properties of Peganum harmala against Candida albicans
N. Sadeghifard* [Ilam, Iran], E. Aboualigalehdari, R. Mohebi, S. Ghafourian

P1599 Once-weekly dosing requires a proportionally higher dosage of micafungin for treatment of experimental disseminated candidiasis caused by Candida glabrata in persistently neutropenic rabbits
R. Petraitiene* [New York, United States], V. Petroaits, B. Maung, N. Skaikh, N. Sekhon, W. Hope, T. Walsh

P1600 Utility of dried sample spot (DSS) for voriconazole TDM
A. Gomez Lopez* [Madrid, Spain], M. Cuadros Nuñez, A. Donoso, L. Bernal Martinez

P1601 Population pharmacokinetics of micafungin in plasma and burn eschar in severely burned critically-ill patients
A. García de Lorenzo Y Mateos, S. Luque, S. Grau* (Barcelona, Spain), A. Agrifoglio, L. Cachafeiro, E. Herrera, M. Asensio, M. Sánchez, J. Roberts

12:30-13:30

Update in fungal resistance and susceptibility

P1603 In vitro exposure to micafungin promotes echinocandin resistance in clinical Candida glabrata isolates
M. Bordallo* [Madrid, Spain], P. Escribano Martos, E. Garcia G. de la Pedrosa, L. Marcos-Zambrana, R. Canton Moreno, E. Bouza Santiago, J. Guinea

P1604 Description of fungicide-driven alterations in azole-resistant Aspergillus fumigatus related to vegetable crops in Colombia, South America
C. Alvarez* [Bogota, Colombia], R. Lavergne, F. Morio, P. Le Pape

P1605 Activity of F901318 against azole-resistant and other difficult-to-treat Aspergillus species
J. Buil* [Nijmegen, Netherlands], A. Rijs, J. Meis, M. Birch, D. Law, W. Melchers, P. Verweij

P1606 Whole-genome sequencing of multidrug-resistant Candida auris isolates demonstrates clonal strains in Indian hospitals
C. Sharma* [Delhi, India], N. Kumar, P. Kumar Singh, R. Pandey, A. Chawdhary

P1607 Echinocandin resistance in Candida spp. isolated from liver transplant recipients

P1609 A case report of septic arthritis and osteomyelitis of the knee caused by Candida viswanathii successfully treated with oral voriconazole
H. Wong* [Singapore, Singapore], J. Chien

P1610 Rapid detection of fluconazole and anidulafungin resistance in Candida glabrata isolates using a MALDI-TOF MS-based assay
E. Mello, A. Vella, E. De Carolis, B. Posteraro, D. Sanglard, D. Perlin, M. Sanguinetti* [Rome, Italy]

P1611 In vitro antifungal susceptibility profile of Trichophyton schoenleinii isolated from 55 Tinea capitis favosa in Iran, China, and Turkey
S. Deng* [Shanghai, China], S. Ansari, M. Ilkit, H. Rofati, M. Hedagati, A. Taloe, H. van der Lee, P. Verweij, S. Seyedmousavi

P1612 Azole resistance in Aspergillus fumigatus in Switzerland; survey in a rural area
A. Imhof* [Langenthal, Switzerland], G. Senn

P1613 Disagreement between the ETest performed directly on blood culture bottles and the standard microdilution procedures to detect fluconazole resistance in C. albicans
P. Escribano Martos, L. Marcos-Zambrana, C. Sánchez-Carrillo, E. Bouza Santiago, J. Guinea* [Madrid, Spain]

P1614 Do patients with fungal rhinosinusitis harbour azole-resistant A. fumigatus isolates? Preliminary findings at a single French centre
F. Mario* [Nantes, France], E. Tamic, O. Malard, R. Lavergne, P. Le Pape

P1615 Molecular analysis by DiversiLab and antifungal susceptibility by YeastOne of clinical isolates of Trichosporon asahii from Turkey
D. Ö zgür* [Mersin, Turkey], . Direkel, E. Oktay, F. Otag

P1616 Growth of Candida albicans on agar plates containing high concentrations of fluconazole: antifungal resistance or trailing?
M. Bordallo* [Madrid, Spain], L. Marcos-Zambrana, E. Garcia G. de la Pedrosa, P. Escribano Martos, E. Bouza Santiago, J. Guinea, R. Canton Moreno
<table>
<thead>
<tr>
<th>P1617</th>
<th>Effect of peritoneal dialysis fluids on activity of echinocandins against Candida spp. biofilm</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>S. Tabudic, M. Kussmann, N. Harrison* [Vienna, Austria], H. Burgmann</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>P1618</th>
<th>Agar-based screening of azole resistance in Aspergillus fumigatus</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>J. Buil* [Nijmegen, Netherlands], H. van der Lee, A. Rijs, J. Havestadt, J. Zoll, W. Melchers, P Verweij</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>P1619</th>
<th>Evaluation of the Sensititre YeastOne colorimetric antifungal panel for susceptibility testing of Candida species to anidulafungin, caspofungin, and micafungin, adopting the new CLSI clinical breakpoints and epidemiological cutoff values</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>N. Karabicak, O. Karatuna* [Istanbul, Turkey], I. Akyar</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>P1620</th>
<th>Molecular genetic analysis of the 14-alpha lanosterol demethylase gene inazole-resistant pathogenic fungi</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>A. Taraskina* [St. Petersburg, Russian Federation], I. Pchelin, K. Dmitriev, E. Lotypova, E. Rausch, I. Vybornova, N. Vasilyeva</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>P1621</th>
<th>Anidulafungin reduced susceptibility of Candida glabrata infective endocarditis</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>I. Prats Sánchez* [Elche, Spain], E. De Miguel, C. Rueda, O. Zaragoza, A. Baeza Romen, M. Parra Grande, V. Sanchez-Hellin, P. Lopez-Garcia</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>P1622</th>
<th>First report of echinocandin-resistant Candida glabrata isolate in Hungary</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>J. Pongrácz* [Budapest, Hungary], E. Juhász, M. Iván, K. Kristóf</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>P1623</th>
<th>Notable trend of increase in azole non-susceptible Candida tropicalis causing invasive candidiasis in China, August 2009 to July 2014</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>X. Fan, X. Meng, T. Kudinha, H. Wang* [Beijing, China], L. Zhang, X. Hou, F. Kong, Y. Xu</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>P1624</th>
<th>Direct inoculation of stored spore suspension for antifungal susceptibility testing of Aspergillus fumigatus</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>J. Buil* [Nijmegen, Netherlands], A. Rijs, J. Havestadt, J. Zoll, W. Melchers, P Verweij</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>12:30-13:30</th>
<th><strong>Fungal diagnosis: from culture to molecular techniques</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>P1625</td>
<td>Identification of dermatophytic fungi using high resolution accurate mass-mass spectrometry</td>
</tr>
<tr>
<td></td>
<td>K. Dukik, A. Jamalian, S. de Hoog* [Utrecht, Netherlands], P. Yip, J. Freeke, B. Stielow</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>P1626</th>
<th>Identification of uncommon Candida species by commercial identification systems: considering the distribution of Candida species in terms of specimen type and the region</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>M. Lee* [Seoul, South Korea], T. Kim</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>P1627</th>
<th>Keratomycosis: clinical presentation and treatment outcome</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>B. Voordouw* [Leiden, Netherlands], S. Nauta, E. Kuijper, Y. Cheng, H. Wunderink</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>P1628</th>
<th>Distribution of bis[methylthio]gliotoxin production within the Aspergillus genus</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>S. Redrado, M. Vidal-García* [Zaragoza, Spain], M. Domingo, C. Colmenareja, J. Meis, J. Pardo Jimeno, A. Rezusta, E. Gálvez</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>P1629</th>
<th>Identification of Candida species by infrared spectroscopy</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>I. Tordoya Titchoca, I. Palacios Harcojada, V. Torres Landivar, J. Iriarte Galarregui, I. Ederra Urzainqui, R. Gonzalo García, A. Gil Setas* [Pamplona, Spain], C. Ezpeleta Baquedano</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>P1630</th>
<th>Discrimination of aspergillosis, mucormycosis, fusariosis and scedosporiosis in formalin-fixed paraffin-embedded tissue specimens using a real-time quantitative PCR assay</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>E. Salehi* [Sari, Iran], W. Melchers, J. Zoll, M. Hedayati, H. Rafati, H. van der Lee, P Verweij, S. Seyedmousavi</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>P1631</th>
<th>High resolution accurate mass-mass spectrometry for identification of clinically relevant yeast species</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>P1632</th>
<th>Intravascular catheters colonized with Candida spp: time-to-tip culture positivity shorter among patients with candidaemia than among those without</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>W. van den Bijlhoardt* [Tilburg, Netherlands], J. Veenemans, P. van Keulen, K. Verduin</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>P1633</th>
<th>Identification of Pseudallescheria/Scedosporidium species using matrix assisted laser desorption/ionization time-of-flight mass spectrometry</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>B. Rodriguez-Sanchez* [Madrid, Spain], A. Collazos, T. Peloaez Garcia, A. Ruiz, E. Bouza</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>P1634</th>
<th>Contribution of Ct pneumocystis/Ct beta-actine ratio in RT-PCR to distinguish Pneumocystis jirovecii colonization and infection</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>N. Argy* [Paris, France], D. Vallois, P. Nivose, D. Haouchine, C. Chachillon, C. Bonnal, S. Houze</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>P1635</th>
<th>Evaluation of two homemade ELISA assays for monitoring exacerbations in patients with allergic broncho-pulmonary aspergillosis</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>I. Durliac Garnier, D. meynial, A. de Mont Martin, P. Le Pape* [Nantes, France]</td>
</tr>
</tbody>
</table>
P1637 Proposal of a new PCR-REA assay allowing for detection of pathogenic Scopulariopsis species
Z. Bakula* (Warsaw, Poland), J. Kalita, M. Gadzalski, T. Jagielski

P1638 Variation of galactomannan optical density index for Aspergillus species in samples of bronchoalveolar lavage fluid
A. Malchikova* (Moscow, Russian Federation), E. Skolateeva, G. Klyasova

P1639 MALDI-TOF MS for identification of filamentous fungi
R. Tomazin* (Ljubljana, Slovenia), T. Zoran, T. Matos

P1640 Use of species-specific real-time PCRs to detect serious pathogens in critically ill patients
K. Vilmovská Dedecová* (Prague, Czech Republic), O. Svbodová, R. Cmejla, L. Capková

P1641 Galactomannan in bronchoalveolar lavage fluid for diagnosis of invasive aspergillosis in non-hematological patients

P1642 Seeking the best cocktail strategy to identify commonly encountered yeast which cannot be identified by chromogenic medium based on API 20C AUX, Vitek 2 Compact YST, Bruker MS, Vitek MS, Diversilab and rDNA sequencing
Y. Zhao* (Beijing, China), X. Meng, Q. Yang, Y. Wang, H. Wang, Y. Xu

P1643 Evaluation of matrix-assisted laser desorption/ionization time-of-flight mass spectrometry for identification of clinically significant filamentous basidiomycetes
P.Kumar Singh* (New Delhi, India), S. Kathuria, A. Chowdhary

P1644 Identification problems of sterile fungi from clinical samples; description of six novel species
S. Ahmed* (Utrecht, Netherlands), S. de Hoog

P1645 Comparison of an enzyme-linked immunosorbent assay and a latex agglutination test of cryptococcal antigen test on cerebrospinal fluid and serum
Y. Wang* (Beijing, China), W. Liu, W. Yan, Y. Xu

P1647 Phylogenetic analysis of dermatophyte species using DNA sequence polymorphism in calmodulin genes
H. Mirhendi* (Isfahan, Iran), B. Ahmadi, K. Makimura, S. de Hoog, S. Mirhendi, M. Nikaee

P1648 Validation of scoring systems and (1, 3)-beta-D-glucan assay for early diagnosis of invasive candidiasis in high-risk non-neutropenic patients in Siriraj Hospital: a prospective cohort study
S. Dngkittikul* (Bangkok, Thailand), M. Chayakulkeeree, A. Chindamporn

P1649 Clinical characteristics, laboratory identification, and in vitro antifungal susceptibility of Trichomonas ciferrii isolates associated with granular myringitis
J. Chan* (Hong Kong, China), C. Tsang, J. Yang, F. Xing, S. Leung, A. Ngan, S. Lau, P.Woo, K. Yuen

P1650 Identification of filamentous fungi in the clinical microbiology laboratory by MALDI TOF MS: robust reference spectra are essential
S. Sleiman, C. Halliday, B. Chapman, A. Lau, M. BROWN, J. Nitschke, S. Chen* (Sydney, Australia)

P1651 Development of a new qPCR assay for the detection of Pneumocystis jirovecii and simultaneous detection of DHPS resistance
D. van Tegelen* (Maastricht, Netherlands), G. Dingemans, D. Hagen, G. Gagetaan, J. Meis, G. Simons

P1652 Calcofluor white: a useful tool for the diagnosis of invasive pulmonary aspergillosis in the molecular diagnosis era
A. Miyares, T. Pelaez Garcia* (Madrid, Spain), A. Galar, R. Garcia-Rubio, J. Guineu, P. ESCRIBANO MARTOS, A. Vena, A. Fernandez Cruz, M. Valerio Minero, P. Munoz, E. Bouza

P1653 Clinical application of a molecular assay for the detection of dermatophytosis and a novel non-invasive sampling technique
A. Kizny Gordon* (Kogarah, Australia), C. McEvoy, P. Taylor

P1654 Evaluation of viability and stability of pathogenic mould and yeast species by using three different maintenance methods over a 12-year period
N. Karabicak, O. Karatuna* (Istanbul, Turkey), I. Akyar

P1655 Molecular characterization and azole susceptibility of Aspergillus flavus species complex clinical isolates
F. Botterel Chartier* (Créteil, France), J. Costa, A. Benmostefa, I. Berghui, N. Lin, A. Briet, C. Guillot, N. Ait-Ammar, J. Guillot, L. Delhaes, E. Dannaoui
P1656  Performance of MALDI-TOF MS for the identification of emerging yeast of hospital patients, species distribution, in a third level hospital Bogotá-Colombia

P1657  Proteomic identification and molecular confirmation of Candida glabrata complex in clinical samples
P. Marin-Casanova, P. Aznar-Marin, F. Galan-Sanchez, M. Rodriguez-Iglesias* (Cádiz, Spain)

12:30-13:30
Clinical parasitology and epidemiology

P1658  The efficacy of albendazole against soil transmitted helminths after a decade of mass drug administration
B. Hamidu* (Kumasi, Ghana), J. Larbi, M. Osei-Atweneboana, E. Tettevi

P1659  Prevalence of mutations associated with sulphadoxine-pyrimethamine resistance in Plasmodium falciparum samples from the general population and pregnant women in Burkina Faso
E. Ruizendaal* (Amsterdam, Netherlands), P. Mens, H. Schallig

P1660  Toxoplasma gondii: anidulafungin activity against toxoplasmosis in a murine model
Z. Sonmez Tamer* (Kocaeli, Turkey), S. Keceli, O. Buyukbaba Boral, N. Sonmez, C. Baydemir

P1661  Liver disfunction in patients receiving artemether plus lumefantrine compared with those receiving quinin plus doxycycline for uncomplicated Plasmodium falciparum malaria treatment
A. Silva-Pinto, F. Almeida* (Porto, Portugal), R. Ruas, R. Dura, A. Santos-Silva, A. Sarmento, C. Abreu

P1662  Effect of stem bark powder extracts of Berberis vulgaris L. on Leishmania major on BALB/c mice
A. Salehobadi* (Birjand, Iran), M. Karamian, F. Motevalli Haghi, M. Minooeian Haghighi

P1663  Availability of anti-malarial treatment in critical care units in the UK
A. Goodman* (London, United Kingdom), M. Armstrong, T. Doherty, R. Shulman

P1664  Combination effect of extract brotowali (Tinospora crispa) and artesunate injection against expression of intercellular adhesion molecule-1 (ICAM-1) and the histopathology of glomerulus in mice infected by Plasmodium berghei
N. Budiarti* (Malang, Indonesia), Y. Rahmawati, L. Fitri

P1665  Molecular epidemiology of autochthonous cases of cutaneous leishmaniasis in Turkey - figures are on the rise lately

P1667  Prevalence and risk factors of cryptosporidiosis in kidney/pancreas transplant recipients: the CRYPTO-GRAFT study
C. Deltombe, M. Lefebvre* (Nantes, France), F. Morio, D. Boutoille, B. Imbert, P. Le Pape, F. Raffi, M. Hourmant

P1668  Moleculispidemologyofautochthonouseasesof

P1669  Prevalence of zoonotic and non-zoonotic genotypes of Giardia intestinalis in cats: a systematic review and meta-analysis

L. Capuani* (Sao Paulo, Brazil), A. Bierrenbach, L. Alencor, E. Cerdeira Sabino

P1672  Randomized single vs double praziquantel treatment for Schistosoma haematobium – consequences for long-term morbidity? The Mali schistosomiasis morbidity study – MaSchisMo
C. Stecher* (Aarhus, Denmark), M. Sacko, E. Petersen, P. Kallestrup, H. Madsen, B. Vennervald

P1673  New and traditional reservoirs of leishmaniasis: experience in the south-west of Madrid autonomous community, Spain

P1674  Urban hospital-based study of seroprevalence and cardiomyopathy related to Trypanosoma cruzi in Bolivia
A. Almueda-Riera* (Granollers, Spain), J. Henderson-Frost, C. Maset-Viader, J. Flores-Franco, R. Gilman, C. Bern
P1675 Current genotypes involved in human cryptosporidiosis in the north of Spain
M. Alkorta* [Donostia-San Sebastian, Spain], J. Mariman, J. Artieda, M. Lopez, M. Alonso Asencor, P. Pérez Trallero

P1676 Imported Mansonnella pertans infection: a 22-year observational study at the Centre for Tropical Diseases, Negar [Italy]
A. Beltrame* [Negar, Italy], S. Staffolani, M. Gabbo, M. Degani, S. Tais, S. Marocco, F. Gabbi, D. Buanfrate, A. Angheben, V. Marchese, G. Monteiro, Z. Bisoffi

P1677 Blastocystis colonization correlates with gut bacterial diversity
L. Andersen, H. Nielsen, J. Bøg, N. Larsen, C. Stensvold* (Copenhagen, Denmark)

P1678 New multilocus genotypes of Giardia lamblia assemblage A in human isolates from Rio Janeiro, Brazil
C. Pérez Faria* [Coimbra, Portugal], G. Zanini, G. Silva Dias, S. Silva, M. Sousa

P1679 Parasitological and molecular study of Cryptosporidium spp. in calves under one year old in liam province, west of Iran
R. Ranjbar* [Tehran, Iran], R. Fattahi, N. Jonaidi Jafari, M. Izadi

P1680 Pathogens of veterinary and zoonotic concern affecting dogs in Tenerife, Spain
P. Foronda Rodríguez, B. Valladares, A. Martin-Alonso* [La Laguna, Spain], K. García Livia, A. González, N. Martín-Carrillo, J. Plata, B. Valladares

P1681 Survey on prevalence of endo- and ecto-parasites of Rattus rattus in Mazandaran province, northern Iran
I. Bakouei Katrimi, A. Daryani, M. Sharif, A. Amouei, M. Rahimi, F. Rezaei* [Sari, Iran]

P1682 Genotyping and characterization of hydatid cysts in patients from Neuquén province, Patagonia, Argentina
A. O'Connor* [Madrid, Spain], M. Anegagrie, D. Zewdie, F. Ferrer, Z. Herrador, A. Benito

P1683 Prevalence of Strongyloides stercoralis in a rural community of Bahirdar, North-western Ethiopia
A. Amor* [Madrid, Spain], M. Anegagrie, D. Zewdie, F. Ferrer, Z. Herrador, A. Benito

P1684 Seroprevalence of Strongyloides stercoralis among immunocompromised patients, south-western of Iran
A. Rafiei* [Ahvaz, Iran], R. Rafiei, M. Rahdar, B. Keikhaei

P1685 Prevalence and period prevalence of malaria and diarrhoea in 0-5 year olds in the Mangochi region of Malawi
L. Rose* [Birmingham, United Kingdom], M. Cox, G. DeWilde, K. Kalua, J. Hart, R. Bailey

P1686 Epidemiological analysis of L. tropica strains isolated from Turkey using multilocus microsatellite typing (MLMT) method
M. Karakus* [Izmir, Turkey], A. Nasereddin, H. Onay, E. Karaca, S. Demir, S. Taz, C. Jaffe, A. Ozbilgin, H. Ertabaklar, Y. Ozbel

P1687 Intestinal parasitosis in relation to CD4+ T cell levels and anaemia among HAART-initiated and HAART-naïve paediatric HIV patients in Model ART Center, Addis Ababa, Ethiopia
H. Mengist* [Nekemte, Ethiopia], B. Taye, A. Tsegaye

P1688 Characterization of the genome of N. lovaniensis, the closest relative of the human pathogenic amoeba N. fowleri
N. Liechti* [Bern, Switzerland]

12:30-13:30

Addressing biofilms

P1690 Assessment of the anti-biofilm properties of polymeric matrices containing silver nanoparticles
L. Ditu* [Bucharest, Romania], M. Husein, G. Mihaescu, M. Chifiriuc

P1691 Isolation of a lipopeptide biosurfactant from Bacillus cereus AK1 that can be used as a potential anti-adhesive coating agent for medical insertion materials
S. Krishnan* [Kannur, India], S. Muhammed

P1692 Biofilm-forming ability of clinical Candida strains isolated from oral cavity, vaginal mucosa and blood
R. Perez Tanoira* [Helsinki, Finland], X. Han, A. Aarnisalo, A. Soininen, V. Tiainen, T. J. Kinnari

P1693 Competitive study between bacteria and cells for colonizing a prostheses
M. Azmy* [Cairo, Egypt], L. Ghanem, F. El–Zahraa, D. Gamal, A. Abdelkhalek, M. Abo Eleneen, E. El-Kholy

P1694 Biofilm on endotracheal tubes
A. O’Connor* [Dublin, Ireland], B. McManus, I. Polyzois, M. O’Sullivan, D. Coleman
P1697 Serum inhibits biofilm formation by influencing twitching motility in *Pseudomonas aeruginosa* PA01
R. Ruhal* [Umea, Sweden]

P1698 Synergistic activity of rifampicin and meropenem with colistin against carbapenem-resistant *Klebsiella pneumoniae* biofilms
A. Geladari, M. Simitsopoulou, I. Stamouli, C. Antachopoulos, E. Rolides, M. Simitsopoulou* [Thessaloniki, Greece]

P1699 Effects of sub-MICs of amikacin, meropenem and colistin on *Acinetobacter baumannii* and *A. pittii* biofilms
M. Lázaro-Díez* [Santander, Spain], T. Navascués-Lejarza, S. Remuzgo-Martínez, L. Martinez-Martínez, J. Ramos-Vivas

P1700 Is there a synergism with penicillin and gentamicin on sessile group B streptococci (GBS)?
C. Ruppen* [Bern, Switzerland], P. Sendi

P1701 A small molecule reduces biofilm and haemolysis of *Staphylococcus aureus*
J. Vomacka* [Munich, Germany], V. S. Karotkov, C. Megan, M. William, L. Katrin, A. Stephan

P1702 Biofilm formation on biomedical surfaces covered by micrometric silver islands
R. Perez Tanoira* [Helsinki, Finland], T. J. Kinnari, J. Endrino, D. Horwat, J. Pierson, C. Pérez-Jorge, E. Gomez-Barrena, J. Esteban

P1703 Implant-associated infection diagnosis using sonication and high-throughput 16S rRNA gene sequencing: a standardization and validation approach
S. Ganschow* [Bad Salzuflen, Germany], J. Kalinowski, C. Tiemann

P1704 Rapid lytic activity of bacteriophages against planktonic and biofilm methicillin-resistant *Staphylococcus aureus* (MRSA) by microcalorimetry
T. Khilaishvili* [Berlin, Germany], M. Javakhadze, A. Trampuz, E. Maiola

P1705 Activity of fosfomycin, rifampin and combination of both against *Streptococcus* biofilm
M. Gonzalez* [Berlin, Germany], E. Maiola, A. Trampuz

P1706 Effects of fosfomycin on biofilm and unattached cells of a clinical *Staphylococcus aureus* isolate from osteoarticular infection
C. Marquès* [La Baule les Grottes, France], V. Collin, A. Pracros, F. Christine, F. Laurent, S. Chatellier, C. Foréster

P1707 Pseudolysogenicity as a possible pathogenicity factor of coagulase-negative staphylococci
M. Kornienko* [Moscow, Russian Federation], A. Manolov, A. Kanujina, M. Malakhova, V. Babenko, E. Kastrukova, E. Zhilenkov, L. Lyubasovskaya, T. Pruputnevich, G. Sukhikh, E. Ilina

P1708 Use of an in vitro assay in order to study the interaction of *Staphylococcus aureus* and *Pseudomonas aeruginosa* clinical isolates from the respiratory tract in biofilm formation
M. Games-Fernandes, D. Yera, R. Villar Hernández, M. Calvet, A. Lacoma* [Badalona, Spain], J. Dominguez, I. Gibert, C. Prat

P1709 A new dual-function regulator modulating GlnR regulon expression and biofilm formation by *Streptococcus mutans* GSS
Y. Chen* [Taoyuan City, Taiwan], Y. Chen

P1710 Exploring biofilm formation and disinfectant penetration as the biological basis for *Salmonella* persistence
A. Bashir* [Birmingham, United Kingdom], Y. Stedman, A. Hilton

P1712 Microbiological diagnosis of biofilm recovered from intra-uterine devices by use of sonication technique
C. Nishimura, G. Klautau, S. Nigro, C. da Silva, M. Murça, S. Tamanaha, J. Aldrighi, M. Salles* [Sao Paulo, Brazil]

P1713 Broad spectrum anti-microbial thin coatings for titanium implants obtained by laser deposition of P(3HB-3HV)/Lys spheres
V. Grumezescu* [Bucharest, Romania], E. Andronescu, A. Grumezescu, L. Sima, S. Safciuc, F. Antohe, A. Holban, M. Chifiruc, G. Sofol

P1714 Diagnosis and understanding of chronic infections - remember the biofilm
T. Thomsen* [Aarhus, Denmark], J. Lorenzen, L. Larsen, Y. Xu

12:30-13:30

**Staphylococcal pathogenesis**

P1715 Comparison of cell biological characteristics and virulence of *Staphylococcus aureus* ST1, ST5, and ST8 clones
G. Lim, H. Kim, G. Kang, J. Kim, H. Kim, J. Yoo, I. Kim* [Cheongju, South Korea]

P1716 Staphylococcal clumping factor A is a novel binding partner for von Willebrand factor-binding protein enabling *Staphylococcus aureus* adhesion to the vessel wall via von Willebrand factor
J. Claes* [Leuven, Belgium], M. Peetermans, L. Liesenborghs, T. Velaso, M. Haylaerts, R. Heying, P. Verhamme, T. Vanasse

P1717 Pseudolysogenicity as a possible pathogenicity factor of coagulase-negative staphylococci
M. Kornienko* [Moscow, Russian Federation], A. Manolov, A. Kanujina, M. Malakhova, V. Babenko, E. Kastrukova, E. Zhilenkov, L. Lyubasovskaya, T. Pruputnevich, G. Sukhikh, E. Ilina
| P1718 | Cluster adherence in *Staphylococcus* spp. – a significant bacterial trait  
O. Sandulescu* (Bucharest, Romania), C. Bleotu, L. Matei, A. Streinu-Cercel, M. Chifiriuc, A. Rafila, D. Talapan, O. Dorobat, A. Negut, I. Bericiu, A. Streinu-Cercel |
| P1719 | Panton valentine leucocidin enhances colonization of the gut intestine by CA-MRSA USA300 and ST80  
F. Couzon* (Lyon, France), Y. Benito, N. Bourgeoi, M. Larroude, F. Doucet-Populaire, F. Vandenesch |
| P1720 | Extracellular DNA in the biofilm matrix of *in vitro* *Staphylococcus epidermidis* biofilms protects the bacteria from bactericidal effects of antibiotics  
J. Claessens, L. Van Mellaert, J. Van Eldere, S. Ombelet* (Leuven, Belgium) |
| P1721 | Ecological overlap and horizontal gene transfer in clinical *Staphylococcus aureus* and *Staphylococcus epidermidis*  
G. Meric* (Swansea, United Kingdom), S. Sheppard |
| P1722 | Persistent airway infection with livestock-associated methicillin-resistant *Staphylococcus aureus* in cystic fibrosis patients  
S. van Alen, B. Ballhausen, A. Dübbers, P. Küster, H. Schültingkemper, K. Becker, B. Kahl* (Münster, Germany) |
| P1723 | Whole genome sequence analysis of *Staphylococcus saprophyticus* involved in urinary tract infections  
K. Mlaga* (Marseille, France), C. Abat, J. Rolain |
| P1724 | Intracytoplasmic compartment of host cells: a bacterial reservoir for vancomycin-intermediate *Staphylococcus aureus* isolates  
S. Trouillet-Assant, V. Tafani, D. Cameron, A. Peleg, F. Laurent* (Lyon, France) |
| P1725 | Polymicrobial interactions influence the quorum-sensing system and AGR copy numbers of *Staphylococcus aureus* isolates from diabetic foot ulcers  
C. Matias, S. van Harten, C. Mattola, J. Mendes, J. Melo-Cristina, P. Cavaco-Silva, L. Tavares, M. Oliveira* (Lisbon, Portugal) |
| P1726 | Detection of sasX, sesI, icaA, icaD and IS256 gene positivity of coagulase-negative *staphylococci*  
A. Tekeli, I. Dolapçi* (Ankara, Turkey), D. Ocal, C. Ates |
| P1727 | Genetic diversity of *Staphylococcus aureus* strains isolated from patients with acute invasive and chronic infection  
S. Gilina, T. Pkhakadze* (Moscow, Russian Federation), S. Rosanova |
| P1728 | Molecular characterization of *Staphylococcus epidermidis* colonizing skin and gut of preterm neonates  
H. Saeorg* (Tartu, Estonia), T. Metsvahdt, I. Eelmäe, S. Treumuth, M. Merila, M. Ilmoja, I. Lutsar |

**12:30-13:30**

| E.coli and Proteus virulence |
| P1729 | Expressed proteome of extraintestinal *Escherichia coli* associated with urinary tract infections and purified from clinical blood cultures  
V. Pettersen* (Bergen, Norway), K. Mosevoll, P. Lindemann, H. Wiker |
| P1730 | Beta-lactam resistance and integrons prevail in recurrences compared to single attacks of childhood urinary tract infection caused by *Escherichia coli*  
K. Truusalu* (Tartu, Estonia), I. Smidt, J. Stepetova, I. Vainumäe, E. Sepp, M. Mikelsaar, S. Kõljalg |
| P1733 | Clonal diversity and virulence characteristics of UPEC strains with their adhesion capability on Caco-2 and A-498 cell lines  
A. Gundogdu* (Kayseri, Turkey), H. Kiliç, D. Astley, M. Katouli |
| P1734 | Determination of virulence genes among uropathogenic *Escherichia coli* (UPEC) and their associations with clinical features of patients with urinary tract infection  
M. Asadi Karam* (Tehran, Iran), M. Tabasi, M. Habibi, A. Dashti, S. Bouzari |
| P1735 | Pathogenicity islands in *Escherichia coli* isolates from community-acquired UTI that belong to phylogenetic group A could be considered commensal or pathogenic?  
A. Eusebio* (Lisbon, Portugal), C. Araujo, M. Andrade, A. Duarte |
| P1736 | Epithelial-cell adhesion and invasion of ESBL-producing ExPEC isolates reveal ST131 superiority  
A. Wallman, K. Kandratyeva, G. Gerlitz, S. Navon-Venezia* (Ariel, Israel) |
| P1738 | Genotypic and phenotypic characteristics of *Escherichia coli* strains involved in transfusion-transmitted bacterial infections: data from six episodes reported between 2002 and 2008 in France  
12:30-13:30

**Klebsiella pneumoniae: a special pathogen**

**P1740** Biofilm formation and multidrug resistance in *Klebsiella pneumoniae* urinary strains
C. Vuotto* (Rome, Italy), C. Pascolini, F. Longo, M. Balice, A. Salvia, G. Donelli, P. Varaldo

**P1741** Impact of glycaemic control on capsular polysaccharide biosynthesis and opsonophagocytosis of *Klebsiella pneumoniae*: correlation of *Klebsiella pneumoniae* invasive syndrome with poor glycaemic control in diabetic patients
C. Lee* (Kaoshiung, Taiwan)

**P1742** Microbial interactions between *Staphylococcus epidermidis* and *Klebsiella pneumoniae*

**P1743** Phenotypic virulence factors among hypermucoviscous *Klebsiella pneumoniae* bloodstream infection isolates, and their relation with the presence of *magA* and *rmpA*
M. Cubero, S. Marti, M. Dominguez Luzon, J. Linares, C. Ardanuy Tisaire* (Barcelona, Spain)

**P1744** Establishment and applications of a murine colonization model of *Klebsiella pneumoniae*
J. Liu* (Taipei, Taiwan), T. Lin, Y. Pan, J. Wang

**P1745** Virulence profile evolution in *Klebsiella pneumoniae* isolates: from TEM-1 to KPC-3
C. Caneiras* (Lisbon, Portugal), L. Marques Lito, J. Melo-Cristino, A. Duarte

12:30-13:30

**Microbial pathogenesis and virulence**

**P1746** Evaluation of the existence and biofilm formation of *Candida* species in denture stomatitis patients
S. Meseli, S. Pelit* (Istanbul, Turkey), G. Erkose Genc, B. Gumru Tarcin, B. Colakoglu, E. Koc

**P1747** Covalent incorporation of protease substrates into the bacterial cell wall

**P1748** Interaction of *Cronobacter* seven type species with nonmalignant human foetal primary small intestinal cell line (H4) cells
M. Agena* (Nottingham, United Kingdom), M. Loughlin, S. Forsythe

**P1749** Comparative genomics on the re-emerged deadly bacterium *Fusobacterium necrophorum*
A. Jensen* (Aarhus, Denmark), S. Bank, L. Hagelskjær Kristensen, J. Prag

**P1750** The role of intramuscular injection of nonsteroidal anti-inflammatory drug (NSAID) in development and severity of deep soft tissue infections in mice
Z. Ture, H. Demiraslan* (Kayseri, Turkey), O. Kontas, E. Alp, M. Doganay

**P1751** Characterization of four clinical isolates of *Streptococcus pyogenes* recovered from different sites of infection under human plasma supplementation
G. Sambrana, C. Thorn, T. Paim, R. Soares* (Porto Alegre, Brazil), A. Rossato, N. Tolfo, P. Alves d’Azevedo, F. Abram

**P1752** Analysis of transcription and translation viral activities of wild type (WT) and 5’ terminally deleted enteroviruses in a model of cultured primary human cardiomyocytes
M. Wehbe, A. Huguenin, A. Bouin, Y. N’Guyen, F. Renois, F. Berri, L. Andreoletti* (Reims, France)

**P1753** A new inflammatory endocarditis mouse model
L. Liesenborghs* (Leuven, Belgium), J. Claes, M. Peetermans, M. Hoylaerts, T. Vanassche, P. Verhamme

**P1754** Functional analysis of the collagen-binding protein homologues in *Streptococcus parasanguinis* FW213
Y. Huang, Y. Chen* (Taoyuan, Taiwan)

**P1755** In vivo monitoring of the inflammatory response induced by metalloproteases and other virulence factors secreted by *Pseudomonas aeruginosa* by using a CFTR-knockout mouse model of cystic fibrosis
A. Sandri* (Verona, Italy), G. Bergamini, F. Stellari, C. Sorio, P. Melotti, M. Lleò Fernandez

**P1756** Influence of cell-to-cell interactions and QS molecules on *Candida albicans* and *Pseudomonas aeruginosa* growth and adherence features
C. Curutiu, F. Iordache* (Bucharest, Romania), A. Holban, L. Ditu, O. Bugnar, A. Stefan, C. Bleatu, V. Lazar, M. Chifiriuc

**P1757** Role of the N-acetyl-anhydromuramyl-L-alanine-amidases (AmpD’s) in the resistance of *Pseudomonas aeruginosa* to lysozyme, peptidoglycan recognition proteins (PGRPs) and osmotic shock
C. Juan Nicolau* (Palma, Spain), G. Torrens, M. Pérez Gallego, A. Oliver
P1758  Hypoxia reduces the virulence of *Pseudomonas aeruginosa*

P1759  Contribution of *Pseudomonas aeruginosa* permeability barrier and lysozyme inhibitors to resistance against C-type bactericidal activity
C. Juan Nicolau* [Palma, Spain], G. Torrens, M. Pérez Gallego, A. Oliver, J. Blazquez

P1760  D-amino acids as anti-virulent agents in Gram-negative pathogens as *Pseudomonas aeruginosa* and *Acinetobacter baumannii*
J. Vallejo* [La Coruña, Spain], C. Rumbo, M. Cabral, A. Pérez, M. Martinez-Guitian, A. Beceiro, G. Bou Arevalo

P1761  The *Burkholderia contaminans* operon participates in switching on the biofilm formation
O. Voronina, M. Kunda* [Moscow, Russian Federation], N. Ruzhova, A. Semenov, Y. Romenova

P1762  Inactivation of st313-td in *Salmonella* Dublin increases virulence in the mouse infection model
A. Herrera-Fresno* [Frederiksborg, Denmark], I. Cartas Espinol, J. Olsen

P1763  Epidemiological characterization and phylogenetic analysis of the emerging *Salmonella enterica* serovar Napoli: the first cause of invasive nontyphoidal salmonellosis in Lombardy, northern Italy
P. Huedo, M. Gori* [Milan, Italy], E. Amato, M. Pontello

P1764  Both host immune status and complement resistance of non-typeable *Haemophilus influenzae* contribute to its ability to cause bacteremia
J. Langereis* [Nijmegen, Netherlands], C. Puig, S. Marti, I. Grau, C. Ardanaz Trisaire, J. Linores, M. de Jonge

P1765  Factors and virulence involved in indole production of *Vibrio cholerae*
V. Vuddhakul* [Hat Yai, Thailand]

12:30-13:30

Clinical epidemiology and host response

P1766  Differentiating between infection and rejection after lung transplantation: biomarkers
C. Mazo* [Barcelona, Spain], J. Riera del Broi, S. Ramirez Estrada, B. Bargatta, L. Lagunes, J. Rello

P1767  Serum level of the soluble form of CD30: a promising biomarker for predicting the risk of bacterial infection in kidney transplant recipients

P1768  Varicella zoster virus infection in children with haematologic malignancies in the acyclovir era
S. Kim* [Seoul, South Korea], S. Kim, S. Han, J. Lee, D. Lee, N. Chung, B. Cho, D. Jeang, J. Kang, H. Kim

P1769  Added value of a transplant infectious diseases [TID] consultation for the diagnosis and prevention of infection in solid-organ transplant candidates
A. Metsini* [Lausanne, Switzerland], C. Berutto, J. Vionnet, P. Yerly, J. Venetz, P. Meylan, M. Pascual, O. Manuel

P1770  Association of previous healthcare facility exposure with characteristics and outcome of sepsis in an elderly cohort
A. Pyrasopoulou* [Thessaloniki, Greece], E. Georgiou, A. Varouktsi, I. Ramopoulos, K. Petidis, C. Antachopoulos, E. Rollides, A. Karagiannis

P1771  Viral or bacterial respiratory infections in lung transplanted patients: impact on respiratory function
M. Dubert, B. Viseaux, A. Birgy, A. Metivier, G. Dauriat, N. Fidouh, Y. Yazdanpanah, N. Gradil, A. Andremont, H. Mol, G. Thabut, X. Lescure* [Paris, France]

P1772  Current prevalence of colistin resistance and its impact on mortality among paediatric cancer patients in Egypt
H. El-Mahallawy, R. Khedr* [Cairo, Egypt], M. Al Swaify, M. Hussein, N. Rafieh

P1773  Alternate day first-line antibiotics for febrile neutropenia - impact on ecology and mortality in a haematology unit
L. Donato, T. Ban Hock* [Singapore, Singapore], A. Tan, S. Kalimuddin, W. Lee, R. de Guzman, G. Wong

P1774  Pneumocystis jirovecii in rheumatological patients: should we discuss horizontal transmission?
M. Salomão* [São Paulo, Brazil], S. Figueiredo Costa, H. Caiaffa Filho, A. Zahredine Abdul Latif, L. Parente Costa Seguro, E. Ferreira Borba Neto, L. Karine Noronha Guedes, A. Proença

12:30-13:30

Clinical epidemiology and host response

P1775  Efficacy and safety of micafungin prophylaxis in paediatric patients with acute myeloid leukaemia in Egypt
R. Khedr, Y. Medaney* [Cairo, Egypt], H. Hafiz, H. El-Mahallawy, N. Ahmed, S. Youssef, O. Hassanain, L. Shalaby

P1776  Epstein-Barr viral load monitoring after haematopoietic stem cell transplantation: dynamics of reactivation and effect of preemptive rituximab
C. Wackenheim, M. Raberahona, R. Germi, M. Carre, C. Bulabeis, A. Thiébaut, P. Marand, O. Epaulard* [Grenoble, France]
**P1777** Infections for carbapenemase-producing Enterobacteriaceae (KPC) in transplant patients - a cohort retrospective
C. Stadnik* (Porto Alegre, Brazil), T. Sukienik, E. Almeida Ribas, D. Santos Branco, D. Wiltgen

**P1778** Distribution of the genes sspB1 and sspB1a among group B streptococcal strains from different countries

**P1779** Influence of prior invasive aspergillosis on outcome of allogeneic haematopoietic stem cell transplantation

**P1780** Characterization of human cytomegalovirus antiviral-resistant strains in allogeneic stem cell transplanted patients from Portugal

**P1781** Epstein-Barr virus (EBV) DNA detection in whole blood at time of post-transplant lymphoproliferative disorder (PTLD) diagnosis in solid organ transplant patients
C. Cervera* [Edmonton, Canada], A. Peters, C. Mabilangan, C. Owen, R. Lai, J. Preiksaitis

**P1782** Bloodstream infections in patients with haematological malignancies
H. Gedik* [Istanbul, Turkey]

**P1783** Fever in hospitalized children post renal transplantation: is empirical antibiotic treatment always justified?
L. Ashkenazi-Hoffnun* [Petah Tikva, Israel], M. Davidovits, E. Bilavsky, R. Yassin, E. Ram, J. Amir

**P1784** Pneumonia in non-ventilated oncological patients: a frequent and heterogenous condition

**P1785** Roles of plasma procalcitonin in haematological patients with febrile neutropenia
P. Phatharodom* [Bangkok, Thailand], U. Jongwutiwes, P. Phikulsod, M. Chayakulkeeree

**P1786** Elevated beta-defensin levels in patients with an infection and their association with IL-6 production
D. Marinou* [Athens, Greece], E. Campos, M. Mavrouli, A. Tsakris, J. Routsias
HIV/AIDS [incl. anti-retroviral drugs, treatment & susceptibility/ resistance, diagnostics & epidemiology]

**EVO001**  STI and HIV prevalence in MSM attending for the first time a metropolitan sexual health service in New Zealand  
*M. Giola* [Tauranga, New Zealand]

**EVO003**  Evaluating the classification of recent HIV infection using HIV antibody avidity assay: anamnesis versus laboratory-based data  
*A. Zorzi* [Verona, Italy], M. Mirandola, L. Gios, M. Recchia, M. Rocco, M. Cardioli, E. Lattuada, M. Lanzafame, G. Cornaglia

**EVO004**  Cost-effectiveness analysis and outcomes of late antiretroviral therapy initiation among HIV-positive Taiwanese patients in the era of treatment scale-up during 3 years of observation  
*C. Cheng* [Tao-Yuan City, Taiwan], K. Lin, P. Wu, S. Chang, C. Hung, S. Cheng

**EVO005**  Evaluation of dolutegravir-metformin drug-drug interactions in a clinical setting  
*A. Masich, M. Badowski* [Chicago, United States], M. Liedtke, P. Fulco

**EVO006**  Immunologic and virologic outcomes in HIV-positive transgender in patients in a telemedicine clinic  
*M. Badowski* [Chicago, United States], M. Patel, J. Young, P. Vaughn, T. Chiampas, L. Shicker

**EVO007**  Evaluation of the new bioelisa HIV-1+2 Ag/Ab assay  
*J. Sanz, M. Marti, À. Mor* [Barcelona, Spain]

**EVO008**  Minimum adherence threshold necessary to achieve virologic suppression  
*J. Yager, T. Lodise, N. Patel* [Albany, United States]

**EVO009**  Dolutegravir experience in the HIV treatment in Albacete’s General Hospital  
*A. Perez Saez, C. Piñero Sáez, M. Garcia del Valle, E. Martinez Alfaro* [Albacete, Spain], F. Mateos Rodriguez, J. Blanch Sancho

**EVO010**  Comparative analysis of the DxN Veris quantification assay and realtime in quantifying HIV-positive plasma samples  
*G. Naeth, P. Braun* [Aachen, Germany], B. Haase, F. Wiesmann, H. Knechten

**EVO011**  Comparison of HIV p24 antigen sensitivity of three commercially available diagnostic assays, using HIV cell culture supernatants from different HIV subtypes  
*A. Pighini* [Saluggia, Italy], D. Zanin, K. Scerbo Polverata, D. Greco, D. Tramontin, L. Pallavicini

**EVO012**  Risk factors for mortality in HIV infected patients admitted to the ICU  
*R. Duro* [Porto, Portugal], J. Alves, A. Santos, R. Serrão, A. Sarmento, L. Santos

**EVO013**  Molecular epidemiology of BK virus in Iranian HIV-infected patients  
*A. Ramezani* [Tehran, Iran], M. Mohraz, K. Azadmanesh, R. Vahabpour, N. Chitsaz, M. Kazemimanesh, M. Banifazl, S. Akhgari, A. Bavand, A. Aghakhani

**EVO014**  Anonymous unlinked testing for estimating occult HIV seroprevalence in Pavia province, Italy  
*F. Genco* [Pavia, Italy], M. Prestia, V. Meroni, G. Albonico, F. Baldanti, G. Cornolli, L. Scudeller

**EVO015**  Preliminary data for resistance to integrase inhibitors among antiretroviral-naïve patients with HIV-1 infection in Northern Greece  

**EVO017**  Laboratory evaluation of the Alere HIV Combo point-of-care test  
*H. Mistry* [London, United Kingdom], M. Habibi, D. Muir

**EVO018**  Determination of the rates of adherence in people living with HIV undergoing pharmacotherapeutic monitoring: is real-world data different?  
*H. Reis* [Fortaleza, Brazil], J. Oliveira Carlos, A. Souza de Araújo, M. Jaqueline Batista, M. de França Fonteles

**EVO019**  Immunologic and virologic outcomes of obese and non-obese HIV-infected incarcerated adults  
*K. Bunnell* [Chicago, IL, United States], A. Aldossari, C. Perkins, M. Badowski

**EVO020**  Impact of DAA therapies in the pattern of use of HAART regimens in clinical practice  
EV0021 HIV and HCV viral-load random access testing: optimizing the workflow and reducing turn-around time  
R. van Houdt* [Amsterdam, Netherlands], M. Bomers, J. Algra, W. Ang

EV0022 HIV/AIDS infection in critical care: epidemiological profile of a Colombian cohort  

EV0023 A European multicentre study on the analytical performance of the DnX Veris System HIV-1 assay  

EV0024 The Maze Runner of HIV/AIDS: it's about you!  
C. Chang* [Taichung, Taiwan]

EV0025 Anal HPV in HIV-positive men who have sex with men (MSM): distribution and clearance  
L. Clemente* [Monfalcone, Italy], F. Fontana, G. Moise, M. Drabeni, L. Bon

EV0026 High rates of unsafe injection practices and needle stick injury: an obstacle in the path of ‘getting to zero’?  
Y. Verma* [New Delhi, India], D. Bandlish, A. Kankaria

EV0027 Bio-Rad Geenius HIV-1/2 assay as an alternative to the INNOLIA HIV-1/2 assay for CLSI M53 algorithm  
A. Aguinaga, A. Navascues Ortega* [Pamplona, Spain], I. Polo Vegas, X. Beristain, C. Ezpeleta Baquedano

EV0028 Influence of gender on viral load and CD4 cells count in HIV-infected patients  
D. Rodrigues* [Covilhã, Portugal], A. Monteiro, P. Pestana, M. Faria

EV0029 Xpert® HIV-1 Viral Load real-time RT-PCR (Cepheid) for rapid HIV-1 quantification  
A. Maleska* [Montpellier, France], A. Mondain, L. Ottomani, J. Ducos

EV0030 HIV late presenters in Greece over the last two years [2014–2015]: possible reasons and consequences  
A. Spanos* [Athens, Greece], D. Kavatha, N. Melachunanopoulos, K. Protopappas, G. Siakalis, E. Fragou, A. Papadopoulos, A. Antoniadou

EV0031 Influence of plasma HIV viraemia on liver stiffness in HIV mono-infected patients and HIV-HCV co-infected patients  
M. Basso, S. Parisi* [Padua, Italy], R. Scaglioni, M. Franzetti, S. Andreis, A. Cattelan, C. Mengoli, M. Cruciani, M. Andreoni, S. Piovesan, G. Palu, A. Alberti

EV0032 Analysis of epidemiological, clinical and laboratory characteristics of late presenters  
B. Ozdemir, M. Yetkin, H. Aslaner, P. Onguru, A. But, A. Bastug, D. Kanyilmaz, E. Akinci, H. Bodur* [Ankara, Turkey]

EV0033 HIV and hepatitis C prevalence, and related risk behaviours among people who inject drugs in three cities in Croatia: findings from respondent-driven sampling surveys  

EV0034 Effects of p6Pol substitution mutations on HIV-1 protease-mediated virus maturation  
F. Yu, K. Huang, C. Wang* [Taipei, Taiwan]

EV0035 Mother’s knowledge and practices on modified infant feeding for prevention of postnatal HIV transmission in post-conflict Northern Uganda district  
R. Naturinda* [Kampala, Uganda], G. Akello

EV0036 Effects of pitavastatin on lipid profiles in HIV-infected patients with dyslipidaemia and receiving atazanavir/ritonavir: a randomized, double-blind, crossover study  
A. Wongprikorn* [Bangkok, Thailand], S. Kiertiburanakul, P. Numthavaj, A. Thakkiinstein

EV0037 Evaluation of Xpert HIV-1 Qual assay for resolution of HIV-1 infection in samples with negative or indeterminate Geenius HIV-1/2 results  
M. Michaeli, M. Wax, Y. Gazlan, A. Rakovsky, E. Mendelson, O. Mor* [Ramat Gan, Israel]

Viral hepatitis (incl. antiviral drugs, treatment & susceptibility/ resistance, diagnostics & epidemiology)

EV0038 Antiviral drug-associated potential vaccine-escape mutants in hepatitis B virus DNA isolated from chronic hepatitis B patients  
M. Arikan, D. Ustek, S. Kaymakoglu, S. Badur, O. Yenen, A. Agacfidan, S. Mese* [Istanbul, Turkey]

EV0039 Dried blood spots as a sample collection method for HBV DNA and HCV RNA: two systematic reviews and meta-analyses of diagnostic accuracy studies  
B. Lange* [Freiburg, Germany], T. Roberts, J. Cohn, J. Greenman, A. Ishizaki, L. Messac, E. Tuallon, P. Van de Perre, C. Walker, C. Denkinger, P. Easterbrook

EV0040 Naturally developing hepatitis B virus (HBV) pol/gene mutation in northern Cyprus  
A. Arikan, T. Sanildag, K. Suer, M. Sayan, S. Akcol, M. Güvenir* [Nicosia, Cyprus]
EV0041  Prevalence and distribution of hepatitis C virus genotypes in Santiago de Compostela District (north-west Spain)
D. Navarro de la Cruz* (Santiago de Compostela, Spain), I. Rivadulla, J. Alba, E. Molina, E. Otero, E. Losada, F. Gude, A. Aguilara

EV0042  Hepatitis E virus ELISA and line immunoassay for diagnosis of acute HEV infections
M. Naewiger* (Neuried, Germany), F. Struck, T. Lüttich, U. Sevgi, C. Noelting, B. Kraemer, D. Boecher, E. Soutschek

EV0043  Precision analysis of the DxN Veris and realtime assays in quantifying HBV-positive plasma samples
P. Braun* (Aachen, Germany), G. Naeth, B. Haase, F. Wiesmann, H. Knechten

EV0044  Interferon-free therapy: sofosbuvir plus ribavirin is equally effective and safe in treatment-naive and interferon resistant chronic hepatitis C genotype 3a infected patients
M. Idrees* (Lahore, Pakistan), M. Waqar

EV0045  Intra-familial transmission of hepatitis B virus infection in Arak City, Iran
M. Sofian, M. Banifazl, M. Ziai, A. Aghakhani, A. Farazi, A. Ramezani* (Tehran, Iran)

EV0046  Analysis of microRNA expression profiles in chronic hepatitis B patients treated with pegylated interferon alpha-2a
K. Praianantathavorn* (Bangkok, Thailand), T. Jinato, W. Poomipak, J. Makkoch, P. Tangkijvanich, T. Pisitkun, S. Payungporn

EV0047  Performance of DxN Veris System for HBV and HCV viral load quantification in the clinical setting
A. Lombardi* (Milan, Italy), V. Micheli, A. Mancon, D. Miletta, N. Zanchetta, C. Magni, E. Angeli, S. Sollima, G. Hubertini, M. Galli, M. Gismondo

EV0048  Plasma level of DHEA linked with haemoglobin during ribavirin-associated HCV therapy
E. Brachot* (Amiens, France), J. Lemouel, G. Duverlie, E. Nguyen-Khac

EV0049  Heads or tails: genotyping of hepatitis C virus concerning the 2K/1B recombinant
W. Schuermans* (Ghent, Belgium), H. Orient, I. Dessembere, P. Descheemaeker, V. Hans, A. Geerts, V. Xavier, E. Padaleta, M. Reynders

EV0050  A high prevalence of Q80K mutation among patients chronically infected with genotype 1 hepatitis C virus due to concurrent circulation of clade I and clade II subtype 1a in Slovenia
M. Lunar* (Ljubljana, Slovenia), M. Maticic, M. Poljak

EV0051  Effect of direct-acting antivirals in liver stiffness measured by elastography
J. Romero León* (Almería, Spain), A. Collado Romecho, M. Gálvez Contreras, P. Sánchez López, A. Lazo Torres, P. Hidalgo Pérez, C. Martínez Mateu, L. Díez García

EV0052  High prevalence of hepatitis B virus among the adults living in three regions in Vietnam
C. Vo Viet, A. Bu Thi Lan, T. Karandashtova, L. Duong Tuan, G. Pham Thi Ha, D. Starkova, O. Pham Ngoc, V. Chulanov, A. Dmitriev* [St. Petersburg, Russian Federation], D. Kalinina

EV0053  The problem of mixed genotype infections in adult Polish patients with chronic hepatitis C eligible for treatment
E. Gowin* (Poznan, Poland), I. Bereszy ska, I. Mozer-Lisewska, J. Wysocki, D. Januszkiewicz-Lewandowska

EV0054  Co-infection with HIV and hepatitis C virus among injecting drug users in north-eastern states of India
S. Sharma* (Mumbai, India)

EV0055  Diagnostic accuracy of the aspartate aminotransferase-to-platelet ratio index for the prediction of hepatitis B-related fibrosis
H. Ben Ayed, M. Koubaa, M. Gargouri, T. Ben Jemaa, A. Bahlaoui, T. Boudawara, C. Marrakchi, M. Ben Jemaa* (Sfax, Tunisia)

EV0056  Correlation between a confirmatory test and S/CO values in the initial HCV antibody assay
A. Navascues Ortega* (Pamplona, Spain), A. Aguinaga, I. Polo Vigas, I. Tordoya Titichoca, C. Ezeleta Baquedano

EV0057  Living with chronic hepatitis B: appraisal of health-related quality of life according to SF-36 survey
Y. Mejdoub, M. Koubaa, J. Trabelsi, T. Ben Jemaa, M. Gargouri, J. Dammak, C. Marrakchi, M. Ben Jemaa* (Sfax, Tunisia)

EV0058  Red cell distribution width to albumin ratio as a new predictive factor of the severity of chronic hepatitis B
R. Huang, Z. Sun, G. Wang, Y. Liu, Z. Pan, E. Tian, J. Xia, X. Yan, X. Zhang, C. Wu* (Nanjing, China)

EV0059  Knowledge, attitudes and practice of primary healthcare physicians towards hepatitis B virus in Al-Jouf province, Saudi Arabia
A. Al-Hazmi* (Skaka, Saudi Arabia)

EV0060  Knowledge, attitudes and practice of primary healthcare physicians concerning the occupational risks of hepatitis B virus in Al Jouf Province, Saudi Arabia
A. Al-Hazmi* (Skaka, Saudi Arabia)
EV0061  Screening of natural compounds as a potential source to prepare anti-viral herbal composition targeting viral reverse transcriptase
C. Sandalli* (Rize, Turkey), G. Ardiç, E. Akyüz Turuntay, H. Turuntay

EV0062  Rilpivirine penetration in the genital compartment of HIV-1 infected women
C. Clavel* (Saint Martin, Saint Martin), C. Crenn-Hebert, G. Pegtyavin, H. Ichou, E. Mortier, M. Blach, A. Simonpoli, J. Rettien, D. Durod, L. Mandelbrot

Influenza and respiratory viruses

EV0063  Rapid molecular diagnosis of acute respiratory tract viral infections should impact on the management of hospitalized patients
M. Bourgeois, N. Ausselet, V. Gérard, L. De Canniere, I. Michaux, Y. Glupczynski, T. Huang, P. Bogaerts, B. Delaere* (Yvoir, Belgium)

EV0064  Sensitive and reliable detection of influenza A (H1N1), influenza A (H3N2) and influenza B by commercial real-time PCR assays: RIDA®GENE Flu and RIDA®GENE Flu LC2.0 real-time PCR
L. Kastl* (Darmstadt, Germany), S. Stender, A. Hiergeist

EV0065  Molecular epidemiology and genetic variability of human metapneumovirus in a cohort of hospitalized children in Saudi Arabia
F. Almajhdi, H. Amer* (Riyadh, Saudi Arabia), M. Farrag, M. Hamad

EV0066  Type-specific influenza vaccine effectiveness of split vaccination in previous seasons and subunit vaccination in the 2014–2015 season
I. Martínez Baz, J. Castilla Catalán, I. Tordoya Titichoca, A. Navascués Ortega* (Pamplona, Spain), I. Polo Vigas, C. Ezeleta Boquedano

EV0067  Aetiology, seasonality and clinical characterization of viral respiratory infections among hospitalized children at a medical care centre, Beirut, Lebanon
M. El Chaar* (Beirut, Lebanon), M. Curran, M. Finianos, R. Issa, C. Afif, M. Rajab, J. Irani, N. Hakimi, A. Naous, M. Hajie

EV0068  Analytical and diagnostic preliminary evaluation of the new RespiFAST RG panel for the detection of influenza virus, respiratory syncytial virus, Bordetella pertussis and Mycoplasma pneumoniae
I. Micolessi* (Bonheiden, Belgium), C. Ar, V. Britt, A. Smismans, V. Bea, J. Frans

EV0069  Performance assessment of the Luminex NxTAG Respiratory Pathogen Panel in clinical testing at the National University Hospital, Singapore
C. Lee* (Singapore, Singapore), C. Ng, L. Chiu, E. Koay

EV0070  Full genome sequence analysis of influenza H1pdm09 and H3N2 viruses related to severe respiratory illness at a tertiary hospital from 2012 to 2015 in Catalonia, Spain
C. Andrés, L. Gimferrer, M. Codina, M. Campins, B. Almirante, S. Melenda, J. Esperalba, F. Fuentes, M. Martín, T. Pumarola Sole, A. Anton* (Barcelona, Spain)

EV0071  The seasonal influenza infection in octogenarians and nonagenarians admitted to a general hospital: risk factors for mortality

EV0072  A rapid, accurate, affordable, palm-sized nucleic acid platform for early diagnosis of infectious disease diagnostic at the point-of-care
H. Cai* (San Diego, United States), R. Cary, M. Nowakowski, M. Hoffmeier, G. Cai, A. Grkovich, C. Lindberg, D. Thomas, B. Yang, W. Salcedo, E. Winn-Deen, M. Rugnetta

EV0073  Evidence of H3 influenza A virus infections in dogs during human influenza season in Croatia
L. Barbic* (Zagreb, Croatia), V. Stevanovic, M. Selimber, T. Villicic-Cavlek, S. Hadina, V. Matijatko, V. Savic

EV0074  Challenges of human respiratory syncytial virus (HRSV) immunochromatographic test in a paediatric population
M. Zamora, S. Perez* (Vigo, Spain), L. Martinez-Lamas, S. Rey, M. Alvarez Fernandez, M. Perez, R. Carbollo, M. Otera, M. Goday, M. Trigo, M. Portugues, M. Garcia-Campello, I. Lopez-Miragaya

EV0075  Epidemiology of human respiratory viruses in children with acute respiratory infections in Russia
O. Kurskaya* (Novosibirsk, Russian Federation), I. Sobolev, K. Sharshov, P. Wang, A. Shestopalov

Emerging/re-emerging and zoonotic viral diseases

EV0077  Surveillance of rabies post-exposure prophylactic treatments, Greece, November 2012 - September 2015
G. Dougas* (Athens, Greece), A. Baka, K. Mitrou, T. Georgakopoulou, A. Liana, G. Meligkonis, C. Hadjichristodoulou, S. Tsiodras

EV0078  Genetic diversity of alpha-coronavirus in bats from China

EV0079  Acute clinical manifestations of children with chikungunya from Tegucigalpa, Honduras
EV0080 Evidence for replication of an unusual G8P[14] human rotavirus strain in the faeces of an alpine goat: zoonotic transmission from caprine species
S. Alaoui Amine, R. Tagajdid, C. Loutfi, N. Toui* (Rabat, Morocco), E. El Mastapha

EV0081 Seroprevalence of West Nile virus-specific antibodies in a cohort of blood donors in north-eastern Italy after five years
S. Semprini, A. Pierro, P. Ghinelli, R. Romeno, L. Mazzotti, P. Billi, M. Dello Strada, V. Sambri* (Pievevesentina di Cesena [FC], Italy)

EV0082 Acute clinical manifestations of patients with chikungunya from La Virginia, Colombia, 2015
J. Castrillón-Spitia* (Pereira, Colombia), J. Londoño-Montes, J. Jaramillo-Patiño, J. Londoño, H. Bedoya-Rendón, J. Cárdenas-Pérez, G. Lagos-Grisales, A. Rodríguez-Morales

EV0083 An unusual ORF case with erythema multiforme and vesiculo-bullous lesions
C. Akalan Kuyumcu, S. Erol* (Istanbul, Turkey), S. Senbayrak, M. Kuskucu, K. Midilli, S. Aytekin, P. Güne

EV0084 Oxidant-antioxidant balance and thiol disulphide homeostasis is impaired in Crimean Congo haemorrhagic fever - a retrospective, cross-sectional study

EV0085 A case of Crimean-Congo haemorrhagic fever in a chronic haemodialysis patient
S. Barut* (Tokat, Turkey), F. Güne, U. Gemicci

EV0086 Person-to-person transmission of severe fever with thrombocytopenia syndrome in the healthcare setting
Y. Kim* (Wonju, South Korea), S. Park, J. Kim, H. Kim, Y. Uh

EV0087 Virulence of genotype I and III Japanese Encephalitis virus in human: estimating the asymptomatic ratios
S. Chiou* (Taichung, Taiwan), Y. Fan, J. Lin

EV0088 Cerebral venous sinus thrombosis associated with Toscana virus meningitis: a case report
R. Rostagno* (Vercelli, Italy), V. Libanore

EV0089 Human antibody responses to enterovirus 71 at the cellular and clonal levels
K. Huang* (Taoyuan, Taiwan)

EV0090 HPV genotypes distribution in Calabria region, southern Italy

EV0091 Occurrence of various HPV genotypes in cervical specimens in a Hungarian university hospital
H. Juhász* (Szeged, Hungary), G. Terhes, P. Zoltán, E. Urbán

EV0092 Molecular characterization of human norovirus in Erzurum, Turkey: first detection of GI.6 and GIV.1 genotypes
M. Timurkan* (Erzurum, Turkey), H. Aydin, O. Aktas

EV0093 Molecular analysis of human bocavirus in children with gastrointestinal and respiratory tract infection
K. Hwang* (Seoul, South Korea), E. Lee, J. Kim, H. Kim, W. Song

EV0094 Molecular epidemiology of BK polyoma virus in the east of England
K. Ramellou* (Cambridge, United Kingdom), N. Verlander, C. Crump, D. Woolridge, S. Gharbia, H. Jalal

EV0095 Prevalence and genetic distribution of human papilloma virus in women with cervical intraepithelial neoplasia
I. Hadji Petrusheva Meloska* (Skopje, Macedonia), A. Hadji-Petrusheva Jankijevikj, K. Icev

EV0096 Incidence, prevalence, and genotypic characterization of human parvovirus B19 and human herpesvirus 6/7 in children with measles- and rubella-like illness in Iran
F. Rezaei* (Tehran, Iran), H. Namdari

EV0097 Molecular analysis of human bocavirus in children with gastrointestinal and respiratory tract infection
K. Hwang* (Seoul, South Korea), E. Lee, J. Kim, H. Kim, W. Song

EV0098 Occult hepatitis B: epidemiological and molecular characterization in anti-HBC isolated individuals in Brazil
A. Santos* (Porto Velho, Brazil), J. Villalobos Salcedo, D. Souza Vieira

Diagnostic virology (other than hepatitis & HIV)

EV0099 Viruses detected in sporadic cases of parotitis
M. Álvarez-Argúelles, C. Sabater, A. Palacio, M. Sanchez, A. Barredo, M. Rodriguez, S. Melón, M. de Oña* (Oviedo, Spain)

EV0100 Performance of BIO-FLASH® Mumps IgG on Biokit’s BIO-FLASH® Analyser
U. Bohn, M. Hartmann, B. Holley, M. Alba* (Barcelona, Spain), T. Bori, M. Wendling, T. Schumacher, J. Serra

EV0101 A next generation assay for CMV viral load monitoring with improved workflow and sensitivity
P. Baum* (Pleasanton, CA, United States), C. Bier, S. Templar, B. Seiverth, C. Simon
EV0103 Performance evaluation of Anyplex II HPV28 and EuroArray HPV for genotyping cervical swab samples
A. Latsuzbaia* [Luxembourg, Luxembourg], J. Tapp, T. Nguyen, M. Fischer, M. Arbyn, S. Weyers, J. Mossong

EV0104 Panther fusion respiratory panels provide a fully automated modular approach to syndromic testing: flu A/B/RSV
P. Douglass, M. Jost* [San Diego, United States], D. Li, J. Zowaiki, C. Nugent, D. Kolk

EV0105 Evaluation of one-hour RT-PCR detection and differentiation of HPV
A. Rabaan* [Dhahran, Saudi Arabia], E. Martinez Alfaro

EV0106 Panther fusion respiratory panels provide a fully automated modular approach to syndromic testing: paraflu 1/2/3/4
M. Jost* [San Diego, United States], P. Douglass, P. Quinones, C. Nugent, D. Kolk

EV0107 Detection of HSV type 1 and 2 on mucocutaneous swabs by Q-loop mediated isothermal amplification technology
G. Bianco, C. Balloco, F. Sidoti, A. Di Vincenzo, C. Costa, R. Cavallo, G. Bianco* [Turin, Italy]

EV0108 Development of an in-house real-time PCR for monitoring BK viral load in renal allograft recipients
S. Hoegh* [Odense, Denmark], M. Skov, M. Kemp

EV0109 Methods to improve the quality of herpes virus detection and quantification by NAT
C. Morris* [Hertfordshire, United Kingdom], J. Fryer, K. Doris, R. Minhas, R. Anderson, N. Almond

EV0110 The performance of the NanoCHIP® HPV screening panel, a novel molecular-based screening test utilizing microarray technology for simultaneous detection of high and low risk human papillomavirus (HPV) infections, in a regional clinical laboratory
Z. Greenberg* [Ashdod, Israel], M. Lederkremer, E. Ron, M. London

EV0111 Utility of the AusDiagnostics HighPlex platform for diagnosis of respiratory viruses and atypical pneumonia pathogens
E. Cunningham, P. Cliff* [London, United Kingdom], S. O’Shea, E. MacMahon

EV0112 Detection and monitoring of human bocavirus 1 infection by a new rapid antigen test
A. Bruning* [Amsterdam, Netherlands], P. Susi, H. Toivola, A. Christensen, M. Söderlund-Venermo, K. Hedman, H. Aatola, A. Zvirbliene, D. Pajkrt, K. Wolters, J. Kaskinen

EV0113 Evaluation of the fully automated Luminex® ARIES® real-time PCR instrument for rapid detection of influenza A/B and respiratory syncytial virus in urgent samples
C. Smedley* [Sheffield, United Kingdom]

EV0114 Evaluation of the recommended cut-off for positivity in the Abbott RealTime HR HPV assay – a comparison to transcription mediated amplification (TMA)
H. Janson* [Växjö, Sweden], G. Kahlmeter, M. Elavsson, O. Ekelund

EV0115 Suitability of HPV-testing in first-void urine for the detection of CIN2+ lesions
A. Leeman, M. de Koning, V. van Kerckhoven, K. Beyers, M. de Koeijer, M. del Pino, A. Rodriguez, J. Ord, W. Quint* [Rijswijk, Netherlands]

EV0116 Investigation of norovirus frequency in children with prediagnosis of acute viral gastroenteritis
Z. Sanmez Tamer* [Kocaeli, Turkey], S. Oncel

EV0117 International standards as an effective tool towards improving diagnostic performance between laboratories
M. van Genne* [Groningen, Netherlands], R. de Boer, R. Poelman, H. Niesters

EV0118 CMV load quantitation by the automated versant k-PCR molecular system in plasma and urine of transplanted patients
C. Fazio, M. Bucci, A. Battista, C. Nazzari, D. Rivanera, G. Antonelli* [Rome, Italy], A. Gaeta, D. Turriziani

EV0119 Relation between human papilloma virus (HPV) and viral load per cells in cervical samples
B. Pino-Calm* [Santa Cruz de Tenerife, Spain], H. Gil-Campesino, R. Bretones-Miguélez, J. Alcoba-Florez

EV0120 Validation of the new ELITEchGroup quantitative one-step real-time PCR assay for enterovirus detection in encephalitis and meningitis
L. Bertola, D. Barberis, S. Costa, C. Olivo, G. Stefanuto, W. Mahoney, A. Estampes* [Puteaux, France]

EV0121 Comparison of Luminex NxTAG™ respiratory pathogen panel (RPP) and CLART® PneumoVir for the diagnosis of respiratory pathogens in bronchoalveolar lavage samples
M. Guerrero* [Madrid, Spain], L. Balsalobre, A. Blanco, E. Gallego, E. Lomas, P. Sánchez, L. Cardeñoso

EV0122 Clinical evaluation of automated cytomegalovirus IgG, IgM and IgG avidity assays for the LIAISON XL analyser platform
T. Lazzarotto* [Bologna, Italy], C. Pavia, A. Moroni, A. Chiereghin, G. Piccirilli, D. Squarzoni, G. Turello, L. Gabrielli
Human herpesvirus-7 encephalitis in an immunocompetent adult with associated polymyeloradiculopathy
M. Parra Grande* [Elche, Spain], C. Amoros, A. Alcalá, A. Baeza, M. Abreu-Di Berardino, J. García Durá, G. Raya, V. Sánchez Hellín

Luminex NxTAG respiratory pathogen panel automation further reduces total assay and hands-on time
M. Phillips, P. van Aarle* [s-Hertogenbosch, Netherlands], A. Benfield

Cyto megalovirus infection in kidney transplantation: 2012-2014 period
A. Escudero-Jimenez* [Albacete, Spain], J. Lozano-Serra, E. Simarro-Cordoba, I. Lorenzo-González, J. Blas-Señalada, M. Creso-Sánchez

Detection of high grade dysplasia in cervical samples via a novel HR HPV E7 ELISA

Comparison of bacterial and viral detections in whole blood and plasma from febrile paediatric patients using a fully automated multiplex PCR system
A. Hemmert* [Salt Lake City, United States], S. Holt, C. Oswald, E. Lo, S. Bellamkonda, J. Daly, R. Crisp

Post-mortem detection of six human herpes viruses [HHV1-HHV-6 in trigeminal and facial nerve ganglia] J. Dunaj, I. Ptaszyńska-Sarosiek, J. Zajkowska* [Biakystok, Poland], A. Janica, S. Pancewicz

Comparison of CMV-ELISPOT and CMV-QuantiFERON assays for the evaluation of CMV-specific T-cell response in pregnant women A. Soldán* [Padua, Italy], G. Forner, C. Mengoli, D. Tinto, L. Fallico, M. Peracchi, N. Gussetti, G. Palu, D. Abate

Pre-analytical protocol for the enrichment and lysis of mycobacteria in blood and tissue samples for the direct analysis with GeneXpert® MTB/RIF
C. Baussmeuth, J. Becker, S. Sarembo, M. Linow, C. Disqué* [Bremen, Germany]

The role of GeneXpert in detecting smear negative, culture positive Mycobacterium tuberculosis strains from Karachi, Pakistan A. Ahmed* [Karachi, Pakistan], S. Asif, S. hafeez, K. Paul, S. Mohsin, M. Rashid Imam, A. Raza


Human tuberculosis caused by Mycobacterium bovis in Navarra (Spain) 2000-2014 I. Tordoya Titichoca, A. Navascues Ortega* [Pamplona, Spain], A. Gil Setas, M. García Cenoz, J. Castilla Catalán, C. Ezpeleta Baquedano

Genotyping and risk factors of multidrug-resistant Mycobacterium tuberculosis isolates in Cantabria, Spain I. Pérez del Molino Bernal* [Santander, Spain], L. Martinez-Martinez, A. Aguirre Quiñonero, P. Agüero

Impact of active case finding on pulmonary TB transmission between inmates from Dhaka Central Jail, Bangladesh J. Berland, T. Rahman, M. Rahman, M. Gauthier, J. Claude, S. Ahmed, S. Banu, J. Hoffmann* [Lyon, France]


A case of haemophagocytic syndrome caused by hepatic and pulmonary tuberculosis R. Esvan* [Rome, Italy], M. Spaziante, E. Biliotti, D. Palazzo, L. Selekova, C. Marsiglia, M. Rivano Capparuccia, M. Santori, F. Tamburini, L. Volpicelli, M. De Angelis, C. Franchi, G. Taliani
EVO141 **New rapid method for identification of non-tuberculosis mycobacteria**
E. Andre* (Brussels, Belgium), L. Goeminne, A. Colmant, J. Ruelle

EVO142 **From whole genome sequencing data toward a simple genotyping tool: application to the animal pathogen Mycobacterium bovis**
L. Michelet* (Maisons-Alfort, France), A. Hauer, T. Cochard, M. Branger, M. Boschirolli, F. Biet

EVO143 **Tuberculous meningoencephalitis: is there a need to use scoring systems?**
H. Ben Ayed, M. Koubaa, M. Gargouri, Y. Mejdoub, T. Ben Jemaa, I. Chaabene, C. Marrakchi, M. Ben Jemaa* (Sfax, Tunisia)

EVO144 **The deadly duo: clinical features and outcomes of 41 patients with HIV-TB**
S. Karabela, S. Gürsoy* (Istanbul, Turkey), A. Kehribar, K. Kart Yasar

EVO145 **Descriptive assessment of isoniazid preventive therapy and HIV disease progression: a retrospective study of St. Paul Hospital HIV cohort**
H. Ayele* (Utrecht, Netherlands), M. van Mourik, M. Bonten

EVO146 **The diagnostic performance of a single GeneXpert MTB/ RIF assay in an intensified tuberculosis (TB) case finding among presumed TB cases in the Republican TB Centre of Armenia**
H. Margaryan* (Abovyan, Armenia), A. Hayrapetyan, A. Mirzoyan

EVO147 **Urogenital tuberculosis: insights from a monocentric study**
M. Gargouri, M. Koubaa, H. Marsit, I. Chaabene, T. Ben Jemaa, Y. Mejdoub, C. Marrakchi, M. Ben Jemaa* (Sfax, Tunisia)

EVO148 **Characteristics and prognostic factors of patients with central nervous system tuberculosis in northern Spain**
A. Arnaiz-Garcia* (Santander, Spain), M. Lisa-Garcia, E. Cabo-Garcia, L. Urbina-Soto, E. Palacio Portilla, J. Pinto-Rafael, M. Pajarón-Guerrero

EVO149 **Identification of Mycobacterium tuberculosis using a nanoparticle in broth culture media**

EVO150 **Allocating resources for childhood TB screening - what are the priorities?**
A. Drogade* (Kaduna, Nigeria)

EVO151 **Serum 25-hydroxyvitamin D levels and outcomes in the critically ill**

EVO153 **Presepsin (soluble CD14 subtype) levels in cirrhotic patients with or without bacterial infections and/or portal hypertension related bleeding**
I. Elefsiniotis* (Athens, Greece), S. Tsakiiris, E. Evangelidou, E. Giannakoulopoulou, D. Vrachatis, C. Mavrogianiss

EVO154 **The BISON (bloodstream infections and sepsis outcomes measurement network) initiative: systematic overview of outcomes used in systematic reviews on interventions for sepsis and/or bloodstream infections**

EVO156 **An overview of antimicrobial susceptibility of anaerobic blood isolates at clinical hospital centre Osijek, Croatia in four-year period**
M. Bogdan* (Osijek, Croatia), A. Antolovic Pozgain, L. Bogdanic, S. Loci Zvocak, I. Roksandic Krizan, N. Ruzman, D. Yukovic, V. Zujic Atalic

EVO157 **Anergic state in elderly patients with sepsis - different pathogens involved and different clinical presentation: absence of fever is not enough**

EVO158 **Impact of HIV infection on the presentation, outcome and host response in patients admitted to the intensive care unit with sepsis**
M. Wiewel* (Amsterdam, Netherlands), M. Huson, L. van Vught, A. Hoogendijk, P. Klein Klouwenberg, J. Horn, R. Lutter, O. Cremer, M. Schultz, M. Bonten, T. van der Poll

EVO159 **Microbiological results, clinical course and case fatality rates of patients with bloodstream infections – results of the Thuringian prospective population-based registry AlertsNet**
R. Schmitz* (Jena, Germany), A. Karch, F. Rißner, M. Jakob, R. Mikołajczyk, F. Brunkhorst
**E V0160** Epidemiology of bloodstream infections in allogeneic haematopoietic stem cell recipients from the Swiss Transplant Cohort Study

**E V0161** AQ sepsis: a large-scale programme for improving sepsis recognition and management in the North West region of England
E. Nsutebu, C. McGrath, L. Kanwar, S. Hammond, N. Beeching* [Liverpool, United Kingdom]

**E V0162** Hypoalbuminaemia and prolongation of prothrombin time-independently predict outcome in elderly patients admitted with sepsis
A. Pyrpasopoulou* [Thessaloniki, Greece], A. Varouktsi, E. Georgianou, I. Rompiopoulos, I. Zografou, C. Antachopoulos, E. Ralides, A. Karagiannis

**E V0163** The epidemiology and outcome of young adults with community-acquired bacteraemia
S. Nielsen* [Odense, Denmark], V. Espeland, D. Henriksen, A. Lassen, H. Kolmos, T. Jensen, K. Gradel, C. Pedersen

**E V0164** Aetiology and antimicrobial susceptibility profile of bloodstream infections in neutropenic and non-neutropenic patients with malignancy
H. Umpleby, S. Harwell, N. Roja* [Gillingham, United Kingdom]

**E V0165** A safe approach to reduce carbapenem prescriptions in an acute hospital
E. Hughes, I. Cartmill, H. Panigrahi, Z. Fang* [Oldham, United Kingdom]

**E V0166** Emergence of *Elizabethkingia meningoseptica* nosocomial infections and role of intravenous minocycline therapy
D. Mukherjee* [Kolkata, India], K. Mandal

**E V0167** Prognostic factors for mortality in bloodstream infections in patients with solid tumours

**E V0168** EOGBS prevention - an audit of four years of effective intrapartum GBS PCR screening in the delivery unit
N. El Helmi* [Paris, France], F. Habibi, A. Le Mannier, E. Azria, F. Autret, G. Rejasse, Y. Giovangrandi

**E V0169** Time for a change in blood culture sampling: from multiple to unique venipuncture in the emergency department?
M. van Dievoet* [Ghent, Belgium], J. Van Acker, C. Pieters, A. Van den Abeele, D. Devriese

**E V0170** Incidence and outcomes of new-onset atrial fibrillation in critically ill patients with sepsis: a cohort study
P. Klein Klouwenberg* [Utrecht, Netherlands], S. Kuipers, J. Frencken, D. Ong, M. Bonten, O. Cremer

**E V0171** A proliferation-inducing ligand (APRIL) as a diagnostic biomarker of bacterial infection
T. Tesic* [Novi Sad, Serbia], D. Lendak, S. Brkic, I. Urosevic, J. Mitic

**E V0172** *Streptococcus bovis* new taxonomy – does subspecies distinction matter?
E. Ben-Chetrit, Y. Viennaer-Well, L. Kashat, A. Marc* [Jerusalem, Israel]

**E V0173** Serum biomarkers (sTREM-1, procalcitonin, C reactive protein, sCD14, sCD163 and IL-6) as prognostic signs in severe sepsis/septic shock
J. Ríos-Toro* [Málaga, Spain], M. Marquez Coello, J. García-Alvarez, L. Pérez-Barrera, R. Rivera-Fernández, J. Girón-Gonzalez

**E V0174** Sepsis and its impact on outcome in elderly patients

**E V0175** Tissue hypoxia, HIF-1alpha and inflammation biomarkers in patients with septic shock
M. Gil Marques* [Seville, Spain], A. Puppo, A. Gutiérrez, A. Díaz Martín, Y. Smani, M. McConnell, J. Pachon-Diaz, J. Garnacho-Montero, M. Pachon-Ibáñez

**E V0176** Intrapartum real-time PCR testing is superior to risk-based IAP in preventing EDD GBS disease: a real-world clinical study
V. Björklund* [Helsinki, Finland], H. Saxén, T. Nieminen, T. Ahola, V. Ulander

**E V0177** A proliferation inducing ligand as a predictor of septic shock
D. Lendak* [Novi Sad, Serbia], D. Mihajlovic, T. Tesic, A. Novakov Mikic, S. Brkic

**E V0178** Aetiology, risk factors and prognosis of bacteraemia in HIV-infected patients between 1995 and 2014 in Barcelona, Spain
C. De la Calle* [Barcelona, Spain], J. Ambrosioni, L. Morata, C. Cardoza, J. Martinez Martinez, J. Mensa, M. Almela, J. Miró, A. Soriano
<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>EV0179</td>
<td>Bacteraemia in very elderly patients in the emergency department</td>
<td>E. Lain Miranda, P. Ruiz, P. Soria Lozano, D. Gil, P. Parrila, V. Cruz, A. Rezusta* (Zaragoza, Spain), M. Revillo</td>
</tr>
<tr>
<td>EV0180</td>
<td>High incidence of Gram-negative bacilli among haemodialysis access-related bacteraemia - how to predict the aetiology, and clinical results of a beta-lactam-free empirical antibiotic scheme</td>
<td>S. Fontserè* (Seville, Spain), N. Nova, J. Muñoz-Terol, L. Gil, J. Praena, J. Lepe, J. Molina</td>
</tr>
<tr>
<td>EV0182</td>
<td>Acinetobacter baumannii bloodstream infection in a tertiary care centre in Beirut: burden of disease of a wicked pathogen</td>
<td>J. Aridi* (Beirut, Lebanon), C. Afif, R. Naserdine, E. Azar</td>
</tr>
<tr>
<td>EV0183</td>
<td>Can fluoroquinolone be a useful alternative to beta-lactam as a definitive monotherapy for treating Pseudomonas aeruginosa bacteraemia?</td>
<td>Y. Lin* (Taipei, Taiwan), P. Wu, F. Wang</td>
</tr>
<tr>
<td>EV0184</td>
<td>Extraction of bacterial RNA from human whole blood</td>
<td>J. Brennecke* (Edinburgh, United Kingdom), T. Bachmann</td>
</tr>
<tr>
<td>EV0185</td>
<td>Pharmacokinetic and pharmacodynamic evaluation of optimized two-step infusion therapy with imipenem in critically ill patients with severe sepsis and septic shock</td>
<td>Y. Huang* (Nanjing, China), Y. Zhan, S. Liu, J. Xie, H. Shao, H. Oiu, Y. Yang</td>
</tr>
<tr>
<td>EV0186</td>
<td>Preliminary study of the OXA-48 card lettest method for the direct detection of OXA-48 carbapenemase in blood and plates culture</td>
<td>A. Sarria Visa* (Madrid, Spain), M. Gomez-Gilmira, G. Ruiz-Carrascosa, M. Romero, J. Garcia Rodriguez</td>
</tr>
<tr>
<td>EV0187</td>
<td>A protective vaccine based on a mutant Haemophilus parasuis transferrin binding protein B (TbpB) defective in binding porcine transferrin induces bacterial clearance, a Th2 cytokine profile and high levels of specific IgGt in pigs</td>
<td>S. Martínez Martínez* (León, Spain), R. Frandoloso, E. Rodríguez Ferri, Á. Álvarez Estrada, C. Gutiérrez Martín</td>
</tr>
<tr>
<td>EV0188</td>
<td>Predictors for length of hospital stay in adult diabetic patients with community-acquired pneumonia</td>
<td>M. Bader, Y. Yi, K. Abouchehade, L. Bishop, B. Haroon, J. Howboldt* (St. John’s, Canada)</td>
</tr>
<tr>
<td>EV0190</td>
<td>Role of the Mycoplasma pneumoniae / interleukin-8 / neutrophil axis in the pathogenesis of pneumonia</td>
<td>Z. Chen* (Suzhou, China)</td>
</tr>
<tr>
<td>EV0193</td>
<td>The role of procalcitonin in diagnosis of pulmonary exacerbations and infectious complications in adults with cystic fibrosis</td>
<td>K. Bielosludtseva* (Dnipropetrovsk, Ukraine), T. Pertzseva, T. Kireyeva</td>
</tr>
<tr>
<td>EV0194</td>
<td>Evaluation of community-acquired pneumonia treatment in an outpatient therapy unit</td>
<td>A. Vivero Larraza* (Badalona, Spain), N. Sopena, L. Pedro-Botet, O. Casanova, M. Bonet, E. De Felipe, G. Bonet</td>
</tr>
<tr>
<td>EV0195</td>
<td>Nasopharyngeal carriage and antimicrobial resistance in isolates of Strep-tococcus pneumoniae in Belarus</td>
<td>A. Kachanka* (Minsk, Belarus), I. Karpov</td>
</tr>
</tbody>
</table>
EV0197  Community-acquired respiratory infection
S. Nandaula* (Kampala, Uganda)

EV0198  Comparative evaluation of the Alegria® anti-
Bordetella pertussis toxin to the SeroPertussis toxin ELISA for the
detection of anti-Bordetella pertussis toxin IgG and IgA
antibodies
J. Jung, S. Schmidt* [Mainz, Germany], K. Pfrepper

EV0199  How do Russian physicians evaluate the severity of
community-acquired pneumonia in clinical practice?
S. Rachina, N. Dekhnich, R. Kozlov* [Smolensk, Russian
Federation], A. Bobylev, G. Batischeva, S. Gordeeva, Y.
Kulakov, M. Lebedeva, U. Partnyagina, I. Zaharenkov

EV0200  Predictors of positive and negative pneumococcal
urinary antigen test in the emergency setting
L. Ludvigsen* [Aalborg, Denmark], M. Ørum, S. Azuz, T.
Roed, D. Fuglsang-Damgaard, H. Nielsen

EV0201  Pertussis in Emilia Romegna region (Italy):
microbiological diagnosis
G. Piccirilli, A. Chiereghin, A. Moroni, D. Squarzoni, G. Turella,
S. Pedrini, M. Landini, T. Lazzarotto* [Bologna, Italy]

EV0202  Aetiology and risk factors of severe community-acquired
pneumonia in Belarus
O. Gorbich, G. Chistenko, Y. Gorbich* [Minsk, Belarus]

EV0203  Ceftaroline in treatment of severe community-acquired
pneumonia
A. Zaytsev* [Moscow, Russian Federation], T. Kondratieva,
A. Makarevich, A. Smirnov

EV0204  Relevance of urinary antigen screening of Streptococcus
pneumoniae in the diagnosis of respiratory tract infections in the
University Hospital Insular of Gran Canaria
H. Zarrif Nabbali* [Las Palmas, Spain], M. Hernández-
Betancor, O. Martin Pujal, I. De Miguel Martinez, F. Canas
Hernandez

EV0205  Novel mucosal sampling methods are well tolerated and
useful for microbiological and immunological research
K. Piddock* [Liverpool, United Kingdom], J. Rylance, S.
Sunny, A. Trimble, A. Collins, A. Seddon, A. Wright, S. Gordon,
D. Ferreira

EV0206  The risk factors of drug-resistant pathogens in
community-acquired pneumonia in a university hospital in
Japan
A. Ueda* [Isehara, Japan]

EV0207  Narrow-spectrum beta-lactam monotherapy in the
treatment of community-acquired pneumonia
P. Naucler* [Stockholm, Sweden], S. Rheidin, I. Galanis, F.
Granath, A. Ternhag, J. Hedlund, C. Spindler

EV0208  Preliminary results of an antimicrobial stewardship
intervention on community-acquired pneumonia in a
teaching hospital
P. Retamar Gentil* [Seville, Spain], M. Macias, R. Criado, I.
Moraes, F. Otra, E. Peral, M. León, P. Guerrero, N. Batista, J.
Rodríguez-Baño

EV0209  An outbreak of community-acquired Legionnaires’
disease
A. Madsen* [Odense, Denmark], S. Uldum, A. Holm, C.
Kjelsø, E. Knudsen, L. Legstrup, M. Nielsen, M. Skov, T.
Jensen, M. Kemp

EV0210  Presence of Neisseria meningitidis, Streptococcus
pneumoniae and Haemophilus influenzae in pharyngeal
samples in suspected pharyngotonsillitis and non-
fected controls
L. Vennberg* [Örebro, Sweden], S. Jacobsson, K. Hedin, M.
Sundqvist

EV0211  Invasive pneumococcal disease in the Valencian
Community, Spain, 2011-2015
A. Gil-Brusola* [Valencia, Spain], M. Garrido Jareño, J.
Frasquet, P. Falomir, J. Sahuguillo-Arce, A. Hernandez
Cabezas, J. López-Hontangas

EV0212  Clinical profile of community-acquired pneumonia
(CAP) and vaccination status among children < 5 years in
public and private sector - a retrospective review of
inpatient records
C. Ghia* [Mumbai, India], S. Marfatia, T. Maniar, B.
Bhaisara, M. Patel, G. Rambhad

EV0213  The correlation of different pneumonia severity
classifications with each other in patients with
community-acquired pneumonia
M. Sonmez, N. Tulek* [Ankara, Turkey], T. Igar, E. Kaya
Kiliç, G. Tuncer Ertem, F. Erdinç

EV0214  Detection of Mycoplasma pneumoniae by a novel ARI
WELL-D-ONE culture-based micro-method
B. Mondeja Rodríguez* [Havana, Cuba], N. Rodriguez
Preval, G. Toraño Peraza, C. Dotros Martinez, M. Illnait
Zaragozi, I. Tamargo Martínez

EV0215  Microbiome of the upper respiratory tract (URT) of
children with atopic bronchial asthma (BA)
T. Eliseeva, V. Bulgakova* [Moscow, Russian Federation], I.
Balabolkin

EV0216  Clinical manifestations and prognostic factors of
necardiosis in Alicante, Spain, over a fifteen-year period
A. Pujades* [Alicante, Spain], A. Garío, C. Gil-Anguita, M.
Lopez-Perezaguz, E. Merino, L. Giner, J. Rodriguez, V.
Ortiz-de la Tabla, F. Jover, B. Martinez-Lopez, J. Gregori, B. Vila, C.
Amador
**Abdominal/gastrointestinal, urinary tract & genital infections**

**EVO218**  
Streptococcus pneumoniae serogroup 6 invasive disease in Veneto, Italy  
E. Santacatterina* [Padua, Italy], D. Marimón Ortiz de Zárate, M. Ercibengoa Arana, L. Rossi, G. Palu

**EVO219**  
Systematic review and meta-analysis of efficacy and safety of metronidazole combination therapy in treatment of complicated intra-abdominal infection  
A. Yuasa* [Tokyo, Japan], K. Wada, B. Crawford, N. Sugimoto, H. Mikamo

**EVO220**  
Bacterial vaginosis is more frequently diagnosed in women with inflammatory changes on routinely performed Papanicolaou smear  
S. Baka* [Athens, Greece], I. Tsirmpa, A. Chasiakou, E. Politi, I. Tsouma, A. Sianou, V. Gennimata, E. Kouskouni

**EVO221**  
Clinical outcomes associated with initial antibiotic therapy among hospitalized patients with complicated intra-abdominal infection (cIAI) based on interim analysis in Europe and Russia of the RECOMMEND Study  
P. Peeters, K. Ryan* [Gaithersburg, United States], S. Karve, D. Potter, E. Baelen, S. Rojas Farreras, E. Pascual, J. Rodríguez-Baño

**EVO222**  
Prevalence of Mycoplasma genitalium and Trichomonas vaginalis - a French nationwide survey  
P. Pereyre* [Bordeaux, France], C. Laurie-Nadalié, C. Bebear, I. Group

**EVO223**  
Potential vaginal probiotics: safety and preliminary impact data in healthy volunteers  
M. Rostok* [Tartu, Estonia], P. Hütt, T. Rööp, I. Smidt, A. Salumets, R. Mändar

**EVO224**  
Changing epidemiology of Clostridium difficile infection in a tertiary hospital  
E. Belesiotou* [Athens, Greece], E. Perivolioti, M. Nepka, C. Vadala, Z. Psaroudaki, E. Kraniotaki, K. Litsakis, E. Iatroudelli, T. Pittaras, A. Skoutelis

**EVO225**  
Infertile women undergoing in vitro fertilization display increased prevalence of bacterial vaginosis  
A. Sianou, D. Moragianni, P. Andromidas, G. Galyfos, V. Gennimata, R. Kapeta, A. Chasiakou, E. Kouskouni, S. Baka* [Athens, Greece]

**EVO226**  
Rapid detection of Trichomonas vaginalis with the Quidel® Solana Trichomonas assay  
H. Kong, L. Fleck, S. Caddle, H. Ty, W. Tang, T. Ranalli* [San Diego, United States]

**EVO227**  
Vaginal infections: evidence for an association with subclinical chlamydia and gonorrhea  
M. Ercibengoa Arana, D. Marimón Ortiz de Zárate, L. Rossi, G. Palu

**EVO228**  
Novel multiplex immunoassay for simultaneous detection of treponemal and nontreponemal antibodies in patients with syphilis infection  
W. Zheng, M. Portella, L. Rabkina, C. Lwatula* [Hercules, United States], R. Walker, R. Kaul

**EVO229**  
Infections with Mycoplasma hominis and Ureaplasma urealyticum in women with infertility or recurrent spontaneous abortion (RSA) in Poland  
I. Chudzicka-Strugala* [Poznań, Poland], E. Głyda, T. Karpinski, L. Powselczyk, A. Zeidler, A. Szkardakiewicz

**EVO230**  
BIO-FLASH® syphilis chemiluminescence immunoassay as a first-line method for reverse syphilis screening  
E. Dopico* [Barcelona, Spain], E. Grenzner, M. Graellis, E. Castro, M. Aguilar, R. Navarro, C. Gallegos

**EVO231**  
The performance of NanoCHIP® STI Plex+, a novel molecular-based screening test utilizing microarray technology for simultaneous detection of 7 major sexually transmitted infections, in a community laboratory  
Z. Greenberg* [Ashdod, Israel], R. Sabban-Amin, G. Elman, D. Ozbonfil

**EVO232**  
Clinical features, aetiology, antimicrobial resistance and outcome of solid tumour patients with bacteremiae cholangiitis  
C. Rojo-Cebrecos* [Barcelona, Spain], L. Garcia, M. Antonio, N. Garcia, M. Marin, R. Jarratalá

**EVO233**  
Clostridium difficile infection associated with healthcare service providers – are there any differences between the statin users and non-users?  
V. Birlutiu, R. Birlutiu* [Sibiu, Romania]

**EVO234**  
Detection by PCR of virulence factors in Aeromonas spp. strains isolated from stool cultures  
A. Bartolini* [Padova, Italy], M. Biasolo, G. Zorzi, W. Akkouche, S. Masiero, V. Besutti

**EVO235**  
VT2d mucus-activatable toxin in non-0157 verocytotoxin-producing E. coli (VTEC) responsible for severe haemolytic uraemic syndrome cases in Spain and first description in VTEC O157:H7  
S. Herrera, M. Llorente, R. Ramiro, M. Remacha, M. de Frutos, B. Fortuño, F. Galan-Sanchez, S. Sanchez* [Madrid, Spain]

**EVO236**  
Pyogenic liver abscess in adults: epidemiology and risk factors for death - a 2-year experience in a French university hospital  
M. Gasperini, G. Rossi, S. Dokmak, E. Lafont, V. Zarrouk, B. Fantin, A. Lefort* [Paris, France]

**EVO237**  
Performance characteristics of STDFinder® 2SMART, a novel 10-plex molecular diagnostic assay for sexually transmitted infections  
A. Brink* [Maastricht, Netherlands], M. Eggen, J. van Wegberg, J. Ossel, G. Simons
EV0238  Bacterial adherence on titanium meshes and other commercial prosthetic meshes used in abdominal surgery
L. Prieto Borja, R. Perez Tanoira, C. Lévano-Linares, Á. Celdrán Uriarte, J. Esteban* [Madrid, Spain]

EV0239  Prevalence of selected sexually transmitted pathogens in pregnant women and their newborn babies in Mongolia
B. Otgonjargal* [Ulaanbaatar, Mongolia], G. Batbaatar, S. Tsogtsaikhan, J. Enkhetsetseg, E. Khjargal, K. Pfeffer, O. Adams, C. Battogtokh, B. Henrich

EV0240  Aerobic vaginitis in pregnant and non-pregnant women in a Greek hospital: a prospective study
M. Falagas, G. Tansarli* [Athens, Greece], E. Pitsouni, N. Legakis, T. Skalidis

EV0241  PCR detection of VTEC *Escherichia coli* and *Salmonella* in the faeces of subjects without diarrhoea — caution needed in the interpretation of NAAT results
J. Taylor, S. Kumar, R. Pollok, T. Planche, J. Taylor* [London, United Kingdom]

EV0242  Mixed infection of genitourinary tract among sexually active adolescents in large cities in Poland
A. Tomusiak* [Krakow, Poland], M. Strus, P. Heczka, M. Czerwiński, N. Miedwiedzka-Stadnik, M. Sadkowska-Todys, M. Rosinka, A. Zieliński

EV0243  Sexually transmitted infections in Barcelona and their impact in the microbiology laboratory
M. Espasa* [Barcelona, Spain], J. Esperalba, M. Locutora, E. Caballero, Z. Moure, J. Cabrera, M. Barbera, A. Andreu Domingo, T. Pumarola Sole

EV0244  The CT findings associated with bacteraemia in adult patients with UTI
C. Lee, J. Hwang, J. Lee* [Iksan, South Korea]

EV0245  Prevalence of sexually transmitted pathogens in women undergoing assisted reproductive techniques
I. Hadji Petrusheva Melasksa* [Skopje, Macedonia], K. Iciv, A. Hadji-Petrusheva Jankijevikj, B. Jaglikovski, B. Curcie-Trajkovska

EV0247  Co-infection of *Trichomonas vaginalis* and *Candida albicans* among women of childbearing age in Ebonyi Lga, Ebonyi State, Nigeria
U. Ugah, M. Alo* [Abakaliki, Nigeria]

EV0248  Safety and efficacy of tigecycline in complicated intrabdominal infections

EV0249  An investigation of bacterial vaginosis-related cohesive and dispersed biofilms in first-void urine of pregnant and non-pregnant women attending a tertiary academic hospital in Pretoria, South Africa
H. Jung* [Pretoria, South Africa], M. Ehlers, H. Lombard, M. Redelinghuys, M. Kok

EV0250  Usefulness of intraoperative bile cultures
C. Armiñanzas, T. Tigera, D. Ferrer, L. Herrera, J. Calvo Montes, C. Salas-Venero M. Gómez-Fleitas, C. Farinas* [Santander, Spain]

EV0251  Characterization of shiga toxin-producing *Escherichia coli* O111:H8 strain associated with an outbreak of haemolytic uraemic syndrome in Spain

EV0252  *Eggerthella lenta* bacteraemia in oncology patients
P. Woerther, E. Chachaty, M. Merad* [Villejuif, France]

EV0253  Use of fidaxomicin in a third-level hospital in Spain
B. Saavedra-Cervera, C. Garcia, F. Gonzalez-Romo, P. Merino* [Madrid, Spain]

EV0254  Detection of human papillomavirus and bacteria as sexual transmitted infection screening using multiplex real-time PCR
W. Lee* [Daegu, South Korea], Y. Kim

EV0255  Outbreak report of fatal *Clostridium perfringens* food poisoning in South African psychiatric hospital
C. Barnford* [Cape Town, South Africa], S. Kaliski, P. Milligan

EV0256  Prevalence of *Mycoplasma genitalium* and *Trichomonas vaginalis* infections in urethral, rectal, and pharyngeal specimens in the MSM population using the S-DiaMGTV qPCR kit
P. Silvestre* [Liège, Belgium], A. Grab, P. Brevet, M. Le Guern Fellous

EV0257  Prevalence and antimicrobial susceptibility of *Mycoplasma hominis*, *Ureaplasma urealyticum*, and *Ureaplasma parvum*
M. Lee, T. Kim* [Seoul, South Korea], O. Kweon

EV0258  *Streptococcus agalactiae* colonization in pregnant women in a tertiary hospital in Spain
J. Bueno* [Zaragoza, Spain], M. Lavilla, A. Bellés Bellés, J. Arribas Garcia, E. Sanchez, S. Salvo
EVO259 Frequency and antimicrobial susceptibilities of *Ureaplasma urealyticum* and *Mycoplasma hominis* in pregnant women
G. Aydin* [Afyonkarahisar, Turkey], I. Aliravci

EVO260 Surveillance study of infectious diseases in umbilical cord blood and maternal samples in a public cord blood bank
A. Xagorari, A. Syrigou, Z. Bousiou, P. Karavassilidou, M. Keramari, M. Ganidou, A. Anagnostopoulou, D. Sotiropoulos* [Thessaloniki, Greece]

EVO261 Emergence of complicated hepatic abscess
N. Achour* [Tizi-Ouzou, Algeria], N. Ouares, A. Lilia, B. Abdelkrim, A. Azam, M. Afiri

EVO262 Early postnatal diagnosis of congenital syphilis: contribution of a comparative Western blot method
A. Marangoni* [Bologna, Italy], M. Capretti, C. Foschi, P. Nardini, M. Compri, L. Corvaglia, G. Faldella, R. Cevenini

EVO263 Where is the evidence? The role of microbiology in the treatment of medication-related osteonecrosis of the jaw (MRONJ)
J. McDonald, H. Changez, A. Smith, P. Wright, L. Cottom* [Glasgow, United Kingdom]

EVO264 Evidence of *Propionibacterium acnes* as a causative agent in progressive macular hypomelanosis
R. Petersen* [Aarhus, Denmark], C. Scholz, H. Lomholt, H. Brüggemann

EVO265 Two cases of granulomatous mastitis associated with an antibiotic-sensitive and a multidrug-resistant *Corynebacterium kroppenstedtii* strain

EVO266 *S. aureus* with Panton-Valentine leukocidin gene among two related families in Milan
C. Pagani, S. Rimoldi, A. Di Gregorio* [Milan, Italy], A. Mancon, L. Fiori, V. Di Cristo, A. Riva, M. Gismondo, C. Gervasoni

EVO267 How is the microbiological diagnosis in vertebral osteomyelitis performed? An 11-year monocentric retrospective study
M. Amsili* [Grenoble, France], O. Epaulard

EVO268 An unusual pathogen causing necrotizing fasciitis in Austria
A. Wechsler-Fördész* [Vienna, Austria], M. Hermann, S. Bernreiter, F. Allerberger, F. Geppert

EVO269 Spontaneous polyarticular septic arthritis due to *Corynebacterium striatum*
C. Rowan* [Leeds, United Kingdom], H. Isenman, P. Chambers

EVO270 Generalized tetanus complicated with Guillain-Barre syndrome
J. Lee* [Iksan, South Korea], C. Lee, J. Hwang

EVO271 Evaluation of post-neurosurgical *Acinetobacter baumannii* meningitis
C. Bulut, C. Ataman Hatipoglu* [Ankara, Turkey], N. Ata, H. Çelik, A. Karakoç, S. Erdinç, A. Demiröz

EVO272 *Neisseria meningitidis* causing primary ventriculitis: case report and review of the literature
F. Gronthoud* [Manchester, United Kingdom], I. Hasson, N. Gill, M. Thornber, P. Newton

EVO273 Oopharyngeal *K. kingae* carriage in healthy children in Norway
K. Lilleba* [Bergen, Norway], R. Breistein, F. Bosse, S. Stigen, O. Kammedal

Zoonotic bacterial diseases

EVO274 Source confirmation of a *Campylobacter fetus* outbreak through next generation sequencing
A. Zomer* [Utrecht, Netherlands], B. Duim, H. Koppenaal, F. Groenendijk, M. van den Berge, E. Verkade, A. Tijsma, M. Spierenburg, K. Verduin, M. te Wierik, J. Wagenaar

EVO275 Protecting chicken against *Campylobacter jejuni* by Camelidae-derived nanobodies
C. Vanmarsenille* [Brussels, Belgium], J. Elseviers, G. Hassanzadeh Ghassabeh, A. Martel, F. Haesebrouck, F. Pasmans, J. Hernalsteens, H. De Greve

EVO276 Diagnosis and control of a listeriosis outbreak in Lombardy
M. Corbella* [Pavia, Italy], M. Fabbri, P. Cambieri, B. Mariani, G. Andreoli, E. Scaltriti, D. Sassera, S. Gaiarsa, S. Pangolini, P. Marone

EVO277 The prevalence and PCR-ribotype distribution of *Clostridium difficile* in pigs in Ireland
K. Stein* [Dublin, Ireland], S. Egan, H. Lynch, C. Harmanus, L. Kyne, C. Herrera, S. McDermott, E. Kuiper, F. Fitzpatrick, S. Fitzgerard, L. Fenelon, D. Drudy

EVO278 Interpretation of serology for detecting and monitoring acute and chronic *Coxiella burnetii* infection in a referral university laboratory in Greece
M. Movrouri* [Athens, Greece], V. Kapsimali, J. Routsiou, G. Vrioni, A. Tsokris

EVO279 Brucellar meningitis
F. Smaoui, M. Koubba, M. Gargouri, A. Znazen, T. Ben Jemaa, A. Hammami, C. Marrakchi, M. Ben Jemaa* [Sfax, Tunisia]
EV0280  Symptoms and laboratory results during course of human granulocytic anaplasmosis [HGA]  
J. Dunaj* (Bialystok, Poland), J. Zajkowska, A. Moniuszko, M. Kandrusik, S. Grygoreczuk, P. Czupryna, R. Swierzbinska, S. Pancewicz

EV0281  Whole genome analysis of *Leptospira interrogans* variant from clinical sources: a pilot study  
S. Rami** (Braunschweig, Germany), S. Bhuj, F. Pessler

Resistance surveillance & epidemiology: MRSA, VRE & other Gram-

EV0282  Community-acquired meticillin-resistant *Staphylococcus aureus* carriage rate and antimicrobial susceptibility: an emerging and on-going challenge  
S. Shakouhi, M. Zamanian, I. Alavi Darazam** (Tehran, Iran)

EV0283  Diversification and emerging resistance among the hypervirulent CC17 clone of *Streptococcus agalactiae*  
E. Ferreira Martins** (Lisbon, Portugal), C. Roussado, J. Melo-Cristino, M. Ramirez

EV0284  Epidemiology and treatment of MRSA in Jeddah hospitals  
R. Sultan* (Jeddah, Saudi Arabia)

EV0285  Increased in vitro resistance to clindamycin, erythromycin and tetracycline of *Streptococcus agalactiae* isolated from pregnant and nonpregnant women  
S. Baka* (Athens, Greece), E. Saltaoura, A. Chasiakou, V. Gennimata, E. Kouskouni

EV0286  Changing epidemiology in group B *Streptococcus* susceptibility to fluoroquinolones in France  

EV0287  Prevalence of *Staphylococcus aureus* isolates with heterogeneous intermediate level resistance to vancomycin in a Dutch university medical centre  
J. da Silva-Voorham* (Groningen, Netherlands), J. Rossen, J. La-Ten-Foe, F. Basma, P. Otto-Langereis, A. Friedrich, B. Sinha, P. Damasco

EV0288  Highly prevalent stg840 and stc830 types of erythromycin-resistant group G streptococci isolated from bacteraemia in southern Taiwan  
P. Zheng, J. Wu* (Tainan City, Taiwan)

EV0289  Defining *Staphylococcus aureus* trimethoprim-sulfamethoxazole resistance; the unusual phenotype of the Gaza CA-MRSA clone  

EV0290  Antibiotic resistance of lactic acid bacteria isolated from some Algerian food products  
B. Taha Ahmed* (Saida, Algeria), K. Nour Eddine

EV0291  Prevalence and molecular characteristics of meticillin-resistant *Staphylococcus aureus* isolates in Serbia 2012-2014  
I. Cirkovic** (Belgrade, Serbia), Z. Jelecic, D. Medic, J. Trojanovic, G. Stefanovic, S. Djukic

EV0292  Nosocomial spread of ST72-SCCmec type IV meticillin-resistant *Staphylococcus aureus* in a neonatal intensive care unit at a tertiary hospital in Daejeon, Korea  
S. Koo* (Daejeon, South Korea), J. Kim, J. Lim

EV0293  Emergence and dissemination of a linezolid-resistant *Staphylococcus capitis* clone in France  

EV0294  Risk factors for invasive multi drug-resistant organisms [MDRO] – one size fits all?  
M. Skally* (Dublin, Ireland), H. Mawi, A. Shoaidi, M. Fitzpatrick, H. Humphreys

EV0295  The global point prevalence survey of antimicrobial consumption and resistance [Global-PPS]: first results of antimicrobial prescribing in a Chinese tertiary hospital  
R. Peng, A. Versporten, L. Bao, H. Goossens, X. Meng* (Hohhot, China)

EV0296  Molecular characterization of antimicrobial resistance and virulence factors of meticillin-resistant *Staphylococcus aureus* strains circulating in the Pretoria region  
R. Schwim, M. Kock, F. Ismail, E. Ehlers* (Pretoria, South Africa)

EV0297  In vitro susceptibility of clinical *Actinobaculum spp.* isolates in Graz, Austria  
E. Ullrich* (Graz, Austria), E. Stangl, G. Feierl, A. Grisold, E. Leitner

EV0298  *Streptococcus agalactiae* in vaginal-rectal samples from pregnant women: clindamycin susceptibility in the Barcelona area  
E. Grenzner* (Barcelona, Spain), E. Dopico, M. Aguilar, A. Tejedor, R. Mancho, S. Herrera

EV0299  Low occurrence of the new species *Staphylococcus argentaeus* in a large *Staphylococcus aureus* collection of human isolates from Belgium 2007-2015  
M. Argudín* (Brussels, Belgium), M. Dodemont, S. Roisin, R. De Mendonca, C. Nonhaff, A. Deplano, O. Denis
EVO300 Molecular characterization of resistance and virulence in MRSA from the private sector in Durban, South Africa
D. Amoako, L. Bester, A. Somboro, S. Bajnath, C. Govind, S. Essack* [Durban, South Africa]

EVO301 Can MALDI-TOF MS separate vonA and vonB type Enterococcus faecium?
K. Jørgensen* [Copenhagen, Denmark], T. Havnhøj Frandsen, A. Hammerum, N. Frimodt-Moller

EVO302 Long-term surveillance of antimicrobial resistance of H. influenzae in Russia: any changes in ten years?
O. Sivaya, R. Kozlov* [Smolensk, Russian Federation], M. Sukhorukova, N. Ivanchik, A. Shevelev

EVO303 Ten-year surveillance of antimicrobial resistance of S. pyogenes in Russia
O. Sivaya, R. Kozlov* [Smolensk, Russian Federation], M. Sukhorukova, N. Ivanchik, A. Kuzmenkov

EVO304 Phenotypic and serotypic characters of Streptococcus agalactiae in pregnant women
X. Liu* [Shenzhen, China], S. Fan, R. Huang

EVO305 Virulence and resistance genes in methicillin resistant Staphylococcus aureus and vancomycin resistant Enterococcus sp. clinical strains isolated from patients with cardiovascular surgery
I. Gheorghe* [Bucharest, Romania], I. Czobor, M. Popa, O. Banu, V. Lazar, M. Chifiriuc

EVO306 Bacteriological data from a French regional centre for healing wounds: an analysis of 5996 isolates
E. Bonnet* [Toulouse, France], J. Galinier, B. Fontenel, P. Léger

EVO307 Molecular characterization of methicillin-susceptible Staphylococcus aureus (MSSA) isolates from bovine subclinical mastitis from different Brazilian states
M. Ribeiro de Souza da Cunha* [Botucatu, Brazil], P. Mella, D. Moraes Riboli, L. Almeida Martins

EVO309 Pooling of samples for MRSA screening by PCR – safe or not?
J. Bangsborg* [Herlev, Denmark], L. Nielsen, B. Holzknecht, L. Nielsen, A. Kailow, B. Olesen

EVO310 Characterization of Staphylococcus lugdunensis isolated from diverse clinical samples in a secondary hospital in Kuwait
K. Al Obaid, T. Verghese, A. Sheikh, E. Udo* [Kuwait, Kuwait]

EVO311 Differences in the microbiological profile of community, healthcare-associated and hospital acquired infections

EVO312 Clinical characteristics of patients with linezolid-resistant Staphylococcus epidermidis
L. Morata* [Barcelona, Spain], C. Pitart, E. Lozano, C. De la Calle, C. Cardozo, J. Martinez Martinez, J. Mensa, F. Marco Reverte, J. Vila, A. Soriano

EVO313 Resistome investigation in Listeria monocytogenes clinical strains circulating in Italy in the period 2000-2010
M. Orsini* [Teramo, Italy]

EVO314 Resistance to antibiotics in Staphylococcus spp. causing bloodstream infections in a multidisciplinary medical centre
E. Barantsevich* [St. Petersburg, Russian Federation], N. Barantsevich, A. Schwarz, N. Rybkova, S. Volkova, I. Churkina, L. Ivanova, E. Shlyakhto

EVO315 Susceptibility of Gram-positive anaerobic pathogens isolated from patients in Europe over nine years; TEST programme 2007-2015
M. Hackel* [Schaumburg, IL, United States], M. Bailey-Person, D. Sahm, H. Leister-Tebbe

EVO316 Large epidemiological study of Staphylococcus aureus colonization in French horses: evidence of very low prevalence of MRSA and antibiotic resistance, heterogeneity of SA carriage in the various farms/centres, and absence of cross-contamination between horse and human

EVO317 Tackling resistance of MRSA with natural pecan extract-derived products
M. Martinez* [Houston, United States], W. Haskell, A. Rosato

EVO318 Distribution of aminoglycoside resistance genes and multilocus sequence typing of Enterococcus faecium strains
A. Sienko* [Bialystok, Poland], P. Wieczorek, P. Sacha, D. Ojdana, P. Majewski, E. Tryniszewska

EVO319 Epidemiology and antimicrobial resistance of Streptococcus agalactiae isolated in Algiers from confirmed neonatal infections and from vaginal carriage settings
S. Mahrane* [Algiers, Algeria], A. Abad, L. Mereghetti, Z. Guechi, P. Lanotte

EVO320 Impact of ciprofloxacin on commensal enterococci from intestinal microbiota: a study in healthy volunteers
V. de Lastours* [Clichy, France], E. Maugy, V. Mathy, F. Chau, V. Cattoir, B. Fantin
EV0321  Emergence of PVL gene-positive MRSA among patients hospitalized in medical wards, Dr. Soetomo Hospital Surabaya-Indonesia  

EV0322  Acquisition of MRSA among patients in medical and surgical wards, Dr. Soetomo Academic Hospital, Surabaya, Indonesia  

Resistance surveillance & epidemiology: Gram-negatives
EV0323  Antibacterial resistance in the nosocomial isolates of Kashmir valley - a major therapeutic challenge  
M. Saleem* (Srinagar, India), G. Kozger, D. Daniel

EV0324  Phenotypic and genotypic methods for detection of metallo-beta-lactamases among carbapenem-resistant Enterobacteriaceae clinical isolates in the Alexandria Main University Hospital  
I. El Ghazzawy, M. Meheissen* (Alexandria, Egypt), D. Adel

EV0325  Antibiotic susceptibility profile and molecular characterization of extended spectrum beta lactamases (ESBL) in uropathogenic Escherichia coli in a tertiary care hospital in Pakistan  
G. Rehana* (Islamabad, Pakistan)

EV0326  Surveillance of plasmid mediated AmpC in Enterobacteriaceae causing UTIs and SSTIs  
I. Roxo* (Mamarrosa, Portugal), E. Ramalheiro, S. Ferreira

EV0327  First description of Klebsiella pneumoniae gene blaKPC carrier ST15 in a university hospital in Buenos Aires, Argentina  
J. Nievas, J. Smayevsky* (Buenos Aires, Argentina), D. Aballay, A. Martínez Caceres, F. Nicola, M. Farber

EV0328  Use of fluoroquinolones in veterinary medicine: results of the German national antibiotic resistance monitoring (GERM-Vet)  
H. Kaspar* (Berlin, Germany), U. Steinacker, A. Karaoalp, A. Roemer, J. Wallmann

EV0329  Surveillance of the susceptibility of ESBL-producing Escherichia coli and Klebsiella pneumoniae isolated from patients with intra-abdominal infections in China: data from the SMART study 2012-2014  
H. Zhang, Q. Yang* (Beijing, China), Y. Wang, Y. Zhao, R. Badal, Y. Xu

EV0330  Surveillance of antimicrobial susceptibility of aerobic and facultative Gram-negative bacilli isolated from patients with urinary tract infections in China: 2010-2014 study for monitoring antimicrobial resistance trends [SMART]  
Q. Yang* (Beijing, China), H. Zhang, Y. Wang, Y. Xu, Y. Zhao, R. Badal

EV0332  High prevalence of undetected highly resistant microorganisms among residents of long-term care facilities in Amsterdam, the Netherlands  
A. Tholen* (Amsterdam, Netherlands), P. Molenaar, I. Willemsen, T. Roest, M. Damen, P. Gruteke, P. Oostvogel, C. Hertog, D. Uitenbroek, C. Vandenbroucke-Grauls, M. Scholing

EV0333  Clonal spread of colistin-resistant clinical Acinetobacter baumannii in a tertiary-care hospital in Korea  
D. Hong* (Seoul, South Korea), H. Lee, K. Jung Ok, J. Hong, S. Park, S. Jeong, D. Yong, K. Lee

EV0334  Antimicrobial susceptibility profiles of Gram-negative bacilli isolated from patients with hepatobiliary infections in China: results from the study for monitoring antimicrobial resistance trends [SMART], 2006–2013  
H. Zhang, Q. Yang* (Beijing, China), Y. Wang, Y. Zhao, R. Badal, Y. Xu

EV0335  Clonal distribution of multidrug-carbapenem-resistant Klebsiella pneumoniae in a Riyadh-based hospital: incidence of New Delhi metallo-beta-lactamase (NDM) carrying ST-15 clone  
T. Uzzaman* (Riyadh, Saudi Arabia), M. Alrodajyuan, M. Albladi, S. Al Johani, H. Balkhy

EV0336  Risk factors associated with the acquisition of Pseudomonas aeruginosa resistant to carbapenems in a university hospital in Zaragoza, Spain  
B. Vela, A. López-Calleja, M. Gámara, R. Núñez, E. Morilla, M. Fernandez, F. Castillo, A. Rezusta* (Zaragoza, Spain), M. Revillo

EV0337  Prevalence of multdrug-resistant Enterobacteriaceae carriage on admission to a university hospital in Spain  
C. Díaz-Agero, N. López-Fresnera, M. Hernández García* (Madrid, Spain), A. Rincón Carlavilla, P. Ruiz-Garbajosa, P. López Pereira, R. Canton Moreno, J. Aranaz Andrés
E00338 Epidemiology and antimicrobial resistance patterns of community-acquired complicated intra-abdominal infections: the data from three tertiary hospitals in Turkey
V. Avkan-Oguz, N. Baykam, V. Korten, M. Abdullayeva* (Izmir, Turkey), D. Yaprak, L. Mulazimoglu, Z. Gulay

E00339 The elephant in the room: could the unregulated marketing of generic faropenem sodium be contributing to penem overuse?
M. Gonzalez Sanz* (Lankien, South Sudan), M. Millar, S. Tiberi

E00340 Faecal carriage of Pseudomonas aeruginosa in community setting in Spain: antimicrobial susceptibility and characterization of porin OprD
A. Bellés Bellés* (Zaragoza, Spain), J. Bueno, Y. Saenz, B. Rojo-Bezares, J. Arribas García, L. Muñoz Muñoz, F. Castillo, C. Seral

E00341 Study of resistance rates of Acinetobacter baumannii complex clinical isolates during a 5-year period in a tertiary hospital
N. Bissenova, A. Yergalieva* (Astana, Kazakhstan)

E00342 A mathematical model for predicting the development of bacterial resistance based on the relationship between the level of antimicrobial resistance and the volume of antibiotic consumption
A. Kolbin, R. Lawson, A. Kurylev, K. Ryan, M. Arepeva* (St. Petersburg, Russian Federation), Y. Balykina, A. Spiridonova, N. Mukhina, S. Sidorenko

E00343 First report on the presence of a variant of OXA-24 gene in one Acinetobacter baumannii strain isolated from chronic leg ulcers in Romania
M. Georgescu, I. Gheorghe* (Bucharest, Romania), T. Andreescu, M. Costache, A. Ecouvoiu, C. Ghiatau, I. Csabor, M. Chifiriuc

E00344 Molecular epidemiologic study of ciprofloxacin-nonsusceptible Escherichia coli sequence types isolated from clinical specimens in a tertiary care university hospital in Korea
H. Yang, Y. Kim, Y. Nam, T. Oh, K. Park, H. Kim, H. Lee* (Seoul, South Korea)

E00345 Non-typeable Haemophilus influenzae biofilm production in lower-respiratory-tract infections in a tertiary hospital from Nuevo Leon, Mexico

E00347 Strong association between XDR phenotype, blaVIM-2+, exoU+, paeM+ genotype and sequence type (ST) 235 in Pseudomonas aeruginosa from Kazakhstan
I. Azizov* (Karaganda, Kazakhstan), D. Babenko, M. Edelstein, A. Lavrenenko, E. Zakharova, I. Belayayev, N. Bissenova, T. Walsh

E00348 Is minocycline coming back for Gram-negative organisms in 21st century India?
D. Sureshkumar, A. Rohith* (Chennai, India)

E00349 Resistance to carbapenems in Gram-negative bacteria in a multidisciplinary medical centre
E. Barantsevich* (St. Petersburg, Russian Federation), N. Barantsevich, A. Schwarz, L. Ivanova, I. Churkina, N. Rybkova, E. Kolobova, S. Volkova, E. Shlyakhto

E00350 Outbreak of CTX-M-15 and SHV-12 extended-spectrum beta-lactamase (ESBL) co-producing Klebsiella pneumoniae in a neonatal intensive care unit (NICU), in Ha’il, Saudi Arabia

E00351 Risk factors for colonization of carbapenemase-producing Enterobacteriaceae in the intensive care unit
J. Lee, D. Cheon* (Anyang, South Korea), S. Lee

E00352 Multidrug resistant and carbapenemase producing Gram-negative bacteria among critically ill patients
Z. Hajjej* (Tunis, Tunisia), H. Naija, B. Trabelsi, W. Sellami, I. Labbene, F. Mustapha

E00353 Trends and molecular characterization of beta-lactamases ESBL in intraabdominal and urinary tract infections in Panama - the SMART study 2009-2013
S. Vega Degracia* (Panama City, Panama), Y. Gil

E00354 Trends and molecular characterization on beta-lactamase ESBL in intra-abdominal and urinary tract infections in Guatemala - the SMART study 2002-2013
C. Mejia-Villatoro* (Guatemala City, Guatemala), Y. Gil
EV0355  Whole-genome sequencing supports the delineation of the multidrug-resistant CG14 and CG15 *Klebsiella pneumoniae* clones

EV0356  Comparison of two laboratory protocols for detection of carbapenem-resistant Enterobacteriaceae
I. Pristas* (Zagreb, Croatia), I. Butic, S. Soprek, S. Bukovski, A. Tomic Andrasevic

EV0357  Coproduction of NDM with KPC in seven isolates of *Klebsiella pneumoniae* and NDM with OXA-23 in two isolates of *Acinetobacter baumannii* from Colombia
S. Saavedra* (Bogota, Colombia), C. Duarte, M. Gonzalez, A. Hidalgo

EV0358  Trends in antimicrobial resistance of *Acinetobacter baumannii* clinical isolates in a Greek university hospital
S. Maraki, E. Mantadakis, V. Mavromanolaki, D. Kafteidis* (Heraklion, Greece), G. Samonis

EV0359  Evaluation of benzylpenicillin/dihydrostreptomycin (Intramicine®, CEVA) against clinically significant veterinary bacterial pathogens
F. Mzali* (Bordeaux, France), P. Butty, M. Hernould, A. Payet, V. Dubois, M. Kann

EV0360  Evaluation of risk factors for infections due to carbapenem-resistant Enterobacteriaceae and demographic features of the infected patients

EV0361  Bacterial profile and antimicrobial susceptibility patterns of otitis media in Ayder Teaching and Referral Hospital, Mekelle University, Northern Ethiopia
A. Wasihun* (Mekelle, Ethiopia), D. Zemene

EV0362  Community and hospital spread of *Escherichia coli* -producing CTX-M extended-spectrum beta-lactamases in Bandar Abbas
A. Karmostaji* (Bandar Abbas, Iran), F. Dehghan, A. Ramezanpoor

EV0363  Community carriage of extended-spectrum beta-lactamase and carbapenemase-producing Enterobacteriaceae in HIV-infected children in Zimbabwe

EV0364  Eradication of the epidemic ESBL-positive strain of *Klebsiella pneumoniae* from the bacterial flora of the intensive neonatal care unit of the University Hospital No. 2 in Bydgoszcz
K. Frankowska, E. Gonia, P. Korbal, A. Kuziemi* (Bydgoszcz, Poland)

EV0365  The effect of probiotics on in vitro growth of carbapenemase producing *Klebsiella pneumoniae* (KPC-Kp)
S. Corcione* (Turin, Italy), L. Mc Dermatt, C. Thorpe, F. de Rosa, D. Snyderman

EV0366  Endemic NDM-1-producing *Klebsiella pneumoniae* in a large intensive care unit in Jakarta, Indonesia

EV0367  The occurrence of *blaKPC* genes among clinical *Klebsiella pneumoniae*
D. Ojdana* (Bialystok, Poland), P. Sacha, A. Sienko, P. Majewski, P. Wieczorek, J. Jaworowska, E. Tryniszewska

EV0368  Colistin resistant *A. baumannii*: is there a role for colistin aerosol therapy?
C. Scuderi* (Milan, Italy), A. Piazza, D. Pacocaterra

EV0369  Trends in mortality of critically ill patients with infection / colonization due to carbapenem-resistant Enterobacteriaceae in a public hospital of Rio de Janeiro: the impact of antimicrobial stewardship of carbapenems

EV0370  Outbreak of NDM-1 producing Enterobacteriaceae causing nosocomial infections in Mexico

EV0371  Economic relevance of colonization of healthy pregnant women with multidrug-resistant pathogens [MRE] and *Staphylococcus aureus* (SA)

EV0372  Presence of plasmid-mediated quinolone resistance gene qnrS is associated with extended spectrum beta-lactamase production in clinical enterobacterial isolates from an intensive care unit in Bucharest
I. Czobor* (Bucharest, Romania), I. Gheorghe, O. Banu, M. Papa, V. Lazar, M. Chifiriuc
**EV0373** Cross-sectional pilot study of *Escherichia coli* urinary tract isolates – phylogenetic characterization and antimicrobial susceptibility
V. Krizan Hergouth* [Ljubljana, Slovenia], M. Pirs, T. Cerar Kišek, D. Barbic

**EV0374** Carbapenem-resistant *K. pneumoniae* and *E. coli* colonization in hospitalized patients
B. Borsa* [İstanbul, Turkey], A. Karakullukçu, A. Gökhan

**EV0375** Effects of CLSI and EUCAST clinical breakpoints on antibiotic susceptibility test reporting of CTX-M-15 ESBL and KPC-3 carbapenemase *Klebsiella pneumoniae* isolates
C. Caneiras* [Lisbon, Portugal], L. Marques Lito, J. Melo-Cristino, A. Duarte

**EV0376** Extended spectrum beta-lactamase (ESBL) producing Enterobacteriaceae in community-acquired urinary tract infection (UTI)
D. Chervet, B. Pilmis* [Paris, France], A. Dufougeray, J. Lourtet, J. Zahar, A. Le Monnier, H. Partouche

**EV0377** Outbreak of OXA-48-producing *Klebsiella pneumoniae* in a surgical ward associated with contaminated environmental sources
J. Tarabeia* [Tel-Aviv, Israel], T. Miller-Roll, D. Schwartz, A. Adler, Y. Carmeli, V. Schechner

**EV0378** The role of trauma on infection and mortality due to *Klebsiella pneumoniae* resistant to carbapenems
L. Campos, D. Garcia, C. Mangini, F. Moraes, S. Figueiredo Costa* [São Paulo, Brazil]

**EV0379** Antibiotic sensitivity pattern of *Escherichia coli* in irritable bowel syndrome – an insight to pathophysiology
D. Lal* [Colombo, Sri Lanka]

**EV0380** Rapid detection tests for antibiotics resistance
H. Boutes* [Gif-sur-Yvette, France], T. Naas, K. Devilliers, L. Dortet, S. Oueslati, M. Plaisance, S. Simon, H. Volland

**EV0381** *Acinetobacter baumannii* isolated from respiratory samples as part of the MagicBullet clinical trial: molecular epidemiology and susceptibility to carbapenems, tigecycline and colistin
E. Zander* [Cologne, Germany], J. Nowak, P. Higgins, I. Roca Subira, J. Vila Estape, H. Seifert

**EV0382** The enterobacteria producing extended spectrum beta lactamas (ESBL) in community environment in children younger than 5 years in Bangui, Central African Republic
A. Farra* [Bangui, Central African Republic], T. Frank, A. Manirakiza, J. Gady, C. Rafai, M. Onambele, B. Garin, S. Breurec

**EV0383** Evolution of antibiotic multiresistance in *Escherichia coli* and *Klebsiella pneumoniae* isolates from blood cultures - a 15-year analysis [2000-2014]
D. Molina Arana* [Madrid, Spain], M. Rubia, J. Cacho, J. Alós Cortés

**EV0384** Antimicrobial resistance patterns among Enterobacteriaceae isolated from outpatients in Latin America
M. Renteria, D. Biedenbach, D. Saum* [Schaumburg, IL, United States], H. Leister-Tebbe

**EV0385** Complexity and evolution of resistance of *Pseudomonas aeruginosa* strains in intensive care units: association with antibiotic exposure
R. Montallegre, S. Druge, P. Plésiat, E. Oswald, J. Conil, G. Bernard, M. Grae* [Toulouse, France]

**Susceptibility testing methods**

**EV0386** Evaluation of in vitro efficacy of several disinfectants against *Salmonella enterica* serovar Enteritidis and *Escherichia coli* strains in poultry
S. Yubero Delgado, E. Rodríguez Ferri, S. Martínez Martínez* [León, Spain], Á. Álvarez Estrada, R. Frandoloso, C. Gutiérrez Martin

**EV0387** Evaluation of the novel beta CARBA test (Bio-Rad) for rapid identification of carbapenemase-producing Enterobacteriaceae in different samples
A. Cellini, E. Venturi, C. Dallenne Regdosz, M. Pedna, V. Sambri* [Pievesestina di Cesena (FC), Italy]

**EV0388** A ‘surprising’ pair: the synergistic antimicrobial activity of polymyxin B in combination with the cystic fibrosis drug ivacaftor against polymyxin-resistant *Pseudomonas aeruginosa*
E. Schneider* [Parkville, Australia], M. Azad, Q. Zhou, J. Wang, J. Huang, M. Cooper, Y. Dai, M. Muller, J. Li, T. Velkov

**EV0389** Activity of daptomycin, fosfomycin and vancomycin against planktonic and biofilm *Staphylococcus aureus* determined by microcalorimetry
M. Butini* [Berlin, Germany], E. Maiolo, A. Trampuz

**EV0390** Antimicrobial activity of photo-activated curcumin against planktonic and biofilm microorganisms determined by microcalorimetry
E. Maiolo, M. Czuban, R. Bizzarri, C. Viappiani, A. Trampuz, M. Di Luca* [Berlin, Germany]

**EV0391** Evaluation of the carbapenem inactivation method (CIM) for detecting carbapenemase activity in clinical isolates
A. Aguirre Quinonero* [Santander, Spain], D. Gamal, M. Cano García, J. Calvo Montes, L. Martinez-Martinez
EV0392 Prevalence of bacterial pathogens isolated from soft tissue infections and their antimicrobial susceptibility profiles
C. Vossou* (Athens, Greece), A. Kouki, D. Ntroulias, P. Mostratou, G. Chronopoulou

EV0393 Detection of extended-spectrum beta-lactamase producing Enterobacteriaceae by chromogenic ESBL-selective media
A. Korobova, I. Frolova, G. Klyasova* (Moscow, Russian Federation)

EV0394 Rapid killing of extended spectrum beta-lactamase positive (ESBL+), E. coli [Ec] and Klebsiella pneumoniae [Kp] clinical isolates by inhaled amikacin pulmonary drug concentration
J. Blondeau* [Saskatoon, Canada], S. Shebelski

EV0395 Killing of Enterobacter cloacae [Ecl], E. coli [Ec] and Klebsiella pneumoniae [Kp] by pulmonary drug concentration of ciprofloxacin dry powder for inhalation [Cdpi]
J. Blondeau* [Saskatoon, Canada], S. Shebelski

EV0396 Induction of biofilm formation by antibiotics in P. aeruginosa is a reversible process
E. Olivares* [Strasbourg, France], S. Badel, C. Provot, B. Jaulhac, G. Prévost, T. Bernardi, F. Jehl

EV0397 Reduced antibiotic susceptibility in wastewater Planktothrix sp.: evaluation of minimum inhibitory concentrations by a method designed for cyanobacteria – molecular identification of resistance genes
E. Dias, M. Oliveira, D. Jones-Dias, V. Manageiro* [Lisbon, Portugal], C. Churro, V. Vasconcelos, E. Ferreira, M. Caniça

EV0398 Clinical effectiveness and In vitro activity of meropenem+ertapenem and colistin+meropenem+ertapenem combinations against carbapenem-producing Klebsiella pneumoniae infections
A. Oliva* [Rome, Italy], D. Castaldi, L. Scorzolini, A. Cipolla, F. Gizzi, M. De Angelis, F. Cancelli, D. Abramo, M. Iannetta, M. Mascellino, C. Mastroianni, V. Vullo

EV0399 Detection of extended-spectrum beta-lactamases in AmpC-producing organisms – a comparison of phenotypic and molecular methods
L. Paterson, K. Hoek, P. Alley, M. Newton-Foot, A. Whitelaw* [Cape Town, South Africa]

EV0401 Activity of fosfomycin and daptomycin-containing bone cements on selected bacterial species being associated with orthopaedic infections
S. Eick* [Bern, Switzerland], K. Hofpeter, S. Klimas, S. Vogt, S. Nietzsche

EV0402 Colistin-based and colistin-sparing antimicrobial combinations against carbapenem-resistant Klebsiella pneumoniae
A. Oliva* [Rome, Italy], A. Cipolla, L. Scorzolini, M. De Angelis, F. Cancelli, D. Castaldi, M. Mascellino, C. Mastroianni, V. Vullo

EV0403 Antimicrobial susceptibility of clinically significant anaerobic bacteria in Slovenia, 2014
S. Jeverica* [Ljubljana, Slovenia], U. Kolenc, L. Papst, B. Beovic, M. Mueller-Premru

EV0404 Evaluation of double-disk synergy test with low-content cephalosporin disks used by EUCAST versus high-content disks used by CLSI for detection of extended-spectrum beta-lactamases in Enterobacteriaceae
M. Sukhorukova* [Smolensk, Russian Federation], N. Ivanchik, E. Sklenova, M. Edelstein, R. Kozlov

EV0405 CHROMagar mSuperCarba screening followed by Rapidec Carba NP test for detection of carbapenemase producers in Enterobacteriaceae
M. García Quintanilla* [Seville, Spain], L. Poirel, P. Nordmann

EV0406 In vitro demonstration of synergy of colistin with various antimicrobial agents by disc diffusion and E testing against clinical isolates of carbapenem resistant Acinetobacter
S. Basireddy* [Kurnool, India], S. Gundela, V. Kabra, M. Singh

EV0407 E-test in susceptibility testing of Helicobacter pylori: seven-year observation of resistance in a region of Slovak republic
R. Botek* [Piešťany, Slovakia], V. Melicháková, S. Vašková, S. Blažícková, Z. Bacová, J. Kabatova

EV0409 Evaluation of the dipstick test for the diagnosis of symptomatic urinary tract infection
F. Bellazreg, M. Abid, Z. Hattab, J. Souissi, W. Hachfi* [Sousse, Tunisia]
Synergistic effects of antimicrobial drug combinations including meropenem against Acinetobacter baumannii, Pseudomonas aeruginosa and carbapenem-resistant enterobacteria
J. Ramirez-Conchas, F. Galan-Sanchez, M. Rodriguez-Iglesias* (Cádiz, Spain)

Can we use the same disks of cefotaxime (5µg) and of ceftriaxone (10µg) for the routine and the detection of ESBL?
N. Brieu* (Aix en Provence, France), J. Gallou, C. Pachetti, C. Ferrali, H. Chardon

Phenotypic disc tests: can we use them to alert infection control in carbapenem-resistant isolates?
S. Yilmaz, A. Karakoc* (Ankara, Turkey), A. Ozisik, A. Adiloglu

GBS screening: does PCR assay target neonatal infectious risk?
C. Azogui* (Toulouse, France), J. Raignoux

Results from the 2015 antimicrobial susceptibility testing external quality assessment (EQA) exercise organized for EARS-Net participants

The ROSCO KPC/MBL confirm kit to detect metallo-beta-lactamases in Bacteroides fragilis
S. Schwensen* (Odense, Denmark), Z. Acar, Å. Johansson, U. Justesen, O. ESCMID Study Group for Anaerobic Infections - ESGAI

Determination the efficiency of nisin against Salmonella enterica serovar Typhimurium SL1344
F. Yüksel, N. Taskale Karatug, N. Akçelik, M. Akçelik* (Ankara, Turkey)

Diagnostic performance of the ESBL combination disk test: the predictive value for the presence of ESBL production in Enterobacteriaceae depends on the size of the zone difference
W. van den Bijl, M. Mutso* (London, United Kingdom), K. Verduin, C. Verhulst, J. Veenemans

Evaluation of the performances of Carba NP test and carbapenem inactivation method for the investigation of carbapenemase activity in Escherichia coli and Klebsiella spp. isolates
O. Karatuna* (Istanbul, Turkey), M. Kaya, D. Kaya, I. Akyar

Rapid detection of carbapenemase production in calcium-alginate embedded Gram-negative bacteria
J. Elas* (Berlin, Germany), V. Belomo, B. Stirzel, M. Kaase, C. Schoen, U. Vogel

Three month experience of Xpert® Carba-R v2 assay for the detection of carbapenemase-producing Enterobacteriaceae
N. Fortineau, Y. Hoyos, L. Dorset, T. Naas* (Le Kremlin-Bicêtre, France)

Development of a rapid molecular test format based on isothermal recombine polymerase amplification technique for detection of blaoXA-48
M. Kuskucu, A. Gokhan, A. Karakullu, C. Erturk, O. Kucukbasmaci, K. Midilli* (Istanbul, Turkey)

Impact of the Xpert Carba-R assay on the management of carbapenemase screening: 1.5 years of follow-up
A. Duboux* (St Jean, France), V. Pietri, J. Gandois

Performance of CarbR GeneXpert(R) assay against culture and PCR for the detection of carbapenem-resistant Enterobacteriaceae (CRE) from rectal swabs
N. Al Merdasi, W. Jamal, V. Rotimi* (Safat, Kuwait)

Comparative evaluation of Vitek 2 using the AST-N223 card and microbroth dilution susceptibility testing for piperacillin/tazobactam in ESBL-producing Escherichia coli and Klebsiella pneumoniae
N. Ester* (Bochum, Germany), M. Kaase, S. Gattermann

Determining the functionality of the erm(41) gene is more important than identifying the subspecies in the Mycobacterium abscessus complex
M. Rubio* (Barcelona, Spain), P. Espinal, M. Español, M. Garriga, C. Morena, P. Coll

RNA expression analysis of efflux pump genes in clinical isolates of multidrug-resistant and extensively drug-resistant Mycobacterium tuberculosis
T. Oh, H. Kang, Y. Kim, C. Kim, H. Lee* (Seoul, South Korea)

Characterization of random Clostridium difficile mutants less susceptible to ridinilazole (SMT19969) in terms of fitness cost
P. Budd* (Nottingham, United Kingdom), M. Kelly, R. Vickers, K. Winzer, N. Minton, S. Kuehne

Evaluation Xpert® Carba-R for detection of carbapenem-resistant Enterobacteriaceae (CRE) from culture
A. Samily* (Riyadh, Saudi Arabia), A. Senok
EV0430  In vitro evaluation of double carbapenem and colistin combinations against OXA-48, NDM and KPC carbapenemase-producing colistin-resistant Klebsiella pneumoniae
F. Erdem, A. Abulaia, Z. Aktas* [Istanbul, Turkey], M. Fevzi Oezsoy, O. Sahingoz, O. Oncul

EV0431  Evaluation of the RAPIDEC® CARBA NP test for the detection of carbapenemases in Gram-negative bacteria
V. Ageevets, S. Sidorenko, I. Lazareva* [St. Petersburg, Russian Federation]

O. Karatuna* [Istanbul, Turkey], M. Kaya, I. Akyar

EV0433  Evaluation of the performances of Mast and Rosco phenotypic carbapenemase detection kits for Escherichia coli and Klebsiella pneumoniae isolates carrying carbapenemase genes
O. Karatuna* [Istanbul, Turkey], M. Kaya, D. Kaya, I. Akyar

EV0434  Genetic characterization of carbapenem-resistant Providencia rettgeri: outbreak isolates from a tertiary hospital
V. Tshisevhe* [Pretoria, South Africa], N. Mbelle, R. Lekalakalo, D. Atanda, J. Antiabong, N. Tshuma, S. Van Rensburg

EV0435  Emergence and clonal spread of carbapenem-resistant Klebsiella pneumoniae in Bulgaria
R. Vatcheva-Dobrevska* [Sofia, Bulgaria], L. Zamorano, X. Mulet, V. Dicheva, E. Nedjalkova, P. Stefanowa, S. Alberti, A. Oliver

EV0436  First report of colistin-resistant OXA-48-producing Klebsiella pneumoniae in Serbia
A. Trudic* [Novi Sad, Serbia], Z. Jelecic, M. Mihajlovic-Ukrupina, D. Medic, B. Milosavjevic, V. Kukucka, V. Gusman

EV0437  Phylogenetic distribution, antimicrobial resistance and molecular docking of integrons in multidrug resistant diarrheagenic E.coli isolates from children under five in Delhi, India
T. Singh* [Delhi, India], S. Das, V. Ramachandran, K. Maroof, A. Rai

EV0438  Detection of a new Inc-X plasmid blaKPC-3 in Serratia marcescens from a kidney–liver transplanted patient
F. Gona* [Palermo, Italy], C. Caio, G. Iannolo, F. Monaco, G. Di Mento, N. Cuscino, I. Fontana, M. Mezzatesta, S. Stefani, P. Conaldi

EV0439  Mecillinam resistance in Enterobacteriaceae urinary tract isolates
L. Cottom, A. Deshpande, A. Speekenbrink, T. Inkster* [Glasgow, United Kingdom]

EV0440  Mutant prevention concentration of imipenem, against Pseudomonas aeruginosa clinical isolates and mutations in the oprD gene
F. Vassilara, I. Galani, M. Souli, K. Papakioalaou, H. Giamarellou, A. Papadopoulos* [Athens, Greece]

EV0441  In vitro activity of mecillinam alone and combined with different beta-lactams and/or beta-lactamase inhibitors against extended spectrum beta-lactamase- and AmpC-producing Escherichia coli and Klebsiella pneumoniae
F. Hansen* [Copenhagen, Denmark], A. Hammerum, H. Hasman, N. Frimodt-Moller, A. Larsen

EV0442  Detection of carbapenemases and other mechanisms of enzymatic resistance to beta-lactams in enterobacteria with diminished susceptibility to carbapenems in a tertiary care hospital in Zaragoza, Spain
M. Góma, A. López-Callego, B. Vela, I. Ferrer, E. Morilla, R. Nuñez, M. Vicente, M. Capape, F. Castillo, A. Rezusta* [Zaragoza, Spain], M. Revillo

EV0443  In vitro effect of deferoxamine on the efficiency of metronidazole against Capnocytophaga spp.
Z. Tamani-Shacouri, E. Ehrmann, O. Loreal, O. Nolwenn, M. Bonnaure, A. Jolivet-Gougeon* [Rennes, France]

EV0444  Effectivity of a double-carbapenem regimen for the treatment of a KPC-producing Klebsiella pneumoniae infection in an immunocompromised patient
J. González-López* [Barcelona, Spain], L. Miguel, N. Piedra-Carrasco, D. Campany, L. Fox, B. Almirante Gragera, M. Larrosa, I. Ruiz

EV0445  OXA-370 is rapidly detected from different culture media using OXA-48 K-SeT® immunochromatography
C. Silva Nodari, A. Barth* [Porto Alegre, Brazil], C. Magagnin, A. Zavascki, A. Gales, C. Carvalhaes

EV0446  Identification and characterization of a non-typeable Haemophilus influenzae clinical isolate auxotroph for thymidine
S. Marti* [Barcelona, Spain], F. Tubau, I. Rodriguez, A. Fernandez, B. Euba, N. Lopez, J. Garmendia, J. Linares, C. Ardanuy Tisaire

EV0447  A rapid test for detection of OXA-48 carbapenemase
I. De Toro Peinado* [Malaga, Spain], M. Mediavilla Gradolph, R. Sainz Rodriguez, M. Valverde Traya, M. Bermúdez Ruiz, B. Balop

EV0448  Klebsiella pneumoniae isolates: a five-year study of mechanisms of carbapenem resistance
V. Papaioannou, A. Stylianakis* [Athens, Greece], A. Kakiaou, E. Koiliari, E. Maggou, D. Dimopoulos, K. Kafantogia, S. Tsipakou
<table>
<thead>
<tr>
<th>Session Code</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>EV0449</td>
<td>Klebsiella pneumoniae co-producing OXA-48 and VIM carbapenemases</td>
<td>A. Sotillo-Torquemada, A. Sarria Visa* [Madrid, Spain], G. Ruiz-Carrascosa</td>
</tr>
<tr>
<td>EV0451</td>
<td>Dissemination of carbapenemase-producing Enterobacteriaceae at the Taher Sfar University Hospital, Mahdia, Tunisia</td>
<td>W. Mansour* [Sousse, Tunisia], G. Raoudha, M. Yosra, B. Anis, E. Saraw, O. Bouallegue, J. Madec</td>
</tr>
<tr>
<td>EV0453</td>
<td>Carbapenemase-producing Enterobacteriaceae in the Clinical Center Nis, Serbia – a new critical point on the map of the Balkans?</td>
<td>S. Mladenovic-Anic* [Nis, Serbia], B. Kocic, M. Dinic, M. Djilos, L. Ristic, Z. Jelesec</td>
</tr>
<tr>
<td>EV0454</td>
<td>Analysis of amino acid substitution mutations of gyrA and parC genes in the clonal lineage of Klebsiella pneumoniae conferring high-level quinolone resistance</td>
<td>M. Shakibaie* [Kerman, Iran], A. Norouzi</td>
</tr>
<tr>
<td>EV0455</td>
<td>Improved detection of Staphylococcus intermedius group in a routine diagnostic laboratory</td>
<td>J. Lee* [Truro, United Kingdom], A. Murray, R. Bendall, W. Gaze, L. Zhang, M. Vos</td>
</tr>
<tr>
<td>EV0456</td>
<td>Improve detection of GBS in pregnant woman using a selective agar: a prospective study about sensitivity, specificity, cost effectiveness and time to detection</td>
<td>M. Jager* [Haarlem, Netherlands], M. Straten, A. Huijbers-Visser, T. Yap, S. Euser, D. Veenendaal</td>
</tr>
<tr>
<td>EV0457</td>
<td>Performance of a new screening agar plate for rapid detection of carbapenemase-producing Enterobacteriaceae</td>
<td>K. Rensing* [Amsterdam, Netherlands], K. van Dijk, A. Reuland, M. van Kerckhoven, M. Kluytmans - van den Bergh, J. Kluytmans, C. Vandenbroucke-Grauls, N. al Naiemi</td>
</tr>
<tr>
<td>EV0458</td>
<td>Unus pro omnibus, omnes pro uno - comparative study of quantitative and semiquantitative catheter tip cultures</td>
<td>J. Zintgraff* [Buenos Aires, Argentina]</td>
</tr>
<tr>
<td>EV0459</td>
<td>Rapid time to detection difference between the BacT/ALERT VIRTUO and the BacT/ALERT 3D</td>
<td>P. Deal* [Durham, United States], M. Ullery, H. Totty, J. Viray, J. Spontak, M. Adamik, W. Dunne</td>
</tr>
<tr>
<td>EV0460</td>
<td>Inoculation of cerebrospinal fluid to blood culture bottles improves yield compared to conventional culture methods</td>
<td>I. Yoo* [Seoul, South Korea], S. Chun, H. Huh, N. Lee</td>
</tr>
<tr>
<td>EV0461</td>
<td>Microbiological and clinical evaluation of a rare case of infection: Raoultella planticola</td>
<td>T. Demiray, M. Koroglu, A. Özbek, M. Altindis* [Sakarya, Turkey]</td>
</tr>
<tr>
<td>EV0462</td>
<td>Specificity of the OXA-48 immunochromatographic K-SeT for the detection of OXA-48-like in Shewanella spp.</td>
<td>P. Bogaerts* [Yvoir, Belgium], S. Evrard, G. Cuzon, T. Huang, T. Naas, Y. Glupczynski</td>
</tr>
<tr>
<td>EV0463</td>
<td>Detection of OXA-48-type carbapenemases from an Egyptian teaching hospital using a novel chromatic OXA agar method</td>
<td>M. El-Bouseary* [Cardiff, United Kingdom], T. Elbanna, F. Sanbol, T. Walsh</td>
</tr>
<tr>
<td>EV0464</td>
<td>Thermo Scientific® Brilliance™ ESBL/Brilliance™ CRE agar provides rapid detection of multiresistant Gram-negative organisms</td>
<td>E. Scopes* [Basingstoke, United Kingdom], J. Screen</td>
</tr>
<tr>
<td>EV0465</td>
<td>Time to blood culture positivity: a tool in the diagnosis of sepsis</td>
<td>T. Sardinha* [Amadora, Portugal], L. Sancho, M. Silva, S. Mendonça, F. Silva, E. Alijeva</td>
</tr>
<tr>
<td>EV0466</td>
<td>Interactions of tigecycline with colistin, gentamicin or meropenem against tigecycline resistant carbapenemase producing Klebsiella pneumoniae isolates</td>
<td>V. Papoutsaki* [Athens, Greece], R. Karantani, I. Galani, M. Souli, I. Karaiskos, E. Papadogeorgaki, H. Giamarelou</td>
</tr>
<tr>
<td>EV0467</td>
<td>ChromID® CARBA SMART selective chromogenic media bi-plate can it be used to detect other multidrug-resistant bacteria?</td>
<td>A. Madueño Alonso, Z. Díaz, L. Sante, R. Kahan, M. Ramos, Y. Pedroso Fernández, T. Delgado Melian* [San Cristobal de la Laguna, Spain], M. Leuyna</td>
</tr>
<tr>
<td>EV0468</td>
<td>Comparison of a new generation blood culture system with the BacT/ALERT® 3D system for the detection of patients with bacteremia</td>
<td>Y. Chan* [Taipei, Taiwan], S. Lee, T. Li</td>
</tr>
<tr>
<td>EV0469</td>
<td>Comparison of two selective media for the detection of carbapenemase-producing Enterobacteriaceae using direct plating and selective broth enrichment</td>
<td>S. Jonckheere* [Eper, Belgium], K. Van Vaerenbergh, A. Boel, H. De Beenhouwer</td>
</tr>
</tbody>
</table>
E0471 Rapid liquid cultures for respiratory samples
V. Brucculeri, C. Ceppatelli, C. Giordano* (Pisa, Italy), A. Vecchione, E. Ghelardi, A. Lupetti, S. Barnini

E0472 Is blind passage from nonsignalling blood culture bottles necessary?
O. Akgul, S. Satilmis* (Istanbul, Turkey), S. Ozsoy, P. Taskin, N. Ulger Toprak, G. Soyletir

E0473 Detection of resident microflora in the urinary tract of healthy controls: standard vs. expanded quantitative urine culture protocols
L. Coorevits* (Ghent, Belgium), S. Heytens, J. Boelens, G. Claeys

E0474 Mycobacterial cultures in MGIT: vancomycin or no vancomycin?
F. Schramm* (Strasbourg, France), A. Chabaud, M. Durand, C. Koebel, B. Jaulhac

E0475 Assessing the diagnostic efficacy of newer tools for diagnosis of paediatric tuberculosis
H. Vashistha* (New Delhi, India), S. Saini, K. Chopra, D. Shrivastava, M. Hanif

E0477 Evaluation of Chromatic™ OXA-48 medium for direct detection of OXA-48 producing Enterobacteriaceae from rectal swabs
A. Antonelli* (Siena, Italy), L. Henrici De Angelis, J. Tyrrell, T. Walsh, D. Vitagliano, F. Brocco, G. Rossolini, M. D’Andrea

E0478 Which culture is more reliable for complicated urinary tract infection?
G. Dede, O. Deveci* (Diyarbakir, Turkey), O. Dede, M. Utangaç, M. Da guli, M. Bodakci, N. Penbegul

E0479 Validation of Copan GN Broth for selective enrichment of Gram-negative bacteria especially Salmonella and Shigella
L. Conte* (Brescia, Italy), B. Massetti, S. Castriciano

E0481 Diagnostic value of leukocyte esterase test for detection of pleocytosis in cerebrospinal fluid of patients with suspected acute meningitis
S. Shokouhi, M. Karamipour, I. Alavi Darazam* (Tehran, Iran)

E0482 Comparison of Illumigene Mycoplasma DNA amplification assay and real-time in-house PCR for detection of M. pneumoniae
K. Loens* (Edegem, Belgium), M. Kuijstermans, M. Leven

E0483 Next generation diagnosis of bacteraemia in septic patients

E0484 Clinical benefits of early microarray-based identification and resistance determinants of organisms causing Gram-negative and Gram-positive bacteraemia
T. Walker* (Los Angeles, United States), S. Dumadag, C. Lee, S. Lee, J. Cupo Abbott, R. She

E0485 Clinical assessment of a rapid molecular assay to detect Salmonella enterica Typhi and Paratyphi A in blood from typhoid suspected patients in Bangladesh
J. Telles* (Lyon, France), S. Pouzol, A. Tanmoy, D. Ahmed, F. Qadri, S. Saha, H. Endtz

E0486 Performance comparison of CHROMagar™ STEC and the SHIGA TOXIN QUIK CHEK™ assay using a panel of shiga toxin Escherichia coli isolates
J. Boone, M. Lubeskie, A. Pendergrass, R. Cormon* (Blacksburg, United States)

E0487 Novel serotype-specific rapid detection method for Cronobacter sakazakii
E. Scharinger* (Oberschleißheim, Germany), K. Schauer, R. Dietrich, E. Märtlbauer

E0488 Application of Xpert ® Carba-R assay to active surveillance of carbapenemase-producing Enterobacteriaceae in a high prevalence setting

E0489 Broad range PCR coupled with electrospray ionization mass spectrometry for the diagnosis of Francisella tularensis infection
D. Florea* (Bucharest, Romania), G. Coltan, C. Marin, M. Anghel, T. Coltan, I. Parvu, D. Otelea

E0490 Comparison of three assays for identification of staphylococci from positive blood cultures
S. Molinos* (Badalona, Spain), C. Prat, A. Lacoma, M. Colomer, N. Pagan, V. Ausina, M. Giménez
EV0491 Epidemiology of Acinetobacter calcoaceticus – Acinetobacter baumannii (ACB) complex species associated with bacteraemia in Angers University Hospital, France, between 2010 and 2014
R. Chenouard, H. Pailliorès, T. Clémence, M. Eveillard, C. Lemarié, M. Chetaou, M. Joly-Guillou, M. Kempf* (Angers, France)

EV0492 Evaluation of a new lateral flow test for the simultaneous detection of Streptococcus pneumoniae and Legionella pneumophila in urine samples
C. Marcó* (Badalona, Spain), C. Prot, M. Pérez, B. Rivaya Sanchez, S. Molinos, V. Ausina

EV0493 The more, the better? When to use highly multiplexed assays for the detection of gastrointestinal pathogens
L. Naef* (Lucerne, Switzerland), L. Berlinger, E. Claas, M. Altwegg

EV0494 Identification of urinary tract pathogens after a 3-hour incubation by MALDI-TOF MS
J. Haiko* (Helsinki, Finland), L. Savolainen, R. Hilla, A. Pätäri-Sampo

EV0495 Disease activity related dysbiosis in inflammatory bowel disease patients
M. Grasman* (Amsterdam, Netherlands), R. van der Borden, A. Budding, A. Eck, N. de Boer, G. Bouma, A. van Bodegraven, P. Savelkoul

EV0496 Diagnostic of Helicobacter pylori infection in gastric biopsies of a paediatric population using quantitative PCR
L. Llorca* (Madrid, Spain), G. Pérez, Z. Gao, P. Urruzuno, M. Martínez, T. Alarcon Cavero

EV0497 What is the actual broadness of the universal panbacterial PCR in diagnostics of infections
J. Tkadlec, M. Antušková, D. Jahoda, L. Šrámková, V. Rohn, M. Kvapil, O. Raszka, P. Drevinek, J. Tkadlec* (Prague, Czech Republic)

EV0498 A rapid method for sterility testing of total parenteral nutrition solution based on the use of HB&L system
K. Athamna, K. Amarney, E. Tannous, S. Freimann* (Hadera, Israel)

EV0499 Evaluation of the IRIDICA system to diagnose prosthetic implant infection

EV0500 Validation of a loop-mediated isothermal amplification (LAMP) assay in comparison with real-time PCR for the detection of C. difficile toxin directly in stool specimens
C. Tauber, U. Eigner* (Heidelberg, Germany), R. Schwarz, M. Holfelder

EV0501 Comparison of traditional blood culture and microarray-based hyb'ORG Dx in septic patients
A. Boesl* (Feldkirch, Austria), K. Baruschke, H. Dirschmid, P. Fae, F. Öffner

EV0502 A novel genetic algorithm for Maldi-ToF mass spectrometry-based identification of bacterial species
E. Lisitsyna* (Moscow, Russian Federation), I. Altukhov, D. Ischenko, D. Alexeev, A. Naumov, E. Ilina, V. Voevodin

EV0503 RIDA®GENE Helicobacter pylori is a sensitive and specific real-time PCR test for the simultaneous detection and differentiation of Helicobacter pylori and its resistance to clarithromycin in human tissue biopsies
R. Bialek, C. Zelck, L. Kastl* (Darmstadt, Germany)

EV0504 Evaluation of the performance of C. DIFF QUIK CHEK COMPLETE, an enzyme immunoassay for simultaneous detection of glutamate dehydrogenase antigen and toxin A/B, and testing algorithm for the diagnosis of Clostridium difficile infection
N. Yang, H. Chung, S. Lee, M. Lee* (Seoul, South Korea)

EV0505 Rapid detection of blaSHV from Escherichia coli and Klebsiella pneumoniae by loop-mediated isothermal amplification (LAMP) method
A. Thuengern, S. Nathsuswan, M. Channawang, C. Wiwat, K. Thirapanmethetee* (Bangkok, Thailand)

EV0506 Influence of DNA extraction on detection limit of 16S rRNA gene amplicon sequencing and contaminating DNA
Y. Xu* (Aarhus, Denmark), L. Larsen, N. Frandsen, T. Thomsen

EV0507 A rapid 3base® real-time PCR for the detection of carbapenemase-resistant organisms using multi-coloured fluorogenic probes
D. Stark, J. Melki, D. Millar* (Sydney, Australia)

EV0508 Detection of sexually transmitted infection-associated pathogens through multiplex real-time PCR
A. Nava* (Milan, Italy), V. Lepera, A. Bielli, D. Fanti, L. Grassi, G. Gesu

EV0509 A novel line immunoassay for diagnosis of Helicobacter pylori infection
C. Noelting* (Neuried, Germany), C. Reichhuber, D. Boecher, L. Formichella, H. Meyer, E. Soutschek, M. Gerhard

EV0510 MALDI-TOF identification of Brucella melitensis, Brucella abortus and Brucella suis
EV0511  Comparison of real-time PCR tests with culture to diagnose enteropathogens in stool samples
S. Valledor, C. Sera* [Zaragoza, Spain], J. Bueno, A. Bellés Bellés, S. Algarate, M. Gil, F. Castilla

EV0512  Performance of Vitek-MS bioMérieux MALDI-TOF for the identification of non tuberculosis mycobacteria
E. Hodille* [Lyon, France], A. Camandone, J. Labbe, C. Pichat, F. Breyssse, M. Perouse-de-Montclos, I. Fredenucci, G. Lina, O. Dumitrescu

EV0513  Development of rapid isothermal recombinase polymerase amplification assays for the detection of carbapenemase genes
C. Turner* [Salisbury, United Kingdom], C. Allen, D. Meunier, K. Hopkins, N. Woodford, M. Sutton

EV0514  Using mESC-derived neurons grown on multi-electrode arrays as an in vitro bioassay for the detection of Clostridium botulinum neurotoxins
S. Jenkinson* [Bern, Switzerland], M. Avondet, D. Grandgirard, M. Heidemann, A. Tscherter, S. Leib

EV0515  Clinical impact of rapid point-of-care tests for acute sore throat
J. Vakkila, M. Mäki* [Espoo, Finland], M. Lindberg, A. Ackermann, T. Siljander, J. Raussi, K. Hatakainen

EV0516  Improved sensitivity by optimizing the DNA extraction and PCR in molecular detection [16S] of bacteria from tissue
M. Bergman* [Linköping, Sweden], D. Sune, Å. Nilsdotter, L. Serrander

EV0517  New multiplex diagnostic test on the microfluidic platform V5 to diagnose MRSA bloodstream infections

EV0519  Validation of Cepheid Xpert® C. difficile assay using 400µL liquid transport medium from Copan Fecal Swab® for the detection of Clostridium difficile DNA in stool samples positive for glutamate dehydrogenase antigen
Y. Caspar* [Grenoble, France], M. Maurin

EV0520  Panton-Valentine leukocidin [PVL] in Staphylococcus aureus isolates: prevalence in healthy carriers and in clinical samples in Switzerland
M. Oberle, C. Ottiger, H. Fankhauser* [Aarau, Switzerland]

EV0521  Evaluation of Copan FecalSwabTM in combination with the Nimbus nucleic acid extractor and AllplexTM GI-Bacterial [I] assay
A. Giambra* [Brescia, Italy], S. Razeti, M. Renzulli, S. Castriciano

EV0522  Prevalence, colonization patterns, antibiotic susceptibility and MALDI-TOF identification of Burkholderia cepacia complex isolates from a Spanish cystic fibrosis unit
J. Caballero Pérez* [Madrid, Spain], L. Martínez García, M. Tato, M. Morosini Reilly, M. Cobo, R. del Campo, R. Canton Moreno

EV0523  Validation of a loop-mediated isothermal amplification assay for rapid diagnosis of invasive pneumococcal disease
P. Brotons de los Reyes, C. Cisneros Camps* [Barcelona, Spain], H. De Paz Fernandez, C. Esteva, C. Muñoz-Almagro

EV0524  How is the Xpert MRSA Gen 3 assay (Cepheid) performing on pooled TSB salt broth?
S. Jonckheere* [Ieper, Belgium], C. De Ridder, R. Joseph, P. Vandecandelaere

EV0525  Microbiota-based IBD diagnostics proved robust for inter-clinic variation
A. Eck* [Amsterdam, Netherlands], E. de Groot, T. de Meij, M. Welling, C. Peeters, P. Savelkoul, A. Budding

EV0526  Application of MALDI-TOF MS combined with PBP2' latex agglutination test for MRSA screening
M. Pappné Ábrók, A. Lázár, M. Szécsényi, E. Urbán* [Szeged, Hungary]

EV0527  Evaluation of a rapid method to detect KPC carbapenemase based on Maldi-TOF spectra analysis
A. Centonze, A. Oliani, G. Cornaglia, A. Mazzariol* [Verona, Italy]

EV0528  Confirmatory testing of Neisseria gonorrhoeae with LightMix modular kits detecting gyrA and opaD
A. Hieregeist, S. Foerster, U. Reischl, J. Osiecki* [Pleasanton, United States], O. Landt

EV0529  Improved sensitivity by optimizing the DNA extraction and PCR in molecular detection (16S) of bacteria from tissue
M. Bergman* [Linköping, Sweden], D. Sune, Â. Nilsdotter, L. Serrander

EV0520  Evaluation of Copan FecalSwabTM in combination with the Nimbus nucleic acid extractor and AllplexTM GI-Bacterial [I] assay
A. Giambra* [Brescia, Italy], S. Razeti, M. Renzulli, S. Castriciano

EV0521  Development of rapid isothermal recombinase polymerase amplification assays for the detection of carbapenemase genes
C. Turner* [Salisbury, United Kingdom], C. Allen, D. Meunier, K. Hopkins, N. Woodford, M. Sutton

EV0514  Using mESC-derived neurons grown on multi-electrode arrays as an in vitro bioassay for the detection of Clostridium botulinum neurotoxins
S. Jenkinson* [Bern, Switzerland], M. Avondet, D. Grandgirard, M. Heidemann, A. Tscherter, S. Leib

EV0515  Clinical impact of rapid point-of-care tests for acute sore throat
J. Vakkila, M. Mäki* [Espoo, Finland], M. Lindberg, A. Ackermann, T. Siljander, J. Raussi, K. Hatakainen

EV0516  Improved sensitivity by optimizing the DNA extraction and PCR in molecular detection [16S] of bacteria from tissue
M. Bergman* [Linköping, Sweden], D. Sune, Â. Nilsdotter, L. Serrander

EV0517  New multiplex diagnostic test on the microfluidic platform V5 to diagnose MRSA bloodstream infections

EV0519  Validation of Cepheid Xpert® C. difficile assay using 400µL liquid transport medium from Copan Fecal Swab® for the detection of Clostridium difficile DNA in stool samples positive for glutamate dehydrogenase antigen
Y. Caspar* [Grenoble, France], M. Maurin
Denaturing gradient gel electrophoresis (DGGE) reveals differences in midgut flora between different populations of *Phlebotomus papatasi* Scopoli (Diptera: Psychodidae) in Turkey
M. Karakus* (Izmir, Turkey), B. Karabay, S. Kalkan, M. Pekagirbas, O. Erisoz Kasap, B. Alten, G. Özdemir, S. Töz, Y. Özbel

**EV0532** Evaluation of the Seegene PCR for detection of enteric pathogens
L. Andersen* (Copenhagen, Denmark), T. Havnhej Frandsen, J. Kurtzhals

**EV0533** PCR analysis for the intrapartum detection of group B streptococci in a routine clinical setting
A. van den Berg* [Utrecht, Netherlands], L. van Belzen, A. van Oppen, N. Hartiti-van de Leur, P. Scheffer, H. Kusters, E. Boel, T. van der Bruggen

Transition from microbiological culture to Cepheid Carba-R nucleic acid amplification technique for the detection of carbapenemase producing Enterobacteriaceae in screening samples in a high-incidence setting
R. Shorten* [Manchester, United Kingdom], A. McEwan, Z. Aiken, A. Dodgson

**EV0535** Evaluation of a commercial *Helicobacter pylori* PCR assay against standard phenotypic culture isolation and antimicrobial sensitivity testing for macrolides and quinolones
G. Godbole* [London, United Kingdom], C. Swift, C. Ohai

**EV0536** Comparison of Xpert® GBS real-time PCR versus culture for intrapartum detection of group B Streptococcus

**EV0537** Evaluation of the novel DiaSorin LIAISON® Campylobacter antigen assay to the established culture method for stool diagnosis of Campylobacter
Z. Moure* [Barcelona, Spain], A. Rando, G. Roig, C. Crespo, T. Pumarola Sole, V. Rodriguez Garrido

**EV0538** Helicobacter pylori: PCR vs. culture - a case study at CHU Mustapha Bacha Algiers, Algeria
D. Fazia* [Alger, Algeria], M. Bachtarzi, L. Kamel, R. Nadjia, C. Burucoa, T. Mohamed

**EV0539** A direct method for rapid identification of yeast and bacteria from positive culture bottles BAcT/ALERT by Vitek MS matrix-assisted laser desorption ionization time of flight mass spectrometry

**EV0540** Sensitivity and specificity of different amplification protocols for detection of *Borrelia burgdorferi sensu lato*: an EU-wide external quality assessment study
M. Faller, A. Hiergeist, G. Margas, U. Reischl, A. Sing* [Oberschleissheim, Germany], V. Fingerle

**EV0541** Native pulmonary valve endocarditis and spondylodiscitis due to *Streptococcus equi* zooepidemicus
D. Iacob* [Bucharest, Romania], D. Florea, B. Manu

**EV0542** Rapid identification of bloodstream infection using MiniION metagenomics sequencing
S. Mwaigwisya* [Norwich, United Kingdom], L. Tim, N. Loman, P. Dark, J. Wain, J. O’Grady

**EV0543** A comparison of two molecular diagnostic methods for accurate and rapid diagnosis of acute leptospirosis in an endemic setting [Lao People’s Democratic Republic]
K. Woods* [Vientiane, Laos], S. Dittrich, A. Chantongthip, M. Vongsavath, L. Bouthchasavang, D. Dance, N. Shetty, C. Arnold, C. Nic-Fhogartaigh, M. Zambon, P. Newton

**EV0544** Modular multiplex PCR in detection of bacterial diarrhoeal pathogens – a pilot study
M. Pirs* [Ljubljana, Slovenia], T. Cerar Kišek, J. Guzej, B. Stalowsky Poglajen, T. Plankar Sravin, T. Lejko Županc

**EV0545** MALDI-TOF identification from urine direct samples
M. Valverde Traya, R. Sainz Rodriguez, M. Mediavilla Gradolph, I. De Toro Peinado* [Malaga, Spain], M. Bermúdez Ruiz, B. Palop

**EV0546** Rapid identification of bloodstream pathogens in sepsis using MALDI-SepSityper kit and direct antibiotic susceptibility testing with Microscan
M. Massiah* [Vicenza, Italy], F. Furlan, L. Braggagno, M. Pascarella, M. Rassu

**EV0547** Multiplex detection of antibiotic resistance using new qPCR technology
E. Mokany* [Sydney, Australia], L. Tan, S. Walker, S. Erskine, A. Todd

**EV0548** Direct diagnosis of bloodstream infection in renal transplant and dialysis patients by polymerase chain reaction/electrospray ionization-mass spectrometry (PCR/ESI-MS)
A. Massiah* [London, United Kingdom], S. Hasson, A. Adwaney, A. Whiley, R. Murphy, S. Law, S. Mohd Afzal, R. Thuraisingham, M. Wilks
EV0549 A review of the public health management of shigellosis in Australia in the era of culture-independent diagnostic testing
A. Tai, M. Easton, J. Encena, J. Rotty, M. Valcanis, B. Howden* [Parkville, Australia], S. Slaton-Kan, J. Gregory

EV0550 An alternative method for urine cultures: direct identification of urinary tract pathogens from urine by MALDI TOF MS
A. Ilki* [Istanbul, Turkey], S. Ozsoy, G. Soyletir

EV0551 Direct identification of microorganisms from positive blood culture by MALDI-TOF
C. Costa, A. Barbui, E. Marra, A. Riccabone, A. Piceghello, G. Bianco, A. Curtoni* [Turin, Italy], R. Cavallo

EV0552 Molecular detection of seven pathogens causing urethritis / vaginosis in a tertiary care hospital, Bangkok, Thailand
N. Chaihongs* [Bangkok, Thailand], S. Thokaew, P. Santanirand

EV0553 Direct detection of Streptococcus agalactiae using GenomEra CDX
K. Ghathian* [Hvidovre, Denmark], L. Dons, A. Tapio

EV0554 Staphylococcus schleiferi: a single species or two separate subspecies?
E. Broens* [Utrecht, Netherlands], J. De Laat, A. Zomer, J. Wagenaar, B. Duim

EV0555 Real-time PCR assay for direct quantification of Staphylococcus aureus DNA in blood samples

EV0556 The accuracy of combined immune experimental tools to distinguish active tuberculosis from latent infection

EV0557 A randomized controlled trial to determine the impact of matrix assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF) based identification directly from positive blood cultures (BC) on patient management
M. Osthoff* [Basel, Switzerland], N. Guertler, M. Weissner, A. Egli

EV0558 Association between virulence factors of shiga toxin-producing Escherichia coli with severity of illness in humans
M. Kooistra-Smid* [Groningen, Netherlands], R. de Boer, I. Friesema, M. Petrigiani, T. Waegemaekers, W. Niessen, P. Croughs, A. Ott, J. Rossen, A. Friedrich

EV0559 Faecal lactoferrin and calprotectin in patients with Clostridium difficile infection: a prospective case-control study
C. Eckert, C. Gouat, L. Suzan, R. Syed-Zaidi, V. Lolland, F. Barbut* [Paris, France]

Molecular bacterial typing methods

EV0560 Molecular serotyping of Salmonella in Tunisian human and poultry isolates
W. Kalai, J. Garoizar, I. Martinez, J. Bikandi, L. Messadi, M. Saidani, A. Rehaim, A. Kammoun, I. Boutiba-Ben Boubaker* [Tunis, Tunisia], A. Slim

EV0561 Genetic relatedness of Pseudomonas aeruginosa isolated from cystic fibrosis patients attending a clinic at a tertiary academic hospital in Pretoria, South Africa
T. Goolam Mahomed* [Pretoria, South Africa], M. Kock, R. Masekela, E. Hoosien, M. Ehlers

EV0562 Molecular characterization of a virulent uropathogenic Escherichia coli from a patient with recurrent urinary tract infections
Q. Guo* [Shanghai, China], M. Wang

EV0563 Identification of bacteria associated with a periodontal disease by comparative metagenomic analysis based on next-generation sequencing
S. Payungporn* [Bangkok, Thailand], P. Arirachakaran, W. Poomipak, J. Makkoch, K. Praianantathavorn, Y. Poovorawan

EV0564 Determination of bacterial communities in Thai fermented foods based on high-throughput DNA sequencing of 16S ribosomal DNA
W. Poomipak* [Bangkok, Thailand], K. Praianantathavorn, J. Makkoch, U. Thangphaom, T. Pitsikun, S. Payungporn

EV0565 Evaluation of PelvoCheck® CT/NG [Greiner Bio-One]: a new diagnostic microarray-based kit for the detection of Chlamydia trachomatis and Neisseria gonorrhoeae DNA in urogenital specimens
B. Vanmassenhove* [Oostende, Belgium], L. Persijn, L. Vynckier, G. Aliet

EV0566 Prediction of MRSA MLST types by MALDI-TOF
J. Lu* [Taoyuan, Taiwan], T. Liu, H. Wang
Universal cloud-based bacterial strain typing for real-time infection control  
A. Budding* [Amsterdam, Netherlands], M. van der Bijl, C. Vandenbroucke-Grauls, P. Savelkoul

Lipo oligosaccharide allele genotyping enables the prediction of ganglioside-mimicking structures on Campylobacter jejuni  
A. Heikema* [Rotterdam, Netherlands], D. Horst-Kreft, R. Louwen, R. Huizinga, M. Gilbert, J. Li, C. Parker, H. Endtz

Detection of Borrelia burgdorferi in patient’s blood samples using real time PCR and its counter type in nested version - comparison of methods  
K. Ufir* [Krakow, Poland], A. Sroka, D. Salamon, M. Bulanda, T. Gosiewski

Genotyping of Shigella sonnei strains isolated from Iranian paediatric patients  
R. Ranjbar* [Tehran, Iran], M. Memariani, M. Izadi, N. Jonaidi Jafari

The reproducibility of matrix-assisted laser desorption ionization-time of flight mass spectrometry (MALDI-TOF) based typing: employment of bioinformatics  
M. Oberle, N. Wohlwend, F. Maurer, G. Jost, D. Jonas, K. Vranckx, A. Egli* [Basel, Switzerland]

The dynamic of vaginal Lactobacillus spp. flora during subsequent trimesters of pregnancy in healthy Polish women tested via the Sanger sequencing method  
A. Piotrowska* [Krakow, Poland], D. Ochonska, T. Gosiewski, W. Pobian, M. Bulanda, M. Brzychczy-Wloch

Clonal diversity of Acinetobacter baumannii in Egyptian hospitals  
L. Al-Hassan* [Brighton, United Kingdom], L. Al-Madboly, R. Abdel Hamid, H. El-Mahallawy, M. Newport

An extended MLST scheme for rapid direct typing of Leptospira from clinical samples  
S. Weiss* [Stockholm, Sweden], A. Menezes, K. Woods, A. Chantongthip, S. Dittrich, A. Opoku-Boateng, M. Kimuli, V. Chalker

Comparison of four different molecular methods for Clastrium difficile outbreak investigations  
S. Zimmermann* [Heidelberg, Germany], J. Rau, F. Günther, C. Seyboldt, I. Burckhardt

Comparative proteomics analysis of two strains of Neisseria meningitidis serogroup B and Neisseria lactamica  
R. Sheikh* [Rasht, Iran], A. Mansour, M. Hamidinia, M. Assarehzadegan, S. Rostami, Z. Moghtahedi

Infections by Streptococcus agalactiae among neonates in Portugal: 2005-2014  
E. Ferreira Martins* [Lisbon, Portugal], C. Roussado, J. Mela-Cristino, M. Ramirez

Encoding microbiology test using LOINC® terminology: challenges from identification systems  
L. Nougier, B. Celliere, M. Olléon* [La Balme les Grottes, France], M. Mary, X. Gansel, M. Dante, S. Spinali, J. Gorse, A. van Belkum, G. Durand

Evaluation of two new chemiluminescence immunoassays for the detection of Clastrium difficile glutamate dehydrogenase and toxin A&B  
A. Blaich, C. Castellano, C. Kiessling, A. Geschke, K. Rentsch, A. Egli, R. Frei* [Basel, Switzerland]

Validation of an improved WASP™ protocol for automated processing of positive blood culture  
M. Pelliccioni* [Rome, Italy], C. Fontana

Encoding microbiology tests using LOINC® terminology: challenges from the Etest® perspective  
M. Olléon* [La Balme les Grottes, France], B. Celliere, L. Nougier, M. Mary, X. Gansel, M. Dante, S. Spinali, J. Gorse, A. van Belkum, G. Durand

Evaluation of Copan FecalSwab and WASP® inoculation for faecal culture  
K. Emmerechts* [Brussels, Belgium], J. Breynaert, D. Pierard

Evaluation of the BD Kiestra™ vision toolbox for automated methicillin-resistant Staphylococcus aureus screening  
L. Dunn* [Oxford, United Kingdom], L. Clarke

Optimization of diagnostic work-flow of neurotropic viruses in a high throughput laboratory  
G. Bianco, S. Brossa* [Turin, Italy], S. Varetto, A. Barbui, F. Sidoti, C. Costa, R. Cavallo

Automation in clinical microbiology: how to choose an automatic incubator?  
D. Dauwolder* [Bron, France], G. Lina, M. Perouse-de-Montclos, L. Landrieue, F. Laurent, F. Vandenesch

Implementation of an automated specimen inoculation system using blood and other body fluids  
Q. Choi, J. Kim, H. Kim, G. Kwon, S. Koo* [Daejeon, South Korea]

Comparison of WASP™ and WASP Lab™ and InoquIA™ for primary specimens’ streaking quality  
M. Jetter, M. Marchesi, M. Hombach, P. Keller* [Zurich, Switzerland]
EV0588 R-medium to culture and antibiotics susceptibility testing of fastidious and anaerobic bacteria
K. Saber, S. Ndongo, D. Niokhor, M. Salomez, J. Lagier, G. Dubourg* [Marseille, France], D. Raoult

EV0589 Transition from transystem to liquid-based microbiology (ESwabTM) specimens collection devices for WASP and WASPLab clinical specimen processing
A. Giambra, L. Navarria* [Brescia, Italy], S. Castriciano

EV0590 TORC assays comparison on two fully automated platforms: LIAISON® XL and Abbott ARCHITECT
F. Genco, A. Sarasini, M. Parea, M. Prestia, V. Meroni* [Pavia, Italy]

EV0591 Performance evaluation of BD BACTEC® FX system with removal and reintroduction of ongoing blood culture bottles after five hours of incubation
A. Bothy* [Brussels, Belgium], A. Simon

EV0592 Copan FecalSwabTM and selenite broth and WASPTM for the detection of enteric pathogens from human and veterinary stool samples
J. Steenbergen* [Antwerp, Belgium]

EV0593 Workflow transformed: DxN VERIS, a new fully-automated system for molecular diagnostics
M. Marcos* [Barcelona, Spain], P. de Molina, J. Vila Estape

EV0594 Fully automated analysis of prepared patient specimen allow high-throughput pathogen identification from a variety of sample materials
W. von Stein, H. Mannsperger, M. Stange* [Düsseldorf, Germany], A. Plesch

EV0595 Introducing the novel DiaSorin LIAISON® XL CLIA method into the department of microbiology made for the first time same-day results available on a fully automated random access system
D. Romero, G. Roig, C. Gulin, S. Mota, T. Pumarola Sole, V. Rodríguez Garrido* [Barcelona, Spain]

EV0596 Performance of established EIA and immunochromatographic assay in comparison to a novel fully automated CLIA system in adenovirus and rotavirus testing for human stool specimens
C. Gulin* [Barcelona, Spain], D. Romero, V. Rodríguez Garrido, A. Sáiz, T. Pumarola Sole, G. Roig

EV0597 Evaluation of a multiplex PCR-based testing system Unyvero Curetis in the management of HAI implant and tissue infections and severe nosocomial pneumonia
R. Vatcheva-Dobrevska* [Sofia, Bulgaria], V. Dicheva, P. Stefanowa, E. Nedjalkova

EV0598 Evaluation of the performance of GRANADA medium (bioMérieux) under CO2 atmosphere for automated incubation
C. Fulchiron* [La Balme les Grottes, France], S. Spinali, D. Archeny, J. Gorse, A. van Belkum, G. Durand

EV0599 Evaluation of the work cell automation system Kiestra on urine culture results versus manual procedure
O. González-Moreno* [Barcelona, Spain], A. Puigdemont, A. Barreales, Y. Rodriguez, T. Contreras, V. Ortiz, M. Vilardébó, T. Castillo, M. Casado, N. Gonzalez, L. Oliver, F. Guimera, S. Rodriguez, S. Pereyra, J. Huguet

General microbiology

EV0600 Crude extracts of medicinal plants can inhibit some bacteria of clinical importance; a preliminary study
C. Ogueke* [Owerri, Nigeria], I. Agunwah

EV0601 Is the presence of Actinomyces spp. in blood culture always significant?
A. Jeffery-Smith* [London, United Kingdom], C. Nic-Fhogartaigh, M. Millar

EV0602 Epidemiology of genital herpes simplex virus infection in Bilbao, Spain, between 2004 and 2014
M. Macho, J. Alava Menica, L. Hernandez Raga, M. Sada Calderon, B. Caceda, R. Cisterna Cáncer* [Bilbao, Spain]

EV0603 Diagnosis and treatment of typhoid fever and associated prevailing drug resistance in Northern Ethiopia
A. Wasihun* [Mekelle, Ethiopia], L. Negash, T. Dejene, S. Muthapudian, T. Dejene, S. Aregawi, A. Luel

EV0604 Comparison of modified culture method for detecting Legionella pneumophila in water samples
S. Yui* [London, United Kingdom], P. Wilson

EV0605 Pertinence of Yersinia biological diagnosis: analyzing clinical data in the University Hospital of Angers, France

EV0606 Evaluation of the performance of GRANADA medium (bioMérieux) under CO2 atmosphere for automated incubation
C. Fulchiron* [La Balme les Grottes, France], S. Spinali, D. Archeny, J. Gorse, A. van Belkum, G. Durand

EV0607 Significance and characterization of Pseudomonas stutzeri from clinical material
N. Bisharat* [Afula, Israel], Y. Kenness

EV0608 Boosted identification of enteropathogenic agents with novel gastrointestinal panel of multiplex PCR system
H. Petitprez* [Pringy, France], B. Stephane, S. Spinali, A. Yveric
EV0609 IgG and IgA response to *Simkania negevensis* and *Chlamydia pneumoniae* in sera of patients undergoing carotid endarterectomy
*R. Biondi* (Bologna, Italy), M. Donati, A. Vacirca, G. Faggioli, G. Pasquinelli

EV0610 Aeration influences the formation of *Acinetobacter calcoaceticus-baumannii* persistor cells
*B. Donamore* (Porto Alegre, Brazil), S. Gallo, C. Ferreira, S. Oliveira

EV0611 How is post-mortem microbiology appraised by pathologists? Results of an ESGFOR practice survey, 2015

EV0612 Retail food contamination in main markets of Tirana
*O. Petri* (Tirana, Albania), E. Abazaj, A. Demo, V. Bara, B. Aropi, B. Brati, A. Luzati

EV0613 Chorionic tissue and peripheral blood as potential reservoir of pathogens responsible of recurrent spontaneous miscarriague in women - preliminary results
*C. Contini* (Ferrara, Italy), M. Maritati, P. Vitale, S. Seraceni, R. Marci, A. Graziano, F. Vesce, J. Rotondo, M. Tognon, F. Martini

EV0614 Identification and characterization of SCA-1 with antimicrobial and anticancer activities
*N. Al-Dhabi* (Riyadh, Saudi Arabia), V. Mariadhas

EV0615 Incidence of *Vibrio* and physicochemical quality of some rivers in Osun State, Nigeria
*M. Adesigan* (Ile Ife, Nigeria), M. Bisi-Johnson, A. Okah

EV0616 Don’t forget the dynamic validation check for group B streptococci testing
*L. De Cooman* (Ghent, Belgium), J. Van Acker, A. Van den Abeele

EV0618 BaseSpace: simplifying metagenomic analysis
*C. Teiling* (San Diego, United States)

EV0619 Genotyping of methicillin resistant *Staphylococcus aureus* and exploring its association with adhesion and biofilm related genes
*N. John* (Coimbatore, India), S. Murugan

EV0620 Mixed infection of *Vibrio cholerae* 01 and different *Salmonella enterica* serovars in hospitalized patients in Delhi, India during 2012-2014
*D. Kumar* (Delhi, India), N. Sharma

EV0621 Next-generation approach for investigating infectious cause of fever
*T. Susilawati* (Cairns, Australia), J. McBride, A. Loukas, A. Jex, C. Contacessi

EV0622 Inactivation of *Enterococcus faecalis* biofilms with sulphated and Europium-doped titanium dioxide photocatalysts
*E. Dworniczek*, G. Plesch, A. Seniuk, R. Adamski, R. Michal, M. Caplovicova, M. Biernat* (Wrocław, Poland)

EV0623 Donor-derived *Ureaplasma* infection leads to fatal hyperammonaemia following lung transplantation
*A. Bharat, K. Waites, D. Crab, S. Buder, M. Ison* (Chicago, IL, United States)

Mechanisms of action, preclinical data & pharmacology of antibacterial agents

EV0624 Comparison of the efficacy of the photoinactivation of *Escherichia coli* using different lamps
*V. Pérez Laguna*, L. Pérez-Artiaga, V. Lampaya, Y. Gilaberte, M. Revillo, A. Rezusta* (Zaragoza, Spain)

EV0625 *In vitro* photodynamic effect of methylene blue versus mesoporous silica nanoparticles with methylene blue on *Staphylococcus aureus* and *Pseudomonas aeruginosa*
*V. Pérez Laguna*, O. Planas, L. Pérez-Artiaga, V. Lampaya, Y. Gilaberte, S. Nonell, O. Gualas, M. Agut, M. Revillo, A. Rezusta* (Zaragoza, Spain)

EV0626 Cellular pharmacokinetics of gepotidacin [GSK2140944] in human THP-1 monocytes [THP-1] and murine macrophages [J774]
*P. Peyrusson*, F. Van Bambeke, P. Tulkens* (Brussels, Belgium)

EV0627 Comparative *in vitro* activities of MCB3681 and 8 comparators against 200 *Clostridium difficile* isolates with known ribotypes and diverse geographical spread
*J. Freeman*, S. Pilling, J. Vernon, M. Wilcox* (Leeds, United Kingdom)

EV0628 *Lactococcus lactis* subsp. Lactis 194 as a candidate metabolite probiotic: preclinical study in the CBRB mouse model of human microbial eczema
*D. Aronov* (Moscow, Russian Federation), E. Moiseeva, L. Stoyanova, E. Ustyugova

EV0629 Mechanism of antimicrobial action of extract from *Mormodica charantia* on pathogenic microorganisms
*D. Mufrawa Kolawole* (Akure, Nigeria)
**EV0630**  
The synergy of colistin plus the SPases inhibitor MD3 against *Acinetobacter baumannii* depends on the colistin resistance mechanism  
M. Martinez-Guitian* (La Coruña, Spain), J. Vazque-Ucha, J. Odinga, T. Parish, M. Poza, G. Bou Arevalo, D. Wareham, A. Beceiro

**EV0631**  
WCK 4282 [high-dose cefepime-tazobactam] extends coverage to carbapenem-resistant *Klebsiella* harbouring multiple ESBLs, OXA 48/181 in conjunction with impermeability  
A. Kulkarni, S. Biniwale, J. Satav, A. Uday, S. Bhagwat, M. Patel* (Aurangabad, India)

**EV0632**  
*In vitro* activity of ceftriaxone, ceftaroline and aztreonam alone and in combination with avibactam against nosocomial bloodstream Enterobacteriaceae isolates in Russia  
R. Kozlov* (Smolensk, Russian Federation), A. Dekhnich, M. Edelstein, M. Sukhorukova

**EV0633**  
Treatment of GBS infections in the elderly: synergism of penicillin plus gentamicin revisited  
C. Ruppen* (Bern, Switzerland), P. Sendi

**EV0634**  
Unconventional daptomycin therapy for the treatment of *Klebsiella pneumoniae* producing carbapenemase (KPC)  
P. Gagetti, M. Martinez, F. Pasteran, M. Fatouraei, W. Rose, D. Faccone, A. Corso, A. Rosato* (Houston, United States)

**EV0635**  
Staphefekt: intervening early in the colonization infection continuum with endolysins  
B. Herpers* (Haarlem, Netherlands)

**EV0636**  
Development and sequential analysis of a new multi-agent, anti-acne formulation based on plant-derived antimicrobial and anti-inflammatory compounds  
B. Ciubuca* (Bucharest, Romania), C. Kamerzan, M. Chifiriuc, O. Banu, P. Sorina, V. Lazar, L. Marutescu

**EV0637**  
Anti-adhesion and biofilm eradication activities of cranberry and sumac extracts against *Streptococcus pyogenes*  
S. Abachi* (Truro, Canada), S. Lee, H. Rupasinghe

**EV0638**  
Newly developed netilmycin dry powder inhaler (NDPI) is effective in multidrug-resistant *Pseudomonas* (MDRP) and *Acinetobacter* (MDRA) pneumonia: development of the dry powder inhaler form and experimental rat pneumonia model  

**EV0639**  
Addition of tigecycline in the treatment regimen is mandatory for the management of infections by carbapenemase-producing *Klebsiella pneumoniae*  
S. Fergadaki, L. Sabracos, D. Droggiti, M. Georgitsi, E. Misiakas, E. Giamarellos-Bourboulis* (Athens, Greece)

**EV0640**  
Probiotic against *Helicobacter pylori: in vitro* efficacy  
N. Baryshnikova, Y. Uspenskiy, A. Suvarov, M. Suvarova* (St. Petersburg, Russian Federation)

**EV0641**  
Extended stability of antimicrobial agents in devices suitable for OPAT administration  
A. Jenkins* (Birmingham, United Kingdom), M. Gilchrist, M. Santillo, T. Hills

**EV0642**  
Influence of novobiocin on ATP levels in gingival fibroblasts  
A. Szkaradkiewicz, T. Karpinski, I. Chudzicka-Strugala* (Poznań, Poland), A. Zeidler

**Pharmacokinetics/pharmacodynamics of antibacterial drugs & therapeutic drug monitoring**

**EV0643**  
A phase-1, 3-part placebo-controlled randomised trial to evaluate the safety, tolerability and pharmacokinetics of aztreonam-avibactam in healthy subjects  

**EV0644**  
Endpoints in bacterial resistance studies using *in vitro* dynamic models: an integral parameter versus a point parameter  
A. Firsov* (Moscow, Russian Federation), M. Golikova, E. Strukova, Y. Portnoy, S. Zinner

**EV0645**  
Clinical and anti-inflammatory efficacy of 6-month course of azithromycin therapy  
T. Mamontova, O. Shlykova, I. Kaidashev, O. Skochko* (Poltava, Ukraine)

**EV0646**  
Evaluation of a vancomycin dosing nomogram in osteoarticular and orthopaedic implant infections  
E. Esteve* (Barcelona, Spain), M. Marin, S. Herrera, L. Sorli, L. Puig, A. Alier, S. Grau, J. Horcajada

**EV0647**  
Pharmacokinetics of colistin in patients with multidrug-resistant Gram-negative bacterial infections  
N. Harivenkatesh* (New Delhi, India), S. Bakhshi, R. Lodha, R. Guleria, T. Velpandian, S. Mahajan, A. Kapil, Y. Gupta

**EV0648**  
Linezolid use in patients with low body weight: is there really a need to reduce the dose to prevent haematological toxicity?  
S. Luque, A. Retamero, N. Campillo, R. Muñoz, L. Sorli, J. Horcajada, F. Alvarez Lerma, E. Sales, S. Grau* (Barcelona, Spain)
**New upcoming weapons against MDR strains M33: a promising candidate**
J. Brunetti, M. Onori* (Siena, Italy), G. Roscia, L. Quercini, I. Lampronti, B. Luisa, J. Hays, I. Bakker-Woudenberg, H. van der Weide, A. Pini, C. Falciani

**Penicillin treatment in infective endocarditis patients – does standard dosing result in therapeutic plasma concentrations?**
K. Öbrink-Hansen* (Aarhus, Denmark), B. Bibby, H. Wiggers, T. Hardlei, M. Kragh Thomsen, B. Brock, E. Petersen

**Integrative multi-omics network analysis of the synergistic killing of polymyxin B (PMB) and chloramphenicol (CHL) combination against an NDM-producing Klebsiella pneumoniae (Kp) isolate**

**Microdialysis of highly adsorbing drugs: evaluation of a probe coating approach exemplified by anidulafungin**
C. Weiser* (Berlin, Germany), S. Wicha, M. Zeitlinger, C. Kloft

**What is the effect of obesity on the population pharmacokinetics of meropenem in critically ill patients?**
A. Alobaid, J. Roberts* (Brisbane, Australia)

**Use of a dynamic in vitro infection model as link between in silico and in vivo: is the standard dose of levofloxacin sufficient to treat septic patients with resistant Escherichia coli?**
E. Göbgen* (Berlin, Germany), C. Kloft

**An in-depth investigation on prulifloxacin dosage adjustment in mild, moderate and severe renal impairment**
V. Tellone* (Rome, Italy), P. Coppola, G. Di Loreta, A. Del Vecchio, A. Comandini

**Factors associated with therapeutic trough serum levels of vancomycin in a tertiary care hospital**

**Evaluation of the efficacy and safety of the fixed drugs combination in tuberculosis**
H. Ben Ayed, M. Koubaa, M. Gargouri, H. Marsit, T. Ben Jemaa, Y. Mejadoub, C. Marrakchi, M. Ben Jemaa* (Sfax, Tunisia)

**Evaluation of colistin-carbapenem combination in clinical isolates of Acinetobacter spp. using the checkerboard technique**
M. Hajjar* (Beirut, Lebanon), Z. Daoud, E. Dahdouh, D. Karam Sarkis

**Could we treat endocarditis and intravascular infections with oral amoxicillin based on PK/PD and MIC?**
V. Hira* (Maastricht, Netherlands), T. Havenith, S. Croes, R. van den Biggelaar, M. Haeseker, F. van Tiel

**Impact of different pH levels on the pharmacodynamics of nitrofurantoin for pathogens involved in urinary tract infections**
F. Fransen* (Nijmegen, Netherlands), C. Lagarde, M. Melchers, J. Meletiadis, J. Mouton

**Pharmacodynamics of fosfomycin against ESBL producing pathogens**
F. Fransen* (Nijmegen, Netherlands), M. Melchers, J. Meletiadis, J. Mouton

**In vitro pharmacokinetic-pharmacodynamic modelling and breakpoint determination of tigecycline for K. pneumoniae**

**Pharmacodynamics of fosfomycin against ESBL producing pathogens**
F. Fransen* (Nijmegen, Netherlands), M. Melchers, J. Meletiadis, J. Mouton

**In vitro evaluation of metal chelators as potential metallo-beta-lactamase inhibitors**

**Hypersusceptibility to r-pyocins of Pseudomonas aeruginosa clinical isolates from cystic fibrosis patients**
M. Redero* (Seville, Spain), C. Lopez Causape, J. Lepe, A. Oliver, J. Blazquez, A. Prieto
Pharmacoepidemiology, improved prescribing and antibiotic stewardship

**EV0668** Gentamicin: can we use this agent in a more cost effective manner to improve outcomes?  
F. Dave* [Blackpool, United Kingdom], M. Parajuli, S. Batool, A. Guleri

**EV0669** Forgotten antibiotics: a follow-up inventory study in Australia, Canada, Europe and the United States  
C. Pulcini* [Vandoeuvre-Lès-Nancy, France], S. Mohrs, B. Beovic, I. Gyssens, U. Theuretzbacher, O. Cars

**EV0670** Evaluation of meropenem use in Irish hospitals  
M. Shah, R. Cafferkey* [Mayo, Ireland], S. McCarthy, A. Oza, R. Cunney

**EV0671** Optimizing unrestricted anti-pseudomonal beta-lactam (APBL) antibiotic use: appropriate indication selection is necessary but not sufficient  
P. Morency-Potvin* [Chicago, United States], G. Itokazu, R. Glowacki, D. Schwartz

**EV0672** The global point prevalence survey of antimicrobial consumption and resistance [Global-PPS]: first results of antimicrobial prescribing in Albanian hospitals  
I. Hoxha, A. Versporten, A. Malaj, H. Goossens, G. Kasmi* [Tirana, Albania]

**EV0673** Beta-lactam allergy record updates after an allergy service consult: potential stewardship intervention  
B. Shaw* [Chicago, United States], M. Ison, E. Gilbert, V. Barr, I. Masic, N. Gargi, N. Kalfayan, M. McLaughlin

**EV0674** Towards better antimicrobial stewardship: medical student preparedness on antibiotic use in Romania  

**EV0675** Irish annual antimicrobial point prevalence survey 2015  
D. Hagan-Murphy* [Cavan, Ireland], M. Philbin, R. Cunney, A. Oza

**EV0676** The global point prevalence survey of antimicrobial consumption and resistance [Global-PPS]: first results of antimicrobial prescribing in University Medical Centre Ljubljana, Slovenia  
A. Versporten, H. Goossens, B. Beovic* [Ljubljana, Slovenia]

**EV0677** A case for introducing a new-old drug [fosfomycin] on the formulary  
P. Zarb* [Msida, Malta], M. Borg

**EV0678** The global point-prevalence survey of antimicrobial consumption and resistance [Global-PPS]: first results of antimicrobial prescribing in Dutch hospitals  
V. Schweitzer, A. Versporten, I. van Heijl* [Hilversum, Netherlands], K. Verduin, M. Leverstein-van Hall, A. Muylaert, M. Becker, H. Pot, E. van Elzakker, H. Goossens, J. Kluytmans

**EV0679** A feasibility study to explore the use of a smartphone apps to collect real-time data on antimicrobial treatment and symptoms of urinary tract infection [UTI Diary App]  
S. Duane, M. Tandon, A. Murphy, A. Vellinga* [Galway, Ireland]

**EV0680** What do front-line prescribers really know? A review of a European Antibiotic Awareness Day quiz for junior doctors and pharmacists  
C. Brookfield* [Manchester, United Kingdom], I. Cartmill, Z. Fang

**EV0681** Are there areas for improvement in the appropriateness of antibiotic use? Point-prevalence survey in a university hospital  
L. Boix Palop* [Terrassa, Spain], L. Gómez, C. Badía, C. Nicolás, P. Arcenillas, M. Xercavins, E. Calbo

**EV0682** Developing a renal antibiotic stewardship round through an education, awareness and feedback methodology to improve specialty engagement and ownership  
M. Gilchrist* [London, United Kingdom], A. Ghazy, R. Bedi, R. Charnì, K. Bamford

**EV0683** The global point prevalence survey of antimicrobial consumption and resistance [Global-PPS]: first results of antimicrobial prescribing in Nigerian hospitals  
O. Oduyebo* [Lagos, Nigeria], A. Olayinka, K. Iregbu, A. Versporten, F. Ogunsola, H. Goossens, O. Aboderin

**EV0684** The global point prevalence survey of antimicrobial consumption and resistance [Global-PPS] in 100 Belgian hospitals  
A. Versporten* [Antwerp, Belgium], K. Magerman, N. Dragier, H. Goossens

**EV0685** An antimicrobial stewardship initiative: how do microbiology laboratory staffs perceive the interaction with clinicians?  
B. Skodvin* [Bergen, Norway], K. Aase, I. Smith

**EV0686** Evaluation of the effectiveness of carbapenem and piperacillin/tazobactam guidance in Scotland  
J. Sneddon* [Glasgow, United Kingdom], A. Cockburn, A. Mohana, W. Malcolm, D. Nathwani, A. Mullen, M. Bennie

**EV0687** Comparable hospital antibiotic data for intervention - the importance of using PDD  
The electronic reporting system of the new German project on antibiotic consumption surveillance in hospitals: a flexible tool for antibiotic stewardship

B. Schweickert* (Berlin, Germany), M. Feig, M. Behnke, L. Pena Diaz, H. Claus, P. Gastmeier, M. Abu Sin, H. Blank, D. Richter, T. Eckmanns

Infectious diseases hotline with smartphone monitoring, a convenient way to trace medical activities and promote antibiotic stewardship

B. Davido* (Garches, France), S. Makhlaoufi, C. Ruxsandra, O. Senard, M. Guillaume, J. Solomon, A. Dinh, P. Christian

The global point-prevalence survey of antimicrobial consumption and resistance (Global-PPS): results on antimicrobial prescribing in Japanese hospitals

Y. Gu* (Sendai, Japan), A. Versporten, H. Goossens, M. Kaku

Supporting nurses’ and midwives’ contribution to antimicrobial stewardship in Scotland

J. Sneddon* (Glasgow, United Kingdom), W. McGregor, G. Walker, J. McEwen

Pilot of a surgical national antimicrobial prescribing survey tool for Australian hospitals

S. Koning* (Melbourne, Australia), K. Buising, C. Chen, R. James, C. Marshall, K. Thursky

The assessment of the implementation of the national strategy on antimicrobial resistance and rational use of antibiotics in Mongolia

G. Dorj* (Ulaanbaatar, Mongolia), G. Dorj

The global point prevalence survey of antimicrobial consumption and resistance (Global-PPS): results of antimicrobial prescribing in Kosovo hospitals


Antibiotherapy of community–acquired urinary tract infection due to multi-susceptible Escherichia coli: also a challenge for infectious disease referrers?

H. Amrane, P. Roger, A. Lombardo, E. Denis, B. Comte, P. Hoffmann, S. Joubert, V. Blanc* (Antibes, France)

The global point prevalence survey of antimicrobial consumption and resistance (Global-PPS): antimicrobial prescribing in Australian hospitals

K. Horne* (Melbourne, Australia), A. Versporten, K. Cairns, E. Hames, F. Doukas, A. Cheng, T. Korman, H. Goossens, T. Gottlieb

Appropriateness of defined daily doses (DDD) and packages as outcome measures for monitoring outpatient antibiotic consumption

A. Versporten* (Antwerp, Belgium), S. Coenen, N. Adriaenssens, J. Paget, D. Lescure, F. Schellevis, L. van Dijk, H. Goossens

Family physicians’ perceptions about antibiotic prescribing in primary care: a qualitative study

S. Hosaglu* (Istanbul, Turkey)

The global point-prevalence survey of antimicrobial consumption and resistance (Global-PPS): first results of antimicrobial prescribing in Russian hospitals


Antibiotic use in acute respiratory tract infections in primary health care: an intervention study

S. Hosaglu* (Istanbul, Turkey), E. Kadi, B. Topal, A. Ceylan

Antimicrobial stewardship interventions in Clostridium difficile infections

M. Veve* (Detroit, United States), J. Wagner, K. Aleshire, M. Frei, R. Kenney, S. Davis

The global point prevalence survey of antimicrobial consumption and resistance (Global-PPS): first results of antimicrobial prescribing in 12 Chilean hospitals

C. Carvajal, A. Versporten, N. Severino, M. Cifuentes, F. Silva, A. Rojas, H. Goossens, J. Labarca* (Santiago, Chile)

Tolerance of subcutaneously administrated ceftriaxone - a French prospective multicentre observational study

C. Roubaud-Baudron, E. Forestier, F. Thibaut, B. de Wazieres, L. Bernard, J. Gaillat, L. Pagani* (Bolzano, Italy), G. Gavazzi, M. Poccalli

The global point prevalence survey of antimicrobial consumption and resistance (Global-PPS): first results of antimicrobial prescribing in Albanian hospitals

EV0706 Assessing the renal safety of aminoglycoside therapy in patients with Gram-negative bacteraemia
S. Hughes* [London, United Kingdom], O. Geoghegan, C. Cassidy

EV0707 New software to help optimize regional antimicrobial stewardship policy? Results from a two-year survey of antibiotic consumption and antimicrobial resistance in five hospitals in southern-eastern France

EV0708 The global point prevalence survey of antimicrobial consumption and resistance (Global-PPS): first results of antimicrobial prescribing in a South African tertiary hospital
H. Finlayson* [Cape Town, South Africa], A. Versporten, A. Whitelaw, H. Goossens, J. Taljaard

EV0709 The global point prevalence survey of antimicrobial consumption and resistance (Global-PPS): first results of antimicrobial prescribing in English hospitals - quality indicators
M. Laundy* [London, United Kingdom], A. Versporten, B. Dhanda, S. Drysdale, D. Lockwood, E. Marshall, D. Sharpe, H. Goossens, M. Gilchrist

EV0710 The global point prevalence survey of antimicrobial consumption and resistance (Global-PPS): first results of antimicrobial prescribing in Israeli hospitals
E. Temkin* [Tel Aviv, Israel], A. Versporten, M. Paul, J. Strahilevitz, M. Katzir, R. Ben-Ami, Y. Carmeli, H. Goossens, Y. Maar

EV0711 The global point prevalence survey of antimicrobial consumption and resistance (Global-PPS): first results of antimicrobial prescribing in United States hospitals
E. Septimus* [Houston, United States], A. Versporten, H. Goossens

EV0712 Antibiotic prescriptions by French general practitioners: adherence to national treatment recommendations
B. Pilmis* [Paris, France], B. Mollo, M. Nadal, K. Amazzough, J. Zahar

EV0713 Point-prevalence of hypersensitivity to antibiotics in a tertiary care hospital and the potential role of the intervention of a department of infectious diseases

EV0714 The search for efficiency of antibiotic stewardship programmes

EV0715 Evaluation of linezolid prescriptions in 3 French hospitals
C. Dentan, E. Forestier, M. Roustit, P. Pavese, J. Stahl* [Grenoble, France]

EV0716 Antimicrobial agents dispensed to companion animals and terrestrial food producing animals in Norway from 2006 to 2014
S. Skreosen, A. Kvalvik* [Trondheim, Norway], K. Halvorsen, L. Småbrekke, R. Primiceria, P. Haugen, O. Karlstad, M. Tryland

EV0717 Outpatient parenteral antimicrobial therapy (OPAT): a national survey in Belgian hospitals
F. Buyle* [Ghent, Belgium], T. Ravelingien, A. Vantrappen, S. Deryckere, S. van Winckelmann, J. Frans, S. Commeyne, D. Vogelaers

EV0718 Retrospective evaluation of the treatment of adult patients with a candidaemia
F. Buyle* [Ghent, Belgium], J. Boelens, J. De Keulenaer, A. Somers, S. Commeyne, D. Vogelaers

EV0719 Innovating the control and prevention of antibiotic resistant infections – a toolkit to monitor and assist antibiotic use and resistance trends
A. Simões* [Lisbon, Portugal], P. Pinto, M. Gil, A. Asfeldt, I. Couto, M. Mira da Silva, G. Simonsen, P. Póvoa, M. Viveiros, L. Velez Lapão

EV0720 The global point-prevalence survey of antimicrobial consumption and resistance (Global-PPS): first results of antimicrobial prescribing in Serbian hospitals
B. Carević, A. Versporten, L. Gojković-bukarica, D. Obradovic, V. Živanović, A. Stojadinovic, L. Radulovic, V. Saponjic, H. Goossens, G. Dragovac* [Novi Sad, Serbia]

EV0721 Regulation and authorization of antibiotics in Europe
A. Versporten* [Antwerp, Belgium], J. Paget, D. Lescure, F. Schellevis, L. van Dijk, H. Goossens

EV0722 Details about penicillin allergy in drug charts are often lacking or inaccurate
G. Calisti* [Manchester, United Kingdom], E. Trautt

EV0723 Outcomes of empiric and definitive carbapenem use in Gram-negative infections
M. Veve* [Detroit, United States], J. Wagner, N. Rhodes, M. Scheetz, S. Davis
EV0724  Skin infections in the emergency department: opportunities for antimicrobial stewardship
M. Veve* [Detroit, United States], S. Davis, M. Jajjaka, J. Mourani

EV0725  Fosfomycin as an alternative antibiotic against KPC-3 producer isolates, including those resistant to tigecycline and/or colistin
C. Caneiras* [Lisbon, Portugal], L. Marques Lito, J. Melocristino, A. Duarte

EV0726  Costs of outpatient parenteral antibiotic therapy (OPAT) in Spain - a multicenter economic evaluation using data from the TADE registry
A. Mujal* [Barcelona, Spain], J. Estrada, M. Mirán-Rubio, V. González-Ramallo, C. Forné, E. Uriá, G. Nacea, A. Rivera, B. Arogán

EV0727  Amoxicillin crystalluria: an emerging complication with an old and well-known antibiotic

EV0728  Impact of the dosing of procalcitonin in lower respiratory tract infections and sepsis at the Hospital Center of the University of Montreal
L. Iran* [Montreal, Canada], A. Ang, C. Ferland

EV1004  Efficacy and safety of carbapenem-sparing regimens for severely-ill patients with MDR Gram-negative infections in ICU and non-ICU inpatients
A. Makina* [Athens, Greece], L. Sybardi, E. Liakopoulou, I. Karaiskos, A. Karaiskou, A. Papadopoulos, M. Souli, H. Giamaretellou

Fungal disease epidemiology & clinical trials
EV0729  Is it necessary to treat the surrounding skin in patients with toehail onychomycosis?
S. De La Fuente, M. Ruiz, Y. Gilaberte, S. Bellosa, A. Lopez, M. Zubiri, A. Morales-Callaghan, M. Revilla, A. Rezusta* [Zaragoza, Spain]

EV0730  Dermatophytosis in pets and its zoonotic potential
E. Broens* [Utrecht, Netherlands], M. van Dijk, L. Veneberg, J. Wagenaar

EV0731  New data for vaginal yeast infections
E. Belesiotsou* [Athens, Greece], E. Perivolioti, M. Nepka, C. Vadala, E. Kraniotaki, Z. Psaroudaki, K. Litsakis, V. Pitiriga, T. Pittaras, A. Skoutelis

EV0732  Estimating serious fungal infections in the Peruvian population
B. Bustamante, P. Campos, D. Denning* [Manchester, United Kingdom]

EV0733  The rising incidence of Trichosporon spp. urinary tract infections in a tertiary hospital
E. Belesiotsou* [Athens, Greece], E. Perivolioti, M. Nepka, C. Vadala, E. Douka, Z. Psaroudaki, E. Kraniotaki, K. Litsakis, E. Jatroudeli, T. Pittaras, A. Skoutelis

EV0734  Invasive aspergillosis in patients with Hodgkin's lymphoma in St. Petersburg, Russia

EV0735  Candidaemia in elderly patients — is there room for medical care improvement?
A. Lerma Verdejo* [Madrid, Spain], E. Cantero, M. Soriano Segura, A. Ramos Martínez, B. Orden, E. Muñíz

EV0736  Nosocomial invasive candidiasis in St. Petersburg, Russia

EV0737  Incidence of candiduria in a tertiary hospital
E. Belesiotsou* [Athens, Greece], M. Nepka, E. Perivolioti, Z. Psaroudaki, C. Vadala, E. Kraniotaki, K. Litsakis, C. Totsikas, A. Naxaki, V. Pitiriga, A. Skoutelis

EV0738  The epidemiology of invasive fungal infections in cancer patients: a nationwide Turkish fungal registry study
E. Senol* [Ankara, Turkey], O. Uzun, G. Yilmaz, B. Mutlu, N. Saltagolu, O. Yildiz, B. Arda, S. Kaya, M. Özcen, S. Köse

EV0739  Epidemiology and risk factors of candidaemia among hospitalized patients in a Turkish tertiary care hospital
E. Senol* [Ankara, Turkey], A. Çiftçi, A. Kalkanci

EV0740  Mould infections at Coimbra burns unit
M. Pessoa Vaz* [Coimbra, Portugal], J. Ferreira, C. Brandao, I. Brito, C. Chaves, L. Cabral

EV0742  Afebrile candidaemia in internal medicine wards: assessment of risk factors
C. Tascini* [Pisa, Italy], M. Falcone, M. Bassetti, F. de Rosa, E. Sozio, A. Russo, F. Sbrana, A. Ripoli, M. Merelli, C. Scarpello, F. Carmassi, M. Venditti, F. Menichetti
| EV0743 | Profile of candidaemia at a tertiary-care hospital in Japan over a 9-year period: characteristics, outcome and predictive factors for mortality  
A. Tokumoto* (Chiba, Japan), R. Hase, E. Hoshina, Y. Otsuka, N. Hosokawa |
| EV0744 | Genetic and phenotypic characterization of commensal and clinical Candida albicans isolates reveals heterogeneous distribution of adherence and invasiveness properties in vitro and in vivo  
F. Vincent, R. Atanasova, C. L'Ollivier, S. Albac, C. D'Enfert, M. Bougnoux, A. Bonnin, F. Dalle, F. Bon* [Dijon, France] |
| EV0745 | Prevalence and distribution of Candida species in Turkish women with vulvovaginitis symptoms  
S. Pelit* [Istanbul, Turkey], A. Baris, G. Erkose Genc |
| EV0746 | Serious fungal infections in north-western Greece, during a five year period  
E. Privaλί, P. Karagianni, C. Gartzonika, D. Papamichail, E. Nita, H. Sakkas, A. Miari, A. Veneti, S. Levidiotou* [Ioannina, Greece] |
| EV0747 | Invasive aspergillosis in liver disease patients: no easy way out  
D. Dudau, N. Ait-Ammar, F. Foulet, J. Merle, E. Levesque, F. Botterel Chartier* [ Créteil, France] |
| EV0748 | Characteristics and predictors of persistent candidaemia in cancer patients receiving routine implementation of a care bundle: a retrospective cohort study  
N. Sekiya* [Tokyo, Japan], S. Sasaki |
| EV0749 | Estimation of serious fungal disease burden in Malaysia  
R. Velayuthan* [Kuala Lumpur, Malaysia], D. Denning |
| EV0750 | Emerging yeasts in a tertiary healthcare setting  
I. Khan* [Kolkata, India] |
| EV0752 | Progressive disseminated histoplasmosis mimicking a flare of systemic lupus erythematosus: a case report  
M. van Doorn-Schepens* [Amsterdam, Netherlands], E. Peters, R. van Vugt, H. van der Spoel, K. van Dijk |
| EV0753 | Cervicofacial actinomycosis in St. Petersburg, Russia  
O. Kožlova, A. Mirzabalaeva, N. Klimko* [St. Petersburg, Russian Federation] |
| EV0754 | Investigation by multi-locus sequence typing of genetic diversity of Candida albicans strains isolated from vaginal candidiasis of women referred to Tehran clinics  
M. Roudbar * [Tehran, Iran], S. Roudbarmohammadi, F. Katiraee, B. Bakhshi, A. Shojaei, M. Falahati |
| EV0755 | Molecular investigation of Aspergillus infections in an Iranian training hospital using RAPD-PCR  
K. Diba, A. Namaki* [Urmia, Iran], N. Jalalizand |
| EV0756 | Do we need aerobic-anaerobic or specific blood culture bottles for diagnosing candidaemia in ICU patients?  
| EV0757 | Possible invasive fungal infection and positive galactomannan assay: evaluation of fungal culture results  
E. Santacattererina* [Padua, Italy], L. Rossi, T. Tommasini |
| EV0758 | ESwab for the collection of fungal surveillance culture from immunocompromised patients  
M. Bossa* [Rome, Italy], S. Monelli, A. Altieri, M. Favara, C. Favalli, C. Fontana |
| EV0759 | Screening with serum galactomannan (sGM) in haematological patients on micafungin prophylaxis: does the test remain useful for diagnosis of invasive aspergillosis?  
A. Vena* [Madrid, Spain], P. Muñoz, F. Cajuste, A. Alvarez-Uría, R. Alonso, P. Martín-Rabadán, T. Pelaez Garcia, J. Gómez-Castelló, M. Valeria Minero, E. Bouza Santiago |
| EV0760 | Identification of Aspergillus section Nigri by MALDI-TOF MS using a proprietary library  
M. Vidal-Acuña* [Seville, Spain], M. Torres-Sánchez, M. Ruiz-Pérez de Pipaón, J. Aznar |
| EV0761 | The impact of oestrogen on the expression of HWP1 gene of Candida albicans  
X. Liu, W. Meng* [Shenzhen, China], S. Fan |
| EV0762 | Evaluation of an algorithm for the differentiation of Candida species directly from blood culture bottles by Gram stain morphology  
D. Meretuk* [Cologne, Germany], A. Hamprecht |
| EV0764 | Statistical assessment of Tachypleus amoebocyte lysate for early diagnosis of invasive fungal disease at an ICU in China  
Z. Qin, J. Zhang, J. Li, D. Liu, Z. Wang, C. Wang, Y. Qin* [Tianjin, China] |
| EV0765 | Genotypic characterization of Trichophyton mentagrophytes complex strains circulating in Belgium by using the Diversilab® system  
R. Sacheli, T. Uttr, C. Adjetey, R. Darouf, M. Hoyette* [Lille, Belgium] |
| EV0766 | Evaluation of quality control SEIMC results for diagnosis of Candida dubliniensis infection  
N. Orta* [Madrid, Spain], R. Guna, R. Medina, E. Ruiz de Gopegui, J. Pérez, C. Gimeno Cardona |
A rare case of *Aspergillus terreus* endogenous endophthalmitis in a non-immunocompromised patient and laboratory research
Y. Zhao* (Beijing, China), P. Wang, Q. Yang, Y. Wang, H. Wang, Y. Xu

Evaluation of the MALDI-TOF MS method for identification of filamentous fungi
D. Cuerva, C. Segura* (Barcelona, Spain), V. Plasencia, G. Soria, F. Ballester, I. Pujol, J. Gené

Fatal invasive pulmonary aspergillosis due to *Aspergillus pseudodeflectus* in a liver transplant patient: first case report
N. Ait-Ammar, E. Levesque, J. Murat, E. Sitterlé, F. Foulet, E. Dannaoui, J. Merle, F. Botterel Chartier* (Créteil, France)

Fatal outcome of isolated renal mucormycosis: a report of two rare cases from north India
D. Shah* (Lucknow, India), R. Marak, L. Pal, S. Sahoo, T. Dhole

Evaluation of local trace element status and 8-isoprostaglandin F2-alpha concentrations in patients with tinea pedis
M. Miraloglu* (Adana, Turkey), E. Belge Kurutas, P. Ozturk, O. Arıcan

Mycology prediction of fungal rhinosinusitis (FRS): comparison, optimization and evaluation of different assays for fungi recovery from the sinuses
V. Arsic* (Belgrade, Serbia), A. Barac, M. Pekmezovic, Z. Rakocevic, V. Tamic Spiric

Assessment of serum (1,3)-beta-D-glucan and galactomannan kinetics in a retrospective study in haematological patients with invasive aspergillosis
A. Minoza, C. Merat, S. Hassan, T. Gastine, P. Le Pape* (Nantes, France)

Micafungin for the treatment of suspected invasive candidiasis in neonates: experience from a tertiary centre in Croatia
J. Markic* (Split, Croatia), B. Polic, J. Mestrovic, T. Kovacevic

Cost-effectiveness of amphotericin B lipid complex in the treatment of cryptococcal meningitis in HIV-infected patients in Brazilian public hospitals
F. Tuon* (Curitiba, Brazil), K. Lino, J. Rocha

Photoinactivation of *Candida albicans* using methylene blue alone or in combination with chlorhexidine
V. Pérez Laguna, L. Pérez-Artiaga, V. Lampaya, Y. Giliberte, L. Fernandez Lacasta, M. Alejandre, M. Revilla, A. Rezusta* (Zaragoza, Spain)

Economic analysis of diagnostic-driven versus empirical strategies for the treatment of immunocompromised patients with suspected fungal infections in Egypt
L. Sholaby, S. Kamal, C. Gao, M. Xue, A. Gab Allah Ibrahim, R. Kotb* (Cairo, Egypt), C. Charbonneau

CT scans, microbiology advice and antifungal prescribing: how to use best?
M. Cabeza Brasa* (London, United Kingdom), P. Panesar, V. Gant

EDTA inhibits *Rhizopus oryzae* (*Rhizopus arrhizus*) growth in vitro in blood of diabetic and non-diabetic individuals - is it an option for combined therapy with antifungal agents in the future?
G. Salazar* (México City, Mexico), E. López Jácome, D. Corzo León, R. Valdez Vázquez, A. Rodríguez Zulueta, R. Franco Cendejas, J. Resendiz-Sanchez

Efficacy of voriconazole-liposomal amphotericin B combination against azole-resistant *Aspergillus fumigatus* in an in vitro pharmacokinetic-pharmacodynamic model

In vivo efficacy of liposomal amphotericin B against clinical *Aspergillus fumigatus* isolates in two different immunosuppression models of invasive aspergillosis
S. Seyedmousavi* (Rotterdam, Netherlands), J. Mouton, W. Melchers, P. Verweij

Assessing use, and potential misuse, of systemic antifungals in a Greek tertiary hospital lacking oncology and haematology wards
N. Zachos, C. Alexanian, M. Gamvrouli, D. Papadaki, M. Demetriou, V. Kordinas, P. Karle, T. Peppas* (Piraeus, Greece)

Amphotericin B lipid complex in the treatment of paracoccidioidomycosis
F. Tuon* (Curitiba, Brazil), P. Pecanha, S. Souza, A. Falgueto, T. Grao-Veloso, L. Liria, C. Ferreira, A. Santos, H. Costa, L. Souza

Assessing use, and potential misuse, of systemic antifungals in a Greek tertiary hospital lacking oncology and haematology wards
N. Zachos, C. Alexanian, M. Gamvrouli, D. Papadaki, M. Demetriou, V. Kordinas, P. Karle, T. Peppas* (Piraeus, Greece)

Efficacy of voriconazole-liposomal amphotericin B combination against azole-resistant *Aspergillus fumigatus* in an in vitro pharmacokinetic-pharmacodynamic model

In vivo efficacy of liposomal amphotericin B against clinical *Aspergillus fumigatus* isolates in two different immunosuppression models of invasive aspergillosis
S. Seyedmousavi* (Rotterdam, Netherlands), J. Mouton, W. Melchers, P. Verweij

Assessing use, and potential misuse, of systemic antifungals in a Greek tertiary hospital lacking oncology and haematology wards
N. Zachos, C. Alexanian, M. Gamvrouli, D. Papadaki, M. Demetriou, V. Kordinas, P. Karle, T. Peppas* (Piraeus, Greece)

Amphotericin B lipid complex in the treatment of paracoccidioidomycosis
F. Tuon* (Curitiba, Brazil), P. Pecanha, S. Souza, A. Falgueto, T. Grao-Veloso, L. Liria, C. Ferreira, A. Santos, H. Costa, L. Souza

Assessing use, and potential misuse, of systemic antifungals in a Greek tertiary hospital lacking oncology and haematology wards
N. Zachos, C. Alexanian, M. Gamvrouli, D. Papadaki, M. Demetriou, V. Kordinas, P. Karle, T. Peppas* (Piraeus, Greece)

Amphotericin B lipid complex in the treatment of paracoccidioidomycosis
F. Tuon* (Curitiba, Brazil), P. Pecanha, S. Souza, A. Falgueto, T. Grao-Veloso, L. Liria, C. Ferreira, A. Santos, H. Costa, L. Souza
EV0786  In vitro antifungal susceptibility of Trichophyton interdigitale isolated from tinea patients  
S. Ansari* (Sari, Iran), M. Hedayati, M. Taghizadeh, H. Rafati, H. van der Lee, A. Rijs, P. Verweij, S. Seyedmousavi

EV0787  Evaluation of echinocandin resistance in Candida krusei isolates by sequencing the FKS1 gene  
A. Piralla* (Pavia, Italy), C. Covanna, F. Mangione, F. Lallitto, P. Marone

EV0788  Species distribution and antifungal susceptibility of Candida bloodstream isolates in a tertiary teaching hospital, Saudi Arabia  
A. Albarrag* (Riyadh, Saudi Arabia)

EV0789  Identification of yeast oropharyngeal isolates of Iranian HIV-positive people and determination of their antifungal susceptibility  
H. Khodadadi, L. Karimi* (Shiraz, Iran), M. Jokari, K. Pakshir, K. Zomorodian, N. Khalaf

EV0790  Candida bloodstream infections in a Greek tertiary hospital: 5-year survey – epidemiology and in vitro antifungal susceptibility profiles  
E. Perivolioti, M. Nepka, E. Kraniotaki* (Athens, Greece), M. Mpournia, E. Douka, V. Papastamopoulos, A. Skoutelis, K. Fountoulis

Diagnostic parasitology

EV0791  Atypical brain lesions in reactivation of Chagas disease in a delayed diagnosis AIDS patient  
L. Alonso Acero, C. Vargas, S. Garcia-Bujalance* (Madrid, Spain), M. Flores-Chavez, M. Subirats, A. Enriquez, D. Montero, J. Garcia Rodriguez

EV0792  The standardization of diagnostic assays for parasitic diseases  
D. Padley* (Potters Bar, United Kingdom), S. Rijpkema, M. Ho, R. Anderson, P. Rigsby, I. Feavers, P. Minor

EV0793  Detection of anti-Trypanosoma cruzi IgM for the early diagnosis of congenital Chagas disease  
Y. Castra* (Baltimore, United States), R. Gilman, C. Bern

EV0795  Rare and dangerous human cystic echinococcosis cases, from almost two decades of experience  
G. Popa* (Bucharest, Romania), C. Popa, I. Popa, I. Tanase, C. Cretu

EV0796  Importance of database usage in species annotation of NGS data  
L. Andersen* (Copenhagen, Denmark), P. Ahrens, N. Larsen, C. Stensvold, H. Nielsen

EV0797  Molecular diagnosis of taeniasis/cysticercosis complex based on conventional and real-time PCR using HDP2 and Ptsol9 repetitive sequences  
M. Flores-Chavez* (Madrid, Spain), C. Dominguez-Hidalgo, Y. Monje, G. Molini, S. Martinez, T. Garate

EV0798  A comparative study for the determination of the IgG avidity during a toxoplasmosis in pregnancy  
Z. Sonmez Tamer* (Kocaeli, Turkey)

EV0799  Comparison of microscopy, ELISA, and real-time PCR for the detection of Giardia intestinalis in human stool specimens  
Y. Beyhan* (Van, Turkey), H. Yilmaz, N. Odemis

EV0800  Detection of B1 gene and REP 529 in Toxoplasma gondii  
B. Peh* (Singapore, Singapore), E. Yau, L. Oon Lin Ean

EV0801  Does the more recent RIDA®QUICK rapid diagnostic tests for the detection of Giardia lamblia and Cryptosporidium spp in faecal samples perform better than the QUIKCHEK™?  
V. Matheeussen* (Edegem, Belgium), M. van Esbroeck, L. Andries, E. De Herdt, I. Mermans, M. leeven

Antiparasitic susceptibility & resistance

EV0803  Immuno-reactivity of Leishmania major TSA recombinant protein vaccine candidate formulated with Freund’s adjuvant, Chitosan and BCG-Alum  
F. Tabatabaei* (Tehran, Iran), N. Khabaz Zadeh Tehrani, S. Zarrati, A. Imani Fooladi, M. Mahdavi, M. Roudbary

Antiparasitic drugs & treatment

EV0804  Antiprotozoal activity of 6-aminonicotinamide against Leishmania infantum promastigotes  
S. Hanau* (Ferrara, Italy), S. Almugadam, F. Dallocchio, C. Cantini, M. Marritati, A. Langhi, G. Rugna, T. Bellini

EV0805  Effects of Juniperus oxycedrus and alpha-pinene on Trypanosoma brucei brucei: inhibition of cathepsin D protease activity  
S. Costa* (Coimbra, Portugal), C. Cavadas, C. Cavaleiro, L. Salgueiro, M. Sousa
EV0806  Treatment of schistosomiasis in a patient allergic to praziquantel: a praziquantel desensitization and treatment protocol
T. Patel* [London, United Kingdom], J. Lukawska, J. Rowe, R. Bailey

EV0807  The Pathogen Box project: a catalyst for neglected disease drug discovery

Parasitic disease epidemiology

EV0808  Demodex mites and co-existence of Chlamydia trachomatis in ocular infections in a tertiary hospital in Greece

EV0809  The incidence of Blastocystis species among different categories of people of the Russian Federation
A. Sigidaev* [St. Petersburg, Russian Federation], S. Zakharov, M. Kuznetsova, S. Kozlov, T. Vavrilyuk, M. Suvorova, E. Vagiakou

EV0810  Cystoisospora belli infection: the first case series in Thailand
B. Skulsujirapa* [Bangkok, Thailand], C. Suankratay

EV0811  Detection of Cryptosporidium spp., Cyclospora spp. and Cystoisospora spp. cysts in faecal samples of immunocompromised patients using real-time PCR
N. Turgay, O. Zorbozan, V. Tunali* [Izmir, Turkey], A. Caner, Y. Guruz, S. Aydogdu, S. Aksoylar, M. Kantar

EV0812  Management of toxoplasmosis in pregnancy: knowledge and attitude of physicians
G. Yilmaz, M. Isikgöz Tasbakan* [Izmir, Turkey], B. Kurtaran, E. Kayra Kilic, O. Sipahi, H. Pullukcu

EV0813  The new profile of visceral leishmaniasis in Kabylia, Algeria
N. Achour* [Tizi-Ouzou, Algeria], K. Mokhtar, B. Rabeh

EV0814  Higher frequency of health facility outpatient department (OPD) visits for epilepsy in onchocerciasis-affected districts in Uganda
K. Couderé* [Borgerhout, Belgium], V. Nathalie, A. Hendy, R. Colebunders, B. Opal, M. Bnyone

EV0815  Evaluation of frequency of anti-Babesia microti antibodies in serum of villagers
Z. Sonmez Tamer* [Kocaeli, Turkey], B. Akcer

EV0816  Cryptosporidium parvum is relatively frequently present, but rarely detected in children with diarrhoea
D. Skovgaard* [Odense, Denmark], G. Hartmeyer, S. Hoegh, M. Skov, M. Kemp

EV0817  Outbreak of severe cases of malaria in a rural area of Angola
R. Pocinho* [Lisbon, Portugal], G. Echóniz, R. Nazário Leão, E. Dacal, J. Gandasegui, N. Malengué, M. Moreno, M. Aznar

EV0818  Cystic echinococcosis, a neglected disease to be better investigated in a rural area of Romania
G. Popa, I. Popa* [Bucharest, Romania], C. Popa, C. Constantin, C. Dragomirescu, D. Janta, B. Mastalier, P. Mihalescu, M. Petrescu, S. Gheorghe, M. Preda, C. Cretu

EV0819  Molecular identification of Giardia duodenalis; is there any correlation between diarrhoea and genotyping in Turkish population?
Z. Sonmez Tamer* [Kocaeli, Turkey], B. Pektas

EV0820  The prevalence of Entamoeba histolytica antibody and antigen in relation to IL-10 levels in serum samples from HIV patients from Limpopo Province, South Africa
A. Amidou* [Thohoyandou, South Africa], R. Ngobeni, P. Mbati, J. Ramalivhana, A. Traore

EV0821  Epidemiology of hydatid cyst disease in Khuzestan, south-west Iran: a 15-year surveillance
F. Yousefi* [Ahvaz, Iran], S. Salamanzadeh, A. Kamali, J. Feizi

EV0822  Echinococcosis in Murcia (Spain)
D. Loaiza Ortiz, A. Hernandez Torres, J. Gámez Gómez, L. Guirado Torrecillas, S. Otálora Valderrama, B. Robles Rabasco, E. García Vázquez* [Murcia, Spain]

EV0823  Estimating the cost of a waterborne outbreak of cryptosporidiosis

Travel medicine & migrant health

EV0824  Differential characteristics of Dientamoeba fragilis infection in immigrant and non-immigrant populations

EV0825  Differential diagnosis of fevers in travellers utilizing NATExpert*, a novel rapid molecular microarray system
Z. Greenberg* [Ashdod, Israel], V. Hurgin, J. Leitman, D. Haddock

EV0826  Human brucellosis
F. Smaoui, M. Koubia, M. Gargouri, A. Znazen, H. Marsit, T. Ben Jemaa, A. Hammami, C. Marrakchi, M. Ben Jemaa* [Sfax, Tunisia]
EV0827  Infectious health problems of migrants
N. Tulek* [Ankara, Turkey], F. Erdinç, C. Bulut, C. Ataman Hatipoglu, G. Ertem, M. Sonmezer, M. Ozsoy, S. Kinikili, A. Demiroz

EV0828  Serologic prevalence of Chagas disease among Latin American blood donors in Spain
C. Rodríguez Lucas, C. Seco, M. Rodríguez-Perez, M. Flores-Chavez, J. Boga, C. Muñoz, A. Rodriguez-Guardado* (Oviedo, Spain)

EV0829  When an infection is not always only an infection
E. Magira* [Athens, Greece], H. Alexopoulos, E. Charitatos, M. Dalakas, S. Zakynthinos

EV0830  Urinary tract infection in a rural area in southern Ethiopia
R. Perez Tanoira* [Helsinki, Finland], L. Prieto-Pérez, J. Cuadros, J. Ramos Rincon, G. Tissiano, M. Gárgolas

EV0831  Cost-effectiveness of Chagas disease screening in Latin American migrants in primary health care: a Markov model analysis
A. Requena-Méndez* [Barcelona, Spain], E. Sicuri, S. Bussion, E. Aldasoro, D. Moore, M. Pinazo, J. Gascon, J. Muñoz

EV0832  Snapshot of infection protection for asylum seekers in North Rhine-Westphalia (NRW), Germany
I. Daniels-Haardt* [Münster, Germany], S. Thole, A. Jurke

EV0833  Isolation of toxigenic Vibrio cholerae serogroup O1 in two patients returning from Dominican Republic in Spain

EV0834  Chagas disease: a neglected tropical disease in the coffee-triangle region of Colombia, 2009-2013 – implications for travel medicine
A. Rodriguez-Morales, G. Lagos-Grisales* [Pereira, Colombia], I. Medina-Gómez, J. Cardona-Ospina, J. Vera-Ospina

EV0835  Patterns of emergency department use among migrants in Europe and implications for infectious disease screening: a systematic review and meta-analysis
L. Nellums* [London, United Kingdom], J. Goldberg, S. Hargreaves, J. Friedland

EV0836  Systematic screening of migrants in Denmark: a cross sectional study of infectious diseases in a population of newly arrived refugees
A. Hvass* [Aarhus, Denmark], C. Wejse

EV0837  Tuberculosis contact-tracing among Syrian refugees: report from early experience in Jordan
E. Hosten* [Brussels, Belgium], M. Mehta, E. Andre, K. Abu Rumman, D. Van der Linden

International & public health

EV0838  Mass vaccination and additional health measures in 2009: a preliminary analysis of the effects on Indonesian Hajj pilgrims
Y. Kang* [Hong Kong, China], M. Pane

EV0839  Isothermal Trichomonas vaginalis PCR [AmpliVue Trichomonas, Quidel. USA] used as confirmation assay in cases when discrepancy between in house real-time PCR and Xpert<sup>®</sup> TV [Cepheid, USA] happened
S. Gregoric, J. Videcnik, M. Maticic, M. Skvarec* [Ljubljana, Slovenia]

EV0840  Ancestral medicine and modern medicine - a dialogue of knowledge that can improve the health of indigenous peoples of the Colombian Pacific through a model of prevention in infectious diseases

EV0841  Acquisition risk of atypically resistant or multidrug-resistant pathogens on subtropical and tropical deployments – the German experience
H. Frickmann* [Hamburg, Germany], R. Hinz, P. Warnke, T. Köller, D. Wiemer, R. Hagen, A. Podbielski

EV0842  The eHISS project: mobile phone-based surveillance for symptom clusters – an approach for resource-poor settings
R. Krumkamp* [Hamburg, Germany], M. Lamshöft, B. Kreuels, A. Mohammed, A. Bonacic Marinovic, J. Brinkel, P. Asihene, J. Fobil, E. Owusu-Dabo, J. May

EV0843  Sepsis incidence in the general population and its predictors: a literature review
S. Mariansdatter* [Aarhus, Denmark], A. Eiset, K. Søgaard, C. Christiansen

EV0844  Serious fungal diseases in the Congo
W. Poaty* [Brazzaville, Congo], D. Denning

EV0845  An estimation of hospital admissions with respiratory disease attributed to sulphur dioxide exposure in Ahvaz, south-west Iran
S. Geravandi, G. Goudarzi, R. Malihi, A. Yari, S. Moaghi, E. Idani, M. Rezaei, F. Yousefi, S. Salmanzadeh, F. Soltani, M. Mohammadi* [Ahvaz , Iran]

EV0846  Listeriosis attitudes and knowledge in pregnant women from Romania
G. Popa, S. Gheorghe* [Bucharest, Romania], M. Preda, M. Huhu, O. laghen, I. Papa

EV0847  Burden of serious fungal infections in Bangladesh
H. Gugnani, D. Denning* [Manchester, United Kingdom], R. Rummana
**Intravascular catheter-related infections**

**EVO856** Central venous catheter bundle implementation in an intensive care unit in Kuwait: effect on central line-associated bloodstream infections

M. Salama* [Kuwait City, Kuwait], H. Al Mousa

**EVO858** Central catheter duration of placement and risk of central line-associated bloodstream infections (CLABSI) in critically ill patients

V. Pitiriga* [Athens, Greece], P. Mariatos, C. Karamanou, E. Campos, K. Saghis, G. Georgiadis, J. Routsias, P. Kanellopoulos, J. Dendrinos, A. Tsakris, G. Saroglou

**EVO859** Methicillin-sensitive Staphylococcus aureus catheter-related bloodstream infection: does the choice of empirical antibiotic matter?


**EVO860** Clinical relevance and outcomes of catheter-related S. aureus bacteraemia in a Spanish tertiary-care hospital

M. Puig-Asensio* [Barcelona, Spain], R. Willekens, C. Pigrau, R. Bartolomé, N. Fernandez-Hidalgo, D. Rodriguez-Pardo, M. Larrosa, B. Almirante Gragera

**EVO861** Prevention of central line associated bloodstream infections by use of a checklist

D. Wichmann* [Hamburg, Germany], C. Belmar Campos, S. Ehrhardt, T. Kock, C. Weber, H. Rohde, S. Kluge

**EVO862** Pseudo-outbreak of Staphylococcus aureus caused by laboratory misclassification

L. Miranda* [Sao Paulo, Brazil], L. del Alamo, L. Nagm, M. Noronha, N. Andrade

**EVO863** Pathogen distribution and frequency of multi-drug resistant pathogens in central line-associated bloodstream infections

V. Pitiriga* [Athens, Greece], P. Mariatos, C. Karamanou, J. Dendrinos, M. Mavrouli, P. Kanellopoulos, E. Campos, A. Tsakris, G. Saroglou

**EVO865** Positive blood cultures in abdominal aortic and aorto-iliac graft infections - do they really indicate the causative pathogen of infection?

N. Bisharat* [Afula, Israel], Y. Kotton

**EVO866** Bacterial and fungal colonization of pancreatic stents in children with chronic pancreatitis

A. Wojcieszek, K. Semczuk, G. Dracz, E. Kołodziejczyk, D. Dzierzanowska, E. Remenowska, B. Franck, K. Dzierzanowska-Fangrat* [Warsaw, Poland]
EV0867 Evaluation of the in vitro activity of the gentamicin-collagen sponge against small colony variants of coagulase-negative staphylococci isolated from prosthetic joint infections
J. Niedwiadek, A. Bogut, T. Mazurkiewicz, A. Olender* (Lublin, Poland)

EV0868 Photocatalytic enhancement of antibacterial effects of TiO2 and silver modified TiO2 nanoparticles studied by in vitro Streptococcus salivarius model

EV1002 High resistance rates to ciprofloxacin in Gram-negative prosthetic joint infections

Surgical site infections

EV0869 Efficacy and cost of three different antimicrobial prophylaxis drugs in microsurgical transsphenoidal surgery: a preliminary report
H. Ulutabanca, A. Ulu Kilic, E. Alp* (Kayseri, Turkey), D. Tülay, A. Selçuklu, M. Daganay

EV0870 Warm while asleep: a systematic review of the role of normothermia for the prevention of surgical site infections
J. Solomkin* (Cincinnati, United States), B. Zayed, S. Gomes, M. Egger

EV0871 Deep sternal wound infection (DSWI) after cardiac surgery: prospective observational study of 86 cases
J. Luján Valencia, L. Lopez-Cortes, R. Calvo-Jambrina, J. Barquero, D. Martin-Sierra, J. Gálvez-Acebal* (Seville, Spain)

EV0872 A systematic review of antiseptics in surgical site preparation
J. Solomkin* (Cincinnati, United States), S. Gomes, B. Zayed, M. Egger

EV0873 Meningitis after endoscopic transsphenoidal surgery: presentation and outcome
P. Pagliano* (Naples, Italy), L. Cavallo, C. Caggiano, N. Carannante, T. Ascione, P. Cappabianca

EV0874 Surgical site infections after spinal surgery: a retrospective study from a neurological rehabilitation centre in northern Italy
M. Ricco, C. Signorelli* (Parma, Italy), F. Pezzetti, D. Nicolotti

Nosocomial infection surveillance & epidemiology

EV0875 Epidemiology and resistance pattern of nosocomial bloodstream infections in developing world: what has changed?
R. Agarwal* (New Delhi, India), D. Shamurailapam

EV0876 Outbreak surveillance: necessity is the mother of invention

EV0877 Spread of mupirocin-resistant methicillin-resistant Staphylococcus aureus (MR-MRSA) and high dependency: lessons to be learned

EV0878 A proof of concept: MALDI-TOF as a new tool in infection control
R. Colodner* (Afula, Israel), Y. Keness, A. Yanovsky, B. Chazan

EV0879 The impact of healthcare-associated infections in intensive care units on the hospital costs, length of stay and mortality
E. Yenilmez* (Istanbul, Turkey), A. Ulcay, H. Diktas, T. Caliskan, A. Acar, V. Turhan, H. Erdem, O. Oncul, L. Gorenk

EV0880 In vitro susceptibility of amikacin against Gram-negative respiratory and blood isolates from US hospitals
C. Sutherland, J. Verastegui, D. Nicolau* (Hartford, United States)

EV0881 Prevalence, characterization and risk factors of infection with multidrug-resistant bacteria (MDR) in a liver care centre: prospective study
V. Khillan* (New Delhi, India), N. Rathor, A. Sahney

EV0882 Investigating an outbreak of Streptococcus pyogenes in a surgical ward at the University Academic Hospital, Bloemfontein, South Africa
A. Hoosen* (Bloemfontein, South Africa), T. Arendse, S. Potgieter

EV0883 Comparison of preliminary treatment methods and selective growth media for effective isolation of Clostridium difficile from stool samples
L. Tkhashko, N. Pascukh, K. Jackson, O. Nitzan, N. Isakovich, A. Peretz* (Teherias, Israel)

EV0884 Point-prevalence survey for decreasing nosocomial infections and antibiotic use
K. Lebay, I. Aharon, A. Peretz, O. Nitzan* (Tivon, Israel)
**EV0885** Evolution of candidaemia during a decade in a tertiary hospital in Greece
M. Orfanidou, V. Kitinos, M. Moutzouri-Sidiri, P. Mantzana, N. Kantas, L. Drosopoulou, G. Ganteris* [Athens, Greece], E. Vagiakou

**EV0886** Seek and you will find - vancomycin-resistant E. faecium in the intensive care unit (ICU)
H. McDermott, M. Skally, J. O’Rourke, H. Humphreys, D. Fitzgerald-Hughes* [Dublin, Ireland]

**EV0887** Changing epidemiology of *Clostridium difficile* infection - clinical features and outcomes of two *Clostridium difficile* ribotypes-RT 244 and RT 027 over a 2-year period from Central Coast, Australia
R. Chavada, G. O’Kane* [Gosford, Australia], D. Dewit, M. Veysey

**EV0888** *Elizabethkingia meningoseptica* infection: the first case series in Thailand
N. Saetiew* [Bangkok, Thailand], C. Suankratay

**EV0889** Spread of multidrug-resistant *Pseudomonas aeruginosa* isolates from ICU sink drains
R. van Mansfeld* [Amsterdam, Netherlands], A. Reuland, P. van Wijk, R. van Houdt, C. Vandenbroucke-Grauls

**EV0890** Spread of carbapenem-resistant international clones of *Acinetobacter baumannii* in Turkey and Azerbaijan: a collaborative study

**EV0891** Using bacteriophages for nasopharyngeal sanitation of *Staphylococcus aureus* for employees in obstetric hospitals
J. Rodchenko, T. Priputnevich, L. Lyubasovskaya* [Moscow, Russian Federation], V. Zubkov, G. Sukhikh, A. Zurabov, V. Popova, E. Zhilenkov

**EV0892** Extended-spectrum beta-lactamase-producing Enterobacteriaceae (ESBL-E) continue to increase despite reduction of methicillin-resistant *Staphylococcus aureus* (MRSA) in France
I. Arnaud* [Paris, France], V. Jarlier, P. Astagneau

**EV0893** *Clostridium difficile* infection in a tertiary hospital in Greece: epidemiology and prognosis
E. Kravvariti* [Athens, Greece], E. Apostolidi, A. Markogiannakis, G. Daikos, N. Sipsas, M. Samarkos

**EV0894** Trace the evolution of an *Acinetobacter baumannii* clone [ST699] causing an outbreak in a university hospital within an one-year period
K. Zhou* [Hangzhou, China], H. Dong, J. Rossen, H. Grundmann, L. Li, Y. Xiao

**EV0895** Ventilator-associated events in European intensive care units - the EU-VAE project
S. Ramirez Estrada* [Barcelona, Spain], L. Lagunes, K. Arvaniti, A. Bastug, N. Oztoprak, A. Radjou, A. Inan, I. Bozkurt, G. Pauloukou, J. Rello

**EV0896** Molecular epidemiological analysis of methicillin-resistant *Staphylococcus aureus* (MRSA) by PCR-based ORF typing (POT) method
Y. Kimura* [Nagasaki, Japan], N. Kaku, K. Kosuke, Y. Marinaga, K. Yanagihara

**EV0897** Application of international guidelines for the control of a nosocomial outbreak: the example of an outbreak due to pandrug-resistant *Acinetobacter baumannii*

**EV0898** Molecular characterization of toxigenic *Clostridium difficile* isolates from a single tertiary hospital in Madrid, Spain
S. García-Fernández* [Madrid, Spain], M. Cabo, J. Romero, E. Loza, J. Cabo, A. López San Román, R. Canton Moreno, M. Marosini Reilly, R. del Campo

**EV0899** Clostridium difficile infection in a university hospital centre Split, Croatia: trends in microbiological diagnosis and antimicrobial susceptibility over a five-year period (2010-2015)
A. Novak* [Split, Croatia], Z. Rubic, N. Boban, B. Luksic, M. Ralic, I. Goic-Barisic, M. Tonkic

**EV0900** Using international guidelines for the control of a nosocomial outbreak: the example of an outbreak due to *Clostridium difficile* infection in a French university hospital
N. Khanafafer* [Lyon, France], F. Barbut, C. Eckert, C. Demont, C. Luxemburger, M. Perraud, P. Vanhems

**EV0901** Factors associated with death in patients with *Clostridium difficile* infection in a French university hospital
N. Khanafer* [Lyon, France], F. Barbut, C. Eckert, C. Demont, C. Luxemburger, M. Perraud, P. Vanhems

**EV0902** Methicillin-resistant *Staphylococcus aureus* infection in a medical ward at a central hospital in Portugal
F. Quaresma* [Lisbon, Portugal], S. Furtado, L. Dias

**EV0903** Clinical characteristics and prognostic factors of systemic pneumococcal infection according to their place of acquisition in Republic of Korea

**EV0904** Possible healthcare-associated transmission as a cause of secondary infection and population structure of *Staphylococcus aureus* isolates from two wound-treatment centres in Ghana
G. Kpeli, E. Owusu Mireku, G. Pluschke, D. Yeboah-Manu* [Legon, Ghana]
EV0905  Changing resistance patterns of nosocomial *Klebsiella pneumoniae* strains: ten-year experience
C. Bulut, F. Erdinç, C. Ataman Hatipoglu* [Ankara, Turkey], G. Tuncer, N. Tülek, S. Kinikli, A. Demiririz, A. Karakoc

EV0906  Immunoparalysis in critically ill patients and its association to nosocomial infections and opportunistic infections - preliminary study
E. Villarreal* [Valencia, Spain], P. Ramirez Galleymore, M. Gordon, R. Jesus

EV0907  Incidence of *Clostridium difficile* infection in critically ill patients
D. Delga, D. Matthaiou, T. Christodouloupoulou, A. Koutsoukou, M. Ntaganou, K. Mandragos, G. Dimopoulos* [Athens, Greece]

EV0908  How do we de-escalate therapy for Gram-negative nosocomial infections in an infectious diseases intensive care unit?
A. Gomes, D. Neves* [Lisbon, Portugal], S. Eduardo Paula, T. Marques, C. Santos, L. Coldeira

EV0909  Use of ATP bioluminescence to control multidrug resistant organisms at a bone marrow transplant unit
G. Prado* [Sao Paulo, Brazil], F. Spadoo, L. Perdigão Neto, C. Rizek, M. Tomaz, T. Lima, T. Guimaraes, S. Figueiredo Costa

EV0910  An outbreak of extended spectrum beta-lactamase producing *Klebsiella pneumoniae* in a neonatal unit at a university teaching hospital, north-western Nigeria
A. Olajinka* [Zaria, Nigeria], O. Jimoh, J. Ejembi, E. Agada

EV0911  Increase of bloodstream infections in a tertiary University Hospital during a three-year period: predominance of carbapenemase-producing Gram-negative bacteria and increasing incidence of staphylococcal infections
M. Papadimitriou-Olivgeris* [Parras, Greece], F. Kolanitsiou, A. Spileopoulou, V. Stamouli, M. Marangos, E. Anastassiou, M. Christofidou, I. Spiliopoulou

EV0912  Bacterial infections and emerging resistance in renal transplant recipients
I. Khan* [Kolkata, India]

EV0913  Risk factors for multiple drug resistant infections after spinal surgery
M. Ricco, C. Signorelli* [Parma, Italy], D. Nicolotti, F. Pezzetti

EV0914  The global hand sanitizing relay: promoting hand hygiene through innovation

EV0915  Incidence and risk factors of *Clostridium difficile* infection in a Greek tertiary care hospital: a retrospective, observational study [2009-2015]
E. Apostolidi, K. Korantani, S. Katsouli, A. Markogiannakis, M. Gamaletsou, S. Smilakou, N. Sipsas* [Athens, Greece]

EV0916  *Moraxella osloensis*: a single centre study analysing its increasing prevalence and potential role in disease
R. Dhillon* [Glasgow, United Kingdom], H. Changez

EV0917  Peripartum group A streptococcal infections - clinico-epidemiological characteristics and preventive strategies
S. Amit* [Tel-Aviv, Israel], S. Shinar, Y. Fouks, D. Pauzner, J. Tarabeia, V. Schechner, A. Many

EV0918  Environmental contamination of patients colonized with extensively drug-resistant *Acinetobacter baumannii* (XDRAB)
D. Ng* [Singapore, Singapore], K. Marimuthu, B. Poh, Z. Wei, P. Rao, M. Raj, P. De, B. Ang

EV0919  The effect of prior antimicrobial therapy for community-acquired infections on bacterial isolates from early and late ventilator-associated pneumonia in a level I trauma intensive care unit
Y. Ramsamy, D. Muckart, K. Han, K. Misana* [Durban, South Africa]

EV0920  Diagnostic value of pentraxin 3 in ventilator-associated pneumonia
H. Bilgin* [Istanbul, Turkey], B. Bilgili, A. Yaman, F. Ture Özdemir, P. Ay, G. Halkar, M. Arslantas, I. Cinel, L. Mulazimoglu

EV0921  Relation between prevalence of hospital-acquired urinary tract infection (HA-UTI) and the duration of UTI used in the case-definition
S. Rasmussen* [Hvidovre, Denmark], C. Østergaard, N. Frimodt-Moller

EV0922  Elevated red blood cell distribution width is associated with increased risk of bacteraemia among children hospitalized in paediatric intensive care units
E. Braun* [Haifa, Israel], T. Barel, T. Mashiah, I. Kassis

Infection control intervention trials

EV0923  Prevention of severe infectious complications after colorectal surgery using preoperative oral antibiotic prophylaxis (POAP): design and rationale of the PreCaution trial
T. Mulder* [Utrecht, Netherlands], M. Kluytmans - van den Bergh, M. Bonten, J. Kluytmans
EV0924 Evaluation of the efficacy of nasal application of silver sulphadiazine for decolonization of patients with methicillin-resistant *Staphylococcus aureus* in hospitals
L. Rodrigues Ferreira* (Ribeirão Preto, Brazil), M. Menegueti, C. Silva Feliciano, S. Barbosa Neto, J. Estétele Massuco, L. Sakamoto, R. Martinez, F. Bellissimo-Rodrigues

EV0925 Carbapenem-resistant *Acinetobacter* spp. outbreak in an adult intensive care unit in South Brazil: the importance of surveillance and cleaning techniques
D. Wittgen* (Porto Alegre, Brazil), M. Bastos, C. Kawski, L. Martins

EV0926 Chitosan derivatives with antioxidant and antimicrobial activity for wound dressing applications
I. Francoliní, A. Amato, A. Piauzzi, A. Martinelli, L. Migneco, G. Donelli, C. Vuotto* (Rome, Italy)

EV0927 Modern approach of infectious disease management using infrared thermal camera scanning of fever in healthcare settings: a single-centre prospective study
M. Bardou, P. Seng* (Marseille, France), E. Honnorat, D. Raoult, A. Stein

EV0928 Successful reduction of contamination rate and increase in percentage of performing two sets of blood cultures through multidisciplinary teamwork
W. Wang* (Taichung, Taiwan), S. Chang

**Disinfection & biocides**

EV0929 The effect of titanium dioxide (TiO2)-based coating on the survival of *Escherichia coli* ST131 in the environment: *in vitro* experiment
J. Stohr* (Breda, Netherlands), C. Verhulst, M. Kluytmans - van den Bergh, J. Kluytmans

EV0930 The efficacy of "self-disinfecting" surfaces on nosocomial pathogens by using the dry inoculation technique
C. Brühwasser* (Innsbruck, Austria), M. Mayr, C. Lass-Flörl

EV0931 Methods of disinfection to prevent transferring human norovirus from vomit and faeces to environment: a systematic review
C. Ciofi-Silva* (Sao Paulo, Brazil), M. Marques Ribeiro, L. Johanna Rueda Diaz, A. Graciele Claudio dos Santos Almeida, S. Nunes, K. Uchikawa Graziano, E. Erika de Souza Guedes

EV0932 Effectiveness in the disinfection of stethoscopes: 70% alcohol vs. commercial wipes
M. Ruiz, V. Pérez Laguna, C. Exposito Sanchez, J. Fondevilla Lopez, B. Artus Uriz, R. Villar Turon, A. Rezusta* (Zaragoza, Spain), M. Revilla

EV0933 Evaluation of hydrogen peroxide and silver cations vs. active chloride disinfection procedures for eradication of multidrug-resistant organisms
A. Anesi* (Lodi, Italy), D. Baroni, S. Astitciali, R. Accetta, M. Ferrari, A. Piazza, M. Tinelli

EV0934 First-time usage of aerial disinfection with hydrogen peroxide to eradicate *Acinetobacter baumannii* endemically in the intensive care unit of Bologna Hospital
W. Amhis* (Algiers, Algeria), R. Aouameur, M. Benredouane, S. Nouar, H. Tirchi

**Microbial pathogenesis & virulence**

EV0935 The enhanced sensitivity of *Acinetobacter baumannii* strains resistant to bactericidal activity of normal human serum after exposure to the subminimal inhibitory concentrations of antibiotics
M. Bogdan* (Osijek, Croatia), D. Drenjan evi, J. Talapko, A. Antolovic Amidzic, D. Vukovic

EV0936 The *Klebsiella pneumoniae* YfgL (BamB) lipoprotein mediates cell adhesion, invasion, type-1 fimbriae expression and virulence
P. Hsieh* (Taipei, Taiwan), T. Lin, J. Hsu, C. Chen, J. Wang

EV0937 Analysis of endothelial adherence of *Bartonella henselae* and *Acinetobacter baumannii* using a dynamic human ex vivo infection model
M. Weidensdorfer* (Frankfurt, Germany), C. Makabe, J. Stahl, B. Averhoff, V. Müller, R. Brandes, G. Wilharm, W. Ballhorn, S. Christ, D. Linke, S. Götzig, V. Kempf

EV0938 Persistence likely associated to biofilm forming *Pseudomonas* spp. isolated from patients on carbapenem treatment
D. Rolo* (Barcelona, Spain), N. Mosqueda, J. Basas, P. Espinal, P. van Duijn, M. Bonten, H. Goossens, J. Gavaldà, J. Vila Estape

EV0939 Epidemiology and pathogenicity of Enterobacter cloacae complex clinical isolates recovered from bone and joint infections
F. Guérin, J. Michan, G. Rachcangar, C. Isnard, J. Giard, V. Cattori* (Caen, France)

EV0940 Association between superantigenic toxin gene and protein isolated from a patient with methicillin-resistant *Staphylococcus aureus* bacteria
M. Maeda* (Tokyo, Japan), H. Shoji, S. Tetsuro, T. Takuma, K. Ugajin, K. Fukuchi, Y. Niki, K. Ishino

EV0941 The competition inside of close relatives of the viridans group streptococci: reciprocal bacteriocin production activity of *S. pneumoniae*, *S. pseudopneumoniae* and *S. mitis* strains
L. Ikryannikova* (Moscow, Russian Federation), M. Malakhova, G. Lominadze, I. Karpova, E. Kostryukova, N. Mayanskiy, V. Dubovickaya, E. Klimova, E. Ilina, V. Gavarun
EV0943 Virulence factors of avian pathogenic Escherichia coli (APEC) isolated from coli-septicaemia in chicken [Gallus gallus domesticus]

G. Camillo* [Santa Maria, Brazil], J. Fernandes Maciel, C. Balzan, L. Matter, S. de Avila Batton, M. Lovato, A. Vargas

EV0944 Epidemiology and characterization of invasive Neisseria meningitidis serogroup Y isolates in Basque country [northern Spain] from 1995 to 2014

D. Marimón Ortiz de Zárate, M. Ercibengoa Arana* [Donostia, Spain], M. Alonso Asencor, C. Mojica, P. Pérez Trallero

EV0945 Bacterial and fungal colonization of biliary stents - preliminary results of a prospective single-centre cohort study

C. Lübbert* [Leipzig, Germany], K. Wendt, J. Feisthammel, A. Moter, J. Mössner, A. Hoffmeister, A. Rodloff

EV0947 Methicillin-resistant Staphylococcus aureus clonal complex 22 in central Germany region: resistance pattern, expression of Panton-Valentine leucocidin and category of acquisition

S. Holch Kragelund* [Aarhus, Denmark], R. Andersen Leth, N. Nørskov-Lauritsen

EV0948 Studying the role of the peptide chain release factor methyltransferase "PrmC" in the pathogenicity of Acinetobacter baumannii

E. Amin* [Cairo, Egypt], A. Hashem, A. Yassin, A. Attia

EV0949 Microbiological evaluation of oral cavity microenrosis in patients with inflammatory periodontal diseases

A. Melkumyan* [Moscow, Russian Federation], G. Kalantarov, R. Viskov, B. Berezhanskiy, . Mitichkin

EV1005 GmY, a small RNA, involved in swarming motility of uropathogenic Proteus mirabilis

S Liaw* [Taipei, Taiwan]

Host-pathogen interaction

EV0950 Influence of biofilm formation on the persistence and virulence of Cronobacter sakazakii

J. Stecklum* [Oberschleißheim, Germany], K. Schauer, E. Märtlbauer

EV0952 The role of hyaluronate lyases of Propionibacterium acnes in tissue colonization and inflammation

S. Nazipi* [Aarhus, Denmark]

EV0953 Cathelicidin modulates the immune response and decreases proinflammatory cytokine

D. Palomari Spolidoria* [Araraquara, Brazil], T. Bedran, P. Belletatti, I. Caetano, N. Nogueira, L. Spolidorio

EV0954 The gut immune response of Drosophila melanogaster consecutive to ingestion of Pseudomonas aeruginosa

M. Mihalache* [Bucharest, Romania], A. Neagu, A. Ratiu, C. Chifiriuc, V. Lazar, A. Ecvouiu

EV0955 Enhanced innate immunity related to INH prophylaxis therapy in patients infected with Mycobacterium tuberculosis

S. Huang* [Taipei, Taiwan], W. Su, S. Chen

EV0956 Selected host factors in patients with Staphylococcus aureus nasal carriage

T. Karpinski, A. Szkaradkiewicz, I. Chudzicka-Strugala* [Poznań, Poland], A. Jaworska, A. Szkaradkiewicz

Preclinical biofilm studies

EV0957 Colistin as a potential drug for combined antibiotic treatment of biofilm-associated infections

M. Kliger-Strobel* [Jena, Germany], C. Stein, O. Makarewicz, M. Pletz

EV0958 Role of bacterial biofilms in chronic rhinosinusitis: a pilot study

M. Di Luca* [Berlin, Germany], S. Esin, E. Novari, M. Menichini, S. Barnini, R. Bizzarri, A. Casani, G. Batani

EV0959 Evaluation of LED emission of blue and violet spectra on multidrug-resistant strains of Pseudomonas aeruginosa in vitro

Y. Mozgova* [Kharkiv, Ukraine], S. Malanchuk, M. Mishyna, A. Korobov, M. Popov, O. Kozlov, Y. Mishyn, B. Malanchuk

EV0960 Highly biofilm-producing Staphylococcus aureus are associated with severe atopic dermatitis

E. Di Domenico* [Rome, Italy], L. Toma, V. Bordignon, G. Prignano, M. Gallo, A. De Santis, F. Di Salvo, C. Perfetta, L. Cili, P. Cardiali Fei, F. Ensoli

EV0961 Biofilm production and antibiotic susceptibility profiles of Staphylococcus strain isolates from urinary catheter at the University Hospital Center of Tiemcen (Algeria)

I. Brixi Nigassa* [Tiemcen, Algeria], H. Hafida, S. Bellifa

EV0962 Clinical isolates of shiga toxigenic Escherichia coli form biofilm under continuous flow at 37°C*

R. Pedersen* [Odense, Denmark], G. Montamat, R. Grønnemose, H. Kolmos, T. Andersen

EV0963 Clonal diversity in biofilm formation in vitro and antimicrobial resistance of Pseudomonas aeruginosa isolated from Peruvian hospitals

S. Horna Quintana* [Barcelona, Spain], H. Guerra Allison, J. Ruiz

EV0964 Biofilm formation by ESBL-producing E. coli and K. pneumoniae

L. Sengers* [Paris, France], B. Anders, G. Arlet, D. Decre

EV0965 Evaluation of biofilm formation and destruction of periodontal pocket

N. Kalchanava* [Vitebsk, Belarus], V. Okulich
Effect of aging on the antibacterial activities of bioactive components containing dental adhesives
G. Demirel, M. Eryılmaz* [Ankara, Turkey], H. Seberol

Discovery of potential blocker(s) for Pseudomonas aeruginosa type IV pili biogenesis applying advanced quantum mechanical-molecular mechanical (QM/MM) dynamics
M. Adnan* [Hail, Saudi Arabia], S. Khan, E. Al-Shammar, M. Khan, M. Saeed, M. Alam

EV0968 DC-SIGN, -336A/G related susceptibility of DENV and HCV infection in Pakistani population
S. Khaliq* [Lahore, Pakistan]

Dynamics of immunological parameters in patients with Hodgkin’s lymphoma and favorable outcome of invasive aspergillosis

Susceptibility to intracerebral Streptococcus pneumoniae infection is not increased in transgenic Tg2576 mice, a model for Alzheimer’s disease
A. Manig, S. Schütze* [Frankfurt, Germany], S. Bunkowski, R. Nau

Host genetics of HCV clearance – a systematic review and meta-analysis
E. Gauthiez* [Lausanne, Switzerland], I. Habfast-Robertson, S. Rueger, Z. Kutalik, V. Aubert, T. Berg, A. Cerny, M. Gorgievski, J. George, M. Heim, R. Malinverni, D. Moradpour, B. Müllhaupt, F. Negro, D. Semela, N. Semmo, J. Villard, S. Bibert, P. Bochud

Relationship between severe prognosis and IL 28-B gene polymorphism in patients with Crimean Congo haemorrhagic fever
F. Yildiz, O. Gunal* [Samsun, Turkey], S. Barut, A. Rüstemoglu, F. Duygu, A. Atay

Clinical epidemiology of infections in immunocompromised hosts
Clinical features of positive blood culture among patients over 100 years old
M. Miyamae, S. Tase, S. Takahashi, S. Asahata-Tago, Y. Hirai* [Tokyo, Japan]

Immune profiling to predict risk of infection in patients with myeloma: a pilot study
B. Teh* [Melbourne, Australia], C. Allison, S. Harrison, M. Slavin, M. Pellegrini

Infectious endocarditis (IE) in solid organ transplantation (SOT)

Risk factors for developing CMV-symptomatic disease and recurrence in heart transplant recipients - expanding target selection for prophylactic treatment and monitoring
L. Muñoz* [Barcelona, Spain], G. Sanclemente, M. Bodro, M. Farrero, M. Castel, F. Pérez-Villa, M. Marcos, A. Moren

Infectious complications in children with acute myeloid leukaemia and down syndrome: analysis of the prospective multicentre trial AML-BFM 2004
A. Hassler, K. Bochennek, S. Schönig, T. Klíngebiel, U. Creutzig, D. Reinhardt, T. Lehnhbecher* [Frankfurt, Germany]

Seroprevalence for Toxoplasma gondii in allogeneic haematopoietic stem cell transplantation recipients: Turkish experience

Pre-transplant chest computed tomography screening in asymptomatic patients with haematological malignancy: is there a value?
Z. El Boghdadly* [Houston, United States], B. Dran, Y. Jiang, G. Rondon, D. Carpinelli, A. Konyagiannis

Autologous haematopoietic stem cell transplant in a patient with leprosy
M. Salomão* [Sao Paulo, Brazil], S. Figueiredo Costa, M. Battista, M. de Macedo, H. Ryoiti Higashino

Infectious complications after autologous haematopoietic stem cell transplantation: preliminary data on spectrum of infections and outcome in a tertiary-care cohort

Clinical and laboratory features of myasthenia gravis patients investigated for general infectious diseases
R. Petre* [Bucharest, Romania], R. Jipa, E. Manea, R. Hristea, A. Hristea

An analysis of bacteraemia in HIV-1 infected adults
A. Bryce* [Brighton, United Kingdom], J. Skittrall, Y. Gilleece, C. Sargent
EV0984  Epidemiology of febrile events (FE) and safety of early antibiotic discontinuation (AD) in neutropenic patients (pts) with acute lymphoblastic leukaemia (ALL)  V. Okhmats [Moscow, Russian Federation], G. Klyasova, V. Traitskaya, E. Parovichnikova

EV0985  Evaluation of the effectiveness of granulocyte transfusions in febrile neutropenia patients  E. Ermis Turak* [Kayseri, Turkey], L. Kanyar, E. Yildizhan, N. Mandaci Sanlı, A. Unal, M. Cetin


EV0987  Epidemiology and risk factors for infection in adult patients with renal transplantation in Colombia  M. López, J. Cortes, N. Yamauya, C. Montero, R. Torres Serrano, M. Ibañez, O. Martínez Nieta, M. Villalobos, S. Usme, E. Vargas, M. Jose* [Bogotá, Colombia]


EV0989  Tacrolimus reduces enterococcal cell viability but increases the resistance to phagocytosis mediated by monocytes  A. Daca* [Gdansk, Poland], T. Jarzembowski, J. Witkowski, E. Bryl, B. Rutkowski

EV0990  Chemotherapy effect on dynamics of immunological markers of HSV 1.2, CMV and EBV in patients with solid tumours  T. Zykova* [Rostov-on-Don, Russian Federation], L. Vladimirova, N. Abramova, I. Pupova, N. Tikhonovskaya

EV0991  Varicella pneumonia and hepatitis in a lung transplant patient  M. Guedes* [Porto, Portugal], N. Rocha Pereira, S. Silva, A. Sarmento

Antiviral vaccines

EV0993  Could we really prevent haemodialysis patients from getting infected with hepatitis B virus?  A. Kevorkyan* [Plovdiv, Bulgaria], M. Atanassova, R. Komitova, P. Teoharov, N. Petrova, E. Kapon, T. Argirova-Pavlova

Antibacterial vaccines

EV0994  Prevalence and seasonal distribution of viral aetiology of respiratory tract infections inpatients and outpatients of paediatric population: 9-years follow-up
## List of Speakers and Authors

<table>
<thead>
<tr>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>Abu Bakar, Noor Amalina P1546</td>
</tr>
<tr>
<td>Abreu-Di Berardino, Melanie EV0123</td>
</tr>
<tr>
<td>Abu Bakar, Noor Amalina P1546</td>
</tr>
<tr>
<td>Abu Budia, Raed P0010</td>
</tr>
<tr>
<td>Abu Rumeman, Khaled EV0837</td>
</tr>
<tr>
<td>Abu Sin, Muna EP023, EV0688</td>
</tr>
<tr>
<td>Abualia, Aham EP0234, EV0430</td>
</tr>
<tr>
<td>Acar, Ali EV0879</td>
</tr>
<tr>
<td>Acar, Hakam Ahmet O0593</td>
</tr>
<tr>
<td>Acar, Ziya EV0415, P0809</td>
</tr>
<tr>
<td>Accetta, Rachel EV0333</td>
</tr>
<tr>
<td>Accoemi, Isabel EV0896</td>
</tr>
<tr>
<td>Acoh, Marisa P1045, P1046</td>
</tr>
<tr>
<td>Achar, Pramod P0530</td>
</tr>
<tr>
<td>Achermann, Yvonne S635</td>
</tr>
<tr>
<td>Achim, Kaufohd EV0010</td>
</tr>
<tr>
<td>Achleitner, Dagmar EP0187, P0690</td>
</tr>
<tr>
<td>Achnour, Wassim EV0261, EV0813</td>
</tr>
<tr>
<td>Acoh, Wara EV0611</td>
</tr>
<tr>
<td>Aickogoz, Ziga Cibai EV0360</td>
</tr>
<tr>
<td>Ackermann, Anne-Marie EV0515</td>
</tr>
<tr>
<td>Ackermann, Nikolaus P1385</td>
</tr>
<tr>
<td>Acosta, Beatriz EV0855</td>
</tr>
<tr>
<td>Acosta, Eva EP1483</td>
</tr>
<tr>
<td>Actis, Luis A. EP0048, P0238</td>
</tr>
<tr>
<td>Adamae, Andre P1535</td>
</tr>
<tr>
<td>Adám, Andrásv EV0886</td>
</tr>
<tr>
<td>Adami, Mary EV0459</td>
</tr>
<tr>
<td>Adamopoulos, Athanasios P0538</td>
</tr>
<tr>
<td>Adams, Clare P1365</td>
</tr>
<tr>
<td>Adams, Orwin EV0259</td>
</tr>
<tr>
<td>Adamski, Rygacard EV0622</td>
</tr>
<tr>
<td>Adang, Eddy P0825</td>
</tr>
<tr>
<td>Addo, Kennedy Kwasi P0160</td>
</tr>
<tr>
<td>Adel, Doaa EV0324</td>
</tr>
<tr>
<td>Adermann, Knut O0533</td>
</tr>
<tr>
<td>Adesjan, Modupe EV0615</td>
</tr>
<tr>
<td>Adib, Lynne P0678, P0798</td>
</tr>
<tr>
<td>Adilgah, Ali EV0412</td>
</tr>
<tr>
<td>Adamianis, Dita EV0366</td>
</tr>
<tr>
<td>Adjeteg, Caroline EV0765</td>
</tr>
<tr>
<td>Adler, A. D115</td>
</tr>
<tr>
<td>Adler, Alexander EV0371, P0237</td>
</tr>
<tr>
<td>Adler, Amai EV0377, P0148, P1286</td>
</tr>
<tr>
<td>Adlerberth, Ingegerd P0216</td>
</tr>
<tr>
<td>Adler-Moore, Jill P1586</td>
</tr>
<tr>
<td>Admani, Dosa P0987</td>
</tr>
<tr>
<td>Adman, Mohd EV0967</td>
</tr>
<tr>
<td>Adone, Rosella EV0510</td>
</tr>
<tr>
<td>Adriaansens, Niels EP0216, EV0698, O0593, P1291, P1294, P1328</td>
</tr>
<tr>
<td>Adou-Sarkodie, Yaw P0494, P0736</td>
</tr>
<tr>
<td>Aduanwary, Anamika EV0548</td>
</tr>
<tr>
<td>Aefelbacher, Martin P0736</td>
</tr>
<tr>
<td>Aerts, Marc P1293</td>
</tr>
<tr>
<td>Afasas, Boris P1779, EV0734, EV0969, P0356</td>
</tr>
<tr>
<td>Affolter, Kristina O136</td>
</tr>
<tr>
<td>Afif, Claude EV0182, EV0067</td>
</tr>
<tr>
<td>Afiri, Malika EV0261</td>
</tr>
<tr>
<td>Afeixa, Vera P0827</td>
</tr>
<tr>
<td>Afrough, Parviz P1432</td>
</tr>
<tr>
<td>Afsat, Jan Egil P0884, P0908</td>
</tr>
<tr>
<td>Agacidan, Ali EV0039</td>
</tr>
<tr>
<td>Agoda, Esi Idowu EV0910</td>
</tr>
<tr>
<td>Agharwal, Vikas EP0285</td>
</tr>
<tr>
<td>Aghbali, Adel EP0128, EP0297</td>
</tr>
<tr>
<td>Aghgevets, Vladimir EV0431, P0184, P1188</td>
</tr>
<tr>
<td>Aghen, Mahmoud P1748</td>
</tr>
<tr>
<td>Aghersa, Yvonne P0643</td>
</tr>
<tr>
<td>Aghgeberaak, Henrik D263</td>
</tr>
<tr>
<td>Aghopi Riehache, Nadjet PG721</td>
</tr>
<tr>
<td>Agha Babaei, Syamak EP0095</td>
</tr>
<tr>
<td>Aghakhani, Arvizo EV0013, EV0045, P1405</td>
</tr>
<tr>
<td>Aghasadehi, Mohammad Reza P1405</td>
</tr>
<tr>
<td>Agin, Mehmet P0935</td>
</tr>
<tr>
<td>Agгляд, Antonella P0705</td>
</tr>
<tr>
<td>Aghoras, Theodore EV0126</td>
</tr>
<tr>
<td>Agnafoti, Katerina P0982</td>
</tr>
<tr>
<td>Agrappa, Carlo P0041</td>
</tr>
<tr>
<td>Agrati, Chiara D143</td>
</tr>
<tr>
<td>Agrawal, Rajat EV0875</td>
</tr>
<tr>
<td>Afgregno, Alexander P1602</td>
</tr>
<tr>
<td>Agriegr, Nelly EP0256, P1247</td>
</tr>
<tr>
<td>Aghuedo Garcia, Jose Maria EV0213, EV0859, EV0986, O1472, P0386, P0620, P0622, P1641</td>
</tr>
<tr>
<td>Aghuedo Garcia, Jose Maria P0447, P1767</td>
</tr>
<tr>
<td>Aghuedo Carlos EV022</td>
</tr>
<tr>
<td>Aghuedo Pena, Sonia P0919, P0921</td>
</tr>
<tr>
<td>Agüero, Jesus EV0136</td>
</tr>
<tr>
<td>Agüero, Ramon P0260</td>
</tr>
<tr>
<td>Agüer, Sara P0661</td>
</tr>
<tr>
<td>Agüier, Mercedes EV0230, EV0298</td>
</tr>
<tr>
<td>Agüier, Mountevens O1425, P1240, P1313</td>
</tr>
<tr>
<td>Agüier, A. EV0411</td>
</tr>
<tr>
<td>Agüier, Ximena P1411</td>
</tr>
<tr>
<td>Agüierta, Corea, John Pino P1129</td>
</tr>
<tr>
<td>Agüirre, Aritz EV0272, EV0556, EV0833</td>
</tr>
<tr>
<td>Agüirre Quiñonero, Amaia EV0136</td>
</tr>
<tr>
<td>Agüirre Quiñonero, Amaia EV0391</td>
</tr>
<tr>
<td>Agüirre Martínez, Laura Marcela P0071</td>
</tr>
<tr>
<td>Agulla Budiño, Jose Andres EP0165</td>
</tr>
<tr>
<td>Agulho, Marine EV0707, P1298</td>
</tr>
<tr>
<td>Agunwah, Ijeoma EV0609</td>
</tr>
<tr>
<td>Agus, Neval P0424</td>
</tr>
<tr>
<td>Agut, Monserrat EV0625</td>
</tr>
<tr>
<td>Aharon, Ilana EV0884</td>
</tr>
<tr>
<td>Ahir, Harbals P1112</td>
</tr>
<tr>
<td>Ahlman, Clas D062</td>
</tr>
<tr>
<td>Ahmad, Alih Wag W1546</td>
</tr>
<tr>
<td>Ahmad, Suhail P0010</td>
</tr>
<tr>
<td>Ahmad, Bahram P1647</td>
</tr>
<tr>
<td>Ahmam, Jenny P0084, P0823, P0824, P0825, P0826</td>
</tr>
<tr>
<td>Ahmed, Atif EV0133</td>
</tr>
<tr>
<td>Ahmed, Dilirwa EV0045</td>
</tr>
<tr>
<td>Ahmed, Mohamed P0435, P0460</td>
</tr>
<tr>
<td>Ahmed, Naglaa P1775</td>
</tr>
<tr>
<td>Ahmed, Nijaz O165</td>
</tr>
<tr>
<td>Ahmed, Rijaz O150</td>
</tr>
<tr>
<td>Ahmed, Salman Shaheer EV0890</td>
</tr>
<tr>
<td>Ahmed, Sarah P1644</td>
</tr>
<tr>
<td>Ahmed, Sairah EV0137</td>
</tr>
<tr>
<td>Ahmed, Syed Shaheer EV0078, P0101</td>
</tr>
<tr>
<td>Ahrn, M Young EP0146</td>
</tr>
<tr>
<td>Name</td>
</tr>
<tr>
<td>---------------------------</td>
</tr>
<tr>
<td>Bhogal, Rashmeet</td>
</tr>
<tr>
<td>Bhuju, Sabin</td>
</tr>
<tr>
<td>Bialek, Ralf</td>
</tr>
<tr>
<td>Bianchi, Roberto</td>
</tr>
<tr>
<td>Bianco, Gabrielle</td>
</tr>
<tr>
<td>Biard, Lucie</td>
</tr>
<tr>
<td>Biarent, Dominique</td>
</tr>
<tr>
<td>Bia, Tiffany</td>
</tr>
<tr>
<td>Biscoli, Maria Angela</td>
</tr>
<tr>
<td>Biasion, Caterina</td>
</tr>
<tr>
<td>Biava, Mirella</td>
</tr>
<tr>
<td>Bibly, Bo M.</td>
</tr>
<tr>
<td>Biber, Asaf</td>
</tr>
<tr>
<td>Biber, Stephanie</td>
</tr>
<tr>
<td>Bicart, See</td>
</tr>
<tr>
<td>Bicenn, M.</td>
</tr>
<tr>
<td>Bidaut, Ghislain</td>
</tr>
<tr>
<td>Bidovic, Strijovic, Urska</td>
</tr>
<tr>
<td>Biedenbach, Doug</td>
</tr>
<tr>
<td>Bilen, Penny</td>
</tr>
<tr>
<td>Bilecki, Julia</td>
</tr>
<tr>
<td>Bilecki, Julia Anna</td>
</tr>
<tr>
<td>Bieli, Alessandra</td>
</tr>
<tr>
<td>Bieke, Franck</td>
</tr>
<tr>
<td>Bietrix, Jacques</td>
</tr>
<tr>
<td>Bijlsma, Merijn</td>
</tr>
<tr>
<td>Bikandi, Josefa</td>
</tr>
<tr>
<td>Bik, Floris</td>
</tr>
<tr>
<td>Bislev, Bjarka</td>
</tr>
<tr>
<td>Biler, Caroline</td>
</tr>
<tr>
<td>Biera, Jörgen</td>
</tr>
<tr>
<td>Bernat, Monika</td>
</tr>
<tr>
<td>Birenbench, Ana Luiza</td>
</tr>
<tr>
<td>Bisbros, Giske</td>
</tr>
<tr>
<td>Biet, Franck</td>
</tr>
<tr>
<td>Blekstrøm-Slættende, Ksenia</td>
</tr>
<tr>
<td>Bleier, Anette</td>
</tr>
<tr>
<td>Bohdare, Helmut</td>
</tr>
<tr>
<td>Bohdari, Katharina</td>
</tr>
<tr>
<td>Bohdari, Svetlana</td>
</tr>
<tr>
<td>Bohdaru, Lidia</td>
</tr>
<tr>
<td>Bohdari, Boaz</td>
</tr>
<tr>
<td>Bohdari, Martin</td>
</tr>
<tr>
<td>Bohdari, Blanka</td>
</tr>
<tr>
<td>Bohdari, Blanca</td>
</tr>
<tr>
<td>Bohdari, Blanca</td>
</tr>
<tr>
<td>Bohdari, Blanka</td>
</tr>
<tr>
<td>Bohdari, Blanca</td>
</tr>
<tr>
<td>Bohdari, Blanka</td>
</tr>
<tr>
<td>Bohdari, Blanka</td>
</tr>
<tr>
<td>Bohdari, Blanka</td>
</tr>
<tr>
<td>Bohdari, Blanka</td>
</tr>
<tr>
<td>Bohdari, Blanka</td>
</tr>
<tr>
<td>Bohdari, Blanka</td>
</tr>
<tr>
<td>Bohdari, Blanka</td>
</tr>
<tr>
<td>Bohdari, Blanka</td>
</tr>
<tr>
<td>Bohdari, Blanka</td>
</tr>
<tr>
<td>Bohdari, Blanka</td>
</tr>
<tr>
<td>Bohdari, Blanka</td>
</tr>
<tr>
<td>Bohdari, Blanka</td>
</tr>
<tr>
<td>Bohdari, Blanka</td>
</tr>
<tr>
<td>Bohdari, Blanka</td>
</tr>
<tr>
<td>Bohdari, Blanka</td>
</tr>
<tr>
<td>Bohdari, Blanka</td>
</tr>
<tr>
<td>Bohdari, Blanka</td>
</tr>
<tr>
<td>Bohdari, Blanka</td>
</tr>
<tr>
<td>Bohdari, Blanka</td>
</tr>
<tr>
<td>Bohdari, Blanka</td>
</tr>
<tr>
<td>Bohdari, Blanka</td>
</tr>
<tr>
<td>Bohdari, Blanka</td>
</tr>
<tr>
<td>Bohdari, Blanka</td>
</tr>
<tr>
<td>Bohdari, Blanka</td>
</tr>
<tr>
<td>Bohdari, Blanka</td>
</tr>
<tr>
<td>Bohdari, Blanka</td>
</tr>
<tr>
<td>Bohdari, Blanka</td>
</tr>
<tr>
<td>Bohdari, Blanka</td>
</tr>
<tr>
<td>Bohdari, Blanka</td>
</tr>
<tr>
<td>List of Speakers and Authors B</td>
</tr>
<tr>
<td>-----------------------------</td>
</tr>
<tr>
<td>Brodick, Hagley EP0247, P0150</td>
</tr>
<tr>
<td>Broens, Ets M. EV0554, EV0350</td>
</tr>
<tr>
<td>Brous, Annoek P0347</td>
</tr>
<tr>
<td>Brookfield, Charlotte EV0680</td>
</tr>
<tr>
<td>Brookman, Gina P0830, P0831</td>
</tr>
<tr>
<td>Brossa, Silvia EV0584</td>
</tr>
<tr>
<td>Brossier, Florence P0958</td>
</tr>
<tr>
<td>Brotons de los Reyes, Pedro EV0523</td>
</tr>
<tr>
<td>Brouqui, Philippe P0578</td>
</tr>
<tr>
<td>Brousses, Paul P0021</td>
</tr>
<tr>
<td>Brouwer, Matthijs EV0155, D018, D019, D024, D025, D026, D026, P1146, P1164, P1162, D026, P1146, P1164, P1162, D026,</td>
</tr>
<tr>
<td>Brown, James P1509</td>
</tr>
<tr>
<td>Brown,发改 Flavia P0230, P0802</td>
</tr>
<tr>
<td>Brown, Alistair P0303</td>
</tr>
<tr>
<td>Brown, Colin P0302</td>
</tr>
<tr>
<td>Brown, Derek EP0572, P1087</td>
</tr>
<tr>
<td>Brown, Derek S. EV0414, M193, P0823</td>
</tr>
<tr>
<td>Brown, Elizabeth EP0254</td>
</tr>
<tr>
<td>Brown, James P0621</td>
</tr>
<tr>
<td>Brown, Mitchell P1650</td>
</tr>
<tr>
<td>Brown, Nicholas P00082, P1050, P1255</td>
</tr>
<tr>
<td>Brown, Rebecca P0299, P0270</td>
</tr>
<tr>
<td>Brownie, Hilary EP0200</td>
</tr>
<tr>
<td>Brown-Ritchie, Vivette P0062</td>
</tr>
<tr>
<td>Brucceleri, Veronica EV041</td>
</tr>
<tr>
<td>Bruggemann, Angela EP0167</td>
</tr>
<tr>
<td>Bruggenmann, Holger EP0264</td>
</tr>
<tr>
<td>Bruggenmann, Roger P1570</td>
</tr>
<tr>
<td>Brunagro, Paolo P1562</td>
</tr>
<tr>
<td>Brühl, Christina EV0930</td>
</tr>
<tr>
<td>Bruininestijn van Copenraen, Lesia E. EV0263, P0665</td>
</tr>
<tr>
<td>Brujinjing-Verhagen, Patricia P0070</td>
</tr>
<tr>
<td>Bruijs, Marjan J. P1023, P1137</td>
</tr>
<tr>
<td>Bruisten, Sylvia EP0193, D474, P1426</td>
</tr>
<tr>
<td>Brouneuer, Andreas P0690</td>
</tr>
<tr>
<td>Brun-Buisson, Christian EP0371</td>
</tr>
<tr>
<td>Brunetti, Enrico P0621, C0324, P0577, P1424</td>
</tr>
<tr>
<td>Brunetti, Grazia P0316</td>
</tr>
<tr>
<td>Bruneti, Jenia EV0649</td>
</tr>
<tr>
<td>Bruning, Andrea EV0112, P181</td>
</tr>
<tr>
<td>Brunkhorst, Frank Martin EV0159, P0490</td>
</tr>
<tr>
<td>Bruno, Marco G. P0384</td>
</tr>
<tr>
<td>Bruns, Tony O312</td>
</tr>
<tr>
<td>Bruxelle, Jean-François D412</td>
</tr>
<tr>
<td>Brudzyn, Ewa EV0983</td>
</tr>
<tr>
<td>Brudzyck, Robin P1293</td>
</tr>
<tr>
<td>Brueche, Agnieszka P0150</td>
</tr>
<tr>
<td>Bruckner, Christian EV0097, P0191, P0918</td>
</tr>
<tr>
<td>Brugina, Ekaterina P0373</td>
</tr>
<tr>
<td>Busa, Alessandro P1562</td>
</tr>
<tr>
<td>Busch, Dirk H. P1008</td>
</tr>
<tr>
<td>Bussenbender, Lukas P0161</td>
</tr>
<tr>
<td>Buset, Olga P0692, P1527, P1562</td>
</tr>
<tr>
<td>Bush, Shed P0143</td>
</tr>
<tr>
<td>Buss, Marina P0274</td>
</tr>
<tr>
<td>Bussquets, Antonio P0968</td>
</tr>
<tr>
<td>Buss, Lewis EP0592</td>
</tr>
<tr>
<td>Bussion, Sheila EV0531</td>
</tr>
<tr>
<td>Bustamante, Beatriz EV0732, P0374</td>
</tr>
<tr>
<td>Bustamante, Carlos EV0193</td>
</tr>
<tr>
<td>Bustone, Zulema P0490</td>
</tr>
<tr>
<td>But, Ayse EV0032</td>
</tr>
<tr>
<td>Butaxe, Arnaud P0169</td>
</tr>
<tr>
<td>Butel, Anna P0148</td>
</tr>
<tr>
<td>Buten, Elke MP0100</td>
</tr>
<tr>
<td>Buti, Flavia EV0033</td>
</tr>
<tr>
<td>Buti, Guy P0100</td>
</tr>
<tr>
<td>Butin, Maria Eugenia EV0389</td>
</tr>
<tr>
<td>Butler, Chris C. P0130</td>
</tr>
<tr>
<td>Butler, Christopher EP0124, P0909</td>
</tr>
<tr>
<td>Butler, Stephen EV0526</td>
</tr>
<tr>
<td>Buttaati, Rossella P1106, P1426</td>
</tr>
<tr>
<td>Butters, Thomas P0181</td>
</tr>
<tr>
<td>Buttrini, Marco EP0193</td>
</tr>
<tr>
<td>Buttrini, Marco EP0300</td>
</tr>
<tr>
<td>Butta, Paolo P1097</td>
</tr>
<tr>
<td>Butten, Mary EP0193</td>
</tr>
<tr>
<td>Buxton, Gemma P0334</td>
</tr>
<tr>
<td>Bygde, Frank EP0712, EV0718</td>
</tr>
<tr>
<td>Bygrén, John P1288</td>
</tr>
<tr>
<td>Buykx, Katerina B0095</td>
</tr>
<tr>
<td>Buykx, Katerina B0095</td>
</tr>
<tr>
<td>Buykx, Katerina B0095</td>
</tr>
<tr>
<td>Buykx, Katerina B0095</td>
</tr>
</tbody>
</table>
List of Speakers and Authors C

Castro, Elisabeth EV0230
Castro, Eduardo P0784
Castro, Antoni P1462
Castillo, Dania P1544
Castillo, Valeria P0182
Caterina, Maria P0394
Castiñeiras, Alba P1225
Castillo, Francisco Javier EV0336, EV0442, EV0511
Castillo, F. Javier P0756
Castilletti, Concetta O143, P0077, P0087
Castilla Catalán, Jesús EV0066, EV0134, EV0135, EV0033, EV0103
Castillo, Ana P0002
Castro, Eduardo P0784
Castro, Elisabeth EV0230
Castro, Lourdes P0638
Castro, Silvia P0084
Castro, Yaghineh EV0393, P0558
Castro-Fuentes, L. Neferetti EV0345
Catado, Maria Adriana P0805
Catana, Remus EV0145, EV0102, P0541
Cataneli Pereira, Valéria P0182
Catellan, Ana Maria EV0311, P1562
Cattor, Lien EV0116
Cattor, Vincent EV0320, EV0393, P0639, P0718, P1543
Cauda, Roberto EV0181, P1207, P1597
Causse, Manuel EV0301, O1217, P0567
Cava, Felipe P0633
Cavaco, Linda P0643
Cavaco-Silva, Patricia P1275
Cavadas, Cláudia EV0805
Cavallerio, Carlos EV0805
Cavallio, Paola P1367
Cavallo, Luigi EV0673
Cavallero, Rossana EV0102, EV0551, EV0584
Cavanillas, Rafael P1594
Cavanna, Caterina EV0878
Cavassini, Matthias P0015
Cavazzi, Marco P0271
Cavina, Augusto P0122
Cavinato, Silvia P1562
Cavie, Ibrahim EV0266, P1669
Cagda, I., Öğuz D033
Cayla, Joan P0263
Cazals, Xavier P0366
Cazanave, Charles P0526
Cazeneuve, Françoise P0268
Cazenave-Roblot, France P0595
Cazet, Lucie P0198
Cecimal, Cyril EV0662
Ceballos, Andrés P1656
Cebreiro-Canguero, Tania EP0132
Cebrián, Cristina P0555
Cecatti, José Gilberthe P0472
Cecarelli, Daniela P1509
Cecchi, Borrello P1208
Cédó, Mar P0106
Ceia, Filipa O371
Ceken, Sabahat EP0156
Celso, Miguel Ev0268
Celliere, Béatrice EV0787
Celli, Silvia P1430
Cellier, Béatrice EV0578, EV0581
Cellini, Agnese EV0387, P0663
Cengiz, Ali Bulent EV0003
Centeno, Madalena P0130
Cenizal, España P0237
César, Pierre Emmanuel O274
Céravolo, Marco EV0336
Cavalerio, Rossana EV0102, EV0551, EV0584
Cevlik, Haydar EV0271
Ceppatelli, Claudia EV0135
Cer, Késh P0663
Cencarini, Claudio EV0373, EV0544
Cenckovic, Svetlana P0680
Cerdan, Benoît P0762
Cuenca, Blanca P1225
Cerletti, Daniele P1509
Cenin, Antonio EP0248
Cerny, Andreas EV0971
Chafi, Ali O306
Chagas, Rebeca EV0578, P0681
Chajes, Elisabeth EV0252
Chaffar, Nathan P1279
Chaidir, Lidia O503
Chaihongna, Narong EV0552
Chaillon, Antoine O268
Chaim, Dahia P0787
Chaine, Manon P0618
Chagásperst, Angkana O139
Chaisiriji, Papada O139
Chakour, Ivan P0911
Chakrabarti, Arnalaleo EV0005, M555
Chakravarty, SouravTE P0457
Chalandon, Yves EV0160
Chalhoub, Hussein P0762
Chalifa-Caspis, Véron EV0490, EV0310
Chalker, Victoria EV0108, EV0574, O561, P0299, P0774
Chalikadaki, Despoina P0518
Challine, Dominique P0038
Chambers, Stephen EV0269
Chambers, Timothy EV0108
Champlin, Richard EV0979
Chan, Denise P0078
Chan, Jaser EV0708, P0101, P1649
Chan, KL EV0101
Chan, Pan EV0135
Chan, Sajesh P0194
Chan, Yu-Juan EV0468, P0408, P0411, P1607
Chan, Yeenne P0393
Chander, Jacques P0366
Chang, Chi-Chang EV0024
Chang, Hyun-Ha P1392
Chang, Jung Hyun P1433
Chang, Nai-Chung D0419
Chang, Guizhi EV0289
Chang, Samii EV0928
Chang, Shwen-Chwen P0164
Chang, Shih-Chun EV0040
Chang, Yu-Chuan P0408
Chang, Yu-Fen P1602
Chang, Shih-Chung EV0263, EV0916
Chantongthip, Anisone EV0543, EV0574
Chantthongkuld, Bunkuea O139
Chaparro, Gustavo P0859
Chapin, Kimberlé EP0216
Chapman, Belinda P1650
Chappell, Jeff P1339
Chappuis, Olivier P0586
Cheralamakis, Nikolletta P0550
Charbonneau, Claudie EV0777, P1593, P1593
Chardon, Hubert EV0411, EV0424
Chafif, Rawya EV0682
Charissoux, Jean Louis P0532
Charitatos, Evangelos EV0829
Charles, Pierre Emmanuel O274
Charllet, Andre EP0124, P0752
Charlier, Caroline P1170
Charlton, Fraser P0365
Chamillon, Alexander P1247
Charoenpong, Lantharita P1232
Chareonpong, Lantharita P1232
Charoikon, Nikolaos P0152
Chareel, Remy S390
Charrier, Cedric P1279
Chas, Julie O211
Chasikou, Athina EV0221, EV0236, EV0285
Chattak, Christina P0604
Chatellier, Sonia P1706
Chathaisong, Piyawadee P0816
List of Speakers and Authors

Chaidlaw, Amanda P1 373
Chidiac, Christian EV0191, EV0192, P0091
Chiche, Jean-Daniel P1 382
Chiche, Arnaud P1 2 15
Chiboub, Emna P0797
Chib, Savita O150, P087 4
Chiari, Erika EV0157
Chiampas, Thomas EV0006
Chezzi, Carlo EP0300, P1 409
Chew, Ka Lip P0960
Cheung, Pauline P0062
Cheung, Manton P0078
Cheung, Jonathan P1 279
Chetchotisakd, Ploenchan O423
Chetaou, Mahaza EV0491
Chesnel, Laurent P06 11, P06 1 2, P06 1 3
Cherkassky, Alexander P1631
Chéret, Antoine P01 29, P01 32
Cheong, Yu Shan P0960
Cheong, Hee Jin P0877, P1 392
Cheong, Elaine P1070
Chenouard, Rachel EV0491
Cheng, Yi-Hsiang O589
Cheng, Y anny P1627
Cheng, Jingwei EP01 36, P0291
Cheng, Chien-Yu EV0004
Cheng, Allen C EV0697
Chen, Zhengrong EV0190
Chen, Yueh-Ying P1 7 10
Chen, Yi-Yin P1 437
Chen, Yin-Yin P1067
Chen, Ying P1092
Chen, Yi-Jyun P1067
Chen, Chen, Hsin-Pai P0411
Chen, Honglin EV0078, P0101
Chen, Er-Zhen P1092
Chen, Chun-Tang EV0936
Chen, Alice P0336
Chen, Caroline P0123, EV0693, P1237
Chen, Chun-Tang EV0936
Chen, Ren-Zhen P1092
Chen, Honglin EV0078, P0101
Chen, Hsin-Pai P0411
Chen, Ke P1211
Chen, Sharon P0291, P1434, P1650
Chen, Sz-Tin EV0855
Chen, Wen Q547
Chen, Yi-Jun P1067
Chen, Ying P1092
Chen, Yin-Yin P1067
Chen, Yi-Yan P1437
Chen, Yi-Yan P1437
Chen, Yueh-Ying P1 7 10
Chen, Yuhui P0224
Chen, Zhengrong EV0190
Cheng, Allen EV0697
Cheng, Chien-Yu EV0004
Cheng, Jingwei EP0136, P0291
Cheng, Shu-Hsing EV0024
Cheng, Yann P1627
Cheng, Yi-Hsiang D859
Chenouard, Rachel EV0491
Cheon, Dae Young EV0351
Choeung, Elaine P1070
Choeung, Hee Jin P0877, P1392
Choeung, Yu Shan P0960
Derret, Antoine P0129, P0132
Derkerkassy, Alexander P1631
Dervet, Delphine EV0376
Demes, Laurent P0611, P0612, P0613
Derter, Mahaza EV0491
Detchotisadik, Ploenchon 0423
Cheung, Jonathan P1279
Cheung, Manton P0078
Cheung, Pauline P0062
Chevalier, Stéphane P0038
Chevalier, Karol P0060
Dhezzi, Carlo EP0300, P1409
Dhimaps, Thomas EV0006
Diari, Erika EV0157
Diib, Savita D1050, P0874
Didibou, Emma P0797
Dicharros, Carmen P1673
Diche, Arsaud P1225
Diche, Jean-Daniel P1382
Didicic, Christophe EV0191, EV0192, P0091
Didlawa, Amanda P1273

Cheiffo, Gabriele P148
Chien, Jaime Mei Feng P0579, P1609
Chien, Jung-Yen P0289, P0448
Chiereghin, Angela EV0122, EV0201
Chifiriuc, Corina EV0154
Chifiriuc, Mariama Carmen EV0064, EV0305, EV0343, EV0372, EV0636, P0579, P0094, P1287, P1669, P1907, P1214, P1718, P1756
Chiliza, Thamsanqa P0157
Chilton, Caroline P1334
Chimedito, Battaglossi EV0026
Chimma, Pattamawan P0566
Chindamporn, Ariya P1648
Chindavijak, Busa P1201
Chinedum Dnwugamba, Francis O168
Chinikar, Sadegh EV0091
Chinners, Patrick P1346
Chinniah, Terrence Rehan P1546
Chiodini, Peter 0324, S629
Chiome, Chrispen EV0092
Chiotinis, Nikos P1530
Chiou, Shyan-Song EV0088
Chipman, Annie P0831
Chipwete, James P0590
Chirico, Claudia EV0157
Chironna, Maria EV0013
Chistenko, Grigory EV0202
Chistyakov, Irina EV0004
Chi-Tai, Fang P0164
Chitra, Suraj P1266
Chi, Lily-Wang EV0669
Chiueh, Tzong-Shi EV0088
Chiurazzi, Chiara P0760, P1313
Chkhartishvili, Nikoloz M176
Chliebowski, Monika A. P0307
Chmielewski, Krzysztof EV0157
Chmielewski, Sylwia Joanna P1470
Chng, Kern Rei Chng P1000
Cho, Bin P168
Cho, Chong Rae P1606
Cho, Sun Young P0406, P0489
Chocchilior, Christian P1634
Chodik, Gabriel P0664
Cho, Jun Yong EV0146
Cho, Min Joo P0087
Cho, Oute EV0586
Cho, W.S. EV0903, P0877
Cho, Wai P0140
Cho, Won Suk P1392
Cho, Young Hwa EV0930
Cho, Young Ki P0087
Choisy, Philippe P1413
Chomnawang, Mullika EV0505, P0264
Chonoco, Louis EV0665
Chong, Chia Yin P0383
Chong, Gaila O226, P0347
Chong, Sung EV0099
Chong, Yunsoo P1544
Chopada, Manojkumar Bhavari EV0880
Chopra, Kamal Kishore EV0495, P0306
Chour, Jacques P0573, P1481
Choudhary, Chedly P0255
Choudhuri, Aniket P0828
Chouman, Rabab EV0006
Choumara, Valerie P0072
Chouvarine, Philippe P0291
Cho, Angela P1121
Cho, Won Suk P1392
Choudhary, Anuradha O225, P1606, P1643
Chrdle, Alex O367
Chrstansfield, Theofilos EV0015
Christ, Mirjam O403
Christ, Sara EV0937
Christaki, Erini P0471, P0999, P1560
Christensen, Andreas EV0112
Christensen, Jens Jørgen P0842
Christiaens, Thierry P1646
Christian, Perronne EV0689
Christian, Ralph Walter P0911
Christiansen, Christian Fynbo EV0843
Christidou, Athanasia P1255
Christine, Franceschi P1706
Christodouloupulu, Theodora EV0097
Christofidou, Myro EV0911, P0259, P0675, P0579
Christoph, Anna P1209
Chronopoulou, Genovefa EV0392, P0004, P1530, P0982
Chu, Mei Ling O467
Chu, Pei-Yu P0001
Chudejeva, Katerina EP0181
Chudnovskikh, Julia EV0734
Chudzicka-Stygula, Izabela EV0229, EV0642, EV0955
Chugh, Rakesh P1260, P1267, P1268, P1269, P1270
Chulanan, Vladimir EV0052
Chun, Byung Chul EV0903
Chun, Seong EV0460
Chung, Doo Ryon P0406, P0489
Chung, Jae-Sung EV0504, P1433
Chung, Jin-Won EV0903
Chung, Keun-Taik O114
Chung, Nack-Gyun P1767
Chung, Panha P0131
Chun, Kyung Hwa EV0930
Chun, Sun Young EV0693
Chun, Won Su EV0397
Chun, Yoon-Young EV0903
Chun, Youn Ki P0089
Choisip, Philippe P1413
Chomnawang, Mullika EV0505, P0264
Chonoco, Louis EV0665
Chong, Chia Yin P0383
Chong, Gala O226, P0347
Chong, Sung EV0099
Chong, Yunsoo P1544
Chopada, Manojkumar Bhavari EV0880
Chopra, Kamal Kishore EV0495, P0306
Chour, Jacques P0573, P1481
Choudhary, Chedly P0255
Choudhuri, Aniket P0828
Chouman, Rabab EV0006
Choumara, Valerie P0072
Chouvarine, Philippe P0291
Cho, Angela P1121
Cho, Won Suk P1392
Chowdhary, Anuradha O225, P1606, P1643
Chrdle, Alex O367
Chriassanthidis, Theofilos EV0015
<table>
<thead>
<tr>
<th>Name</th>
<th>Cite</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Coia, John E</td>
<td>EP0102</td>
<td></td>
</tr>
<tr>
<td>Coignard-Biehler, Hélène</td>
<td>P0091, P0078, P0078, S555</td>
<td></td>
</tr>
<tr>
<td>Cointe, Aurélie</td>
<td>P0074</td>
<td></td>
</tr>
<tr>
<td>Colakoglu, Gizem</td>
<td>P1460</td>
<td></td>
</tr>
<tr>
<td>Colapietro, Martina</td>
<td>P1185</td>
<td></td>
</tr>
<tr>
<td>Colavita, Francesca</td>
<td>P0077, P0052, P0413</td>
<td></td>
</tr>
<tr>
<td>Collers, Angelia</td>
<td>P1570</td>
<td></td>
</tr>
<tr>
<td>Cole, Stewart T</td>
<td>P1456</td>
<td></td>
</tr>
<tr>
<td>Copley, Robert L</td>
<td>EV0018</td>
<td></td>
</tr>
<tr>
<td>Coldeyman, David C</td>
<td>P0103, P0132, P1696</td>
<td></td>
</tr>
<tr>
<td>Colens, Samir</td>
<td>P0137</td>
<td></td>
</tr>
<tr>
<td>Collot, Isabelle</td>
<td>P1281</td>
<td></td>
</tr>
<tr>
<td>Colin, Pieter</td>
<td>P1242, P1246</td>
<td></td>
</tr>
<tr>
<td>Colin, Yves</td>
<td>EV0031</td>
<td></td>
</tr>
<tr>
<td>Coll, Francesc</td>
<td>P1500</td>
<td></td>
</tr>
<tr>
<td>Coll, Pere</td>
<td>EV0426, P1167</td>
<td></td>
</tr>
<tr>
<td>Colado Ramacho, Antonio</td>
<td>Ramón</td>
<td>P0051</td>
</tr>
<tr>
<td>Collazes, Ana</td>
<td>P1633</td>
<td></td>
</tr>
<tr>
<td>Collier, Dami</td>
<td>P0052</td>
<td></td>
</tr>
<tr>
<td>Collignon, Anne</td>
<td>P0074</td>
<td></td>
</tr>
<tr>
<td>Collignon, Peter</td>
<td>P0062</td>
<td></td>
</tr>
<tr>
<td>Collin, Simon</td>
<td>P0054</td>
<td></td>
</tr>
<tr>
<td>Collin, Valerie</td>
<td>P1006</td>
<td></td>
</tr>
<tr>
<td>Collins, Andrea</td>
<td>EV0205</td>
<td></td>
</tr>
<tr>
<td>Collins, Tim</td>
<td>P0126</td>
<td></td>
</tr>
<tr>
<td>Collonier, Alexandre</td>
<td>EV0014</td>
<td></td>
</tr>
<tr>
<td>Colmenero Castillo, Juan de Dios</td>
<td>P0051</td>
<td></td>
</tr>
<tr>
<td>Colodner, R</td>
<td>EV0087</td>
<td></td>
</tr>
<tr>
<td>Colom, Gloria</td>
<td>P0050</td>
<td></td>
</tr>
<tr>
<td>Colombini, Paolo</td>
<td>P0272</td>
<td></td>
</tr>
<tr>
<td>Colombo, Filippo</td>
<td>EV0085</td>
<td></td>
</tr>
<tr>
<td>Colomer Roig, Ester</td>
<td>P0040</td>
<td></td>
</tr>
<tr>
<td>Colomer, Mari</td>
<td>EV0040</td>
<td></td>
</tr>
<tr>
<td>Colson, Philippe</td>
<td>P1053</td>
<td></td>
</tr>
<tr>
<td>Coltan, Gabriel</td>
<td>EV0049</td>
<td></td>
</tr>
<tr>
<td>Coltan, Tatiana</td>
<td>EV0499</td>
<td></td>
</tr>
<tr>
<td>Comandatore, Francesco</td>
<td>PV0688</td>
<td></td>
</tr>
<tr>
<td>Comandini, Alessandro</td>
<td>EV0055</td>
<td></td>
</tr>
<tr>
<td>Comas, iliaki</td>
<td>P0074, P0040</td>
<td></td>
</tr>
<tr>
<td>Combadere, Beahzine</td>
<td>P0082</td>
<td></td>
</tr>
<tr>
<td>Cornello, Florence</td>
<td>P1486</td>
<td></td>
</tr>
<tr>
<td>Cornelis, Ann Marie</td>
<td>EV0087</td>
<td></td>
</tr>
<tr>
<td>Commame, Marion</td>
<td>P0074</td>
<td></td>
</tr>
<tr>
<td>Commegne, Sabrina</td>
<td>EV0072, EV0018</td>
<td></td>
</tr>
<tr>
<td>Comoli, Patrizia</td>
<td>P0122</td>
<td></td>
</tr>
<tr>
<td>Comolli, Giuditta</td>
<td>EV0014</td>
<td></td>
</tr>
<tr>
<td>Compain, Fabricie</td>
<td>P0224, P1518</td>
<td></td>
</tr>
<tr>
<td>Compri, Monica</td>
<td>EV0062, EV0048, P1416</td>
<td></td>
</tr>
<tr>
<td>Complete, Béatrice</td>
<td>EV0066</td>
<td></td>
</tr>
<tr>
<td>Cona, Andrea</td>
<td>P1526</td>
<td></td>
</tr>
<tr>
<td>Conalidi, Pier Giuseppe</td>
<td>EV0043, P0074</td>
<td></td>
</tr>
<tr>
<td>Concepción, Carla</td>
<td>P0094</td>
<td></td>
</tr>
<tr>
<td>Concepción, Teresa</td>
<td>P0028, P0020</td>
<td></td>
</tr>
<tr>
<td>Conc, Eric</td>
<td>P0134, P0047, P1562</td>
<td></td>
</tr>
<tr>
<td>Coney, Anna</td>
<td>P1129</td>
<td></td>
</tr>
<tr>
<td>Conde, M. Carmen</td>
<td>EP0132, P0035, P0086, P1315</td>
<td></td>
</tr>
<tr>
<td>Conner, Anna</td>
<td>S157</td>
<td></td>
</tr>
<tr>
<td>Conforto, Mario</td>
<td>P0027</td>
<td></td>
</tr>
<tr>
<td>Cong Tri, Tran</td>
<td>P0015, P0018</td>
<td></td>
</tr>
<tr>
<td>Congiu, Claudia</td>
<td>P1444</td>
<td></td>
</tr>
<tr>
<td>Conil, Jean-Marie</td>
<td>EV0085</td>
<td></td>
</tr>
<tr>
<td>Connally, Sheila</td>
<td>P0075</td>
<td></td>
</tr>
<tr>
<td>Connally, Robin</td>
<td>P0092</td>
<td></td>
</tr>
<tr>
<td>Conner, Thomas</td>
<td>EP0020, P0236</td>
<td></td>
</tr>
<tr>
<td>Concia, Ericco</td>
<td>P0134, P0047, P1562</td>
<td></td>
</tr>
<tr>
<td>Conda, Anna</td>
<td>P1129</td>
<td></td>
</tr>
<tr>
<td>Conde, Josës</td>
<td>M. Carmen</td>
<td>EP0132, P0035, P0086, P1315</td>
</tr>
<tr>
<td>Conner, Anna</td>
<td>S157</td>
<td></td>
</tr>
<tr>
<td>Costa, Pieter</td>
<td>P0027</td>
<td></td>
</tr>
<tr>
<td>Costa, Tran</td>
<td>P0015, P0018</td>
<td></td>
</tr>
<tr>
<td>Costa, Gonzalo</td>
<td>S1444</td>
<td></td>
</tr>
<tr>
<td>Costa, Laura</td>
<td>P1115</td>
<td></td>
</tr>
<tr>
<td>Cooke, Graham</td>
<td>S392</td>
<td></td>
</tr>
<tr>
<td>Cookson, Barry</td>
<td>P0235, P0236</td>
<td></td>
</tr>
<tr>
<td>Coole, Louise</td>
<td>P0020</td>
<td></td>
</tr>
<tr>
<td>Cools, Piet</td>
<td>P0275</td>
<td></td>
</tr>
<tr>
<td>Cooper, Ben</td>
<td>P0230</td>
<td></td>
</tr>
<tr>
<td>Cooper, Ian</td>
<td>P0279, EV0011</td>
<td></td>
</tr>
<tr>
<td>Cooper, Matthew</td>
<td>EV0088, EV0061</td>
<td></td>
</tr>
<tr>
<td>Cooper, Paul</td>
<td>EP0076</td>
<td></td>
</tr>
<tr>
<td>Coorevits, Liselotte</td>
<td>EV0073, P0025</td>
<td></td>
</tr>
<tr>
<td>Coorsens, Jens</td>
<td>S1532</td>
<td></td>
</tr>
<tr>
<td>Coppelli, Alberto</td>
<td>P1489</td>
<td></td>
</tr>
<tr>
<td>Coppens, Jasmine</td>
<td>P0045, P0110</td>
<td></td>
</tr>
<tr>
<td>COPPO, Erika</td>
<td>P0079</td>
<td></td>
</tr>
<tr>
<td>Coppel, Poala</td>
<td>EV0056</td>
<td></td>
</tr>
<tr>
<td>Coppy, Maider</td>
<td>PV058</td>
<td></td>
</tr>
<tr>
<td>Coque, Teresa</td>
<td>EV0025, EV0055, P0057, P0086, P0061, P0065, P0066, P0067</td>
<td></td>
</tr>
<tr>
<td>Cordova, Alexander</td>
<td>P1462</td>
<td></td>
</tr>
<tr>
<td>Cordovano, Miriam</td>
<td>P0047</td>
<td></td>
</tr>
<tr>
<td>Cormican, Martin</td>
<td>EV0082, P0046, P0054</td>
<td></td>
</tr>
<tr>
<td>Cornaglia, Giuseppe</td>
<td>EV0003, EV0057, EV0061, P0039, P0050, P0051, P1345, S202</td>
<td></td>
</tr>
<tr>
<td>Cerque-Sánchez, Thais</td>
<td>P1184</td>
<td></td>
</tr>
<tr>
<td>Cornillien, Jan</td>
<td>P0226, P0047</td>
<td></td>
</tr>
<tr>
<td>Cornell, Oliver A</td>
<td>EV0010, P0034, P1340, P1559</td>
<td></td>
</tr>
<tr>
<td>Cornet, Muriel</td>
<td>EV0076</td>
<td></td>
</tr>
<tr>
<td>Cornish, Darren</td>
<td>P0080</td>
<td></td>
</tr>
<tr>
<td>Corru, Marjorie</td>
<td>P0134</td>
<td></td>
</tr>
<tr>
<td>Corrao, Tumena</td>
<td>S1564</td>
<td></td>
</tr>
<tr>
<td>Corsetti, Tiziana</td>
<td>P1208</td>
<td></td>
</tr>
<tr>
<td>Corso, Alexandra</td>
<td>EV0064, P0029, P0070</td>
<td></td>
</tr>
<tr>
<td>Corso, Gaia</td>
<td>P1284</td>
<td></td>
</tr>
<tr>
<td>Corsiglio, Paolo</td>
<td>P0074</td>
<td></td>
</tr>
<tr>
<td>Cortes, Claudia P</td>
<td>P1411</td>
<td></td>
</tr>
<tr>
<td>Cortes, Gloria</td>
<td>P1565</td>
<td></td>
</tr>
<tr>
<td>Cortes, Jorge</td>
<td>EV0087, P1566</td>
<td></td>
</tr>
<tr>
<td>Cortes, Valerio</td>
<td>P0047</td>
<td></td>
</tr>
<tr>
<td>Cortez, Joana</td>
<td>P1302, P1401</td>
<td></td>
</tr>
<tr>
<td>Corti, Natascia</td>
<td>P1197, P1236</td>
<td></td>
</tr>
<tr>
<td>Cortjens, Bart</td>
<td>P0145</td>
<td></td>
</tr>
<tr>
<td>Covaglia, Luigi Tommaso</td>
<td>EV0026</td>
<td></td>
</tr>
<tr>
<td>Corvec, Stéphane</td>
<td>P0019, P0053, P1543</td>
<td></td>
</tr>
<tr>
<td>Corzo León, Dora</td>
<td>EV0079</td>
<td></td>
</tr>
<tr>
<td>Corzo, Juan Enrique</td>
<td>P0087</td>
<td></td>
</tr>
<tr>
<td>Cosentino, Marina</td>
<td>P1045</td>
<td></td>
</tr>
<tr>
<td>Cosgaya Castro, Clara</td>
<td>EV0023</td>
<td></td>
</tr>
<tr>
<td>Cosserant, Bernard</td>
<td>P1124</td>
<td></td>
</tr>
<tr>
<td>Costa Pires, Maria Daniela</td>
<td>P1100</td>
<td></td>
</tr>
<tr>
<td>Costa, Cristina</td>
<td>EV0010, EV0051, EV0084</td>
<td></td>
</tr>
<tr>
<td>Costa, Damien</td>
<td>P0102, P0107</td>
<td></td>
</tr>
<tr>
<td>Costa, Eliana</td>
<td>P0071</td>
<td></td>
</tr>
<tr>
<td>Costa, Helena</td>
<td>EV0083</td>
<td></td>
</tr>
<tr>
<td>Costa, Jean-Marc</td>
<td>P1045, P1055</td>
<td></td>
</tr>
<tr>
<td>Costa, Marit</td>
<td>P0027</td>
<td></td>
</tr>
<tr>
<td>Costa, Silvia</td>
<td>EV0120, P0108</td>
<td></td>
</tr>
<tr>
<td>Costa, Sonya</td>
<td>EV0085</td>
<td></td>
</tr>
<tr>
<td>Costache, Marieta</td>
<td>EV0034</td>
<td></td>
</tr>
<tr>
<td>Costa-de-Gliveira, Sofia</td>
<td>P0072, P0046</td>
<td></td>
</tr>
<tr>
<td>Costantine, Gabriele</td>
<td>P0530</td>
<td></td>
</tr>
<tr>
<td>Costantini, Viviana</td>
<td>P0126</td>
<td></td>
</tr>
<tr>
<td>Costello, Sarah E</td>
<td>P0295</td>
<td></td>
</tr>
<tr>
<td>Costerus, Jost</td>
<td>P0026</td>
<td></td>
</tr>
</tbody>
</table>
List of Speakers and Authors F-G

Fortunato, Francesca EP0013
Fortunato, Simona P1126
Fortuño, Blanca EV0235
Forward, Philip P1279
Foschi, Claudio EV0262, PO420, PO421, P1576
Foschi, Federico O231, S522
Foster, Clayton EP0084
Foster, Nicholas EV0499
Foteinos, Charalampos PO518
Fothergill, Annette P1575
Fouks, Yuval EV0917
Foulet, Françoise EV0747, EV0679, PO537, PO372
Fournoulis, Kymon EV0790, PO711, PO723
Fourati, Slim PO038, PO625
Fourcade, Camille PO495
Fournier, Anne P1120
Fournier, Camille P1120
Fournier, Damien PO249
Fournier, Emmanuel PO072
Fournier, Isabelle PO289
Foussadegh, Ayres PO2067
Fowler, Vancel G. PO306, PO315
Fox, Laura PO444
Frazier, Anne PO101
Frazier, Vicente PO001, PO358
Frickham, Hajo EV0841
Friedlund, Jimmy PO124
Fridman, Ahuva PO624
Friedman, Diego PO0118
Friedman, Tail PO1142
Friedmann, Yasmim PO599
Friedrich, Alexander W. PO31, PO102, PO219, PO221, PO308, PO227, PO558, PO558, PO64, PO667, PO670, PO791, P1029, PO627, P1034
Friesema, Ingrid PO558
Friss-Moller, Alice PO196
Friss-Moller, Nina PO863
Frolova, Irina PO785, PO361
Ganbaatar, Baldan PO076
Ganaie, Feroze PO213, PO970
Gamvrouli, Maria PO782
Gammelsrud, Karianne Wiger PO783
Gambero Gaspar, Gilberto PO461
Gambell, Doaa PO391, PO695
Galyfos, George PO226
Gálvez-Acebal, Juan PO610, P1154
Gálvez, Aurelia EV0235, EV0251, EV0410, P1657
Gálvez-Sánchez, Fatima PO1128
Gallegos, Carolina PO230
Gallegos, Iria PO184
Gallegos, María Teresa PO960
Galea, Stéphane PO610, PO266
Galleani, Antonia PO955
Galín, Jean-Philippe PO129
Gallego, Daniel PO840
Gallego, Ester PO121
Gallego, Lucia PO280
Gallegos, Carmen PO203
Galbert, Herbert PO651, P1503
Galli, Luisa PO200
Galli, Massimo PO047, PO501
Galli, Silvia PO1416
Gallo, Maria Teresa PO690
Gallou, Jean PO441, PO424
Gallot, Gérald PO351
Galtier, Florence PO1386
Gálvez Contreras, Maria Carmen PO051
Gálvez, Eva Maria PO159, P1628
Gálvez-Acebal, Juan PO482, PO610, P1154
Galfyos, George PO0265
Gama, Doaa PO391, P1695
Gamaletou, Maria PO656, PO915
Gambero Gaspar, Gilberto PO1461
Gamboa, Dionicia PO265, PO802
Gammelsrud, Karianne Wiger PO783
Ganmou, Maria PO982
Ganai, Feroze PO213, P0970
Garbaatar, Baldan PO076
Garassagui, Javier PO801
Gardos, Jean-Marc PO422
Gargiulà, Jean Pierre PO132, P1580
Gasbeek, André PO471
Gab Allah Ibrahim, Ahmed PO777
Gabor, Tati EV0981
Gabrielli, Liliana PO0207, PO1022
Gabrielis, Christina PO0884, PO908
Gabrjelksi, Lior PO341
Gachot, Bertrand PO988
Gadea Gironés, Ignacio PO092, P1473
Gadzalksi, Marek PO1637
Gaeta, Aurelia PO1118
Gaggiotti, Paula PO634
Gagnaire, Julie PO1055
Gagnard, Jean-Charles PO988
Gagnex, Sebastien PO420
Gagnon, Bruno PO827
Gagné, Inca PO296
Gai, Olivier PO429
Galañian, Daniel PO785
Galan Ladero, Maria Ángeles PO312
Galan Ladero, Maria Ángeles PO292
Galan, Juan Carlos PO127, P1398
Galani, Irene PO440, PO466
Galanis, Ilias PO2027
Galan-Sánchez, Fatima PO1179
Galan, Alicia PO229, PO355, PO370, P1652
Galati, Luisa PO0902
Galaverna, Federica PO122
Gale, Stéphanie PO933
Galeno, Carlos PO022
Gales, Ana PO444, PO515
Galia, Liliana PO1345
Gallina, Carlos PO955
Galinier, Jean-Louis PO306
Gallego, Daniel PO840
Gallego, Ester PO121
Gallego, Iria PO1784
Gallego, Lucía PO261
Gallegos, Carmen PO203
Galler, Herbert PO651, P1503
Galli, Luisa PO200
Galli, Massimo PO047, PO501
Galli, Silvia PO1416
Gallo, Maria Teresa PO690
Gallo, Stephanie PO610, PO266
Gallou, Jenny PO441, PO424
Galotzan, Gennady PO351
Galtier, Florence PO1386
Gálvez Contreras, María Carmen PO051
Gálvez, Eva María PO159, P1628
Gálvez-Acebal, Juan PO482, PO610, P1154
Galfyos, George PO0265
Gama, Doaa PO391, P1695
Gamaletou, Maria PO656, PO915
Gambero Gaspar, Gilberto PO1461
Gamboa, Dionicia PO265, PO802
Gammelsrud, Karianne Wiger PO783
Ganmou, Maria PO982
Ganai, Feroze PO213, P0970
Garbaatar, Baldan PO076
Garassagui, Javier PO801
Gardos, Jean-Marc PO422
Gargiulà, Jean Pierre PO132, P1580
Ganidou, Maria PO050
List of Speakers and Authors G
List of Speakers and Authors I-J

[List of speakers and authors from Izzo to Janjai, including their affiliations and roles at ECCMID 2016.]

Final Programme 26th ECCMID, Amsterdam, Netherlands, 2016

J

J. K.innanni, Teemu E0603, P1694, P1702
Jaama, Kadi G0563
Jack, Alison E0047, E0067
Jackson, Jami E0026
Jackson, Karen E0883
Jackson, Yves E0831
Jacobs, Frédérique D025, D052, D044
Jacobs, Jan O310
Jacobs, Peter O206, O2070
Jacobsen, Gunnar E0688
Jaccobsen, Susanne E0201
Jacotol, Anne P0974
Jacomet, Christine P0088
Jacquet, Caroline E0255
Jacquier, Herve P0975, P1543, P0520, P0524
Jaen, Angelis P1483
Jaen, Felissa P0662
Jaffe, Charles P1686
Jaffe, Joseph P0987
Jafari, Hassan S. E0663, O335
Jäger, Maren P1114
Jager, Mischa E0456, P0575
Jagelski, Tomas E0209, P1637
Jagljakoski, Branko E0245
Jah, Hanawatan O144, P0093
Jahaj, Ehsan E0151
Jahn, Silke P1505
Jahoda, David E0497
Jais, Jean-Philippe O444
Jaij, Ires P0494
Jajk, Mina E0724
Jal, Mohamad Boie O144, P0093
Jalam, Wafa E0423, P0683
Jama, Azadeh P1625, P1631
Jamal, Reza E0033, P1227
Jamieson, Brian E0137, P1338
Jamieson, Connor P1297
Jammot, Alexandre E0316, P0845
Jan, Aurélien P1362
Jana, Bimal P0194, P1276
Janczorek, Wolfgang E0123, E0693, P1227
Jansen, Peter Østrup EP0068
Jenkinson, Stephen E0663
Jensen, Anders P1179
Jensen, Bent Ø2681
Jensen, Jørgen Skov M346, P0926
Jensen, Kathyrn E0663
Jensen, Peter Østrup E0068
Jensen, Rasmus Hare E0002, D1277, E0369
Jenner, Stephen E0663
Jenner, Théodore E0663
Jenner, Vladimir E0663
Jenner, Vincent E0663
Jenner, Wolf E0663
Jenner, Yoann E0663
Jenner, Young E0663
Jenner, Yuji E0663
Jeremiah, Natasha E0286
Jesuis, Ruiz E0606
Jeter, Marion E0087, P0957
Jeverica, Sano EP0301, P0682, P0686, P0923
Jex, Aaron E0602
Jeyagaraman, Dakshin P0505
Jeyaraseel, Visali O316, P0498
Jezek, Peter P1088
List of Speakers and Authors J-K

<table>
<thead>
<tr>
<th>Name</th>
<th>Code</th>
<th>Year</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jones-Dias, Daniela</td>
<td>EP0397, P0070, P0073</td>
<td></td>
</tr>
<tr>
<td>Jongrúa, Núria</td>
<td>P0139</td>
<td></td>
</tr>
<tr>
<td>Jongwutiwes, Ubornan</td>
<td>P1785</td>
<td></td>
</tr>
<tr>
<td>Joopt, Insa P0148</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Jordan, Lilya, Elena</td>
<td>P0079</td>
<td></td>
</tr>
<tr>
<td>Jordano, Duarte</td>
<td>P1483</td>
<td></td>
</tr>
<tr>
<td>Jorens, Philippe</td>
<td>P0600, P1742</td>
<td></td>
</tr>
<tr>
<td>Jürg, Nitschke</td>
<td>P1013</td>
<td></td>
</tr>
<tr>
<td>Jorge, Arel P0429</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Jörgens, Karin Meinike</td>
<td>EV0301</td>
<td></td>
</tr>
<tr>
<td>Jörgens, J. O.</td>
<td>EP0061</td>
<td></td>
</tr>
<tr>
<td>Jose, Eva P0591</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Jose, Maria EV0987</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Joseph, Mercy P0097</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Joseph, Rafael EV0524</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Josh, Shruil P0905</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Jost, Claudia O1468</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Jost, Geraldine EV0574</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Jost, Matthias EV0104, EV0106</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Jouv, Daniela 0147</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Joubert, Stéphanie EV0696</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Joublé, Caroline EV0536</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Jouneau, Stéphane P1386</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Jouisset, Agnès P0925, P0952</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Jousten, Svi P0281</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Jouvion, Gregory P0366</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Jovanovic, Petra P0114</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Joven, Jorge P1462</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Jover, Saénz Alfredo P0057</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Jover, Francisca EV0217</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Jogeux, Florence P0821</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Juan, Carlos, P1757, P1759</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Juegns, Christine P0990</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Juffermans, Nicole EP0112, P1244, P1396</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Juhász, Ernse P1622</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Juhász, Hajnalika EV0923</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Juiz González, Pedro Miguel EP0165</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Junckerstorff, Ralph EP0118</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Jung, Ok, Kim EV0333, P0663</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Jung, Annette P0007</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Jung, Chae Won P1407</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Jung, Hyun-Sil EV0249</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Jung, Julia EV0198</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Jung, Sook In P0029, P1205</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Junghans, Thomas 0324</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Junjungwirth, Andreas P1094</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Junie, Lia Monica EV0986</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Junghanss, Thomas O324</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Junjungwirth, Andreas P1094</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Junie, Lia Monica EV0986</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Junger, Roland P0960</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Jurke, Annette EV0832, P1034</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Justesen, Ulrik Stenz EV0415, P0680, P0681, P0684, P0809</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Juul, Hedvig P0118</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Juvín, Marie-Emmanuelle P0198, P0626</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

K

<table>
<thead>
<tr>
<th>Name</th>
<th>Code</th>
<th>Year</th>
</tr>
</thead>
<tbody>
<tr>
<td>K awakening</td>
<td></td>
<td></td>
</tr>
<tr>
<td>K, Eklund, Kari EP0365, P1694</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kaak, Michael EP0004</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kaasch, Achim P0484</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kaase, Martin EP0187, EV0419, EV0425, P0256, P0326, P0303, P0464, P1523</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kabatova, Jarmla EV0407</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kabeta, Mohammed P0205</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kabir, Muhammad Hmaunam EP0312, P0953</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kabra, Vassanti EV0406</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kacan, Turgut P0260</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kachanka, Alena EV0195</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kachaninoudou, Melina P1560</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kaci, Rachid P0524</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kadahalli Linggewdala, Ravikumar EP0213, P0970</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kadár, Béla O238</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kadhan, Tokozani P0700</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kadi, Esma EP0701</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kadižglo, Paschalis P1384</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kadioglu, Hakan Hadi P1141</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kadelic, Kristina O1241</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kaepp, Klaus-Peter P1081</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kaesbohrer, Annemarie EP0442, EP0447, P1505</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kafantogia, Konstantina EV0448</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kafasi, Afnasiana P0403</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kafitakis, Magnus P1193</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kafaltzizeva, Ana P0644</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kagalou, Georgi P1560</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kali, Barbara P0702, P1222</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kalmeter, Gunnar EP03, EV0114, P0804, P0805, P0823, P0824, P0825, P0826, P0850, SS66</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kaldashev, Ig E0645</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kailow, Anne EV0309</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kaindl, Thomas O1424</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kaiser, Julie P0156</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kaiser, Laurent EP0851</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kaiser, Rolf P0057</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kakikou, Anastasia EV0448</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kakouris, Georgios EV0784</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kaku, Mitsuju EP0991</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kalai, Wissal EV0560</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kalantarov, Gazdzhiala EV0949</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kalajjian, Robert O286</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kalchanaova, Natalia EV0965</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kalid, John EP0281</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kaliko, Michael EP0175</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kalfajian, Neree EV0673</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kalimash, Jehona P0413</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kalimuddin, Shirin P173</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kalinina, Olg EV0052</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kalinogorskaya, Olga P0184</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kalinowski, Jörn P1703</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kalisik, Sean EV0255</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kalita, Joanna P1637</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kalkan, Abir 039 EV0531</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kalkanci, Ay EV0379</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kalkman, Gino D465</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kallas, Evel EP0223</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kallen, Marlon D297</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kallestrup, Per P1672</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kallen, Teemu EV0083, P0247</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kalmantaeva, Olga EV0248</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kalogeropoulou, Elena P0949, P1663</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kalpern, Malka P1002</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kaloford, Barbara P0161, P0453</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kaluza, Khumbo EP0274, P1685</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kamal, Sherif EV0777</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kamali, Amin EV0821</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kamans, Wendy P1747</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kamara, TB P0092</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kamarios, Spyros P0538</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kamel, Layada EV0538</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kamenska, Nina P1524</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kamerezan, Crina EV0636</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kammoun, Atef EV0560</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kamtsi, Katalin O228</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kampsergionizi, Maria EV0808</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kampers, Greetje P262, P0652</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kampshreur, Linda D393, P0544</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kamran, Rubina P0158</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kanagawa, Shuzo EP0270</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kandilli, Anthousa P0550</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kan, Philip EP0144</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kanellopoulos, Petros EP0090, EP0091, EV0858, EV0863, P0385</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kang, Cheol-In EP0489</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kang, Cheol-In EP0489</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kang, Cheol-In P0489</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kang, Cheol-In P0489</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kang, Cheol-In P0489</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kang, Cheol-In P0489</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kang, Cheol-In P0489</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kang, Cheol-In P0489</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
List of Speakers and Authors A

26th ECCMID, Amsterdam, Netherlands, 2016
List of Speakers and Authors

Park, Kyung Sun EV0344
Park, Kyung-Hwa P0029, P1205, P1392
Park, So Young EV0333, P0663
Park, Soon Chang EV0086
Park, Yoon-Joon P0848
Pávková, Zdeněk EP0014
Parker, Christine P1070
Parker, Craig EV0568
Parfak, Ali Haydar P1448
Parlak, Emine EV0059
Parreira, Pierre O604
Parodi, Aurora P0116
Parolin, Carolin Eleonora P0420
Paroni, Roberto P1020
Parovícnikova, Elena EV0984, P0351, P0360, P1574, P1590
Pari, Tom O528
Parra Giraldo, Claudia Marcela P1656
Parra Grande, Monica EV0123, P1621
Parra, Patricia O447, P0366, P1767
Parra, Pedro EV0179
Parri, Giustino O267, P0467
Parr, C.M. P0352
Partouche, Camille EP0150
Partouche, Henri EP0376
Parvizi, Vinoodh P0278
Patz, Pierre P0395, P1215
Patijn, Gijs A. P1213
Pathan, Rashid Khan EP0265
Passweg, Jakob EV0399
Pastukh, Nina EV0883, P1002
Pastor, María Dolores P0186
Pastor, María Dolores EV0123
Pastor, María Dolores P1621
Pasquier, Jérôme EV0150
Pasquerazzi, Caterina EP0199
Pasquau, Juan EV0414, O152
Pasquazzini, Caterina P1419
Pasquet, Amelle EP0150
Pasquinet, dossier EP0150
Pasquinet, Giannandrea EV0609
Passweg, Jakob EV0610, O136, P1059
Pastieran, Fernando EV0634, P0293, P0710
Pastor, María Dolores O0186
Pastukh, Nina EV0883, P1002
Patane, Salvatore P0108
Patiarn-Sampo, Anu EV0494, O296
Patel, Bharat P1037
Patel, Denise P0053
Patel, Dipen A P193
Patel, Hina P0342, P0343
Patel, Mahesh EV0006, EV0631, P1245, P1259, P1264, P1266
Patel, Mauli P0597
Patel, Meera EV0414
Patel, Mohak EV0212
Patel, Minshu EV0008, P0268, P0012, P0016
Patel, Rakesh EV0005
Paterson, David L. EP0051, D119, O587, P0492, P0732, S329, S127
Paterson, Gavin EV0399
Paterson, Lauren EV0399
Pathan, Rashidkhan EV0347, O449, P0900
Patijn, J.P. P1137
Patino-Barbosa, Andredes Mauricio P148, P0352
Pata, Caterina EP0101
Patoz, Pierre P0395, P1215
Patra, Kalash P. EP0265
Patrani, Maria P1309
Patrani, Maria O288
Patrick, Sheila E074
Patrick, Andrea P1217
Patrick, Andrea O1345
Paul, John EP0045, O450
Paul, Kasriel EV0133
Paul, Mcal O312, P1475, P1476, S110, EV0120, P0504
Paul, Nandini EP0005
Paula Rosa Ignácio, Ana Cláudia P1152
Paulino da Silva, Adriana P0353
Paulmam, Dorte P0582, P0929
Paulussen, Aimee D.C. P0032, P0033
Paunovic, Radica P0007
Pauw, Christine P0484
Pauw, David EV0917
Pavan, Rhea O133
Pavesic, Patricia EV0215, EV0756
Pavia, Andrea EP0110, EP0216
Pavia, Charles P1455
Pavia, Claudia EV0122, EP0207
Pavlak, Maria O365
Pavlickova, Silvie P1366
Pavlovskaja, Olga P1555
Pavli, Jiri P0700
Pawelczyk, Lieszka EV0229
Pawelsky, Jean-Michel P0038
Paget, Audrey EV0359
Page, Susan EV0407
Pajunggoen, Charnchai EV0046, EV0563, EV0564, P1422
Paz Vidal, Isabel EP0165
Paz, Silvia P1594
Pechlin, Ivan P1620
Peacock, Sharon EP0082, P0247, P1050
Pecanha, Paulo EV0783
Peck, Kang Hay P1406, P0489
Pecorari, Monica P1429
Pedersen, Court EV0183
Pedersen, Rune P0597
Pedersen, Torunn P0661, P0672, S357
Pedrosa Fernández, Yañet EV0467, P0662, P0665, P0766
Pedro-Botet, Luisa EV0099, O194
Pedro, Alison EV0036
Pedrini, Silvia EV0201
Pedroni, Silvia EV0201
Pérez-Artiaga, Luna EV0173
Pérez-Argüello, Amaresh P0304
Pérez, Miguel P0446, EV0492
Pérez, Sonia EV0074
Pérez-Arquillo, Ammehi P0304
Pérez-Artiaga, Luna EV0624, EV0625, EV0776, EV0932
Pérez, Diego P0229
Pérez, Diego P0228
Pérez-Argüello, Amaresh P0304
Pérez-Artiaga, Luna EV0624, EV0625, EV0776
Pérez-Borrero, Lourdes EV0173
Pérez-Elías, M.J. EV0220, P1417
Pérez-Elías, M.J. EV0220
Pérez-Garcia, Alejandro P0274
Pérez-Garcia, Ana P1025, P1027
Pérez-Garcia, Felipe P0337, P0350
Pérez-Granda, Mario Jesús EV0069, P0380, P0387,
List of Speakers and Authors

P0345, P1047, P1039, P1034, P1035, P1036, P1037, P1038, P1039, P1040, P1041, P1042, P1043, P1044, P1045, P1046

Sanidag, Tamer EV0040
Sannikova, Irina P0049
Santacaterina, Erica EV0218, EV0275, P0214
Santayana, Maria P0144
Santangelo, Rosaria P0109
Santinelli, Walter EV0248
Sanianirand, Ptak EV0552, P0837
Sante, Laura EV0467
Santerre Henriksen, Anne P025, P1343
Santilli, Elena O591
Santillo, Mark EV0641
Santin, Juliana P0912
Santin, Miguel P0260
Santori, Marta EV0140
Santoro, Antonella EP0159
Santoro, Domenico P0274
Santos Branco, Daniela P1777
Santos Costa, Sofia P0530
Santos Sanchez, Ilda P1778
Santos, Ilda P0295
Santos, Isabel P0202
Santos, Alexine EV0100
Santos, Aline EV0823
Santos, Ana Sofia EV0012, P0018
Santos, Andrea EP0170
Santos, Carla EV0908
Santos, Jazmin P0261
Santos, Juan Luis EV0214
Santos, Lurdess EV0012, O371, P0018
Santos, Ricardo P0439
Santos, Silva P1200, P1241
Santos, Silvia P0745, P0746
Santos, Nina P0571
Santos, Santhanieng, Dewi EV0321, EV0322
Santos-Lopez, Alfonso P0652, P0772
Santosaningsih, Dewi EV0321, EV0322
Santos, Isabel P0018
Santos, Juan Luis EV0714
Santos, Jazmin P0242
Santos, Mark P0641
Santos, Ana Sofia EV0012, P0018
Santos, Andrea EP0170
Santos, Carla EV0908
Santos, Jazmin P0261
Santos, Juan Luis EV0214
Santos, Lurdess EV0012, O371, P0018
Santos, Ricardo P0439
Santos, Silva P1200, P1241
Santos, Silvia P0745, P0746
Santos, Nina P0571
Santos, Santhanieng, Dewi EV0321, EV0322
Santos-Lopez, Alfonso P0652, P0772
Santos-Silva, André P0717, P1665
Santos-Lopez, Alfonso P0652, P0772
Santosaningsih, Dewi EV0321, EV0322
Santos, Isabel P0018
Santos, Juan Luis EV0714
Santos, Jazmin P0242
List of Speakers and Authors

Stadnik, Claudio P1777
Staedel, Cathy EP0039
Staffolani, Silvia EP0152, P1676
Stahl, Jean Paul EV0215, 0261, P0510
Stahl, Jean Paul P1169
Stahl, Julie EV0937
Stalenhoef, Janneke E. 0471
Stallmach, Andreas P1099
Stalons, Don P0838
Stalowsky Poglajen, Barbara EV0544
Stalpa, Jitka P0059
Stals, Frans P0429
Stalsby Lundborg, Cecilia EV0674, P1304, P1305
Stalter, Collen EV0679
Stalter, Patrick P1949
Stamboulian, Daniel EP0018
Stamouli, Ioanna P1698
Stamouli, Vasiliki EV0911
Stan, Gabriela EP0064
Stanek, Maciej P0278
Stange, Mirjam EV0584
Stangl, Elisabeth EV0297
Stancic, Helga EV0297, P1074
Stancic, Mirjana EP0026, 0599, P1291, P1294, P1328
Stano, Pasquale P1133
Stananton, Ian 0417
Stares, Mark EP0200
Stark, Damien EV0507
Starkova, Daria EV0052
Starzengruber, Patrick P1153
Stavropoulou, Anastasia EV0529
Stavnsbjerg, Camilla P0277
Stead, A. EV0544, P1023
Steadman, Yvonne P1711
Steel, Eva O226
Steenbergen, Judith P1325
Steenbergen, Joachim EV0592
Steenbergen, Joachim EV0592
Steen, Andreas EP0201
Stefos, Angelos O365
Stefanuto, Riccardo P1291
Stefanowa, Petya EV0435, P0332, P0333, P0334, P0399
Stengele, Anja P1517
Stegeman, Coen A. O575
Stegeman, Arjan P1517
Stegbauer, Bettina P0007
Stegmayer, Mareike P1291
Stein, Michal P0889
Stein, Michael EP0019
Steinacker, Ulrike EV0328
Steinbach, Martin P0329
Steiner, Ted P1115
Steinhagen, Katja EP0261, P0562
Steinmann, Joerg P0269, P1708
Stellani, Fabio P1255
Stellini, Roberto EV0154, 0222
Stender, Sonja EV0664
Stensvold, Christen Rune E005, EP0263, EV0936, P0569, P1074
Stepanova, Darja P1009
Stephan, Anja P0054
Stephan, Anja P0054
Stephan, Marie P0289
Stephanie, Rapin P0555
Stephen, John P1003
Stephens, Jennifer P1593
Stephenson, James P1631
Sterberg, Anja P0054
Sterkenburg, Naomi EP0273
Sterkers, Olivier P0985
Stern, Jean-Baptiste P333
Sterlini,
<table>
<thead>
<tr>
<th>Name</th>
<th>Affiliation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Timke, Markus</td>
<td>P0066</td>
</tr>
<tr>
<td>Timm, Karen</td>
<td>EP0289</td>
</tr>
<tr>
<td>Timmer, Marlies</td>
<td>P042</td>
</tr>
<tr>
<td>Timmeister, Arjen J.</td>
<td>P1517</td>
</tr>
<tr>
<td>Timmofenik, Xenia</td>
<td>P0548</td>
</tr>
<tr>
<td>Timnit, Jean-François</td>
<td>EV0526, P0333, P1580</td>
</tr>
<tr>
<td>Timurkan, Mehmet</td>
<td>Ozkan EV0094, P1425</td>
</tr>
<tr>
<td>Timvaskas, Pavlina</td>
<td>P0367</td>
</tr>
<tr>
<td>Tinelli, Marco</td>
<td>EV0933, P1056</td>
</tr>
<tr>
<td>Tinguely, Regula</td>
<td>P061</td>
</tr>
<tr>
<td>Tinti, Francesca</td>
<td>P029</td>
</tr>
<tr>
<td>Tinto, Daniel</td>
<td>EV0329</td>
</tr>
<tr>
<td>Tipping, Robert</td>
<td>EP0126, P1341</td>
</tr>
<tr>
<td>Tirchi, Haget</td>
<td>EV0934</td>
</tr>
<tr>
<td>Tirczka, Tamás</td>
<td>EP0014, EP0164, P0176</td>
</tr>
<tr>
<td>Tirindelli, Mariacristina</td>
<td>P0112</td>
</tr>
<tr>
<td>Tisoe, Giusy</td>
<td>P1564</td>
</tr>
<tr>
<td>Tisi, Mara</td>
<td>P1206</td>
</tr>
<tr>
<td>Tissiano, Gabre</td>
<td>EV0830</td>
</tr>
<tr>
<td>Tissot, Frederic</td>
<td>EP0066</td>
</tr>
<tr>
<td>Titani, Paola</td>
<td>P1682</td>
</tr>
<tr>
<td>Titeca, Marie</td>
<td>EP0141</td>
</tr>
<tr>
<td>Tittarelli, Manuela</td>
<td>EV0510</td>
</tr>
<tr>
<td>Tjernberg, Ivar</td>
<td>EP0306</td>
</tr>
<tr>
<td>Tjihio, Joyce</td>
<td>P0830, P0831</td>
</tr>
<tr>
<td>Tija, Jennifer</td>
<td>P1107</td>
</tr>
<tr>
<td>Tjon-A-Tsien, Aimée M.</td>
<td>P1057</td>
</tr>
<tr>
<td>Tkachenko, Evgenij</td>
<td>P0192</td>
</tr>
<tr>
<td>Tkadlec, Jan</td>
<td>EV0497</td>
</tr>
<tr>
<td>Tkanhkwo, Linda</td>
<td>EV0883</td>
</tr>
<tr>
<td>Tikhiaisshili, Tatia</td>
<td>P1704</td>
</tr>
<tr>
<td>Tijani, Asma</td>
<td>P0756</td>
</tr>
<tr>
<td>Tobudic, Selma</td>
<td>EP0252, P1617</td>
</tr>
<tr>
<td>Todd, Alison</td>
<td>EV0547</td>
</tr>
<tr>
<td>Todhunter, Sharie</td>
<td>P1324</td>
</tr>
<tr>
<td>Todor, Nicolae</td>
<td>P0609, P1160</td>
</tr>
<tr>
<td>Todorova, Bozhana</td>
<td>P0716</td>
</tr>
<tr>
<td>Toft, Annette</td>
<td>P1192</td>
</tr>
<tr>
<td>Tognon, Mauro</td>
<td>EV0613</td>
</tr>
<tr>
<td>Tognik, Mikael</td>
<td>EP0204</td>
</tr>
<tr>
<td>Togola, Anne</td>
<td>P0166</td>
</tr>
<tr>
<td>Toivola, Hanna</td>
<td>EV0112</td>
</tr>
<tr>
<td>Tokumoto, Akiko</td>
<td>EV0443</td>
</tr>
<tr>
<td>Toleman, Mark</td>
<td>P0310</td>
</tr>
<tr>
<td>Tolfo, Neidimar</td>
<td>P0912, P1751</td>
</tr>
<tr>
<td>Tolczko, Justyna</td>
<td>P0468</td>
</tr>
<tr>
<td>Tooleo, Ali</td>
<td>P1611</td>
</tr>
<tr>
<td>Tolosana, José</td>
<td>P0438, P1147</td>
</tr>
<tr>
<td>Toma, Luigi</td>
<td>EV0960</td>
</tr>
<tr>
<td>Tomarchio, Valeria</td>
<td>P0112</td>
</tr>
<tr>
<td>Tomasseli, Sharon</td>
<td>P1257</td>
</tr>
<tr>
<td>Tomaz, Mariavera</td>
<td>EV0909</td>
</tr>
<tr>
<td>Tomazin, Rok</td>
<td>P1639</td>
</tr>
<tr>
<td>Tomczak, Magdalena</td>
<td>EV0517, P0191</td>
</tr>
<tr>
<td>Tomèi, Enora</td>
<td>P0126</td>
</tr>
<tr>
<td>Tomic, Spirci</td>
<td>Vesna P0368, EV072</td>
</tr>
<tr>
<td>Tomic, Viktorija</td>
<td>P0600, P0199</td>
</tr>
<tr>
<td>Tommasini, Tiziana</td>
<td>EV0572, P0214</td>
</tr>
<tr>
<td>Tomsiusiak, Anna</td>
<td>EV0242</td>
</tr>
<tr>
<td>Tong, Kristy</td>
<td>P0457</td>
</tr>
<tr>
<td>Tonglani, Serena</td>
<td>P1278, P1281, P1284</td>
</tr>
<tr>
<td>Tonaldi, Carolina</td>
<td>P0353</td>
</tr>
<tr>
<td>Tonali, Paula de Abreu</td>
<td>P0911</td>
</tr>
<tr>
<td>Tonum, Tine</td>
<td>EV0057</td>
</tr>
<tr>
<td>Tonik, Marija</td>
<td>EV0900</td>
</tr>
<tr>
<td>Tontodonati, Monica</td>
<td>P0467</td>
</tr>
<tr>
<td>Topal, Betul</td>
<td>EV0201</td>
</tr>
<tr>
<td>Tópan, Adriana Víla</td>
<td>P1160</td>
</tr>
<tr>
<td>Topcuoglu, Pervin</td>
<td>EV0728</td>
</tr>
<tr>
<td>Toracao, Peraza</td>
<td>Gilda EV0255</td>
</tr>
<tr>
<td>Tordoga, Titchoha</td>
<td>Ígberto J. EV056, EV0134, P1629, EV066, EV0135</td>
</tr>
<tr>
<td>Torelli, Lucio</td>
<td>P1527</td>
</tr>
<tr>
<td>Tornoss, PEV0101</td>
<td></td>
</tr>
<tr>
<td>Torik, M. Esteé</td>
<td>P0247, P1050</td>
</tr>
<tr>
<td>Toropainen, Maija</td>
<td>P1286, P1161</td>
</tr>
<tr>
<td>Toropova, Inessa</td>
<td>P1574, P1590</td>
</tr>
<tr>
<td>Torpy, Ethan Daniel</td>
<td>EV0085</td>
</tr>
<tr>
<td>Torquato Salles Buscione</td>
<td>Fernanda P1075</td>
</tr>
<tr>
<td>Torrani Cerenizia</td>
<td>Maria P0312</td>
</tr>
<tr>
<td>Torre Cisneros, Julián</td>
<td>Carlos O119, P0263</td>
</tr>
<tr>
<td>Torre-Giménez, Álvaro</td>
<td>P0263</td>
</tr>
<tr>
<td>Torrella, Teresa</td>
<td>P0120</td>
</tr>
<tr>
<td>Torres, Gabriel</td>
<td>P0335, P1752, P1759</td>
</tr>
<tr>
<td>Torres, Eduard</td>
<td>EV0567</td>
</tr>
<tr>
<td>Torres Fajardo, Katherine</td>
<td>EV0025, EV0802</td>
</tr>
<tr>
<td>Torres Landivar, Victor</td>
<td>P1629</td>
</tr>
<tr>
<td>Torres Martos, Eva Maria</td>
<td>P0552</td>
</tr>
<tr>
<td>Torres Serrano, Rodolfo</td>
<td>EV0887</td>
</tr>
<tr>
<td>Torres, André</td>
<td>P1415</td>
</tr>
<tr>
<td>Torres, Antonio</td>
<td>P0288, P0760, P1240, P1309, P1313</td>
</tr>
<tr>
<td>Torres, Carmen</td>
<td>P0219, P0659, P1514, P1521</td>
</tr>
<tr>
<td>Torres, Eva</td>
<td>P0807</td>
</tr>
<tr>
<td>Torres, Eva</td>
<td>P0317</td>
</tr>
<tr>
<td>Torres, Victor</td>
<td>EP0031</td>
</tr>
<tr>
<td>Torres-Sánchez, María José</td>
<td>EV0760, P0361</td>
</tr>
<tr>
<td>Torri, Stefania</td>
<td>P0272</td>
</tr>
<tr>
<td>Torta, Ilaria</td>
<td>P0099</td>
</tr>
<tr>
<td>Toscano, Cristina</td>
<td>EP0170</td>
</tr>
<tr>
<td>Totic, T.</td>
<td>P0115</td>
</tr>
<tr>
<td>Tosti, Maria Elena</td>
<td>P1424</td>
</tr>
<tr>
<td>Tostmann, Alma</td>
<td>P0619</td>
</tr>
<tr>
<td>Toter, Anne</td>
<td>P0367</td>
</tr>
<tr>
<td>Tóth, Ákos</td>
<td>P0276, P0245</td>
</tr>
<tr>
<td>Töthpál, Adrienn</td>
<td>EP0145</td>
</tr>
<tr>
<td>Totsikas, Charisís</td>
<td>EV0377</td>
</tr>
<tr>
<td>Totty, Heather</td>
<td>EV0459</td>
</tr>
<tr>
<td>Touah, Gerald</td>
<td>EV0286</td>
</tr>
<tr>
<td>Touati, Caroline</td>
<td>P1480</td>
</tr>
<tr>
<td>Touilane, Julie</td>
<td>P1382</td>
</tr>
<tr>
<td>Touilane, Sophie</td>
<td>P0535</td>
</tr>
<tr>
<td>Touchon, Marie</td>
<td>P0104</td>
</tr>
<tr>
<td>Tougeron, David</td>
<td>P0918</td>
</tr>
<tr>
<td>Touli, Nadia</td>
<td>EV0080, P0899</td>
</tr>
<tr>
<td>Toulemende, Julien</td>
<td>P0525</td>
</tr>
<tr>
<td>Toumi, Adrienne</td>
<td>P0035</td>
</tr>
<tr>
<td>Toupet, Gaelle</td>
<td>P0333</td>
</tr>
<tr>
<td>Touvenneau, Sylvie</td>
<td>EV0096, P1116</td>
</tr>
<tr>
<td>Touw, Daan</td>
<td>P1159</td>
</tr>
<tr>
<td>Touze, Antoine</td>
<td>P0576</td>
</tr>
<tr>
<td>Town, Kat</td>
<td>P0430, P0433</td>
</tr>
<tr>
<td>Townsend, Robert</td>
<td>P0452, P1522</td>
</tr>
<tr>
<td>Touyama, Masaaki</td>
<td>P1420</td>
</tr>
<tr>
<td>Touyama, Noriko</td>
<td>P0909</td>
</tr>
<tr>
<td>Touyakawa, Takao</td>
<td>P0090</td>
</tr>
<tr>
<td>Töz, Seraj</td>
<td>EV0511, P1166, EV0256</td>
</tr>
<tr>
<td>Tozzi, Alberto Eugenio</td>
<td>S361</td>
</tr>
<tr>
<td>Trabelsi, Becem</td>
<td>EV0352</td>
</tr>
<tr>
<td>Trabelsi, Ijen</td>
<td>EV0057</td>
</tr>
<tr>
<td>Traczewski, Maria</td>
<td>P1325</td>
</tr>
<tr>
<td>Traföjer, Ursula</td>
<td>P0289</td>
</tr>
<tr>
<td>Train, Maria</td>
<td>P0207</td>
</tr>
<tr>
<td>Trajkovic, Jasmina</td>
<td>EV0291</td>
</tr>
<tr>
<td>Trajkovska-Dikic, Elena</td>
<td>P0664</td>
</tr>
<tr>
<td>Trajman, Adriana</td>
<td>P0334</td>
</tr>
<tr>
<td>Tramontin, Diario</td>
<td>EV0011</td>
</tr>
<tr>
<td>Tramer-Stranders, Gerardin</td>
<td>P0467</td>
</tr>
<tr>
<td>Trampuz, Andre</td>
<td>EP0142, EV0389, EV0390, P0493, P0494, P1585, P1704, P1705</td>
</tr>
<tr>
<td>Tran Ba Loc, Pierre</td>
<td>P1049</td>
</tr>
<tr>
<td>Tran, Lucia</td>
<td>EV0728</td>
</tr>
<tr>
<td>Tranquilli, Giulia</td>
<td>P0035</td>
</tr>
<tr>
<td>Traore, Afasato</td>
<td>EV0820</td>
</tr>
<tr>
<td>Traore, Madou</td>
<td>P0510</td>
</tr>
<tr>
<td>Traore, Dusmane</td>
<td>P1666, P0550, P1124</td>
</tr>
</tbody>
</table>
List of Speakers and Authors V

Villalon, Pilar P0479
Villamí-Gómez, Wilmer E. EV0853, P0071
Villano, Stephen P1318, P1319, P1321
Villar Hernández, Raquel P0446, P1709
Villar Turan, Raquel EV0932
Villard, Jean EV0591
Villar-García, Judit EV0714
Villarreal, Esther P0030, EV0350
Villarreal-Treviño, Letic EV0070 Viñas Boas do Prado, Gla dys P1545
Villaverde, Aia P0487
Ville, Muriel P0021
Villena, Isabel P0724
Villalpe, Francisco P0821
Villiet, Maxime P1145
Virátd, M.Belen P1148
Vinaj, Miguel O0452
VINCat Program, on behalf of O341
Vivace, Mercedes P0071, P0071
Viclín, Dámaso O432, P1212
Vivar, Ester O315
Vivas, Ana P0469
Vivante, Guido O489, P1154
Vivante, Delfina O446
Vivi, Giorgio P1148
Vivian, Jose P0186, P0820, P1348, P1352
Viniatt, William O371
Vinck, Gert P0392
Vincent, Clairet P0267
Vincent, E. EV0717
Vincent, Roel P0038, P0038, P0039, P1114
Vinciati, Susanna P0725
Vincenzi, Michela P0501
Vinci, Gaetana EV0390
Vinciguerra, Giampaolo P0441
Vinci, Giovanni P0441
Vincenzi, Alessandro P0442
Vincenzi, Stefano P0442
Vinci, Carlito O468
Vinci, Paolo P0442
Vinci, Giovanni P0442
Vincent, Gerard P0442
Vincent, Laurent P0442
Vincent, Michel P0442
Vincent, Paul P0442
Vinci, Lamberto P0442
Vinci, Giuseppe P0442
Vinci, Giuseppe P0442
Vinci, Giuseppe P0442
Vinci, Giuseppe P0442
Vinci, Giuseppe P0442
Vinci, Giuseppe P0442
Vinci, Giuseppe P0442
Vinci, Giuseppe P0442
Vinci, Giuseppe P0442
Vinci, Giuseppe P0442
Vinci, Giuseppe P0442
Vinci, Giuseppe P0442
Vinci, Giuseppe P0442
Vinci, Giuseppe P0442
Vinci, Giuseppe P0442
Vinci, Giuseppe P0442
Vinci, Giuseppe P0442
Vinci, Giuseppe P0442
Vinci, Giuseppe P0442
Vinci, Giuseppe P0442
Vinci, Giuseppe P0442
Vinci, Giuseppe P0442
Vinci, Giuseppe P0442
Vinci, Giuseppe P0442
Vinci, Giuseppe P0442
Vinci, Giuseppe P0442
List of Speakers and Authors

Ziza, Jean Marc EV0277, P0529
Zlatian, Ovidiu EV0611
Znazen, Abir EV0829, EV0886, P0576
Zobek, Natalia EP0061
Zocaro, Rosa Maria P0467
Zografou, Joanna EV0162
Zoll, Jan EP0059, P0378, P1630, P1618, P1624
Zoller, Michael P1239
Zolner-Swietz, Ines P0998
Zolnai-Dovec, Manca P0459
Zoltan, Pal EVO093
Zomborszki, Emese P1500
Zomer, Aldert EV0274, EV0554, O294, O451
Zomer, Tizza P0223
Zmorodian, Kamil EV0889
Zona, Stefano EP0159, EP0184
Zonaro, Emanuele P1280
Zoncada, Alessia P1216, P1217
Zong, Zhiyong O592
Zoran, Tamara P1639
Zorbozan, Orcun EV0811
Zorgani, Abdulaziz P0255
Zorzi, Antonella EV0003
Zorzi, Giulia EV0234
Zorzi, Willy P0926
Zotou, Anastasia P0259
Zou, Wuxin P0140
Zowalki, Jonathon EV0104
Zawawi, Hosam O587, P0732
Zubareva, Nadezda EV0700
Zabarovskaya, Ludmila P0356, P1779, EV0734, EV0860
Zubir, Maria Luisa EV0029
Zubkov, Vector EV0891, P1556
Zuccala, Paola P0179
Zucchi, Paola C. P0336
Zujic Atalic, Vlasta EV0156
Zumbrunn, Thomas EP0120
Zumbir, Alimuiddin O143
Zurabov, Alexander EV0891
Zurawska, Joanna EV0450
Zurita, Jeannete P0211, P0497
Zusman, Oren P1475, P1476, P0504, P1341
Zver, Samo P0376
Zvezdikina, Natalia P1361
Zvibliene, Aurelia EV0112
Zweigner, Janine EV0852, P0734, P0789
Zwinderman, A O618
Zykov, Tatiana EV0990
Zyryanov, Sergey O189
Zyzugin, Ilya EV0736, P0364
Opening Ceremony and Networking Reception

The traditional Opening Ceremony will be held on Saturday, 9 April at 19:00 in Hall A at the RAI Amsterdam. All participants and exhibitors are invited to attend. You are kindly requested to wear your badge.

Opening programme:

Greetings from our evening’s MC
Michael Jackson (the other Michael Jackson)

Welcome by the ESCMID President,
Murat Akova

Performance by Karsu Donmez

Karsu is a multi-talent. The Dutch musician with Turkish roots is not only a gifted singer but also a pianist. She has been performing on many national and international stages like the North Sea Jazz Festival, Carnegie Hall in New York and the Istanbul Jazz Festival. During our event, Karsu will be performing for us in her native Turkish.

Welcome by the ECCMID Programme Director,
Winfried V. Kern

Performance by Wouter Hamel

Wouter is a Dutch pop singer that has made his debut in 2007 with his album Hamel. He has performed in several television shows and has performed on the stage of the internationally known North Sea Jazz festival. Next to the national success, Wouter’s song 'Breezy' was released in Japan and scored the number 36 position on the Tokia Hot 100 chart.

Networking Reception

After the Opening Ceremony all participants and exhibitors are invited to attend the Networking Reception, giving you a taste of Turkey! The reception will be held in the Exhibition Area.

The Opening Ceremony and the Networking Reception are included in the registration fee.
General Informations (A-Z)

**App**
Please see – Mobile website

**Badges**
All participants and exhibitors are required to wear their badges throughout the congress.
Color Code:

<table>
<thead>
<tr>
<th>Committees</th>
<th>Exhibitor</th>
<th>Exhibitor Visitor</th>
</tr>
</thead>
<tbody>
<tr>
<td>Faculty</td>
<td>Media</td>
<td>Staff</td>
</tr>
</tbody>
</table>

**Cameras and Recordings**
Any kind of electronic recording as well as photograph taking is prohibited in all lecture halls during all sessions.

**Certificates of Attendance**
From the afternoon of Monday, 11 April 2016 onwards, certificates of attendance can be printed at self-service stations in the registration area, using the barcode on your name badge.

**Cloakroom / Left Luggage**
A cloakroom will be available at the RAI Amsterdam.

**Currency**
All official congress prices are indicated in Euro (€). The official currency in Amsterdam is the EURO (€). All major credit cards are accepted in most hotels, restaurants and shops. Exchange rates are available on: www.oanda.com/currency/converter

**ESCMID World**
During the congress, ESCMID staff will welcome you and be happy to answer your questions at their booth located in the foyer of Hall B just outside the exhibition area.

**ESCMID Networking Corner**
The ESCMID Networking Corner is located in the corridor from the exhibition to Halls A, B, C and Posters. ESCMID Study Groups, ESCMID Collaborative Centres and related organizations provide information on posters about their various initiatives. Learn more about these initiatives and meet individuals involved in these groups. In addition to the paper posters, eposters of all organizations will be available through terminals located in the same area as well as through the mobile website of the congress and the eLibrary of ESCMID.

**Exhibition**
A commercial and industrial exhibition will take place within the framework of the congress. Please refer to the List of Exhibitors in the Integrated Symposia and Exhibition Guide for further information.

The Exhibition will be open as follows:
- Saturday, 9 April 2016: 12:00-18:00 / 20:00-21:30 (For Networking Reception)
- Sunday, 10 April 2016: 09:30-17:30
- Monday, 11 April 2016: 09:30-17:30
- Tuesday, 12 April 2016: 09:30-14:00

**Integrated Symposia**
For the list of Integrated Symposia organized by commercial companies and session details, please refer to the Integrated Symposia and Exhibition Guide or the mobile website of the congress.

**Internet**
See Social Media Lounge

**Liability and Insurance**
The organizer is not able to take any responsibility whatsoever for injury or damage involving persons and property during the congress. Participants are advised to take out their own personal travel and health insurance for their trip.

**Language**
The official language of the congress is English. Simultaneous translation will not be provided.

**Meeting Boxes**
Next to the Pipeline Corner, ESCMID provides space for small meetings. The meeting boxes can be used free of charge and will be pre-bookable onsite. Each meeting booked shall not be longer than 1 hour. Please visit the reception desk for further information.

**Mobile website**
Navigate through the entire 26th ECCMID programme and all important information from your mobile phone. View sessions by day and category, access the abstracts being presented, locate exhibitors through the interactive map and directory and create your own itinerary to fully exploit your congress experience www.eccmidlive.org

**Photography**
Taking photographs and electronic recording are prohibited in all lecture halls during all sessions. Please note, that the congress is documented by official photographers. Pictures will be posted on the congress website.

**Pipeline Corner**
For the second time, ECCMID hosts the Pipeline Corner. SMEs from Europe and Oversea will present their ideas and pipeline. The Pipeline Corner is located in the exhibition area and is equipped with two ePoster terminals showing contributions of the participating companies. The official presentation will be on Sunday, 10 April 2016 from 13.00 – 14.00h in the Pipeline Corner.

**Press**
The press centre will be located in rooms F101-102 near the exhibition. There will be a well-equipped press working room with PC workstations (internet connected) and printer.
Publication – ESCMID eLibrary
All accepted abstracts, electronic versions of posters as well as presentations are published in the ESCMID Online Lecture Library. There is no printed abstract book or CD available. In addition, many sessions will be recorded and made available to congress participants. All on-site material will be available at the ECCMID Live! terminals located in the ESCMID World. You can also visit the ESCMID website at www.escmid.org/eLibrary to access the eLibrary.

Registration Desk
The onsite registration desk will be open as follows:
- Friday, 8 April 2016: 14:00 – 19:00
- Saturday, 9 April 2016: 07:00 – 18:30
- Sunday, 10 April 2016: 07:00 – 18:00
- Monday, 11 April 2016: 07:00 – 18:00
- Tuesday, 12 April 2016: 07:00 – 15:30

Responsibility
The participant acknowledges that he/she has no right to lodge damage claims against the organizers should the holding of the congress be hindered or prevented by unexpected political or economic events or by force majeure, or should the non-appearance of speakers or other reasons necessitate programme changes. By registering, the participant accepts this proviso.

Smoking Policy
There is a strict non-smoking policy throughout the RAI Amsterdam.

Social Media Lounge
Internet terminals for all delegates are located in the Social Media Lounge in the exhibition hall and are available during exhibition hours. Free WiFi will be available throughout the congress venue. No user name and password is needed. The network name is ECCMID2016.

Travel within Amsterdam
Travel Passes
How to Reach the Congress Venue by Public Transportation
- Metro
  The RAI has its own metro station. Amsterdam metro line 51 will take you to the central station and downtown Amsterdam.
- Taxi
  From the city center: A taxi from the centre will cost €15-25, take around 15 – 30 minutes for the 6 kilometers.
  From Schiphol Airport: A taxi from the airport will cost €30-35 and take around 15 – 20 minutes for the 14 kilometers.
- Tram
  You will find a tram stop right outside the venue. Tram line 4 takes you directly to the central station.
- Car
  Right next to the A10 ring road, RAI Amsterdam is easily accessible by car. The RAI also provides up to 5,000 parking spaces. General costs €17 per day.

Venue
RAI Amsterdam
Europaplein
NL 1078 GZ
Amsterdam, Netherlands
http://www.rai.nl/en/
Fastest access to ECCMID material on ECCMIDlive
www.eccmidlive.org

Improved search function: quicker more relevant results

After the congress, get all material from ESCMID's educational events, conferences and its congress ECCMID.
www.escmid.org/eLibrary